
TABLE OF CONTENTS

ABOUT ISHLT

2015-2016 BOARD OF DIRECTORS

ISHLT STAFF

ANNUAL MEETING SCIENTIFIC PROGRAM COMMITTEE

ABSTRACT REVIEWERS

COMMITTEE ROSTERS

Education Committee

Grants and Awards Committee

International and Inter-Society Coordination Committee (I2C2)

ISHLT Mechanically Assisted Circulatory Support (IMACS®) Registry Steering Committee

International Pediatric Heart Failure Registry (IPHFR) Steering Committee

International Thoracic Transplant Registry Steering Committee

Journal of Heart and Lung Transplantation (JHLT) Editorial Board

Nominating Committee

Registries and Databases Committee

Standards and Guidelines Committee

Links Newsletter Editorial Staff

COUNCIL OPERATING BOARDS

Basic Science and Translational Research

Heart Failure and Transplantation

Infectious Diseases

Junior Faculty and Trainees

Mechanical Circulatory Support

Nursing, Health Sciences and Allied Health

Pathology

Pediatric Thoracic Transplantation and Heart Failure

Pharmacy and Pharmacology

Pulmonary Hypertension

Pulmonary Transplantation

PAST PRESIDENTS

PAST PROGRAM CHAIRS

JOURNAL AND LINKS NEWSLETTER EDITORS

[REGISTRY MEDICAL DIRECTORS   
](index_split_011.html#id_ref_TOC_Directors)  
ISHLT AWARD RECIPIENTS

OUTSTANDING ACHIEVEMENT AWARDS

GRANTS AND SCHOLARSHIPS

ISHLT Norman E. Shumway Career Development Award

ISHLT Nursing Research Grant Award

ISHLT Research Fellowship Award

ISHLT Transplant Registry Early Career Award (Formerly Junior Faculty Award)

ISHLT/Bayer Pulmonary Hypertension Research Grant Award

ISHLT/HeartWare Award for Translational Research in MCS

ISHLT Branislav Radovancevic Memorial Fellowship Grant

ISHLT International Traveling Scholarship Award

ISHLT Leach-Abramson-Imhoff Links Travel Awards

ABSTRACT AWARDS

Philip K. Caves Award

Nursing, Health Sciences & Allied Health Excellence in Research Award

JFTC Clinical Case Dilemmas in Thoracic Transplantation Best Presentation Award

ISHLT Branislav Radovancevic Memorial Best MCS Abstract Award

ACCREDITATION INFORMATION

COMMERCIAL SUPPORT

HIGHLIGHTS OF THE MEETING

Basic Science

Heart Failure and Transplantation

Infectious Diseases

Lung Failure and Transplantation

Mechanical Circulatory Support

Nursing, Health Science, Allied Health

Pathology

Pediatrics

Pharmacy and Pharmacology

Pulmonary Hypertension

HOTEL FLOOR PLANS

Exhibition Level

Lobby Level

Mezzanine Level

ACRONYMS

DAILY SCHEDULE

Monday, April 25, 2016

Tuesday, April 26, 2016

Wednesday, April 27, 2016

Thursday, April 28, 2016

Friday, April 29, 2016

Saturday, April 30, 2016

WEDNESDAY ANNUAL MEETING SCIENTIFIC PROGRAM APRIL 27, 2016

Pre-Meeting Symposium 1: Anticoagulation and MCS: Can We Do Better?

Pre-Meeting Symposium 2: Controversies in Heart Transplantation: Past, Present and Future

Pre-Meeting Symposium 3: Current Innovations and Future of EVLP

Pre-Meeting Symposium 4: Under Pressure: Pulmonary Hypertension in Parenchymal Lung Disease

Pre-Meeting Symposium 5: Making It Work: Heart Transplant Challenges from the Surgeon's Perspective

Pre-Meeting Symposium 6: Back to the Future: Cell Therapy for Thoracic Organ Failure and Transplant?

Pre-Meeting Symposium 7: The Future is Here: Emerging Issues in Infectious Disease

Pre-Meeting Symposium 8: Joint ISHLT-ICCAC MCS Symposium: Joined at the Heart - International Perspectives on MCS Issues

Pre-Meeting Symposium 9: Donor Heart Selection: Strategies to Improve Organ Utilization

Pre-Meeting Symposium 10: Joint ISHLT/ESC Symposium: Left, Right, and Together: The Facts and Future of PH in Left Heart Disease (in collaboration with the ISHLT Scientific Council on PH and the ESC RV/Pulmonary Circulation Working Group)

Pre-Meeting Symposium 11: Multiorgan Transplantation for Lung Recipients: When is Two Better than One?

Pre-Meeting Symposium 12: It's All in the Translation: CMV from Bedside to Bench and Back Again

Pre-Meeting Symposium 13: Child's Play: Infectious Risk After Transplant During Everyday Life

Pre-Meeting Symposium 14: Genomics: What Do I Have to Know and How Will It Affect My Practice?

Pre-Meeting Symposium 15: Achilles Heel: Infectious Complications in MCS

Pre-Meeting Symposium 16: When Right is Wrong! Management of the Dying Right Ventricle

Pre-Meeting Symposium 17: The Biology of Aging and Lung Transplantation

Pre-Meeting Symposium 18: Proximal, Distal, Balloons, and Scalpels: Current Issues in CTEPH

Pre-Meeting Symposium 19: Between a Rock and a Hard Place: Debating Treatment Decisions for Marginal Psychosocial Candidates

Pre-Meeting Symposium 20: Big Data to Answer Big Questions: Biobanking to "Omics" to Personalized Medicine in Thoracic Organ Transplantation

Pre-Meeting Symposium 21: Unraveling "Chronic Rejection" in the Heart

Pre-Meeting Symposium 22: Great Debates in MCS

Pre-Meeting Symposium 23: A 2016 Focused Update on AMR in Cardiac Transplantation: Immunologic Diagnostics and the Treatment of Refractory AMR

Pre-Meeting Symposium 24: Endotypes of CLAD and Novel Treatment Strategies

Pre-Meeting Symposium 25: Inflammation and Altered Metabolism in Pulmonary Hypertension

Pre-Meeting Symposium 26: Hanging in the Balance: Minimizing Risk and Maximizing Benefit with Donor Derived Infection

Pre-Meeting Symposium 27: VAD in Patients with Congenital Heart Disease

Pre-Meeting Symposium 28: Lifecycle Journey of Hepatitis C Heart Failure Patient in 2016

THURSDAY ANNUAL MEETING SCIENTIFIC PROGRAM APRIL 28, 2016

Opening Plenary Session: Transplantation: Where Does the Science End and the Art Begin?

Concurrent Session 1: Too Much of a Bad Thing? Complications after Mechanical Support

Concurrent Session 2: On the Road to Recovery: Treating Chronic Heart Failure with Mechanical Support

Concurrent Session 3: Donor Organ Allocation and Management – What's Hot and New?

Concurrent Session 4: Keep It Down: New Insights on Immunosuppression

Concurrent Session 5: Improving Heart Failure Outcomes with Pills, Procedures and Sex

Concurrent Session 6: Pediatric Heart Transplant Outcomes

Concurrent Session 7: It's Tough to Make Predictions, Especially about the Future: Outcomes in MCS

Concurrent Session 8: Quality Over Quantity? Quality of Life in MCS

Concurrent Session 9: Rolling the Dice: Risk Prediction in Cardiac Transplantation

Concurrent Session 10: The Frailty Construct and Body Composition - Impact on Lung Transplant Outcomes

Concurrent Session 11: The Heartbreak of Rejection: All Against the Graft

Concurrent Session 12: Pediatric Lung Transplantation

Concurrent Session 13: Philip K. Caves Award Candidate Presentations

Symposium 29: Joint ISHLT/PVRI Symposium: Exploring Combination Therapy in PAH

Concurrent Session 14: Bright Shiny Toys for Good Girls and Boys: New Technology and Techniques in MCS

Concurrent Session 15: Let's Be Specific: Donor Specific Antibodies - Challenges Ahead

Concurrent Session 16: Novel Therapeutic Strategies for Chronic Lung Allograft Dysfunction

Concurrent Session 17: Pediatric Mechanical Circulatory Support

Concurrent Session 18: Game of Clones: an Epic Cellular Battle Between Rejection and Tolerance

Concurrent Session 19: Improving Outcomes: Body and Soul

Concurrent Session 20: Condemnatory or Commendatory Effects of Thoracic Transplantation

Mini Oral Session 1: Science, Surgery and Shock in MCS

Mini Oral Session 2: Donor Dilemmas in Heart Transplantation

Mini Oral Session 3: Candidate and Recipient Management in Heart Transplantation

Mini Oral Session 4: Donor and Recipient Management in Lung Transplantation

Mini Oral Session 5: Pediatrics: Organ Support and Transplantation

Mini Oral Session 6: Pharmacy & Pharmacology and Mechanical Circulatory Support

FRIDAY ANNUAL MEETING SCIENTIFIC PROGRAM APRIL 29, 2016

Sunrise Symposium 1: MCS Challenges and Engineering Solutions

Sunrise Symposium 2: Timing Support in Cardiogenic Shock: When to Move Forward

Sunrise Symposium 3: Thoracic Organ Transplantation and Malignancy

Sunrise Symposium 4: Let's Come to Some Closure on the Issue of Pulmonary Hypertension in Congenital Heart Disease

Sunrise Symposium 5: Back to Basics: What the Thoracic Transplant Clinician Needs to Know About Immunobiology

Sunrise Symposium 6: The Fly in the Ointment: Nosocomial Infections

Plenary Session: Where is the Future for Innovation?

Concurrent Session 21: Pimp My Pump: Novel MCS Design and Management

Concurrent Session 22: What a Bloody Mess: Novel Therapeutics and Diagnostics for GI Bleeding after MCS

Concurrent Session 23: Choosing a Gift: Donor Selection

Concurrent Session 24: What's New in Primary Graft Dysfunction Post Lung Transplantation

Concurrent Session 25: Beyond Adherence: What's New Out There?

Concurrent Session 26: Mechanisms of AMR: Can We Protect The Body From The Anti-Body?

Symposium 30: JHLT at ISHLT: The Year in a Capsule

Concurrent Session 27: Are Two Pumps Better Than One? RV Failure and MCS

Concurrent Session 28: Pump Thrombosis: What's Hot with the Clot

Concurrent Session 29: The Dark Side of Heart Transplant: Living With CAV

Concurrent Session 30: What You Need to Know About Donors and Early Outcome Following Lung Transplantation

Concurrent Session 31: Pediatric Early Post Transplant Problems

Concurrent Session 32: Cardiothoracic Transplantation and MCS Infections: Cracking the Code for Diagnosis, Monitoring, and Treatment

Concurrent Session 33: "A Bipartisan Effort": Antibodies and Complement in Heart and Lung Allografts

Symposium 31: Performing Under Pressure: Lung Transplantation in PH and PAH

Concurrent Session 34: How Much is Too Much? Assessing Risk Prior to MCS

Concurrent Session 35: Too Thick or Too Thin? Assessing Anticoagulation in MCS

Concurrent Session 36: Is It Really A Wonderful Life? Problems Post Heart Transplant

Concurrent Session 37: Prognostic Variables Associated with CLAD Onset and Progression

Concurrent Session 38: New Insights in Pulmonary Hypertension

Concurrent Session 39: Junior Faculty and Trainee Council's Clinical Case Dilemmas: The Best of the Best

Concurrent Session 40: Too Much of a Good Thing: Balancing Benefit and Medication Complexity

Mini Oral Session 7: Patient Management and Outcomes in MCS

Mini Oral Session 8: Technology, Physiology and Complications in MCS

Mini Oral Session 9: Risk Factors and Lung Transplant Outcomes

Mini Oral Session 10: Heart Transplantation and Heart Failure

Mini Oral Session 11: Models in Transplantation: From Mouse to Rat to Pig to Human

Mini Oral Session 12: Applied Health Research and Pulmonary Hypertension

SATURDAY ANNUAL MEETING SCIENTIFIC PROGRAM APRIL 30, 2016

Sunrise Symposium 7: Clear as Mud: Assessing the Right Ventricle

Sunrise Symposium 8: Rethinking Valvular Disease in Heart Failure

Sunrise Symposium 9: Lung Transplant Benefit is More Than Just Survival

Sunrise Symposium 10: Ambulatory ECMO in Adults: We Like to Move It, Move It

Sunrise Symposium 11: Controversies in Pediatric Heart Failure

Sunrise Symposium 12: Precision Medicine in Transplantation: Drug Levels and Beyond

Concurrent Session 41: You Get Out What You Put In: Assessing Risk in Mechanical Support

Concurrent Session 42: Difficult Decisions in Mechanical Support

Concurrent Session 43: Paying the Tolls: Effects of Bridge to Transplant

Concurrent Session 44: Lung Transplantation - Advanced Diagnostics!

Concurrent Session 45: Pediatric Heart Failure

Concurrent Session 46: From 'Jeans' to Proteins: Mechanisms of Ischemia Reperfusion Injury and Translation to Advanced Diagnostics

Plenary Session: Pushing New Scientific Frontiers: It's In Our Heritage

Concurrent Session 47: Medicines or Machines? The Failing Right Ventricle in MCS

Concurrent Session 48: Not Just to Survive, But to Thrive: Comprehensive Care of the MCS Patient

Concurrent Session 49: My Heart Is Broken: Primary Graft Dysfunction and Early Problems

Concurrent Session 50: Recipient Factors and Outcome After Lung Transplantation - Are We Getting It Right?

Concurrent Session 51: Heart Failure Risk Prediction: From Molecules to Mechanism

Concurrent Session 52: Factors Determining Outcomes in Pulmonary Hypertension

WEDNESDAY POSTER SESSION 1 APRIL 27, 2016

Basic Science

Heart Transplantation

Lung Transplantation

Mechanical Circulatory Support

Pathology

THURSDAY POSTER SESSION 2 APRIL 28, 2016

Economics, Ethics, Public Policy

Heart Failure

Heart Transplantation

Lung Transplantation

Mechanical Circulatory Support

Nursing, Health Sciences, Allied Health

Pediatrics

Pulmonary Hypertension

FRIDAY POSTER SESSION 3 APRIL 29, 2016

Infectious Diseases

Lung Transplantation

Mechanical Circulatory Support

Pediatrics

Pharmacy and Pharmacology

Junior Faculty Clinical Case Reports

ISHLT ACADEMY: CORE COMPETENCIES IN HEART FAILURE AND CARDIAC TRANSPLANT MEDICINE SCIENTIFIC PROGRAM

ISHLT ACADEMY: CORE COMPETENCIES IN MECHANICAL CIRCULATORY SUPPORT SCIENTIFIC PROGRAM

ISHLT ACADEMY: MASTER CLASS IN PULMONARY TRANSPLANTATION SCIENTIFIC PROGRAM

ISHLT ACADEMY: MASTER CLASS IN MECHANICAL CIRCULATORY SUPPORT SCIENTIFIC PROGRAM

CORPORATE EVENT AND INDUSTRY THEATER LISTINGS

EXHIBIT HALL FLOOR PLAN

EXHIBITORS AND BOOTH NUMBER

EXHIBITOR DESCRIPTIONS

FUTURE ANNUAL MEETINGS

ABOUT ISHLT

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy.

ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 3,000 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, transplant coordinators, and infectious disease specialists. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.

The purposes of the Society are:

To associate persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease, and related sciences.

To encourage and stimulate basic and clinical research in these disciplines and to promote new therapeutic strategies.

To hold scientific meetings featuring presentations and discussions relevant to these disciplines.

To sponsor a scientific journal for the publication of manuscripts related to these disciplines.

To establish and maintain an international registry for heart and lung transplantation.

To award research grants and establish endowments for the study of these disciplines.

ABOUT WASHINGTON, DC

Washington, DC is a living history book full of powerful moments and memorable experiences. It's the only city in the world where you can visit with a 19-foot President Lincoln, read the real U.S. Constitution, see Dorothy's ruby-red slippers, immerse yourself in internationally acclaimed art and explore space travel - all in one day.

When you're not in sessions we hope that you will be able to explore America's educational and entertaining venues, world-class museums and monuments, unique neighborhoods, top-rated restaurants, gorgeous parks and gardens, and endless performing arts choices.

To learn more about Washington, DC, please visit <http://washington.org/>
2015-2016 BOARD OF DIRECTORS

R. Duane Davis, MD, MBA, President, Florida Hospital, Orlando, FL

Maryl R. Johnson, MD, President-Elect, University of Wisconsin, Madison, WI

Hermann Reichenspurner, MD, PhD, Past-President, University Heart Center Hamburg, Hamburg, Germany

Stuart C. Sweet, MD, PhD, Secretary-Treasurer, St. Louis Children's Hospital, St. Louis, MO

Carla C. Baan, PhD, Director, Erasmus Medical Center, Rotterdam, The Netherlands

Christian Benden, MD, Director, University Hospital Zurich, Zurich, Switzerland

Lara Danziger-Isakov, MD, MPH, Director, Cincinnati Children's Hospital, Cincinnati, OH

Tobias Deuse, MD, PhD, Director, University of California at San Francisco, San Francisco, CA

Andrew J. Fisher, FRCP, PhD, Director, Freeman Hospital, Newcastle, United Kingdom

Daniel J. Goldstein, MD, Director, Montefiore Medical Center, Bronx, NY

Daniel R. Goldstein, MD, Director, Yale New Haven Hospital, New Haven, CT

Peter M. Hopkins, FRACP, Director, The Prince Charles Hospital, Brisbane, Australia

Myung H. Park, MD, Director, Houston Methodist Hospital, Houston, TX

Michael G. Petty, PhD, RN, CNS, Director, University of Minnesota Medical Center, Minneapolis, MN

Jeffrey J. Teuteberg, MD, Director, University of Pittsburgh/Presbyterian, Pittsburgh, PA

Ex Officio Board Members

Mandeep R. Mehra, MD, Editor-in-Chief, Journal of Heart and Lung Transplantation

Josef Stehlik, MD, MPH, International Thoracic Transplant Registry Medical Director

Christopher H. Wigfield, MD, FRCS (C/Th), Medical Director of Educational Affairs

Amanda W. Rowe, ISHLT Executive Director
ISHLT STAFF

Amanda W. Rowe

Executive Director

Phyllis Glenn

Director of Membership Services

Lisa Edwards

Director of Meetings

Lee Ann Mills

Director of Operations

Susie Newton

Communications Manager

Megan Barrett

Communications Assistant

14673 Midway Road, Suite 200

Addison, TX 75001

Phone: 972-490-9495

Fax: 972-490-9499

www.ishlt.org
ANNUAL MEETING SCIENTIFIC PROGRAM COMMITTEE

• Symposium Planning Committee

*Abstract Selection Committee

Andrew J. Fisher, FRCP, PhD, Newcastle upon Tyne, UK, 2016 Program Chair **• ***

Duane Davis, MD, MBA, Orlando, FL, ISHLT President **• ***

Jeffrey J. Teuteberg, MD, Pittsburgh, PA, 2017 Program Chair **• ***

Andreas O. Zuckermann, MD, Vienna, Austria, 2015 Program Chair **• ***

David A. Baran, MD, Newark, NJ **• ***

Christian Benden, MD, Zurich, Switzerland *****

Andrew J. Boyle, MD, Atlanta, GA *****

Stephen C. Clark, FRCS, Newcastle upon Tyne, UK *****

Hannah Copeland, MD, Carmel, IN • *

Lara Danziger-Isakov, MD, MPH, Cincinnati, OH **• ***

Sabina M. De Geest, RN, PhD, Basel, Switzerland **• ***

Goran Dellgren, MD, PhD, Goteborg, Sweden *****

Shashank S. Desai, MD, Falls Church, VA *****

Kumud K. Dhital, MD, PhD, Sydney, Australia *****

Stephan Ensminger, MD, DPhil, Bad Oeynhausen, Germany **• ***

Christopher R. Ensor, PharmD, BCPS-CV, Pittsburgh, PA *****

Benjamin H. Freed, MD, Chicago, IL *****

Andrew E. Gelman, PhD, St. Louis, MO **• ***

Patricia Ging, PharmD, Dublin, Ireland **• ***

Christopher S. Hayward, MD, Sydney, Australia *****

Peter M. Hopkins, FRACP, Brisbane, Australia **• ***

Jonathan N. Johnson, MD, Rochester, MN **• ***

Annemarie Kaan, MCN, RN, Vancouver, BC, Canada **• ***

Mary E. Keebler, MD, Nashville, TN *****

Kiran K. Khush, MD, Stanford, CA *****

Richard Kirk, FRCP, FRCPCH, Newcastle upon Tyne, UK **• ***

Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Melbourne, Australia *****

Haifa Lyster, MSc, Harefield, UK **• ***

Tereza Martinu, MD, Toronto, ON, Canada **• ***

Mandeep R. Mehra, MD, MBBS, FACC, FACP, Boston, MA **• ***

Hirsch S. Mehta, MD, San Diego, CA *****

Anna L. Meyer, MD, Leipzig, Germany *****

Carmelo A. Milano, MD, Durham, NC *****

Dylan V. Miller, MD, Murray, UT **• ***

Martha L. Mooney, MD, FACP, Norfolk, VA *****

Orla Morrissey, MD, Melbourne, Australia *****

Desley Neil, FRCPath, Birmingham, UK **• ***

Joseph G. Rogers, MD, Durham, NC *****

Eulalia Roig, MD, Barcelona, Spain **• ***

Antonio Roman, MD, PhD, Barcelona, Spain **• ***

Joanna M. Schaenman, MD, PhD, Los Angeles, CA **• ***

Jan Schmitto, MD, PhD, MBA, Hannover, Germany **• ***

Oksana A. Shlobin, MD, Falls Church, VA **• ***

Laurie D. Snyder, MD, Durham, NC *****

Ryan J. Tedford, MD, Baltimore, MD **• ***

Mitesh V. Thakrar, MD, Calgary, AB, Canada *****

Robin Vos, MD, PhD, Leuven, Belgium **• ***

Gregor Warnecke, MD, Hannover, Germany **• ***

Neil W. Wrightson, RN, Newcastle upon Tyne, UK **• ***

Vincent G. Valentine, MD, Galveston, TX *****

Christopher H. Wigfield, MD FRCS(C/Th), Chicago, IL **• ***

Tahir Yagdi, MD, PhD, Izmir, Turkey **• ***
ABSTRACT REVIEWERS

Richa Agarwal, MD, W. Penn Allegheny Hospital, Pittsburgh, PA

Clemens Aigner, MD, Medical University of Vienna, Vienna, Austria

Ruchan Akar, MD, Ankara University, Ankara, Turkey

Arezu Z. Aliabadi, MD, Medical University of Vienna, Vienna, Austria

Christopher Almond, MD, Stanford University, Stanford, CA

Annalisa Angelini, MD, University of Padua, Padua, Italy

Samantha J. Anthony, PhD, MSW, Hospital for Sick Children, Toronto, ON, Canada

Martine Antoine, MD, Erasme University Hospital, Brussels, Belgium

Ani C. Anyanwu, MD, Mount Sinai Medical Center, New York, NY

Saima Aslam, MD, MS, University of California at San Diego, San Diego, CA

Robin K. Avery, MD, Johns Hopkins Hospital, Baltimore, MD

Estelle Azeka, MD, University of Sao Paulo, Sao Paulo, Brazil

Carla Baan, PhD, Erasmus Medical Center, Rotterdam, The Netherlands

Markus J. Barten, MD, PhD, University Heart Center Hamburg, Hamburg, Germany

Jay Baumwol, MBBS, FRACP, Fiona Stanley Hospital, Murdoch, Australia

Alexander Bernhardt, MD, University Heart Center Hamburg, Hamburg, Germany

Gerald J. Berry, MD, Stanford University, Stanford, CA

Reshma M. Biniwale, MD, UCLA, Los Angeles, CA

Nancy P. Blumenthal, CRNP, Hospital of the University of Pennsylvania, Philadelphia, PA

Hilde Bollen, RN, UZLeuven, Leuven, Belgium

Lee A. Borthwick, PhD, Newcastle University, Newcastle upon Tyne, UK

Patrick Bruneval, MD, Hospital European George Pompidou, Paris, France

Deborah Budge, MD, Intermountain Medical Center, Murray, UT

Caron L. Burch, MSN, Stanford Hospital & Clinics, Stanford, CA

Fay S. Burrows, PharmD, BCPS, St. Vincent's Hospital, Sydney, Australia

Fiorella Calabrese, MD, University of Padova, Padova, Italy

Edward Cantu, MD, Hospital of the University of Pennsylvania, Philadelphia, PA

Kevin C. Carney, MSN, CRNP, CCTC, Hospital of the University of Pennsylvania, Philadelphia, PA

Marilia Cascalho, MD, PhD, University of Michigan Hospital, Ann Arbor, MI

Chesney Castleberry, MD, Cincinnati Children's Hospital MC, Cincinnati, OH

Alexandre S. Cauduro, MD, Heart Institute Sao Paulo University, Sao Paulo, Brazil

Daniel Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, Australia

Susan M. Chernenko, RN, MN, NP, Toronto General Hospital, Toronto, ON, Canada

Laveena Chhatwani, MD, Stanford University, Stanford, CA

Sharon Chih, MD, University of Ottawa Heart Institute, Ottawa, ON, Canada

Jose M. Cifrian, MD, Hospital University Marques Valdecilla, Santander, Spain

Tamara E. Claridge, PharmD, Hospital of the University of Pennsylvania, Philadelphia, PA

Joseph C. Cleveland, Jr, MD, University of Colorado School of Medicine, Aurora, CO

Adam B. Cochrane, PharmD, Inova Fairfax Hospital, Falls Church, VA

Erin Coglianese, MD, Loyola University Medical Center, Maywood, IL

Rebecca J. Cogswell, MD, University of Minnesota, Minneapolis, MN

Monica M. Colvin, MD, MS, FAHA, University of Michigan Health System, Ann Arbor, MI

Pamela S. Combs, PhD, RN, Seton Medical Center, Austin, TX

Jennifer L. Cook, MD, University of Arizona Sarver Heart Center, Tucson, AZ

Jennifer Cowger, MD, St Vincent Heart Center, Indianapolis, IN

Rachel M. Crackett, MSc, Freeman Hospital, Newcastle upon Tyne, UK

Maria G. Crespo-Leiro, MD, Hospital University A Coruna, La Coruna, Spain

Michiel Dalinghaus, MD, PhD, Erasmus Medical Center, Rotterdam, The Netherlands

Mani A. Daneshmand, MD, Duke University Medical Center, Durham, NC

Teresa De Marco, MD, FACC, University of California at San Francisco, San Francisco, CA

Fabio De Robertis, MD, Harefield Hospital, Harefield, UK

Juan F. Delgado Jimenez, PhD, University Hospital 12 de Octubre, Madrid, Spain

Goran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden

Eugene C. DePasquale, MD, David Geffen School of Medicine, Los Angeles, CA

Tobias Deuse, MD, PhD, University of California at San Francisco, San Francisco, CA

Gundeep S. Dhillon, MD, Stanford University, Stanford, CA

Joshua M. Diamond, MD, University of Pennsylvania, Philadelphia, PA

Esme Dijke, PhD, University of Alberta, Edmonton, AB, Canada

Fabienne Dobbels, MSc, PhD, KU Leuven, Leuven, Belgium

Debra A. Dodd, MD, Vanderbilt Children's Hospital, Nashville, TN

Stavros G. Drakos, MD, University of Utah School of Medicine, Salt Lake City, UT

Anique Ducharme, MD, MSC, Montreal Heart Institute, Montreal, QC, Canada

Debi H. Dumas-Hicks, RN, BS, CCTC, CCTN, Ochsner Medical Center, New Orleans, LA

Jean-Paul Duong-Van-Huyen, MD, PhD, Hospital Necker, Paris, France

Howard J. Eisen, MD, Drexel University College of Medicine, Philadelphia, PA

Jerry D. Estep, MD, The Methodist Hospital, Houston, TX

Roger W. Evans, PhD, UNRTP, Transplant Professionals.com, LLC, Rochester, MN

Katherine Y. Fan, MD, Grantham Hospital, Aberdeen, Hong Kong

Maryjane A. Farr, MD, Columbia University Medical Center, New York, NY

Carol F. Farver, MD, Cleveland Clinic, Cleveland, OH

Brian Feingold, MD, MS, Children's Hospital of Pittsburgh, Pittsburgh, PA

Mark E. Fenton, MD, FRCPC, Royal University Hospital, Saskatoon, SK, Canada

Katrina Ford, BPharm, Great Ormond Street Hospital, London, UK

Jennifer L. Franzwa, MSN, RN, CCTC, University of Iowa Hospitals and Clinics, Iowa City, IA

Darren H. Freed, MD, PhD, FRCSC, University of Alberta Hospital, Edmonton, AB, Canada

Jason S. Fritz, MD, FCCP, University of Pennsylvania, Philadelphia, PA

Laura K. Frye, MD, University of Pennsylvania, Philadelphia, PA

Louise M. Fuller, PT, Alfred Hospital, Melbourne, VIC, Australia

Rochelle M. Gellatly, PharmD, Alfred Hospital, Melbourne, VIC, Australia

Helen Gibbs, RN, Auckland City Hospital, Auckland, New Zealand

Claudia G. Gidea, MD, Barnabas Health, New York, NY

Allan R. Glanville, MBBS, MD, FRACP, St. Vincent's Hospital, Sydney, NSW, Australia

Martin J. Goddard, FRCS, MRCPa, Papworth Hospital, Cambridge, UK

Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY

Mardi Gomberg-Maitland, MD, University of Chicago Medical Center, Chicago, IL

Jose Gonzalez-Costello, MD, Hospital Universitari de Bellvitge, Barcelona, Spain

Francisco Gonzalez-Vilchez, MD, PhD, Hospital Marques de Valdecilla, Santander, Spain

Jens Gottlieb, MD, Medical School Hannover, Hannover, Germany

Kathleen L. Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, IL

John R. Greenland, MD, PhD, University of California at San Francisco, San Francisco, CA

Aric L. Gregson, MD, UCLA School of Medicine, Los Angeles, CA

Cynthia J. Gries, MD, MSc, Florida Hospital, Orlando, FL

Jan F. Gummert, MD, PhD, Herz-und Diabeteszentrum NRW, Bad Oeynhausen, Germany

Richard Ha, MD, Stanford University, Stanford, CA

Kieran Halloran, MD, University of Alberta, Edmonton, AB, Canada

Margaret M. Hannan, MD, Mater Hospital, Dublin, Ireland

Matthew G. Hartwig, MD, Duke University, Durham, NC

Reema Hasan, MD, University of Michigan, Ann Arbor, MI

Are Martin Holm, MD, PhD, Oslo University Hospital, Oslo, Norway

Edward Horn, PharmD, BCPS, Allegheny General Hospital, Pittsburgh, PA

Douglas A. Horstmanshof, MD, Integris Baptist Medical Center, Oklahoma City, OK

Howard J. Huang, MD, Baylor University Medical Center, Dallas, TX

Sharon A. Hunt, MD, Stanford University Medical Center, Stanford, CA

Shahid Husain, MD, MS, Toronto General Hospital, Toronto, ON, Canada

Michael Ison, MD, MS, Northwestern Memorial Hospital, Chicago, IL

Martin P. Iversen, MD, PhD, Rigshospitalet, Copenhagen, Denmark

George Javorsky, MBBS, FRACP, The Prince Charles Hospital, Brisbane, Australia

Ulrich P. Jorde, MD, Columbia University, New York, NY

Susan M. Joseph, MD, Baylor University Medical Center, Dallas, TX

Stephen C. Juvet, MD, PhD, FRCPC, University Health Network, Toronto, ON, Canada

Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA

Cassie Kennedy, MD, Mayo Clinic, Rochester, MN

Anne Keogh, MBBS, MD, St. Vincent's Hospital, Sydney, Australia

Feras Khaliel, MD, PhD, King Faisal Specialist Hospital & RC, Riyadh, Saudi Arabia

Ivan Knezevic, MD, University Clinical Centre, Ljubljana, Slovenia

Thomas Krabatsch, MD, PhD, German Heart Center, Berlin, Germany

Daniel Kreisel, MD, PhD, Washington University School of Medicine, St. Louis, MO

Christiane Kugler, PhD, University Witten, Witten, Germany

Jose Luis Lambert Rodriguez, FESC, FHFA, MD, PhD, Hospital University Central de Asturias, Oviedo, Spain

Brent C. Lampert, DO, The Ohio State University Wexner Medical Center, Columbus, OH

Jacob Lavee, MD, Sheba Medical Center, Tel Hashomer, Israel

Lorriana E. Leard, MD, University of California at San Francisco, San Francisco, CA

Erika D. Lease, MD, University of Washington, Seattle, WA

David J. Lederer, MD, Columbia University Medical Center, New York, NY

Karl B. Lemstrom, MD, PhD, Helsinki University, Helsinki, Finland

Choon Pin Lim, MBBS, National Heart Center, Singapore, Singapore

Ugolino Livi, MD, S. Maria della Misericordia General Hospital, Udine, Italy

Gabriel Loor, MD, University of Minnesota, Minneapolis, MN

Angela Lorts, MD, Cincinnati Children's Hospital, Cincinnati, OH

Lars Lund, MD, PhD, Karolinska University Hospital, Stockholm, Sweden

Me-Linh Luong, MD, St. Luc Hospital, Montreal, QC, Canada

Peter Macdonald, MD, PhD, St. Vincent's Hospital, Sydney, Australia

Claudius Mahr, DO, University of Washington, Seattle, WA

George

B. Mallory, MD, Texas Children's Hospital, Houston, TX

Monique Malouf, FRACP, St. Vincent's Hospital, Sydney, NSW, Australia

Simon Maltais, MD, PhD, Mayo Clinic, Rochester, MN

Pradeep P. A. Mammen, MD, FACC, FAHA, UT Southwestern Medical Center, Dallas, TX

Charles C. Marboe, MD, Columbia University, New York, NY

Bradley A. Maron, MD, Brigham and Women's Hospital, Boston, MA

Stanley I. Martin, MD, Geisinger Health System, Danville, PA

Oliver Mauthner, PhD, University of Basel, Basel, Switzerland

John McDyer, MD. University of Pittsburgh Medical Center, Pittsburgh, PA

Dana P. McGlothlin, MD, Kaiser San Francisco, San Francisco, CA

Tanya J. McWilliams, MD, PhD, Auckland City Hospital, Auckland, New Zealand

Tina Melicoff, MD, Baylor College of Medicine, Houston, TX

Sonia Mirabet, MD, Hospital Sant Pau, Barcelona, Spain

Nader Moazami, MD, Cleveland Clinic, Cleveland, OH

Paul J. Mohacsi, MD, University Hospital, Bern, Switzerland

Thomas Moller, MD, PhD, Oslo University Hospital, Oslo, Norway

Joshua J. Mooney, Stanford University, Stanford, CA

Michiel Johan Morshuis, MD, Heart Center NRW, Bad Oeynhausen, Germany

Michael S. Mulligan, MD, University of Washington School of Medicine, Seattle, WA

Jayan Nagendran, MD, University of Alberta, Edmonton, AB, Canada

Takeshi Nakatani, MD, PhD, National Cerebral & Cardiovascular Center, Osaka, JAPAN

Sanem

Nalbantgil, MD, Ege University, Izmir, Turkey

Tomohiro Nishinaka, MD, Tokyo Women's Medical University, Tokyo, Japan

Robert F. Padera, MD, PhD, Brigham & Women's Hospital, Boston, MA

Francis D. Pagani, MD, PhD, University of Michigan Health, Ann Arbor, MI

Maryse Palardy, MD, University of Michigan, Ann Arbor, MI

Kruti A. Pandya, MD, UCLA, Los Angeles, CA

Chetan B Patel, MD, Duke University Medical Center, Durham, NC

Caroline M. Patterson, MD, Papworth Hospital, Cambridge, UK

Simon Pecha, MD, University Heart Center Hamburg, Hamburg, Germany

Michael Pham, MD, MPH, Stanford University, Palo Alto, CA

Daniela Pini, MD, Istituto Clinico Humanitas, Milan, Italy

Sean P. Pinney, MD, Mt Sinai Medical Center, New York, NY

Christophe Pison, MD, PhD, Université de Grenoble, Grenoble, France

Evgenij V. Potapov, MD, PhD, Deutsches Herzzentrum, Berlin, Germany

Ioana R. Preston, MD, Tufts Medical Center, Boston, MA

Yuriy Pya, MD, National Research Cardiac Surgery Center, Astana, Kazakhstan

Axel Rahmel, MD, German Procurement Organization DSO, Frankfurt, Germany

Keshava Rajagopal, MD, PhD, University of Texas Health Science Center at Houston, Houston, TX

J. Eduardo Rame, MD, Pennsylvania Heart & Vascular Center, Philadelphia, PA

Danny Ramzy, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, CA

Aaron M. Ranasinghe, MD, FRCS, Freeman Hospital, Newcastle upon Tyne, United Kingdom

Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

Yazhini Ravi, MD, Baylor Scott & White Memorial Hospital, Temple, TX

Leigh C. Reardon, MD, UCLA, Los Angeles, CA

Anja C. Roden, MD, Mayo Clinic, Rochester, MN

Joseph W. Rossano, MD, The Children's Hospital of Philadelphia, Philadelphia, PA

Dmitry Rozenberg, MD, University of Toronto, Toronto, ON, Canada

Stuart D. Russell, MD, Johns Hopkins Hospital, Baltimore, MD

John J. Ryan, MD, FACC, FAHA, University of Utah, Salt Lake City, UT

Leonardo Salazar, MD, Fundacion Cardiovascular de Colombia, Floridablanca, Colombia

Christopher T. Salerno, MD, St. Vincent's Heart Center, Indianapolis, IN

Murat Sargin, MD, Siyami Ersek Hospital, Istanbul, Turkey

Sonja Schrepfer, MD, PhD, University Heart Center Hamburg, Hamburg, Germany

Stephan Schubert, MD, German Heart Center, Berlin, Germany

Stephan Schueler, MD, PhD, FRCS, Freeman Hospital, Newcastle upon Tyne, United Kingdom

Martin Schweiger, MD, Children's Hospital, Zurich, Switzerland

Nicolaus Schwerk, MD, Hannover Medical School, Hannover, Germany

Javier Segovia, MD, PhD, Hospital Puerta De Hierro, Madrid, Spain

Ashish S. Shah, MD, Johns Hopkins Hospital, Baltimore, MD

Keyur B. Shah, MD, Virginia Commonwealth University, Richmond, VA

Palak Shah, MD, MS, Inova Fairfax Hospital, Falls Church, VA

Pali Shah, MD, Johns Hopkins University, Baltimore, MD

Esther Shao, MD, Maine Health Cardiology, Portland, ME

Michael Shullo, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA

Scott C. Silvestry, MD, Washington University School of Medicine, St. Louis, MO

Andre R. Simon, MD, PhD, Harefield Hospital, London, UK

Marc A. Simon, MD, University of Pittsburgh, Pittsburgh, PA

Kathleen Simpson, MD, Washington University St. Louis, St. Louis, MO

Tajinder P. Singh, MD, MSc, Boston Children's Hospital, Boston, MA

Cumara C. Sivathasan, MBBS, FRCS, National Heart Centre, Singapore, Singapore

Mark S. Slaughter, MD, University CT Surgical Associates, Louisville, KY

George G. Sokos, DO, Allegheny General Hospital, Pittsburgh, PA

Amparo Sole, MD, PhD, Hospital Universitario la Fe Unidad de Trasplante Pulmonar, Valencia, Spain

Melinda Solomon, MD, FRCPC, Hospital for Sick Children, Toronto, ON, Canada

Wiebke Sommer, MD, Hannover Medical School, Hannover, Germany

Ajay V. Srivastava, MD, Stanford University, San Jose, CA

William E. Stansfield, MD, Toronto General Hospital, Toronto, ON, Canada

Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT

Emily Stimpson, MSN, CCTC, Cedars-Sinai Medical Center, Los Angeles, CA

Valentina Stosor, MD, Northwestern University/Feinberg School of Medicine, Chicago, IL

Martin Strueber, MD, Spectrum Health Hospital, Grand Rapids, MI

Zsolt Szepfalusi, MD, Medical University of Vienna, Vienna, Austria

Carmela D. Tan, MD, Cleveland Clinic, Cleveland, Ohio

Thenappan Thenappan, MD, University of Minnesota, Minneapolis, MN

Adriana Torres, MD, Fundacion Cardioinfantil, Bogota, Colombia

Christopher Towe, MD, Cincinnati Children's Hospital, Cincinnati, OH

Wayne M. Tsuang, MD, Cleveland Clinic, Cleveland, OH

Walter Uber, PharmD, Medical University of South Carolina, Charleston, SC

Marian Urban, MD, Freeman Hospital, Newcastle upon Tyne, United Kingdom

Nir Uriel, MD, University of Chicago, Chicago, IL

Simon Urschel, MD, University of Alberta, Edmonton, AB, Canada

Jean-Luc Vachiery, MD, Erasme University Hospital ULB, Brussels, Belgium

Victor H. Van Berkel, MD, PhD, University of Louisville Physicians, Louisville, KY

Rebecca R. Vanderpool, PhD, University of Pittsburgh, Pittsburgh, PA

Rhea A. Varughese, MD, Alberta Health Services, Edmonton, AB, Canada

Rajamiyer Venkateswaran, FRCS, Wythenshawe Hospital, Manchester, UK

Geert M. Verleden, MD, PhD, University Hospital Gathuisberg, Leuven, Belgium

Stijn Verleden, PhD, KU Leuven, Leuven, Belgium

Erik A. M. Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands

Gary A. Visner, DO, Boston Children's Hospital, Boston, MA

C Dario Vizza, MD, University of Rome, Rome, Italy

I-Wen Wang, MD, PhD, Methodist Hospital, Indianapolis, IN

Katherine Watkins, PharmD, University of California, San Francisco, San Francisco, CA

Robert G. Weintraub, FRACP, FACC, Royal Children's Hospital, Melbourne, Australia

Glen P. Westall, FRACP, PhD, Alfred Hospital, Melbourne, VIC, Australia

George M. Wieselthaler, MD, University of California at San Francisco, San Francisco, CA

Keith M. Wille, MD, MSPH, University of Alabama at Birmingham, Birmingham, AL

Jo Wray, PhD, Great Ormond Street Hospital, London, United Kingdom

Daniel Zimpfer, MD, Medical University of Vienna, Vienna, Austria
ISHLT COMMITTEES

EDUCATION COMMITTEE

Christopher H. Wigfield, MD, FRCS(C/TH), Director of Educational Affairs

Esme Dijke, PhD, Committee Vice Chair

Maryl R. Johnson, MD, Board of Directors Liaison

Andrew J. Fisher, FRCP, PhD, 2016 Scientific Program Chair

Jeffrey J. Teuteberg, MD, 2017 Scientific Program Chair

Kevin M. Chan, MD, 2016 Master Lung Academy Program Chair

Teresa De Marco, MD, FACC, 2016 Core Heart Academy Program Chair

Stavros G Drakos, MD, 2016 Master MCS Academy Program Co-Chair

Simon Maltais, MD, PhD, 2016 Master MCS Academy Program Co-Chair

Jennifer A. Beckman, MSN-FNP, RN, CHFN, 2016 Core MCS Academy Program Co-Chair

Jennifer Cowger, MD, MS, 2016 Core MCS Academy Program Co-Chair

Daniel Zimpfer, MD, 2016 Core MCS Academy Program Co-Chair

Marilia Cascalho, MD, PhD, Basic Science and Translational Research Council Workforce Leader

Bojan Vrtovec, MD, PhD, Heart Failure and Transplantation Council Workforce Leader

Me-Linh Luong, MD, Infectious Disease Council Workforce Leader

Martin Schweiger, MD, Junior Faculty and Trainee Council Workforce Leader

Salpy V. Pamboukian, MD, MSPH, Mechanical Circulatory Support Council Workforce Leader

Caron Burch, RN, MSN, FNP, CCTC, Nursing, Health Sciences and Allied Health Council Workforce Leader

Carol F. Farver, MD, Pathology Council Workforce Leader

Debra A. Dodd, MD, Pediatric Thoracic Transplantation and Heart Failure Council Workforce Leader

Kyle L. Dawson, PharmD, Pharmacy and Pharmacology Council Workforce Leader

Ioana R. Preston, MD, Pulmonary Hypertension Council Workforce Leader

Lorriana E. Leard, MD, Pulmonary Transplantation Council Workforce Leader

GRANTS AND AWARDS COMMITTEE

Daniel R. Goldstein, MD, Co-Chair

Stephan M. Ensminger, MD, DPhil, Co-Chair

Daniel Kreisel, MD, PhD, Co-Chair

Jeffrey J. Teuteberg, MD, Board of Directors Liaison

Andrew E. Gelman, PhD, Lead Reviewer

Mark S. Slaughter, MD, Lead Reviewer

Laurie D. Snyder, MD, Lead Reviewer

Dirk Van Raemdonck, MD, PhD, Lead Reviewer

Oliver Mauthner, PhD, Lead Reviewer

Josef Stehlik, MD, MPH, Lead Reviewer

INTERNATIONAL AND INTER-SOCIETY COORDINATION COMMITTEE (I2C2)

Andreas Zuckermann, MD, Co-Chair (International)

Howard J. Eisen, MD, FAHA, FACC, FACP, Co-Chair (Inter-Societal)

Hermann Reichenspurner, MD, PhD, Board of Directors Liaison

David O. Taylor, MD, Standards & Guidelines Committee Vice-Chair

Christopher H. Wigfield, MD, FRCS(C/Th), Director of Educational Affairs

Stuart C. Sweet, MD, PhD, Finance Committee Chair

Josef Stehlik, MD, MPH, Thoracic Registry Medical Director

Daniel H. Kim, MD, Heart Failure & Transplantation Council Workforce Leader

Martha L. Mooney, MD, Infectious Disease Council Workforce Leader

Reema Hasan, MD, Junior Faculty & Trainee Council Workforce Leader

Sean Pinney, MD, Mechanical Circulatory Support Council Workforce Leader

Pamela S. Combs, PhD, RN, Nursing, Health Sciences & Allied Health Council Workforce Leader

Annalisa Angelini, MD, Pathology Council Workforce Leader

James D. St. Louis, MD, Pediatric Thoracic Transplantation & Heart Failure Council Workforce Leader

Rochelle M. Gellatly, PharmD, Pharmacy & Pharmacology Council Workforce Leader

Oksana A. Shlobin, MD, Pulmonary Hypertension Council Workforce Leader

Lianne G. Singer, MD, FRCPC, Pulmonary Transplantation Council Workforce Leader

Jacob Lavee, MD, Ad Hoc Member

Lori J. West, MD, DPhil, Ad Hoc Member

Alejandro Bertolotti, MD (Argentina), Global Ambassador

Karine Nubret, MD (France), Global Ambassador

Denis Hadjiliadis, MD (Greece), Global Ambassador

Sandeep G. Attawar, MD (India, New Delhi), Global Ambassador

Yuriy Pya, MD (Kazakhstan), Global Ambassador

Ashari Yunus, MD (Malaysia), Global Ambassador

Amal A. Alotaibi, MD (Saudi Arabia), Global Ambassador

Cumara C. Sivathasan, MBBS, FRCS (Singapore), Global Ambassador

Ivan Knezevic, MD (Slovenia, Ljubljana), Global Ambassador

Martin Schweiger, MD (Switzerland), Global Ambassador

ISHLT MECHANICALLY ASSISTED CIRCULATORY SUPPORT (IMACS®) REGISTRY STEERING COMMITTEE

James K. Kirklin, MD, Chair

Craig Collum, MPH, Administrator to Dr. Kirklin

Rongbing Xie, MPH, Statistician

Ryan Cantor, MSPH, Consulting Statistician

Josef Stehlik, MD, MPH, Board of Directors Liaison

Francisco Arabia, MD, USA

Theo DeBy, MBA, Germany

Anne I. Dipchand, MD, Canada

Daniel J. Goldstein, MD, USA

Margaret M. Hannan, MD, Ireland

Ulrich P. Jorde, MD, USA

Robert L. Kormos, MD, USA

Lars H. Lund, MD, PhD, Sweden

Mandeep Mehran, MD, MBBS, FACC, FACP, USA

Chris J. Merry, MD, Australia

Takeshi Nakatani, MD, PhD, Japan

Stephan Schueler, MD, PhD, FRCS, United Kingdom

Cumara C. Sivathasan, MBBS, FRCS, Singapore

Duane Davis, MD, MBA, ISHLT President, Ex-Officio

Amanda Rowe, Executive Director, Ex-Officio

INTERNATIONAL PEDIATRIC HEART FAILURE REGISTRY (IPHFR) STEERING COMMITTEE

Anne I. Dipchand, MD, Chair

Christopher Almond, MD

Scott Auerbach, MD

Estela Azeka, MD

Leah Edwards, PhD

Robert Gajarski, MD

Richard Kirk, FRCP, FRCPCH

Yuk Law, MD

Angela Lorts, MD

Elfriede Pahl, MD

Christina VanderPluym, MD

Warren Zuckerman, MD

INTERNATIONAL THORACIC TRANSPLANT REGISTRY STEERING COMMITTEE

Josef Stehlik, MD, MPH, Medical Director & Chair

Stuart C. Sweet, MD, PhD, Board of Directors Liaison

Lars H. Lund, MD, PhD, Associate Medical Director (Adult Heart)

Roger D. Yusen, MD, MPH, Associate Medical Director (Adult Lung/Heart-Lung)

Anne I. Dipchand, MD, Associate Medical Director (Pediatric Heart)

Joseph W. Rossano, MD, Associate Medical Director (Pediatric Heart)

Samuel B. Goldfarb, MD, Associate Medical Director (Pediatric Lung/Heart-Lung)

Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Outcomes

Bruno M. Meiser, MD, OEO Relations

Leah Edwards, PhD, Biostatistics

Jaime Williamson, SAS Analyst

Anna Kucheryavaya, MD, Assistant Biostatistician

JOURNAL OF HEART AND LUNG TRANSPLANTATION (JHLT) EDITORIAL BOARD

Mandeep R. Mehra, MD, MBBS, FACC, FACP, Editor-in-Chief

Patricia A. Uber, PharmD, Executive Editor

Erica N. Bartmanis, Journal Office Coordinator

Maria Rosa Costanzo, MD, Consulting Editor (Editor Emeritus 1995-1999)

James K. Kirklin, MD, Consulting Editor (Editor Emeritus 2000-2009)

Claus B. Andersen, MD, DMSc (Denmark), Editorial Board Consultant

Annalisa Angelini, MD (Italy), Editorial Board Consultant

Robert Aris, MD (USA), Editorial Board Consultant

David A. Baran, MD (USA), Editorial Board Consultant

Christian Benden, MD (Switzerland), Editorial Board Consultant

Gerald Berry, MD (USA), Editorial Board Consultant

Marcelo Cantarovich, MD (Canada), Editorial Board Consultant

Charles E. Canter, MD (USA), Editorial Board Consultant

Pablo Castro, MD (Chile), Editorial Board Consultant

Cornelius J. Clancy, MD (USA), Editorial Board Consultant

Paul A. Corris, MB, FRCP (UK), Editorial Board Consultant

John Dark, MB, FRCS (UK), Editorial Board Consultant

Duane Davis, MD, MBA (USA), Editorial Board Consultant

Mary Amanda Dew, PhD (USA), Editorial Board Consultant

Fabienne Dobbels, MSc, PhD (Belgium), Editorial Board Consultant

Howard Eisen, MD (USA), Editorial Board Consultant

Roger W. Evans, PhD (USA), Editorial Board Consultant

Melanie Everitt, MD (USA), Editorial Board Consultant

Kimberly L. Gandy, MD, PhD (USA), Editorial Board Consultant

Edward R. Garrity, Jr, MD (USA), Editorial Board Consultant

James F. George, PhD (USA), Editorial Board Consultant

Allan R. Glanville, MBBS, MD, FRACP (Australia), Editorial Board Consultant

Marius M. Hoeper (Germany), Editorial Board Consultant

Valluvan Jeevanandam, MD (USA), Editorial Board Consultant

Maryl R. Johnson, MD (USA), Editorial Board Consultant

Shaf Keshavjee, MD, FRCSC (Canada), Editorial Board Consultant

Kiran Kaur Khush, MD (USA), Editorial Board Consultant

Richard Kirk, FRCP, FRCPCH (UK), Editorial Board Consultant

Jon Kobashigawa, MD (USA), Editorial Board Consultant

Neal K. Lakdawala, MD (USA), Editorial Board Consultant

JoAnn Lindenfeld, MD (USA), Editorial Board Consultant

Bruce McManus, MD, PhD (Canada), Editorial Board Consultant

Bruno Meiser, MD (Germany), Editorial Board Consultant

Thalachallour Mohanakumar, PhD (USA), Editorial Board Consultant

Martha Mooney, MD, FACP (USA), Editorial Board Consultant

David Morales, MD (USA), Editorial Board Consultant

Jeffery A. Morgan, MD (USA), Editorial Board Consultant

Jonah Odim, MD (USA), Editorial Board Consultant

Francis Pagani, MD, PhD (USA), Editorial Board Consultant

Jayan Parameshwar, FRCP (UK), Editorial Board Consultant

Myung H. Park, MD (USA), Editorial Board Consultant

Jeffery L. Platt, MD (USA), Editorial Board Consultant

Evgenij V. Potapov, MD, PhD (Germany), Editorial Board Consultant

Luciano Potena, MD, PhD (Italy), Editorial Board Consultant

Joseph G. Rogers, MD (USA), Editorial Board Consultant

Heather J. Ross, MD, MHSc, FRCPC (Canada), Editorial Board Consultant

Lewis Rubin, MD (USA), Editorial Board Consultant

Stephan Schueler, MD, PhD, FRCS (UK), Editorial Board Consultant

Keyur B. Shah, MD (USA), Editorial Board Consultant

Mark S. Slaughter, MD (USA), Editorial Board Consultant

Stuart C. Sweet, MD, PhD (USA), Editorial Board Consultant

David O. Taylor, MD (USA), Editorial Board Consultant

Jean Luc Vachiery, MD (Belgium), Editorial Board Consultant

Hector O. Ventura, MD (USA), Editorial Board Consultant

Geert Verleden, MD, PhD (Belgium), Editorial Board Consultant

Aaron Waxman, MD, PhD (USA), Editorial Board Consultant

Lori J. West, MD, DPhil (Canada), Editorial Board Consultant

Roger D. Yusen, MD, MPH (USA), Editorial Board Consultant

Michael Zakliczynski, MD (Poland), Editorial Board Consultant

NOMINATING COMMITTEE

Hermann Reichenspurner, MD, PhD, Chair

Duane Davis, MD, MBA, President

Allan Glanville, MBBS, MD, FRACP, Past President

David O. Taylor, MD, Past President

Lori J. West, MD, DPhil, Past President

Christian Benden, MD, Ad-Hoc Member

Jeffrey J. Teuteberg, MD, Ad-Hoc Member

REGISTRIES AND DATABASES COMMITTEE

Josef Stehlik, MD, MPH, Chair

Stuart C. Sweet, MD, PhD, Board of Directors Liaison

Leah Edwards, PhD, Biostatistician

James K. Kirklin, MD, IMACS Registry Committee Chair

Anne I. Dipchand, MD, International Pediatric Heart Failure Registry Committee Chair

Dirk Van Raemdonck, MD, PhD, International Donation after Cardiac Death (DCD) Registry Committee Chair

STANDARDS AND GUIDELINES COMMITTEE

Maryl R. Johnson, MD, Chair

David O. Taylor, MD, Vice Chair

James K. Kirklin, MD, Past Chair

Duane Davis, MD, MBA, Board of Directors Liaison

David A. Baran, MD, Heart Failure & Transplantation Council Workforce Leader

Valentina Stosor, MD, Infectious Disease Council Workforce Leader

Steven Kindel, MD, Junior Faculty & Trainee Council Workforce Leader

Jose Nativi, MD, Junior Faculty & Trainee Council Workforce Leader (non-voting until April 2016)

Jennifer Cowger, MD, MS, Mechanical Circulatory Support Council Workforce Leader

Annemarie Kaan, MCN, RN, Nursing, Health Sciences & Allied Health Council Workforce Leader

Joseph J. Maleszewski, MD, Pathology Council Workforce Leader

Robert J. Boucek, Jr, MD, Pediatric Thoracic Transplantation & Heart Failure Council Workforce Leader

Kevin Daly, MD, Pediatric Thoracic Transplantation & Heart Failure Council Workforce Leader (Non-voting mentee through 2017)

Christopher R. Ensor, PharmD, BCPS-CV, Pharmacy & Pharmacology Council Workforce Leader

Teresa De Marco, MD, FACC, Pulmonary Hypertension Council Workforce Leader

Peter Hopkins, FRACP, Pulmonary Transplantation Council Workforce Leader

LINKS NEWSLETTER EDITORIAL STAFF

Vincent Valentine, MD, Editor

Megan Barrett, Managing Editor

Paul Corris, MB, FRCP, Senior Associate Editor

John Dark, MB, FRCS, Senior Associate Editor

Roger Evans, PhD, Senior Associate Editor

Allan Glanville, MBBS, MD, FRACP, Senior Associate Editor

Maryl Johnson, MD, Senior Associate Editor

Lori West, MD, DPhil, Senior Associate Editor

Emma Birks, MD, PhD, Associate Editor Cardiology

Stavros Drakos, MD, Associate Editor Cardiology

Daniel Dilling, MD, Associate Editor Junior Faculty & Trainee

Stanley I. Martin, MD, Associate Editor Infectious Disease

Tereza Martinu, MD, Associate Editor Pulmonary Transplantation & Pulmonary Transplantation Council Communications Liaison

Javier Carbone, MD, PhD, International Correspondents Board

Takeshi Nakatani, MD, PhD, International Correspondents Board

Luciano Potena, MD, PhD, International Correspondents Board

Andreas Zuckermann, MD, International Correspondents Board

Howard J. Eisen, MD, Basic Science & Translational Research Council Communications Liaison

David P. Nelson, MD, Heart Failure & Transplantation Council Communications Liaison

Stephanie Pouch, MD, Infectious Disease Council Communications Liaison

Jorge Silva Enciso, MD, Junior Faculty & Trainee Council Communications Liaison

Evgenij Potapov, MD, PhD, Mechanical Circulatory Support Council Communications Liaison

Emily Stimpson, MSN, RN, CCTC, Nursing, Health Sciences & Allied Health Council Communications Liaison

Brandon Larsen, MD, PhD, Pathology Council Communications Liaison

Martin Schweiger, MD, Pediatric Thoracic Transplantation & Heart Failure Council Communications Liaison

Ed Horn, PharmD, BCPS, Pharmacy & Pharmacology Council Communications Liaison

Amresh Raina, MD, Pulmonary Hypertension Council Communications Liaison
ISHLT SCIENTIFIC COUNCIL OPERATING BOARDS

BASIC SCIENCE AND TRANSLATIONAL RESEARCH

Sonja Schrepfer, MD, PhD, Chair

Edward Cantu, III, MD, Vice Chair

Kimberly L. Gandy, MD, PhD, Past Chair

Carla C. Baan, PhD, Board of Directors Liaison

Doris A. Taylor, PhD, Senior Advisor

Jeffrey L. Platt, MD, Senior Advisor

Marilia Cascalho, MD, PhD, Education Committee Workforce Leader

Howard J. Eisen, MD, FAHA, FACC, FACP, ISHLT Links Newsletter Liaison

Pradeep P. A. Mammen, MD, FACC, FAHA, Heart Failure & Transplantation Council Liaison

Orla Morrissey, MD, Infectious Diseases Council Liaison

J. Michael DiMaio, MD, Mechanical Circulatory Support Council Liaison

Monica Horn, RN, CCRN, CCTC, Nursing, Health Sciences & Allied Health Council Liaison

Annalisa Angelini, MD, Pathology Council Liaison

Carol K. Conrad, MD, Pediatric Thoracic Transplantation & Heart Failure Council Liaison

Tam Khuu, PharmD, BCPS, Pharmacy & Pharmacology Council Liaison

Aaron B. Waxman, MD, PhD, Pulmonary Hypertension Council Liaison

Joshua M. Diamond, MD, Pulmonary Transplantation Council Liaison

HEART FAILURE AND TRANSPLANTATION

Monica M. Colvin, MD, Chair

Michael Pham, MD, MPH, Vice Chair

Jignesh K. Patel, MD, PhD, Vice Chair Elect

Jose Tallaj, MD, Past Chair

Maryl R. Johnson, MD, Board of Directors Liaison

Bojan Vrtovec, MD, PhD, Education Committee Workforce Leader

Daniel H. Kim, MD, I2C2 Workforce Leader

David A. Baran, MD, Standards & Guidelines Committee Workforce Leader

David P. Nelson, MD, ISHLT Links Newsletter Liaison

Pradeep P.A. Mammen, MD, FACC, FAHA, Basic Science & Translational Research Council Liaison

Hannah Copeland, MD, Junior Faculty & Trainee Council Liaison

Quincy Young, PhD, RPsych, Nursing, Health Sciences & Allied Health Council Liaison

INFECTIOUS DISEASES

Paolo A. Grossi, MD, PhD, Chair

Stanley I. Martin, MD, Vice Chair

Fernanda Silveira, MD, Past Chair

Lara Danziger-Isakov, MD, MPH, Board of Directors Liaison

Me-Linh Luong, MD, Education Committee Workforce Leader

Martha Mooney, MD, I2C2 Workforce Leader

Valentina Stosor, MD, Standards & Guidelines Committee Workforce Leader

Stephanie M. Pouch, MD, ISHLT Links Newsletter Liaison

Catherine Orla Morrissey, MD, Basic Science & Translational Research Council Liaison

Saima Aslam, MD, MS, Junior Faculty & Trainee Council Liaison

JUNIOR FACULTY AND TRAINEES

Eugene C. DePasquale, MD, Chair

Keyur B. Shah, MD, Vice Chair

Evan P. Kransdorf, MD, PhD, Vice Chair Elect

Manreet Kanwar, MD, Past Chair

Hermann Reichenspurner, MD, PhD, Board of Directors Liaison

Martin Schweiger, MD, Education Committee Workforce Leader

Reema Hasan, MD, I2C2 Workforce Leader

Steven Kindel, MD, Standards & Guidelines Committee Workforce Leader

Jose Nativi, MD, Standards & Guidelines Committee Workforce Leader

Jorge Silva Enciso, MD, ISHLT Links Newsletter Liaison

Hannah Copeland, MD, Heart Failure & Transplantation Council Liaison

Saima Aslam, MD, MS, Infectious Diseases Council Liaison

Palak Shah, MD, MS, Mechanical Circulatory Support Council Liaison

Chesney Castleberry, MD, Pediatric Thoracic Transplantation & Heart Failure Council Liaison

Marco A. Caccamo, MD, Pulmonary Hypertension Council Liaison

Robin Vos, MD, PhD, Pulmonary Transplantation Council Liaison

MECHANICAL CIRCULATORY SUPPORT

Stephan Schueler, MD, PhD, FRCS, Chair

Nir Uriel, MD, Vice Chair

Ulrich P. Jorde, MD, Past Chair

Jeffrey J. Teuteberg, MD, Board of Directors Liaison

Salpy V. Pamboukian, MD, MSPH, Education Committee Workforce Leader

Sean P. Pinney, MD, I2C2 Workforce Leader

Jennifer Cowger, MD, MS, Standards & Guidelines Committee Workforce Leader

Evgenij V. Potapov, MD, ISHLT Links Newsletter Liaison

Dawn M. Christensen, MS, CRNP, VAD Coordinator Liaison

J. Michael DiMaio, MD, Basic Science & Translational Research Council Liaison

Palak Shah, MD, MS, Junior Faculty & Trainee Council Liaison

Jennifer A. Beckman, MSN-FNP, RN, CHFN, Nursing, Health Sciences & Allied Health Council Liaison

NURSING, HEALTH SCIENCES AND ALLIED HEALTH

Samantha J. Anthony, PhD, MSW, Chair

Kevin Carney, MSN, CRNP, CCTC, Vice Chair

Pamela S. Combs, PhD, RN, Vice Chair Elect

Masina Scavuzzo, RN, Past Chair

Michael G. Petty, PhD, RN, CCNS, CNS, Board of Directors Liaison

Caron Burch, RN, MSN, FNP, CCTC, Education Committee Workforce Leader

Pamela S. Combs, PhD, RN, I2C2 Workforce Leader

Annemarie Kaan, MCN, RN, Standards & Guidelines Committee Workforce Leader

Oliver Mauthner, PhD, Grants & Award Committee Workforce Leader

Emily Stimpson, MSN, RN, CCTC, ISHLT Links Newsletter Liaison

Monica Horn, RN, CCRN, CCTC, Basic Science & Translational Research Council Liaison

Quincy Young, PhD, RPsych, Heart Failure & Transplantation Council Liaison

Jennifer A. Beckman, MSN-FNP, RN, CHFN, Mechanical Circulatory Support Council Liaison

Erin Wells, RN, Pediatric Thoracic Transplantation and Heart Failure Council Liaison

Rachel M. Crackett, MSc, Pulmonary Hypertension Council Liaison

Tara R. Fuller, Pulmonary Transplantation Council Liaison

PATHOLOGY

Martin J. Goddard, FRCS, MRCPa, Chair

Robert F. Padera, MD, PhD, Vice Chair

Carmela D. Tan, MD, Past Chair

Daniel R. Goldstein, MD, Board of Directors Liaison

Carol F. Farver, MD, Education Committee Workforce Leader

Annalisa Angelini, MD, I2C2 Workforce Leader & Basic Science & Translational Research Council Liaison

Joseph J. Maleszewski, MD, Standards & Guidelines Committee Workforce Leader

Brandon T. Larsen, MD, PhD, ISHLT Links Newsletter Liaison

PEDIATRIC THORACIC TRANSPLANTATION AND HEART FAILURE

Tajinder P. Singh, MD, MSc, Chair

Brian Feingold, MD, MS, Vice Chair

Janet N. Scheel, MD, Past Chair

Christian Benden, MD, Board of Directors Liaison

Debra A. Dodd, MD, Education Committee Workforce Leader

James D. St. Louis, MD, I2C2 Workforce Leader

Robert J. Boucek, Jr, MD, Standards & Guidelines Committee Workforce Leader

Kevin Daly, MD, Standards & Guidelines Committee Workforce Leader

Ryan Butts, MD, Pediatric Heart Failure Workforce Leader

Martin Schweiger, MD, ISHLT Links Newsletter Liaison

Carol K. Conrad, MD, Basic Science & Translational Research Council Liaison

Chesney Castleberry, MD, Junior Faculty & Trainee Council Liaison

Erin Wells, RN, Nursing, Health Sciences & Allied Health Council Liaison

PHARMACY AND PHARMACOLOGY

Walter Uber, PharmD, Chair

Adam B. Cochrane, PharmD, Vice Chair

Tamara E. Claridge, PharmD, Past Chair

Tobias Deuse, MD, PhD, Board of Directors Liaison

Kyle L. Dawson, PharmD, Education Committee Workforce Leader

Rochelle M. Gellatly, PharmD, I2C2 Workforce Leader

Christopher R. Ensor, PharmD, BCPS-CV, Standards & Guidelines Committee Workforce Leader

Edward Horn, PharmD, BCPS, ISHLT Links Newsletter Liaison

Tam Khuu, PharmD, BCPS, Basic Science & Translational Research Council Liaison

PULMONARY HYPERTENSION

Mardi Gomberg-Maitland, MD, MSc, Chair

Dana P. McGlothlin, MD, Vice Chair

Jean-Luc Vachiery, MD, Vice Chair Elect

Robert P. Frantz, MD, Past Chair

Myung H. Park, MD, Board of Directors Liaison

Ioana R. Preston, MD, Education Committee Workforce Leader

Oksana A. Shlobin, MD, I2C2 Workforce Leader

Teresa De Marco, MD, FACC, Standards & Guidelines Committee Workforce Leader

Amresh Raina, MD, ISHLT Links Newsletter Liaison

Aaron B. Waxman, MD, PhD, Basic Science & Translational Research Council Liaison

Marco A. Caccamo, MD, Junior Faculty & Trainee Council Liaison

Rachel M. Crackett, MSc, Nursing, Health Sciences & Allied Health Council Liaison

PULMONARY TRANSPLANTATION

Michael Mulligan, MD, Chair

Cynthia J. Gries, MD, MSc, Vice Chair

Ramsey R. Hachem, MD, Vice Chair Elect

David Weill, MD, Past Chair

Peter M. Hopkins, FRACP, Board of Directors Liaison & Standards & Guidelines Committee Workforce Leader

Lorriana E. Leard, MD, Education Committee Workforce Leader

Lianne G. Singer, MD, FRCPC, I2C2 Workforce Leader

Jonathan P. Singer, MD, MS, Quality of Life Workforce Leader

Tereza Martinu, MD, ISHLT Links Newsletter Liaison

Joshua Diamond, MD, Basic Science & Translational Research Council Liaison

Robin Vos, MD, PhD, Junior Faculty & Trainee Council Liaison

Tara R. Fuller, Nursing, Health Sciences & Allied Health Council Liaison
PAST PRESIDENTS

1981-1982  | Michael Hess, MD

---|---

1982-1984  | Jack Copeland, MD

1984-1986  | Terence English, FRCS

1986-1988  | Stuart Jamieson, MD

1988-1990  | Bruno Reichart, MD

1990-1991  | Margaret Billingham, MD

1991-1992  | Christian Cabrol, MD

1992-1993  | John O'Connell, MD

1993-1994  | Eric Rose, MD

1994-1995  | John Wallwork, FRCS

1995-1996  | Sharon Hunt, MD

1996-1997  | William Baumgartner, MD

1997-1998  | Leslie Miller, MD

1998-1999  | Alan Menkis, MD, FRCS(C)

1999-2000  | Robert L. Kormos, MD

2000-2001  | Anne Keogh, MBBS, MD

2001-2002  | James B. Young, MD

2002-2003  | Stephan Schueler, MD

2003-2004  | Jon Kobashigawa, MD

2004-2005  | Alec Patterson, MD

2005-2006  | Mark L. Barr, MD

2006-2007  | Robert C. Robbins, MD

2007-2008  | Paul A. Corris, MB FRCP

2008-2009  | Mandeep R. Mehra, MD

2009-2010  | James K. Kirklin, MD

2010-2011  | John Dark, MB, FRCS

2011-2012  | Lori J. West, MD, DPhil

2012-2013  | David O. Taylor, MD

2013-2014 | Allan R. Glanville, MBBS, MD, FRACP

2014-2015 | Hermann Reichenspurner, MD, PhD
PAST PROGRAM CHAIRS

1981  | San Francisco, CA  | Edward B. Stinson, MD and Michael L. Hess, MD

---|---|---

1982  | Phoenix, AZ  | Michael Kaye and Bernard Gersh

1983  | New Orleans, LA  | Stuart W. Jamieson, MD and Mark E. Thompson, MD

1984  | New York, NY  | Randall B. Griepp, MD

1985  | Anaheim, CA  | Terence A. H. English and Hillel Laks

1986  | New York, NY

|

1987  | New Orleans, LA

|

1988  | Los Angeles, CA  | John C. Baldwin, MD

1989  | Munich, Germany  | Bruno Reichart, MD

1990  | San Diego, CA  | D. Glenn Pennington, MD

1991  | Paris, France  | John B. O'Connell, MD

1992  | San Diego, CA  | Eric A. Rose, MD

1993  | Boca Raton, FL  | Maria Rosa Costanzo, MD

1994  | Venice, Italy  | John Wallwork, MBChB, FRCS

1995  | San Francisco, CA  | Leslie W. Miller, MD

1996  | New York, NY  | William A. Baumgartner, MD

1997  | London, England  | Stephan Schueler, MD

1998  | Chicago, IL  | James B. Young, MD

1999  | San Francisco, CA  | Mark L. Barr, MD

2000  | Osaka, Japan  | Jon Kobashigawa, MD

2001  | Vancouver, Canada  | David O. Taylor, MD

2002  | Washington, DC  | Robert C. Robbins, MD

2003  | Vienna, Austria  | Bruce R. Rosengard, MD

2004  | San Francisco, CA  | Mandeep R. Mehra, MD

2005  | Philadelphia, PA  | Shaf Keshavjee, MD

2006  | Madrid, Spain  | John Dark, MB, FRCS

2007  | San Francisco, CA  | Duane Davis, MD

2008  | Boston, MA  | Lori J. West, MD, DPhil

2009  | Paris, France  | Randall C. Starling, MD, MPH

2010  | Chicago, IL  | Hermann Reichenspurner, MD, PhD

2011  | San Diego, CA  | Richard N. Pierson, III, MD

2012  | Prague, Czech Republic | Stuart C. Sweet, MD, PhD

2013  | Montreal, Canada  | Allan R. Glanville, MBBS, MD, FRACP

2014 | San Diego, CA | Jason D. Christie, MD

2015 | Nice, France | Andreas Zuckermann, MD
EDITORS

JOURNAL OF HEART AND LUNG TRANSPLANTATION

1981-1985  | Jacques G. Losman, MD

---|---

1986-1994  | Michael P. Kaye, MD

1995-1999  | Maria Rosa Costanzo, MD

2000-2009  | James K. Kirklin, MD

2010-Present  | Mandeep R. Mehra, MD

LINKS NEWSLETTER

2008-2011  | David S. Feldman, MD, PhD

---|---

2011-Present  | Vincent G. Valentine, MD
REGISTRY MEDICAL DIRECTORS

INTERNATIONAL REGISTRY FOR HEART AND LUNG TRANSPLANTATION

1987-1993  | Michael P. Kaye, MD

---|---

1993-2001  | Jeffrey D. Hosenpud, MD

2001-2012  | Marshall I. Hertz, MD

2012-Present  | Josef Stehlik, MD, PhD

ISHLT REGISTRY FOR MECHANICALLY ASSISTED CIRCULATORY SUPPORT (IMACS®)

2012-Present

James K. Kirklin, MD

INTERNATIONAL PEDIATRIC HEART FAILURE REGISTRY (iPHFR)

2015-Present

Anne I. Dipchand, MD
ISHLT AWARD RECIPIENTS

OUTSTANDING ACHIEVEMENT AWARDS

ISHLT PIONEER AWARD

2000  | Christiaan Barnard, MD

---|---

|

Joel D. Cooper, MD

|

Norman E. Shumway, MD

2002  | Michael DeBakey, MD

|

Bruce A. Reitz, MD

2006  | Leonard L. Bailey, MD

2008  | Richard E. Lower, MD

2009  | Christian E. A. Cabrol, MD

2011  | Elizabeth Hammond, MD

2013  | Jack G. Copeland, MD

2015 | Bruno Reichart, MD

ISHLT LIFETIME ACHIEVEMENT AWARD

1996  | Norman Shumway, MD

---|---

1999  | Keith Reemtsma, MD

2004  | Sir Magdi Yacoub, MD

2010  | Margaret Billingham, MD

2012  | Sharon Hunt, MD

2014 | Sir Terence English, KBE, FRCS

ISHLT LIFETIME SERVICE AWARD

1996  | Michael P. Kaye, MD

---|---

1997  | Jacques G. Losman, MD

EMERITUS MEMBERSHIP

Margaret D. Allen, MD

Christian Cabrol, MD

Sir Terence English, KBE, FRCS

Albert J. Guerraty, MD

Sharon A. Hunt, MD

Carl V. Leier, MD

Bruno Reichart, MD

Marlene Rose, PhD

John Wallwork, FRCS

Elaine M. Winkel, MD

Prof. Magdi Yacoub, MD
GRANTS AND SCHOLARSHIPS

ISHLT NORMAN E. SHUMWAY CAREER DEVELOPMENT AWARD

2000  | Gordon D. Wu, MD (supported by Roche)

---|---

2002  | Anthony Azakie, MD (supported by Roche)

2004  | Allan M. Ramirez, MD (supported by Novartis Pharma)

2006  | Dennis W. Wigle, MD, PhD (supported by Astellas Pharma)

2008  | Glen Westall, MD, PhD (supported by Roche)

2010  | Sonja Schrepfer, MD, PhD (supported by Astellas)

2012  | Tereza Martinu, MD, PhD

2014 | Keshava Rajagopal, MD, PhD

2015 | Xingan Wang, MD, PhD

ISHLT NURSING RESEARCH GRANT AWARD

1997  | Eileen Collins, RN, PhD

---|---

1998  | Katherine St. Clair, RN, MSN

1999  | Jeanne Salyer, PhD

2000  | Nancy M. Albert, MSN, RN

2001  | Lynn Doering, RN, DNSc

2002  | Annette J. De Vito Dabbs, RN, MN, PhD

2003  | Diane H. Leloudis, RN, MSN

|

Janet E. Madill, PhD

2004  | Deidre E. Logan, PhD

2005  | Annemarie F. Kaan, MCN

2006  | Thierry Troosters, PhD

2007  | Mi-Kyung Song, PhD

2008  | Stacey M. Pollock-BarZiv, PhD

2009  | Jane MacIver, RN, MSc

2010  | Heike Spaderna, PhD

|

Gerdi Weidner, PhD

2011  | Christiane Kugler, PhD (supported by CSL Behring)

|

Hilde Bollen, RN

2012  | Lut Berben, PhD, RN (supported by CSL Behring)

|

Connie White-Williams, PhD, RN, FAAN

2013  | Jo Wray, PhD

|

Jane Haines, DNP, RN, CMSRN

2014 | Lea Ann Matura, PhD, RN

2015 | JiYeon Choi, PhD, RN

ISHLT RESEARCH FELLOWSHIP AWARD

1995  | Frances L. Johnson, MD (supported by Ortho-Biotech)

---|---

1996  | Tuija S. Ikonen, MD (supported by Roche)

|

Andrew F. Pierre, MD (supported by Ortho-Biotech)

1997  | Jonathan Chen, MD (supported by Roche)

|

Alyssa M. Krasinskas, MD (supported by Astellas)

|

Owen T. Lawrence, MD (supported by Ortho-Biotech)

|

Anne K. Raisanen-Sokolowski, MD (supported by Roche)

1998  | Kelly S.A. Blair, MD (supported by Roche)

|

A.M. El Gamel, MD (supported by Roche)

|

Christine L. Lau, MD (supported by Wyeth-Ayerst)

|

Scott D. Ross, MD

|

Margaret L. Schwarze, MD (supported by Novartis)

1999  | George Juang, MD (supported by Novartis)

|

Sivasai Krovvidi, PhD (supported by Roche)

|

Satoshi Saito, MD (supported by Novartis)

|

Donald Wong, PhD (supported by Roche)

2000  | Richard S. Lee, MD (supported by Novartis)

|

Christopher H. Wigfield, FRCS (supported by Roche)

2001  | Arnar Geirsson, MD (supported by Roche)

|

Matteo Vatta, PhD (supported by Roche)

2002  | Ruediger Hoebelt, MD (supported by Roche)

2003  | Ewout J. van den Bos, MD (supported by Astellas)

|

Felix Fernandez, MD (supported by Roche)

2004  | Christian A. Gleissner, MD (supported by Astellas)

|

Tsuyoshi Shoji, MD, PhD (supported by Actelion)

|

Kendra N. Taylor, PhD (supported by Roche)

|

Monica Zwierzchonieuska, MD (supported by XDx)

2005  | Ryan C. Fields, MD (supported by Chiron)

|

Arne Neyrinck, MD (supported by Astellas)

|

Ahmad Saad, MD (supported by Roche)

2006  | Rachel L. Anderson, MBBS (supported by Roche)

|

Zhaohui Li, PhD (supported by Transmedics)

|

Heather E. Merry, MD (supported by Encysive)

|

Edward N. Seung, PhD (supported by XDx)

|

Matthew J. Weiss, MD (supported by Novartis)

2007  | J. Raymond Fitzpatrick, III, MD (supported by Encysive)

|

Howard J. Huang, MD (supported by Transmedics)

|

Mylvganam Jeyakanthan, MD (supported by XDx)

|

Timothy M. Millington, MD (supported by Novartis)

|

Satish N. Nadig, MD (supported by Roche)

|

Takeshi Oyaizu, MD, PhD (supported by Actelion)

|

Sonja Schrepfer, MD (supported by Astellas)

2008 | Jonathan Choy, PhD (supported by XDx)

|

Satoshi Itoh, MD (supported by Transmedics)

|

Tereza Martinu, MD (supported by Novartis)

|

Deepti Saini, PhD (supported by Gilead)

|

Atsushi Shiozaki, MD, PhD (supported by Astellas)

|

Seiichiro Sugimoto, MD, PhD (supported by Roche)

2009  | Hua Shen, MD, PhD (supported by Astellas)

|

Tobias Deuse, MD, PhD (supported by Novartis)

|

Masahiro Miyajima, MD, PhD (supported by XDx)

|

Shin Hirayama, MD, PhD (supported by Gilead)

2010  | Esme Dijke, PhD (supported by Novartis)

|

Smita Sihag, MD (supported by Genentech)

|

Sumiharu Yamamoto, MD (supported by Gilead)

|

Khurram Shahzad, MD (supported by United Therapeutics)

|

Nina Pilat, MSc, PhD (supported by XDx)

2011  | Alejandro Bribriesco, MD (supported by Astellas)

|

Alexey Dashkevich, MD (supported by XDx)

|

Patricia E. de Almeida, DVM, MS, PhD

|

Tiago Machuca, MD, PhD

2012  | Stephen C. Juvet, MD, FRCPC

|

Maria Lucia L. Madariga, MD

|

Jessica H. Spahn, PhD

|

Konstantinos Malliaras, PhD

2013  | Nikolaos Diakos, MD

|

Raymond Givens, MD, PhD

|

Pablo Sanchez, MD, PhD

2014 | Charles Evans, MD

|

Christine Lin, MD

|

Stijn Verleden, PhD

2015 | Jonathan Merola, MD

ISHLT TRANSPLANT REGISTRY EARLY CAREER AWARD

(formerly Junior Faculty Award)

2007  | Beth D. Kaufman, MD

---|---

2008  | Cynthia Gries, MD, MSc

|

Scott Halpern, MD, PhD

|

Josef Stehlik, MD, MPH

2010  | Jennifer Conway, MD, FRCPC

|

Kiran K. Khush, MD, MAS

2011  | Jose Nativi, MD

2012  | Erin M. Lowery, MD

|

Omar E. Wever-Pinzon, MD

2013  | Chesney Castleberry, MD

|

Eugene DePasquale, MD

|

Aaron Healy, MD

2014 | Marian Urban, MD

|

Miranda Paraskeva, MBBS

|

Hrishikesh Kulkarni, MD

|

Agnieszka Ciarka, MD, PhD

2015 | Livia Goldraich, MD, MSc

|

Deipanjan Nandi, MD, MSc

|

Evan Kransdorf, MD, PhD

|

Manreet Kanwar, MD

|

Natasha Loghmanpour, PhD

|

Alexander Bernhardt, MD

|

Jong-Chan Youn, MD, PhD
ISHLT/BAYER PULMONARY HYPERTENSION RESEARCH GRANT AWARD

2014 | Benjamin Freed, MD

---|---

ISHLT/HEARTWARE AWARD FOR TRANSLATIONAL RESEARCH IN MCS

2014 | Leigh Reardon, MD

---|---

2015 | Alexander Bernhard, MD

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL FELLOWSHIP GRANT

(supported by Thoratec)

2009 | Sasa D. Borovic, MD

---|---

2010 | Iki Adachi, MD

2012 | Antigone Koliopoulou, MD

2014 | Masahiro Ono, MD, PhD

ISHLT INTERNATIONAL TRAVELING SCHOLARSHIP AWARD

2011  | Stephanie T. Yerkovich, PhD

---|---

|

Sarah E. Gilpin, PhD

|

Kimberly M. Derkatz, BNSc

|

Jennifer Conway, MD, FRCPC

2012  | Ramin E. Beygui, MD

|

Kevin C. Carney, MSN

|

Alexandre Souza Cauduro, MD

|

Esme Dijke, PhD

|

Ana Belen Mendez, MD

|

David Schibilsky, MD

|

Aleem Siddique, MBBS

|

Amparo Solé, MD, PhD

|

Manon Huibers, MSc

|

Daniel R. Goldstein, MD

|

Laveena Munshi, MD, FRCPC

|

Marco Masetti, MD

|

Rochelle M. Gellatly, PScPharm, ACPR, PharmD

2013  | Alison Gareau, MSc

|

Erin Schumer, MD, MS

|

Bojan Vrtovec, MD, PhD

|

Marsha Renikunta, PhD (student)

|

Katie Morley, BA(Hons), RCN, MA

|

Ali Yeginsu, MD

|

Fabrizio Gandolfo, MD

|

Marian Urban, MD

|

Alexander Bernhardt, MD

|

Victor Rossel, MD

|

Mohammed Quader, MD

2014 | Marny Fedrigo, MD, PhD

|

Zachary Kon, MD

|

Evgenios Neofytou, MD

|

Dong, Wang, MD

|

Stephen Clark, DM, FRCS

|

Caroline Patterson, BMBS, BMedSci, MRCP

|

Tahaunty Pena, MD

2015 | Oisin O'Connell, MD, MRCPI

|

Lucas Van Aelst, MD, PhD

|

Arezu Aliabadi, MD

|

Timothy Sladden, MBBS, BVSc

|

Bao Tran, MD

|

L G Saptharishi, MD, DM

|

Allison Carroll, MD

|

Akshay Pendyal, MD

|

Stefania Paolillo, MD, PhD

|

Soumitra Sinha Roy, MD

ISHLT LEACH-ABRAMSON-IMHOFF LINKS TRAVEL AWARDS

2012  | Tereza Martinu, MD, Writer of the Year

---|---

|

Stanley I. Martin, MD, First Runner-Up

|

Luciano Potena, MD, PhD, First Runner-Up

|

Nancy P. Blumenthal, CRNP, Honorable Mention

|

Bronwyn J. Levvey, RN, Honorable Mention

|

Javier Carbone, MD, PhD, Honorable Mention

|

Stavros G. Drakos, MD, Honorable Mention

|

Daniel F. Dilling, MD, Honorable Mention

2013  | Michele Estabrook, MD, Writer of the Year

|

Melanie Everitt, MD, First Runner-Up

|

Christina Migliore, MD, First Runner-Up

|

Veronica Franco, MD, Honorable Mention

|

Manreet Kanwar, MD, Honorable Mention

|

Luciano Potena, MD, PhD, Honorable Mention

|

Macé Schuurmans, MD, Honorable Mention

|

Jeffrey J. Teuteberg, MD, Honorable Mention

2014 | Christopher R. Ensor, PharmD, BCPS-CV, Writer of the Year

|

Amanda Ingemi, PharmD, First Runner-Up

|

Simon Urschel, MD, Honorable Mention

2015 | Pamela S. Combs, PhD, RN, Writer of the Year

|

Manreet Kanwar, MD, First Runner-Up

|

Oveimar De la Cruz, MD, Honorable Mention

|

Heather T. Henderson, MD, Honorable Mention

|

Simon Urschel, MD, Honorable Mention

|

Erin Wells, RN, BSN, CPN, Honorable Mention
ABSTRACT AWARDS

PHILIP K. CAVES AWARD

1983  | Robbin G. Cohen, MD

---|---

1984  | Hermann Reichenspurner, MD

1985  | Michael A. Breda, MD

1986  | Stuart J. Knechtle, MD

1987  | Wim Van Der Bij, MD

1988  | Charles D. Fraser, Jr., MD

1989  | A.M. Wood, MD

1990  | Andres J. Duncan, MD

1991  | A. Jiminez, MD

1992  | David P. Kapelanski, MD

1993  | David Marshman, MD

1994  | Jobst Winter, MD

|

Alain Chapelier, MD

1995  | Elizabeth A. Davis, MD

1996  | Moninder S. Bhabra, MD

1997  | Simon D. Eiref, MD

1998  | Carla C. Baan, MD

1999  | Joerg Koglin, MD

2000  | Michael P. Fischbein, MD

2001  | Alexander S. Krupnick, MD

2002  | Peter Blaha, MD

2003  | Sigrid Sandner, MD

2004  | M.D. Peterson, MD

2005  | Sigrid Sandner, MD

|

Frank D'Ovidio, MD

2006  | Gregor Warnecke, MD

2007  | Heather E. Merry, MD

2008  | Satish N. Nadig, MD

2009  | Howard Huang, MD

2010  | Tobias Deuse, MD, PhD

2011  | Ankit Bharat, MD

2012  | Simo Syrjälä, MD

2013  | Alexey Dashkevich, MD

2014 | Jessica Spahn

2015 | Simon Pecha, MD

NURSING, HEALTH SCIENCES & ALLIED HEALTH EXCELLENCE IN RESEARCH AWARD

2005  | Mary Amanda Dew, PhD

---|---

2006  | Kathleen L. Grady, PhD, RN

2007  | Christiane Kugler, PhD

2008  | Annette DeVito Dabbs, RN, PhD

2009  | Connie White-Williams, MSN

2010  | Bronwyn Levvey, RN

2011  | Samantha J. Anthony, PhD, MSW

2012  | Kate Hayes, MPhysio (Cardio)

2013  | Jane Haines, DNP, RN, CMSRN

2014 | Louise Fuller, PT

2015 | Catherine Murks, PhD, APN

JFTC CLINICAL CASE DILEMMAS IN THORACIC TRANSPLANTATION AWARD

2011  | Michelle M. Kittleson, MD, PhD

---|---

2012  | Erin Albers, MD

2013  | Mustafa Ahmed, MD

2014 | Lauren Sacha

2015 | Ankit Bharat, MD

**ISHLT BRANISLAV RADOVANCEVIC MEMORIAL BEST MCS ABSTRACT AWARD** (supported by Thoratec)

2009  | Nishant Shah, MD

---|---

2010  | Jose N. Nativi, MD

2012  | Arun Raghav Mahankali Sridhar, MD, MPH

2013  | Claire Watkins, MD

2014 | Jason O. Robertson, MD
ACCREDITATION INFORMATION

Disclosure

Current guidelines state that participants in continuing medical and allied health profession education activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty, and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

Objectives

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their needs.

Goals

The educational goals of this activity are: to enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.

Target Audience

The audience for this program includes physicians, surgeons, scientists, pharmacists, nurses, transplant coordinators and other allied health and social science professionals engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end stage heart or lung disease.

Learning Objectives

1. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding the latest information and approaches regarding transplant research, surgical techniques, medical therapies, donor management, and patient management for the treatment of patients suffering from end stage heart and lung disease

2. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding the state-of-the-art treatment approaches, risk factors, risk management approaches, patient selection criteria, disease prevention strategies, outcome implications, and psychosocial management strategies for patients with end stage heart and lung failure.

3. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding emerging technologies, medical advances, and the clinical applications of basic science models of end stage heart and lung disease management and prevention.

ACCREDITATION INFORMATION (Continued)

ACCME Accreditation Statement

The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians and allied health professionals.

CME Credit Designation Statement

ISHLT designates this live activity for a maximum of 30 _AMA PRA Category 1 Credits_ ™. Participants should claim only the credit commensurate with the extent of their participation in the activity.

ACPE Accreditation

 Pharmacists

Amedco is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Successful completion of this program qualifies for up to 13.0 contact hours. Full attendance is required. No partial contact hours will be awarded for partial attendance. Unique Activity Numbers: 0453-9999-16-029-L04-P through 0453-9999-16-047-L04-P

**ABTC Accreditation**  
The ABTC Board of Governors has granted a total of 30 Category 1 Continuing Education Points for Transplant Certification (CEPTC) to the International Society for Heart & Lung Transplantation's _ISHLT 36th Annual Meeting and Scientific Sessions_.

ANCC Accreditation

ANCC credits for this activity have been applied for.
The International Society for Heart and Lung Transplantation extends its heartfelt gratitude to the following companies for their unrestricted educational grants in support of the 36th Annual Meeting and Scientific Sessions:

Actelion Pharmaceuticals

United Therapeutics

Gilead Sciences

Bayer Healthcare

*****************************************************

The International Society for Heart and Lung Transplantation is grateful for the support of the following companies for the Society and its endeavors in 2016:

Tier 1

Actelion Pharmaceuticals

Tier 2

Bayer Healthcare  
Gilead Sciences  
HeartWare  
St. Jude  
United Therapeutics

Tier 3

CareDx

Lung Bioengineering

Transmedics
HIGHLIGHTS OF THE MEETING

Basic Science and Translational Research

The 2016 ISHLT Annual Meeting will include a range of sessions covering basic science and translational research topics in heart and lung failure and transplantation. These carefully crafted symposia will feature internationally recognized leaders in the field. The aim of each session will be to bring together in one room basic scientists as well as clinicians and clinical researchers who wish to explore the given topics. The pre-meeting symposium entitled, _Big Data to Answer Big Questions: Biobanking to "Omics" to Personalized Medicine in Thoracic Organ Transplantation_ , will include talks given by experts in biobanking, omics data analysis, big data modeling, and multi-center study design. Speakers will also explore the potential clinical applications of the resulting datasets. _Back to the Future: Cell Therapy for Thoracic Organ Failure and Transplant?_ will be an exciting state-of-the-art set of lectures by world-renowned pioneers in tissue engineering, cell therapy, and tolerance induction presented in the context of heart and lung failure and transplantation. A sunrise symposium will offer a more basic coverage of transplant immunology and biology: _Back to Basics: What the Thoracic Transplant Clinician Needs to Know About Immunobiology_. This will be an opportunity for all ISHLT members to brush up on their basic science knowledge and also review the clinical relevance of underlying mechanisms of allograft rejection and injury. In addition to these three core symposia, other talks focused on basic and translational research have been incorporated into other sessions in order to create a well-rounded high-quality program for the ISHLT conference attendees.

Heart Failure and Transplantation

The ISHLT 2016 in Washington DC will bring dynamic and thought provoking symposia in heart failure and transplantation for clinicians, surgeons and allied health professionals. _Timing Support in Cardiogenic Shock: When to Move Forward_ will confront us with the difficult question of when is the best time to intervene in an emergent situation? Then we will challenge our current paradigm with _Rethinking Valvular Heart Disease in Heart Failure_ from percutaneous intervention to surgical interventions. We will also explore how to select the best donor and optimize the current donor shortage with the session, _Donor Heart Selection: Strategies to Improve Organ Utilization_. A comprehensive discussion on how to diagnose and manage right heart failure will be included in _When Right Is Wrong: Management of the Dying Right Ventricle_. We will look at post-transplant surgical challenges with a session on _Making It Work: Heart Transplant Challenges from the Surgeon's Perspective_ that will discuss topics such as technical considerations in adult congenital heart transplantation, surgical management of primary graft dysfunction and surgical options for late graft failure. We will tackle post heart transplant immunology with a _Focused Update on AMR in Cardiac Transplantation: Immunologic Diagnostics and the Treatment of Refractory AMR_ from the most update diagnoses to the best treatments. We will continue with immunology to immunosuppression with _Controversies in Heart Transplantation: Past, Present and Future_.

Infectious Diseases

ISHLT 2016 will offer wide-ranging insight into topics of vital importance to infection in thoracic organ transplantation and MCSD, with symposia of interest both to the diehard Transplant Infectious Diseases provider as well as to other clinicians and scientists with interest in Infectious Diseases. We lead off with _The Future is Here: Emerging Issues in Infectious Disease_ , a whirlwind tour of challenging topics including Mycobacterium abscessus, RSV, Scedosporium and other emerging fungi, Clostridium difficile, and those troublesome resistant Gram-negative organisms. Next up is a comprehensive look at CMV in _It's All in the Translation: CMV from Bedside to Bench and Back_ , which will examine the impact of CMV on the heart and lung allograft, the anti-CMV immune response, and review our current antiviral armamentarium and preview new tools on the horizon. We end the day with a not-to-be-missed session entitled _Hanging in the Balance: Minimizing Risk and Maximizing Benefit with Donor Derived Infections_ with an update on UNOS data on donor derived infections and a review of the European perspective, a look at the donor with possible encephalitis, nucleic acid based testing for HIV, hepatitis C, and hepatitis B, and new opportunities ahead for HIV-positive organs. Grab some coffee for our Sunrise Symposium on _The Fly in the Ointment: Nosocomial Infections_ , a novel look at antimicrobial stewardship, infection prevention, and outbreaks in the transplant center, with a special look at patients with open chest or ECMO. But that's not all—our colleagues in MCS are presenting _Achilles Heel: Infectious Complications in MCS_ , our friends in Pharmacy will review the lifecycle of Hepatitis C patient with heart failure, specialists from the Pediatrics community will discuss _Child's Play: Infectious Risk After Transplant During Everyday Life_ , and from Lung Transplantation, a session on infection in the elderly lung transplant recipient.

Lung Failure and Transplantation

This year there will be numerous stimulating sessions with 4 Pre-meeting Symposia and 2 Sunrise Symposia dedicated to lung transplantation. _Current Innovations and Future of EVLP_ will explore the future of EVLP with respect to lung repair using cell or gene based therapies and drug or molecular interventions. Advanced techniques of ex-vivo perfusion using portable systems and dual artery cannulation techniques will be discussed. EVLP as a platform to reduce infection and possible allo responsiveness will be summarized. _Multiorgan Transplantation for Lung Recipients: When is Two Better than One?_ will summarize key recommendations pertaining to heart-lung, lung-liver and lung-kidney transplantation. Furthermore, the ethics and equity debate of multi organ transplantation shall be outlined as well as issues of possible immunological allograft protection. _The Biology of Aging and Lung Transplantation_ will cover issues of immunosenescence, impact of telomerase mutations, measures of frailty and other challenges in the elderly recipient including infection and immunosuppressive regimens. Our persistent nemesis CLAD will be reviewed in _Endotypes of CLAD and Novel Treatment Strategies_. The symposium will include a presentation on the historical basis for CLAD phenotypes and review of current clinical, radiological and pathological criteria. Contemporary medical and surgical treatment practices for patients as directed by phenotype will be outlined, along with future perspectives with regards to CLAD prevention. _Thoracic Organ Transplantation and Malignancy_ , will review key issues including relevance to lung transplant candidate selection and overview of current cancer screening guidelines. _Lung Transplant Benefit is More Than Just Survival_ will question the outcome of survival as the only relevant measure of success with lung transplantation. The session will assess contemporary assessment tools of health related quality of life, functioning and disability and their relevance to measuring important patient outcomes, as well as the impact of neuro cognitive changes post lung transplant.

Mechanical Circulatory Support

We are looking forward to the 2016 Annual Meeting and expect the MCS content will stimulate the broad interests of the MCS community and actively represent the variety of subspecialties which contribute to the advancement of the field. The challenges of managing anticoagulation and antiplatelet therapy, the use of platelet functional assays, and the approach to high-risk patients will be addressed in _Anticoagulation and MCS: Can We Do Better?_ The ISHLT is very pleased to introduce the first joint ISHLT/ICCAC symposium, _Joined at the Heart - International Perspectives on MCS Issues_ , which has leaders from both societies exploring the factors which allow multidisciplinary teams to achieve excellent results across a wide array of practice environments. _Achilles Heel: Infectious Complications in MCS_ will have representatives from both MCS and infectious disease review the diagnosis, therapy, prevention and long-term consequences of infections in patients with MCS. We will tackle several controversial issues such as transplantation versus DT in the elderly, mechanical support in less sick patients, and the use of minimally invasive implant techniques in _Great Debates in MCS_. The debates will be case-based and will provide both an informative and entertaining review of these contentious topics. The MCS community recognizes the importance of patient selection and management on outcomes and the incidence of adverse events, but device engineering also plays a critical role. In _MCS Challenges and Engineering Solutions_ , we will review the role of shear stress, the impact of pump miniaturization, the use of physiologic controls and available engineering options to improve outcomes and reduce adverse events. These engineering principles will be presented in the context of their clinical applications and in a manner that is accessible to the practicing MCS care provider. _Clear as Mud: Assessing the Right Ventricle_ will address the always challenging issues of preoperative assessment of RV function, intraoperative treatment strategies and the approach to treatment of chronic RV failure.

Nursing, Health Science, Allied Health

This year, we are showcasing how art and evidence can inspire innovation in several areas of clinical care. An attractive program has been created through the collaboration of several different specialties including three diverse symposia in the areas of genomics, selection of marginal donors and ECMO. _Genomics: What do I Have to Know and How Will It Affect My Practice?_ will provide all attendees with the basics of this new field and provides examples of how genomics will impact clinical transplant care in the future. The ethical reflection on this field and a discussion of nursing competencies will complete this session. In _Between a Rock and a Hard Place: Debating Treatment Decisions for Marginal Psychosocial Candidates_ , treatment decisions for marginal transplant and mechanical support candidates will be tackled in three debates developed around difficult issues that clinicians face every day. Should we, or should we not list this patient? What is the evidence base? Which ethical reflections influence our decisions? An interactive response system and a panel discussion will maximize the involvement of the audience. _Ambulatory ECMO in Adults: We Like to Move It, Move It_ addresses the issue at the forefront of critical care practice: ambulation in adult ECMO patients. What are the risks and benefits? What is required to implement such a practice in your program? Which team members should be involved? In addition, there will be nursing, health sciences, and allied health content being presented in other symposia. This "cross-pollination" will serve to make this year's ISHLT conference richer and more relevant.

Pathology

This year's pathology satellite symposium takes aim at "chronic rejection" in the heart. Controversy and confusion surrounding this topic stem from varying definitions of what "chronic" means as well as whether the observed changes in the allograft are truly rejection. Speakers in this session will address the myocardial alterations (beyond CAV) seen after years of repetitive rejection episodes, novel mechanisms of CAV development, the role of complement and other mechanisms in potentiating late graft damage, a morphologic comparison to analogues of chronic rejection in other organs, and a review of animal models of late graft loss.

Pediatrics

We all recognize that there are major variations in pediatric heart failure and transplant management, and so this year's pediatric symposia will spotlight major controversies in these fields. _VADs in Patients with Congenital Heart Disease_ will focus on the big questions in this difficult group of patients, both pediatric and adult. _Child's Play: Infectious Risk After Transplant During Everyday Life_ will examine the prevailing dogma after heart and lung transplantation in children, addressing whether isolation is necessary, which pets are allowed, what limits can be placed on travel, which water and food sources are safe, and current vaccination practices for endemic diseases. _Controversies in Pediatric Heart Failure_ will focus squarely on the heart failure community, engaging the audience with discussions of novel pharmaceutical agents in pediatric heart failure, and how to prevent sudden death in the pediatric heart failure patient. We will continue the important discussion from last year's meeting on making palliative care part of the plan for every patient, and conclude with a presentation on the new ISHLT pediatric heart failure registry – will it result in useable data, or just make more work?

Pharmacy and Pharmacology

The 2016 ISHLT Annual Meeting will showcase clinical care and research initiatives through a diverse program of informative sessions. Two Pharmacy and Pharmacology sessions, which focus on drug therapy, lend applicability across all disciplines represented by the ISHLT membership. Join us in the return of the ever-popular lifecycle journey series, with a look at a _Lifecycle Journey of Hepatitis C Heart Failure Patient in 2016_. An enduring case will be presented, interspersed with a best practice based discussion at pre-defined, key "journey intervals". In this session, we focus on how the new hepatitis treatments have altered management at all stages of this lifecycle; pay particular consideration to the controversial areas of listing these patients for transplant; evaluate the tricky issue of immunosuppression; malignancy post-transplantation; and finally when to consider palliation? This is certain to be a lively session giving challenging insights into this developing area of practice, definitely not to be missed! The sunrise symposium on Saturday, _Precision Medicine in Transplantation: Drug Levels and Beyond_ , involve a bench-to-bedside exploration of pharmacogenetics and the impact on drug metabolism and predicting adverse effects. We then approach the problem from the other angle as we consider therapeutic gene modulation, learning from the field of cystic fibrosis.

Pulmonary Hypertension

Pulmonary hypertension is truly at the forefront of the 2016 ISHLT Scientific Sessions with a total of seven provocative symposia! Areas covered will include pulmonary hypertension related to chronic thromboembolic disease, parenchymal lung disease, left heart disease and congenital heart disease. Sessions will also detail important issues in lung transplantation related to pulmonary hypertension, the use of combination therapy in pulmonary artery hypertension, and a translational symposium on emerging biology of pulmonary hypertension and the right heart. The two joint sessions with the European Society of Cardiology (ESC) and the Pulmonary Vascular Research Institute (PVRI) in particular are not to be missed. 
HOTEL FLOOR PLANS – EXHIBITION LEVEL

HOTEL FLOOR PLANS – LOBBY LEVEL

HOTEL FLOOR PLANS – MEZZANINE LEVEL

ACRONYMS

To help you navigate your way through the meeting content and find those sessions most likely to be of interest to you, we have coded each session according to the primary professional audience it was designed for. These codes are explained as follows:

BSI | BASIC SCIENCE

---|---

CASE | JUNIOR FACULTY CLINICAL CASE REPORTS

EEP | ECONOMICS, ETHICS, PUBLIC POLICY

HF | HEART FAILURE –ADULT

HTX | HEART TRANSPLANTATION - ADULT

ID | INFECTIOUS DISEASES

LBCS | LATE BREAKING CLINICAL SCIENCE

LF | LUNG FAILURE – ADULT

LTX | LUNG TRANSPLANTATION – ADULT

MCS | MECHANICAL CIRCULATORY SUPPORT – ADULT

NHSAH | NURSING, HEALTH SCIENCES, ALLIED HEALTH

PATH | PATHOLOGY

PEDS | PEDIATRICS

PHARM | PHARMACY AND PHARMACOLOGY

PH | PULMONARY HYPERTENSION
DAILY SCHEDULE

All meetings and activities will take place at the Marriott Wardman Park Hotel in Washington, DC, USA, unless otherwise specified. All papers will be presented in English. Please check the ISHLT web site (www.ishlt.org) for updates. This Final Program reflects the latest session schedule and room assignments.

#

# Monday, April 25, 2016

8:00 AM - 11:00 PM

Exhibit Hall Build (Exhibit Hall A)

9:00 AM - 5:00 PM

ISHLT Strategic Planning Meeting (Delaware Suite)

6:00 PM - 9:00 PM

Academy Registration Open (Thurgood Marshall Foyer)

Speaker Ready Room Open (Madison)

#

# Tuesday, April 26, 2016

6:00 AM - 7:00 PM

Speaker Ready Room Open (Madison)

7:00 AM - 3:00 PM

Academy Registration Open (Thurgood Marshall Foyer)

8:00 AM - 2:00 PM

ISHLT Board of Directors Meeting (Harding)

8:00 AM - 6:00 PM

**ISHLT Academy: Core Competencies in Heart Failure and Cardiac Transplant Medicine** (Thurgood Marshall North)

**ISHLT Academy: Core Competencies in Mechanical Circulatory Support** (Thurgood Marshall East)

**ISHLT Academy: Master Class in Pulmonary Transplantation** (Thurgood Marshall South & West)

9:00 AM – 11:00 AM

Airway Complications after Lung Transplantation Writing Committee (Balcony B)

12:00 PM – 1:00 PM

I2C2 Asia Meeting (Balcony A)

2:00 PM - 6:00 PM

ISHLT Board/Committee/Council Leadership Orientation (Hoover)

2:00 PM - 7:00 PM

Registration Open (Convention Registration)

5:00 PM - 7:00 PM

Press Office Open (Park Tower 8219)

6:00 PM - 8:00 PM

I2C2 Committee Meeting (Balcony A)

Education Committee Meeting (Balcony B)

Grants & Awards Committee Meeting (Park Tower 8212)

International Transplant Registry Committee Meeting (Park Tower 8217)

Standards and Guidelines Committee Meeting (Park Tower 8216)

#

# Wednesday, April 27, 2016

6:00 AM - 7:00 PM

Speaker Ready Room Open (Madison)

7:00 AM - 7:00 PM

Registration Open (Convention Registration)

7:00 AM - 10:00 AM

Exhibitor Set-Up (Exhibit Hall A)

Poster Session 1 Mount (Exhibit Hall B & C)

8:00 AM - 10:00 AM

**Pre-Meeting Symposium 1: Anticoagulation and MCS: Can We Do Better?** (Salons 2-3) **** (MCS, HF, PHARM)

**Pre-Meeting Symposium 2: Controversies in Heart Transplantation: Past, Present and Future** (Thurgood Marshall) **** (HTX, HF, ID, NHSAH, PATH, PEDS, PHARM)

**Pre-Meeting Symposium 3: Current Innovations and Future of EVLP** (Salon 1) **** (LTX, LF, MCS)

**Pre-Meeting Symposium 4: Under Pressure: Pulmonary Hypertension in Parenchymal Lung Disease** (Maryland Suite) **** (PH, HF, LF, LTX)

**Pre-Meeting Symposium 5: Making It Work: Heart Transplant Challenges from the Surgeon's Perspective** (Virginia Suite) **** (HTX, HF, MCS, NHSAH, PEDS)

**Pre-Meeting Symposium 6: Back to the Future: Cell Therapy for Thoracic Organ Failure and Transplant?** (Delaware Suite) **** (ALL)

**Pre-Meeting Symposium 7: The Future is Here: Emerging Issues in Infectious Disease** (Washington Ballroom 2) **** (ID, HTX, LF, LTX, MCS, NHSAH, PEDS, PHARM)

9:00 AM - 7:00 PM

Press Office Open (Park Tower 8219)

9:00 AM – 10:30 AM

Smithsonian Curators Meeting (Cap BoD)

10:00 AM - 7:00 PM

Exhibit Hall Open (Exhibit Hall A)

Poster Hall Open (Exhibit Hall B & C)

10:00 AM - 10:15 AM

Coffee Break (Exhibit Hall A)

View Posters (Exhibit Hall B & C)

10:15 AM - 12:15 PM

**Pre-Meeting Symposium 8: Joint ISHLT-ICCAC MCS Symposium: Joined at the Heart - International Perspectives on MCS Issues** (Salons 2-3) **** (MCS, HF, HTX, NHSAH)

**Pre-Meeting Symposium 9: Donor Heart Selection: Strategies to Improve Organ Utilization** (Thurgood Marshall) **** (HTX, LTX, MCS, NHSAH, PEDS)

**Pre-Meeting Symposium 10: Joint ISHLT/ESC Symposium: Left, Right, and Together: The Facts and Future of PH in Left Heart Disease (in collaboration with the ISHLT Scientific Council on PH and the ESC RV/Pulmonary Circulation Working Group)** (Salon 1) **** (PH, ALL)

**Pre-Meeting Symposium 11: Multiorgan Transplantation for Lung Recipients: When is Two Better than One?** (Maryland Suite) **** (LTX, HTX)

**Pre-Meeting Symposium 12: It's All in the Translation: CMV from Bedside to Bench and Back Again** (Virginia Suite) **** (ALL)

**Pre-Meeting Symposium 13: Child's Play: Infectious Risk After Transplant During Everyday Life** (Delaware Suite) **** (PEDS, HTX, ID, LTX, NHSAH, PHARM)

**Pre-Meeting Symposium 14: Genomics: What Do I Have to Know and How Will It Affect My Practice?** (Washington Ballroom 2) **** (NHSAH, BSI, HF, HTX, LTX)

12:15 PM - 1:45 PM

Lunch Break

Junior Faculty and Mentor Lunch Meeting (Wilson)

IMACS Registry Committee Meeting (Taft)

**Basic Science and Translational Research Scientific Council Meeting** (Hoover)

**Nursing, Health Sciences & Allied Health Scientific Council Meeting** (Washington Ballroom 2)

**Pharmacy and Pharmacology Scientific Council Meeting** (Harding)

DCD Registry Committee Meeting (Taylor)

1:45 PM - 3:45 PM

**Pre-Meeting Symposium 15: Achilles Heel: Infectious Complications in MCS** (Salons 2-3) **** (MCS, HTX, ID, NHSAH, PHARM)

**Pre-Meeting Symposium 16: When Right is Wrong! Management of the Dying Right Ventricle** (Thurgood Marshall) **** (ALL)

**Pre-Meeting Symposium 17: The Biology of Aging and Lung Transplantation** (Salon 1) **** (LTX, ID, LF, MCS, NHSAH, PH)

**Pre-Meeting Symposium 18: Proximal, Distal, Balloons, and Scalpels: Current Issues in CTEPH** (Maryland Suite) **** (PH, HF, LF, PEDS)

**Pre-Meeting Symposium 19: Between a Rock and a Hard Place: Debating Treatment Decisions for Marginal Psychosocial Candidates** (Virginia Suite) **** (NHSAH, HF, HTX, LTX, MCS)

**Pre-Meeting Symposium 20: Big Data to Answer Big Questions: Biobanking to "Omics" to Personalized Medicine in Thoracic Organ Transplantation** (Delaware Suite) **** (ALL)

**Pre-Meeting Symposium 21: Unraveling "Chronic Rejection" in the Heart** (Washington Ballroom 2) **** (PATH, BSI, HF, HTX, LTX, PEDS)

3:45 PM - 4:00 PM

Coffee Break (Exhibit Hall A)

View Posters (Exhibit Hall B & C)

4:00 PM - 6:00 PM

**Pre-Meeting Symposium 22: Great Debates in MCS** (Salons 2-3) **** (MCS, HF, HTX, NHSAH)

**Pre-Meeting Symposium 23: A 2016 Focused Update on AMR in Cardiac Transplantation: Immunologic Diagnostics and the Treatment of Refractory AMR** (Thurgood Marshall) **** (HTX, BSI, HF, NHSAH, PATH, PEDS, PHARM)

**Pre-Meeting Symposium 24: Endotypes of CLAD and Novel Treatment Strategies** (Salon 1) **** (LTX, BSI, PATH, PEDS)

**Pre-Meeting Symposium 25: Inflammation and Altered Metabolism in Pulmonary Hypertension** (Maryland Suite) **** (PH, ALL)

**Pre-Meeting Symposium 26: Hanging in the Balance: Minimizing Risk and Maximizing Benefit with Donor Derived Infection** (Virginia Suite) **** (ALL)

**Pre-Meeting Symposium 27: VAD in Patients with Congenital Heart Disease** (Delaware Suite) **** (PEDS, HF, HTX, MCS, NHSAH, PH)

**Pre-Meeting Symposium 28: Lifecycle Journey of Hepatitis C Heart Failure Patient in 2016** (Washington Ballroom 2) **** (PHARM, HF, HTX, ID, MCS, NHSAH)

6:00 PM - 7:00 PM

Exhibit Hall Grand Opening Reception (Exhibit Hall A)

**Poster Session 1** (Exhibit Hall B & C) (ALL)

EUROMACS Meeting (Room 8205)

6:00 PM – 9:00 PM

Pulmonary AMR Workforce Meeting (Park Tower 8216)

7:00 PM – 7:30 PM

Poster Session 1 Removal (Exhibit Hall B & C)

7:00 PM - 10:00 PM

ICCAC Annual Meeting (Virginia Suite)

#

# Thursday, April 28, 2016

7:00 AM - 7:00 PM

Registration Open (Convention Registration)

Speaker Ready Room Open (Madison)

7:00 AM - 10:00 AM

Poster Session 2 Mount (Exhibit Hall B & C)

7:00 AM - 8:00 AM

**Junior Faculty and Trainees Council Meeting** (Harding)

8:00 AM - 10:00 AM

**Opening Plenary Session – Transplantation: Where Does the Science End and the Art Begin?** (Salons 1-3) (ALL)

9:00 AM - 7:00 PM

Press Office Open (Park Tower 8219)

10:00 AM - 7:00 PM

Exhibit Hall Open (Exhibit Hall A)

Poster Hall Open (Exhibit Hall B & C)

10:00 AM – 10:30 AM

Coffee Break (Exhibit Hall A)

View Posters (Exhibit Hall B & C)

10:30 AM - 12:00 PM

**Concurrent Session 1: Too Much of a Bad Thing? Complications after Mechanical Support** (Salons 1-3) (MCS, HF, ID, NHSAH)

**Concurrent Session 2: On the Road to Recovery: Treating Chronic Heart Failure with Mechanical Support** (Thurgood Marshall) (MCS, BSI, HF)

**Concurrent Session 3: Donor Organ Allocation and Management – What's Hot and New?** (Maryland Suite) (LTX, BSI, EEP, ID, NHSAH, PEDS, PHARM)

**Concurrent Session 4: Keep It Down: New Insights on Immunosuppression** (Virginia Suite) (HTX, ID, NHSAH, PATH, PEDS, PHARM)

**Concurrent Session 5: Improving Heart Failure Outcomes with Pills, Procedures and Sex** (Delaware Suite) (HF, MCS, NHSAH, PHARM)

**Concurrent Session 6: Pediatric Heart Transplant Outcomes** (Washington Ballroom 2) (PEDS, HTX, NHSAH)

12:00 PM - 2:00 PM

Lunch Break

JHLT Editorial Board Lunch Meeting (Wilson)

ID Symposium Planning Workgroup Meeting (Park Tower 8205)

IPLTC Meeting (Park Tower 8212)

**Mechanical Circulatory Support Scientific Council Meeting** (Delaware Suite)

**Pathology Scientific Council Meeting** (Harding)

**Pulmonary Hypertension Scientific Council Meeting** (Washington Ballroom 1)

**Pulmonary Transplantation Scientific Council Meeting** (Washington Ballroom 2)

1:00 PM – 2:00 PM

I2C2 Latin American Meeting (Balcony A)

2:00 PM - 3:30 PM

**Concurrent Session 7: It's Tough to Make Predictions, Especially about the Future: Outcomes in MCS** (Salons 2-3) (MCS, HTX, NHSAH)

**Concurrent Session 8: Quality Over Quantity? Quality of Life in MCS** (Thurgood Marshall) (MCS, EEP, NHSAH)

**Concurrent Session 9: Rolling the Dice: Risk Prediction in Cardiac Transplantation** (Salon 1) (HTX, EEP, ID, MCS, NHSAH, PEDS, PHARM)

**Concurrent Session 10: The Frailty Construct and Body Composition - Impact on Lung Transplant Outcomes** (Maryland Suite) (LTX, NHSAH, PEDS, PHARM)

**Concurrent Session 11: The Heartbreak of Rejection: All Against the Graft** (Virginia Suite) (HTX, BSI, NHSAH, PATH, PEDS, PHARM)

**Concurrent Session 12: Pediatric Lung Transplantation** (Delaware Suite) (PEDS, LTX)

**Concurrent Session 13: Philip K. Caves Award Candidate Presentations** (Washington Ballroom 2) (ALL)

**Symposium 29: Joint ISHLT/PVRI Symposium: Exploring Combination Therapy in PAH** (Washington Ballroom 1) (PH, BSI, LF, LTX, NHSAH, PHARM)

3:30 PM - 4:00 PM

Coffee Break (Exhibit Hall A)

View Posters (Exhibit Hall B & C)

2017 Symposium Planning Committee Meeting (Harding)

4:00 PM - 5:30 PM

**Concurrent Session 14: Bright Shiny Toys for Good Girls and Boys: New Technology and Techniques in MCS** (Salons 2-3) (MCS, HF)

**Concurrent Session 15: Let's Be Specific: Donor Specific Antibodies - Challenges Ahead** (Thurgood Marshall) (HTX, BSI, ID, MCS, PATH, PEDS, PHARM)

**Concurrent Session 16: Novel Therapeutic Strategies for Chronic Lung Allograft Dysfunction** (Salon 1) (LTX, BSI, PEDS, PHARM)

**Concurrent Session 17: Pediatric Mechanical Circulatory Support** (Maryland Suite) (PEDS, MCS)

**Concurrent Session 18: Game of Clones: an Epic Cellular Battle Between Rejection and Tolerance** (Virginia Suite) (BSI, HTX, LTX)

**Concurrent Session 19: Improving Outcomes: Body and Soul** (Delaware Suite) (NHSAH, EEP, HF, HTX, LTX, MCS, PEDS, PH)

**Concurrent Session 20: Condemnatory or Commendatory Effects of Thoracic Transplantation** (Washington Ballroom 2) (EEP, HF, HTX, LTX, MCS, NHSAH)

5:30 PM – 6:00 PM

Coffee Break (Exhibit Hall A)

View Posters (Exhibit Hall B & C)

6:00 PM - 7:00 PM

**Mini Oral 1: Science, Surgery and Shock in MCS** (Thurgood Marshall) (MCS, BSI, HTX, NHSAH)

**Mini Oral 2: Donor Dilemmas in Heart Transplantation** (Salon 1) (HTX, ID, NHSAH, PATH, PEDS, PHARM)

**Mini Oral 3: Candidate and Recipient Management in Heart Transplantation** (Maryland Suite) (HTX, ID, NHSAH, PATH, PEDS, PHARM)

**Mini Oral 4: Donor and Recipient Management in Lung Transplantation** (Virginia Suite) (LTX, BSI, EEP, ID, NHSAH, PATH, PEDS, PH, PHARM)

**Mini Oral 5: Pediatrics: Organ Support and Transplantation** (Delaware Suite) (PEDS, HTX)

**Mini Oral 6: Pharmacy & Pharmacology and Mechanical Circulatory Support** (Washington Ballroom 1 & 2) (PHARM, HTX, ID, LTX, MCS)

Wine & Cheese Reception (Exhibit Hall A)

**Poster Session 2** (Exhibit Hall B & C) (ALL)

Past Presidents Committee Meeting (Harding)

7:00 PM – 7:30 PM

Poster Session 2 Removal (Exhibit Hall B & C)

#

# Friday, April 29, 2016

6:00 AM - 7:00 PM

Speaker Ready Room Open (Madison)

7:00 AM - 7:00 PM

Registration Open (Convention Registration)

7:00 AM - 10:00 AM

Poster Session 3 Mount (Exhibit Hall B & C)

7:00 AM - 8:00 AM

**Sunrise Symposium 1: MCS Challenges and Engineering Solutions** (Thurgood Marshall) (MCS, HF, HTX, NHSAH)

**Sunrise Symposium 2: Timing Support in Cardiogenic Shock: When to Move Forward** (Salon 1) (ALL)

**Sunrise Symposium 3: Thoracic Organ Transplantation and Malignancy** (Maryland Suite) (LTX, HF, HTX, LF, NHSAH, PEDS, PHARM)

**Sunrise Symposium 4: Let's Come to Some Closure on the Issue of Pulmonary Hypertension in Congenital Heart Disease** (Virginia Suite) (PH, LTX, NHSAH, PEDS)

**Sunrise Symposium 5: Back to Basics: What the Thoracic Transplant Clinician Needs to Know About Immunobiology** (Delaware Suite) (ALL)

**Sunrise Symposium 6: The Fly in the Ointment: Nosocomial Infections** (Washington Ballroom 2) (ID, ALL)

8:00 AM - 10:00 AM

**Plenary Session: Where is the Future for Innovation?** (Salons 2-3) (ALL)

9:00 AM - 7:00 PM

Press Office Open (Park Tower 8219)

10:00 AM - 4:00 PM

Exhibit Hall Open (Exhibit Hall A)

10:00 AM - 7:00 PM

Poster Hall Open (Exhibit Hall B & C)

10:00 AM – 10:30 AM

Annual Business Meeting (Salons 2-3)

Coffee Break (Exhibit Hall A)

View Posters (Exhibit Hall B & C)

10:30 AM - 12:00 PM

**Concurrent Session 21: Pimp My Pump: Novel MCS Design and Management** (Salons 2-3) (MCS, HF, NHSAH)

**Concurrent Session 22: What a Bloody Mess: Novel Therapeutics and Diagnostics for GI Bleeding after MCS** (Thurgood Marshall) (MCS, HF, NHSAH, PHARM)

**Concurrent Session 23: Choosing a Gift: Donor Selection** (Salon 1) (HTX, EEP, ID, NHSAH, PATH, PEDS, PHARM)

**Concurrent Session 24: What's New in Primary Graft Dysfunction Post Lung Transplantation** (Virginia Suite) (LTX, BSI, ID, NHSAH, PEDS, PHARM)

**Concurrent Session 25: Beyond Adherence: What's New Out There?** (Delaware Suite) (NHSAH, EEP, HF, HTX, LTX, MCS, PEDS, PH, PHARM)

**Concurrent Session 26: Mechanisms of AMR: Can We Protect The Body From The Anti-Body?** (Washington Ballroom 2) (BSI, HTX, LTX, MCS, PEDS)

**Symposium 30: JHLT at ISHLT: The Year in a Capsule** (Maryland Suite) (ALL)

12:00 PM - 2:00 PM

Lunch Break

**Heart Failure and Transplantation Scientific Council Meeting** (Delaware Suite)

**Infectious Diseases Scientific Council Meeting** (Hoover)

**Pediatric Thoracic Transplantation and Heart Failure Scientific Council Meeting** (Washington Ballroom 2)

IMACS Users Group Meeting (Harding)

ISHLT/AST Lung Transplant Benefit Meeting (Wilson)

Registries and Databases Committee Meeting (Taft)

12:00 PM - 1:00 PM

Lung Quality of Life Workforce Meeting (Jefferson)

ID Symposium Planning Workgroup Meeting (Park Tower 8205)

12:15 PM – 1:30 PM

Women in Transplantation Meeting (Salon 1)

1:00 PM – 2:00 PM

Pulmonary AMR Workgroup Meeting (McKinley)

2:00 PM - 3:30 PM

**Concurrent Session 27: Are Two Pumps Better Than One? RV Failure and MCS** (Salons 2-3) (MCS, HF, NHSAH, PH)

**Concurrent Session 28: Pump Thrombosis: What's Hot with the Clot** (Thurgood Marshall) (MCS, HF, NHSAH)

**Concurrent Session 29: The Dark Side of Heart Transplant: Living With CAV** (Salon 1) (HTX, BSI, MCS, NHSAH, PATH, PEDS, PHARM)

**Concurrent Session 30: What You Need to Know About Donors and Early Outcome Following Lung Transplantation** (Maryland Suite) (LTX, BSI, ID, NHSAH, PATH, PEDS, PHARM)

**Concurrent Session 31: Pediatric Early Post Transplant Problems** (Virginia Suite) (PEDS, HTX, MCS)

**Concurrent Session 32: Cardiothoracic Transplantation and MCS Infections: Cracking the Code for Diagnosis, Monitoring, and Treatment** (Delaware Suite) (ID, HTX, LTX, MCS, NHSAH)

**Concurrent Session 33: "A Bipartisan Effort": Antibodies and Complement in Heart and Lung Allografts** (Washington Ballroom 2) (PATH, BSI, HF, HTX, LTX, PEDS)

**Symposium 31: Performing Under Pressure: Lung Transplantation in PH and PAH** (Washington Ballroom 1) (PH, ALL)

3:30 PM – 4:00 PM

Coffee Break (Exhibit Hall A)

View Posters (Exhibit Hall B & C)

4:00 PM - 5:30 PM

**Concurrent Session 34: How Much is Too Much? Assessing Risk Prior to MCS** (Salons 2-3) (MCS, HTX, NHSAH)

**Concurrent Session 35: Too Thick or Too Thin? Assessing Anticoagulation in MCS** (Thurgood Marshall) (MCS, HF, NHSAH, PHARM)

**Concurrent Session 36: Is It Really A Wonderful Life? Problems Post Heart Transplant** (Salon 1) (HTX, EEP, ID, NHSAH, PATH, PEDS, PHARM)

**Concurrent Session 37: Prognostic Variables Associated with CLAD Onset and Progression** (Maryland Suite) (LTX, BSI, ID, NHSAH, PEDS, PHARM)

**Concurrent Session 38: New Insights in Pulmonary Hypertension** (Virginia Suite) (PH, BSI, HF, HTX, LTX, MCS, PEDS, PH, PHARM)

**Concurrent Session 39: Junior Faculty and Trainee Council's Clinical Case Dilemmas: The Best of the Best** (Delaware Suite) (CASE, ALL)

**Concurrent Session 40: Too Much of a Good Thing: Balancing Benefit and Medication Complexity** (Washington Ballroom 2) (PHARM, HTX, ID, LTX, MCS, NHSAH)

5:30 PM – 6:00 PM

Coffee Break (Exhibit Hall A)

View Posters (Exhibit Hall B & C)

5:30 PM – 6:30 PM

Psychosocial Guidelines Writing Group Meeting (Park Tower 8216)

6:00 PM - 7:00 PM

**Mini Oral 7: Patient Management and Outcomes in MCS** (Thurgood Marshall) (MCS, HF, NHSAH)

**Mini Oral 8: Technology, Physiology and Complications in MCS** (Salon 1) (MCS, HTX, NHSAH)

**Mini Oral 9: Risk Factors and Lung Transplant Outcomes** (Maryland Suite) (LTX, BSI, EEP, ID, NHSAH, PATH, PEDS, PHARM)

**Mini Oral 10: Heart Transplantation and Heart Failure** (Virginia Suite) (HTX, BSI, LTX, NHSAH, PATH, PEDS, PHARM)

**Mini Oral 11: Models in Transplantation: From Mouse to Rat to Pig to Human** (Delaware Suite) (BSI, HTX, LTX, MCS)

**Mini Oral 12: Applied Health Research and Pulmonary Hypertension** (Washington Ballroom 2) (NHSAH, EEP, HTX, LTX, MCS, PEDS)

Wine & Cheese Reception (Exhibit Hall A)

**Poster Session 3** (Exhibit Hall B & C) (ALL)

7:00 PM – 7:30 PM

Poster Session 3 Removal (Exhibit Hall B & C)

8:00 PM - 9:30 PM

PRESIDENT'S COCKTAIL RECEPTION (Smithsonian National Museum of Natural History)

#

# Saturday, April 30, 2016

6:00 AM - 5:00 PM

Speaker Ready Room Open (Madison)

7:00 AM - 12:00 PM

Registration Open (Convention Registration)

7:00 AM - 8:00 AM

**Sunrise Symposium 7: Clear as Mud: Assessing the Right Ventricle** (Thurgood Marshall) (MCS, ALL)

**Sunrise Symposium 8: Rethinking Valvular Disease in Heart Failure** (Maryland Suite) (HF, HTX, MCS, NHSAH, PEDS, PH)

**Sunrise Symposium 9: Lung Transplant Benefit is More Than Just Survival** (Virginia Suite) (LTX, ALL)

**Sunrise Symposium 10: Ambulatory ECMO in Adults: We Like to Move It, Move It** (Delaware Suite) (NHSAH, HF, HTX, LTX, MCS)

**Sunrise Symposium 11: Controversies in Pediatric Heart Failure** (Washington Ballroom 2) (PEDS, HF, HTX, NHSAH, PHARM)

**Sunrise Symposium 12: Precision Medicine in Transplantation: Drug Levels and Beyond** (Washington Ballroom 1) (ALL)

7:45 AM - 9:45 PM

Committee/Council Reports to Board (Harding)

8:00 AM - 9:30 AM

**Concurrent Session 41: You Get Out What You Put In: Assessing Risk in Mechanical Support** (Thurgood Marshall) (MCS, HTX, NHSAH)

**Concurrent Session 42: Difficult Decisions in Mechanical Support** (Maryland Suite) (MCS, HTX, NHSAH)

**Concurrent Session 43: Paying the Tolls: Effects of Bridge to Transplant** (Virginia Suite) (HTX, EEP, ID, MCS, NHSAH, PEDS, PHARM)

**Concurrent Session 44: Lung Transplantation - Advanced Diagnostics!** (Delaware Suite) (LTX, BSI, NHSAH, PATH, PEDS, PHARM)

**Concurrent Session 45: Pediatric Heart Failure** (Washington Ballroom 2) (PEDS, HF, HTX)

**Concurrent Session 46: From 'Jeans' to Proteins: Mechanisms of Ischemia Reperfusion Injury and Translation to Advanced Diagnostics** (Washington Ballroom 1) (BSI, HF, HTX, LTX, MCS)

9:30 AM – 9:45 AM

Coffee Break (Convention Registration)

9:45 AM - 11:45 AM

**Plenary Session - Pushing New Scientific Frontiers: It's In Our Heritage** (Thurgood Marshall) (ALL)

11:45 AM – 12:00 PM

Coffee Break (Convention Registration)

12:00 PM - 1:30 PM

**Concurrent Session 47: Medicines or Machines? The Failing Right Ventricle in MCS** (Thurgood Marshall) (MCS, HF, NHSAH, PH)

**Concurrent Session 48: Not Just to Survive, But to Thrive: Comprehensive Care of the MCS Patient** (Maryland Suite) (MCS, HTX, NHSAH)

**Concurrent Session 49: My Heart Is Broken: Primary Graft Dysfunction and Early Problems** (Virginia Suite) (HTX, BSI, ID, MCS, NHSAH, PATH, PEDS, PHARM)

**Concurrent Session 50: Recipient Factors and Outcome After Lung Transplantation - Are We Getting It Right?** (Delaware Suite) (LTX, BSI, ID, NHSAH, PATH, PHARM)

**Concurrent Session 51: Heart Failure Risk Prediction: From Molecules to Mechanism** (Washington Ballroom 2) (HF, BSI, HTX, NHSAH)

**Concurrent Session 52: Factors Determining Outcomes in Pulmonary Hypertension** (Washington Ballroom 1) (PH, BSI, HF, LTX, PEDS, PH, PHARM)

12:00 PM - 6:00 PM

ISHLT Board of Directors Meeting (Harding)

12:00 PM - 3:00 PM

Academy Registration Open (Convention Registration)

1:45 PM - 6:30 PM

**ISHLT Academy: Master Class in Mechanical Circulatory Support** (Washington Ballroom 1 & 2)
ANNUAL MEETING SCIENTIFIC PROGRAM

WEDNESDAY APRIL 27, 2016

8:00 AM - 10:00 AM

Pre-Meeting Symposium 1: Anticoagulation and MCS: Can We Do Better?

Location:

Salons 2-3

Target Audience:

MCS, HF, PHARM

Chairs:

Michael A Shullo, PharmD, and Sanem Nalbantgil, MD

**Session Summary** : The goal of this symposium is to familiarize clinicians with current, widely available tests of blood coagulability and pitfalls in their interpretation in the MCS population. Additional topics will include comorbid states, such as acquired von Willebrand's disease and genetic variations like Factor V mutations, and how they impact patients after device implantation.

8:00 AM

Too Thick or Too Thin? Bleeding and Thrombosis in MCS

Ulrich Jorde, MD, Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, USA

8:15 AM

Q & A

8:20 AM

Pre-operative Genetic Screening for Coagulation Abnormalities and Impact on Post-operative Management

Douglas L. Jennings, PharmD, New York - Presbyterian, New York, NY, USA

8:35 AM

Q & A

8:40 AM

Who Should Be Monitoring INR and How?

Anna L Meyer, MD, Leipzig Heart Center, Leipzig, Germany

8:55 AM

Q & A

9:00 AM

Heparin Monitoring: Xa vs. aPTT

Christopher S. Hayward, MD, St. Vincent's Hospital, Sydney, Australia

9:15 AM

Q & A

9:20 AM

Is There a Role for Antiplatelet Monitoring in MCS?

Robert L Page, PharmD, MSPH, University of Colorado, Denver, CO, USA

9:35 AM

Q & A

9:40 AM

Alternative Approaches to Recurrent Bleeding - Octreotide, Hormonal Therapy, Etc.

Nir Uriel, MD, University of Chicago, Chicago, IL, USA

9:55 AM

Q & A

8:00 AM - 10:00 AM

Pre-Meeting Symposium 2: Controversies in Heart Transplantation: Past, Present and Future

Location:

Thurgood Marshall

Target Audience:

HTX, HF, ID, NHSAH, PATH, PEDS, PHARM

Chairs:

Savitri E Fedson, MD, and Eulalia Roig, MD

**Session Summary** : This session will review current immunosuppressant pharmacology as well as the current status of rejection surveillance. The utility of endomyocardial biopsy will be debated and then a report on future of heart transplant immunosuppression will be presented including perspectives on where the next advances will come from.

8:00 AM

Back to Basics: Pharmacology & Pharmacodynamics of Immunosuppressants

Tam Khuu, PharmD, UCLA, Los Angeles, CA, USA

8:20 AM

Putting it Together: Approaches to Immune Monitoring

Michael Pham, MD, Stanford University, Palo Alto, CA, USA

8:40 AM

DEBATE: Cardiac Biopsy is Essential for Post-transplant Rejection Surveillance (PRO)

Stuart D Russell, MD, Johns Hopkins Hospital, Baltimore, MD, USA

8:55 AM

DEBATE: Cardiac Biopsy is Essential for Post-transplant Rejection Surveillance (CON)

Howard Eisen, MD, Drexel University, Philadelphia, PA, USA

9:10 AM

DEBATE REBUTTAL (PRO)

9:15 AM

DEBATE REBUTTAL (CON)

9:20 AM

The Future of Heart Transplant Immunosuppression: Something's Old, Something's New, Something's Borrowed, Somebody's Blue

David A Baran, MD, Newark Beth Israel, Newark, NJ, USA

9:40 AM

PANEL DISCUSSION

8:00 AM - 10:00 AM

Pre-Meeting Symposium 3: Current Innovations and Future of EVLP

Location:

Salon 1

Target Audience:

LTX, LF, MCS

Chairs:

Christopher H. Wigfield, MD, FRCS, and Jasleen Kukreja, MD, MPH

**Session Summary** : This symposia will explore the prospect of gene, cell, drug and molecular interventions during EVLP to improve outcomes for lung transplant recipients. How essential EVLP is to the running of a modern day program will be debated.

8:00 AM

The Future of Lung Repair - Drug and Molecular Interventions during EVLP

Christine L Lau, MD, University of Virginia, Charlottesville, VA, USA

8:15 AM

Q & A

8:20 AM

The Future of Lung Repair - Cell and Gene Interventions during EVLP

Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, ON, Canada

8:35 AM

Q & A

8:40 AM

The Future of Lung Preservation Techniques

Gregor Warnecke, MD, FRCSC, Hannover Medical School, Hannover, Germany

8:55 AM

Q & A

9:00 AM

EVLP as a Platform to Reduce Infection

John Dark, MB, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

9:15 AM

Q & A

9:20 AM

Is Reduced Allo Responsiveness after EVLP a Reality? - Long Term Follow Up

Goran Dellgren, MD, PhD, Salgrenska University Hospital, Goteborg, Sweden

9:35 AM

Q & A

9:40 AM

DEBATE: My Clinical Program Needs an EVLP Service (PRO)

Frank d'Ovidio, MD, FRCS, Columbia University, New York, NY, USA

9:50 AM

DEBATE: My Clinical Program Needs an EVLP Service (CON)

David C McGiffin, MB, BS, FRACS, Alfred Hospital, Melbourne, Australia

8:00 AM - 10:00 AM

Pre-Meeting Symposium 4: Under Pressure: PH in Parenchymal Lung Disease

Location:

Maryland Suite

Target Audience:

PH, HF, LF, LTX

Chairs:

Oksana A. Shlobin, MD, and Trevor J Williams, MD

**Session Summary** : Pulmonary hypertension (PH) is a common and serious complication of interstitial lung diseases (ILD). Its occurrence and severity are highly variable. This session will summarize the clinical features of this challenging condition and review its impact on gas exchange and cardiac function. Challenges related to lung transplantation for ILD with PH will be reviewed. A pro-con debate will discuss the controversies regarding the use of PAH targeted therapies for this indication.

8:00 AM

PH in ILD: Pathophysiology and Epidemiology

John Granton, MD, University of Toronto, Toronto, ON, Canada

8:15 AM

Q & A

8:20 AM

Shrinking with Age: The Role of Telomerases in ILD and PH-ILD

Leann Silhan, MD, Johns Hopkins School of Medicine, Baltimore, MD, USA

8:35 AM

Q & A

8:40 AM

Connective Tissue Disease PH-ILD: Which One Matters?

Jerome Le Pavec, MD, Hôpital Marie Lannelongue, Le Plessis Robinson, France

8:55 AM

Q & A

9:00 AM

Sarcoid-associated Pulmonary Hypertension: An Enigma or a Run of the Mill Complication?

Robert P Baughman, MD, University of Cincinnati, Cincinnati, OH, USA

9:15 AM

Q & A

9:20 AM

Impact of PH on Transplant Outcomes in ILD

Jens Gottlieb, MD, Medical School Hannover, Hannover, Germany

9:35 AM

Q & A

9:40 AM

Are PAH Specific Therapies Beneficial in PH-ILD?

Steven Nathan, MD, Inova Fairfax Hospital, Falls Church, VA, USA

9:55 AM

Q & A

8:00 AM - 10:00 AM

Pre-Meeting Symposium 5: Making It Work: Heart Transplant Challenges from the Surgeon's Perspective

**Location** :

Virginia Suite

Target Audience:

HTX, HF, MCS, NHSAH, PEDS

Chairs:

Hannah Copeland, MD, and Tahir Yagdi, MD

**Session Summary** : To discuss the controversies, advances, and new directions in heart transplant surgery.

8:00 AM

Out of Time: Surgical Options for Late Graft Failure

Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

8:20 AM

Surgical Management of Cardiac Primary Graft Dysfunction

Yoshifumi Naka, MD, Columbia University, New York, NY, USA

8:40 AM

When Great Vessels Go Bad Following Transplantation

Gregorio Rabago, MD, Clinica Universitaria Apartado, Pamplona, Spain

9:00 AM

Valvular Heart Disease after Heart Transplant

Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

9:20 AM

Advanced Plumbing: How to Manage Complex Connections in Adult Congenital Heart Transplant Recipients

Jonathan M Chen, MD, Seattle Children's Hospital, Seattle, WA, USA

9:40 AM

PANEL DISCUSSION

8:00 AM - 10:00 AM

Pre-Meeting Symposium 6: Back to the Future: Cell Therapy for Thoracic Organ Failure and Transplant?

**Location** :

Delaware Suite

Target Audience:

ALL

Chairs:

Daniel Chambers, MBBS, MRCP, FRACP, MD, and Lori J. West, MD, DPhil

**Session Summary** : This session will focus on cutting edge therapies that involve cells. There will be a focus on using cells to repair or fully regenerate a failing organ, for transplant tolerance induction or treatment of chronic rejection.

8:00 AM

Tissue Engineering for Dummies: How to Build a Heart or Lung

Doris Taylor, PhD, Texas Heart Institute, Houston, TX, USA

8:15 AM

Q & A

8:20 AM

Cell Therapy for the Failing Organ: Patch Up the Heart

Eduardo Marban, MD, PhD, Cedars-Sinai, Los Angeles, CA, USA

8:35 AM

Q & A

8:40 AM

Cell Manipulation for Transplant Tolerance

Joren C. Madsen, MD, DPhil, Massachusetts General Hospital, Boston, MA, USA

8:55 AM

Q & A

9:00 AM

Myeloid Cells to Induce Transplant Tolerance

Angus Thomson, PhD, DSc, University of Pittsburgh, Pittsburgh, PA, USA

9:15 AM

Q & A

9:20 AM

Stem Cells to Cure the Incurable: Treatment for Chronic Lung and Heart Allograft Dysfunction

Sonja Schrepfer, MD, PhD, Stanford University Transplant and Stem Cell Immunobiology Lab (TSI), Stanford, CA, USA

9:35 AM

Q & A

9:40 AM

Case Presentation: Back to the Future - Real Life Example of Cell Therapy and Tolerance in Lung Transplantation

Alice L Gray, MD, Duke University Medical Center, Durham, NC, USA

9:45 AM

Case-Based Discussion: Back to the Future - Real Life Example of Cell Therapy and Tolerance in Lung Transplantation

Duane Davis, MD, MBA, Florida Hospital, Orlando, FL, USA

8:00 AM - 10:00 AM

Pre-Meeting Symposium 7: The Future is Here: Emerging Issues in Infectious Disease

**Location** :

Washington Ballroom 2

Target Audience:

ID, HTX, LF, LTX, MCS, NHSAH, PEDS, PHARM

Chairs:

Me-Linh Luong, MD, and Denis Hadjiliadis, MD

**Session Summary** : This symposium will explore the emergence and resurgence of difficult to treat pathogens in thoracic transplant and MCSD patients that challenge practitioners worldwide.

8:00 AM

Mycobacterium Abscessus and Friends

Fernanda Silveira, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

8:15 AM

Q & A

8:20 AM

RSV and the Paramyxoviruses: Should We Treat?

Peter M Hopkins, FRACP, Prince Charles Hosp, Brisbane, Australia

8:35 AM

Q & A

8:40 AM

The Unwelcome Guests: Strongyloides and Chagas Disease

Fernando Bacal, MD, Heart Institute, University of Sao Paulo, Sao Paulo, Brazil

8:55 AM

Q & A

9:00 AM

The Fungus Among Us: Scedosporium and Other Emerging Fungi

Orla Morrissey, MD, Alfred Hospital, Melbourne, Australia

9:15 AM

Q & A

9:20 AM

Running Away With It: C. difficile and Norovirus

Ignacio Echenique, MD, Cleveland Clinic Florida, Weston, FL, USA

9:35 AM

Q & A

9:40 AM

The Coming Apocalypse: Resistant Gram negatives, B cepaciae, Achromobacter, Stenotrophomonas

Shirish Huprikar, MD, Mount Sinai Medical Center, New York, NY, USA

9:55 AM

Q & A

10:15 AM – 12:15 PM

Pre-Meeting Symposium 8: Joint ISHLT-ICCAC MCS Symposium: Joined at the Heart - International Perspectives on MCS Issues

**Location** :

Salons 2-3

Target Audience:

MCS, HF, HTX, NHSAH

Chairs:

Jennifer Beckman, MSN-FNP, RN, CHFN, and Stephan Schueler, MD, PhD

**Session Summary** : This session will discuss questions frequently asked by MCS Teams around the world regarding program structure, practice guidelines, international variations in care delivery from a program perspective, and challenges faced by patients, families and staff caring for them.

10:15 AM

Coordinator Perspective: Characteristics of a Successful MCS Program

Tonya I Elliott, MSN, RN, CCTC, CHFN, MedStar Washington Hospital Center, Washington, DC, USA

10:30 AM

Q & A

10:35 AM

Engaging Patients and Caregivers: Successful Strategies to Care for Patients Living Far Far Away - The International Perspective

Desiree Robson, RN, BSc (Hons), St Vincent's Hospital, Sydney, Australia

10:50 AM

Q & A

10:55 AM

Engaging Patients and Caregivers: Successful Strategies to Care for Patients Living Far Far Away - The North American Perspective

Annemarie Kaan, MCN, RN, St. Paul's Hospital, Vancouver, BC, Canada

11:10 AM

Q & A

11:15 AM

Collaborative Care in the ICU

Aly El Banayosy, MD, Nazih Zuhdi Transplant Institute, Oklahoma City, OK, USA

11:30 AM

Q & A

11:35 AM

Delivering Optimal Care While Reaching For Exceptional Outcomes - The North American Perspective

Carole Ballew, MSN, University of Virginia Health System, Charlottesville, VA, USA

11:50 AM

Q & A

11:55 AM

Delivering Optimal Care While Reaching For Exceptional Outcomes - The International Perspective

Thomas Schlöglhofer, BSc, Medical University of Vienna, Vienna, Austria

12:10 PM

Q & A

10:15 AM – 12:15 PM

Pre-Meeting Symposium 9: Donor Heart Selection: Strategies to Improve Organ Utilization

**Location** :

Thurgood Marshall

Target Audience:

HTX, LTX, MCS, NHSAH, PEDS

Chairs:

Jon A. Kobashigawa, MD, and Maria G Crespo-Leiro, MD

**Session Summary** : This symposium will focus on strategies to improve organ utilization in heart transplantation. Since lack of donor organs and appropriate donor management guidelines is a pressing problem worldwide, it will be of great importance to have a symposium dedicated to delivering the outcomes of two recent consensus conferences in this area.

10:15 AM

US and European Donor Management Consensus Conferences: Key Messages to Improve Heart and Lung Utilization

Kiran K Khush, MD, MAS, Stanford University, Stanford, CA, USA

10:35 AM

Q & A

10:39 AM

Donor Management vs Organ Reconditioning: Lessons From Lung Transplantation

Arne Neyrinck, MD, PhD, University Hospital Leuven, Leuven, Belgium

10:59 AM

Q & A

11:03 AM

Heart Allocation Score: Insights from Eurotransplant

Jacqueline M Smits, MD, PhD, Eurotransplant International, Leiden, Netherlands

11:23 AM

Q & A

11:27 AM

DCD Hearts: An Additional Resource or the Answer to the Donor Crisis?

Kumud Dhital, MD, St Vincent's Hospital, Sydney, Australia

11:47 AM

Q & A

11:51 AM

Donor Risk Scores and Allocation Algorithms: Will Numbers Do Better than the Surgeon's Basic Instinct?

Abbas Ardehali, MD, University of California Los Angeles, Los Angeles, CA, USA

12:11 PM

Q & A

10:15 AM – 12:15 PM

Pre-Meeting Symposium 10: Joint ISHLT/ESC Symposium: Left, Right, and Together: The Facts and Future of PH in Left Heart Disease (in collaboration with the ISHLT Scientific Council on PH and the ESC RV/Pulmonary Circulation Working Group)

**Location** :

Salon 1

Target Audience:

PH, ALL

Chairs:

Stavros Konstantinides, MD, PhD, FESC, and Mardi Gomberg-Maitland, MD

**Session Summary** : This session will explore the role of the pulmonary circulation in heart failure from left heart disease. It will discuss the interdependence of the right and left heart as well as diagnostic strategies and treatments. It is a joint session with the European Society of Cardiology Working Group of the Right Ventricle and the Pulmonary Circulation.

10:15 AM

Pulmonary Hypertension-Left Heart Disease: Defining Group 2 PH

Irene Lang, MD, Medical University of Vienna, Vienna, Austria

10:35 AM

Is All Heart Failure the Same on the Pulmonary Circulation, and How Does It Impact Survival?

Nazzareno Galiè, MD, Bologna University Hospital, Bologna, Italy

10:55 AM

Monitoring and Therapeutic Options for Pulmonary Hypertension in Left Heart Disease

Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA

11:15 AM

Provocative Testing in Pulmonary Hypertension in Left Heart Disease

Robert Naeije, MD, Free University of Brussels, Brussels, Belgium

11:35 AM

DEBATE: Diastolic Pulmonary Gradient is a Marker of Pulmonary Vasculopathy in Pulmonary __ Hypertension in Left Heart Disease (PRO)

Jean-Luc Vachiery, MD, Erasme University Hospital - ULB, Brussels, Belgium

11:43 AM

DEBATE: Diastolic Pulmonary Gradient is a Marker of Pulmonary Vasculopathy in Pulmonary Hypertension in Left Heart Disease (CON)

Stephan Rosenkranz, MD, Herzzentrum der Universität zu Köln, Koln, Germany

11:51 AM

DEBATE REBUTTAL (PRO)

11:53 AM

DEBATE REBUTTAL (CON)

11:55 AM

A Challenging Case of Pulmonary Hypertension

Myung H. Park, MD, Houston Methodist, Houston, TX, USA

12:00 PM

PANEL DISCUSSION

10:15 AM – 12:15 PM

Pre-Meeting Symposium 11: Multiorgan Transplantation for Lung Recipients: When is Two Better than One?

**Location** :

Maryland Suite

Target Audience:

LTX, HTX

Chairs:

Peter M Hopkins, FRACP, and Lianne G. Singer, MD, FRCPC

**Session Summary** : Referrals for multi-organ transplantation have increased as patients accumulate more complex comorbidities and those considered for re-transplantation have acquired renal disease. This session will evaluate the indications, benefits, disadvantages and challenges of performing multi-organ transplantation in patients with advanced lung disease. This will include how organ allocation policies differ in this group of potential recipients.

10:15 AM

Heart-Lung Transplantation is Dead - The Right Ventricle Will Remodel

Walter Klepetko, MD, Medical University of Vienna, Vienna, Austria

10:30 AM

Q & A

10:35 AM

Combined Lung-Liver Transplantation - How Bad Does the Liver Have to Be?

Daniel Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, Australia

10:50 AM

Q & A

10:55 AM

Combined Lung-Liver Transplantation - Surgical Approach and Post-operative Management

John J. Dunning, FRCS, Papworth Hospital, Cambridge, United Kingdom

11:10 AM

Q & A

11:15 AM

Combined Lung-Kidney Transplantation - What to Do with Vulnerable Kidneys Pre-lung Transplant?

Gregory I. Snell, FRACP, MBB, Alfred Hospital, Melbourne, Australia

11:30 AM

Q & A

11:35 AM

Ethics and Equity in Multi-Organ Transplantation

Edward J. Garrity, MD, MSc, The University of Chicago, Chicago, IL, USA

11:50 AM

Q & A

11:55 AM

Is There an Allograft Combi Effect in Multi-Organ Transplantation?

Mark Greer, MB BCh, Hanover Medical School, Hannover, Germany

12:10 PM

Q & A

10:15 AM – 12:15 PM

Pre-Meeting Symposium 12: It's All in the Translation: CMV from Bedside to Bench and Back Again

**Location** :

Virginia Suite

Target Audience:

ALL

Chairs:

Jutta K Preiksaitis, MD, and Martin Zamora, MD

**Session Summary** : This session seeks to evaluate the latest epidemiologic studies in CMV, new antiviral agents, and understanding the effective immune response to CMV. These effects range from direct organ-specific disease, to the burden of potentially toxic drug use, to indirect effects on the graft including CLAD and cardiac allograft vasculopathy.

10:15 AM

Be Still My Heart: CMV and CAV

Juan F. Delgado Jimenez, PhD, University Hospital 12 de Octubre, Madrid, Spain

10:35 AM

Q & A

10:39 AM

Breathless: CMV and CLAD

Glen Westall, FRACP, PhD, Alfred Hospital, Melbourne, Australia

10:59 AM

Q & A

11:03 AM

Measuring the Immune Response to CMV: Expanding Our Options

Laurie D. Snyder, MD, Duke University Medical Center, Durham, NC, USA

11:23 AM

Q & A

11:27 AM

The CMV Toolkit: What do we have now?

Kyle L Dawson, PharmD, Houston Methodist, Houston, TX, USA

11:47 AM

Q & A

11:51 AM

The CMV Toolkit: What is on the horizon?

Robin K. Avery, MD, Johns Hopkins, Baltimore, MD, USA

12:11 PM

Q & A

10:15 AM – 12:15 PM

Pre-Meeting Symposium 13: Child's Play: Infectious Risk After Transplant During Everyday Life

**Location** :

Delaware Suite

Target Audience:

PEDS, HTX, ID, LTX, NHSAH, PHARM

Chairs:

Debra A. Dodd, MD, and Richard Kirk, FRCP, FRCPCH

**Session Summary** : This session addresses commonly encountered situations in the care of thoracic transplant recipients that place them at increased risk of infection. Audience will be invited to participate using an electronic response system.

10:15 AM

Isolation - So Old Hat!

Michele Estabrook, MD, St. Louis Children's Hospital, St Louis, MO, USA

10:30 AM

The Cystic Fibrosis Child - a Risk to their Transplanted Twin or Not?

Nicolaus Schwerk, MD, Hannover Medical School, Hannover, Germany

10:45 AM

Outbreak - Measles, Varicella and Mumps

Marian G. Michaels, MD, MPH, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

11:00 AM

Food and Water - Dangerous Stuff!

Shirish Huprikar, MD, Mount Sinai Medical Center, New York, NY, USA

11:15 AM

You Ain't Nothing but a Hound Dog!

Nancy P Blumenthal, DNP, CRNP, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

11:30 AM

Can We Visit Grandma?

Lara Danziger-Isakov, MD, MPH, Children's Hospital Medical Center, Cincinnati, OH, USA

11:45 AM

PANEL DISCUSSION

10:15 AM – 12:15 PM

Pre-Meeting Symposium 14: Genomics: What Do I Have to Know and How Will It Affect My Practice?

**Location** :

Washington Ballroom 2

Target Audience:

NHSAH, BSI, HF, HTX, LTX

Chairs:

Evan P Kransdorf, MD, PhD, and Bernice L. Coleman, PhD, NP

**Session Summary** : This session will provide an introduction to genomics and will discuss it's application in the care of thoracic transplant patients. The session will highlight the need for development of nursing competencies related to genomics.

10:15 AM

Genomics: A Crash Course

Edward Cantu, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

10:45 AM

Proteomic and Genomic Biomarkers of Allograft Injury: Coming Soon to a Lab Near You

Bruce McManus, MD, PhD, St. Paul's Hospital, Vancouver, BC, Canada

11:00 AM

Differences in Minority Tacrolimus Levels: Would Genotyping Shed Light on Dosing?

Patricia A. Uber, PharmD, Virginia Commonwealth University, Richmond, VA, USA

11:15 AM

Behavioral Genetics: Is there a Future for Personalized Medicine to Support Patient Self-Management in Transplantation?

Sabina M. De Geest, RN, PhD, University of Basel, Basel, Switzerland

11:30 AM

It's Not All Smooth Sailing: Ethical Implications of Genomic Applications in Transplantation

Neal K Lakdawala, MD, Brigham & Women's Hospital, Boston, MA, USA

11:45 AM

Emerging Age of Personal Medicine: Need for Genetic Nursing Competencies in Transplantation

Kathleen Calzone, PhD, APGN, FAAN, National Cancer Institute, Bethesda, MD, USA

12:00 PM

PANEL DISCUSSION

1:45 PM - 3:45 PM

Pre-Meeting Symposium 15: Achilles Heel: Infectious Complications in MCS

**Location** :

Salons 2-3

Target Audience:

MCS, HTX, ID, NHSAH, PHARM

Chairs:

Neil W. Wrightson, RN, and Orla Morrissey, MD

**Session Summary** : Infections account for clinically significant morbidity/mortality, increased cost of care, and reduced quality of life in MCS patients. This session will discuss strategies to reduce complications and identify and treat them effectively.

1:45 PM

MCS Infection - What is the Scope of the Problem?

Shashank S. Desai, MD, Inova Fairfax Hosp, Falls Church, VA, USA

2:00 PM

Q & A

2:05 PM

Preventing DLI: Role of a Dressing Change Protocol

Barbara Cagliostro, MSN, New York-Presbyterian / Columbia University, New York, NY, USA

2:20 PM

Q & A

2:25 PM

If We Can't See It, Does It Not Exist? Imaging Modalities for Diagnosis of MCSD Infections

Stanley I. Martin, MD, Geisinger Health System, Danville, PA, USA

2:40 PM

Q & A

2:45 PM

Approach to the MCSD Recipient with Bloodstream Infection

Saima Aslam, MD, MS, University of California, San Diego, CA, USA

3:00 PM

Q & A

3:05 PM

PANEL DISCUSSION

3:25 PM

DEBATE: Device Infection, Thrombosis, and CVA - It Is All Linked (PRO)

Nader Moazami, MD, Cleveland Clinic, Cleveland, OH, USA

3:35 PM

DEBATE: Device Infection, Thrombosis, and CVA - It Is All Linked (CON)

Stephan Schueler, MD, PhD, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

1:45 PM - 3:45 PM

Pre-Meeting Symposium 16: When Right is Wrong! Management of the Dying Right Ventricle

**Location** :

Thurgood Marshall

Target Audience:

HF, ALL

Chairs:

Teresa De Marco, MD, and Daniel H. Kim, MD

**Session Summary** : This session will show how evaluation of right heart function plays an important role in the assessment of patients undergoing placement of left ventricular assist devices or heart transplantation.

1:45 PM

Deconstructing the Right Ventricle: An Overview of RV Structure and Function, Mechanical, Electrical, and Chemical Signaling

Eduardo Rame, MD, University of Pennsylvania, Philadelphia, PA, USA

2:02 PM

Q & A

2:05 PM

Peering Through the Looking Glass: Imaging the Right Ventricle

Marc A. Simon, MD, University of Pittsburgh, Pittsburgh, PA, USA

2:22 PM

Q & A

2:25 PM

Finger on the Pulse: Hemodynamic Considerations in RV Failure

Ryan J Tedford, MD, Johns Hopkins University, Baltimore, MD, USA

2:42 PM

Q & A

2:45 PM

RV-PA Coupling in PAH: Can Medical Management Restore the Balance?

Rogerio Souza, MD, University of Sao Paulo, Sao Paulo, Brazil

3:02 PM

Q & A

3:05 PM

OR in the Morning: "Buffing" the Bad Right Ventricle

Vigneshwar Kasirajan, MD, Virginia Commonwealth University, Richmond, VA, USA

3:22 PM

Q & A

3:25 PM

Heterotopic Heart Transplant - What's Old is What's New Again!

Hannah Copeland, MD, Indiana University, Indianapolis, IN, USA

3:42 PM

Q & A

1:45 PM - 3:45 PM

Pre-Meeting Symposium 17: The Biology of Aging and Lung Transplantation

**Location** :

Salon 1

Target Audience:

LTX, ID, LF, MCS, NHSAH, PH

Chairs:

John McDyer, MD, and Tanya J. McWilliams, MD, PhD

**Session Summary** : This session will provide the latest clinical and translational science on aging and lung transplant. By the end of this session, attendees will recognize basic science concepts such as genetic telomeropathies and immunosenescence that may impede post transplant outcomes. These insights will enhance our approach to elderly lung transplant candidates/recipients.

1:45 PM

Immunobiology of Aging in Lung Transplantation

Daniel R Goldstein, MD, Yale University, New Haven, CT, USA

2:00 PM

Q & A

2:05 PM

The Long and Short Of It: Telomerase Mutations and Implications for Lung Transplantation

Mary Armanios, MD, Johns Hopkins University, Baltimore, MD, USA

2:20 PM

Q & A

2:25 PM

Frailty is a Superior Measure of Age than Date of Birth

Jonathan Singer, MD, University of California, San Francisco, CA, USA

2:40 PM

Q & A

2:45 PM

Immunosuppressive Regimens Including CNI Sparing Protocols in the Elderly Lung Transplant Patient

Steve Ivulich, PharmD, Alfred Hospital, Melbourne, Australia

3:00 PM

Q & A

3:05 PM

Infectious Challenges in the Older Lung Transplant Recipient

Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada

3:20 PM

Q & A

3:25 PM

DEBATE: Septuagenarians Should Be Eligible For Lung Transplantation (PRO)

Erik A. Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands

3:35 PM

DEBATE: Septuagenarians Should Be Eligible For Lung Transplantation (CON)

Steven Hays, MD, FRCPC, University of California, San Francisco, CA, USA

1:45 PM - 3:45 PM

Pre-Meeting Symposium 18: Proximal, Distal, Balloons, and Scalpels: Current Issues in CTEPH

**Location** :

Maryland Suite

Target Audience:

PH, HF, LF, PEDS

Chairs:

William Auger, MD, and Olaf Mercier, MD, PhD

**Session Summary** : This session will focus on indications for pulmonary endarterectomy (PEA), updated definitions, medical therapy both pre and post PEA, as well as the use of balloon pulmonary angioplasty in CTEPH.

1:45 PM

Epidemiology and Diagnosis of CTEPH: From Initial Insult to Elusive V/Q Scan

Carmine Dario Vizza, MD, University of Rome, Rome, Italy

2:05 PM

Q & A

2:09 PM

The Surgeon's Paradise: Pre-operative Risk Stratification and Intra-operative Grading System of CTEPH

Michael M. Madani, MD, UCSD Medical Center, San Diego, CA, USA

2:29 PM

Q & A

2:33 PM

BPA vs PEA: Selection Criteria for the Appropriate Use of Balloon Pulmonary Angioplasty

Elie Fadel, MD, Hospital Marie Lannelongue, Le Plessis Robinson, France

2:53 PM

Q & A

2:57 PM

Distal Disease: Who is a Surgical Candidate and Not?

Marc De Perrot, MD, University of Toronto, Toronto, ON, Canada

3:17 PM

Q & A

3:21 PM

CTEPH Thereafter: How to Define Residual PH After PEA?

Marion Delcroix, MD, University Hospital Leuven, Leuven, Belgium

3:41 PM

Q & A

1:45 PM - 3:45 PM

Pre-Meeting Symposium 19: Between a Rock and a Hard Place: Debating Treatment Decisions for Marginal Psychosocial Candidates

**Location** :

Virginia Suite

Target Audience:

NHSAH, HF, HTX, LTX, MCS

Chairs:

Michael G. Petty, PhD, RN, CNS, and Michael A. McDonald, MD

**Session Summary** : This session will include three debates, each one presenting a marginal psychosocial candidate for transplant (TX) listing and/or mechanical circulatory support (MCS) implantation. Speakers will use best available evidence and current clinical practice in different healthcare systems to guide the arguments.

1:45 PM

Case Presentation for DEBATE 1: You Can Go Your Own Way

Michael A. McDonald, MD, Toronto General Hospital, Toronto, ON, Canada

1:50 PM

DEBATE 1: You Can Go Your Own Way (PRO)

Fabienne Dobbels, MSc, PhD, KU Leuven, Leuven, Belgium

2:00 PM

DEBATE 1: You Can Go Your Own Way (CON)

Luke J Burchill, MD, Oregon Health Sciences University, Portland, OR, USA

2:10 PM

PANEL DISCUSSION

2:25 PM

Case Presentation for DEBATE 2: MCS: I Don't Need Anyone's Help!

Finn Gustafsson, MD, PhD, ViCare Medical Rigshospitalet, Copenhagen, Denmark

2:30 PM

DEBATE 2: MCS: I Don't Need Anyone's Help! (PRO **)**

Quincy Young, PhD, RPsych, St. Paul's Hospital, Vancouver, BC, Canada

2:40 PM

DEBATE 2: MCS: I Don't Need Anyone's Help! (CON)

Jeremy Kobulnik, MD, University of Toronto, Toronto, ON, Canada

2:50 PM

PANEL DISCUSSION

3:05 PM

Case Presentation for DEBATE 3: Substance Use: It's OK To Dabble

Nancy P. Blumenthal, CRNP, Hospital of University of Pennsylvania, Philadelphia, PA, USA

3:10 PM

DEBATE 3: Substance Use: It's OK To Dabble (PRO)

Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

3:20 PM

DEBATE 3: Substance Use: It's OK To Dabble (CON)

Jay Baumwol, MBBS, FRACP, Royal Perth Hospital, Perth, Australia

3:30 PM

PANEL DISCUSSION

1:45 PM - 3:45 PM

Pre-Meeting Symposium 20: Big Data to Answer Big Questions: Biobanking to "Omics" to Personalized Medicine in Thoracic Organ Transplantation

**Location** :

Delaware Suite

Target Audience:

ALL

Chairs:

Howard Eisen, MD, and Glen P Westall, FRACP, PhD

**Session Summary** : As organ transplant research programs continue to develop worldwide, there will be an urgent need to externally validate individual findings before clinical application. This session will review how and why we collect each biospecimen and ensure proper use of those specimens. The aim is to personalize modern medicine by integrating multilevel clinical and omic data into clinical management tools.

1:45 PM

Why to Biobank? How It Has Advanced Our Understanding of Transplant Immunobiology?

Peter Heeger, MD, Mount Sinai Medical Center, New York, NY, USA

2:00 PM

Q & A

2:05 PM

How to Biobank? Lessons Learned (The Hard Way)

Jason D. Christie, MD, University of Pennsylvania, Philadelphia, PA, USA

2:20 PM

Q & A

2:25 PM

Big Data and Modeling: Turning Diversity Into Patient Care Benefit

Octavio Pajaro, MD, Mayo Clinic, Phoenix, AZ, USA

2:40 PM

Q & A

2:45 PM

OMICS in Heart Transplant: Pumping Out the Answers?

Hendrik Milting, PhD, Heart & Diabetes Center, Bad Oeynhausen, Germany

3:00 PM

Q & A

3:05 PM

OMICS in Lung Transplant: Airing Out the Data

Christophe Pison, MD, PhD, Université de Grenoble, Grenoble, France

3:20 PM

Q & A

3:25 PM

Turning Dream Into Reality: How Will Omics and Big Data Deliver Personalized Medicine?

Mario C. Deng, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

3:40 PM

Q & A

1:45 PM - 3:45 PM

Pre-Meeting Symposium 21: Unraveling "Chronic Rejection" in the Heart

**Location** :

Washington Ballroom 2

Target Audience:

PATH, BSI, HF, HTX, LTX, PEDS

Chairs:

Carmela D. Tan, MD, and Martin J. Goddard, FRCS MRCPa

**Session Summary** : This session will evaluath=e "chronic rejection"; a controversial and somewhat ambiguous term. Despite major advances in HLA matching, rejection surveillance, and immunosuppression in cardiac transplantation, allograft vasculopathy (CAV) and other "chronic rejection" changes at the microvascular and myocardial levels continue to contribute to premature demise of transplanted hearts.

1:45 PM

Beyond CAV: Immunopathology, Histopathology, and Ultrastructural Pathology in "Chronic Rejection" of the Cardiac Allograft

M. Elizabeth H. Hammond, MD, LDS Hospital, Salt Lake City, UT, USA

2:05 PM

Q & A

2:09 PM

Evidence for Local Antibody Production in Cardiac Allograft Vasculopathy

Manon Huibers, PhD, University Medical Center, Utrecht, Netherlands

2:29 PM

Q & A

2:33 PM

Complement and Non-complement Mediated Mechanisms of Graft Injury and Their Role in "Chronic Rejection"

William M Baldwin III, MD PhD, Cleveland Clinic, Cleveland, OH, USA

2:53 PM

Q & A

2:57 PM

"Chronic Rejection" Elsewhere: Analogs and Lessons from the Transplanted Lung, Kidney, and Liver

Martin J. Goddard, FRCS MRCPa, Papworth Hospital, Cambridge, United Kingdom

3:17 PM

Q & A

3:21 PM

Animal Models of Graft Vasculopathy - Evidence for Antibodies and Potential Therapeutic Targets

Sonja Schrepfer, MD, PhD, University Heart Center Hamburg, Hamburg, Germany

3:41 PM

Q & A

4:00 PM - 6:00 PM

Pre-Meeting Symposium 22: Great Debates in Mechanical Circulatory Support

**Location** :

Salons 2-3

Target Audience:

MCS, HF, HTX, NHSAH

Chairs:

Eugene C DePasquale, MD, and Steven SL Tsui, MD, FRCS

**Session Summary** : The role of MCS worldwide is steadily increasing, however, certain challenges remain in management of LVAD patients. This session focuses on controversial treatment strategies for patients at the boundaries of accepted MCS management.

4:00 PM

Case Presentation for DEBATE 1: Age > 70: Destination Therapy, Not Heart Transplant

Sebastian V Rojas, MD, Hannover Medical School, Hannover, Germany

4:05 PM

DEBATE 1: Age > 70: Destination Therapy, Not Heart Transplant (PRO)

Andrew J. Boyle, MD, Piedmont Heart Institute, Atlanta, GA, USA

4:15 PM

DEBATE 1: Age > 70: Destination Therapy, Not Heart Transplant (CON)

Joseph G Rogers, MD, Duke University Medical Center, Durham, NC, USA

4:25 PM

DEBATE REBUTTAL (PRO)

4:30 PM

DEBATE REBUTTAL (CON)

4:35 PM

Case Presentation for DEBATE 2: INTERMACS 4-7: The Time is Now

Brent C Lampert, DO, Ohio State University Wexner Medical Center, Columbus, OH, USA

4:40 PM

DEBATE 2: INTERMACS 4-7: The Time is Now (PRO)

Jeffrey J. Teuteberg, MD, University of Pittsburgh, Pittsburgh, PA, USA

4:50 PM

DEBATE 2: INTERMACS 4-7: The Time is Now (CON)

Daniel Zimpfer, MD, Medical University of Vienna, Vienna, Austria

5:00 PM

DEBATE REBUTTAL (PRO)

5:05 PM

DEBATE REBUTTAL (CON)

5:10 PM

Case Presentation for DEBATE 3: Minimally Invasive Implantation is the Procedure of Choice

Julia Riebandt, MD, Medical University of Vienna, Vienna, Austria

5:15 PM

DEBATE 3: Minimally Invasive Implantation is the Procedure of Choice (PRO)

Jan D. Schmitto, MD, PhD, MBA, Hannover Medical School, Hannover, Germany

5:30 PM

DEBATE 3: Minimally Invasive Implantation is the Procedure of Choice (CON)

Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA

5:45 PM

DEBATE REBUTTAL (PRO)

5:50 PM

DEBATE REBUTTAL (CON)

4:00 PM - 6:00 PM

Pre-Meeting Symposium 23: A 2016 Focused Update on AMR in Cardiac Transplantation: Immunologic Diagnostics and the Treatment of Refractory AMR

**Location** :

Thurgood Marshall

Target Audience:

HTX, BSI, HF, NHSAH, PATH, PEDS, PHARM

Chairs:

Palak Shah, MD, MS, and A. G. Kfoury, MD, FACC

**Session Summary** : This symposium will provide a state-of-the-art evaluation of diagnosing and managing antibody-mediated rejection (AMR) of the cardiac allograft with a focus on immunologic, pathologic and genomic diagnostics as well as the pharmacologic and non-pharmacologic treatment of more refractory AMR.

4:00 PM

It is Time to Move to Molecular Technologies for Detection of AMR

Elaine F Reed, PhD, UCLA Immunogenetics Center, Los Angeles, CA, USA

4:20 PM

Q & A

4:24 PM

Do We Need Both Histologic and Immunologic Features on Biopsy to Accurately Diagnose Antibody-Mediated Rejection?

Annalisa Angelini, MD, University of Padua, Padua, Italy

4:44 PM

Q & A

4:48 PM

What Drug Therapies, What Data for Refractory AMR?

Jignesh Patel, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

5:08 PM

Q & A

5:12 PM

What Immunologic Testing Features Suggest Clinically Significant Antibodies vs an Innocent Bystander?

Kathryn J Tinckam, MD, University Health Network, Toronto, ON, Canada

5:32 PM

Q & A

5:36 PM

Management of Antibodies in Heart Transplantation: Insights from 2016 Consensus Conference

Jon A. Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

5:56 PM

Q & A

4:00 PM - 6:00 PM

Pre-Meeting Symposium 24: Endotypes of CLAD and Novel Treatment Strategies

**Location** :

Salon 1

Target Audience:

LTX, BSI, PATH, PEDS

Chairs:

Tereza Martinu, MD, and Stijn E Verleden, PhD

**Session Summary** : The aim of this symposium is to provide both basic and clinical data regarding different CLAD phenotypes, their differing prognoses and treatment algorithms. Novel treatments will be reviewed including the role of cell based therapies and extracorporeal photopheresis.

4:00 PM

Current and Historical Evidence for Phenotyping of CLAD

Miranda Paraskeva, MBBS, Alfred Hospital, Melbourne, Australia

4:15 PM

Q & A

4:20 PM

CLAD Endotypes - Diagnosis, Radiology and Pathology

Masaaki Sato, MD, University of Tokyo, Tokyo, Japan

4:35 PM

Q & A

4:40 PM

Contemporary Medical and Surgical Treatment Options for CLAD Phenotypes - Are All CLAD Patients Created Equal?

Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany

4:55 PM

Q & A

5:00 PM

Extracorporeal Photopheresis and Regulatory T cells - Role in CLAD?

Christian Benden, MD, University Hospital Zurich, Zurich, Switzerland

5:15 PM

Q & A

5:20 PM

Cell-Based Therapy for CLAD - Current Evidence and Future Prospects

Cesar Keller, MD, The Mayo Clinic, Jacksonville, FL, USA

5:35 PM

Q & A

5:40 PM

Future Perspectives: Prevention of CLAD - Why are We Failing and How to Improve?

Scott M. Palmer, MD, MHS, Duke University, Durham, NC, USA

5:55 PM

Q & A

4:00 PM - 6:00 PM

Pre-Meeting Symposium 25: Inflammation and Altered Metabolism in Pulmonary Hypertension

**Location** :

Maryland Suite

Target Audience:

PH, ALL

Chairs:

Thenappan Thenappan, MD, and John Granton, MD

**Session Summary** : This session will combine basic and translational research focusing on alteration in metabolism and inflammation in pulmonary vascular disease.

4:00 PM

The Pathobiology of Inflammation in Pulmonary Hypertension

Marc Humbert, MD, Université Paris-Sud, Clamart, France

4:15 PM

Q & A

4:20 PM

The Impact of Insulin Resistance in Pulmonary Hypertension

Anna Hemnes, MD, Vanderbilt University, Nashville, TN, USA

4:35 PM

Q & A

4:40 PM

Inflammatory Cytokines And Their Role In Pulmonary Hypertension

Mark Nicolls, MD, Stanford University, Palo Alto, CA, USA

4:55 PM

Q & A

5:00 PM

Alterations in Lipid Metabolism in Pulmonary Hypertension

Ioana Preston, MD, Tufts Medical Center, Boston, MA, USA

5:15 PM

Q & A

5:20 PM

MicroRNAs in Pulmonary Hypertension: Insights in Signaling Pathways

Lars Huber, MD, University Hospital of Zurich, Zurich, Switzerland

5:35 PM

Q & A

5:40 PM

Neurohormonal and Metabolic Modulations for Improving Right Ventricular-Pulmonary Artery Coupling in PAH

Lisa M Mielniczuk, MD, University of Ottawa Heart Institute, Ottawa, ON, Canada

5:55 PM

Q & A

4:00 PM - 6:00 PM

Pre-Meeting Symposium 26: Hanging in the Balance: Minimizing Risk and Maximizing Benefit with Donor Derived Infection

**Location** :

Virginia Suite

Target Audience:

ALL

Chairs:

Martha L. Mooney, MD, FACP, and Kate Gould, FRCPath

**Session Summary** : Maintaining the balance between the shortage of donor organs and avoiding transmission of infection is an ongoing challenge in thoracic transplantation. Attendees at this session will receive a complete update of the current state of donor-derived infections to be prepared for that next complex donor call.

4:00 PM

Donor Derived Infections: The European Perspective

Paolo A Grossi, MD, PhD, University of Insubria, Varese, Italy

4:17 PM

Q & A

4:20 PM

Donor Derived Infections: The North American Perspective

Joanna M. Schaenman, MD, PhD, UCLA School of Medicine, Los Angeles, CA, USA

4:37 PM

Q & A

4:40 PM

The Infected Donor: Pre-transplant & Post-transplant Management

Phillip Zakowski, MD, Tower ID Medical Associates, Inc., Los Angeles, CA, USA

4:57 PM

Q & A

5:00 PM

The Encephalitic Donor: A Cautionary Tale

Me-Linh Luong, MD, St. Luc Hospital, Montreal, QC, Canada

5:17 PM

Q & A

5:20 PM

Playing the Odds: The ABCs of NAT for HIV, HCV and HBV in Increased Risk Donors

Michael G Ison, MD MS, Northwestern Memorial Hospital, Chicago, IL, USA

5:37 PM

Q & A

5:40 PM

The HIV-positive Donor: "Hope" or Havoc?

Emily A. Blumberg, MD, University of Pennsylvania, Philadelphia, PA, USA

5:57 PM

Q & A

4:00 PM - 6:00 PM

Pre-Meeting Symposium 27: VAD in Patients with Congenital Heart Disease

**Location** :

Delaware Suite

Target Audience:

PEDS, HF, HTX, MCS, NHSAH

Chairs:

Angela Lorts, MD, and Martin Schweiger, MD

**Session Summary** : This session will focus on VAD therapy for heart failure in congenital heart disease and will debate current organ allocation policies for ACHD patients.

4:00 PM

VADs for Univentricular Circulation - Fact or Fiction?

Pirooz Eghtesady, MD, PhD, St. Louis Children's Hospital, St. Louis, MO, USA

4:15 PM

Q & A

4:20 PM

Can We Get VAD Patients Home?

Jennifer Conway, MD, Stollery Children's Hospital, Edmonton, AB, Canada

4:35 PM

Q & A

4:40 PM

Collateral Damage From VADs - What Will Compromise Transplant Outcomes?

Kathleen Simpson, MD, Washington University and St. Louis Children's Hospital, St. Louis, MO, USA

4:55 PM

Q & A

5:00 PM

ACHD Patients - Why Are They Different?

Leigh C Reardon, MD, UCLA, Los Angeles, CA, USA

5:15 PM

Q & A

5:20 PM

DEBATE: Congenital Heart Disease Patients Should Get Priority Organ Allocation (PRO)

David Crossland, MRCP, Freeman Hospital, Newcastle upon Tyne, United Kingdom

5:30 PM

DEBATE: Congenital Heart Disease Patients Should Get Priority Organ Allocation (CON)

Heather J. Ross, MD, MHSc, FRCPC, Toronto General Hospital, Toronto, ON, Canada

5:40 PM

PANEL DISCUSSION

4:00 PM - 6:00 PM

Pre-Meeting Symposium 28: Lifecycle Journey of Hepatitis C Heart Failure Patient in 2016

**Location** :

Washington Ballroom 2

Target Audience:

PHARM, HF, ID, MCS, NHSAH

Chairs:

Jerrica E Shuster, PharmD, and Andreas Zuckermann, MD

**Session Summary** : The lifecycle journey of a heart failure patient with hepatitis C will be used to evaluate issues including candidate selection, balancing the risk of immunosuppression and malignancy post transplant and finally, when to palliate.

4:00 PM

Case Presentation: Lifecycle Journey

Jerrica E Shuster, PharmD, Barnes-Jewish Hospital, St. Louis, MO, USA

4:04 PM

Hepatitis C Medications - New Armamentarium Has Arrived!

Adam B Cochrane, PharmD, Inova Fairfax Hospital, Falls Church, VA, USA

4:21 PM

Lifecycle Journey Case Update

Jerrica E Shuster, PharmD

4:25 PM

Chronic Hepatitis C Candidate - Timing of Intervention

Paolo A Grossi, MD, PhD, University of Insubria, Varese, Italy

4:37 PM

Lifecycle Journey Case Update

Jerrica E Shuster, PharmD

4:41 PM

Immunosuppression - A Tricky Balance?

Michael Shullo, PharmD, University of Pittsburgh, Pittsburgh, PA, USA

4:58 PM

Lifecycle Journey Case Update

Jerrica E Shuster, PharmD

5:02 PM

Malignancies in Heart Transplant

Donna M. Mancini, MD, New York Presbyterian Hospital, New York, NY, USA

5:19 PM

Lifecycle Journey Case Update

Jerrica E Shuster, PharmD

5:23 PM

Heavy is the Heart....

Deborah E. Meyers, MD. FRACP, FACC, Texas Heart Institute, Houston, TX, USA

5:45 PM

PANEL DISCUSSION
ANNUAL MEETING SCIENTIFIC PROGRAM

THURSDAY, APRIL 28, 2016

8:00 AM - 10:00 AM

Opening Plenary Session - Transplantation: Where Does the Science End and the Art Begin?

**Location** :

Salon 1-3

Target Audience:

ALL

Chairs:

Duane Davis, MD, MBA, and Andrew J. Fisher, FRCP, PhD

8:00 AM

Welcome/Program Chair Report

Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, UK

8:05 AM

Thoracic Registry Report

Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA

8:25 AM

IMACS Registry Report

James K. Kirklin, MD, University of Alabama at Birmingham, Birmingham, AL, USA

8:35 AM

**(1) FEATURED ABSTRACT:** HeartMate 3 Fully Magnetically Levitated Left Ventricular Assist Device for the Treatment of Advanced Heart Failure -1 Year Results from the CE Mark Trial; T. Krabatsch1, J. D. Schmitto2, Y. Pya3, D. Zimpfer4, J. Garbade5, V. Rao6, M. Morshuis7, S. Marasco8, F. Beyersdorf9, P. Sood10, L. Damme10, I. Netuka11. 1 _Deutsches Herzzentrum Berlin, Berlin, Germany,_ 2 _Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany,_ 3 _National Research Cardiac Surgery Center, Astana, Kazakhstan,_ 4 _University of Vienna, Vienna, Austria,_ 5 _Heart Center Leipzig, Leipzig, Germany,_ 6 _Toronto General Hospital, Toronto, ON, Canada,_ 7 _Thoracic and Cardiovascular Surgery Clinic, Bad Oeynhausen, Germany,_ 8 _The Alfred Hospital, Melbourne, Australia,_ 9 _University Heart Center Freiburg-Bad Krozingen, Freiburg, Germany,_ 10 _Thoratec Corporation, Burlington, MA,_ 11 _Institute for Clinical and Experimental Medicine, Prague, Czech Republic_

8:45 AM

Expert Discussant Q & A

Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA

8:50 AM

Introduction to Speaker

Reda E. Girgis, MD, Spectrum Health Hospitals, Grand Rapids, MI, USA

8:52 AM

From Lung Transplant to Lincoln Center

Charity Tilleman-Dick, Washington, DC, USA

9:15 AM

President's Report

Duane Davis, MD, Florida Hospital, Orlando, FL, USA

9:30 AM

Pioneer Award Recipient Lecture: The Quest for Effective Immunosuppression

Sir Roy Calne, FRCP, FRCS, FRS, Cambridge University, London, UK

10:30 AM - 12:00 PM

Concurrent Session 1: Too Much of a Bad Thing? Complications after Mechanical Support

**Location** :

Salons 1-3

Target Audience:

MCS, HF, ID, NHSAH

Chairs:

Michel Morshuis, MD, and Chetan B Patel, MD

**10:30 AM (2)** _Temporal Changes in Adverse Events in the ENDURANCE Trial;_ C. A. Milano1, F. D. Pagani2, A. J. Tatooles3, N. A. Mokadam4, J. Miller5, T. C. Wozniak6, C. H. Selzman7, K. Leadley8, K. D. Aaronson2, J. G. Rogers9. 1 _Department of Surgery, Duke University School of Medicine, Durham, NC,_ 2 _University of Michigan, Ann Arbor, MI,_ 3 _Advocate Christ Medical Center, Oak Lawn, IL,_ 4 _University of Washington, Seattle, WA,_ 5 _Emory Healthcare, Atlanta, GA,_ 6 _Indiana University Health, Indianapolis, IN,_ 7 _University of Utah, Salt Lake City, UT,_ 8 _HeartWare, Framingham, MA,_ 9 _Duke University School of Medicine, Durham, NC_

**10:45 AM (3)** _Stroke with Continuous-Flow LVADs;_ D. Acharya1, C. Morgan2, S. Pamboukian1, R. Loyaga-Rendon1, J. Kirklin1, W. Holman1, J. Tallaj1. 1 _University of Alabama at Birmingham, Birmingham, AL,_ 2 _Biostatistics, University of Alabama at Birmingham, Birmingham, AL_

**11:00 AM (4)** _Hemorrhagic Transformation of Ischemic Strokes in Patients with Continuous Flow Left Ventricular Assist Devices;_ J. K. Wong, A. L. Melvin, A. K. Lidder, W. J. Archibald, J. Lehoux, P. A. Knight. _Division of Cardiac Surgery, University of Rochester Medical Center, Rochester, NY_

**11:15 AM (5)** _Clinical Outcomes Reveal a Spectrum of Early Right Heart Failure after Left Ventricular Assist Device;_ E. W. Grandin1, G. S. Troutman1, A. A. Gulati2, P. Zamani1, J. A. Mazurek1, E. Y. Birati1, J. W. Wald1, K. B. Margulies1, P. Atluri3, J. E. Rame1. 1 _Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA,_ 2 _University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA,_ 3 _Division of Cardiothoracic Surgery, University of Pennsylvania, Philadelphia, PA_

**11:30 AM (6)** _Incidence and Impact of Sustained Ventricular Arrhythmias after Continuous-Flow Left Ventricular Assist Device Implantation_ ; S. Yap1, R. Muslem1, F. Ramjankhan2, N. De Jonge3, A. A. Constantinescu1, O. C. Manintveld1, T. Szili-Torok1, K. Caliskan1. 1 _Cardiology, Erasmus MC, Rotterdam, Netherlands,_ 2 _Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, Netherlands,_ 3 _Cardiology, University Medical Center Utrecht, Utrecht, Netherlands_

**11:45 AM (7)** _Device-Related Infection Rates of Continuous-Flow Ventricular Assist Devices Using a Thoracic Driveline Exit Site;_ M. A. Psotka1, D. Lowe2, J. C. Cox2, R. G. Kiel1, M. Janmohamed1, V. N. Selby1, T. De Marco1, L. Klein1, G. M. Wieselthaler2. 1 _Cardiology, University of California San Francisco, San Francisco, CA,_ 2 _Cardiothoracic Surgery, University of California San Francisco, San Francisco, CA_

10:30 AM - 12:00 PM

Concurrent Session 2: On the Road to Recovery: Treating Chronic Heart Failure with Mechanical Support

**Location** :

Thurgood Marshall

Target Audience:

MCS, BSI, HF, LBCS

Chairs:

Martin Strueber, MD, and Stavros G Drakos, MD

**10:30 AM (8)** _LVAD Explantation for Cardiac Recovery: Insights from the Interagency Registry for Mechanically Assisted Circulatory Support;_ O. Wever-Pinzon1, S. G. Drakos1, S. H. McKellar2, A. Koliopoulou2, J. Stehlik1, C. H. Selzman2. 1 _Cardiology, University of Utah, Salt Lake City, UT,_ 2 _Cardiothoracic Surgery, University of Utah, Salt Lake City, UT_

**10:45 AM (9)** _Association of Pre-Implant Inflammatory Profile and Functional Recovery with Chronic LVAD Unloading;_ L. McCreath, S. G. Drakos, P. Ferrin, N. Diakos, S. Navankasattusas, H. Javan, D. Budge, S. H. McKellar, W. T. Caine, O. Wever-Pinzon, M. Bonios, K. Skedros, A. Ragnhildstveit, K. Afshar, D. Y. Li, J. Stehlik, A. G. Kfoury, C. H. Selzman. _UTAH Cardiac Transplant Program, Salt Lake City, UT_

**11:00 AM (10)** _LVAD Support Is Associated with Reduced Serum VEGF-D Levels;_ B. A. Houston1, J. Vaishnav2, D. P. Judge1, R. J. Tedford1, S. D. Russell1, R. Rouf1. 1 _Cardiology, Johns Hopkins Hospital, Baltimore, MD,_ 2 _Medicine, Johns Hopkins Hospital, Baltimore, MD_

**11:15 AM (11)** _Relationship of Myocardial Fibrosis with the Potential of Mechanical Unloading to Induce Favorable Cardiac Structural and Functional Response;_ P. Ferrin1, L. McCreath1, N. Diakos1, S. Navankasattusas1, A. G. Kfoury1, O. Wever-Pinzon1, M. Al-Sarie1, A. Catino1, M. Bonios1, R. Alharethi1, G. Russell2, A. Ragnhildstveit1, K. Skedros1, E. H. Hammond1, D. Y. Li1, C. H. Selzman1, W. Caine1, J. Stehlik1, S. G. Drakos1. 1 _UTAH Cardiac Transplant Program (University of Utah, Intermountain Medical Center, Salt Lake VA Medical Center), Salt Lake City, UT,_ 2 _Intermountain Donor Services, Salt Lake City, UT_

**11:30 AM (12)** _Soluble ST2 Levels in End-Stage Heart Failure and during LVAD Support;_ C. C. Tseng1, M. M. Huibers2, L. Gaykema2, S. A. Chamuleau1, N. de Jonge1. 1 _Cardiology, University Medical Center Utrecht, Utrecht, Netherlands,_ 2 _Pathology, University Medical Center Utrecht, Utrecht, Netherlands_

**11:45 AM (13)** _Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients with Left Ventricular Assist Devices;_ A. H. Healy1, M. E. Bowen1, B. S. Brooke1, S. H. McKellar1, S. G. Drakos2, C. H. Selzman1. 1 _Surgery, University of Utah, Salt Lake City, UT,_ 2 _Medicine, University of Utah, Salt Lake City, UT_

10:30 AM - 12:00 PM

Concurrent Session 3: Donor Organ Allocation and Management – What's Hot and New?

**Location** :

Maryland Suite

Target Audience:

LTX, BSI, EEP, ID, LBCS, NHSAH, PEDS, PHARM

Chairs:

Michael S Mulligan, MD, and Marc De Perrot, MD

**10:30 AM (14)** _Lung Allocation Score Does Not Reflect Post-Lung Transplant Outcome in a Use of Low Risk Donor;_ T. Kurosaki, K. Miyoshi, K. Imanishi, T. Okawa, S. Otani, S. Sugimoto, M. Yamane, S. Miyoshi, T. Oto. _Department of Thoracic Surgery, Organ Transplant Center, Okayama University Hospital, Okayama, Japan_

**10:45 AM (15)** _Low Correlation in Longevity between Lung Grafts from the Same Donor;_ M. Zemtsovski1, M. Perch2, C. H. Møller3, P. Bredahl1, M. Iversen2. 1 _Cardiothoracic Anaesthesia, Rigshospitalet, Copenhagen, Denmark,_ 2 _Department of Cardiology, Division of Lung Transplantation, Rigshospitalet, Copenhagen, Denmark,_ 3 _Department of Cardiothoracic Surgery, Rigshospitalet, Copenhagen, Denmark_

**11:00 AM (16)** _'Unacceptable' Human Leukocyte Antigens in Lung Re-Transplantation;_ W. Sommer1, M. Hallensleben2, F. Ius1, C. Kuehn1, I. Tudorache1, M. Avsar1, J. Salman1, T. Siemeni1, M. Greer3, J. Gottlieb3, D. Boethig4, R. Blasczyk2, A. Haverich1, G. Warnecke1. 1 _Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany,_ 2 _Transfusion Medicine, Hannover Medical School, Hannover, Germany,_ 3 _Pneumology, Hannover Medical School, Hannover, Germany,_ 4 _Pediatric Cardiology and Intensive Care Medicine, Hannover Medical School, Hannover, Germany_

**11:15 AM (17)** _Lung First vs. Liver First Sequence for Combined Lung and Liver Transplantation;_ J. Salman1, F. Ius1, W. Sommer1, T. Siemeni1, I. Tudorache1, M. Avsar1, C. Kuehn1, G. Grannas2, J. Gottlieb3, T. Welte3, F. Lehner1, N. Richter2, J. Klempnauer2, A. Haverich1, G. Warnecke1. 1 _Department for Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany,_ 2 _Department for General, Abdominal and Transplant Surgery, Hannover Medical School, Hannover, Germany,_ 3 _Department of Pneumology, Hannover Medical School, Hannover, Germany_

**11:30 AM (18)** _Single Center Results with Normothermic Ex Vivo Lung Perfusion: A Propensity Matched Analysis;_ J. C. Yeung, P. Reck dos Santos, J. Reeb, K. Yasufuku, M. de Perrot, A. F. Pierre, T. K. Waddell, L. G. Singer, S. Keshavjee, M. Cypel. _University of Toronto, Toronto, ON, Canada_

**11:45 AM (19)** _Mid and Long-Term Clinical Results of OCS Lung INSPIRE International Trial;_ G. Warnecke1, D. Van Raemdonck2, J. Kukreja3, M. Smith4, G. Loor5, F. Rea6, G. Massard7, F. De Robertis8, J. Nagendran9, J. Moradiellos10, K. Dhital11, C. Knosalla12, C. Bermudez13, S. Tsui14, J. Madsen15, I. Wang16, K. McCurry17, T. Deuse18, P. Thomas19, W. Sommer1, B. Weigmann1, C. Khun1, I. Tudorache1, M. Avsar1, M. Schiavon6, N. Santelmo20, A. Olland20, P. Falcoz20, A. Varela10, M. Hertz21, A. Simon8, H. Resichenspurner22, A. Haverich1, A. Ardehali23. 1 _Thoracic Surgery, Hannover Medical School, Hannover, Germany,_ 2 _Thoracic Surgery, Leuven University Hospital, Leuven, Belgium,_ 3 _Thoracic Surgery, University of California San Francisco Medical, San Francisco, CA,_ 4 _Thoracic Surgery, St. Joseph's Medical Center, Phoenix, AZ,_ 5 _Cardiothoracic Surgery, University of Minnesota Medical Center, Minneapolis, MN,_ 6 _Thoracic Surgery, University of Padua Hospital, Padua, Italy,_ 7 _Thoracic Surgery, 7Strasbourg University Hospital, Strasbourg, France,_ 8 _Thoracic Surgery, Harefield Hospital, London, United Kingdom,_ 9 _Thoracic Surgery, 9University of Alberta Medical Center, Edmonton, ON, Canada,_ 10 _Thoracic Surgery, University Puerta de Hierro Hospital, Madrid, Spain,_ 11 _Thoracic Surgery, 11St. Vincent's Hospital, Sydney, Australia,_ 12 _Thoracic Surgery, German Heart Institute, Berlin, Germany,_ 13 _Thoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA,_ 14 _Cardiothoracic Surgery, Papworth Hospital, Papworth, United Kingdom,_ 15 _Cardiothoracic Surgery, Massachusetts General Hospital, Boston, MA,_ 16 _Cardiothoracic Surgery, Indiana University Medical Center, Indianapolis, IN,_ 17 _Thoracic Surgery, Cleveland Clinic Foundation, Cleveland, OH,_ 18 _Thoracic Surgery, Hamburg University Hospital, Hamburg, Germany,_ 19 _Thoracic Surgery, University Hospitals of Marseille, Marseille, France,_ 20 _Thoracic Surgery, Strasbourg University Hospital, Strasbourg, France,_ 21 _Transplant Pulmonary Medicine, University of Minnesota Medical Center, Minneapolis, MN,_ 22 _Cardiothoracic Surgery, Hamburg University Hospital, Hamburg, Germany,_ 23 _Cardiothoracic Surgery, Ronald Reagan UCLA Medical Center, Los Angeles, CA_

10:30 AM - 12:00 PM

Concurrent Session 4: Keep It Down: New Insights on Immunosuppression

**Location** :

Virginia Suite

Target Audience:

HTX, ID, LBCS, NHSAH, PATH, PEDS, PHARM

Chairs:

Mario C Deng, MD, and Anique Ducharme, MD, MSC

**10:30 AM (20)** _Urine Cell-Free Donor-Derived DNA (ucfdDNA) after Heart Transplantation;_ S. Agbor-Enoh1, J. Doveikis1, J. Zhu1, i. Tunc1, X. Wang1, A. Jackson2, M. Solomon1, H. Valantine1. 1 _Nat'l Inst. of Health, Bethesda, MD,_ 2 _Johns Hopkins Hospital, Baltimore, MD_

**10:45 AM (21)** _Outcomes with Gene Expression Profiling for Cardiac Transplant Recipients within North America;_ P. Shah1, D. Hiller2, M. Maydosz1, E. Deljkich2, J. Yee2, A. Cochrane1. 1 _Heart Failure & Transplantation, Inova Heart and Vascular Institute, Falls Church, VA, _2 _CareDx, Inc., Brisbane, CA_

**11:00 AM (22)** _The Effect of Everolimus Initiation and Early Calcineurin Inhibitor Withdrawal on Allograft Vasculopathy Assessed by Virtual Histology: Results of the SCHEDULE Trial;_ S. Arora1, O. Solberg1, F. Gustafsson2, K. Karason3, H. Eiskjær4, H. E. Bøtker4, G. Rådegran5, G. Dellgren3, D. Ioanes3, E. Gude1, D. Solbu6, A. K. Andreassen1, L. Gullestad1. 1 _Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway,_ 2 _Cardiology, Copenhagen University Hospital, Copenhagen, Denmark,_ 3 _Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden,_ 4 _Cardiology, Skejby University Hospital, Aarhus, Denmark,_ 5 _Cardiology, Skåne University Hospital and Lund University, Lund, Sweden,_ 6 _Novartis Norge AS, Oslo, Norway_

**11:15 AM (23)** _Duration of Corticosteroid (CS) Use as Maintenance Immunosuppression and Long-Term Outcomes after Adult Heart Transplantation: A Contemporary Analysis of the International Society for Heart and Lung Transplantation (ISHLT) Registry;_ L. A. Goldraich1, J. Stehlik2, L. B. Edwards3, A. Dipchand4, H. J. Ross5. 1 _Cardiac Transplant Program, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil,_ 2 _University of Utah School of Medicine, Salt Lake City, UT,_ 3 _International Society for Heart and Lung Transplantation, Richmond, VA,_ 4 _Cardiac Transplant Program, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada,_ 5 _Cardiac Transplant Program, Peter Munk Cardiac Center, University of Toronto, Toronto, ON, Canada_

**11:30 AM (24)** _Calcineurin Inhibitor (CNI) Delay with ATG Induction: Teaching an Old Dog, New Tricks;_ A. Z. Aliabadi1, J. Goekler1, O. Salameh1, T. Haberl1, B. Steinlechner2, P. Opfermann2, A. Kaider1, K. Uyanik-Ünal1, G. Laufer1, A. O. Zuckermann1. 1 _Cardiac Surgery, Med Univ of Vienna, Vienna, Austria,_ 2 _Cardiothoracic and Vascular Anaesthisiology, Med Univ of Vienna, Vienna, Austria_

**11:45 AM (25)** _Molecular Correlates of Endothelial mTOR Activation in Heart Transplant Recipients;_ M. Racapé1, A. Loupy1, J. Reeve2, J. Venner2, R. Guillemain3, L. Hidalgo2, C. Lefaucheur1, X. Jouven1, P. Bruneval3, J. Duong Van Huyen1, P. Halloran2. 1 _PARCC INSERM U970, Paris, France,_ 2 _ATAGC, University of Alberta, Edmonton, AB, Canada,_ 3 _Hôpital Européen Georges Pompidou, Paris, France_

10:30 AM - 12:00 PM

Concurrent Session 5: Improving Heart Failure Outcomes with Pills, Procedures and Sex

**Location** :

Delaware Suite

Target Audience:

HF, MCS, NHSAH, PHARM

Chairs:

Christopher S Hayward, MD, and Jose Gonzalez-Costello, MD

**10:30 AM (26)** _Assessing Renal Blood Flow Hemodynamics and Autoregulation in Humans Using Intrarenal Doppler Flow Velocity Measurement: A Novel Pilot Study;_ D. H. Kim1, A. Kiepas2, E. Nath2, N. Mitrou3, W. A. Cupples4, B. Braam5. 1 _Cardiology, University of Alberta, Edmonton, AB, Canada,_ 2 _Medicine, University of Alberta, Edmonton, AB, Canada,_ 3 _Medicine, University of Western Ontario, London, ON, Canada,_ 4 _Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada,_ 5 _Nephrology, University of Alberta, Edmonton, AB, Canada_

**10:45 AM (27)** _Renal Response to Levosimendan in Patients Listed for Heart Transplantation Predicts Postoperative Renal Function Course;_ G. Zemljic1, G. Poglajen1, I. Knezevic1, F. Haddad2, B. Vrtovec1. 1 _Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia,_ 2 _Stanford Cardiovascular Institute, Stanford, CA_

**11:00 AM (28)** _Bilateral Sympathetic Denervation Improves Left Ventricular Function and Prevents Post-Infarction Chamber Remodeling in Rats;_ F. L. Zanoni, L. F. Moreira, R. Simas, R. G. da Silva, F. B. Jatene. _Department of Cardiovascular Surgery, Heart Institute (Incor), University of Sao Paulo Medical School, Sao Paulo, Brazil_

**11:15 AM (29)** _Long-Term Adaptive Servo-Ventilator Treatment Prevents Cardiac Death and Improves Clinical Outcome in Patients with Advanced Heart Failure;_ T. Imamura1, K. Kinugawa1, D. Nitta2, M. Hatano2, I. Komuro2. 1 _Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo, Japan,_ 2 _Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan_

**11:30 AM (30)** _Laparoscopic Sleeve Gastrectomy: Safe and Effective in Heart Failure and LVAD Patients;_ S. C. George, A. A. Phancao, D. H. Karia, M. J. Sasevich, H. C. Wright, H. S. Le, S. M. Kitchen, J. W. Long, D. A. Horstmanshof. _INTEGRIS Advanced Cardiac Care, Integris Baptist Med Center, Oklahoma City, OK_

**11:45 AM (31)** _Bringing Sexy Back: Sexuality and Intimacy Concerns in an Advanced Heart Failure Population Receiving Palliative Care Consultation;_ A. Kelemen1, J. Groninger1, J. Cagle2, K. Walker3. 1 _Section of Palliative Care, Department of Medicine, MedStar Washington Hospital Center, Washington, DC,_ 2 _University of Maryland School of Social Work, Baltimore, MD,_ 3 _Section of Palliative Care, Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD_

10:30 AM - 12:00 PM

Concurrent Session 6: Pediatric Heart Transplant Outcomes

**Location** :

Washington Ballroom 2

Target Audience:

PEDS, HTX, NHSAH

Chairs:

Richard E Chinnock, MD, and Rakesh K. Singh, MD, MS

**10:30 AM (32)** _Health Related Quality of Life after Pediatric Heart Transplantation in Young Children;_ G. Garcia Guerra, A. R. Joffe, G. Y. Alton, C. Sheppard, J. Pugh, J. Conway, C. M. Robertson, S. Urschel. _Pediatrics, University of Alberta, Edmonton, AB, Canada_

**10:45 AM (33)** _Congenital Heart Disease and Severe Peri-Transplant Course Are Associated with Worse Neurocognitive Outcomes in Children Post-Heart Transplant;_ S. Urschel1, G. Alton1, F. Moradi1, I. Dinu1, J. Conway1, G. Guerra1, B. Acton2, A. Joffe1, M. AlAklabi3, I. M. Rebeyka3, C. Robertson1. 1 _Pediatrics, University of Alberta, Edmonton, AB, Canada,_ 2 _Pediatrics, University of Saskatoon, Saskatoon, SK, Canada,_ 3 _Cardiac Surgery, University of Alberta, Edmonton, AB, Canada_

**11:00 AM (34)** _Cancer Recurrence and Mortality After Pediatric Heart Transplantation for Anthracycline Cardiomyopathy;_ M. J. Bock1, E. Pahl2, P. G. Rusconi3, G. J. Boyle4, J. J. Parent5, C. J. Twist6, J. K. Kirklin7, E. Pruitt7, D. Bernstein8. 1 _Pediatric Cardiology, Loma Linda University Children's Hospital, Loma Linda, CA,_ 2 _Cardiology, Ann & Robert H. Lurie Children's Hospital of Northwestern University, Chicago, IL, _3 _Pediatric Cardiology, University of Miami, Jackson Memorial Hospital, Miami, FL,_ 4 _Pediatric Cardiology, Cleveland Clinic Foundation, Cleveland, OH,_ 5 _Pediatric Cardiology, Riley Hospital for Children, Indianapolis, IN,_ 6 _Pediatric Hematology and Oncology, Lucile Packard Children's Hospital at Stanford, Palo Alto, CA,_ 7 _Cardiovascular and Thoracic Surgery, University of Alabama at Birmingham, Birmingham, AL,_ 8 _Pediatric Cardiology, Lucile Packard Children's Hospital at Stanford, Palo Alto, CA_

**11:15 AM (35)** _Bacterial Infections in Pediatric Heart Transplant Recipients: Epidemiology, Risk Factors, and Outcomes;_ C. A. Rostad1, K. Wehrheim2, K. Berkowitz3, T. M. Hoffman4, T. L'Ecuyer5, W. T. Mahle6, E. Pruitt7, J. K. Kirklin8, J. Scheel9. 1 _Pediatric Infectious Diseases, Emory University, Atlanta, GA,_ 2 _Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, _3 _Pediatric Cardiology, Children's Healthcare of Atlanta, Atlanta, GA,_ 4 _Pediatric Cardiology, UNC Children's, Chapel Hill, NC,_ 5 _Pediatric Cardiology, University of Virginia, Charlottesville, VA,_ 6 _Pediatric Cardiology, Emory University, Atlanta, GA,_ 7 _School of Public Health, University of Alabama, Birmingham, AL,_ 8 _Cardiothoracic Surgery, University of Alabama, Birmingham, AL,_ 9 _Pediatric Cardiology, Children's National Medical Center, Washington, DC_

**11:30 AM (36)** _Number of Refusals for Donor Quality Does Not Impact Post-Transplant Outcomes in Pediatric Heart Transplantation;_ D. L. Morales1, R. Rizwan1, R. Bryant 3rd1, J. S. Tweddell1, C. Chin2, F. Zafar1. 1 _Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH,_ 2 _Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH_

**11:45 AM (37)** _Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients: Coronary Stenting as a Prognostic Indicator;_ T. Samad1, A. Razzouk2, M. Bock3, R. Chinnock1, L. Bailey2, N. Hasaniya2, M. Kuhn3, H. Anthony1, L. Stoletniy1. 1 _Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA,_ 2 _Cardiothoracic Surgery, Loma Linda University Children's Hospital, Loma Linda, CA,_ 3 _Pediatrics, Division of Cardiology, Loma Linda University Children's Hospital, Loma Linda, CA_

2:00 PM - 3:30 PM

Concurrent Session 7: It's Tough to Make Predictions, Especially about the Future: Outcomes in MCS

**Location** :

Salons 2-3

Target Audience:

MCS, HTX, NHSAH

**Chairs** :

James L Kirklin, MD, and Jeffrey J Teuteberg, MD

**2:00 PM (38)** _Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients (ROADMAP) - 2 Year Results;_ R. C. Starling1, J. D. Estep2, D. A. Horstmanshof3, C. A. Milano4, C. H. Selzman5, K. B. Shah6, B. A. Bruckner2, S. Lee7, J. W. Long3, J. Stehlik5, V. Kasirajan6, D. C. Haas8, A. J. Boyle9, J. Chuang10, D. J. Farrar10, J. G. Rogers4, .. for the ROADMAP Study Investigators11. 1 _Cleveland Clinic, Cleveland, OH,_ 2 _Houston Methodist Hospital, Houston, TX,_ 3 _INTEGRIS Baptist Medical Center, Oklahoma City, OK,_ 4 _Duke University, Durham, NC,_ 5 _University of Utah School of Medicine, Salt Lake City, UT,_ 6 _Virginia Commonwealth University, Richmond, VA,_ 7 _Spectrum Health, Grand Rapids, MI,_ 8 _Abington Memorial Hospital, Abington, PA,_ 9 _Piedmont Hospital, Atlanta, GA,_ 10 _St. Jude Medical, Pleasanton, CA,_ 11 _., ., OH_

**2:15 PM (39)** _Insights from INTERMACS into Patient Characteristics Leading to Futility in LVAD Therapy;_ R. L. Kormos1, F. D. Pagani2, A. D. Althouse3, L. Warner Stevenson4, J. J. Teuteberg5, J. B. Young6, J. K. Kirklin7. 1 _Cardiothoracic Surgery, Univ of Pittsburgh Med Ctr, Pittsburgh, PA,_ 2 _Cardiothoracic Surgery, Univ of Michigan Hlth, Ann Arbor, MI,_ 3 _Heart and Vascular Institute, Univ of Pittsburgh Med Ctr, Pittsburgh, PA,_ 4 _Cardiology, Brigham & Women 's Hosp, Boston, MA, _5 _Cardiology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA,_ 6 _Cardiology, Cleveland Clinic Foundation, Cleveland, OH,_ 7 _Cardiothoracic Surgery, Univ of Alabama, Birmingham, AL_

**2:30 PM (40)** _An Updated Bayesian Model for Predicting Mortality in Continuous Flow-Left Ventricular Assist Device Patients;_ L. E. Lohmueller1, M. K. Kanwar2, N. L. Loghmanpour1, S. Murali2, J. F. Antaki1. 1 _Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA,_ 2 _Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA_

**2:45 PM (41)** _Muscular Strength Predicts Functional Capacity in Left Ventricular Assist Device Supported Patients;_ R. Y. Loyaga-Rendon1, S. V. Pamboukian1, D. Acharya1, J. Tallaj1, F. Siric2, C. Hoopes2, W. Holman1, J. Kirklin1, E. P. Plaisance3. 1 _Division of Cardiology, University of Alabama at Birmingham, Birmingham, AL,_ 2 _Division of Cardiovascular Surgery, University of Alabama at Birmingham, Birmingham, AL,_ 3 _Department of Human Studies and Nutrition Obesity Research Center, University of Alabama at Birmingham, Birmingham, AL_

**3:00 PM (42)** _Long-Term Outcomes in Continous-Flow Left Ventricular Assist Device Patients with and without ICD;_ X. Mai1, V. K. Topkara1, K. Wong1, F. Castagna1, P. N. Trinh2, S. Sreekanth3, K. Ross3, A. Uryevick1, J. Eadie3, J. Murphy3, K. Takeda3, H. Takayama3, Y. Naka3, M. Maurer1, D. M. Mancini1, M. Yuzefpolskaya1, P. C. Colombo1, A. R. Garan1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Epidemiology, Columbia University, New York, NY,_ 3 _Surgery, Columbia University, New York, NY_

**3:15 PM (43)** _Impact of Morbid Obesity on Left Ventricular Assist Device Support and Heart Transplantation;_ S. Cohen1, L. Wolfe1, D. Tang1, G. Katlaps1, V. Kasirajan1, K. Shah2, R. Cooke3, M. Smallfield3, I. Tchoukina3, K. Rao3, M. Quader1. 1 _Cardio-Thoracic Surgery, Virginia Commonwealth University, Richmond, VA,_ 2 _Cardioloy, Virginia Commonwealth University, Richmond, VA,_ 3 _Cardiology, Virginia Commonwealth University, Richmond, VA_

2:00 PM - 3:30 PM

Concurrent Session 8: Quality Over Quantity? Quality of Life in MCS

**Location** :

Thurgood Marshall

Target Audience:

MCS, EEP, NHSAH

Chairs:

Mary Amanda Dew, PhD, and Brent C Lampert, DO

**2:00 PM (44)** _Impact of Baseline Measures and Adverse Events on Functional Assessments in the ENDURANCE Destination Therapy Trial;_ J. G. Rogers1, C. A. Milano1, S. V. Pamboukian2, G. Bhat3, E. J. Birks4, S. S. Najjar5, B. B. Reid6, D. Meyer7, K. Leadley8, F. D. Pagani9. 1 _Duke University School of Medicine, Durham, NC,_ 2 _University of Alabama at Birmingham, Birmingham, AL,_ 3 _Advocate Heart Institute, Oak Lawn, IL,_ 4 _University of Louisville, Louisville, KY,_ 5 _MedStar Washington Hospital Center, Washington, DC,_ 6 _University of Utah School of Medicine, Salt Lake City, UT,_ 7 _University of Texas Southwestern Medical Center, Dallas, TX,_ 8 _HeartWare, Framingham, MA,_ 9 _University of Michigan, Ann Arbor, IL_

**2:15 PM (45)** _HRQOL Improves from Before to 2 Years After MCS, Regardless of Implant Strategy: Analyses from INTERMACS;_ C. White-Williams1, P. Fazeli-Wheeler1, S. Myers1, J. Kirklin1, S. Pamboukian1, D. Naftel1, K. Grady2. 1 _University of Alabama, Birmingham, AL,_ 2 _Northwestern University, Chicago, IL_

**2:30 PM (46)** _Reduced Anxiety and Depression in Patients with Advanced Heart Failure after Left Ventricular Assist Device Implantation;_ G. Yost1, G. Bhat2, E. Mahoney1, A. Tatooles2. 1 _Heart Transplant, Advocate Christ Medical Center, Oak Lawn, IL,_ 2 _Heart Institute, Advocate Christ Medical Center, Oak Lawn, IL_

**2:45 PM (47)** _Patient Reported Quality of Life with Mechanical Circulatory Support vs Continued Medical Therapy in Ambulatory Heart Failure Patients;_ J. Stehlik1, J. D. Estep2, C. H. Selzman1, J. G. Rogers3, K. B. Shah4, J. Chuang5, D. J. Farrar5, R. C. Starling6, .. for the ROADMAP Study Investigators7. 1 _University of Utah School of Medicine, Salt Lake City, UT,_ 2 _Houston Methodist Hospital, Houston, TX,_ 3 _Duke University, Durham, NC,_ 4 _Virginia Commonwealth University, Richmond, VA,_ 5 _St Jude Medical, Pleasanton, CA,_ 6 _Cleveland Clinic, Cleveland, OH,_ 7 _., ., UT_

**3:00 PM (48)** _Caregiver Burden in Post-Ventricular Assist Device Patients;_ R. Ghashghaei, A. Sabet, D. Nagle, H. Tran, E. D. Adler. _Cardiology, University of California, San Diego, San Diego, CA_

**3:15 PM (49)** _Hospital Readmission during Left Ventricular Assist Device Support: Causes, Temporal Trends, and Terminal Readmissions;_ M. L. Inra1, S. M. Dunlay2, D. L. Joyce3, L. D. Joyce3, R. C. Daly3, S. Maltais3, J. M. Stulak3. 1 _Surgery, Mayo Clinic, Rochester, MN,_ 2 _Cardiovascular Disease, Mayo Clinic, Rochester, MN,_ 3 _Cardiovascular Surgery, Mayo Clinic, Rochester, MN_

2:00 PM - 3:30 PM

Concurrent Session 9: Rolling the Dice: Risk Prediction in Cardiac Transplantation

**Location** :

Salon 1

Target Audience:

HTX, EEP, ID, MCS, NHSAH, PEDS, PHARM

Chairs:

Donna M. Mancini, MD, and Gregorio Rabago, MD

**2:00 PM (50)** _Frailty Measures in Advanced Heart Failure Patients Listed for Transplantation;_ S. R. Jha1, M. K. Hannu1, K. Wilhelm2, P. J. Newton3, S. Chang3, S. Chang3, E. Montgomery1, M. Harkess1, P. Tunnicliff1, A. Smith1, C. Hayward1, A. Jabbour1, A. Keogh1, E. Kotlyar1, K. Dhital1, E. Granger1, P. Jansz1, P. Spratt1, P. S. Macdonald1. 1 _Heart and Lung Clinic, St. Vincent's Hospital, Darlinghurst, Sydney, Australia,_ 2 _Psychiatry, St. Vincent's Hospital, Darlinghurst, Sydney, Australia,_ 3 _Health Science, University of Technology, Sydney, Australia_

**2:15 PM (51)** _Risk Stratification to Improve Transplant Benefit in Older Candidates: Are All Comorbidities Created Equal?;_ M. Masetti, M. Sabatino, V. Manfredini, L. Borgese, A. Loforte, G. Marinelli, G. Magnani, F. Grigioni, C. Rapezzi, L. Potena. _University of Bologna, Bologna, Italy_

**2:30 PM (52)** _Evaluating Hepatorenal Factors for Perioperative Transplant Mortality in Adult Congenital Heart Disease;_ E. Adams, L. Reardon. _David Geffen School of Medicine, UCLA, Los Angeles, CA_

**2:45 PM (53)** _Influence of the MELD-XI (Model of End-Stage Liver Disease Excluding INR) on Heart Transplant Outcomes;_ A. Iyengar, C. Eisenring, L. Reardon, A. Nsair, M. Deng, A. Ardehali, E. DePasquale. _University of California - Los Angeles, Los Angeles, CA_

**3:00 PM (54)** _Reversibility of Frailty in Advanced Heart Failure Patients Listed for Transplantation;_ S. R. Jha1, M. K. Hannu1, K. Wilhelm2, P. J. Newton3, S. Chang3, E. Montgomery1, M. Harkess1, P. Tunnicliff1, A. Smith1, C. Hayward1, A. Jabbour1, A. Keogh1, E. Kotlyar1, K. Dhital1, E. Granger1, P. Jansz1, P. Spratt1, P. Macdonald1. 1 _Heart and Lung Clinic, St. Vincent's Hospital, Darlinghurst, Sydney, Australia,_ 2 _Psychiatry, St. Vincent's Hospital, Darlinghurst, Sydney, Australia,_ 3 _Health Science, University of Technology, Sydney, Australia_

**3:15 PM (55)** _Donor-Recipient Matching Using Cardiac Donor Risk Score Allows Optimization of Graft Survival;_ C. Jasseron1, C. Legeai1, C. Cantrelle1, P. Leprince2, C. Dambrin3, A. Vincentelli4, R. Bronchard1, O. Huot1, O. Bastien1, R. Dorent1. 1 _Medical & Scientific, Agence de la Biomedecine, La Plaine Saint Denis, France, _2 _Cardiovascular Surgery, Hopital la Pitié-Salpétrière, Paris, France,_ 3 _Cardiovascular Surgery, Hopital Rangueil, Toulouse, France,_ 4 _Cardiovascular Surgery, Hopital Calmette, Lille, France_

2:00 PM - 3:30 PM

Concurrent Session 10: The Frailty Construct and Body Composition - Impact on Lung Transplant Outcomes

**Location** :

Maryland Suite

Target Audience:

LTX, NHSAH, PEDS, PHARM

Chairs:

Joshua J Mooney, MD, and Jonathan P Singer, MD, MS

**2:00 PM (56)** _Frailty Score Predicts Death on the Waiting List, but Not Early Outcome Post Lung Transplantation (LTx);_ H. M. Whitford1, L. Fuller2, R. Stewart2, Y. Cristiano1, B. Levvey1, M. Paraskeva1, G. P. Westall1, T. J. Williams1, G. I. Snell1. 1 _Respiratory Medicine, Alfred Hospital, Melbourne, Australia,_ 2 _Physiotherapy, Alfred Hospital, Melbourne, Australia_

**2:15 PM (57)** _Frailty and Clinical Benefits with Lung Transplantation;_ D. Rozenberg1, S. Mathur2, L. Wickerson3, N. A. Chowdhury4, L. G. Singer1. 1 _Medicine, Respirology, Lung Transplant Program, University of Toronto, University Health Network, Toronto, ON, Canada,_ 2 _Physical Therapy, University of Toronto, Toronto, ON, Canada,_ 3 _Physical Therapy, Lung Transplant Program, University of Toronto, University Health Network, Toronto, ON, Canada,_ 4 _Lung Transplant Program, University Health Network, Toronto, ON, Canada_

**2:30 PM (58)** _Improvement in Frailty Is Associated with Improved Disability in Lung Transplantation;_ J. P. Singer1, P. Shrestha1, A. Soong1, D. Huang1, M. Mindo1, L. Leard1, J. Golden1, S. Hays1, K. Jasleen1, R. Shah1, D. Lederer2, P. Katz1, P. D. Blanc1. 1 _Medicine, UCSF Medical Center, San Francisco, CA,_ 2 _Medicine, Columbia University, New York, NY_

**2:45 PM (59)** _Change in Body Mass Index at Listing from Primary Transplant to Re-Transplantation Predicts Re-Transplant Survival;_ J. Kim1, E. Barr2, M. Terrin2, I. Timofte1, P. Sanchez3, Z. Kon3, R. Pierson3, M. Wijesinha1, S. Pham3, A. Iacono1. 1 _Pulmonary Critical Care, University of Maryland, Baltimore, MD,_ 2 _Epidemiology, University of Maryland, Baltimore, MD,_ 3 _Cardiothoracic Surgery, University of Maryland, Baltimore, MD_

**3:00 PM (60)** _Pectoralis Muscle Area Change Following Lung Transplantation Is Related to Underlying Disease;_ V. Hoang1, G. Li1, G. Dronovalli1, N. Capuano2, C. Kao1, A. Parulekar1. 1 _Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX,_ 2 _Lung Transplant Program, Cooley Transplant Center, CHI St. Luke's Health - Baylor St. Luke's Medical Center, Houston, TX_

**3:15 PM (61)** _Outcome in Age-Mismatched Lung Transplant Recipients;_ H. Auråen1, A. Fiane2, O. Geiran2, V. Lyngstadaas1, U. Christen3, I. Leuckfeld1, S. Hans Henrik4, M. Iversen4, E. Andreas5, A. M. Holm1. 1 _Department of Respiratory Medicine, Oslo University Hospital, Oslo, Norway,_ 2 _Department of Cardiothoracic Surgery, Oslo University Hospital, Oslo, Norway,_ 3 _Department of Transplantation, Oslo University Hospital, Oslo, Norway,_ 4 _Department of Cardiology, Division of Lung Transplantation, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark,_ 5 _Department of Anaesthesiology, Oslo University Hospital, Oslo, Norway_

2:00 PM - 3:30 PM

Concurrent Session 11: The Heartbreak of Rejection: All Against the Graft

**Location** :

Virginia Suite

Target Audience:

HTX, BSI, NHSAH, PATH, PEDS, PHARM

Chairs:

Maryjane A Farr, MD, and Kumud K Dhital, MD,PhD

**2:00 PM (62)** _Capillary Damage and Fibrin in Heart Transplantation: Significant Impact on Survival with or without Rejection;_ D. Budge1, D. V. Miller2, G. L. Snow3, M. P. Revelo4, J. Stehlik5, K. Molina6, R. Alharethi1, C. Selzman5, B. Reid1, S. Drakos5, E. M. Gilbert5, J. Nativi-Nicolau5, E. H. Hammond2, A. G. Kfoury1. 1 _U.T.A.H. Cardiac Transplant Program, Intermountain Medical Center/ Intermountain Healthcare, Salt Lake City, UT,_ 2 _Pathology, Intermountain Medical Center/ Intermountain Healthcare, Salt Lake City, UT,_ 3 _Statistical Data Center, Intermountain Medical Center/ Intermountain Healthcare, Salt Lake City, UT,_ 4 _Pathology, University of Utah Health Sciences Center, Salt Lake City, UT,_ 5 _U.T.A.H. Cardiac Transplant Program, University of Utah Health Sciences Center, Salt Lake City, UT,_ 6 _U.T.A.H. Cardiac Transplant Program, Primary Childrens Medical Center, Salt Lake City, UT_

**2:15 PM (63)** _Role of Novel Cardiovascular Magnetic Resonance Based Tissue Characterization in the Detection of Cardiac Transplant Rejection;_ M. Imran1, L. Wang1, J. McCrohon1, C. Yu1, J. Huang1, C. Holloway1, O. James2, C. Stehning3, K. Moffat4, J. Ross4, E. Kotlyar1, C. Hayward1, A. Keogh1, P. Macdonald1, A. Jabbour1. 1 _Cardiology, St. Vincent`s Hospital, Sydney, Australia,_ 2 _Cardiology, Liverpool Hospital, Sydney, Australia,_ 3 _Philips GmbH Innovative Technologies, Philips, Hamburg, Germany,_ 4 _Medical Imaging, St. Vincent`s Hospital, Sydney, Australia_

**2:30 PM (64)** _Heart Transplantation without Routine Endomyocardial Biopsies Is Feasible: Experience with a Clinical-Echocardiographic Strategy;_ J. A. Vazquez de Prada, F. J. Gonzalez Vilchez, F. Rodriguez Entem, J. Ruano, M. del Olmo, R. Martin Duran. _Cardiology Department, Hospital Valdecilla, Santander, Spain_

**2:45 PM (65)** _Biomarkers Monitoring for Absence of Acute Allograft Rejection;_ Z. Hollander1, D. L. Dai1, C. Shannon1, V. Chen1, K. K. Lam1, J. E. McManus1, S. Assadian1, M. Toma2, S. J. Tebbutt1, R. Balshaw3, C. H. Borchers4, R. A. Davies5, D. Delgado6, H. Haddad5, A. Ignaszewski2, D. L. Isaac7, D. Kim8, A. Mui2, M. Rajda9, H. Ross10, L. J. West11, M. White12, S. Zieroth13, W. McMaster2, P. A. Keown2, R. T. Ng2, B. M. McManus14. 1 _The PROOF Centre of Excellence, Vancouver, BC, Canada,_ 2 _University of British Columbia, Vancouver, BC, Canada,_ 3 _BC Centre for Disease Control, Vancouver, BC, Canada,_ 4 _University of Victoria, Victoria, BC, Canada,_ 5 _University of Ottawa Heart Institute, Ottawa, ON, Canada,_ 6 _Toronto General Hospital, Toronto, ON, Canada,_ 7 _University of Calgary, Calgary, AB, Canada,_ 8 _University of Alberta & Mazankowski Alberta Heart Institute, Edmonton, AL, Canada, _9 _Dalhousie University, Halifax, NS, Canada,_ 10 _MultiOrgan Transplant Program, Toronto General Hospital, Toronto, ON, Canada,_ 11 _University of Alberta, Edmonton, AB, Canada,_ 12 _Montreal Heart Institute, Montreal, QC, Canada,_ 13 _University of Manitoba, Winnipeg, MB, Canada,_ 14 _Universitiy of BC & PROOF Centre of Excellence, Vancouver, BC, Canada_

**3:00 PM (66)** _Initial Analysis of the Donor-Derived Cell-Free DNA - Outcomes AlloMap Registry (D-OAR) Study in Heart Transplant Recipients Undergoing Surveillance for Rejection;_ J. A. Kobashigawa1, K. Khush2, J. Teuteberg3, M. Song4, M. Grskovic4, D. Hiller4, R. Woodward4, E. Deljkich4, J. Yee4, F. Latif5, N. Sulemanjee6, S. Murali7. 1 _Cedars-Sinai Heart Institute, Los Angeles, CA,_ 2 _Stanford University, Palo Alto, CA,_ 3 _University of Pittsburgh Medical Center, Pittsburgh, PA,_ 4 _CareDx, Brisbane, CA,_ 5 _Columbia University Medical Center, New York, NY,_ 6 _Aurora St. Luke's Medical Center, Milwaukee, WI,_ 7 _Allegheny General Hospital, Pittsburgh, PA_

**3:15 PM (67)** _Utility of Gene Expression (Allomap Score) in Antibody Mediated Rejection Detection;_ S. Adatya1, E. Delijkich2, D. Hiller2, G. Sayer1, J. Yee2, N. Uriel1. 1 _University of Chicago, Chicago, IL,_ 2 _CareDx, San Francisco, CA_

2:00 PM - 3:30 PM

Concurrent Session 12: Pediatric Lung Transplantation

**Location** :

Delaware Suite

Target Audience:

PEDS, LTX

Chairs:

Carol K Conrad, MD, and Stuart C Sweet, MD, PhD

**2:00 PM (68)** _Are We Refusing Good Organs? Outcomes of Ventilator Management of Sub-Optimal Lung Donors;_ B. B. Scully1, D. Horne2, J. S. Heinle2, E. D. McKenzie2, K. E. Hosek3, W. Zhang3, G. B. Mallory4, E. Melicoff4. 1 _Surgery, Baylor College of Medicine, Houston, TX,_ 2 _Congenital Heart Surgery, Texas Children's Hospital, Houston, TX,_ 3 _Outcomes and Impact Services, Texas Children's Hospital, Houston, TX,_ 4 _Pulmonology, Texas Children's Hospital, Houston, TX_

**2:15 PM (69)** _Controlled Donation after Circulatory Death (DCD) Donors and Pediatric Lung Transplant (pLTx): Enhanced Opportunities and Excellent Outcomes;_ G. I. Snell, B. J. Levvey, M. Paraskeva, H. Whitford, T. Williams, J. Hobson, A. Henriksen, D. McGiffin, G. Westall. _Alfred Hospital, Melbourne, Australia_

**2:30 PM (70)** _Improved Waitlist and Transplant Outcomes for Pediatric Lung Transplantation After Implementation of the Lung Allocation Score;_ T. S. Lancaster1, J. R. Miller1, D. J. Epstein1, N. C. DuPont1, S. C. Sweet2, P. Eghtesady1. 1 _Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO,_ 2 _Pediatrics, Washington University School of Medicine, St. Louis, MO_

**2:45 PM (71)** _Respiratory Viral Infections Are Common in the First Year After Pediatric Lung Transplantation: A Multi-Center Prospective Study;_ L. Danziger-Isakov1, R. Buller2, N. Williams3, S. Mason2, M. Fenchel1, T. Astor4, C. Conrad5, A. Faro2, S. Goldfarb6, D. Hayes7, E. Melicoff-Portillo8, M. Schecter1, G. Visner9, D. Ikle10, G. Storch2, S. Sweet2. 1 _Cincinnati Children's Hosp Med Ctr, Cincinnati, OH,_ 2 _Washington University, St. Louis, MO,_ 3 _National Institutes of Health, Bethesda, MD,_ 4 _Massachusetts General Hospital, Boston, MA,_ 5 _Lucille Packard Children's Hospital, Palo Alto, CA,_ 6 _Children's Hopsital of Philadelphia, Philadelphia, PA,_ 7 _Nationwide Children's Hospital, Columbus, OH,_ 8 _Texas Children's Hospital, Houston, TX,_ 9 _Boston Children's Hospital, Boston, MA,_ 10 _Rho, Inc., Chapel Hill, NC_

**3:00 PM (72)** _Pediatric Lung Transplantation - 25 Years of Experience;_ R. Waseda1, P. Jaksch1, G. Muraközy1, S. Gruber2, C. Lambers1, A. Benazzo1, Z. Szepfalusi2, E. Nachbaur2, W. Klepetko1. 1 _Thoracic Surgery, Medical University Vienna, Vienna, Austria,_ 2 _Department of Pediatrics, Medical University Vienna, Vienna, Austria_

**3:15 PM (73)** _The Hard Truth: Outcomes of Adolescent Recipients Following Lung Transplantation;_ M. Paraskeva1, L. B. Edwards2, B. Levvey1, J. Stehlik2, S. Goldfarb2, R. D. Yusen2, G. P. Westall1, G. I. Snell1. 1 _Lung Transplant Service, Alfred Hospital, Melbourne, Australia,_ 2 _ISHLT Transplant Registry, Dallas, TX_

2:00 PM - 3:30 PM

Concurrent Session 13: Philip K. Caves Award Candidate Presentations

**Location** :

Washington Ballroom 2

Target Audience:

ALL

Chairs:

John A. Belperio, MD, and Sonja Schrepfer, MD, PhD

**2:00 PM (74)** _Increased Angiogenesis and Non-Surgical Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices Are Mediated by Thrombin-Induced Angiopoietin-2;_ C. E. Tabit1, G. H. Kim1, S. E. Fedson2, G. Sayer1, M. J. Coplan1, V. Jeevanandam3, N. Uriel1, J. K. Liao1. 1 _Cardiology, The University of Chicago Medical Center, Chicago, IL,_ 2 _Baylor Center for Medical Ethics and Health Policy, Baylor University, Houston, TX,_ 3 _Cardiac and Thoracic Surgery, The University of Chicago Medical Center, Chicago, IL_

**2:15 PM (75)** _Prevalence of Polyreactive Innate-Like B Cells Among Graft-Infiltrating B Cells in Human Cardiac Allograft Vasculopathy;_ D. Chatterjee1, C. Moore2, B. Gao3, K. J. Clerkin1, S. B. See1, D. Shaked1, K. J. Rogers1, S. Nunez1, Y. Veras1, L. Addonizio1, M. M. Givertz4, Y. Naka1, D. Mancini1, R. Vasilescu5, C. Marboe5, S. Restaino1, J. C. Madsen2, E. Zorn1. 1 _Dept. of Medicine, Columbia University, New York, NY,_ 2 _Massachusetts General Hospital Transplant Center, Boston, MA,_ 3 _First Hospital of Jilin University, Changchun, China,_ 4 _Brigham and Women's Hospital, Boston, MA,_ 5 _Dept. of Pathology & Cell Biology, Columbia University, New York, NY_

**2:30 PM (76)** _Feasibility of Detecting Fungal DNA in Exhaled Breath Condensate by the Luminex Multiplex xTAG Fungal PCR Assay in Lung transplant Recipients: A Pilot Study;_ A. Bhimji1, L. G. Singer2, D. Kumar2, A. Humar2, R. Pavan2, H. Zhang3, C. Rotstein2, S. Keshavjee2, T. Mazzulli2, S. Husain2. 1 _Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada, _2 _Medicine, University Health Network, Toronto, ON, Canada,_ 3 _Luminex Molecular Diagnostics, Toronto, ON, Canada_

**2:45 PM (77)** _Graft-Infiltrating Neutrophils Cannibalize Dying Neutrophils to Produce IL-10 and to Protect Lung Transplants from Ischemia-Reperfusion Injury;_ M. Zhu, X. Wang, D. Scozzi, K. A. Toth, J. Zhu, X. Lin, A. S. Krupnick, D. Kreisel, A. E. Gelman. _Department of Surgery, Washington University in Saint Louis, Saint Louis, MO_

**3:00 PM (78)** _Clara Cell Secretory Protein Limits Small Airway Inflammation and Fibrosis Induced by De Novo Donor Specific Antibodies;_ D. Nayak1, F. Zhou2, T. Mohanakumar3. 1 _Washington University School of Medicine, St. Louis, MO,_ 2 _Surgery, Washington University School of Medicine, St. Louis, MO,_ 3 _Surgery, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO_

**3:15 PM (79)** _Early CD20+ B Cell Depletion Attenuates Cardiac Allograft Vasculopathy in Anti-CD154 Treated Non-Human Primate Model;_ N. A. O'Neill, A. M. Azimzadeh, X. Cheng, T. Zhang, A. Hershfeld, G. Wu, S. S. Kelishadi, T. Stoddard, A. Kronfli, E. Rybak, L. Burdorf, R. N. Pierson. _Surgery, University of Maryland School of Medicine, Baltimore, MD_

2:00 PM - 3:30 PM

Symposium 29: Joint ISHLT/PVRI Symposium: Exploring Combination Therapy in PAH

**Location** :

Washington Ballroom 1

Target Audience:

PH, BSI, LF, LTX, NHSAH, PHARM

Chairs:

Paul A. Corris, MB BS FRCP, and Myung H. Park, MD

**Session Summary** : This joint symposium between ISHLT and the Pulmonary Vascular Research Institute (PVRI), will explore the clinical data regarding combination therapy in PAH and identify differences suggesting that not all combinations are the same. The potential for drug interactions and differences in pharmacology of drugs in the same broad class will be discussed. Finally the strategy of when to introduce combination therapy including triple therapy will be discussed.

2:00 PM

Combination Therapy in PAH: What Do The Clinical Trials Tell Us?

Paul A Corris, MBBS FRCP, Freeman Hospital, Newcastle upon Tyne, United Kingdom

2:20 PM

The Differing Pharmacology Between Drugs in PDE5i and ERA Class and their Interactions

Martin Wilkins, MD, Imperial College, London, United Kingdom

2:40 PM

The Pharmacology of sGC Stimulators from Bench to Bedside, Single Therapy and In Combination

Ardeschir Ghofrani, MD, University of Giessen, Giessen, Germany

3:00 PM

Which Combinations, and Upfront or Sequential When Treating PAH?

Mardi Gomberg-Maitland, MD, University of Chicago, Chicago, IL, USA

3:20 PM

PANEL DISCUSSION

4:00 PM - 5:30 PM

Concurrent Session 14: Bright Shiny Toys for Good Girls and Boys: New Technology and Techniques in MCS

**Location** :

Salons 2-3

Target Audience:

MCS, HF

Chairs:

Mark Slaughter, MD, and Francis D. Pagani, MD, PhD

**4:00 PM (80)** _The Jarvik 2000: Results of the United States Bridge to Transplant Trial;_ C. H. Selzman1, E. Felker2, B. C. Sheridan3, S. Silvestry4, R. C. Daly5, A. Anyanwu6, D. Madigan7, O. Frazier8, B. P. Griffith2. 1 _Cardiothoracic Surgery, University of Utah, Salt Lake City, UT,_ 2 _University of Maryland, Baltimore, MD,_ 3 _University of North Carolina, Chapel Hill, NC,_ 4 _Florida Hospital, Orlando, FL,_ 5 _Mayo Clinic, Rochester, MN,_ 6 _Mt. Sinai, New York City, NY,_ 7 _Columbia University, New York City, NY,_ 8 _Texas Heart Institute, Houston, TX_

**4:15 PM (81)** _HeartMate 3 Left Ventricular Assist Device Pre- and Post-Approval Experience Through 1 Year at a Single Center;_ Y. Pya1, S. Bekbossynov2, M. Bekbossynova3, S. Andossova4, S. Dzhetybayeva5, A. Medressova6, M. Murzagaliyev7, S. Novikova7, R. Salov8, R. Abildayeva9, L. Damme10. 1 _CEO, National Research Cardiac Surgery Center, Astana, Kazakhstan,_ 2 _Head of Cardiac Surgery Department N_ o _2, National Research Cardiac Surgery Center, Astana, Kazakhstan,_ 3 _First Vice of the CEO, National Research Cardiac Surgery Center, Astana, Kazakhstan,_ 4 _Head of the LVAD Department, National Research Cardiac Surgery Center, Astana, Kazakhstan,_ 5 _Head of Cardiology, National Research Cardiac Surgery Center, Astana, Kazakhstan,_ 6 _Cardiac Surgery N_ o _2, National Research Cardiac Surgery Center, Astana, Kazakhstan,_ 7 _Cardiac Department N_ o _2, National Research Cardiac Surgery Center, Astana, Kazakhstan,_ 8 _LVAD Department, National Research Cardiac Surgery Center, Astana, Kazakhstan,_ 9 _Cardiology, National Research Cardiac Surgery Center, Astana, Kazakhstan,_ 10 _Thoratec Corporation, Burlington, MA_

**4:30 PM (82)** _Open Chest Epicardial Voltage Mapping during Left Ventricular Assist Device Implant in Patients with End-Stage Heart Failure;_ J. D. Moss1, M. J. Raiman2, E. E. Flatley1, T. Ota1, V. Jeevanandam1, N. Uriel1. 1 _University of Chicago, Chicago, IL,_ 2 _St. Jude Medical, St. Paul, MN_

**4:45 PM (83)** _Lessons Learned from over 250 Continuous-Flow Centrifugal Left Ventricular Assist Device Implantation: Growing Experience and Outcomes in Alternative Approaches Era;_ S. Maltais1, N. Haglund2, P. Shah3, J. Cowger4, K. A. Aaronson5, F. Pagani5, S. Dunlay1, J. M. Stulak1. 1 _Mayo Clinic, Rochester, MN,_ 2 _Vanderbilt, Nahsville, TN,_ 3 _Inova Fairfax, Virginia, VA,_ 4 _St-Vincent, Indianapolis, IN,_ 5 _Michigan, Michigan, MI_

**5:00 PM (84)** _Less-Invasive Left Ventricular Assist Device Implantations: Experience after More Than 100 Treated Patients;_ J. D. Schmitto1, S. V. Rojas1, M. Avsar1, J. S. Hanke1, A. Uribarri1, D. Burkhoff2, K. Tümler1, P. Ahrens1, U. Molitoris1, A. Martens1, D. Berliner3, J. Bauersachs3, M. Shrestha1, S. Cebotari1, M. Strueber1, A. Haverich1. 1 _Department of Cardiothoracic-, Transplantation- and Vascular Surgery, Hannover Medical School, Hannover, Germany,_ 2 _Department of Cardiology, Columbia University, New York, NY,_ 3 _Department of Cardiology, Hannover Medical School, Hannover, Germany_

**5:15 PM (85)** _An Examination of Bleeding and Thromboembolic Complications during the First Year of Support with the HeartMate 3 Fully Magnetically-Levitated Left Ventricular Assist Device;_ V. Rao1, I. Netuka2, J. Schmitto3, Y. Pya4, J. Heatley5, L. Damme6. 1 _Toronto General Hospital, Toronto, ON, Canada,_ 2 _Institute for Clinical and Experimental Medicine, Prague, Czech Republic,_ 3 _Hannover Medical School, Hanover, Germany,_ 4 _National Research Cardiac Surgery Center, Astana, Kazakhstan,_ 5 _Thoratec Corp, Pleasanton, CA,_ 6 _Thoratec, Pleasanton, CA_

4:00 PM - 5:30 PM

Concurrent Session 15: Let's Be Specific: Donor Specific Antibodies - Challenges Ahead

**Location** :

Thurgood Marshall

Target Audience:

HTX, BSI, ID, MCS, PATH, PEDS, PHARM

Chairs:

Deborah Budge, MD, and Jayan Parameshwar, FRCP

**4:00 PM (86)** _Discordance between C4d Staining by Immunohistochemistry and Immunofluorescence and Clinical Outcomes;_ S. Kalantari Tannenbaum1, I. Uraizee2, J. Grinstein1, B. Smith1, K. Marinescu1, G. Sayer1, N. Sarswat1, G. H. Kim1, S. Adatya1, V. Jeevanandam3, T. Ota3, A. Husain2, N. Uriel1. 1 _Cardiology, University of Chicago, Chicago, IL,_ 2 _Pathology, University of Chicago, Chicago, IL,_ 3 _Cardiac Surgery, University of Chicago, Chicago, IL_

**4:15 PM (87)** _Donor Specific Antibodies Associated with Micro- and Macrovascular Coronary Disease and Restrictive Myocardial Damage in Heart Transplanted Patients;_ T. S. Clemmensen1, P. Koefoed-Nielsen2, S. H. Poulsen1, N. R. Holm1, B. B. Løgstrup1, E. H. Christiansen1, L. P. Tolbod3, H. J. Harms3, H. Eiskjær1. 1 _Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, Aarhus N, Denmark,_ 2 _Department of Immunology, Aarhus University Hospital, Skejby, Denmark, Aarhus N, Denmark,_ 3 _Department of Nuclear Medicine & PET Center, Aarhus University Hospital, Skejby, Denmark, Aarhus N, Denmark_

**4:30 PM (88)** _The Timeline of DSA after Cardiac Transplantation;_ A. Vu1, J. J. Teuteberg1, A. Zeevi2, M. A. Shullo1. 1 _University of Pittsburgh Medical Center, Pittsburgh, PA,_ 2 _University of Pittsburgh, Pittsburgh, PA_

**4:45 PM (89)** _Human Leukocyte Antigen-G Polymorphisms Association with Post Heart Transplant Donor Specific Antibodies;_ J. Lazarte1, L. Goldraich2, C. Manlhiot2, H. Kawajiri3, A. Ghashghai1, L. Grosman-Rimon3, V. Rao3, D. Delgado2. 1 _Faculty of Medicine, University of Toronto, Toronto, ON, Canada,_ 2 _Cardiology, Toronto General Hospital, Toronto, ON, Canada,_ 3 _Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada_

**5:00 PM (90)** _Pre-Transplant Donor Specific Antibody Levels Using Single Antigen Bead Assay and Long-Term Survival Post Heart Transplant;_ R. Dhingra, M. D. Yu, M. Johnson, L. Lozonschi, T. Kohmoto, S. A. Akhter, T. Ellis. _University of Wisconsin-Madison, Madison, WI_

**5:15 PM (91)** _De Novo DQ Donor-Specific Antibodies Are Associated with Worse Outcomes Compared to Non-DQ DSA Following Heart Transplantation;_ R. T. Cole, J. Gandhi, A. Morris, C. Lambert, A. McCue, M. Yin, S. Laskar, A. Smith, J. D. Vega, D. Gupta. _Cardiology, Emory Univ Sch of Med, Atlanta, GA_

4:00 PM - 5:30 PM

Concurrent Session 16: Novel Therapeutic Strategies for Chronic Lung Allograft Dysfunction

**Location** :

Salon 1

Target Audience:

LTX, BSI, LBCS, PEDS, PHARM

Chairs:

Michael T Musk, MBBS, and Sangeeta M Bhorade, MD

**4:00 PM (92)** _Results of a First-in-Man Study of Mesenchymal Stem Cell Therapy for Bronchiolitis Obliterans Syndrome;_ D. Chambers1, D. Enever1, S. Lawrence2, N. Lawson2, S. T. Yerkovich1, L. Sparkes3, R. Herrmann4, M. Sturm4, M. Musk2, P. Hopkins1. 1 _Qld Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia,_ 2 _WA Lung Transplant Service, Royal Perth Hospital, Perth, Australia,_ 3 _Qld Heart Valve Bank, The Prince Charles Hospital, Brisbane, Australia,_ 4 _Cell & Tissue Therapies WA, Royal Perth Hospital, Perth, Australia_

**4:15 PM (93)** _Preliminary Report on the Effect of Mesenchymal Stem Cell (MSC) Infusion in Lung Function on Patients with Chronic Allograft Dysfunction (CLAD);_ C. A. Keller1, D. B. Erasmus1, F. G. Alvarez1, J. M. Mallea1, K. E. Hurst1, H. A. David-Robinson1, A. C. Zubair2. 1 _Transplant, Mayo Clinic, Jacksonville, FL,_ 2 _Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL_

**4:30 PM (94)** _Montelukast for Bronchiolitis Obliterans Syndrome After Lung Transplantation: A Randomized Controlled Trial;_ D. Ruttens, S. Verleden, E. Vandermeulen, H. Bellon, D. Van Raemdonck, J. Yserbyt, L. Dupont, B. Vanaudenaerde, R. Vos, G. Verleden. _KULeuven, Leuven, Belgium_

**4:45 PM (95)** _Comparison of Extracorporeal Photophoresis (ECP) or Alemtuzumab (AL) Treatment Efficacy for Chronic Lung Allograft Dysfunction (CLAD);_ K. Townsend1, A. Moniodis2, A. Rabin3, O. Aloum4, J. Stempel4, P. Burkett5, P. Camp6, M. Divo7, S. El-Chemaly5, H. Mallidi6, I. Rosas5, A. Fuhlbrigge5, H. J. Goldberg5, S. Koo4. 1 _Lung Transplant Program, Dept. of Pharmacy, Brigham & Women's Hospital, Boston, MA, _2 _Division of Pulmonary & Critical Care Medicine, Brigham & Women's Hospital, Boston, MA, _3 _Division of Pulmonary & Critical Care Medicine, Massachusetts General Hospital, Boston, MA, _4 _Transplant Infectious Disease, Infectious Disease Division, Brigham & Women's Hospital, Boston, MA, _5 _Lung Transplant Program, Division of Pulmonary Critical Care Medicine, Brigham & Women's Hospital, Boston, MA, _6 _Lung Transplant Program, Division of Thoracic Surgery, Brigham & Women's Hospital, Boston, MA, _7 _Lung Transplant Program, Pharmacy Department, Brigham & Women's Hospital, Boston, MA_

**5:00 PM (96)** _High Doses of Vitamin D to Reduce Chronic Lung Allograft Dysfunction After Lung Transplantation: A Randomized Trial;_ R. Vos, D. Ruttens, E. Vandermeulen, H. Bellon, S. E. Verleden, D. Van Raemdonck, L. Dupont, J. Yserbyt, B. Vanaudenaerde, G. Verleden. _KU Leuven, Leuven, Belgium_

**5:15 PM (97)** _A Single Center, Randomized, Open-Label, Controlled Pilot Study to Demonstrate Efficacy and Safety of the Addition of Inhaled Liposomal Cyclosporine (L-CsA) Therapy versus Standard Therapy Alone in the Treatment of Bronchiolitis Obliterans Syndrome (BOS) Following Lung Transplantation;_ A. Iacono1, M. Terrin2, K. Rajakopal3, J. McGrain1, E. Barr2, J. Rinaldi1, A. Patel1, I. Timofte4, J. Kim4, Z. Kon3, P. G. Sanchez3, R. Pierson3, B. Griffith3, S. Pham3. 1 _Shock Trauma and Transplantation, University of Maryland, Baltimore, MD,_ 2 _Epidemiology, University of Maryland, Baltimore, MD,_ 3 _Cardiothoracic Surgery, University of Maryland, Baltimore, MD,_ 4 _Pulmonary Critical Care, University of Maryland, Baltimore, MD_

4:00 PM - 5:30 PM

Concurrent Session 17: Pediatric Mechanical Circulatory Support

**Location** :

Maryland Suite

Target Audience:

PEDS, MCS

Chairs:

Tajinder P Singh, MD, MSc, and Christina J VanderPluym, MD

**4:00 PM (98)** _Global Experience with the Heartware HVAD® in Pediatric Patients: A Preliminary Analysis;_ J. Conway1, O. Miera2, H. T. Henderson3, C. VanderPluym4, H. Buchholz1, M. Fenton5, R. A. Niebler6, M. Padalino7, M. Slaughter8, A. Lorts9, M. Schweiger10, M. Hassan11, J. D. Schmitto12, J. N. Scheel13, B. Martin1, Y. Li14, P. E. Parrino15, D. L. Morales9, R. Kirk16. 1 _Stollery Children 's Hospital, Edmonton, AB, Canada,_ 2 _Deutsches Herzzentrum Berlin, Berlin, Germany,_ 3 _Duke University Medical Center, Durham, NC,_ 4 _Boston Children's Hospital, Boston, MA, Canada,_ 5 _Great Ormond Street Hospital, London, United Kingdom,_ 6 _Medical College of Wisconsin, Children's Hospital of Wisconsin, Milwaukee, WI, Canada,_ 7 _University of Padova Medical School, Padova, Italy,_ 8 _University of Louisville, Louisville, KY,_ 9 _Cincinnati Children's Hospital, Cincinnati, OH,_ 10 _University Children's Hospital Zurich, Zurich, Switzerland,_ 11 _Aswan Heart Centre, Cairo University, Aswan, Egypt,_ 12 _Medizinische Hochschule Hannover, Hannover, Germany,_ 13 _Children's National Health System, Washington, DC,_ 14 _University Heart Center Freiburg, Freiburg, Germany,_ 15 _Ochsner Clinic Foundation, New Orleans, LA,_ 16 _Freeman Hospital, Newcastle Upon Tyne, United Kingdom_

**4:15 PM (99)** _Utilization and Outcomes of Temporary Ventricular Assist Devices in Children: A Report from the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs);_ A. Lorts1, R. R. Davies2, J. C. Alejos3, K. R. Kanter4, J. G. Gossett5, R. S. Cantor6, I. Adachi7. 1 _Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH,_ 2 _Nemours Cardiac Center, Nemours/A.I. duPont Hospital for Children, Wilmington, DE,_ 3 _Pediatrics, Mattel Children's Hospital-UCLA, Los Angeles, CA,_ 4 _Pediatric Cardiac Surgery, Emory University School of Medicine, Atlanta, GA,_ 5 _Pediatric Cardiology, Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, IL,_ 6 _Department of Surgery, The University of Alabama at Birmingham, Birmingham, AL,_ 7 _Congenital Heart Surgery, Texas Children's Hospital/Baylor College of Medicine, Houston, TX_

**4:30 PM (100)** _In Vitro Examination of the HeartWare Circulite VAD in the Fontan Circulation;_ M. Tree1, P. Trusty2, B. Munz3, M. Samuel4, T. Slesnick5, K. O. Maher5, A. P. Yoganathan6, S. R. Deshpande5. 1 _School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA,_ 2 _Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA,_ 3 _School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, _4 _School of Chemical & Biomolecular Engineering,, Georgia Institute of Technology, Atlanta, GA, _5 _Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA,_ 6 _Wallace H. Coulter School of Biomedical Engineering, Georgia Institute of Technology & Emory University, Atlanta, GA_

**4:45 PM (101)** _Mechanical Circulatory Support as a Bridge to Transplantation in Children with Single Ventricle Physiology: A Multicenter Study;_ B. B. Das1, J. Kirklin2, E. Pruitt2, M. Chrisant3, K. Lin4, B. Hong5, S. Daneman6, C. Canter7. 1 _UT Southwestern Med Ctr, Dallas, TX,_ 2 _University of Alabama at Brimingham, Brimingham, AL,_ 3 _Joe DiMaggio Children's Hospital, Hollywood, FL,_ 4 _Children's Hospital of Philadelphia, Philadelphia, PA,_ 5 _Seattle Children's Hopsital, Seattle, WA,_ 6 _Children's Medical Center, Dallas, TX,_ 7 _St Louis Children's Hospital, St Louis, MO_

**5:00 PM (102)** _Infectious Complications of Ventricular Assist Device Use in Children in the US: Data from the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs);_ S. R. Auerbach1, M. E. Richmond2, K. R. Schumacher3, D. Lopez-Colon4, M. B. Mitchell5, M. W. Turrentine6, R. S. Cantor7, R. A. Niebler8, P. Eghtesady9. 1 _Pediatrics, Division of Cardiology, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, CO,_ 2 _Division of Pediatric Cardiology, Columbia University, New York, NY,_ 3 _Pediatrics, Cardiology, University of Michigan, Ann Arbor, MI,_ 4 _Pediatrics, Congenital Heart Center, University of Florida, Gainesville, FL,_ 5 _Surgery, Children's Hospital Colorado, Aurora, CO,_ 6 _Dept of Surgery, Division of Thoracic & Cardiovascular Surgery, Indiana University School of Medicine, Indianapolis, IN, _7 _Department of Surgery, The University of Alabama at Birmingham, Birmingham, AL,_ 8 _Pediatrics, Medical College of Wisconsin, Milwaukee, WI,_ 9 _Surgery - Cardiothoracic, Washington University School of Medicine, St. Louis, MO_

**5:15 PM (103)** _Measuring the Effect of Dipyridamole and Clopidogrel Using Thromboelastography/Platelet Mapping®: Is There Evidence of a Meaningful Dose-Response Relationship in Children Supported with the Berlin Heart EXCOR Ventricular Assist Device?;_ L. J. May1, C. Lo2, T. M. Tesoro2, J. L. Zehnder3, L. Yang2, S. Chen3, J. Lee2, D. B. McElhinney2, D. N. Rosenthal3, K. Maeda2, C. S. Almond3. 1 _Pediatric Cardiology, University of Utah, Salt Lake City, UT,_ 2 _Stanford University, Palo Alto, CA,_ 3 _Pediatric Cardiology, Stanford University, Palo Alto, CA_

4:00 PM - 5:30 PM

Concurrent Session 18: Game of Clones: an Epic Cellular Battle Between Rejection and Tolerance

**Location** :

Virginia Suite

Target Audience:

BSI, HTX, LTX

Chairs:

Stephen C Juvet, MD, PhD, FRCPC, and Andrew Gelman, PhD

**4:00 PM (104)** _Multi-Transgenic Expression for Improved Xenograft Survival in Pig-to-Baboon Heart Xenotransplantation Model;_ J. L. Chan1, A. K. Singh1, M. L. Thomas2, D. L. Ayares3, K. A. Horvath1, M. M. Mohiuddin1. 1 _Cardiothoracic Surgery Research Program/National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD,_ 2 _Division of Veterinary Resources/Office of Research Services, National Institutes of Health, Bethesda, MD,_ 3 _Revivicor Inc., Blacksburg, VA_

**4:15 PM (105)** _The Real Time Visualization of Neutrophil Extracellular Trap Formation in Lung Transplants Reveals a Critical Role in Tolerance;_ X. Wang1, D. Scozzi1, D. Kreisel1, A. Krupnick1, M. J. Miller2, A. E. Gelman1. 1 _Surgery, Washington University School of Medicine, St. Louis, MO,_ 2 _Medicine, Washington University School of Medicine, St. Louis, MO_

**(106)** WITHDRAWN

**4:30 PM (374)** _Tissue Injury and Loss of Regulatory T Cells Leads to Lung-Specific Autoantibodies Following Lung Transplantation;_ S. Chiu1, V. Subramanian2, D. Kreisel2, G. S. Budinger3, H. Perlman4, M. M. DeCamp1, T. Mohanakumar2, A. Bharat1. 1 _Thoracic Surgery, Northwestern University, Chicago, IL,_ 2 _Surgery, Washington University, St. Louis, MO,_ 3 _Pulmonary and Critical Care Medicine, Northwestern University, Chicago, IL,_ 4 _Rheumatology, Northwestern University, Chicago, IL_

**4:45 PM (107)** _Leukocytes Transfer More Severe Rejection from Lung Transplant Recipients with Severe PGD into Humanized Mice and Are Sensitive to T Cell Regulation;_ T. Siemeni, A. Knöfel, N. Madrahimov, W. Sommer, D. Bobylev, M. Avsar, F. Ius, K. Jansson, J. Salman, I. Tudorache, C. Kühn, A. Haverich, G. Warnecke. _Hannover HTTG, Hannover, Germany_

**5:00 PM (108)** _Thalidomide Treatment Prevents Chronic Graft Rejection after Transplantation in Rats;_ K. K. Miller1, X. Hua1, T. Deuse1, X. Hu1, E. Neofytou1, T. Renne2, H. Reichenspurner3, S. Schrepfer1, D. Bernstein4. 1 _TSI Lab, University Heart Center Hamburg, Hamburg, Germany,_ 2 _Clinical Chemistry, University Medical Center Hamburg, Hamburg, Germany,_ 3 _CT Surgery, University Heart Center Hamburg, Hamburg, Germany,_ 4 _Pediatric Cardiology, Stanford University School of Medicine, Stanford, CA_

**5:15 PM (109)** _BOS Is Associated with Increased Cytotoxic Pro-Inflammatory CD8 T and NKT-Like and NK Cells in the Distal Airways;_ G. Hodge, S. Hodge, A. Yeo, P. Nguyen, E. Hopkins, C. Holmes-Liew, P. N. Reynolds, M. Holmes. _Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia_

4:00 PM - 5:30 PM

Concurrent Session 19: Improving Outcomes: Body and Soul

**Location** :

Delaware Suite

Target Audience:

NHSAH, EEP, HF, HTX, LTX, MCS, PEDS, PH

Chairs:

Louise M Fuller, PT, and Erin Wells, RN

**4:00 PM (110)** _Change in Body Mass Index over Time after Continuous Flow Left Ventricular Assist Device Implantation;_ J. M. Tatum1, S. Abdoli1, F. S. Schenkel1, T. Possemato1, M. L. Barr1, P. Crookes2, M. E. Bowdish1. 1 _Cardiothoracic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA,_ 2 _Upper GI and Bariatric Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA_

**4:15 PM (111)** _Pre-Lung Transplant Body Composition and Associations with Post Transplant Outcomes;_ E. M. Capel1, M. O'Driscoll1, A. Tierney1, G. Snell2. 1 _Nutrition Services, The Alfred Hospital, Melbourne, Australia,_ 2 _Lung Transplantation Services, The Alfred Hospital, Melbourne, Australia_

**4:30 PM (112)** _Single Centre Observational Study on Adequacy and Tolerance of Nutrition Support on the First 7 Days of ECMO as Bridge to Lung Transplant;_ R. Patel, P. Mohite, S. Soresi, M. Carby, A. Simon, A. Reed. _Royal Brompton and Harefield Hospital, Middlesex, United Kingdom_

**4:45 PM (113)** _Lung Transplantation Does Not Impact on Daily Physical Activity Despite Substantial Improvements in Respiratory Function and Exercise Capacity;_ J. R. Walsh1, D. C. Chambers1, S. T. Yerkovich1, P. M. Hopkins1, N. R. Morris2. 1 _Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia,_ 2 _School of Rehabilitation Sciences and Griffith Health Institute, Griffith University, Gold Coast, Australia_

**5:00 PM (114)** _Incidence of Vocal Cord Palsy and Aspiration Status in the Lung Transplant Population;_ Z. Meszarich1, N. Patel1, A. Reed2, A. Simon3. 1 _Speech and Language Therapy, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom,_ 2 _Transplant Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom,_ 3 _Surgery, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom_

**5:15 PM (115)** _A Multi-Centre Study on the Effects of Iyengar Yoga on Health Related Quality of Life in Patients with Pulmonary Arterial Hypertension;_ M. V. Thakrar1, D. S. Helmersen1, N. Hirani1, K. Jackson2, D. C. Lien2, M. J. Santana3. 1 _Department of Medicine, Division of Respirology, University of Calgary, Calgary, AB, Canada,_ 2 _Alberta Lung Transplant Program, University of Alberta, Edmonton, AB, Canada,_ 3 _Department of Medicine, W21C, University of Calgary, Calgary, AB, Canada_

4:00 PM - 5:30 PM

Concurrent Session 20: Condemnatory or Commendatory Effects of Thoracic Transplantation

**Location** :

Washington Ballroom 2

Target Audience:

EEP, HF, HTX, LTX, MCS, NHSAH

Chairs:

Helen Gibbs, RN, and Soma S Jyothula, MD

**4:00 PM (116)** _Single Versus Double Lung Transplantation in the Setting of Constrained Donor Availability;_ P. Samson1, S. Chang2, R. Hachem3, D. Byers3, E. Trulock3, C. Witt3, R. D. Yusen3, D. Kreisel1, A. Krupnick1, G. Patterson1, B. Meyers1, V. Puri1. 1 _Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, MO,_ 2 _Department of Surgery, Washington University in St. Louis, St. Louis, MO,_ 3 _Division of Pulmonary and Critical Care Medicine, Washington University in St. Louis, St. Louis, MO_

**4:15 PM (117)** _Changes in Smoking Habits in Potential Lung Transplant (LTx) Candidates;_ J. Nuttall, H. Newton, C. Culshaw, L. Pate, C. Leonard, M. Al-Aloul. _Cardiothoracic Transplant Unit, University Hospital of South Manchester, Manchester, United Kingdom_

**4:30 PM (118)** _Implementation of the 7-Day National Health Service (NHS) Working Week in UK will be Detrimental to Heart and Lung Transplantation; Fact or Fiction?;_ L. Ong, G. Parry, S. C. Clark. _Cardiothoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, United Kingdom_

**4:45 PM (119)** _Impact of Socioeconomic Status on Bridging with Contemporary Left Ventricular Assist Device (LVAD): Analysis of the UNOS Registry;_ V. K. Topkara1, B. J. Wayda1, S. D. Rao2, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda3, H. Takayama3, F. Castagna1, A. M. Clemons1, K. Wong1, P. N. Trinh4, S. Restaino1, F. Latif1, J. Haythe1, M. A. Farr1, M. Maurer1, D. M. Mancini1, Y. Naka3, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Medicine, New York University, New York, NY,_ 3 _Surgery, Columbia University, New York, NY,_ 4 _Epidemiology, Columbia University, New York, NY_

**5:00 PM (120)** _Socioeconomic Deprivation Is Associated with Worse Survival After Heart Transplantation in England;_ J. D. Evans1, S. Kaptoge2, E. Di Angelantonio2, C. Lewis1, J. Parameshwar1, S. J. Pettit1. 1 _Transplant Unit, Papworth Hospital, Cambridge, United Kingdom,_ 2 _Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom_

**5:15 PM (121)** _Cost-Effectiveness of a Blood-Based Biomarker Compared to Endomyocardial Biopsy for the Diagnosis of Acute Allograft Rejection;_ Z. Hollander1, T. H. Mohammadi2, S. Assadian1, J. E. Wilson-McManus1, K. K. Lam1, R. T. Ng3, W. McMaster4, P. A. Keown4, B. M. McManus3, C. Marra5. 1 _PROOF Centre of Excellence, Vancouver, BC, Canada,_ 2 _Centre for Health Evaluation & Outcome Sciences, Vancouver, BC, Canada, _3 _University of BC & PROOF Centre of Excellence, Vancouver, BC, Canada, _4 _University of British Columbia, Vancouver, BC, Canada,_ 5 _School of Pharmacy, Memorial University, St. John's, NL, Canada_

6:00 PM - 7:00 PM

Mini Oral 1: Science, Surgery and Shock in Mechanical Circulatory Support

**Location** :

Thurgood Marshall

Target Audience:

MCS, BSI, HTX, NHSAH

Chairs:

Scott Silvestry, MD, and Theodoros Kofidis, MD, PhD, FRCS

**6:00 PM (122)** _Access Matters: Survival Advantage with Minimally Invasive Implantation of LVAD as Destination Therapy;_ V. Tarzia1, M. Di Mauro2, G. Bortolussi1, J. Bejko1, D. Marinelli2, M. Foschi2, M. Maccherini3, S. Bernazzali3, M. Maiani4, V. Tursi4, P. Agostoni5, A. Apostolo5, F. Alamanni5, U. Livi4, G. Sani3, T. Bottio1, G. Di Giammarco2, G. Gerosa1. 1 _Cardiac Surgery, University of Padova, Padova, Italy,_ 2 _Cardiac Surgery, University of Chieti, Chieti, Italy,_ 3 _Cardiac Surgery, University of Siena, Siena, Italy,_ 4 _Cardiac Surgery, University of Udine, Udine, Italy,_ 5 _Cardiac Surgery, University of Milano, Milano, Italy_

**6:05 PM (123)** _Heparin-Free Off-Pump LVAD Implantation Reduces Early Adverse Events Compared with On-Pump Implantation;_ S. K. Balasubramanian, E. Pavlushkov, S. Pettit, C. Lewis, Y. Abu-Omar, M. Berman, J. K. Parameshwar, S. Tsui. _Transplantation, Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom_

**6:10 PM (124)** _Short-, Mid- and Long-Term Efficacy of Aortic Valve Repair in Patients Supported with Continuous Flow-Left Ventricular Assist Device;_ S. Fukuhara, H. Takayama, K. Takeda, J. Han, P. Kurlansky, A. R. Garan, M. Yuzefpolskaya, P. C. Colombo, V. K. Topkara, Y. Naka. _Columbia University Medical Center, New York, NY_

**6:15 PM (125)** _Severe Mitral Regurgitation at Time of Left Ventricular Assist Device Implantation - Comparison of Systematic Mitral Valve Repair vs Surgical Abstention;_ A. Pawale1, S. Itagaki1, N. Moss2, S. Pinney2, D. H. Adams1, A. C. Anyanwu1. 1 _Cardiovascular Surgery, Mount Sinai Medical Center, New York, NY,_ 2 _Cardiology, Mount Sinai Medical Center, New York, NY_

**6:20 PM (126)** _Use of Impella 5.0 Ventricular Assist Device as a Bridge to Decision during Acute Decompensation of End-Stage Chronic Heart Failure;_ S. A. Hall1, S. Carey1, M. Edens1, G. Gong1, M. Esposito2, R. O'Kelly2, S. Annamalai2, N. Aghili2, S. Adatya3, A. Medjami4, M. Hout4, N. Josephy4, N. Kapur2, N. Uriel3. 1 _Baylor University Medical Center, Dallas, TX,_ 2 _Tufts Medical Center, Boston, MA,_ 3 _University of Chicago, Chicago, IL,_ 4 _Abiomed, Danvers, MA_

**6:25 PM (127)** _A Shock Team Improves Survival in Cardiogenic Shock by Decreasing Time to Intervention;_ C. Dillane, A. Bove, H. Cohen, R. Bashir, B. O'Murchu, B. O'Neill, J. Gomez-Abraham, A. Shiose, D. Schwartz, D. Dries, L. Punnoose, Y. Toyoda, R. Alvarez, E. Hamad. _Internal Medicine, Temple University Hospital, Philadelphia, PA_

**6:30 PM (128)** _Contemporary Outcome of Unplanned Right Ventricular Assist Device for Severe Right Heart Failure After Continuous Flow Left Ventricular Assist Device Insertion;_ K. Takeda1, H. Takayama1, R. A. Garan2, V. K. Topkara2, J. Han1, S. Fukuhara1, P. A. Kurlansky1, M. Yuzefpolskaya2, P. C. Colombo2, Y. Naka1. 1 _Cardiac Surgery, Columbia University, NY, NY,_ 2 _Cardiology, Columbia University, NY, NY_

**6:35 PM (129)** _Extracorporeal Membrane Oxygenator Therapy after Heart Transplantation;_ P. Vallabhajosyula1, A. Habertheuer1, S. Miller1, P. Atluri1, C. Bermudez1, M. Acker1, L. Goldberg2, M. Williams1. 1 _Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA,_ 2 _Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA_

**6:40 PM (130)** _Increase in Frequency of Terminally Differentiated and Exhausted CD8+ T Cells Is Associated with Worse Clinical Outcomes after Mechanical Circulatory Support Device Implantation;_ J. M. Schaenman1, Y. Korin2, T. Sidwell2, E. Chang3, M. Bakir3, N. Wisniewski4, G. Bondar3, M. Cadeiras3, M. Kwon5, E. Reed2, M. Deng3. 1 _Medicine/Infectious Diseases, UCLA School of Medicine, Los Angeles, CA,_ 2 _Pathology, UCLA School of Medicine, Los Angeles, CA,_ 3 _Medicine/Cardiology, UCLA School of Medicine, Los Angeles, CA,_ 4 _Department of Integrative Biology and Physiology, UCLA School of Medicine, Los Angeles, CA,_ 5 _Cardiovascular Surgery, UCLA School of Medicine, Los Angeles, CA_

**6:45 PM (131)** _Increased Aortic Stiffness Index Among Patients Bridged to Transplant with Non-Pulsatile Left Ventricular Assist Devices;_ A. C. Patel1, R. B. Dodson1, K. S. Hunter1, A. Brieke1, J. Lindenfeld2, A. V. Ambardekar1. 1 _University of Colorado, Aurora, CO,_ 2 _Vanderbilt Heart and Vascular Institute, Nashville, TN_

**6:50 PM (132)** _Changes in Metabolic Substrate Utilization and Pyruvate Mitochondrial Oxidation Mismatch during Mechanical Unloading of the Failing Human Heart: Implications for Cardiac Reloading and Conditioning;_ N. Diakos1, S. Navankasattusas1, S. H. McKellar1, A. G. Kfoury1, P. Ferrin1, L. McCreath1, D. Miller1, S. Wright1, K. Skedros1, M. Al-Sari1, A. Ragnhildstveit1, O. Wever-Pinzon1, G. Russel2, A. Koliopoulou1, B. Reid1, J. Stehlik1, C. H. Selzman1, S. G. Drakos1. 1 _UTAH Cardiac Transplant Program, Salt Lake City, UT,_ 2 _Intermountain Donor Services, Salt Lake City, UT_

**6:55 PM (133)** _A Gene Expression Biomarker Panel for Predicting Mechanical Circulatory Support Outcomes;_ N. Wisniewski1, G. Bondar1, C. Rau2, J. Chittoor1, E. Chang1, A. Esmaeili1, M. Deng1. 1 _Department of Medicine (Cardiology), University of California, Los Angeles, Los Angeles, CA,_ 2 _Department of Anesthesiology, University of California, Los Angeles, Los Angeles, CA_

6:00 PM - 7:00 PM

Mini Oral 2: Donor Dilemmas in Heart Transplantation

**Location** :

Salon 1

Target Audience:

HTX, ID, NHSAH, PATH, PEDS, PHARM

Chairs:

Daniel Zimpfer, MD, and Carmelo A Milano, MD

**6:00 PM (134)** _Impact of a New Urgency-Based Cardiac Allocation System on Candidate Outcomes: Results from a Simulated Allocation Study;_ C. Jacquelinet, B. Audry, C. Jasseron, C. Canterelle, C. Legeai, O. Bastien, R. Dorent. _Direction Médicale et Scientifique, Agence de la Biomedecine, Saint Denis la Plaine, France_

**6:05 PM (135)** _Prolonged Cardiac Allograft Donor Distance Does Not Impact Long-Term Survival;_ A. C. Gaffey1, C. W. Chen1, J. J. Chung1, J. Wald2, M. A. Acker1, P. Atluri1. 1 _Department of Surgery, University of Pennsylvania, Philadelphia, PA,_ 2 _Department of Cardiology, University of Pennsylvania, Philadelphia, PA_

**6:10 PM (136)** _Low Ejection Fraction in Young Donor Hearts Is Not Associated with Increased Recipient Mortality;_ C. W. Chen1, A. C. Gaffey1, M. H. Sprys1, J. J. Chung1, K. B. Margulies2, M. A. Acker1, P. Atluri1. 1 _Department of Surgery, University of Pennsylvania, Philadelphia, PA,_ 2 _Department of Medicine, University of Pennsylvania, Philadelphia, PA_

**6:15 PM (137)** _Predicting One-Year Cardiac Transplant Survival Using a Donor/Recipient Risk Assessment Tool;_ D. L. Joyce1, Z. Li1, L. B. Edwards2, J. A. Kobashigawa3, R. C. Daly1. 1 _Cardiovascular Surgery, Mayo Clinic, Rochester, MN,_ 2 _Assistant Director of Research, UNOS, Richmond, VA,_ 3 _Cardiology, Cedars-Sinai Heart Institute, Beverly Hills, CA_

**6:20 PM (138)** _Are Pediatric Donor Hearts Viable in Adult Recipients?;_ M. Kittleson, J. Patel, L. Czer, T. Aintablian, J. Rush, M. Johnson, D. Chang, D. Ramzy, D. Geft, J. A. Kobashigawa. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**6:25 PM (139)** _The Overall Concept of Bridging to Transplantation by an Ventricular Assist Device in Comparison to Bridging by Conservative Treatment - Results Using the United Network for Organ Sharing Database;_ A. M. Bernhardt1, A. P. Levin2, A. Schaefer1, F. M. Wagner1, H. Reichenspurner1. 1 _Department of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany,_ 2 _Columbia University Medical Center, New York City, NY_

**6:30 PM (140)** _Prolonged Corrected QT Interval in the Donor Heart: Is There a Risk?;_ J. Patel, M. Kittleson, L. Czer, T. Aintablian, D. Phan, D. Leong, J. Rush, E. Stimpson, D. Chang, A. Hage, A. Trento, J. A. Kobashigawa. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**6:35 PM (141)** _Impact of Cytomegalovirus on Survival after Heart Transplant: Analysis of 20,000 Patients from the UNOS Registry Data;_ G. Ashrith, A. Daoud, L. D. Teeter, J. Amione-Guerra, A. M. Cordero-Reyes, E. Graviss, B. H. Trachtenberg, A. Bhimaraj, A. Gaber, S. Scheinin, G. Torre-Amione, J. D. Estep. _Cardiology, Houston Methodist Hospital, Houston, TX_

**6:40 PM (142)** _Stress Cardiomyopathy in Donor Hearts Does Not Affect the Outcome after Heart Transplantation;_ T. Pintar1, G. Poglajen2, R. Okrajšek2, J. Kšela3, I. Kneževič3, B. Vrtovec2. 1 _Dept. of Anesthesiology and Intensive Therapy, UMC Ljubljana, Ljubljana, Slovenia,_ 2 _Advanced Heart Failure and Transplantation Programme, Dept. of Cardiology, UMC Ljubljana, Ljubljana, Slovenia,_ 3 _Dept. of Cardiovascular Surgery, UMC Ljubljana, Ljubljana, Slovenia_

**6:45 PM (143)** _Similar Post-Heart Transplant Outcomes with Undersized or Oversized Donors When Left Ventricular End Diastolic Dimension (LVEDD) Is within Range;_ N. Bassi1, C. Murks2, S. Adatya2, G. Kim2, N. Sarswat2, G. Sayer2, D. Rodgers2, T. Ota3, N. Uriel2, V. Jeevanandam3. 1 _Medicine, University of Chicago, Chicago, IL,_ 2 _Medicine (Section of Cardiology), University of Chicago, Chicago, IL,_ 3 _Surgery (Section of Cardiac and Thoracic Surgery), University of Chicago, Chicago, IL_

**6:50 PM (144)** _Heart Transplantation Following Donor Circulatory Death in Patients Bridged to Transplant with Implantable Left Ventricular Assist Devices;_ D. García Sáez, P. Mohite, C. T. Bowles, O. Maunz, B. Zych, M. Zeriouh, A. F. Popov, S. Rahman-Haley, N. Banner, A. R. Simon. _Heart Lung Transplantation and Mechanical Circulatory Support, Harefield Hospital NHS Trust, Harefield, London, United Kingdom_

**6:55 PM (145)** _Early and Late Outcomes of Cardiac Transplanted Patients with Marginal Donors: A Single Centre 10 Years Experience;_ A. Galeone1, G. Lebreton1, S. Ouldamar1, G. Coutance1, M. Schimdt2, J. Amour3, P. Leprince1. 1 _Department of Thoracic and Cardiovascular Surgery, La Pitiè-Salpêtrière Hospital, Paris, France,_ 2 _Department of Medical Reanimation, La Pitiè-Salpêtrière Hospital, Paris, France,_ 3 _Department of Anesthesiology, La Pitiè-Salpêtrière Hospital, Paris, France_

6:00 PM - 7:00 PM

Mini Oral 3: Candidate and Recipient Management in Heart Transplantation

**Location** :

Maryland Suite

Target Audience:

HTX, ID, NHSAH, PATH, PEDS, PHARM

Chairs:

Simon Maltais, MD, PhD, and Daniela Pini, MD

**6:00 PM (146)** _Treating the Failing Heart: An Evaluation of the Past Decade;_ M. C. Black, J. R. Trivedi, E. M. Schumer, A. Cheng, H. T. Massey, M. S. Slaughter. _Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY_

**6:05 PM (147)** _Induction Immunosuppression Strategies and Long-Term Outcomes after Heart Transplantation;_ D. Ansari1, J. Stehlik2, L. H. Lund3, B. Andersson4, L. B. Edwards5, J. Nilsson1. 1 _Cardiothoracic Surgery, Lund University and Skane University Hospital, Lund, Sweden,_ 2 _Cardiovascular Medicine, University of Utah School of Medicine, Utah, UT,_ 3 _Medicine, Unit of Cardiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden,_ 4 _Surgery, Lund University and Skane University Hospital, Lund, Sweden,_ 5 _The ISHLT Transplant Registry, Dallas, TX_

**6:10 PM (148)** _Implications of Amiodarone Use Before Heart Transplantation;_ L. B. Cooper1, R. J. Mentz1, L. B. Edwards2, A. Wilk2, J. G. Rogers1, C. B. Patel1, C. A. Milano1, A. F. Hernandez1, J. Stehlik3, L. H. Lund4. 1 _Duke University, Durham, NC,_ 2 _United Network for Organ Sharing, Richmond, VA,_ 3 _University of Utah School of Medicine, Salt Lake City, UT,_ 4 _Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden_

**6:15 PM (149)** _Impact of Cytomegalovirus Infection on Longitudinal Gene-Expression Profiling Score: Results from the Outcomes AlloMap_ ® _Registry;_ M. Kanwar1, S. Murali1, D. Hiller2, E. Deljkich2. 1 _Allegheny General Hospital, Pittsburgh, PA,_ 2 _CareDx, San Fransisco, CA_

**6:20 PM (150)** _Outcomes of Heart Transplantation for Transthyretin-Related Amyloid Cardiomyopathy;_ M. Sabatino, L. Potena, S. Longhi, M. Masetti, C. Gagliardi, A. Milandri, V. Manfredini, M. Cinelli, G. Marinelli, A. D. Pinna, C. Rapezzi, F. Grigioni. _University of Bologna, Bologna, Italy_

**6:25 PM (151)** _Outcomes of Heart Transplantation in Adults with Hypertrophic Cardiomyopathy (HCM): UNOS Registry Analysis;_ E. C. DePasquale1, M. Deng1, A. Ardehali1, D. Jacoby2. 1 _David Geffen Sch Med, Los Angeles, CA,_ 2 _Yale, New Haven, CT_

**6:30 PM (152)** _Assessment of Molecular Mechanisms of Non-Transplant Cardiac Hypertrophy in Cardiac Allograft Hypertrophy- An Exploratory Gene Array Study of Myocardial Biopsy Samples;_ R. Araujo-Gutierrez1, M. Park2, J. D. Estep2, G. Ashrith2, B. H. Trachtenberg2, G. Torre-Amione2, A. Bhimaraj2. 1 _DeBakey Heart & Vascular Center, Houston Methodist Research Institute, Houston, TX, _2 _Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX_

**6:35 PM (153)** _Temporal Trends of Incidence and Types of De Novo Malignancy after Heart Transplantation;_ J. Youn1, L. B. Edwards2, L. H. Lund3, J. Stehlik4, S. Kang1, J. A. Kobashigawa5. 1 _Division of Cardiolgoy, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of,_ 2 _United Network for Organ Sharing, Richmond, VA,_ 3 _Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden,_ 4 _Division of Cardiology, University of Utah Health Sciences Center, Salt Lake City, UT,_ 5 _Division of Cardiolgoy, Cedars-Sinai Medical Center, Los Angeles, CA_

**6:40 PM (154)** _Heart Transplantation Versus Ventricular Assist Device: Which Therapy for Patient with Refractory Cardiogenic Shock?;_ C. Vidal, G. Lebreton, N. Djavidi, S. Varnous, A. Bouglé, A. Genton, E. Barreda, P. Leprince, J. Amour. _Institut de Cardiologie, Hôpital Pitié Salpétrière, Paris, France_

**6:45 PM (155)** _Immune Mediators IL-10 and TNF-alpha as a Potential Diagnostic Tool for Detection of Developed Cardiac Allograft Vasculopathy;_ C. L. Bara1, B. Przybylek2, A. Neumann1, A. Haverich1, C. S. Falk3. 1 _Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School (MHH), Hannover, Germany,_ 2 _Hannover Medical School (MHH), Hannover, Germany,_ 3 _Institute of Transplant Immunology, IFB-Tx, Hannover Medical School, Hannover, Germany_

**6:50 PM (156)** _Differences in the Impact of Donor-Related Variables on Post-Heart Transplantation Outcomes in Mechanically Bridged Recipients and Recipients without Prior Mechanical Support - An Analysis from the ISHLT Registry;_ M. Urban1, L. Edwards2, J. Stehlik3, K. Booth4, J. Pirk1, I. Netuka1. 1 _Cardiac Surgery, IKEM, Prague, Czech Republic,_ 2 _Biostatistics, United Network for Organ Sharing, Richmond, VA,_ 3 _University of Utah, Salt Lake City, UT,_ 4 _Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom_

**6:55 PM (157)** _Competing Outcomes of Heart Transplantation in Adults Bridged with Total Artificial Heart (TAH): UNOS Registry Analysis;_ E. C. DePasquale, A. Salimbangon, A. Chang, E. Howell, E. Howell, A. Nsair, M. Deng, A. Ardehali. _David Geffen Sch Med, Los Angeles, CA_

6:00 PM - 7:00 PM

Mini Oral 4: Donor and Recipient Management in Lung Transplantation

**Location** :

Virginia Suite

Target Audience:

LTX, BSI, EEP, ID, LBCS, NHSAH, PATH, PEDS, PH, PHARM

Chairs:

Mark Benzimra, MD, MRCP and Christophe Pison, MD, PhD

**6:00 PM (158)** _Obstacles to Lung Transplant from Uncontrolled Donation After Circulatory Determination of Death Donors (uDCDDs);_ T. M. Egan1, J. J. Requard2, P. Stewart3, C. Thys4. 1 _Surgery, U. North Carolina Sch Med, Chapel Hill, NC,_ 2 _Lung Banks of America, Chapel Hill, NC,_ 3 _Biostatistics, U. North Carolina Gillings School of Public Health, Chapel Hill, NC,_ 4 _Carolina Donor Services, Durham, NC_

**6:05 PM (159)** _Lung Function: How Good Does It Get?;_ M. Paraskeva1, B. Borg2, E. Paul3, J. Fuller4, G. Westall5, G. I. Snell5. 1 _Alfred Hospital, Melbourne, Australia,_ 2 _Lung Function Service, Alfred Hospital, Melbourne, Australia,_ 3 _Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Australia,_ 4 _Monash University, Melbourne, Australia,_ 5 _Lung Transplant Service, Alfred Hospital, Melbourne, Australia_

**6:10 PM (160)** _Long-Term Impact of Coronary Artery Disease in Lung Transplantation;_ W. S. Ragalie1, J. D. Maloney2, K. C. Meyer3, R. D. Cornwell3, N. C. De Oliveira2. 1 _Surgery, Medical College of Wisconsin, Milwaukee, WI,_ 2 _Cardiothoracic Surgery, University of Wisconsin, Madison, WI,_ 3 _Pulmonary Medicine, University of Wisconsin, Madison, WI_

**6:15 PM (161)** _Does Single Lung Transplantation Change Perfusion in Relation to Native Lung in Pulmonary Fibrosis? Implications in Choosing Laterality;_ L. S. Reddy, M. Daneshmand, J. C. Haney, L. Snyder, A. L. Gray, J. M. Reynolds, M. G. Hartwig. _Transplant Division, Duke University Medical Center, Durham, NC_

**6:20 PM (162)** _Simulated Regionalization of Lung Transplantation in the United States;_ J. Magruder1, T. C. Crawford2, J. C. Grimm2, A. S. Shah3, B. Kim4, E. L. Bush2, R. S. Higgins2, C. A. Merlo4. 1 _Johns Hopkins, Baltimore, MD,_ 2 _Division of Cardiac Surgery, Johns Hopkins, Baltimore, MD,_ 3 _Department of Cardiac Surgery, Vanderbilt, Nashville, TN,_ 4 _Division of Pulmonary and Critical Care Medicine, Johns Hopkins, Baltimore, MD_

**6:25 PM (163)** _The OCS Lung EXPAND International Trial Interim Results;_ G. Loor1, G. Warnecke2, M. Smith3, J. Kukreja4, A. Ardehali5, J. Moradiellos6, A. Varela6, J. Madsen7, M. Hertz1, D. Van Raemdonck8. 1 _University of Minnesota Medical Center, Mineapolis, MN,_ 2 _Hannover Medical School, Hannover, Germany,_ 3 _St. Joseph's Medical Center, Phoenix, AZ,_ 4 _University of California San Francisco Medical Center, San Francisco, CA,_ 5 _Ronald Reagan UCLA Medical Center, Los Angeles, CA,_ 6 _University Puerta de Hierro Hospital, Madrid, Spain,_ 7 _Massachusetts General Hospital, Boston, MA,_ 8 _Leuven University Hospital, Leuven, Belgium_

**6:30 PM (164)** _Impact of OCS Lung Portable EVLP on Pulmonary Function and Bronchiolitis Obliterans in Standard Lung Transplant Recipients - Prospective Evidence from the OCS Lung INSPIRE Trial Patients;_ A. Ardehali1, G. Warnecke2, D. Van Raemdonck3, G. Loor4, J. Kukreja5, M. Smith6, F. Rea7, G. Massard8, F. De Robertis9, J. Nagendran10, J. Moradiellos11, K. Dhital12, C. Knosalla13, C. Bermudez14, S. Tsui15, I. Wang16, K. McCurry17, T. Deuse18, P. Thomas19, W. Sommer2, B. Wiegmann2, I. Tudorache2, C. Khun2, M. Avsar2, M. Schiavon7, N. Santelmo8, A. Olland8, P. Falcoz8, A. Varela11, A. Simon9, H. Reichenspurner18, A. Haverich2, J. Madsen20, M. Hertz21. 1 _Ronald Reagan UCLA Medical Center, Los Angeles, CA,_ 2 _Hannover Medical School, Hannover, Germany,_ 3 _Leuven University Hospital, Leuven, Belgium,_ 4 _University of Minnesota Medical Center, Mineapolis, MN,_ 5 _University of California San Francisco Medical Center, San Francisco, CA,_ 6 _St. Joseph's Medical Center, Phoenix, AZ,_ 7 _University of Padua Hospital, Padua, Italy,_ 8 _Strasbourg University Hospital, Strasbourg, France,_ 9 _Harefield Hospital, London, United Kingdom,_ 10 _University of Alberta Medical Center,, Edmonton, ON, Canada,_ 11 _University Puerta de Hierro Hospital, Madrid, Spain,_ 12 _St. Vincent's Hospital, Sydney, Australia,_ 13 _German Heart Institute, Berlin, Germany,_ 14 _University of Pittsburgh Medical Center, Pittsburgh, PA,_ 15 _Papworth Hospital, Papworth, Cambridge, United Kingdom,_ 16 _Indiana University Medical Center, Indianapolis, IN,_ 17 _Cleveland Clinic Foundation, Cleveland, OH,_ 18 _Hamburg University Hospital, Hamburg, Germany,_ 19 _University Hospitals of Marseille, Marseille, France,_ 20 _Massachusetts General Hospital, Boston, MA,_ 21 _University of Minnesota Medical Center, Minneapolis, MN_

**6:35 PM (165)** _On-Demand Immunoglobulin-G Replacement Is Not Associated with Benefits in Lung Transplant Recipients with Hypogammaglobulinemia;_ A. B. Lichvar, C. R. Ensor, M. R. Morrell, J. M. Pilewski, J. Hayanga, J. D'Cunha, A. Zeevi, J. F. McDyer, A. A. Petrov. _University of Pittsburgh, Pittsburgh, PA_

**6:40 PM (166)** _Carfilzomib-Based Therapy Produces Favorable Outcomes for Antibody Mediated Rejection of the Lung Allograft;_ C. R. Ensor, A. Zeevi, M. Marrari, M. R. Morrell, S. A. Yousem, J. M. Pilewski, J. D'Cunha, J. F. McDyer. _University of Pittsburgh, Pittsburgh, PA_

**6:45 PM (167)** _Total Lymphoid Irradiation (TLI) for the Management of Bronchiolitis Obliterans Syndrome (BOS) Post Lung Transplant: A Single Centre Experience;_ R. Miller1, B. Hartog2, J. Frew1, G. Parry1, A. Fisher1, P. Corris1, G. Meachery1, J. Lordan1. 1 _Freeman Hospital, Newcastle upon Tyne, United Kingdom,_ 2 _University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom_

**6:50 PM (168)** _Extracorporeal Membrane Oxygenation (ECMO) as a Bridge to Lung Transplantation: Identifying Predictors of Mortality;_ J. A. Hayanga1, N. Shigemura1, E. Chan1, T. Richards1, M. Morrell2, J. D. Luketich1, J. D'Cunha1. 1 _Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA,_ 2 _Pulmonary Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA_

**6:55 PM (169)** _Age Trends for Cystic Fibrosis Patients Undergoing Lung Transplantation: An Analysis of the ISHLT Thoracic Transplant Registry;_ C. Benden1, L. B. Edwards2, S. B. Goldfarb3, R. D. Yusen4, J. Stehlik5. 1 _University Hospital Zurich, Zurich, Switzerland,_ 2 _ISHLT Thoracic Transplant Registry, Dallas, TX,_ 3 _Children's Hospital of Philadelphia, Philadelphia, PA,_ 4 _Washington University School of Medicine, St. Louis, MO,_ 5 _University of Utah Health Care, Salt Lake City, UT_

6:00 PM - 7:00 PM

Mini Oral 5: Pediatrics: Organ Support and Transplantation

**Location** :

Delaware Suite

Target Audience:

PEDS, HTX, LBCS

Chairs:

Estela Azeka, MD, and Chesney Castleberry, MD

**6:00 PM (170)** _Pancreas: The Forgotten Organ in Children Undergoing Implantable Continuous-Flow VAD Support;_ S. Burki1, D. Horne1, S. C. Tume2, A. Jeewa3, A. G. Cabrera3, E. McKenzie1, C. D. Fraser, Jr.1, I. Adachi1. 1 _Congenital Heart Surgery, Texas Children's Hospital, Houston, TX,_ 2 _Pediatric Critical Care, Texas Children's Hospital, Houston, TX,_ 3 _Pediatric Cardiology, Texas Children's Hospital, Houston, TX_

**6:05 PM (171)** _Pre-Transplantation Mechanical Circulatory Support Duration Effects Candidacy and Graft Longevity;_ F. Zafar1, D. L. Morales1, A. Lorts2, C. Villa2, N. Kimura1, R. Rizwan1, C. Chin2, R. Bryant 3rd1. 1 _Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH,_ 2 _Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH_

**6:10 PM (172)** _Steroid Therapy as a Strategy to Treat Hyperfibrinogenemia in Pediatric Ventricular Assist Device Patients: Does It Actually Hasten the Decline?;_ J. Murray, J. Lee, N. Do, S. Chen, C. Almond, S. A. Hollander, K. Maeda, V. Yarlagadda, D. Rosenthal, M. Gowen, P. Shuttleworth. _Lucile Packard Children's Hospital, Palo Alto, CA_

**6:15 PM (173)** _Impact of Donor Cause of Death on Graft Utilization in Pediatric Heart Transplantation;_ A. M. Khan1, S. Malerba1, M. Bock2, I. Lytrivi1. 1 _Icahn School of Medicine at Mount Sinai, New York, NY,_ 2 _Loma Linda University Children's Hospital, Loma Linda, CA_

**6:20 PM (174)** _Impact of Induction Therapy Type in High and Low Risk Pediatric Patients After Heart Transplant: Analysis of the PHTS Database;_ C. Castleberry1, R. Amenduri2, K. Schowengerdt3, E. Edens4, N. Hagin1, E. Pruitt5, J. Kirklin6, S. Urschel7. 1 _Pediatric Cardiology, Washington University in St. Louis, St. Louis, MO,_ 2 _Pediatric Cardiology, University of Minnesota, Amplatz Children's Hospital, Minneapolis, MN,_ 3 _Pediatric Cardiology, Cardinal Glennon Children's Medical Center, St. Louis, MO,_ 4 _Pediatric Cardiology, University of Iowa Children's Hospital, Iowa City, IA,_ 5 _Cardiovascular Surgery, University of Alabama at Birmingham, Birmingham, AL,_ 6 _Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL,_ 7 _Pediatric Cardiology, University of Alberta, Edmonton, AB, Canada_

**6:25 PM (175)** _Increased Frequency of Surveillance Biopsy Does Not Improve Pediatric Heart Transplant Outcomes: Time for a Change in Practice?;_ J. Godown1, M. McKane1, B. A. Mettler2, A. C. Westrick3, C. N. Shannon3, H. Chen4, S. Zhao4, D. A. Dodd1. 1 _Pediatric Cardiology, Monroe Carell Jr. Children's Hospital, Nashville, TN,_ 2 _Pediatric Cardiothoracic Surgery, Monroe Carell Jr. Children's Hospital, Nashville, TN,_ 3 _Surgical Outcomes Center for Kids, Monroe Carell Jr. Children's Hospital, Nashville, TN,_ 4 _Biostatistics, Vanderbilt University, Nashville, TN_

**6:30 PM (176)** _Donor-Specific Anti-HLA Antibodies of Immunoglobulin G3 Subclass Correlate with Cellular Rejection after Cardiac Transplantation;_ S. Khan1, C. Chin1, E. Portwood2, P. A. Brailey2, A. Tica3, A. L. Girnita4. 1 _Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH,_ 2 _Transplant Immunology Division, Hoxworth Blood Center, Cincinnati, OH,_ 3 _Department of Pharmacology, University of Medicine and Pharmacy, Craiova, Romania,_ 4 _Department of Surgery, COM, Transplant Immunology Division, University of Cincinnati, Cincinnati, OH_

**6:35 PM (177)** _Application of New Antibody-Mediated Rejection Classification (pAMR) on Pediatric Heart Transplant: A Retrospective Study * ;_ M. Fedrigo1, A. Angelini1, G. J. Berry2. 1 _Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy,_ 2 _Pathology Department, Stanford University, Stanford, CA_

**6:40 PM (178)** _Pediatric Heart Transplant Waitlist Time Is Increased and Survival Is Decreased in Overweight-Obese (BMI >85%) Individuals; _T. D. Ryan, F. Zafar, R. M. Siegel, C. R. Villa, R. Bryant, C. Chin. _The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH_

**6:45 PM (179)** _Heart Transplantation in Adolescents: Does Pediatric Experience Improve Outcomes?;_ R. R. Davies1, S. J. Kindel2, M. A. McCulloch1, C. Pizarro1, W. T. Mahle3, D. L. Morales4. 1 _Nemours/A.I. duPont Hospital for Children, Wilmington, DE,_ 2 _Children's Hospital of Wisconsin, Milwaukee, WI,_ 3 _Children's Healthcare of Atlanta, Atlanta, GA,_ 4 _Cincinnati Children's Hospital Medical Center, Cincinnati, OH_

**6:50 PM (180)** _The Quilty Effect in Pediatric Heart Transplant Recipients;_ A. Joong1, M. E. Richmond1, K. O. Stack2, R. J. Rodriguez1, J. M. McAllister2, W. A. Zuckerman1, T. M. Lee1, S. Law1, L. J. Addonizio1. 1 _Pediatric Cardiology, Columbia University, New York, NY,_ 2 _Surgery, Columbia University, New York, NY_

**6:55 PM (181)** _Circulating Cell-Free DNA as a Non-Invasive Marker of Pediatric Heart Transplant Rejection and Immunosuppressive Treatment;_ K. K. Khush1, M. Grskovic2, H. Luikart1, G. Cohen1, C. Strehl1, J. Wylie1, K. Thompson2, B. Christie2, J. Collins2, D. Hiller2, J. Yee2, D. Bernstein3. 1 _Medicine/Cardiology, Stanford University, Stanford, CA,_ 2 _CareDx, Inc, Brisbane, CA,_ 3 _Pediatrics/Cardiology, Stanford University, Stanford, CA_

6:00 PM - 7:00 PM

Mini Oral 6: Pharmacy & Pharmacology and Mechanical Circulatory Support

**Location** :

Washington Ballroom 2

Target Audience:

PHARM, HTX, ID, LTX, MCS

Chairs:

Peter J Bergin, MBBS, FRACP, and Walter Uber, PharmD

**6:00 PM (182)** _Genotype-Guided Warfarin Dosing in Continuous-Flow Left-Ventricular Assist Device (CF-LVAD) Patients;_ D. L. Jennings1, R. C. Li1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda1, H. Takayama1, B. Cagliostro2, M. A. Flannery1, B. Toennes1, M. A. Farr1, D. M. Mancini1, Y. Naka1, P. C. Colombo1, V. K. Topkara1. 1 _Columbia University Medical Center, New York, NY,_ 2 _New York Presbyterian Hospital, New York, NY_

**6:05 PM (183)** _Suppressive Antibiotics for LVAD-Associated Infections: Are They Helpful or Harmful?;_ S. Strout, T. Veasey, K. Rieger, C. Floroff, D. Wray, M. Brisco, J. Cook, M. Craig, J. Toole, A. Van Bakel, D. Heyward, W. Uber, H. Meadows. _Medical University of South Carolina, Charleston, SC_

**6:10 PM (184)** _CYP3A5 Pharmacogenetic Testing Predicts High Tacrolimus Dose Requirements Early after Cardiac Transplantation;_ K. M. Deininger1, A. Vu2, R. L. Page II3, A. V. Ambardekar4, J. Lindenfeld5, C. L. Aquilante1. 1 _Pharmaceutical Sciences, University of Colorado, Aurora, CO,_ 2 _University of Pittsburgh, Pittsburgh, PA,_ 3 _Clinical Pharmacy, University of Colorado, Aurora, CO,_ 4 _Division of Cardiology, University of Colorado, Aurora, CO,_ 5 _Vanderbilt Heart and Vascular Institute, Vanderbilt University, Nashville, TN_

**6:15 PM (185)** _Carfilzomib-Rituximab Desensitization in Sensitized Heart Transplant Candidates: A Single Center Experience;_ P. Weeks1, A. Sieg1, M. Ling2, Y. Bai3, S. Nathan4, I. Rajapreyar4. 1 _Pharmacy, Memorial Hermann - Texas Medical Center, Houston, TX,_ 2 _Transplant Immunology, University of Texas Health Science Center, Houston, TX,_ 3 _Pathology, University of Texas Health Science Center, Houston, TX,_ 4 _Center for Advanced Heart Failure, University of Texas Health Science Center, Houston, TX_

**6:20 PM (186)** _Early Experience with Carfilzomib as an Adjunct to Current Therapies for Donor Specific Antibodies After Lung Transplantation;_ T. L. Molina, K. L. Dawson, A. Fuentes, A. Goodarzi, J. Youssef, N. Sinha, T. Kaleekal. _Houston Methodist Hospital, Houston, TX_

**6:25 PM (187)** _Hepatitis B Immunity Prior to Lung Transplantation: Three Shots and You're Out?;_ A. B. Cochrane, M. LoRusso, M. Fregoso, M. Bowen, S. Nathan, A. W. Brown. _Inova Advanced Lung Disease and Lung Transplant Program, Inova Fairfax Hospital, Falls Church, VA_

**6:30 PM (188)** _Single Center Experience with Medical Therapy for Management of LVAD Pump Thrombosis;_ D. T. Majure, M. E. Rodrigo, F. H. Sheikh, M. Hofmeyer, A. Pratt, E. J. Molina, L. M. Peters, S. W. Boyce, S. S. Najjar. _MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC_

**6:35 PM (189)** _Prospective Evaluation of Urine Dipstick for Detection of Significant Hemolysis in Outpatients on CF-LVAD Support;_ M. Gavalas1, A. Breskin2, A. B. Eisenberger1, M. Yuzefpolskaya1, A. R. Garan1, F. Castagna1, K. Wong1, M. Tiburcio3, R. Te-Frey3, J. Haythe1, D. M. Mancini1, H. Takayama3, K. Takeda3, Y. Naka3, V. K. Topkara1, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Epidemiology, Columbia University, New York, NY,_ 3 _Surgery, Columbia University, New York, NY_

**6:40 PM (190)** _Fibrin Density and Platelet Location Varies Based on HeartMate II Thrombus Site;_ L. Baumann Kreuziger1, M. Slaughter2, K. Sundareswaran3, A. Mast1. 1 _BloodCenter of Wisconsin, Milwaukee, WI,_ 2 _University of Louisville, Louisville, KY,_ 3 _Thoratec Corporation, Pleasanton, CA_

**6:45 PM (191)** _Clinical Predictors and Outcomes of Patients with Left Ventricular Assist Device Related Gastrointestinal Bleeding in the ROADMAP Study;_ K. B. Shah1, P. A. Uber1, J. G. Rogers2, V. Kasirajan1, J. S. Chuang3, D. J. Farrar3, J. D. Estep4. 1 _Virginia Commonwealth Univ, Richmond, VA,_ 2 _Duke University, Durham, NC,_ 3 _St. Jude Medical, Pleasanton, CA,_ 4 _Houston Methodist Hospital, Houston, TX_

**6:50 PM (192)** _Increased Risk of Gastrointestinal Bleeding in HeartMate II Compared to HeartWare Left Ventricular Assist Devices - A Single Center Retrospective Cohort;_ W. T. Love, G. M. Zawadowski, J. Noelting, J. L. Horsley-Silva, L. L. Staley, M. E. Amity, L. Schroedl, M. D. Crowell, B. W. Hardaway, F. C. Ramirez, O. E. Pajaro. _Mayo Clinic Arizona, Scottsdale, AZ_

**6:55 PM (193)** _Early Heparin Bridging after Left Ventricular Assist Device Implantation Is Associated with Increased Length of Stay and a High Rate of Hospital Readmission;_ S. S. Roy1, J. Larson2, S. Phanco2, D. Ramu1, M. Bearns2, R. John3, R. Cogswell1. 1 _Cardiology, University of Minnesota, Minneapolis, MN,_ 2 _University of Minnesota, Minneapolis, MN,_ 3 _Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN_
ANNUAL MEETING SCIENTIFIC PROGRAM

FRIDAY, APRIL 29, 2016

7:00 AM - 8:00 AM

Sunrise Symposium 1: MCS Challenges and Engineering Solutions

**Location** :

Thurgood Marshall

Target Audience:

MCS, HF, HTX, MCS

Chairs:

Jan D. Schmitto, MD, PhD, MBA, and George M. Wieselthaler, MD

**Session Summary** : In this session the latest technologies and trends in MCS will be presented, with particular focus on challenges such as bleeding and thrombosis, new pump concepts and pump miniaturization, physiologic pump control or usability of peripherals.

7:00 AM

Flow, Shear and MCS Coagulopathies: Mechanisms, Design Implications, Next Steps

Mark Slaughter, MD, University of Louisville, Louisville, KY, USA

7:12 AM

Q & A

7:15 AM

Size Matters: Limitations and Drawbacks of Pump Miniaturization

Ulrich Steinseifer, PhD, University Hospital Aachen, Aachen, Germany

7:27 AM

Q & A

7:30 AM

What Technologies Will Be the Most Impactful to Reduce Adverse Events?

Scott C Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FL, USA

7:42 AM

Q & A

7:45 AM

Smarter Pumps: Hemodynamic Monitoring and Physiological Control

Francesco Moscato, PhD, Medical Univ of Vienna, Vienna, Austria

7:57 AM

Q & A

7:00 AM - 8:00 AM

Sunrise Symposium 2: Timing Support in Cardiogenic Shock: When to Move Forward

**Location** :

Salon 1

Target Audience:

ALL

Chairs:

Francisco Arabia, MD, and Susan M. Joseph, MD

**Session Summary** : Cardiogenic shock remains a clinical challenge with a high mortality despite advances in medical and surgical therapies. This session will describe techniques to evaluate and manage to promote improved outcomes.

7:00 AM

INTERMACS 0: Making A Case for Severe Refractory Cardiogenic Shock

Jaime A Hernandez-Montfort, MD MPH, Newark Beth Israel Medical Center, Newark, NJ, USA

7:12 AM

Q & A

7:15 AM

Choice of Support: Evidence Based or Expertise Driven?

Pranav Loyalka, MD, Memorial Hermann, Houston, TX, USA

7:27 AM

Q & A

7:30 AM

Friday Night Disaster: Considerations Before, During and After the OR

Evgenij V Potapov, MD, PhD, Berlin Heart Center, Berlin, Germany

7:42 AM

Q & A

7:45 AM

Transition from Acute Support to Durable Ventricular Support or Transplant: Challenges and Limitations

Bart Meyns, MD, PhD, KU Leuven, Leuven, Belgium

7:57 AM

Q & A

7:00 AM - 8:00 AM

Sunrise Symposium 3: Thoracic Organ Transplantation and Malignancy

**Location** :

Maryland Suite

Target Audience:

LTX, HF, HTX, LF, NHSAH, PEDS, PHARM

Chairs:

Robin Vos, MD, PhD, and Cassie C. Kennedy, MD

**Session Summary** : This session will discuss the controversies in managing thoracic organ transplant candidates who have previously had cancer and in recipients who develop a malignancy after transplant.

7:00 AM

When is Malignancy a Contraindication To or Indication For Lung Transplantation?

David Weill, MD, Stanford University Medical Center, Stanford, CA, USA

7:12 AM

Q & A

7:15 AM

Cancer Screening Guidelines - Are They Good Enough for Thoracic Organ Transplant Recipients?

Monique Malouf, FRACP, St. Vincent's Hospital, Sydney, Australia

7:27 AM

Q & A

7:30 AM

Lung Transplantation for Patients with Chronic GVHD Following Allogeneic Stem Cell Transplant

Sam Goldfarb, MD, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA

7:42 AM

Q & A

7:45 AM

Management of Patients with Unexpected Cancer in Explanted Lung or in the Pulmonary Allograft

Thomas K. Waddell, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

7:57 AM

Q & A

7:00 AM - 8:00 AM

Sunrise Symposium 4: Let's Come to Some Closure on the Issue of Pulmonary Hypertension in Congenital Heart Disease

**Location** :

Virginia Suite

Target Audience:

PH, LTX, NHSAH, PEDS

Chairs:

Jacqueline R. Szmuszkovicz, MD, and Maurice Beghetti, MD

**Session Summary** : The aims of this session are to explain the classification and physiology of different congenital shunt lesions and to discuss indications and risks for shunt closure. Furthermore use of PAH therapies and timing of referral for transplantation for Eisenmenger's syndrome and Fontan circulation will be discussed.

7:00 AM

Not Every Hole is Created Equal: Congenital Shunt Physiology, Classification, and the Association with Pulmonary Hypertension

Warren A. Zuckerman, MD, Columbia University Medical Center, New York, NY, USA

7:12 AM

Q & A

7:15 AM

ASD with PAH: To Close or Not to Close, That is the Question...

Dana P McGlothlin, MD, Kaiser San Francisco, San Francisco, CA, USA

7:27 AM

Q & A

7:30 AM

Feelin' Blue: Advanced PAH Therapies for Eisenmenger's Syndrome and Timing of Referral for Transplantation

Maurice Beghetti, MD, HUG Children's University Hospital, Geneva, Switzerland

7:42 AM

Q & A

7:45 AM

The Fontan Under Pressure: a Role for PAH Therapies?

Alexander R Opotowsky, MD, Boston Children's and Brigham & Women's Hospital, Boston, MA, USA

7:57 AM

Q & A

7:00 AM - 8:00 AM

Sunrise Symposium 5: Back to Basics: What the Thoracic Transplant Clinician Needs to Know About Immunobiology

**Location** :

Delaware Suite

Target Audience:

ALL

Chairs:

Monica Colvin, MD, and Andrew E. Gelman, PhD

**Session Summary** : The goal of this symposium is to provide the clinical thoracic transplant professional with a basic yet clinically oriented overview of the immunobiology responsible for thoracic allograft injury after transplantation.

7:00 AM

Where Do We Start? Link Between Innate and Adaptive Immunity in Early Events After Transplantation

Daniel Kreisel, MD, PhD, Washington University School of Medicine, St. Louis, MO, USA

7:15 AM

Q & A

7:20 AM

The Bat CAV: Mechanisms of the Vanishing Coronaries

Stephan M. Ensminger, MD, DPhil, Heart & Diabetes Center NRW, Bad Oeynhausen, Germany

7:35 AM

Q & A

7:40 AM

So CLAD You Came! Mechanisms of Chronic Lung Allograft Rejection

Lee Borthwick, RN, Freeman Hospital, Newcastle upon Tyne, United Kingdom

7:55 AM

Q & A

7:00 AM - 8:00 AM

Sunrise Symposium 6: The Fly in the Ointment: Nosocomial Infections

**Location** :

Washington Ballroom 2

Target Audience:

ID, ALL

Chairs:

Kathleen L. Grady, PhD, APN, FAAN, and Margaret M. Hannan, MD

**Session Summary** : Nosocomial infections are a dreaded reality in critically ill patients either awaiting or following organ transplantation. This sessions will review antimicrobial stewardship practices, preventative clinical care strategies, and management options that decrease the rate of infections and improve outcomes in the hospital setting.

7:00 AM

Educate Before You Medicate: Antimicrobial Stewardship

Mary Bradbury, PharmD, Inova Fairfax Hospital, Falls Church, VA, USA

7:12 AM

Q & A

7:15 AM

An Ounce of Prevention is Worth a Pound of Cure: Infection Prevention

Valentina Stosor, MD, Northwestern University, Chicago, IL, USA

7:27 AM

Q & A

7:30 AM

Devices, SIRS and Open Chest - The Role of Antibiotics?

Angela Lorts, MD, Cincinnati Children's Hosp, Cincinnati, OH

7:42 AM

Q & A

7:45 AM

Outbreak! Infection Clusters and the Transplant Center

Barbara D Alexander, MD, Duke University, Durham, NC, USA

7:57 AM

Q & A

8:00 AM - 10:00 AM

Plenary Session: Where is the Future for Innovation?

**Location** :

Salons 2-3

Target Audience:

ALL

Chairs:

John Dark, MB, FRCS, and Lori J. West, MD, DPhil

8:00 AM

Innovation in an Age of Risk Adversity and Regulation

Robert M Califf, MD, US Food and Drug Administration, Washington, DC, USA

8:25 AM

**(194) FEATURED ABSTRACT:** Functional Assessment of the Donor Heart Following Circulatory Death and Clinical Transplantation _;_ **** S. Messer1, R. Axell2, S. Colah1, P. White2, A. Page1, B. Parizkova1, K. Valchanov1, J. Dunning1, J. Parameshwar1, A. Ali1, S. Tsui1, S. Large1. 1 _Transplant Surgery, Papworth Hospital, Cambridgeshire, United Kingdom,_ 2 _Medical Physics, Addenbrookes Hospital, Cambridge, United Kingdom_

8:35 AM

Expert Discussant Q & A

Kumud K Dhital, MD, PhD, St Vincent's Hospital, Sydney, Australia

8:40 AM

Cell Therapy for Advanced Lung Disease: Pathway to the Clinic

Dennis Wigle, MD, Mayo Clinic, Rochester, MN, USA

9:00 AM

**(195) FEATURED ABSTRACT:** A Study of Donor Ex-Vivo Lung Perfusion in UK Lung Transplantation (DEVELOP-UK);

A. J. Fisher1, N. Yonan2, J. Mascaro3, N. Marczin4, S. Tsui5, A. Simon6, J. Dark1 **, &** on behalf of the DEVELOP-UK Investigators7. 1 _Institute of Transplantation, Newcastle University, Newcastle Upon Tyne, United Kingdom,_ 2 _Wythenshawe Hospital, Manchester, United Kingdom,_ 3 _Queen Elizabeth Hospital, Birmingham, United Kingdom,_ 4 _Imperial College, London, United Kingdom,_ 5 _Papworth Hospital, Cambridge, United Kingdom,_ 6 _Harefield Hospital, London, United Kingdom,_ 7 _All Adult, Lung Transplant Centres,_ _United Kingdom_

9:10 AM

Expert Discussant Q & A

Goran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden

9:15 AM

Research and Innovation by Crowdfunding

Denny Luan, Experiment, San Francisco, CA, USA

9:35 AM

Minimizing the Risk of Preventable Patient Deaths

Michael Shabot, MD, Memorial Hermann Health System, Houston, TX, USA

10:30 AM - 12:00 PM

Concurrent Session 21: Pimp My Pump: Novel MCS Design and Management

**Location** :

Salons 2-3

Target Audience:

MCS, HF, NHSAH

Chairs:

Ugolino Livi, MD, and George Javorsky, MBBS, FRACP

**10:30 AM (196)** _Invasive Hemodynamic Ramp Test: A Comparison of Ventricular Unloading between Current Generation Continuous-Flow LVADs;_ K. Abdullah, N. Badoe, S. Phillips, J. Nabut, R. Singh, S. S. Desai, P. Shah. _Inova Heart and Vascular Institute, Falls Church, VA_

**10:45 AM (197)** _HVAD Waveform as a Surrogate Marker of Cardiac Index and Pulmonary Capillary Wedge Pressure;_ J. Grinstein1, D. E. Rodgers1, S. Kalantari Tannenbaum1, S. Adatya1, N. Sarswat1, G. H. Kim1, G. Sayer1, T. Ota1, V. Jeevanandam1, V. Mor-Avi1, D. Burkhoff2, N. Uriel1. 1 _University of Chicago, Chicago, IL,_ 2 _Columbia University, New York, NY_

**11:00 AM (198)** _LVAD Device Design Features and Operational Settings Minimize von Willebrand Factor Degradation;_ J. Kang1, D. Zhang1, T. Motomura2, M. Acker1, P. Atluri1, C. R. Bartoli1. 1 _University of Pennsylvania, Philadelphia, PA, PA,_ 2 _EVAHEART, Houston, TX, TX_

**11:15 AM (199)** _Impact of Aortic Valve Closure on Adverse Events and Outcomes with the HeartWare HVAD;_ D. Dobarro1, M. Urban2, K. Booth2, N. Wrightson2, J. Castrodeza1, J. Jungschleger2, N. Robinson-Smith2, A. Woods2, G. Parry3, S. Schueler2, G. MacGowan3. 1 _Cardiology, Hospital Clinico Universitario de Valladolid and Newcastle Freeman Hospital, Valladolid, Spain,_ 2 _Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom,_ 3 _Cardiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom_

**11:30 AM (200)** _Competing Flow Between Partial Circulatory Support and Native Cardiac Output: A Computational Fluid Dynamics-Study;_ J. Engelke1, A. Popov2, A. R. Simon3, S. Partovi4, M. Karck1, F. Rengier5, A. Weymann1, P. W. Raake6, A. Doesch6, J. Lotz7, C. Karmonik8, A. Ruhparwar1. 1 _Department of Cardiac Surgery, University Hospital Heidelberg, Heidelberg, Germany,_ 2 _Royal Brompton & Harefield NHS Foundation Trust, Harefield, United Kingdom, _3 _Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, Harefield, United Kingdom, _4 _Department of Radiology, University Hospitals Case Medical Center, Cleveland, OH,_ 5 _Department of Radiology, University Hospital Heidelberg, Heidelberg, Germany,_ 6 _Department of Cardiology, University Hospital Heidelberg, Heidelberg, Germany,_ 7 _Department of Radiology, University Hospital Goettingen, Goettingen, Germany,_ 8 _Translational Imaging MRI Core, Houston Methodist Research Institute, Houston, TX_

**11:45 AM (201)** _Minimally Invasive Exchange of the HeartMate II (HMII) Left Ventricular Assist Device (LVAD) to the Intrapericardial HeartWare Ventricular Assist Device (HVAD);_ B. Soleimani, B. Burk, E. Stephenson, W. Pae. _Cardiothoracic Surgery, Penn State Hershey Medical Center, Hershey, PA_

10:30 AM - 12:00 PM

Concurrent Session 22: What a Bloody Mess: Novel Therapeutics and Diagnostics for GI Bleeding after MCS

**Location** :

Thurgood Marshall

Target Audience:

MCS, HF, NHSAH, PHARM

Chairs:

Anna L Meyer, MD, and Ulrich Jorde, MD

**10:30 AM (202)** _Use of Long Acting Octreotide in an Outpatient Clinic Reduces the Rate of Gastro-Intestinal Bleeding in Continuous Flow LVAD Patients;_ C. Juricek, V. Kagan, H. Ruedlinger, W. Lee. _Cardiac Surgery, University of Chicago, Chicago, IL_

**10:45 AM (203)** _Serial Evaluation of Von Willebrand Factor Performance with a Fully Magnetically Levitated Centrifugal Continuous Flow Left Ventricular Assist Device;_ I. Netuka1, J. Kvasnička2, T. Kvasnička2, I. Hrachovinová3, P. Ivák1, J. Bílková2, I. Malíková2, M. Jančová4, F. Mareček3, J. Malý1, J. M. Connors5, M. R. Mehra6. 1 _Cardiac Surgery, Institute for Clinical & Experimental Medicine, Prague, Czech Republic, _2 _Thrombotic Centre and Central Hematology Laboratory, Institute of Medical Biochemistry and Laboratory Diagnostics of The General University Hospital and of The First Faculty of Medicine of Charles University in Prague, Prague, Czech Republic,_ 3 _NRL for Hemostasis, Institute of Hematology and Blood Transfusion, Prague, Czech Republic,_ 4 _Laboratory Methods, Institute for Clinical & Experimental Medicine, Prague, Czech Republic, _5 _Hematology, Brigham Womens Hospital, Boston, MA,_ 6 _Heart and Vascular Center, Brigham and Women's Hospital, Boston, MA_

**11:00 AM (204)** _Danazol for the Treatment of Gastrointestinal Bleeding in Left Ventricular Assist Device (LVAD) Patients: A Multicenter Experience;_ S. Schettle1, B. Al Bawardy2, S. Sherazi3, C. Cheyne3, S. Kushwaha4, E. Rajan2, N. Pereira4. 1 _Cardiovascular Surgery, Mayo Clinic Rochester, Rochester, MN,_ 2 _Gastroenterology, Mayo Clinic Rochester, Rochester, MN,_ 3 _Cardiovascular Surgery, University of Rochester Medical Center, Rochester, NY,_ 4 _Cardiology, Mayo Clinic Rochester, Rochester, MN_

**11:15 AM (205)** _Vascular Abnormalities of the Nasal Mucosa Are Associated with Gastrointestinal Bleeding During Continuous Flow LVAD Support;_ S. R. Patel, O. Saeed, S. Madan, M. Algodi, A. Luke, M. Gibber, D. J. Goldstein, U. P. Jorde. _Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY_

**11:30 AM (206)** _Warfarin Sensitive Patients Have Higher Risk of Gastrointestinal Bleeding and Device Thrombosis on Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Support;_ V. K. Topkara1, A. B. Eisenberger1, R. Knotts1, D. Jennings1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, R. C. Li1, J. A. Fried1, F. Castagna1, B. Cagliostro1, M. Tiburcio2, D. M. Mancini1, Y. Naka2, P. C. Colombo1, U. P. Jorde3. 1 _Medicine, Columbia University, New York, NY,_ 2 _Surgery, Columbia University, New York, NY,_ 3 _Medicine, Montefiore Medical Center, New York, NY_

**11:45 AM (207)** _Predictors of Out-of-Therapeutic-Range INR during Support with Continuous-Flow Left Ventricular Assist Device;_ M. Yin, W. Schultz, Y. Ko, R. T. Cole, D. Gupta, S. Laskar, A. Smith, D. Vega, D. Nguyen, A. Pekarek, K. Wittersheim, A. Morris. _Emory University School of Medicine, Atlanta, GA_

10:30 AM - 12:00 PM

Concurrent Session 23: Choosing a Gift: Donor Selection

**Location** :

Salon 1

Target Audience:

HTX, EEP, ID, NHSAH, PATH, PEDS, PHARM

Chairs:

Luciano Potena, MD, PhD, and David A Baran, MD

**10:30 AM (208)** _Early Results of Heart Transplantation Using Donation after Circulatory Death Donors;_ M. B. Connellan, H. Chew, A. Iyer, A. Watson, C. Soto, A. Dinale, P. Nair, E. Granger, P. Jansz, A. Jabbour, E. Kotlyar, A. Keogh, C. Hayward, P. Spratt, P. MacDonald, K. Dhital. _Heart and Lung Transplant Unit, St. Vincent 's Hospital, Sydney, Australia_

**10:45 AM (209)** _Heart Transplantation from Donors Outside Standard Acceptability Criteria Using Ex-Vivo Normothermic Preservation;_ D. García Sáez, B. Zych, P. Mohite, A. Sabashnikov, F. De Robertis, A. F. Popov, T. Bahrami, N. R. Banner, A. R. Simon. _Heart Lung Transplantation and Mechanical Circulatory Support, Harefield Hospital NHS Trust, Harefield, London, United Kingdom_

**11:00 AM (210)** _Utility of Heart Transplant by Waitlist Mortality and Donor/Recipient Match;_ V. Nguyen, J. Beckman, R. Cheng, W. Levy, C. Mahr, N. Mokadam, J. Pal, T. Dardas. _University of Washington, Seattle, WA_

**11:15 AM (211)** _High Donor Sequence Number Grafts Can Be Safely Transplanted into Select Patients;_ J. J. Squiers1, G. Saracino2, T. Chamogeorgakis3, J. C. MacHannaford3, A. E. Rafael3, G. V. Gonzalez-Stawinski3, S. A. Hall4, J. M. DiMaio1, B. Lima3. 1 _Baylor Research Institute, Baylor Scott & White Health, Dallas, TX, _2 _Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX,_ 3 _Cardiac and Thoracic Surgery, Baylor University Medical Center, Dallas, TX,_ 4 _Cardiology, Baylor University Medical Center, Dallas, TX_

**11:30 AM (212)** _Too Much Information: Interaction of Donor Sequence and Acceptance in the UNOS Database;_ D. A. Baran, K. Liaquat, J. Pieretti, C. Gidea, M. Munagala, M. Camacho, C. Patel, M. Divita, M. J. Zucker. _Transplant Center, Newark Beth Israel Med Ctr, Newark, NJ_

**11:45 AM (213)** _Intermediate Outcomes with Ex-Vivo Allograft Perfusion for Heart Transplantation;_ F. Esmailian1, J. L. Chan2, H. Reich2, D. Ramzy2, M. Thottam3, Z. Xu3, T. Aintablian3, F. Liou3, J. Patel3, M. Kittelson3, L. S. Czer3, A. Trento2, J. Kobashigawa3. 1 _Cedars-Sinai Heart Institute, Los Angeles, CA,_ 2 _Surgery, Cedars-Sinai Heart Institute, Los Angeles, CA,_ 3 _Medicine, Cedars-Sinai Heart Institute, Los Angeles, CA_

10:30 AM - 12:00 PM

Concurrent Session 24: What's New in Primary Graft Dysfunction Post Lung Transplantation

**Location** :

Virginia Suite

Target Audience:

LTX, BSI, ID, LBCS, NHSAH, PEDS, PHARM

Chairs:

Jason D Christie, MD, and Helen M Whitford, MBBS, FRACP

**10:30 AM (214)** _Plasma RIP3 Is Decreased in PGD after Lung Transplantation;_ C. D'Errico1, M. Hotz1, E. Cantu1, M. Porteous1, M. Oyster1, R. Shah2, S. Arcasoy3, L. Snyder4, K. M. Wille5, M. Hartwig4, L. B. Ware6, P. Shah7, M. Crespo8, C. Hage9, A. Weinacker10, V. Lama11, Y. Suzuki1, J. Orens7, S. Kawut1, S. Palmer4, D. J. Lederer3, J. D. Christie1, N. Mangalmurti1, J. M. Diamond1. 1 _University of Pennsylvania, Philadelphia, PA,_ 2 _University of California San Francisco, San Francisco, CA,_ 3 _Columbia University, New York, NY,_ 4 _Duke University, Durham, NC,_ 5 _University of Alabama Birmingham, Birmingham, AL,_ 6 _Vanderbilt University, Nashville, TN,_ 7 _Johns Hopkins University, Baltimore, MD,_ 8 _University of Pittsburgh, Pittsburgh, PA,_ 9 _Indiana University, Indianapolis, IN,_ 10 _Stanford University, Stanford, CA,_ 11 _University of Michigan, Ann Arbor, MI_

**10:45 AM (215)** _Role of Donor Microbiota in the Development of Primary Graft Dysfunction Following Human Lung Transplantation;_ Z. Xu1, R. Schuessler1, D. Nayak1, W. Yang2, E. Trulock3, A. Patterson1, D. Kreisel1, R. Hachem3, T. Mohanakumar4. 1 _Surgery, Washington University School of Medicine, St. Louis, MO,_ 2 _Genetics, Washington University School of Medicine, St. Louis, MO,_ 3 _Medicine, Washington University School of Medicine, St. Louis, MO,_ 4 _Surgery, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO_

**11:00 AM (216)** _Profiling Biomarkers of Inflammation and Tissue Injury during Human Ex Vivo Lung Perfusion in the DEVELOP-UK Study;_ A. Andreasson1, N. Yonan2, J. E. Fildes3, J. Mascaro4, N. Marczin5, S. Tsui6, A. Simon7, J. H. Dark1, A. J. Fisher1, &. on behalf of the DEVELOP-UK Investigators8. 1 _Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom,_ 2 _University Hospital of South Manchester, Manchester, United Kingdom,_ 3 _Machester Collaborative Centre for Inflammation Research, University of Manchester, Manchester, United Kingdom,_ 4 _Queen Elizabeth Hospital, Birmingham, United Kingdom,_ 5 _Imperial College, London, United Kingdom,_ 6 _Papworth Hospital, Cambridge, United Kingdom,_ 7 _Harefield Hospital, London, United Kingdom,_ 8 _All Adult Lung Transplant Centers, United Kingdom_

**11:15 AM (217)** _Warm Ischemic Time (WIT) Measurements Do Not Correlate with Early Lung Allograft Function: Analysis from the Australian Donation after Circulatory Death (DCD) Lung Transplant (LTx) Collaborative;_ B. Levvey1, M. Harkess2, D. Chambers3, S. Lawrence4, M. Musk4, P. Hopkins3, A. Glanville2, G. Snell1. 1 _Alfred Hospital, Melbourne, Australia,_ 2 _St Vincent's Hospital, Sydney, Australia,_ 3 _Prince Charles Hospital, Brisbane, Australia,_ 4 _Royal Perth /Fiona Stanley Hospital, Perth, Australia_

**11:30 AM (218)** _Down Regulation of microRNA-21 Is Significantly Associated with Signaling and Activation of the Toll-Like Receptor in Human Lung Transplant Recipients with Primary Graft Dysfunction;_ Z. Xu1, A. Gelman1, R. Hachem2, T. Mohanakumar3. 1 _Surgery, Washington University School of Medicine, St. Louis, MO,_ 2 _Medicine, Washington University School of Medicine, St. Louis, MO,_ 3 _Surgery, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO_

**11:45 AM (219)** _Redefining Primary Graft Dysfunction after Lung Transplantation;_ E. Cantu1, J. Diamond1, J. Nellen1, B. Beduhn1, Y. Suzuki1, C. Borders1, J. Lasky1, C. Schaufler1, R. Shah1, M. Porteous1, D. J. Lederer2, S. M. Kawut1, S. Arcasoy2, S. M. Palmer3, L. Snyder3, M. G. Hartwig3, V. N. Lama4, M. Crespo5, K. Wille6, J. Orens7, P. D. Shah7, A. Weinacker8, L. B. Ware9, S. L. Bellamy1, J. D. Christie1. 1 _University of Pennsylvania, Philadelphia, PA,_ 2 _Columbia University College of Physicians and Surgeons, New York, NY,_ 3 _Duke University Medical Center, Durham, NC,_ 4 _University of Michigan, Ann Arbor, MI,_ 5 _University of Pittsburgh, Pittsburgh, PA,_ 6 _University of Alabama at Birmingham, Birmingham, AL,_ 7 _Johns Hopkins University Hospital, Baltimore, MD,_ 8 _Stanford University, Palo Alto, CA,_ 9 _Vanderbilt University, Nashville, TN_

10:30 AM - 12:00 PM

Concurrent Session 25: Beyond Adherence: What's New Out There?

**Location** :

Delaware Suite

Target Audience:

NHSAH, EEP, HF, HTX, LTX, MCS, PEDS, PH, PHARM

Chairs:

Connie White-Williams, RN, PhD, and Christiane Kugler, PhD

**10:30 AM (220)** _Impact of Early Adoption of Affordable Care Act Medicaid Expansion on Heart Transplant Listings in the United States;_ S. G. Al-Kindi, M. Farhoud, M. Sabeh, M. Ginwalla, C. ElAmm, M. Zacharias, R. D. Benatti, M. Kattea, S. Deo, B. Sareyyupoglu, B. Medalion, S. Park, G. H. Oliveira. _Harrington Heart and Vascular Institute, University Hospitals Case Medical Center, Cleveland, OH_

**10:45 AM (221)** _Medical Adherence in the Late-Term after Lung Transplant;_ K. R. Fox1, A. J. DeVito Dabbs2, A. F. DiMartini3, D. M. Posluszny4, E. M. Rosenberger5, J. M. Pilewski4, M. A. Dew3. 1 _Psychology, Ohio University, Athens, OH,_ 2 _Acute and Tertiary Care Nursing, Univ of Pittsburgh Sch Nursing, Pittsburgh, PA,_ 3 _Psychiatry, Univ of Pittsburgh Sch Med, Pittsburgh, PA,_ 4 _Medicine, Univ of Pittsburgh Sch Med, Pittsburgh, PA,_ 5 _Clinical and Translational Science Institute, Univ of Pittsburgh Sch Med, Pittsburgh, PA_

**11:00 AM (222)** _Adequate Health Literacy Is Associated with Sufficient Physical Activity: Findings from the BRIGHT Study;_ M. I. Cajita1, K. Denhaerynck2, F. Dobbels3, L. Berben2, C. L. Russell4, S. De Geest2. 1 _School of Nursing, Johns Hopkins University, Baltimore, MD,_ 2 _Institute of Nursing Science, Universität Basel, Basel, Switzerland,_ 3 _Center for Health Services and Nursing Research, Katholieke Universiteit Leuven, Leuven, Belgium,_ 4 _School of Nursing and Health Studies, University of Missouri, Kansas City, MO_

**11:15 AM (223)** _Testing the Efficacy of a Multicomponent Theory-Based Tailored Behavioral Medication Adherence Intervention in Transplantation: The MAESTRO-TX RCT;_ F. Dobbels1, L. De Bleser1, L. Berben2, P. Kristanto3, L. Dupont4, F. Nevens5, J. Vanhaecke6, G. Verleden7, S. De Geest2. 1 _Department of Public Health and Primary Care, University of Leuven (KU Leuven), Leuven, Belgium,_ 2 _Institute of Nursing Science, University of Basel, Basel, Switzerland,_ 3 _Aardex Group, Meadwestveco Healthcare Company, Visé, Belgium,_ 4 _Lung Transplantation Program, University Hospitals of Leuven, Leuven, Belgium,_ 5 _Liver Transplant Program, University Hospitals of Leuven, Leuven, Belgium,_ 6 _Heart Transplantation Program, University Hospitals of Leuven, Leuven, Belgium,_ 7 _Lung Transplant Program, University Hospitals of Leuven, Leuven, Belgium_

**11:30 AM (224)** _Self-Efficacy and Adherence Are Predictors of Quality of Life in Patients with Left Ventricular Assist Devices;_ J. Casida1, H. Wu2, V. Senkiv1, J. Yang1. 1 _School of Nursing, University of Michigan, Ann Arbor, MI,_ 2 _Office of Nursing Research, Barnes-Jewish College School of Nursing, St. Louis, MO_

**11:45 AM (225)** _A Multicenter Quality of Life (QoL) Survey Regarding LVAD Drivelines: A Look Beyond the Medical Aspects;_ L. J. Bogar1, S. Phillips2, F. D. Pagani3, N. A. Haglund4, J. A. Cowger5, S. Maltais6, A. Ravichandran7, J. M. Stulak6, M. Binetti8, M. Lefebvre9, S. E. Womak4, P. Shah2. 1 _Cardiac Surgery, Inova Fairfax Heart and Vascular Institute, Falls Church, VA,_ 2 _Heart Failure and Transplantation, Inova Fairfax Heart and Vascular Institute, Falls Church, VA,_ 3 _Cardiac Surgery, University of Michigan Hospital, Ann Arbor, MI,_ 4 _Cardiolgy, Vanderbilt, Nashville, TN,_ 5 _Cardiology, St. Vincent Heart Center of Indiana, Indianapolis, IN,_ 6 _Cardiac Surgery, Mayo Clinic, Rochester, MN,_ 7 _Cardiac Surgery, St. Vincent Heart Center of Indiana, Indianapolis, IN,_ 8 _Advanced Heart Failure and Transplant, Inova Fairfax Heart and Vascular Institute, Falls Church, VA,_ 9 _Cardiolgy, University of Michigan Hospital, Ann Arbor, MI_

10:30 AM - 12:00 PM

Concurrent Session 26: Mechanisms of AMR: Can We Protect The Body From The

Anti-Body?

**Location** :

Washington Ballroom 2

Target Audience:

BSI, HTX, LTX, MCS, PEDS

Chairs:

Marilia Cascalho, MD, PhD, and John R Greenland, MD, PhD

**10:30 AM (226)** _Left-Ventricular Assist Device Is Associated with Elevated Serum Levels of Natural IgG Reactive to Apoptotic Cells and Oxidized Epitopes;_ S. B. See1, P. J. Kennel2, M. Weber2, K. Rogers1, D. Chatterjee1, Y. Gu1, G. Vlad3, K. J. Clerkin2, V. K. Topkara2, P. C. Colombo2, D. M. Mancini2, Y. Naka4, M. A. Farr2, E. R. Vasilescu3, S. W. Restaino2, P. C. Schulze2, E. Zorn1. 1 _Columbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, New York, NY,_ 2 _Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, NY,_ 3 _Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY,_ 4 _Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Medical Center, New York, NY_

**10:45 AM (227)** _T-Cell Dependence of Antibody Response to Blood Group A-Antigen;_ I. Adam1, B. Motyka2, K. Tao2, J. Pearcey2, L. West3. 1 _Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada,_ 2 _Pediatrics, University of Alberta, Edmonton, AB, Canada,_ 3 _Depts. of Pediatics, Surgery, and Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada_

**11:00 AM (228)** _Exosomes from Rejected Syngeneic Cardiac Grafts Express Myosin and Vimentin and Immunoregulatory miRNA and Induce Graft Rejection;_ M. Sharma, M. Gunasekaran, Z. Xu, W. Liu, N. Benshoff, T. Mohanakumar. _Surgery, Washington University, St. Louis, MO_

**11:15 AM (229)** _NK Cells Require the Secretion of Interferon- to Mediate Allograft Vasculopathy in a Model of Antibody-Mediated Chronic Rejection;_ C. M. Lin1, R. J. Plenter1, R. G. Gill2. 1 _Medicine, University of Colorado, Denver - Anschutz Medical Campus, Aurora, CO,_ 2 _Surgery, University of Colorado, Denver - Anschutz Medical Campus, Aurora, CO_

**11:30 AM (230)** _Bortezomib and ONX0914 in Experimental Heart Transplantation;_ M. Waechter1, J. Abicht2, B. Reichart3, J. Kindermann1, M. C. Langenmayer4, T. Mayr5, P. Brenner1, C. Hagl1, P. Beck6, M. Groll6, R. Wanke7, S. Guethoff8. 1 _Department of Cardiac Surgery, Ludwig-Maximilians-Universität München, Munich, Germany,_ 2 _Department of Anaesthesiology,, Ludwig-Maximilians-Universität München, Munich, Germany,_ 3 _Walter Brendel Centre of Experimental Medicine, Ludwig-Maximilians-Universität München, Munich, Germany,_ 4 _Institute of Veterinary Pathology and Institute for Infectious Diseases and Zoonoses, Ludwig-Maximilians-Universität München, Munich, Germany,_ 5 _Department of Anaesthesiology, Ludwig-Maximilians-Universität München, Munich, Germany,_ 6 _Munich Center for Integrated Protein Science at the Department of Chemistry, Technische Universität München, Munich, Germany,_ 7 _Institute of Veterinary Pathology at the Centre for Clinical Veterinary Medicine, Ludwig-Maximilians-Universität München, Munich, Germany,_ 8 _Department of Cardiac Surgery and Walter Brendel Centre of Experimental Medicine, Ludwig-Maximilians-Universität München, Munich, Germany_

**11:45 AM (231)** _Ibrutinib Suppresses De Novo Alloantibodies and Recall Antibody Responses in a Mouse Model of Allosensitization: A Preliminary Report;_ G. D. Wu, I. Kim, N. Chai, A. S. Klein, S. Jordan. _Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA_

10:30 AM - 12:00 PM

Symposium 30: JHLT at ISHLT: The Year in a Capsule

**Location** :

Maryland Suite

Target Audience:

ALL

Chairs:

Jonathan N Johnson, MD, and Maryl R. Johnson, MD

**Session Summary** : This session will highlight the most exciting publications in JHLT over the past year, followed by a discussion by one of the senior editorial consultants of the journal to relate the presented articles to the greater body of published literature and discuss how they advance our understanding in the field.

10:30 AM

Introduction and Recognition of Top Papers of the Year

Mandeep R. Mehra, MD, MBBS, FACC, FACP, Brigham & Women's Hospital, Boston, MA, USA

10:40 AM

Highlights of Heart Transplantation and Mechanical Circulatory Support

Eugene C DePasquale, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

10:55 AM

EXPERT DISCUSSANT: Highlights of Heart Transplantation and Mechanical Circulatory Support

Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

11:00 AM

Highlights of Lung Transplantation

Howard J. Huang, MD, Baylor University Medical Center, Dallas, TX, USA

11:15 AM

EXPERT DISCUSSANT: Highlights of Lung Transplantation

John Dark, MB, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

11:20 AM

Highlights of Pediatric Heart and Lung Transplantation

Ranny Goldwasser, MD, University Hospital Heidelberg, Heidelberg, Germany

11:35 AM

EXPERT DISCUSSANT: Highlights of Pediatric Heart and Lung Transplantation

David Morales, MD, Cincinnati Children's Hospital, Cincinnati, OH, USA

11:40 AM

Highlights of Pulmonary Hypertension

Bradley Maron, MD, Brigham and Women's, Boston, MA, USA

11:55 AM

EXPERT DISCUSSANT: Highlights of Pulmonary Hypertension

Myung H. Park, MD, Houston Methodist, Houston, TX, USA

2:00 PM - 3:30 PM

Concurrent Session 27: Are Two Pumps Better Than One? RV Failure and MCS

**Location** :

Salons 2-3

Target Audience:

MCS, HF, NHSAH, PH

Chairs:

Ivan Netuka, MD, PhD, and Daniel J. Goldstein, MD

**2:00 PM (232)** _Risk Factors Associated with Right Ventricular Assist Device Implantation: Insights from INTERMACS;_ M. S. Kiernan1, D. DeNofrio1, D. T. Pham2, N. K. Kapur1, R. Ruthazer3, E. W4, J. E. Rame4, P. Alturi4, E. Y. Birati4, S. L. Myers5, G. H. Oliveira6, J. K. Kirklin5, R. L. Kormos7, F. D. Pagani8, J. Teuteberg7. 1 _Cardiology, Tufts Medical Center, Boston, MA,_ 2 _Cardiology, Northwestern University Medical Center, Chicago, IL,_ 3 _Tufts Clinical and Translational Science Institute, Boston, MA,_ 4 _University of Pennsylvania, Philedelphia, PA,_ 5 _University of Alabama, Birmingham, Birmingham, AL,_ 6 _Case Western Reserve University, Cleveland, OH,_ 7 _University of Pittsburg Medical Center, Pittsburg, PA,_ 8 _University of Michigan, Ann Arbor, MI_

**2:15 PM (233)** _A Novel, Highly Discriminatory Risk Model Predicting Acute Severe Right Ventricular Failure in Patients Undergoing Continuous-Flow Left Ventricular Assist Device Implant;_ V. Tchantchaleishvili1, S. Maltais2, N. A. Haglund3, M. E. Davis3, J. Cowger4, P. Shah5, K. D. Aaronson6, F. D. Pagani6, S. M. Dunlay2, J. M. Stulak2. 1 _University of Rochester, Rochester, NY,_ 2 _Mayo Clinic, Rochester, MN,_ 3 _Vanderbilt University, Nashville, TN,_ 4 _St.Vincent Medical Group, Indianapolis, IN,_ 5 _Inova Fairfax Hospital, Falls Church, VA,_ 6 _University of Michigan, Ann Arbor, MI_

**2:30 PM (234)** _Chemokine Receptor Down Regulation in Mechanical Circulatory Support Patients with Right Ventricular Failure;_ A. Nayak1, T. N. Bachman2, K. Hanley-Yanez3, C. McTiernan2, D. McNamara3, R. L. Kormos3, O. Hunter4, A. Inashvili1, L. Lagazzi3, J. Teuteberg3, M. A. Simon3. 1 _Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA,_ 2 _Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA,_ 3 _Heart and Vascular Institute at UPMC Presbyterian, University of Pittsburgh Medical Center, Pittsburgh, PA,_ 4 _University of Pittsburgh Medical School, University of Pittsburgh, Pittsburgh, PA_

**2:45 PM (235)** _Biventricular Bridge to Transplant: Total Artificial Heart (TAH) vs Thoratec Paracorporeal VADs (PVADs) Outcomes Post Heart Transplant (HT);_ E. C. DePasquale, A. Salimbangon, E. Howell, A. Chang, A. Nsair, A. Ardehali. _David Geffen Sch Med, Los Angeles, CA_

**3:00 PM (236)** _Early Results of Biventricular Support with Durable, Intracorporeal Continuous Flow Centrifugal Ventricular Assist Devices: Analysis from INTERMACS;_ F. Arabia1, C. A. Milano2, C. Mahr3, E. C. McGee Jr.4, S. Maltais5, S. W. Boyce6, V. Pretorius7, A. B. Civitello8, H. R. Mallidi9, N. A. Mokadam10, J. E. Rame11, D. C. Naftel12, S. L. Myers12, J. K. Kirklin12. 1 _Cardiothoracic Surgery, Cedars-Sinai Medical Center, Los Angeles, CA,_ 2 _Duke University Medical Center, Durham, NC,_ 3 _University of Washington, Seattle, WA,_ 4 _Loyola University Medical Center, Maywood, IL,_ 5 _Mayo Clinic, Rochester, MN,_ 6 _Washington Hospital Center, Washington, DC,_ 7 _University of California at San Diego Medical Center, La Jolla, CA,_ 8 _Baylor St. Luke's Medical Center, Houston, TX,_ 9 _Brigham and Women's Hospital, Boston, MA,_ 10 _University of Washington Medical Center, Seattle, WA,_ 11 _Penn Heart and Vascular Center, Philadelphia, PA,_ 12 _University of Alabama at Birmingham, Birmingham, AL_

**3:15 PM (237)** _Total Artificial Heart (TAH): Survival Outcomes, Risk Factors, Adverse Events in Intermacs;_ F. Arabia1, I. Gregoric2, V. Kasirajan3, J. D. Moriguchi4, D. C. Naftel5, S. L. Myers5, J. K. Kirklin5. 1 _Cardiothoracic Surgery, Cedars-Sinai Medical Center, Los Angeles, CA,_ 2 _University of Texas Health Science Center Houston, Houston, TX,_ 3 _Virginia Commonwealth University Medical Center, Richmond, VA,_ 4 _Cedars-Sinai Medical Center, Los Angeles, CA,_ 5 _University of Alabama at Birmingham, Birmingham, AL_

2:00 PM - 3:30 PM

Concurrent Session 28: Pump Thrombosis: What's Hot with the Clot

**Location** :

Thurgood Marshall

Target Audience:

MCS, HF, NHSAH

Chairs:

Andrew J Boyle, MD, and Andre R Simon, MD, PhD

**2:00 PM (238)** _Outcomes of Medical and Surgical Therapy for Patients with Left Ventricular Assist Device Pump Thrombosis;_ D. T. Majure, F. H. Sheikh, S. I. Ahmed, M. E. Rodrigo, R. K. Young, T. I. Elliott, E. J. Molina, S. W. Boyce, S. S. Najjar. _MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC_

**2:15 PM (239)** _Diagnosis and Treatments of Three Different Types of Blood Flow Abnormalities in Patients Supported with HeartWare HVAD: Analysis of More Than 600 Cases;_ A. Scandroglio1, F. Kaufmann2, M. Pieri1, A. Kretzschmar2, M. Muller2, P. Pergantis2, S. Dreysse3, V. Falk2, T. Krabatsch2, E. Potapov2. 1 _Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy,_ 2 _Department for Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany,_ 3 _Department of Internal Medicine-Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany_

**2:30 PM (240)** _Does High Blood Pressure Early Post LVAD Implant Increase the Risk of Pump Thrombosis?;_ A. K. Johnson, R. McCubrey, N. C. Ridge, A. Rauf, H. H. Choi, A. C. Millers, S. Stoker, R. Alharethi, W. T. Caine, D. Budge, B. Y. Rasmusson, K. Afshar, B. B. Reid, A. G. Kfoury. _Mechanical Circulatory Support, Intermountain Medical Center Intermountain Medical Center, Murray, UT_

**2:45 PM (241)** _Utility of Echocardiography in Defining Inflow Cannula Malposition in Left Ventricular Assist Device and the Association with Adverse Outcome;_ M. Kassi, C. Eshelbrenner, J. Amione-Guerra, J. Estep. _Cardiology, Houston Methodist Hospital, Houston, TX_

**3:00 PM (242)** _Micro-Embolic Signals Correlate with Pump Thrombus Formation and Non-Thrombotic Outflow Graft Occlusion in Patients with Left Ventricular Assist Devices;_ K. Dimitrov1, J. Riebandt1, T. Haberl1, D. Wiedemann1, P. Simon1, R. Moayedifar1, T. Schlöglhofer1, G. Necid1, C. Gross2, M. Maw2, H. Schima2, G. Laufer1, D. Zimpfer1. 1 _Cardiac Surgery, Medical University of Vienna, Vienna, Austria,_ 2 _Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria_

**3:15 PM (243)** _Hemolysis Does Not Lead to Increased Discordance between Measured APTT and ANTI-XA Levels in Patients with Continuous-Flow Left Ventricular Assist Devices;_ V. K. Topkara1, A. B. Eisenberger1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, D. Jennings1, R. Givens1, J. Fried1, K. Wong1, M. Torres2, K. Ross2, G. Parkis1, M. Maurer1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Surgery, Columbia University, New York, NY_

2:00 PM - 3:30 PM

Concurrent Session 29: The Dark Side of Heart Transplant: Living With CAV

**Location** :

Salon 1

Target Audience:

HTX, BSI, MCS, NHSAH, PATH, PEDS, PHARM

Chairs:

Sonia Mirabet, MD, and Vivek Rao, MD, PhD

**2:00 PM (244)** _Myocardial Capillary Loss in Cardiac Allograft Vasculopathy: A Longitudinal Case-Control Study;_ D. Budge1, M. Revelo2, K. D. Brunisholz3, E. H. Hammond2, A. G. Kfoury1, R. Alharethi1, K. Afshar1, J. R. Doty4, T. A. Jensen5, J. C. Fang1, J. Stehlik1, E. Gilbert1, C. H. Selzman4, K. M. Molina6, D. V. Miller2. 1 _Cardiology, UTAH Cardiac Transplant Program, Salt Lake City, UT,_ 2 _Pathology, UTAH Cardiac Transplant Program, Salt Lake City, UT,_ 3 _Biostatistics, UTAH Cardiac Transplant Program, Salt Lake City, UT,_ 4 _Cardiac Surgery, UTAH Cardiac Transplant Program, Salt Lake City, UT,_ 5 _Intermountain Biorepository, UTAH Cardiac Transplant Program, Salt Lake City, UT,_ 6 _Pediatric Cardiology, UTAH Cardiac Transplant Program, Salt Lake City, UT_

**2:15 PM (245)** _Development of a Clinical Prediction Model for Cardiac Allograft Vasculopathy: Comparison of Three Mutlivariate Methods;_ E. P. Kransdorf1, N. A. Loghmanpour2, M. K. Kanwar3, M. H. Temkit4, J. Stehlik5. 1 _Division of Cardiovascular Diseases, Mayo Clinic Arizona, Phoenix, AZ,_ 2 _Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA,_ 3 _Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA,_ 4 _Division of Health Sciences Research, Mayo Clinic Arizona, Scottsdale, AZ,_ 5 _Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT_

**2:30 PM (246)** _Incremental Value to Coronary Angiography by Optical Coherence Tomography for Detection and Interpretation of Cardiac Allograft Vasculopathy;_ T. S. Clemmensen1, H. Eiskjær1, N. R. Holm1, B. B. Løgstrup1, E. H. Christiansen1, C. J. Terkelsen1, M. Maeng1, J. Dijkstra2, S. H. Poulsen1. 1 _Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, Aarhus N, Denmark,_ 2 _Division of Image Processing, Leiden University Medical Center, Leiden, Netherlands_

**2:45 PM (247)** _Circulating Exosomes Expressing Cardiac Self-Antigens (Myosin and Vimentin) and miRNA Are Induced in Cardiac Transplant Recipients with Cardiac Allograft Vasculopathy;_ M. Sharma1, Z. Xu1, N. Steward1, T. Mohanakumar2. 1 _Surgery, Washington University School of Medicine, St. Louis, MO,_ 2 _Surgery, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO_

**3:00 PM (248)** _Early Use of Antiplatelet Therapy and Development of Cardiac Allograft Vasculopathy: A 5 Year Outcomes Analysis;_ M. Kim, M. R. Mehra, G. C. Stewart, G. S. Couper, D. S. Page, E. L. Woodcome, J. A. Smallwood, S. Gabardi, M. M. Givertz. _Brigham & Women's Hospital, Boston, MA_

**3:15 PM (249)** _Utility of sAXL, hs-cTnT , Lp-PLA2, GDF-15 Biomarkers and Th1/Treg Ratio in the Detection of Cardiac Allograft Vasculopathy;_ S. Mirabet1, P. Gacia de Frutos2, J. Ordóñez3, V. Brossa1, L. Lopez1, C. Gelpi4, A. Ferrero1, E. Sole1, A. Sionis1, J. Cinca1, J. Padro5, E. Roig1. 1 _Cardiology, Hospital Sant Pau, Barcelona, Spain,_ 2 _Institut d'Investigacions Biomèdiques de Barcelona, IIBB-CSIC, Barcelona, Spain,_ 3 _Bioquimca, Hospital Sant Pau, Barcelona, Spain,_ 4 _Immunology, Hospital Sant Pau, Barcelona, Spain,_ 5 _Cardiac Surgery, Hospital Sant Pau, Barcelona, Spain_

2:00 PM - 3:30 PM

Concurrent Session 30: What You Need to Know About Donors and Early Outcome Following Lung Transplantation

**Location** :

Maryland Suite

Target Audience:

LTX, BSI, ID, NHSAH, PATH, PEDS, PHARM

Chairs:

Bryan A Whitson, MD, and Dirk Van Raemdonck, MD, PhD

**2:00 PM (250)** _Treating Donor Lung Inflammation by Blocking Interleukin-1Β - An In Vitro Therapy Testing Platform for Ex Vivo Lung Perfusion;_ A. Andreasson1, D. Karamanou1, C. Gillespie2, L. Borthwick3, K. Jiwa1, P. Henderson1, F. Özalp1, T. Butt1, S. C. Clark1, H. Pauli1, P. A. Corris1, S. Ali3, J. H. Dark1, A. J. Fisher1. 1 _Institute of Transplantation, Newcastle upon Tyne, United Kingdom,_ 2 _School of Mathematics & Statistics, Newcastle University, Newcastle upon Tyne, United Kingdom, _3 _Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom_

**2:15 PM (251)** _Donation After Circulatory Death (DCD) versus Donation After Brain Death (DBD): Contrasting Donor and Recipient Characteristics in the ISHLT DCD Lung Transplant (LTx) Registry;_ B. Levvey1, G. Snell1, L. Edwards2, J. Stehlik3, M. Erasmus4, A. Glanville5, M. Hertz6, P. Hopkins7, D. Chambers7, M. Musk8, M. Budev9, D. Mason10, V. Puri11, R. Yusen11, F. D'Ovidio12, S. Keshavjee13, M. Cypel13, D. Van Raemdonck14. 1 _Lung Transplant Service, Alfred Hospital, Melbourne, Australia,_ 2 _United Network for Organ Sharing, Richmond, VA,_ 3 _University of Utah, Salt Lake City, UT,_ 4 _Univeristair Medisch Centrum, Gronigen, Netherlands,_ 5 _St Vincent's Hospital, Sydney, Australia,_ 6 _University of Minnesota Medical Center, Minneapolis, MN,_ 7 _Prince Charles Hospital, Brisbane, Australia,_ 8 _Royal Perth Hospital, Perth, Australia,_ 9 _The Cleveland Clinic Foundation, Clevland, OH,_ 10 _Baylor University Medical Center, Dallas, TX,_ 11 _Barnes Jewish Hospital-Washington University, St Louis, IL,_ 12 _New York-Presbyterian Columbia, New York City, NY,_ 1 _Toronto General Hospital & Hospital for Sick Children, Toronto, ON, Canada, _14 _Department of Thoracic Surgery, University Hospitals, Leuven, Belgium_

**2:30 PM (252)** _Long-Term Persistence of Alveolar Macrophages in Donor Lungs after Human Lung Transplantation;_ D. Nayak1, F. Zhou1, D. Kreisel1, R. Hachem2, T. Mohanakumar3. 1 _Surgery, Washington University School of Medicine, St. Louis, MO,_ 2 _Medicine, Washington University School of Medicine, St. Louis, MO,_ 3 _Surgery, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO_

**2:45 PM (253)** _Does Donor Age Impact Recipient Survival Post-Lung Transplant: A Study of the International Society of Heart and Lung Transplantation Database;_ A. M. Bernhardt1, A. P. Levin2, J. Stehlik3, C. Benden4, L. Edwards5, H. Reichenspurner1, F. M. Wagner1. 1 _Department of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany,_ 2 _Columbia University Medical Center, New York City, NY,_ 3 _School of Medicine Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT,_ 4 _Division of Pulmonary Medicine, University Hospital Zurich, Zurich, Switzerland,_ 5 _United Network for Organ Sharing, Richmond, VA_

**3:00 PM (254)** _Airway Inflammation in the Donor Prior to Explant Increases the Risk of Primary Graft Dysfunction;_ E. M. Lowery1, M. Yong1, L. Ramirez2, S. Kliethermes3, S. Jeffrey4, E. J. Kovacs2. 1 _Medicine, Loyola University Chicago, Chicago, IL,_ 2 _Surgery, Loyola University Chicago, Chicago, IL,_ 3 _Public Health, Loyola University Chicago, Chicago, IL,_ 4 _Cardiovascular Surgery, Loyola University Med Center, Maywood, IL_

**3:15 PM (255)** _Donor Derived Exosomes Expressing Lung Associated Self-antigens (Collagen V and K alpha 1 Tubulin) in Acute and Chronic Rejection Following Human Lung Transplantation;_ M. Gunasekaran1, Z. Xu1, D. Nayak1, M. Sharma1, R. Hachem2, T. Mohanakumar3. 1 _Surgery, Washington University School of Medicine, St. Louis, MO,_ 2 _Medicine, Washington University School of Medicine, St. Louis, MO,_ 3 _Surgery, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO_

2:00 PM - 3:30 PM

Concurrent Session 31: Pediatric Early Post Transplant Problems

**Location** :

Virginia Suite

Target Audience:

PEDS, HTX, MCS

Chairs:

Janet N Scheel, MD, and Kurt R Schumacher, MD

**2:00 PM (256)** _Regional Variation in the Use of 1A Status Exceptions for Pediatric Heart Transplant Candidates: Is This Equitable?;_ J. Godown1, M. McKane1, B. A. Mettler2, D. A. Dodd1. 1 _Pediatric Cardiology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN,_ 2 _Pediatric Cardiothoracic Surgery, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN_

**2:15 PM (257)** _The Use of Urgent Listing Exceptions in Pediatric Heart Transplantation: Is Waitlist Survival Equivalent to Standard Criteria Patients?;_ R. R. Davies, M. A. McCulloch, S. Haldeman, S. S. Gidding, C. Pizarro. _Nemours/A.I. duPont Hospital for Children, Wilmington, DE_

**2:30 PM (258)** _Mechanical Circulatory Support after Pediatric Heart Transplantation;_ J. D. Simmonds1, E. Pruitt2, D. C. Naftel2, D. Gupta3, D. Dodd4, S. D. Zangwill5, J. K. Kirklin2, L. Addonizio6. 1 _Great Ormond Street Hospital for Children, London, United Kingdom,_ 2 _University of Alabama at Birmingham, Birmingham, AL,_ 3 _Congenital Heart Center, University of Florida, Gainesville, FL,_ 4 _Division of Cardiology, Vanderbilt Heart and Vascular Institute, Nashville, TN,_ 5 _Phoenix Children's Heart Center, Phoenix, AZ,_ 6 _Columbia University College of Physicians and Surgeons, New York, NY_

**2:45 PM (259)** _A Novel Donor Risk Scoring System to Predict 1-Year Mortality in Pediatric Heart Transplantation;_ F. Zafar1, R. D. Jaquiss2, C. S. Almond3, A. Lorts4, C. Chin4, R. Rizwan1, R. Bryant 3rd1, J. S. Tweddell1, D. L. Morales1. 1 _Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH,_ 2 _Cardiothoracic Surgery, Duke University School of Medicine, Durham, NC,_ 3 _Pediatric Cardiology, Stanford University School of Medicine, Stanford, CA,_ 4 _Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH_

**3:00 PM (260)** _Development and Validation of a Major Adverse Transplant Event (MATE) Score to Predict Graft Loss after Pediatric Heart Transplantation;_ C. S. Almond1, J. W. Rossano2, H. Hoen1, C. Castleberry3, S. Auerbach4, L. Yang1, A. K. Lal5, M. D. Everitt4, E. Pahl6, M. Fenton7, S. A. Hollander1, D. B. McElhinney1, D. N. Rosenthal1, K. P. Daly8, M. Desai1. 1 _Stanford University, Palo Alto, CA,_ 2 _Children's Hospital of Philadelphia, Philadelphia, PA,_ 3 _Washington University/St. Louis, St. Louis, MO,_ 4 _Denver Children's Hospital, Denver, CO,_ 5 _Primary Children's Hospital, Salt Lake City, UT,_ 6 _Lurie Children's Hospital, Chicago, IL,_ 7 _Great Ormond Street Children's Hospital, London, United Kingdom,_ 8 _Boston Children's Hospital, Boston, MA_

**3:15 PM (261)** _Early Neurologic Outcomes after Pediatric Heart Transplantation;_ C. Cammock, C. Castleberry, S. Choudhry, K. Simpson, C. Canter. _Pediatric Cardiology, St Louis Children's Hospital, St. Louis, MO_

2:00 PM - 3:30 PM

Concurrent Session 32: Cardiothoracic Transplantation and MCS Infections: Cracking the Code for Diagnosis, Monitoring, and Treatment

**Location** :

Delaware Suite

Target Audience:

ID, HTX, LTX, MCS, NHSAH

Chairs:

Aric L Gregson, MD, and Amparo Sole, MD, PhD

**2:00 PM (262)** _Clinical Characteristics and Outcomes of Mycobacterium abscessus Isolation in Lung Transplant Candidates and Recipients: A Systematic Review;_ O. Morrissey1, G. Snell2, B. Levvey2, G. Westall2, A. Cheng1, H. Bills3. 1 _Department of Infectious Diseases, The Alfred Hospital, Melbourne, Australia,_ 2 _Lung Transplant Service, The Alfred Hospital, Melbourne, Australia,_ 3 _Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia_

**2:15 PM (263)** _Universal Versus Culture-Directed Pre-Emptive Treatment (CDPET) among Lung Transplant Recipients: A Propensity-Score Matched Analysis;_ B. Hamandi1, C. Fegbeutel2, F. P. Silveira3, E. A. Verschuuren4, P. Ussetti5, P. V. Chin-Hong6, A. Sole7, C. Holmes-Liew8, E. M. Billaud9, P. A. Grossi10, O. Manuel11, D. J. Levine12, R. G. Barbers13, D. Hadjiliadis14, L. G. Singer15, S. Husain1. 1 _University Health Network, Toronto, ON, Canada,_ 2 _Hannover Medical School, Hannover, Germany,_ 3 _University of Pittsburgh, Philadelphia, PA,_ 4 _University Medical Center Groningen, University of Gron, Groningen, Netherlands,_ 5 _Hospital Puerta de Hierro, Madrid, Spain,_ 6 _University of California, San Francisco, San Francisco, CA,_ 7 _University and Polytechnic Hospital La Fe, Universidad de Valencia, Valencia, Spain,_ 8 _Royal Adelaide Hospital, Adelaide, Australia,_ 9 _APHP Hopital Européen G Pompidou, Paris Descartes, France,_ 10 _University of Insubria, Varese, Italy,_ 11 _University Hospital of Lausanne, Lausanne, Switzerland,_ 12 _University of Texas Health Science Center San Antonio, San Antonio, TX,_ 13 _KECK Medical Center of University of Southern California, Los Angeles, CA,_ 14 _University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia, PA,_ 15 _University Health Network, University of Toronto, Toronto, ON, Canada_

**2:30 PM (264)** _Interim Analysis: A Study of QuantiFERON-CMV-Directed CMV Prophylaxis Versus Standard-of-Care to Reduce Late CMV Reactivation in Patients Undergoing Lung Transplantation;_ G. P. Westall1, Y. Cristiano1, A. Y. Peleg2, M. Paraskeva1, B. Levvey1, H. Whitford1, G. Snell1. 1 _Lung Transplant Service, Alfred Hospital, Melbourne, Australia,_ 2 _Department of Infectious Disease, Alfred Hospital, Melbourne, Australia_

**2:45 PM (265)** _A Pre-Transplant Humoral Immunity Score to Identify Risk of Severe Infection in Heart Recipients. A Multicenter Study;_ J. Carbone1, J. Fernandez-Yañez2, M. Gomez-Sanchez3, M. Crespo-Leiro4, L. Almenar5, G. Rabago6, J. Segovia7, J. Lopez8, L. Garcia-Guereta9, S. Mirabet10, J. Navarro1, E. Sarmiento1. 1 _Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain,_ 2 _Hospital General Universitario Gregorio Marañon, Madrid, Spain,_ 3 _Hospital Universitario Doce de Octubre, Madrid, Spain,_ 4 _Complexo Hospitalario Universitario A Coruña, La Coruña, Spain,_ 5 _Hospital Universitario La Fe, Valencia, Spain,_ 6 _Clínica Universitaria de Navarra, Navarra, Spain,_ 7 _Hospital Universitario Puerta de Hierro, Madrid, Spain,_ 8 _Hospital Clínico Universitario, Valladolid, Spain,_ 9 _Hospital Universitario La Paz, Madrid, Spain,_ 10 _Hospital de la Santa Creu i Sant Pau, Barcelona, Spain_

**3:00 PM (266)** _Quantiferon Monitor: A Novel Assay for Prediction of Infectious Risk in Heart Transplant Recipients;_ L. Potena, L. Righini, V. Manfredini, L. Borgese, D. Sgreccia, A. Chiereghin, G. Piccirilli, M. Masetti, T. Lazzarotto, F. Grigioni. _University of Bologna, Bologna, Italy_

**3:15 PM (267)** _Positron Emission Tomography Accurately Diagnosis Ventricular Assist Device Infection;_ E. Feller1, A. Shah2. 1 _Medicine/Cardiology, University of Maryland, Baltimore, MD,_ 2 _School of Medicine, University of Maryland, Baltimore, MD_

2:00 PM - 3:30 PM

Concurrent Session 33: "A Bipartisan Effort": Antibodies and Complement in Heart and Lung Allografts

**Location** :

Washington Ballroom 2

Target Audience:

PATH, BSI, HF, HTX, LTX, PEDS

Chairs:

Elizabeth N Pavlisko, MD, and Patrick Bruneval, MD

**2:00 PM (268)** _PU.1 and CD34 Immunohistochemistry for the Diagnosis of Antibody-Mediated Rejection in the Heart;_ G. A. Fishbein, Y. P. Hung, R. N. Mitchell, R. F. Padera. _Department of Pathology, Brigham and Women's Hospital, Boston, MA_

**2:15 PM (269)** _Histologic Features of Mixed Rejection in Heart Transplantation: More Than Just Cellular + Antibody-Mediated Rejection?;_ D. V. Miller1, A. G. Kfoury2, G. L. Snow3, M. Revelo4, A. Lal5, J. Stehlik2, S. H. McKellar6, J. C. Fang2, W. Caine6, K. Ashfar2, S. G. Drakos2, O. Wever-Pinzon2, K. M. Molina5, M. H. Hammond4. 1 _UTAH Cardiac Transplant Program, Murray, UT,_ 2 _Cardiology, UTAH Cardiac Transplant Program, Murray, UT,_ 3 _Biostatistics, UTAH Cardiac Transplant Program, Murray, UT,_ 4 _Pathology, UTAH Cardiac Transplant Program, Murray, UT,_ 5 _Pediatric Cardiology, UTAH Cardiac Transplant Program, Murray, UT,_ 6 _Cardiac Surgery, UTAH Cardiac Transplant Program, Murray, UT_

**2:30 PM (270)** _Clearance of C3d Immunostaining Occurs More Often and Earlier Than Clearance of C4d after Antibody Mediated Rejection: An Earlier Marker for Resolving Rejection?;_ D. V. Miller1, M. Revelo1, A. G. Kfoury1, G. L. Snow2, K. Afshar3, D. Budge3, R. Alharethi3, S. G. Drakos3, J. N. Nativi3, E. H. Hammond1. 1 _Pathology, Intermountain Central Lab, Salt Lake City, UT,_ 2 _Biostatistics, Intermountain Central Lab, Salt Lake City, UT,_ 3 _Cardiology, Intermountain Central Lab, Salt Lake City, UT_

**2:45 PM (271)** _Intrapulmonary Local Production of Antibodies Specific to Donor Major Histocompatibility Complex Class I in Association with the Progression of Chronic Rejection in Lung Allografts;_ E. Miyamoto1, M. Sato2, H. Motoyama1, A. Aoyama1, T. Menju1, K. Shikuma1, T. Sowa1, M. Saito1, A. Takahagi1, S. Tanaka1, M. Takahashi1, K. Ohata1, T. Kondo1, K. Hijiya1, T. F. Chen-Yoshikawa1, T. Sato1, M. Sonobe1, H. Date1. 1 _Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan,_ 2 _Thoracic Surgery, The University of Tokyo, Tokyo, Japan_

**3:00 PM (272)** _Complement-Fixing Donor Specific Antibody and Pathologic Findings in Lung Allografts;_ L. Chhatwani1, J. Mooney1, K. Patel1, A. Emtiazjoo2, A. Lawrence1, G. Berry3, D. Tyan3, G. Dhillon1. 1 _Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA,_ 2 _Pulmonary and Critical Care Medicine, University of Florida, Gainesville, FL,_ 3 _Department of Pathology, Stanford University, Stanford, CA_

**3:15 PM (273)** _Insufficient Post-Transplant Immunosuppression Induces Restrictive Allograft Syndrome-Like Fibrosis in the Pleura and Lung Parenchyma After Lung Transplantation;_ E. Miyamoto1, M. Sato2, H. Motoyama1, A. Aoyama1, T. Menju1, K. Shikuma1, T. Sowa1, M. Saito1, A. Takahagi1, S. Tanaka1, M. Takahashi1, K. Ohata1, T. Kondo1, K. Hijiya1, T. F. Chen-Yoshikawa1, T. Sato1, M. Sonobe1, H. Date1. 1 _Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan,_ 2 _Thoracic Surgery, The University of Tokyo, Tokyo, Japan_

2:00 PM - 3:30 PM

Symposium 31: Performing Under Pressure: Lung Transplantation in PH and PAH

**Location** :

Washington Ballroom 1

Target Audience:

PH, ALL

Chairs:

Reda E. Girgis, MD, and Walter Klepetko, MD

**Session Summary** : The session will focus on the opportunities, pitfalls, and challenges in bridging patients with PAH and advanced lung disease complicated by PH to lung transplantation.

2:00 PM

Prognosis of PAH: Eligibility and Timing of Transplant Referral

Antonio Roman, MD, Hospital Universitari Vall d'Hebron, Barcelona, Spain

2:15 PM

The LAS for PAH: Impact of New Revisions

Sangeeta Bhorade, MD, Northwestern Memorial Hospital, Chicago, IL, USA

2:30 PM

PH and the risk of Primary Graft Dysfunction in Lung Transplantation

James Lee, MD, University of Pennsylvania, Philadelphia, PA, USA

2:45 PM

Matching Bridging Strategies to Unique Clinical Situations in PH and Lung Transplant

Erika Berman Rosenzweig, MD, Columbia University, New York, NY, USA

3:00 PM

Perioperative and Early Postoperative Challenges in PH and Lung Transplantation

Martin Strueber, MD, Spectrum Health Hospitals, Grand Rapids, MI, USA

3:15 PM

PANEL DISCUSSION

4:00 PM - 5:30 PM

Concurrent Session 34: How Much is Too Much? Assessing Risk Prior to MCS

**Location** :

Salons 2-3

Target Audience:

MCS, HTX, NHSAH

Chairs:

Shashank S Desai, MD, and Yuriy Pya, MD

**4:00 PM (274)** _Accuracy of Seattle Heart Failure Model and HeartMate II Risk Score in Non-Inotrope Dependent Advanced Heart Failure Patients: Insights from the ROADMAP Study;_ D. E. Lanfear1, W. C. Levy2, J. Stehlik3, J. D. Estep4, J. G. Rogers5, K. B. Shah6, A. J. Boyle7, J. Chuang8, D. J. Farrar8, R. C. Starling9. 1 _Henry Ford Hospital, Detroit, MI,_ 2 _University of Washington, Seattle, WA,_ 3 _University of Utah, Salt Lake City, UT,_ 4 _Houston Methodist Hospital, Houston, TX,_ 5 _Duke University, Durham, NC,_ 6 _Virginia Commonwealth University, Richmond, VA,_ 7 _Piedmont Hospital, Atlanta, GA,_ 8 _St. Jude Medical, Pleasanton, CA,_ 9 _Cleveland Clinic, Cleveland, OH_

**4:15 PM (275)** _Physician Prediction of Outcomes in Ambulatory Patients with Advanced Heart Failure;_ M. M. Kittleson1, C. B. Patel2, R. S. Cantor3, A. D. DeVore4, A. V. Ambardekar5, J. T. Thibodeau6, L. M. Cadaret7, S. V. Pamboukian8, J. Teuteberg9, R. C. Forde-McLean10, M. M. Mountis11, M. Palardy12, G. C. Stewart13, M. A. Hamilton1. 1 _Cardiology, Cedars-Sinai Heart Institute, Los Angeles, CA,_ 2 _Division of Cardiology, Duke University Medical Center, Durham, NC,_ 3 _Department of Surgery, The University of Alabama at Birmingham, Birmingham, AL,_ 4 _Cardiology, Duke Clinical Research Institute, Durham, NC,_ 5 _Medicine-Cardiology, University of Colorado, Aurora, CO,_ 6 _Internal Medicine/Cardiology, UT Southwestern, Dallas, TX,_ 7 _Internal Medicine, The University of Iowa, Iowa City, IA,_ 8 _Cardiovascular Diseases, The University of Alabama at Birmingham, Birmingham, AL,_ 9 _Heart and Vascular Intstitute, The University of Pittsburgh, Pittsburgh, PA,_ 10 _Cardiology, University of Pennsylvania, Philadelphia, PA,_ 11 _Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH,_ 12 _Internal Medicine/Cardiovascular, The University of Michigan, Ann Arbor, MI,_ 13 _Advanced Heart Disease, Brigham and Women's Hospital, Boston, MA_

**4:30 PM (276)** _Effect of Body Mass Index on Outcomes of Heart Transplant Candidates Supported by Continuous-Flow Left Ventricular Assist Devices (CF-LVADs);_ V. K. Topkara1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, F. Castagna1, B. Cagliostro1, G. Parkis1, S. Restaino1, F. Latif1, M. Maurer1, M. A. Farr1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Surgery, Columbia University, New York, NY_

**4:45 PM (277)** _Red Cell Distribution Width (RDW) Predicts 90-Day Mortality in Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Patients;_ V. K. Topkara1, A. R. Garan1, V. Ton1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, D. Jennings1, F. Castagna1, B. Cagliostro1, M. A. Farr1, M. Maurer1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Surgery, Columbia University, New York, NY_

**5:00 PM (278)** _Heart Failure Etiology Influences Outcomes after Continuous-Flow LVAD Implantation;_ S. Maltais1, N. A. Haglund2, M. E. Davis2, J. Cowger3, P. Shah4, F. D. Pagani5, K. D. Aaronson5, S. M. Dunlay1, J. M. Stulak1. 1 _Mayo Clinic, Rochester, MN,_ 2 _Vanderbilt, Nashville, TN,_ 3 _St-Vincent Hospital, Indianapolis, IN,_ 4 _Inova Fairfax, Virginia, VA,_ 5 _Michigan, Michigan, MI_

**5:15 PM (279)** _Survival Following Orthotopic Heart Transplantation in Bridge-to-Transplant Heartware HVAD versus Heartmate II Patients;_ J. Magruder1, J. C. Grimm1, T. C. Crawford1, R. J. Tedford2, S. D. Russell2, C. M. Sciortino1, G. J. Whitman1, A. S. Shah3. 1 _Division of Cardiac Surgery, Johns Hopkins, Baltimore, MD,_ 2 _Division of Cardiology, Johns Hopkins, Baltimore, MD,_ 3 _Department of Cardiac Surgery, Vanderbilt, Nashville, MD_

4:00 PM - 5:30 PM

Concurrent Session 35: Too Thick or Too Thin? Assessing Anticoagulation in MCS

**Location** :

Thurgood Marshall

Target Audience:

MCS, HF, NHSAH, PHARM

Chairs:

Nir Uriel, MD, and Nader Moazami, MD

**4:00 PM (280)** _Aspirin Responsiveness Predicts Mucosal Bleeding Events in Patients with Continuous-Flow Left Ventricular Assist Devices;_ V. K. Topkara1, A. B. Eisenberger1, A. R. Garan1, D. Jennings1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, F. Castagna1, B. Cagliostro1, M. Flannery2, R. Te-Frey2, A. L. Uryevick2, F. Latif1, M. Maurer1, M. A. Farr1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Surgery, Columbia University, New York, NY_

**4:15 PM (281)** _Genomic Reprogramming of the Platelet Transcriptome with Chronic LVAD Support;_ A. Koliopoulou1, M. T. Rondina2, H. Javan2, S. Men2, S. G. Drakos3, J. Stehlik3, S. H. McKellar1, A. S. Weyrich2, C. H. Selzman1. 1 _Division of Cardiothoracic Surgery, University of Utah, Salt Lake City, UT,_ 2 _Molecular Medecin Program, University of Utah, Salt Lake City, UT,_ 3 _Division of Cardiovascular Medecine, University of Utah, Salt Lake City, UT_

**4:30 PM (282)** _Coagulation Factors Abnormalities in LVAD Patients with Anti-Factor 10a and PTT Discordance;_ S. Adatya1, S. Roy2, M. Fitzpatrick2, P. Eckman2, G. Sayer1, S. Kalantari Tannenbaum1, T. Thenappan2, R. John2, M. Pritzker2, U. Nir1. 1 _Cardiology, University of Chicago, Chicago, IL,_ 2 _Cardiology, University of Minnesota, Minneapolis, MN_

**4:45 PM (283)** _Bleeding Complications after Left Ventricular Assist Device Implantation: Association of Events and Impact on Survival;_ S. Maltais1, J. VanMeeteren1, S. Dunlay1, N. Haglund2, F. Pagani3, K. Aaronson3, J. Cowger4, P. Shah5, J. Stulak1. 1 _Mayo Clinic, Rochester, MN,_ 2 _Vanderbilt, Nashville, TN,_ 3 _Michigan, Michigan, MI,_ 4 _St-Vincent Hospital, Indianapolis, IN,_ 5 _Inova Fairfax, Virginia, VA_

**5:00 PM (284)** _Use of Four-Factor Prothrombin Concentrate Complex in LVAD Recipients Undergoing Transplantation: Impact on Blood Loss, Blood Use, Blood Bank Costs and Clinical Outcomes;_ D. J. Goldstein1, J. Uehlinger2, J. Szymanski2, K. Mohandas2, R. Walsh2, S. Karim2, E. Marks2, E. Himchak2, R. Gupta2, D. Wu2. 1 _Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY,_ 2 _Pathology, Montefiore Medical Center, Bronx, NY_

**5:15 PM (285)** _Aortic Root Thrombus Formation in Patients with Continuous-Flow Left Ventricular Assist Devices (CF-LVADs);_ J. A. Fried1, S. Fukuhara1, A. R. Garan1, M. Yuzefpolskaya1, H. Takayama1, F. Castagna1, A. M. Clemons1, S. Singh1, D. Jennings1, B. Cagliostro1, L. Effner2, M. A. Farr1, R. Bijou1, M. Maurer1, D. M. Mancini1, Y. Naka2, P. C. Colombo1, H. Takayama2, K. Takeda2, V. K. Topkara1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Surgery, Columbia University, New York, NY_

4:00 PM - 5:30 PM

Concurrent Session 36: Is It Really A Wonderful Life? Problems Post Heart Transplant

**Location** :

Salon 1

Target Audience:

HTX, EEP, ID, NHSAH, PATH, PEDS, PHARM

Chairs:

Adriana Torres, MD, and Marco A Caccamo, DO

**4:00 PM (286)** _Outcomes in Patients Older Than 60 Years of Age Undergoing Orthotropic Heart Transplantation Since Broadening of Eligibility Criteria;_ S. Rao, C. Hawyard, P. MacDonald, A. Jabbour, E. Kotlyar, A. Keogh. _Heart and Lung Transplantation Unit, St Vincent's Hospital, Sydney, Australia_

**4:15 PM (287)** _Neoplasia after Heart Transplantation. Differences in Incidence and Prognosis between Genders. Data from the Spanish Post-Heart Transplant Tumor Registry;_ M. G. Crespo-Leiro1, J. Segovia Cubero2, J. F. Delgado-Jiménez3, E. Roig-Minguell4, E. Barge-Caballero1, I. Sousa-Casasnovas5, L. Almenar-Bonet6, F. González-Vilchez7, J. González-Costello8, B. Díaz-Molina9, J. M. Sobrino-Márquez10, G. Rábago11, J. M. Arizón del Prado12, F. Pérez-Villa13, T. Blasco Peiró14, L. de la Fuente-Galán15, I. P. Garrido Bravo16, J. Muñiz17. 1 _Complexo Hospitalario Universitario A Coruña e Instituto de Investigación Biomédica de A Coruña (INIBIC), La Coruna, Spain,_ 2 _Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain,_ 3 _Hospital Universitario 12 de Octubre, Madrid, Spain,_ 4 _Hospital de la Santa Creu i Sant Pau, Barcelona, Spain,_ 5 _Hospital General Universitario Gregorio Marañón, Madrid, Spain,_ 6 _Hospital Universitari i Politècnic La Fe, Valencia, Spain,_ 7 _Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain,_ 8 _Hospital Universitari de Bellvitge, L´Hospitalet de Llobregat, Barcelona, Spain,_ 9 _Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain,_ 10 _Hospital Universitario Virgen del Rocio, Sevilla, Spain,_ 11 _Clínica Universidad de Navarra, Pamplona, Navarra, Spain,_ 12 _Hospital Universitario Reina Sofía, Córdoba, Spain,_ 13 _Hospital Clinic i Provincial, Barcelona, Spain,_ 14 _Hospital Universitario Miguel Servet, Zaragoza, Spain,_ 15 _Hospital Clínico Universitario de Valladolid, Valladolid, Spain,_ 16 _Hospital Universitario Virgen de la Arrixaca, Murcia, Spain,_ 17 _Instituto Universitario de Ciencias de la Salud e Instituto de Investigación Biomédica de A Coruña (INIBIC), Universidade da Coruña, La Coruna, Spain_

**4:30 PM (288)** _Donor Age Associated with Short-Term and Recipient Age Associated with Long-Term Mortality in Heart Transplantation;_ H. Bergenfeldt1, J. Stehlik2, L. Lund3, B. Andersson4, J. Nilsson1. 1 _Cardiothoracic Surgery, Skane University Hospital, Lund, Sweden,_ 2 _Division of Cardiovascular Medicine, University of Utah, School of Medicine, Salt Lake City, UT,_ 3 _Cardiology, Karolinska Institutet, Stockholm, Sweden,_ 4 _Surgery, Skane University Hospital, Lund, Sweden_

**4:45 PM (289)** _The Obesity Epidemic and Its Effect on Donor Body Mass Index and Recipient Survival-A UNOS Database Review of Heart Transplantation;_ Y. Ravi1, E. M. Stock2, P. C. Rosas3, B. A. Whitson4, E. A. Amulraj1, R. C. Scott5, S. Emani6, S. Bansal7, C. B. Sai-Sudhakar1. 1 _Cardiothoracic Surgery-Surgery, Baylor Scott & White Healthcare Affliated With Texas A&M, Temple, TX, _2 _Center for Applied Health Research,, Central Texas Veterans Health Care System, Jointly With Baylor Scott & White Health, Temple, TX, _3 _Medical Physiology, Texas A &M, Temple, TX, _4 _Cardiac Surgery, The Ohio State University, Columbus, OH,_ 5 _Cardiology-Internal Medicine, Scott & White, Texas A&M, Temple, TX, _6 _Cardiology-Internal Medicine, The Ohio State University, Columbus, OH,_ 7 _Cardiac Surgery, Mayo Clinic, Jacksonville, FL_

**5:00 PM (290)** _Outcomes of Heart Transplantation in Adults with Sarcoidosis: UNOS Registry Analysis;_ E. C. DePasquale1, A. Iyengar1, A. Nsair1, K. Pandya2, M. Deng1, A. Ardehali1. 1 _David Geffen Sch Med, Los Angeles, CA,_ 2 _UCLA, Los Angeles, CA_

**5:15 PM (291)** _Cytomegalovirus Infection after Cardiac Transplantation;_ O. Kiamanesh, A. Khosla, C. Imai, E. Johansson, S. Virani, M. Davis, A. Cheung, J. Bashir, B. Munt, A. Ignaszewski, A. Kaan, M. Toma. _University of British Columbia, Vancouver, BC, Canada_

4:00 PM - 5:30 PM

Concurrent Session 37: Prognostic Variables Associated with CLAD Onset and Progression

**Location** :

Maryland Suite

Target Audience:

LTX, BSI, ID, NHSAH, PEDS, PHARM

Chairs:

Massaki Sato, MD, and Kevin M. Chan, MD

**4:00 PM (292)** _Shortened Allograft Epithelial Telomere Length - A Lasting Legacy of Donor Age and Smoking History;_ S. T. Yerkovich, M. Tan, L. Samson, A. Fiene, P. Hopkins, D. Chambers. _The Prince Charles Hospital, Brisbane, Australia_

**4:15 PM (293)** _Implication of Human Leukocyte Antigen (HLA) Mismatching on Survival and CLAD After Lung Transplantation;_ G. Chery, A. Copeland, M. Durham, S. Palmer, L. Snyder. _Department of Medicine, Duke University School of Medicine, Durham, NC_

**4:30 PM (294)** _FVC, TLC and CT as Independent Predictors for Prognosis after Onset of CLAD;_ H. L. Schultz1, S. Verleden2, R. Vos2, B. Vanaudenaerde2, G. Verleden2, M. Perch1, A. Holm3, M. Iversen1. 1 _Dept of Cardiology, Section for Lung Transpantation, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark,_ 2 _Lab of Lung Transplantation, Department of Pneumonology, University of Leuven, Leuven, Belgium,_ 3 _Department of Respiratory Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway_

**4:45 PM (295)** _Baseline Lung Allograft Dysfunction Negatively Impacts Survival Following Lung Transplantation;_ J. Liu1, K. Jackson2, J. Weinkauf1, A. Kapasi1, A. Hirji1, B. Laing2, J. Mullen2, D. Freed2, J. Nagendran2, S. Meyer2, D. Lien1, K. Halloran1. 1 _Medicine, University of Alberta, Edmonton, AB, Canada,_ 2 _Surgery, University of Alberta, Edmonton, AB, Canada_

**5:00 PM (296)** _Evaluation of an FVC-Based Definition of Restrictive Chronic Lung Allograft Dysfunction (CLAD) in a Multi-Center Cohort;_ M. T. Durheim1, D. M. Wojdyla1, C. L. Green1, S. Keshavjee2, K. McCurry3, A. O. Lidor4, R. D. Davis5, S. M. Palmer1, J. L. Todd1. 1 _Duke Clinical Research Institute, Durham, NC,_ 2 _University of Toronto, Toronto, ON, Canada,_ 3 _Cleveland Clinic, Cleveland, OH,_ 4 _Johns Hopkins University, Baltimore, MD,_ 5 _Florida Hospital Transplant Institute, Orlando, FL_

**5:15 PM (297)** _A Multicenter Study on Long-Term Outcomes after Lung Transplantation Comparing Donation after Circulatory Death and Donation after Brain Death;_ V. van Suylen1, B. Luijk2, R. A. Hoek3, E. A. van de Graaf2, E. A. Verschuuren4, C. Van De Wauwer1, J. A. Bekkers5, R. C. Meijer6, W. van der Bij4, M. E. Erasmus1. 1 _Department of Cardiothoracic Surgery, University Medical Center Groningen, Groningen, Netherlands,_ 2 _Department of Respiratory Medicine, University Medical Center Utrecht, Utrecht, Netherlands,_ 3 _Department of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, Netherlands,_ 4 _Department of Pulmonary Medicine and Tuberculosis, University Medical Center Groningen, Groningen, Netherlands,_ 5 _Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands,_ 6 _Department of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, Netherlands_

4:00 PM - 5:30 PM

Concurrent Session 38: New Insights in Pulmonary Hypertension

**Location** :

Virginia Suite

Target Audience:

PH, BSI, HF, HTX, LTX, MCS, PEDS, PH, PHARM

Chairs:

Ryan J Tedford, MD, and Antonio B Roman, MD, PhD

**4:00 PM (298)** _Subclinical Pulmonary Hypertension Is Common and Associated with Increased Mortality in a Large Electronic Medical Record-Based Cohort;_ T. R. Assad1, I. M. Robbins1, A. R. Hemnes1, M. Xu1, B. A. Maron2, G. Choudhary3, Q. S. Wells1, E. Farber-Eger1, E. Hess4, A. E. Baron4, T. M. Maddox4, E. L. Brittain1. 1 _Vanderbilt University Med Center, Nashville, TN,_ 2 _VA Boston Health Care System and Brigham & Women's Hospital and Harvard Medical School, Boston, MA, _3 _Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI,_ 4 _VA Eastern Colorado Health Care System, Denver, CO_

**(299)** WITHDRAWN

**4:15 PM (387)** _Right Ventricular Dyssynchrony and Exercise Capacity in Idiopathic Pulmonary Arterial Hypertension: Insights Form Echocardiography and Cardiopulmonary Exercise Test;_ R. Badagliacca, R. Poscia, M. Reali, B. Pezzuto, S. Papa, G. Manzi, S. Sciomer, F. Fedele, C. D. Vizza. _Cardiovascular and Respiratory Science, Sapienza University of Rome, Rome, Italy_

**4:30 PM (300)** _Exercise Hemodynamics in PAH: Lessons Utilizing an Indwelling Hemodynamic Monitor;_ R. L. Benza, P. Correa-Jaque, D. V. Thompson, A. Raina, R. Agarwal, G. Sokos, M. Kanwar, M. Patarroyo-Aponte, S. Murali, M. Doyle, J. White, R. Biederman. _Cardiology, Allegheny Gen Hosp, Pittsburgh, PA_

**4:45 PM (301)** _Right Ventricular Reserve Limitation in Systemic Sclerosis-Associated Versus Idiopathic Pulmonary Arterial Hypertension;_ S. Hsu1, B. A. Houston1, E. Tampakakis1, A. C. Bacher1, P. S. Rhodes2, S. C. Mathai3, R. L. Damico3, T. M. Kolb3, L. K. Hummers4, A. A. Shah4, Z. McMahan4, S. L. Zimmerman5, F. M. Wigley4, P. M. Hassoun3, D. A. Kass1, R. J. Tedford1. 1 _Cardiology, Johns Hopkins University, Baltimore, MD,_ 2 _Physiology, Johns Hopkins University, Baltimore, MD,_ 3 _Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD,_ 4 _Rheumatology, Johns Hopkins University, Baltimore, MD,_ 5 _Radiology, Johns Hopkins University, Baltimore, MD_

**5:00 PM (302)** _Influence of Pulmonary Hypertension on Adverse Outcomes Following Non-Cardiac Surgery;_ D. P. McGlothlin1, J. G. Zaroff1, A. C. Goh1, D. H. See2, S. B. Tate2, C. Conell3. 1 _Cardiology, Kaiser Permanente San Francisco Med Ctr, San Francisco, CA,_ 2 _Internal Medicine, Kaiser Permanente San Francisco Medical Center, San Francisco, CA,_ 3 _Division of Research, Kaiser Permanente San Francisco Med Ctr, Oakland, CA_

**5:15 PM (303)** _Anticoagulant Therapy Is Not Associated with Long Term Outcome in Patients with Pulmonary Arterial Hypertension (PAH): Insights from the GRIPHON Study;_ V. F. Tapson1, R. Channick2, K. Chin3, L. Di Scala4, H. Farber5, S. Gaine6, N. Galiè7, H. A. Ghofrani8, I. Lang9, V. McLaughlin10, R. Preiss4, L. J. Rubin11, G. Simonneau12, O. Sitbon12, M. M. Hoeper13. 1 _Cedars-Sinai Medical Center, Los Angeles, CA,_ 2 _Massachusetts General Hosp, Boston, MA,_ 3 _UT Southwestern Med Ctr, Dallas, TX,_ 4 _Actelion Pharmaceuticals Ltd, Allschwil, Switzerland,_ 5 _Pulmonary Hypertension Center, Boston Univ School of Medicine, Boston, MA,_ 6 _National Pulmonary Hypertension Unit, Mater Misericordiae Univ Hospital, Dublin, Ireland,_ 7 _Istituto di Malattie dell'Apparato Cardiovascolare, Univ of Bologna, Bologna, Italy,_ 8 _Univ of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany,_ 9 _Medical Univ of Vienna, Dept of Internal Medicine II, Division of Cardiology, Allgemeines Krankenhaus, Vienna, Austria,_ 10 _Univ of Michigan Health System Division of Cardiovascular Medicine, Ann Arbor, MI,_ 11 _Division of Pulmonary and Critical Care Medicine, Univ of California, San Diego, CA,_ 12 _Hôpital Universitaire de Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France,_ 13 _Department of Respiratory Medicine, Hannover Medical School and German Center of Lung Research, Hannover, Germany_

4:00 PM - 5:30 PM

Concurrent Session 39: Junior Faculty and Trainee Council's Clinical Case Dilemmas: The Best of the Best

**Location** :

Delaware Suite

Target Audience:

CASE, ALL

Chairs:

Mitesh V Thakrar, MD, and Hermann Reichenspurner, MD, PhD

4:00 PM

**(304)** _Will Relaxation Improve Things?_ K. B. Berfield1, J. Huang2, G. S. Aldea2, J. W. Smith2, N. A. Mokadam2, J. D. Pal2. 1 _University of Washington, Seattle, WA,_ 2 _Univ of Washington, Seattle, WA_

4:05 PM

EXPERT DISCUSSANT

David O. Taylor, MD, Cleveland Clinic, Cleveland, OH, USA

4:09 PM

MODERATED DISCUSSION

4:15 PM

**(305)** _Can Anything Make It Better?_ J. M. Friedland-Little1, R. J. Gajarski2, K. R. Schumacher3. 1 _Cardiology, Seattle Children's Hospital, Seattle, WA,_ 2 _Cardiology, Nationwide Children's Hospital, Columbus, OH,_ 3 _Pediatric Cardiology, University of Michigan, Ann Arbor, MI_

4:20 PM

EXPERT DISCUSSANT

Jennifer Conway, MD, Stollery Children's Hospital, Edmonton, AB, Canada

4:24 PM

MODERATED DISCUSSION

4:30 PM

**(306)** _Are You Ready to Take the Next Step?_ J. Steiner, S. Wiafe, J. Camuso, K. Milley, D. D'Alessandro, J. Garcia, G. Lewis. _MGH, Boston, MA_

4:35 PM

EXPERT DISCUSSANT

Sharon Hunt, MD, Stanford University, Stanford, CA, USA

4:39 PM

MODERATED DISCUSSION

4:45 PM

**(307)** _Why Don't These Drugs Work Anymore?_ R. M. La Hoz1, J. Le1, M. Mohanka2, J. V. Philley3, K. Kowalske4, A. Banga2, S. Bollineni2, V. Kaza2, M. Wait5, F. Torres2. 1 _Division of Infectious Diseases, UT Southwestern Medical Center, Dallas, TX,_ 2 _Division of Pulmonary and Critical Care Medicine, UT Southwestern Medical Center, Dallas, TX,_ 3 _Department of Medicine, University of Texas Health Science Center, Tyler, TX,_ 4 _Department of Physical Medicine & Rehabilitation, UT Southwestern Medical Center, Dallas, TX, _5 _Department of Cardiovascular and Thoracic Surgery, UT Southwestern Medical Center, Dallas, TX_

4:50 PM

EXPERT DISCUSSANT

Margaret Hannan, MD, Mater Hospital, Dublin, Ireland

4:54 PM

MODERATED DISCUSSION

5:00 PM

**(308)** _Who's Going to Fix This Now That It's Broken?_ S. S. Thomas1, R. Gallagher1, J. Steiner1, T. H. Song2, I. Palacios1, S. Elmariah1, S. Wiafe2, N. Roy2, G. Cudemus3, M. J. Semigran1, G. D. Lewis1, J. P. Garcia2, K. Rosenfield1. 1 _Cardiology, Massachusetts General Hospital, Boston, MA,_ 2 _Cardiac Surgery, Massachusetts General Hospital, Boston, MA,_ 3 _Anesthesia, Critical Care and Pain Management, Massachusetts General Hospital, Boston, MA_

5:05 PM

EXPERT DISCUSSANT

George Wieselthaler, MD, University of California, San Francisco, CA, USA

5:09 PM

MODERATED DISCUSSION

5:15 PM

**(309)** _Does Size Matter Anymore?_ Y. Goda. _Department of Thoracic Surgery Kyoto University, Kyoto, Japan_

5:20 PM

EXPERT DISCUSSANT

Shaf Keshavjee, MD, Toronto General Hospital, Toronto, ON, Canada

5:24 PM

MODERATED DISCUSSION

4:00 PM - 5:30 PM

Concurrent Session 40: Too Much of a Good Thing: Balancing Benefit and Medication Complexity

**Location** :

Washington Ballroom 2

Target Audience:

PHARM, HTX, ID, LTX, MCS, NHSAH

Chairs:

Adam B Cochrane, PharmD, and Haifa Lyster, MSc

**4:00 PM (310)** _Evaluation of Anticoagulation and Non-Surgical Major Bleeding in Recipients of Continuous-Flow Left Ventricular Assist Devices;_ T. Veasey, S. Strout, K. Rieger, C. Floroff, M. Brisco, J. Cook, J. Toole, M. Craig, A. VanBakel, D. Heyward, W. Uber, H. Meadows. _Medical University of South Carolina, Charleston, SC_

**4:15 PM (311)** _A Multidisciplinary Team-Based Process Improves Outpatient Anticoagulation Quality in Patients with Continuous-Flow Left-Ventricular Assist Devices;_ Y. Kuyumjian1, J. Leverock2, M. M. Miyares1, B. Bednar2, S. Chaparro3, A. Panos3, W. Baker4, D. L. Jennings5. 1 _Jackson Memorial Hospital, Miami, FL,_ 2 _Miami Transplant Institute, Miami, FL,_ 3 _University of Miami, Miami, FL,_ 4 _University of Connecticut, Storrs, CT,_ 5 _Columbia University Medical Center, New York, NY_

**4:30 PM (312)** _Post Transplant Thrombosis and Atrial Arrhythmia May Be Safely Managed by Direct Oral Anticoagulants in Cardiac Transplant Patients;_ M. Kim, S. Gabardi, K. R. Townsend, D. S. Page, E. L. Woodcome, M. M. Givertz. _Brigham & Women's Hospital, Boston, MA_

**4:45 PM (313)** _Durability of Bortezomib for Treatment of Antibody Mediated Rejection in Cardiac Transplantation;_ A. B. Cochrane1, J. R. Giaquinto2, S. Desai1, P. Shah1. 1 _Inova Transplant Center, Inova Fairfax Hospital, Falls Church, VA,_ 2 _Butler University, Indianapolis, IN_

**5:00 PM (314)** _Do Your Patients Take Their Tablets?... High Prevalence of Non-Adherence to Immunosuppression in Lung Transplant Recipients (LTR);_ A. Madden1, S. Ivulich1, M. Paraskeva2, G. Snell2, M. Dooley1. 1 _Pharmacy, Alfred Hospital, Prahran, Australia,_ 2 _Respiratory Medicine, Alfred Hospital, Prahran, Australia_

**5:15 PM (315)** _Effect of Aerosolized Antipseudomonals on Pseudomonas Recurrence and Bronchiolitis Obliterans Syndrome after Lung Transplantation;_ C. A. Moore1, J. M. Pilewski1, K. M. Robinson1, M. R. Morrell1, C. J. Gries2, A. Zeevi1, J. F. McDyer1, C. R. Ensor1. 1 _University of Pittsburgh, Pittsburgh, PA,_ 2 _Florida Hospital, Orlando, FL_

6:00 PM - 7:00 PM

Mini Oral 7: Patient Management and Outcomes in MCS

**  
Location** :

Thurgood Marshall

Target Audience:

MCS, HF, NHSAH

Chairs:

Gregory A Ewald, MD, and Ruchan Akar, MD

**6:00 PM (316)** _Characteristics and Outcomes of African American LVAD Recipients: A Single Center Experience;_ F. H. Sheikh, D. T. Majure, M. E. Rodrigo, S. M. Jani, M. Hofmeyer, S. W. Boyce, S. S. Najjar. _MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC_

**6:05 PM (317)** _Infectious Complications after Cardiac Transplantation in Patients Bridged to Transplantation with Mechanical Circulatory Support Devices Versus Medical Therapy;_ B. Varr, S. W. Restaino, M. Farr, P. Colombo, Y. Naka, D. M. Mancini. _Cardiology, Columbia University, New York, NY_

**6:10 PM (318)** _Multicenter Canadian Experience with the Heartware HVAD - 5 Year Update;_ W. E. Stansfield1, A. D. Nagpal2, W. D. Kent3, R. G. MacArthur4, R. J. Baskett5, A. Cheung6, M. Toma7, V. Rao1. 1 _Surgery, University of Toronto, Toronto, ON, Canada,_ 2 _Surgery, University of Western Ontario, London, ON, Canada,_ 3 _Surgery, University of Calgary, Calgary, AB, Canada,_ 4 _Surgery, University of Alberta, Edmonton, AB, Canada,_ 5 _Surgery, Dalhousie University, Halifax, NS, Canada,_ 6 _Surgery, University of British Columbia, Vancouver, BC, Canada,_ 7 _Medicine, University of British Columbia, Vancouver, BC, Canada_

**6:15 PM (319)** _Surgical Management of Driveline Infection in Continuous Flow Left Ventricular Assist Devices;_ S. Taghavi1, D. Tandon2, A. G. Diamant2, A. Keith1, G. A. Ewald3, S. J. Lawrence4, M. F. Masood1, K. R. Balsara1, A. Itoh1. 1 _Division of Cardiothoracic Surgery, Washington University School of Medicine, Saint Louis, MO,_ 2 _Washington University School of Medicine, Saint Louis, MO,_ 3 _Division of Cardiology, Washington University School of Medicine, Saint Louis, MO,_ 4 _Division of Infectious Disease, Washington University School of Medicine, Saint Louis, MO_

**6:20 PM (320)** _The Value of PET-CT Scans in Patients with Ventricular Assist Devices;_ A. M. Bernhardt, M. J. Barten, A. Schaefer, B. Sill, F. M. Wagner, H. Reichenspurner, T. Deuse. _Department of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany_

**6:25 PM (321)** _Predictors of Long Term Survival on Left Ventricular Assist Device Support;_ J. R. Spratt1, S. Roy2, D. Plack3, R. J. Cogswell2, K. Liao1, R. John1. 1 _Department of Surgery, University of Minnesota, Minneapolis, MN,_ 2 _Department of Medicine, University of Minnesota, Minneapolis, MN,_ 3 _University of Minnesota Medical School, Minneapolis, MN_

**6:30 PM (322)** _Risk of Death or Rehospitalization After LVAD and Baseline Cognitive Status;_ K. Bryce1, D. E. Lanfear1, C. T. Williams1, J. Lindenfeld2, L. A. Allen3, C. McIlvennan3. 1 _Henry Ford Hospital, Detroit, MI,_ 2 _Vanderbilt University, Nashville, TN,_ 3 _University of Colorado, Denver, CO_

**(323)** MOVED TO CONCURRENT SESSION 47

**6:35 PM (693)** _When Antibiotics Are Not Enough: Frequency, Etiology and Durability of the Surgical Management of Driveline Infections;_ M. Lander1, L. Lagazzi2, R. L. Kormos2, G. O'Shea2, S. Weaver2, T. Schweke2, M. Shullo1, J. J. Teuteberg1. 1 _Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA,_ 2 _Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA_

**6:40 PM (324)** _Effects of LVADs on Exercise Performance in Heart Failure;_ W. K. Cornwell. _Cardiology, Univ of Texas SW, Coppell, TX_

**6:45 PM (325)** _Left Ventricular, Biventricular and Total Artificial Heart Support are Associated with Similar Levels of Allosensitization in Bridge-to-Transplant Patients: An Analysis of the UNOS Database;_ M. Yuzefpolskaya1, P. N. Trinh2, A. R. Garan1, K. Takeda3, H. Takayama3, D. M. Mancini1, Y. Naka1, V. K. Topkara1, K. Wong1, F. Castagna1, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Epidemiology, Columbia University, New York, NY,_ 3 _Surgery, Columbia University, New York, NY_

**6:50 PM (326)** _Log Files from the HVAD: What Can Daily and Long-Term Changes in Flow Tell Us about Patients?;_ A. Potter1, S. Anderson1, J. Teuteberg2, R. Kormos2, J. Holtz2. 1 _Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA,_ 2 _Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA_

**6:55 PM (327)** _Electrical Remodeling After Continuous-Flow Left Ventricular Assist Device Implantation;_ K. Wong1, V. K. Topkara1, F. Castagna1, P. N. Trinh2, S. Sreekanth3, D. Jennings1, R. Te-Frey3, K. Takeda3, H. Takayama3, Y. Naka3, M. Maurer1, D. M. Mancini1, M. Yuzefpolskaya1, P. C. Colombo1, A. R. Garan1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Epidemiology, Columbia University, New York, NY,_ 3 _Surgery, Columbia University, New York, NY_

6:00 PM - 7:00 PM

Mini Oral 8: Technology, Physiology and Complications in MCS

**Location** :

Salon 1

Target Audience:

MCS, HTX, NHSAH

Chairs:

Bart Meyns, MD, PhD, and Michael S Kiernan, MD

**6:00 PM (328)** _Generating Pulsatility by Pump Speed Modulation with Continuous-Flow Total Artificial Heart in Awake Calves;_ K. Fukamachi1, J. H. Karimov1, G. Sunagawa1, D. J. Horvath1, N. Byram1, B. D. Kuban1, R. Dessoffy1, S. Sale2, N. Moazami3. 1 _Biomedical Engineering, Cleveland Clinic Foundation, Cleveland, OH,_ 2 _Cardiothoracic Anesthesiology, Cleveland Clinic Foundation, Cleveland, OH,_ 3 _Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH_

**6:05 PM (329)** _Impact of Left Atrial Appendage Occlusion on Thromboembolic Complications in Patients Supported by the Heartmate II Left Ventricular Assist Device;_ R. S. Lewis, M. Mangum, L. Wang, M. Puhlman, K. Evenson, J. Remick, G. Ott, J. Abraham. _Center for Advanced Heart Failure, Providence St. Vincent Medical Center, Portland, OR_

**6:10 PM (330)** _Resource Utilization and Hospital Readmission Rates Associated with Gastrointestinal Bleeding in Patients with Continuous Flow Left Ventricular Assist Devices;_ A. Carnicelli, A. Thakkar, D. Deicicchi, A. Storm, J. Connors, G. Couper, M. Mehra, J. Groarke, M. M. Givertz. _Brigham & Women's Hospital, Boston, MA_

**6:15 PM (331)** _Does Preoperative Atrial Fibrillation Increase the Incidence of Thromboembolic Complications in Patients Supported with Long-Term LVADs?;_ L. Xuereb, B. Kaur, S. Akrawe, H. W. Nemeh, J. Borgi, D. E. Lanfear, C. T. Williams, G. Paone, J. A. Morgan. _Cadiac Surgery, Henry Ford Hospital, Detroit, MI_

**(332)** _MOVED TO CONCURRENT SESSION 41_

**6:20 PM (1066)** _LVAD Outflow Cannula Systolic Slope in Patients with Left Ventricular Assist Devices: A Marker of Myocardial Contractility;_ J. Grinstein, E. Kruse, G. Sayer, G. H. Kim, N. Sarswat, N. Sarswat, S. Adatya, T. Ota, V. Jeevanandam, V. Mor-Avi, R. M. Lang, N. Uriel. _University of Chicago, Chicago, IL_

**6:25 PM (333)** _Biologically-Inspired Spiral Laminar-Flow Generation and Its Role in Cardiovascular Implantable Devices;_ P. S. Huang Zhang, J. Kresh. _Cardiothoracic Surgery, Drexel University College of Medicine, Philadelphia, PA_

**6:30 PM (334)** _Association of Body Mass Index and Thrombosis in Left Ventricular Assist Device Recipients;_ A. Keibel1, C. Abouzeid1, A. Yoon2, M. W. Fong2, H. Yousaf2, L. P. Grazette1. 1 _Medicine, Keck Hospital of USC, Los Angeles, CA,_ 2 _Cardiology, Keck Hospital of USC, Los Angeles, CA_

**6:35 PM (335)** _The Impact of Angiotensin II Type 1 Receptor Antibodies on Morbidity and Mortality of Heart Mate II Supported Patients;_ M. Urban, J. Pirk, P. Ivak, I. Netuka. _Cardiac Surgery, IKEM, Prague, Czech Republic_

**6:40 PM (336)** _Gynecological Complications in Female Patients with Left Ventricular Assist Device Support;_ E. Hisamatsu1, O. Seguchi1, N. Okada1, K. Kuroda1, H. Sunami1, S. Nakajima1, T. Sato1, H. Hata2, M. Yanase1, T. Fujita2, N. Fukushima1, J. Kobayashi2, T. Nakatani1. 1 _Department of Advanced Heart Failure and Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan,_ 2 _Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan_

**6:45 PM (337)** _Rate Responsive Pacing Improves Aerobic Exercise Capacity and 6 min Walk in CF-LVAD Patients;_ C. Guerrero-Miranda1, M. Pamirsad2, S. Madan1, A. Negassa3, O. Saeed1, J. Shin1, S. Murthy1, D. Goldstein4, D. Sims1, S. Patel1, U. Jorde1. 1 _Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY,_ 2 _Cardiothoracic Surgery, University Heart Center, Hamburg, Germany,_ 3 _Epidemiology and Population Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY,_ 4 _Cardiothoracic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY_

**6:50 PM (338)** _MELD Score Is the Most Significant Parameter Predicting Outcome in Patients Receiving Long-Term Ventricular Assist Device After Extracorporeal Life Support;_ D. Saeed, M. Abdeen, A. Albert, B. Maxhera, A. Lichtenberg. _Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany_

**6:55 PM (339)** _Evidence of Mild Hepatic Dysfunction Identifies Patients Most Likely to Experience Improvement in Renal Function Following Mechanical Circulatory Support;_ M. A. Brisco1, M. R. Zile1, W. Tang2, J. M. Testani3. 1 _Medicine-Cardiology, Med Univ of South Carolina, Charleston, SC,_ 2 _Cardiology, Cleveland Clinic Foundation, Cleveland, OH,_ 3 _Program of Applied Translational Research, Yale University School of Medicine, New Haven, CT_

6:00 PM - 7:00 PM

Mini Oral 9: Risk Factors and Lung Transplant Outcomes

**Location** :

Maryland Suite

Target Audience:

LTX, BSI, EEP, ID, NHSAH, PATH, PEDS, PHARM

Chairs:

Ramsey R Hachem, MD, and Are M Holm, MD, PhD

**6:00 PM (340)** _Association of Anti DQ Donor Specific Antibody with Antibody Mediated Rejection in Lung Transplantation;_ A. Roux1, I. Lelan Bendib1, S. Holifanjaniaina2, K. Thomas3, C. Picard1, D. Grenet1, S. De Miranda1, B. Douvry1, L. Beaumont Azuar1, E. Sage4, J. Devaquet5, C. Elise6, M. Le Guen1, C. Suberbielle Boissel7, C. Gautreau7, M. Stern1, M. Rossetti8, A. M. Hamid1, F. Parquin6. 1 _Pneumology, Adult CF Center and Lung Transplantation, Foch Hospital, Suresnes, France,_ 2 _Pathology Department, Foch Hospital, Suresnes, France,_ 3 _Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA,_ 4 _Thoracic Surgery, Foch Hospital, Suresnes, France,_ 5 _Intensive Care Medecine, Foch Hospital, Suresnes, France,_ 6 _Thoracic Intensive Care Unit, Foch Hospital, Suresnes, France,_ 7 _Laboratoire Régional d'histocompatibilité, Saint- Louis Hospital, Paris, France,_ 8 _Department of Pathology and Laboratory Medecine, UCLA, Los Angeles, CA_

**6:05 PM (341)** _Early Donor Specific Antibodies Correlate with a Distinct Peripheral Cellular Immune Phenotype after Lung Transplantation;_ A. Knoefel1, T. Nakagiri1, F. Ius1, J. Salman1, W. Sommer1, M. Avsar1, K. Jansson1, L. Pauksch1, G. Preissler2, R. Hatz2, C. Kühn1, I. Tudorache1, C. Falk3, T. Welte4, J. Gottlieb4, A. Haverich1, G. Warnecke1. 1 _HTTG, MHH, Hannover, Germany,_ 2 _Thoraxchirurgie, LMU, München, Germany,_ 3 _Institute of Transplant Immunology, MHH, Hannover, Germany,_ 4 _Pneumology, MHH, Hannover, Germany_

**6:10 PM (342)** _The Prognostic Value of Blood Eosinophilia on Survival After Restrictive CLAD Diagnosis;_ S. E. Verleden1, D. Ruttens1, E. Vandermeulen1, H. Bellon1, D. Van Raemdonck1, B. Vanaudenaerde1, G. Verleden1, C. Benden2, R. Vos1. 1 _KU Leuven, Leuven, Belgium,_ 2 _University Hospital Zurich, Zurich, Switzerland_

**6:15 PM (343)** _Outcomes in Lung Transplant Recipients with Mycobacterium Abscessus Infection;_ Y. Hamad1, J. M. Pilewski2, J. D'Cunha3, E. J. Kwak1. 1 _Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, PA,_ 2 _Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA,_ 3 _Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA_

**6:20 PM (344)** _Analysis of the Airways Virome after Lung Transplantation and Its Association with Clinical Outcomes;_ B. C. Keller1, G. Zhao2, L. Droit2, C. Desai2, S. A. Handley2, R. R. Hachem3, D. E. Byers3, H. W. Virgin2. 1 _Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH,_ 2 _Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO,_ 3 _Internal Medicine, Washington University School of Medicine, Saint Louis, MO_

**6:25 PM (345)** _Impact of Donor Positive End Expiratory Pressure on Lung Utilization Rates and Short and Long Term Outcomes;_ C. Towe1, F. Zafar2, J. Johnson1, J. S. Tweddell2, R. Bryant III2, D. L. Morales2, M. G. Schecter1. 1 _Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH,_ 2 _Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH_

**6:30 PM (346)** _Donor Derived Variables as Predictors of Prolonged Hospital Stay after Transplant Surgery among Patients with Lung Transplantation;_ A. Banga, M. Mohanka. _UT Southwestern Medical Center, Dallas, TX_

**6:35 PM (347)** _Sarcopenia of Respiratory Muscle in Lung Transplantation Patients Is Not a Poor Predictor of Early Survival;_ J. Lee, K. Nam, S. Lee, H. Jung, J. Suh, C. Lee, S. Haam, J. Hur, H. Paik. _Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of_

**6:40 PM (348)** _Risk Factors and Impact of Bronchial Stenoses after Lung Transplantation: Ten Year Single Center Experience with over 1,100 Patients;_ F. Ius1, W. Sommer1, R. Poyanmehr1, I. Tudorache1, C. Kuehn1, M. Avsar1, T. Siemeni1, J. Salman1, U. Molitoris1, M. Greer2, M. Verboom3, D. Boethig1, N. Schwerk4, T. Welte2, A. Haverich1, G. Warnecke1, J. Gottlieb2. 1 _Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany,_ 2 _Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany,_ 3 _Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany,_ 4 _Department of Paediatric Pneumology, Hannover Medical School, Hannover, Germany_

**6:45 PM (349)** _Bilateral Lung Transplantation for Idiopathic Pulmonary Arterial Hypertension: Cardiac Remodelling at One Year;_ J. Salman1, I. Tudorache1, F. Ius1, W. Sommer1, T. Siemeni1, M. Avsar1, C. Kuehn1, U. Molitoris1, C. Bara1, J. Gottlieb2, T. Welte2, A. Haverich1, G. Warnecke1. 1 _Department for Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany,_ 2 _Department of Pneumology, Hannover Medical School, Hannover, Germany_

**6:50 PM (350)** _Importance of Thoracic Shape for Postoperative Pulmonary Function in Living Donor Lobar Lung Transplantation;_ R. Miyoshi, T. F. Chen-Yoshikawa, A. Takahagi, H. Motoyama, K. Hijiya, A. Aoyama, H. Date. _Kyoto University Hospital, Kyoto, Japan_

**6:55 PM (351)** _Interleukin 12-Dependent CMV-Specific CD4+ T Cell Proliferation, T-bet Induction and Effector Function During Primary Infection Are Key Determinants for Early Immune Control in Lung Transplant Recipients;_ I. Popescu1, M. R. Pipeling1, H. Mannem1, P. D. Shah2, J. B. Orens2, J. F. McDyer1. 1 _UPMC, Pittsburgh, PA,_ 2 _Johns Hopkins University, Baltimore, MD_

6:00 PM - 7:00 PM

Mini Oral 10: Heart Transplantation and Heart Failure

**Location** :

Virginia Suite

Target Audience:

HTX, BSI, HF, LTX, NHSAH, PATH, PEDS, PHARM

Chairs:

Peter MacDonald, MD, PhD, and Jack G Copeland, MD

**(352)** WITHDRAWN

**6:00 PM (585)** _Multicenter Evaluation of a National Organ Sharing Policy for Highly Sensitized Patients Listed for Heart Transplantation in Canada;_ B. Clarke1, A. Ducharme2, N. Giannetti3, D. Kim4, M. McDonald5, O. Kiamanesh6, P. Pflugfelder7, M. Rajda8, M. Senechal9, E. Stadnick10, M. Toma6, S. Zieroth11, D. Isaac1. 1 _Libin Cardiovascular Institute/University of Calgary, Calgary, AB, Canada,_ 2 _Montreal Heart Institute/Universite de Montreal, Montreal, QC, Canada,_ 3 _McGill University Health Centre, Montreal, QC, Canada,_ 4 _University of Alberta Hospital, Edmonton, AB, Canada,_ 5 _Toronto General Hospital, University of Toronto, Toronto, ON, Canada,_ 6 _St. Pauls Hospital, University of British Columbia, Vancouver, BC, Canada,_ 7 _London Health Science Centre, University of Western Ontario, London, ON, Canada,_ 8 _QE II Health Science Centre, Dalhousie University, Halifax, NS, Canada,_ 9 _Universite Laval, Quebec, QC, Canada,_ 10 _Ottawa Heart Institute, University of Ottawa, Ottawa, ON, Canada,_ 11 _St Boniface Hospital, University of Manitoba, Winnipeg, MB, Canada_

**6:05 PM (353)** _Survival After Heart Transplant for Previously Palliated Complex Congenital Cardiac Patients;_ H. Copeland1, K. Lane2, C. Shen3, Z. Hashmi1, G. Makdisi1, T. Wozniak1, I. Wang1. 1 _Cardiothoraci Surgery Transplant, Indiana University, Indianapolis, IN,_ 2 _Biostatistics, Indiana University, Indianapolis, IN,_ 3 _Biostatistics, Indiana University School of Medicine, Indianapolis, IN_

**6:10 PM (354)** _Donor and Recipient Risk Factors for Combined Heart-Lung Transplantation;_ A. Cheng, J. R. Trivedi, V. H. Van Berkel, H. T. Massey, M. S. Slaughter. _Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY_

**6:15 PM (355)** _Combined Heart and Kidney Transplant: A 23 Year Experience;_ L. S. Czer1, M. Awad1, M. A. De Robertis1, J. Mirocha1, J. Patel1, D. H. Chang1, M. Kittleson1, J. Kobashigawa1, F. Esmailian1, S. Jordan2, A. Trento1. 1 _Heart Institute, Cedars-Sinai Med Ctr, Los Angeles, CA,_ 2 _Cedars-Sinai Med Ctr, Los Angeles, CA_

**6:20 PM (356)** _Heart-Lung Transplantation for Congenital Heart Disease: A 25 Years Single Center Experience;_ D. Bobylev1, J. Salman1, W. Sommer1, I. Tudorache1, F. Ius1, T. Siemeni1, C. Kuehn1, M. Avsar1, C. Bara1, A. Horke1, D. Boethig1, N. Schwerk2, J. Gottlieb3, A. Haverich1, G. Warnecke1. 1 _Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany,_ 2 _Pediatric Pulmonology and Neonatology, Hannover Medical School, Hannover, Germany,_ 3 _Pulmonary Medicine, Hannover Medical School, Hannover, Germany_

**6:25 PM (357)** _Heart-Lung Transplantation: A Viable Option for Systemic Sclerosis;_ L. K. Stern, R. G. Kiel, M. Janmohamed, L. Klein, T. De Marco, V. N. Selby. _Cardiology, University of California, San Francisco, San Francisco, CA_

**6:30 PM (358)** _Repeated Levosimendan Infusions in Refractory Heart Failure. Single Center Experience.;_ E. Perna, E. Ammirati, F. M. Turazza, M. Cipriani, L. D'Angelo, G. Foti, A. Garascia, F. Macera, G. Masciocco, M. Frigerio. _A. DeGasperis CardioCenter, Niguarda-Ca' Granda Hospital, Milan, Italy_

**6:35 PM (359)** _The Hemodynamic Effects of Milrinone in the Beta-Blocker Era;_ S. Kalantari Tannenbaum, J. Grinstein, B. Smith, K. Marinescu, N. Sarswat, S. Adatya, G. Sayer, G. H. Kim, T. Ota, V. Jeevanandam, N. Uriel. _Cardiology, University of Chicago, Chicago, IL_

**6:40 PM (360)** _Value of N-Terminal Pro-Brain Natriuretic Peptide in the Assessment of Aerobic Capacity in Heart Failure Patients;_ J. Huang. _Department of Heart Transplant Center, Fuwai Hospital, Peking Union Medical College, Beijing, China_

**6:45 PM (361)** _Correlation of GDF-15 with Worsening Functional Capacity and Echocardiographic Parameters in Idiopathic Dilated Cardiomyopathy;_ N. Nair1, E. Gongora2. 1 _Cardiology, S &W, Temple , TX, Texas Tech Health Scieces Center, Lubbock, TX, _2 _Cardiology, S &W, Temple , TX, Memorial Heart and Vascular Center, Hollywood, FL_

**6:50 PM (362)** _Vepoloxamer (Purified Sodium-Free Poloxamer-188) Improves LV Systolic Function in Dogs with Advanced Heart Failure and Protects Failing Cardiomyocytes from Calcium Overload;_ H. N. Sabbah1, R. C. Gupta2, M. Emanuele3. 1 _Henry Ford Hospital, Detroit, MI,_ 2 _Medicine, Henry Ford Hospital, Detroit, MI,_ 3 _Mast Therapeutics, Inc., San Diego, CA_

**6:55 PM (363)** _Impact of Health Literacy on Knowledge and Self-Care in Heart Failure Patients, Pre- and Post-Intervention;_ J. McConnery, J. MacIver, C. Alba, F. Foroutan, H. J. Ross. _Heart Failure and Transplantation, University Health Network, Toronto, ON, Canada_

6:00 PM - 7:00 PM

Mini Oral 11: Models in Transplantation: From Mouse to Rat to Pig to Human

**Location** :

Delaware Suite

Target Audience:

BSI, HTX, LTX, MCS

Chairs:

Marcelo Cypel, MD, and William E Stansfield, M.D.

**6:00 PM (364)** _Alloantibody Suppression by Bruton Tyrosine Kinase Antagonist Ibrutinib Is Associated with Splenic B-Cell Reduction: A Study of Multiparameter Flow Cytometry;_ I. Kim, G. D. Wu, N. Chai, A. S. Klein, S. Jordan. _Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA_

**6:05 PM (365)** _Assessment of Neonatal Tolerance to Blood Group A-Antigen in a Mouse Model of ABO-Incompatible Heart Transplantation;_ B. Motyka1, B. Lamarche1, K. Labonte1, S. Wang1, J. Pearcey1, K. Tao1, M. Mengel2, B. Sis2, P. J. Cowan3, L. J. West4. 1 _Dept. Pediatrics, University of Alberta, Edmonton, AB, Canada,_ 2 _Dept. Laboratory Medicine & Pathology, University of Alberta, Edmonton, AB, Canada, _3 _St Vincent's Hospital, Melbourne, Australia,_ 4 _Dept. Pediatrics, Surgery, Medical Microbiology & Immunology, University of Alberta, Edmonton, AB, Canada_

**6:10 PM (366)** _Impact of Methylprednisolone on the Development of Myocardial Edema in Hearts Donated After Circulatory Death During Ex Vivo Perfusion;_ J. K. Sandha1, C. White2, A. Müller3, E. Ambrose4, J. Thliveris5, I. Dixon4, R. Arora6, G. Tian7, L. Hryshko4, J. Nagendran2, D. H. Freed2. 1 _Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada,_ 2 _Cardiac Surgery, University of Alberta, Edmonton, AB, Canada,_ 3 _Physiology, University of Alberta, Edmonton, AB, Canada,_ 4 _Institute of Cardiovascular Sciences, St. Boniface Research Centre, Winnipeg, MB, Canada,_ 5 _University of Manitoba, Winnipeg, MB, Canada,_ 6 _Cardiac Surgery, St. Boniface Research Centre, University of Manitoba, Winnipeg, MB, Canada,_ 7 _National Research Council Institute for Biodiagnostics, Winnipeg, MB, Canada_

**6:15 PM (367)** _Cytokine Filtration Modulates Pulmonary Metabolism and Edema Formation During Ex Vivo Lung Perfusion;_ I. Iskender1, T. Cosgun1, S. Arni1, M. Trinkwitz2, S. Fehlings2, N. Cesarovic2, T. Frauenfelder2, W. Weder1, I. Inci1. 1 _Department of Thoracic Surgery, University Hospital Zurich - University of Zurich, Zurich, Switzerland,_ 2 _University Hospital Zurich - University of Zurich, Zurich, Switzerland_

**6:20 PM (368)** _Pre- and Reconditioning of DCD Donor Lungs on Ex-Vivo Lung Perfusion by Methylprednisolone;_ A. Martens1, D. E. Van Raemdonck2, B. M. Vanaudenaerde3, S. E. Verleden3, G. M. Verleden3, R. Vos3, A. P. Neyrinck1. 1 _Cardiovascular Sciences - Anesthesiology and Algology, KU Leuven, Leuven, Belgium,_ 2 _Department of Clinical and Experimental Medicine - Experimental Thoracic Surgery, KU Leuven, Leuven, Belgium,_ 3 _Department of Clinical and Experimental Medicine - Pneumology, KU Leuven, Leuven, Belgium_

**6:25 PM (369)** _Cyclosporine A Can Mitigate Mitochondrial Dysfunction in Lung Grafts during Ex Vivo Lung Perfusion: A Potent Contributor for Better Preconditioning;_ S. Haam, K. Noda, J. D'Cunha, J. D. Luketich, N. Shigemura. _Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA_

**6:30 PM (370)** _Prolonged Warm Ischemia Prevents Lung Allograft Acceptance in Lung Transplantation from Donation after Cardiac Death in the Mouse;_ Y. Hirano1, S. Sugimoto1, T. Kurosaki2, S. Otani2, K. Miyoshi1, M. Yamane1, T. Oto2, S. Miyoshi1. 1 _Department of General Thoracic Surgery, Okayama University Hospital, Okayama City, Japan,_ 2 _Organ Transplant Center, Okayama University Hospital, Okayama City, Japan_

**6:35 PM (371)** _Protective Effect of Imatinib on Ischemia-Reperfusion Injury in Rat Lung;_ S. Tanaka, T. F. Chen-Yoshikawa, T. Menju, M. Saito, A. Takahagi, E. Miyamoto, M. Takahashi, K. Ohata, T. Kondo, K. Hijiya, H. Motoyama, A. Aoyama, H. Date. _Department of Thoracic Surgery, Kyoto University, Graduate School of Medicine, Kyoto, Japan_

**6:40 PM (372)** _Lung Storage in Hydrogen-Rich Saline Attenuates Lung Ischemia-Reperfusion Injury;_ M. Takahashi, T. F. Chen-Yoshikawa, M. Saito, S. Tanaka, E. Miyamoto, A. Takahagi, K. Ohata, T. Kondo, H. Motoyama, K. Hijiya, A. Aoyama, H. Date. _Graduate School of Medicine, Kyoto University, Kyoto, Japan_

**6:45 PM (373)** _MHC-Inbred CLAWN Miniature Swine as Preclinical Large Animal Model for Lung Transplantation;_ H. Sahara, M. Sekijima, T. Iwanaga, Y. Ichinari, A. Shimizu, K. Yamada. _Division of Organ Replacement and Xenotransplantation Surgery, Center for Advanced Biomedical Science and Swine Research, Kagoshima University, Kagoshima, Japan_

**(374)** MOVED TO CONCURRENT SESSION 18

**6:50 PM (477)** _Circulating Cytokines vs. Leukocytes: A Therapeutic Target during Ex Vivo Lung Perfusion;_ K. Noda, S. Haam, D. Zaldonis, J. D'Cunha, J. D. Luketich, N. Shigemura. _Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA_

**6:55 PM (375)** _Recapitulating T Cell Development in the Immature Environment of the Neonate to Induce Transplant Tolerance;_ R. A. Bascom1, K. Tao1, L. J. West2. 1 _University of Alberta, Edmonton, AB, Canada,_ 2 _Pediatrics, Surgery, Medical Microbiology/Immunology, University of Alberta, Edmonton, AB, Canada_

6:00 PM - 7:00 PM

Mini Oral 12: Applied Health Research and Pulmonary Hypertension

**Location** :

Washington Ballroom 2

Target Audience:

NHSAH, EEP, HTX, LTX, MCS, PEDS, PH

Chairs:

Caron L Burch, MSN, and Ioana R Preston, MD

**6:00 PM (376)** _Associations Among Care Dependency, Cognition, and Self-Efficacy in Patients with Left Ventricular Assist Devices (LVADs);_ J. Casida1, H. Wu2. 1 _School of Nursing, University of Michigan, Ann Arbor, MI,_ 2 _Goldfarb School of Nursing, Barnes-Jewish College, St. Louis, MO_

**6:05 PM (377)** _Care Giver Support for Heart Transplant: Does the Type of Provider Matter?;_ E. Stimpson, A. Velleca, T. Kao, L. Kim, M. Kittleson, J. Patel, L. Czer, D. Chang, M. Hamilton, D. Ramzy, J. A. Kobashigawa. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**6:10 PM (378)** _Effects of Pre-Transplant Depression and Anxiety Symptoms on Morbidity and Mortality Post-Heart Transplant: A Retrospective Cohort Study;_ F. R. Epstein1, A. Lucero2. 1 _Heart Transplant, Kaiser Permanente Northern California, Santa Clara, CA,_ 2 _Internal Medicine, Kaiser Permanente Northern California, Santa Clara, CA_

**6:15 PM (379)** _Variability in Depressive Symptoms Among Heart Transplant Patients Across Different Countries: A Cross-Sectional Study;_ N. Duerinckx1, S. De Geest2, L. Berben2, K. Denhaerynck2, C. Russell3, R. Helmy2, J. Vanhaecke4, M. G. Crespo-Leiro5, F. Dobbels1. 1 _Departement of Public Health and Primary Care, Academic Centre for Nursing and Midwifery, Leuven, Belgium,_ 2 _Institute of Nursing Science, Basel, Switzerland,_ 3 _School of Nursing and Health Studies, Missouri, KS,_ 4 _Department of Cardiology, University Hospitals of Leuven, Leuven, Belgium,_ 5 _Advanced Heart Failure and Heart Transplant Unit, Hospital Universitario A Coruña, La Coruña, Spain_

**6:20 PM (380)** _Functional Outcomes and Quality of Life in Patients Undergoing Extracorporeal Membrane Oxygenation Pre or Post Lung Transplantation - An Observational Study;_ K. Hayes, C. L. Hodgson, V. A. Pellegrino, G. Snell, B. Tarrant, L. M. Fuller, A. E. Holland. _The Alfred Hospital, Melbourne, Australia_

**6:25 PM (381)** _Nurse Practitioners Provide Safe and Effective Care to Patients in the First Year after Cardiac Transplantation in a Combined Nurse Practitioner-Physician Clinic;_ C. M. Murks, T. RIley, J. Powers, G. Sayer, M. Reilly, B. Valentine-Bates, J. Legaretta, G. Kim, N. Sarswat, S. Adatya, N. Uriel. _Medicine, University of Chicago, Chicago, IL_

**6:30 PM (382)** _Inflammatory Cytokines and Markers of Vascular Remodeling and Angiogenesis Are Associated with Functional Capacity, Hospitalizations and NT-ProBNP Levels in Patients with Pulmonary Arterial Hypertension;_ R. A. Davey1, Y. Rao2, K. Shen2, R. L. Benza1, A. Raina1. 1 _Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA,_ 2 _United Therapeutics, Triangle Park, NC_

**6:35 PM (383)** _Elevated Diastolic Pulmonary Gradient Is Common in the Acute Respiratory Distress Syndrome but Does Not Predict Mortality;_ T. Metkus1, E. Tampakakis1, C. Mullin1, T. Kolb1, S. Mathai1, R. Damico1, V. Selby2, T. De Marco2, P. Hassoun1, R. Brower1, R. Tedford1. 1 _Johns Hopkins Hospital, Baltimore, MD,_ 2 _University of California San Francisco, San Francisco, CA_

**6:40 PM (384)** _Short-Term Venoarterial Extracorporeal Membrane Oxygenation for Endobronchial Hemorrhage after Pulmonary Endarterectomy;_ S. Guth1, C. B. Wiedenroth1, T. Kramm1, T. Risch2, M. Wollenschlaeger3, M. J. Richter4, H. A. Ghofrani4, M. Arlt2, E. Mayer1. 1 _Department of Thoracic Surgery, Kerckhoff-Clinic, Bad Nauheim, Germany,_ 2 _Department of Anesthesiology, Kerckhoff-Clinic, Bad Nauheim, Germany,_ 3 _Perfusion Service, Kerckhoff-Clinic, Bad Nauheim, Germany,_ 4 _Department of Pulmonology, Kerckhoff-Clinic, Bad Nauheim, Germany_

**6:45 PM (385)** _Searching for CTEPH; a Swedish National Follow-Up after en Episode of Acute Pulmonary Embolism;_ T. Andersson1, B. Carlberg2, F. Larsen3, S. Soderberg1. 1 _Department of Public Health and Clinical Medicine, Cardiology, Umea University, Umea, Sweden,_ 2 _Department of Public Health and Clinical Medicine, Medicine, Umea University, Umea, Sweden,_ 3 _Department of Clinical Physiology, Karolinska University Hopsital, Stockholm, Sweden_

**6:50 PM (386)** _Incremental Benefit of Echocardiographic Imaging and Cardiopulmonary Exercise Test in Prognostic Evaluation of Idiopathic Pulmonary Arterial Hypertension;_ R. Badagliacca1, S. Papa1, G. Valli1, B. Pezzuto1, R. Poscia1, G. Manzi1, E. Giannetta2, S. Sciomer1, F. Fedele1, C. D. Vizza1. 1 _Cardiovascular and Respiratory Science, Sapienza University of Rome, Rome, Italy,_ 2 _Experimental Medicine, Sapienza University of Rome, Rome, Italy_

**(387)** MOVED TO CONCURRENT SESSION 38

**6:55 PM (986)** _Impaired Right Ventricular Function after Exercise Assessed by First-Pass Radionuclide Angiography in Pulmonary Hypertension;_ P. Hsu1, Y. Wu2, M. Cheng3, Y. Lin4, J. Chen5, H. Hsu5. 1 _Nuclear Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin County, Taiwan,_ 2 _Cardiology Division of Cardiovascular Medical Center and Department of Nuclear Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan,_ 3 _Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan,_ 4 _Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan,_ 5 _Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan_
ANNUAL MEETING SCIENTIFIC PROGRAM

SATURDAY, APRIL 30, 2016

7:00 AM - 8:00 AM

Sunrise Symposium 7: Clear as Mud: Assessing the Right Ventricle

**Location** :

Thurgood Marshall

Target Audience:

MCS, ALL

Chairs:

Pascal N. Leprince, MD, PhD, and Palak Shah, MD, MS

**  
Session Summary:** This session will address the challenges of the diagnosis, pre- and post-operative management, and long-term consequences of right ventricular dysfunction after left ventricular mechanical support.

7:00 AM

How Do We Assess RV Function and Predict RV Dysfunction After LVAD?

Michael S. Kiernan, MD, Tufts Medical Center, Boston, MA, USA

7:15 AM

Q & A

7:20 AM

Peri-operative Approach to RV Dysfunction

Tobias Deuse, MD, PhD, University of California - San Francisco, San Francisco, CA, USA

7:35 AM

Q & A

7:40 AM

What If We Guess Wrong? The Approach to Chronic RV Dysfunction

Susan M Joseph, MD, Baylor University Medical Center, Dallas, TX, USA

7:55 AM

Q & A

7:00 AM - 8:00 AM

Sunrise Symposium 8: Rethinking Valvular Disease in Heart Failure

**Location** :

Maryland Suite

Target Audience:

HF, HTX, MCS, NHSAH, PEDS, PH

Chairs:

Richard Cheng, MD and Choon Pin Lim, MD

**  
Session Summary:** Valvular heart disease is emerging as a progressively more common cause of congestive heart failure. Proper timing is crucial in managing these patients. However, it is not uncommon to find patients with valvular disease and advanced heart failure that may have missed the surgical window. The question often arises "Does left or right ventricle dysfunction become so far advanced that surgery is impossible? The advent of percutaneous devices may advance the timing of mechanical intervention further with potential improvement in outcomes and delay the need of mechanical support or transplant. This session will provide guidance on how to approach these patients based on current knowledge and the future in an area that is evolving.

7:00 AM

Lost Cause: When is the Ventricle Too Poor to Fix the Aortic Valve?

Stephan M. Ensminger, MD, DPhil, Heart & Diabetes Centre NRW, Bad Oeynhausen, Germany

7:12 AM

Q & A

7:15 AM

The Forgotten Valve: Lessons to be Learned in Tricuspid Regurgitation

Ivan Knezevic, MD, University Clinical Centre, Ljubljana, Slovenia

7:27 AM

Q & A

7:30 AM

Medical / Percutaneous Treatment of Mitral Valve Disease: The Future Beckons

Sofia C Masri, MD, University of Washington, Seattle, WA, USA

7:42 AM

Q & A

7:45 AM

Mitral Intervention with Poor LVEF: Worth the Risk?

Hermann Reichenspurner, MD, PhD, University Heart Centre Hamburg, Hamburg, Germany

7:57 AM

Q & A

7:00 AM - 8:00 AM

Sunrise Symposium 9: Lung Transplant Benefit is More Than Just Survival

**Location** :

Virginia Suite

Target Audience:

LTX, ALL

Chairs:

Fabienne Dobbels, MSc, PhD, and Cynthia J. Gries, MD, MSc

**  
Session Summary:** This session will discuss how quality of life outcomes such as sense of wellbeing, functional status and relief from disability that clinicians and patient's consider fundamental, define the net benefit of lung transplantation.

7:00 AM

What is Health-Related Quality of Life Really, and Does Lung Transplant Improve It?

Christiane Kugler, RN, PhD, University Witten, Witten, Germany

7:12 AM

Neurocognitive Changes After Lung Transplantation - Are They Important?

Patrick Smith, PhD, MPH, Duke University, Durham, NC, USA

7:24 AM

Integrating Quality of Life and Survival Outcomes in Lung Transplantation

Roger D. Yusen, MD, MPH, Washington University School of Medicine, St. Louis, MO, USA

7:36 AM

How to Assess Functional Impairment and Disability Post Lung Transplant

Jonathan P Singer, MD, University of California, San Francisco, CA, USA

7:48 AM

PANEL DISCUSSION

7:00 AM - 8:00 AM

Sunrise Symposium 10: Ambulatory ECMO in Adults: We Like to Move It, Move It

**Location** :

Delaware Suite

Target Audience:

NHSAH, HF, HTX, LTX, MCS

Chairs:

Maria C Gazzaneo, MD, and Kevin C. Carney, MSN, CRNP, CCTC

**  
Session Summary:** Ambulation of patients supported on ECMO is a relatively new concept. This session will explore the risks and benefits of mobilizing adult patients supported on ECMO with a focus on the importance of the team approach.

7:00 AM

What Lessons Can We Learn From Our Children?

Christian Benden, MD, University Hospital Zurich, Zurich, Switzerland

7:12 AM

Medical Considerations in the Ambulation of ECMO patients

Enrique Diaz Guzman Zavala, MD, University of Alabama, Birmingham, AL, USA

7:24 AM

It Takes a Village: Implementing Ambulatory ECMO in the Adult Setting

Bryan Boling, RN, BSN, DNPc, University of Kentucky, Lexington, KY, USA

7:36 AM

Physiotherapy Considerations in the Ambulation of ECMO Patients

Kate Hayes, BPhysio (Hons), MPhysio (Cardio), PhD(c), The Alfred Hospital, Melbourne, Australia

7:48 AM

PANEL DISCUSSION

7:00 AM - 8:00 AM

Sunrise Symposium 11: Controversies in Pediatric Heart Failure

**Location** :

Washington Ballroom 2

Target Audience:

PEDS, HF, NHSAH, PHARM

Chairs:

Joshua D. Sparks, MD, and Thomas Moller, MD, PhD

**  
Session Summary:** Pediatric heart failure therapy is coming of age. Medication, MCS and SCD prevention will be discussed. The new heart failure registry's importance in informing treatment decisions in the future will be considered.

7:00 AM

Pharmaceutical Options - Are The New Ones Any Better?

Robert E. Shaddy, MD, The Children's Hospital, Philadelphia, PA, USA

7:12 AM

Q & A

7:15 AM

Who Dies Suddenly And Can We Prevent It?

Robert G. Weintraub, FRACP, FACC, Royal Children's Hospital, Melbourne, Australia

7:27 AM

Q & A

7:30 AM

Making Palliative Care Part of the Plan

Elizabeth Blume, MD, Children's Hospital, Boston, MA, USA

7:42 AM

Q & A

7:45 AM

Will the New ISHLT Pediatric Heart Failure Registry (iPHFR) Save Lives or Just Create More Work?

Anne I. Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada

7:57 AM

Q & A

7:00 AM - 8:00 AM

Sunrise Symposium 12: Precision Medicine in Transplantation: Drug Levels and Beyond

**Location** :

Washington Ballroom 1

Target Audience:

ALL

Chairs:

Mandeep R. Mehra, MD, MBBS, FACC, FACP, and Patricia Ging, PharmD

**  
Session Summary:** The goal of this session is to examine the role of precision medicine in transplantation. From understanding whether pharmacogenetics can both guide dosing of immunosuppressants and predict adverse effects to how in the modern era we have medications that alter gene expression.

7:00 AM

Pharmacogenetics: Is It Ready for Prime Time?

Tam Khuu, PharmD, UCLA, Los Angeles, CA, USA

7:15 AM

Q & A

7:20 AM

Genetic Predictors of Medication-Induced Adverse Effects

Christina Aquilante, PharmD, University of Colorado, Aurora, CO, USA

7:35 AM

Q & A

7:40 AM

Therapeutic Gene Modulation - What Can We Learn From CF?

Denis Hadjiliadis, MD, University of Pennsylvania, Philadelphia, PA, USA

7:55 AM

Q & A

8:00 AM - 9:30 AM

Concurrent Session 41: You Get Out What You Put In: Assessing Risk in Mechanical Support

**Location** :

Thurgood Marshall

Target Audience:

MCS, HTX, NHSAH

Chairs:

Cumara C Sivathasan, MBBS, FRCS, and Jennifer A Cowger, MD, MS

**8:00 AM (388)** _Destination Therapy in a Single European Country. Insights from the ITAMACS Registry;_ G. Feltrin1, F. Pappalardo2, G. Gerosa3, C. F. Russo4, M. Rinaldi5, M. Maccherini6, A. Apostolo7, G. Faggian8, U. Livi9, A. Iacovoni10, M. Massetti11, F. Musumeci12, G. Di Giammarco13, G. Ambrosio14, A. Loforte15, D. Pini16, C. Falletta17, C. Amarelli18, A. Grimaldi19, F. M. Pagani20, G. leonardi21, A. Frigo22, L. Rizzato23, A. Nanni Costa24. 1 _Veneto Regional Centre for Transplant Coordination, Padova, Italy,_ 2 _Cardioth. Dept, San Raffaele Hospital, Vita Salute Univ, Milan, Italy,_ 3 _Cardiac, Thoracic, Vascular Sciences, Univ Hospital of Padova, Padova, Italy,_ 4 _Dept of Cardiovascular Surgery, A. De Gasperis Cardio Center Niguarda Hospital, Milan, Italy,_ 5 _Surgical Sciences, Univ of Turin, Turin, Italy,_ 6 _Cardiothoracic Dept, Le Scotte Hospital, Siena, Italy,_ 7 _Centro Cardiologico Fondazione Monzino IRCCS, Milan, Italy,_ 8 _Cardiac Surgery Unit, Univ Hospital of Verona, Verona, Italy,_ 9 _Cardiothoracic Department, Univ Hospital of Udine, Udine, Italy,_ 10 _Cardiovascular Dept, Hospital Papa Giovanni XXIII, Bergamo, Italy,_ 11 _Cardiac Surgery Unit, Sacro Cuore Univ, Rome, Italy,_ 12 _Dept of Cardiac Surgery, San Camillo Forlanini Hospital, Rome, Italy,_ 13 _Dept of Neurosciences Imaging and Clinical Sciences, Univ of Chieti, Chieti, Italy,_ 14 _Cardioth. Dept, Univ Hospital of Perugia, Perugia, Italy,_ 15 _Dept of Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna, Italy,_ 16 _Dept of Cardiology, Humanitas Research Hospital, Milan, Italy,_ 17 _Dept for Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, IRCCS ISMETT, Palermo, Italy,_ 18 _Dept of Cardiovascular Surgery and Transplantation, Monaldi Hospital, Naples, Italy,_ 19 _Cardiac Surgery, Univ of Bari, Bari, Italy,_ 20 _Dept of Cardiac Surgery, IRCCS Foundation Policlinico San Matteo, Pavia, Italy,_ 21 _Univ Hospital "V- Emanuele", Catania, Italy,_ 22 _Cardiac, Thoracic, Vascular Sciences, Univ of Padova, Padova, Italy,_ 23 _Veneto Region, National Centre for Transplant Coordination, Rome, Italy,_ 24 _National Centre for Transplant Coordination, Rome, Italy_

**(389)** WITHDRAWN

**8:15 AM (332)** _Mechanical Circulatory Support for the Fontan Circulation;_ L. C. Reardon1, H. Laks2, R. Biniwale2, A. Hageman3, R. Bolanos3, K. Delacruz3, A. Salimbangon3, K. Wetzlar4, G. Derk3, J. Aboulhosn5. 1 _Departments of Adult and Pediatric Cardiology, UCLA, Los Angeles, CA,_ 2 _Department of Cardiothoracic Surgery, UCLA, Los Angeles, CA,_ 3 _UCLA, Los Angeles, CA,_ 4 _Department of Mechanical Engineering, UCLA, Los Angeles, CA,_ 5 _Department of Cardiology, UCLA, Los Angeles, CA_

**8:30 AM (390)** _Permanent Atrial Fibrillation and 1-Year Clinical Outcome in Patients with Left Ventricular Assist Device Implants;_ C. U. Oezpeker, M. Morshuis, M. Schoenbrodt, A. Zittermann, J. Gummert. _Cardiac Surgery, HDZ-NRW, Bad Oeynhausen, Germany_

**8:45 AM (391)** _Differential Assessment of von Willebrand Factor Dysfunction in Durable Mechanical Circulatory Support: A Plead for Standardization;_ S. Maltais1, D. Gailani2, M. E. Davis2, A. Matafonov2, N. A. Haglund2. 1 _Mayo Clinic, Rochester, MN,_ 2 _Vanderbilt, Nashville, TN_

**9:00 AM (392)** _Relationship of Factor II and Factor X Activity with International Normalized Ratio (INR) in Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Patients: A Cross-Sectional Study;_ V. K. Topkara1, A. B. Eisenberger1, D. Jennings1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, V. Ton1, F. Castagna1, A. M. Clemons1, M. Flannery2, R. Te-Frey2, A. L. Uryevick2, M. Maurer1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Surgery, Columbia University, New York, NY_

**9:15 AM (393)** _Multi-Institutional Analysis of Temporal Patterns and Nature of Neurological Events after Left Ventricular Assist Device Implant;_ J. M. Stulak1, S. Dunlay1, S. Sharma1, N. Haglund2, F. D. Pagani3, K. Aaronson3, P. Shah4, J. Cowger5, S. Maltais1. 1 _Cardiovascular Surgery, Mayo Clinic, Rochester, MN,_ 2 _Cardiovascular Surgery, Vanderbilt Heart, Nashville, TN,_ 3 _Cardiovascular Surgery, University of Michigan, Ann Arbor, MI,_ 4 _Cardiovascular Surgery, Inova Fairfax, Falls Church, VA,_ 5 _Cardiovascular Surgery, St. Vincent's Hospital, Indianapolis, IN_

8:00 AM - 9:30 AM

Concurrent Session 42: Difficult Decisions in Mechanical Support

**Location** :

Maryland Suite

Target Audience:

MCS, HTX, NHSAH

Chairs:

Alejandro M Bertolotti, MD, and Jerry D Estep, MD

**8:00 AM (394)** _Utilization and Outcomes of Ventricular Assist Device Support in Adult Congenital Heart Disease: An Analysis of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS);_ C. J. VanderPluym1, P. Eghtesady2, B. G. Maxwell3, J. M. Gelow4, L. J. Burchill5, S. Maltais6, R. S. Cantor7, E. D. Blume1. 1 _Cardiology, Boston Children's Hospital, Boston, MA,_ 2 _Surgery - Cardiothoracic, Washington University School of Medicine, St. Louis, MO,_ 3 _Anesthesiology, Randall Children's Hospital, Portland, OR,_ 4 _Knight Cardiovascular Institute, Oregon Health and Science University, Portland, OR,_ 5 _Cardiology, Knight Cardiovascular Institute at Oregon Health Science University, Portland, OR,_ 6 _Division of Cardiovascular Surgery, Department of Surgery, Mayo Clinic, Rochester, MN,_ 7 _Department of Surgery, The University of Alabama at Birmingham, Birmingham, AL_

**8:15 AM (395)** _ECMO with Multiple-Organ Failure: Can Liver Dialysis Improve Survival?;_ B. Sparks, H. Hirose, N. Cavarocchi. _Department of Surgery, Thomas Jefferson University, Philadelphia, PA_

**8:30 AM (396)** _Characteristics and In-Hospital Outcomes of Adults Undergoing Extracorporeal Membrane Oxygenation;_ C. K. McIlvennan, D. P. Kao. _University of Colorado, Aurora, CO_

**8:45 AM (397)** _Outcomes of Continuous-Flow Left Ventricular Assist Device Insertion for Acute Myocardial Infarction and Cardiogenic Shock: Importance of Bridging Strategy;_ H. Ikegami1, K. Takeda1, H. Takayama1, A. R. Garan2, V. K. Topkara2, S. Fukuhara1, P. Kurlansky1, M. Yuzefpolskaya2, P. C. Colombo2, Y. Naka1. 1 _Department of Surgery, Division of Cardiothoracic Surgery, Columbia University, New York, NY,_ 2 _Department of Medicine, Division of Cardiology, Columbia University, New York, NY_

**9:00 AM (398)** _Equivalent Mortality but Higher Morbidity in Patients Receiving Temporary Mechanical Support Prior to Permanent LVAD Implantation;_ L. E. Johnston1, G. Ailawadi1, E. A. Downs1, J. B. Rich2, A. M. Speir3, M. A. Quader4, J. L. Kennedy5, L. T. Yarboro1, J. A. Kern1, S. Mazimba5. 1 _Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, VA,_ 2 _Sentara Heart Hospital, Norfolk, VA,_ 3 _Inova Heart and Vascular Center, Falls Church, VA,_ 4 _Virginia Commonwealth University, Richmond, VA,_ 5 _University of Virginia, Charlottesville, VA_

**9:15 AM (399)** _Outcome of Patients Treated with Left Ventricular Assist Device (LVAD) as Bridge to Transplantation (BTT) or Bridge to Candidacy (BTC) vs. Marginal Heart Transplantation;_ A. Loforte1, A. Montalto2, G. Jafrancesco1, M. Cefarelli1, P. Lilla Della Monica2, F. Grigioni3, M. Masetti3, L. Potena3, F. Sbaraglia2, V. Polizzi2, G. Marinelli1, F. Musumeci2. 1 _Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy,_ 2 _Cardiac Surgery and Transplantation, S. Camillo Hospital, Rome, Italy,_ 3 _Cardiology and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy_

8:00 AM - 9:30 AM

Concurrent Session 43: Paying the Tolls: Effects of Bridge to Transplant

**Location** :

Virginia Suite

Target Audience:

HTX, EEP, ID, MCS, NHSAH, PEDS, PHARM

Chairs:

Finn Gustafsson, MD, PhD, and Jan F Gummert, MD, PhD

**8:00 AM (400)** _LVAD BTT Risk Score Predicts 1-Year Mortality in Patients Bridged to Transplant with a CF-Left Ventricular Assist Device (LVAD);_ G. Ashrith, D. T. Nguyen, J. Amione-Guerra, B. H. Trachtenberg, A. Bhimaraj, B. Bruckner, E. E. Suarez, A. Gaber, E. A. Graviss, M. H. Park, J. D. Estep. _Cardiology, Houston Methodist Hospital, Houston, TX_

**8:15 AM (401)** _Impact of Mechanical Circulatory Support Before Cardiac Transplantation on Early and Late Rejection, Allograft Vasculopathy and Survival: Analysis of the ISHLT Adult Heart Transplant Registry;_ S. K. Bhagra1, J. Duero Posada1, C. Manlhiot2, J. Murray2, A. Dipchand3, J. Stehlik4, H. Ross1. 1 _Cardiology, Toronto General Hospital, Toronto, ON, Canada,_ 2 _Cardiovascular Data Management Center, The Hospital for Sick Children, Toronto, ON, Canada,_ 3 _Cardiology, The Hospital for Sick Children, Toronto, ON, Canada,_ 4 _Cardiology, University of Utah, Salt Lake City, UT_

**8:30 AM (402)** _Continuous Flow Left Ventricular Assist Device as a Risk Factor for Intraoperative Vasoplegia during Orthotopic Heart Transplantation;_ L. Truby, K. Takeda, M. Farr, M. Lippel, M. Yuzefpolskaya, P. Colombo, H. Takayama, D. Mancini, Y. Naka. _Columbia University College of Physicians and Surgeons, New York, NY_

**8:45 AM (403)** _Obesity and Wait-List Outcomes in Patients with Continuous Flow Left Ventricular Assist Devices as Bridge to Transplantation;_ S. G. Al-Kindi1, M. Kattea1, M. Farhoud1, M. Ginwalla1, C. ElAmm2, M. Zacharias2, R. Benatti2, B. Sareyyupoglu1, S. Park2, B. Medalion1, S. Deo1, G. H. Oliveira1. 1 _University Hospitals Case Medical Center, Cleveland, OH,_ 2 _Harrington Heart and Vascular Institute, University Hospitals Case Medical Center, Cleveland, OH_

**9:00 AM (404)** _Does Left Ventricular Assist Device Mechanics Impact Pre Cardiac Transplant Allosensitization and Post-Transplant Survival?;_ S. Allana, J. Liou, E. Jacobs, T. Ellis, P. Rahko, S. Akhter, R. Dhingra. _University of Wisconsin-Madison, Madison, WI_

**9:15 AM (405)** _Outcome of Patients Having Multiple Mechanical Circulatory Support Devices before Orthotopic Heart Transplantation;_ B. Li1, K. Takeda1, P. A. Kurlansky1, S. Fukuhara1, M. Wright1, S. Sreekanth1, J. Han1, C. Chiuzan2, L. K. Truby3, A. R. Garan3, V. Topkara3, M. Yuzefpolskaya3, P. C. Colombo3, M. A. Farr3, H. Takayama1, Y. Naka1. 1 _Surgery, Columbia University Medical Center, New York, NY,_ 2 _Biostatistics, Columbia University Medical Center, New York, NY,_ 3 _Medicine, Columbia University Medical Center, New York, NY_

8:00 AM - 9:30 AM

Concurrent Session 44: Lung Transplantation - Advanced Diagnostics!

**Location** :

Delaware Suite

Target Audience:

LTX, BSI, NHSAH, PATH, PEDS, PHARM

Chairs:

Allan R Glanville, MBBS, MD, FRACP, and Arne Neyrinck, MD, PhD

**8:00 AM (406)** _Microarray Analysis of Endobronchial Lung Transplant Biopsies: Detection of T-cell Mediated Inflammation in a Safer Biopsy;_ K. Halloran1, J. Chang1, V. Ramassar2, J. Weinkauf1, A. Kapasi1, A. Hirji1, D. Lien1, J. Reeve2, P. Halloran2. 1 _Medicine, University of Alberta, Edmonton, AB, Canada,_ 2 _Alberta Transplant Applied Genomics Center, University of Alberta, Edmonton, AB, Canada_

**8:15 AM (407)** _Mitochondria Release Leads from Human Lung Transplant Recipients Promotes Primary Graft Dysfunction;_ D. Scozzi1, X. Lin1, X. Wang1, M. Ibrahim1, M. Zhu1, A. Krupnick1, D. Kreisel1, M. Miller2, A. Gelman1. 1 _Surgery, Washington University, St. Louis, MO,_ 2 _Pathology and Immunology, Washington University, St. Louis, MO_

**8:30 AM (408)** _Endothelial-Bound TLR-Dependent CX3CR1+CCR2-Ly6Clow Monocytes in Donor Lungs Mediate Primary Graft Dysfunction Following Murine Lung Transplantation;_ S. Chiu1, Z. Zheng2, H. Sun1, M. M. DeCamp1, D. Kreisel3, G. S. Budinger4, H. Perlman5, A. Misharin4, A. Bharat1. 1 _Thoracic Surgery, Northwestern University, Chicago, IL,_ 2 _Transplant Surgery, Northwestern University, Chicago, IL,_ 3 _Thoracic Surgery, Washington University, St. Louis, MO,_ 4 _Pulmonary and Critical Care Medicine, Northwestern University, Chicago, IL,_ 5 _Rheumatology, Northwestern University, Chicago, IL_

**8:45 AM (409)** _Normothermic Donor Lung Preservation with Portable EVLP Maintains IL-33-Driven Epithelial Integrity and Suppresses Inflammation in the Recipient;_ B. Wiegmann1, C. Falk2, M. Seyda3, C. Neudörfl2, C. Kühn1, I. Tudorache1, M. Avsar1, A. Haverich1, G. Warnecke1. 1 _Dpt. for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany,_ 2 _Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany,_ 3 _Division of Transplant Surgery, Harvard Medical School, Boston, MA_

**9:00 AM (410)** _Long Pentraxin3 Deficiency Enhance Chronic Lung Allograft Dysfunction in a Mouse Orthotopic Lung Transplantation Model;_ M. Yoshida1, H. Oishi1, T. Martinu1, D. Hwang1, T. McKee2, X. Bai1, Z. Guan1, H. Cho1, S. Juvet1, M. Cypel1, S. Keshavjee1, M. Liu1. 1 _Surgery, Latner Thoracic Surgery Laboratories, Division of Thoracic Surgery, Toronto, ON, Canada,_ 2 _Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada_

**9:15 AM (411)** _Biological Effects of Mesenchymal Stem Cell (MSC) Therapy in Patients with Chronic Lung Allograft Dysfunction (CLAD);_ A. Z. Zubair1, A. L. Russell1, R. C. Lefavor1, C. M. Desmond1, C. A. Keller2. 1 _Laboratory Medicine and Pathology, Mayo Clinic Transplant Center, Jacksonville, FL,_ 2 _Transplant, Mayo Clinic, Jacksonville, FL_

8:00 AM - 9:30 AM

Concurrent Session 45: Pediatric Heart Failure

**Location** :

Washington Ballroom 2

Target Audience:

PEDS, HF, HTX

Chairs:

Yuk M Law, MD, and Heather T Henderson, MD

**8:00 AM (412)** _Risk Factors at Presentation Predict Outcomes of Pediatric Myocarditis: A Contemporary Multi-Center Cohort;_ S. C. West1, G. J. Boyle2, R. J. Butts3, S. R. Deshpande4, K. Gambetta5, K. R. Knecht6, A. K. Lal7, Y. Law8, A. C. Prada-Ruiz9, M. Richmond10. 1 _Pediatric Cardiology, Children's Hosp of Pittsburgh, Pittsburgh, PA,_ 2 _Cleveland Clinic Children's Hosp, Cleveland, OH,_ 3 _Pediatrics, Medical Univ of South Carolina, Charleston, SC,_ 4 _Pediatric Cardiology, Children's Healthcare, Emory Univ, Atlanta, GA,_ 5 _Ann & Robert H. Lurie Children's Hosp, Chicago, IL, _6 _Univ of Arkansas for Medical Sciences, Little Rock, AR,_ 7 _Pediatric Cardiology, Primary Children's Hosp, Univ of Utah, Salt Lake City, UT,_ 8 _Seattle Children's Hosp, Seattle, WA,_ 9 _Cleveland Clinic Children's Hosp, Cleveland, OH,_ 10 _Morgan Stanley Children's Hosp of Columbia Univ, New York City, NY_

**8:15 AM (413)** _A Prospective Randomised Open-Label Clinical Trial of Rapid versus Prolonged Captopril Initiation and Up-Titration in Paediatric Cardiology Inpatients;_ S. L. Roche1, K. Timberlake2, C. Manlhoit3, M. Balasingam4, J. Wilson4, K. George4, B. W. McCrindle4, P. F. Kantor5. 1 _Adult Congenital Heart Disease, Univ of Toronto, Toronto, ON, Canada,_ 2 _Pharmacy, Hosp for Sick Children, Toronto, ON, Canada,_ 3 _Cardiology, Univ of Toronto, Toronto, ON, Canada,_ 4 _The Labatt Family Heart Center, Hosp for Sick Children, Toronto, ON, Canada,_ 5 _Paediatric Cardiology, Stollery Children's Hosp, Edmonton, AB, Canada_

**8:30 AM (414)** _Utilization and Safety of Long-Term Carvedilol in Pediatric Dilated Cardiomyopathy: A Multicenter Study from the Pediatric Cardiomyopathy Registry;_ J. W. Rossano1, C. E. Canter2, D. T. Hsu3, E. Pahl4, D. Dodd5, S. A. Webber5, J. A. Towbin6, S. D. Colan7, P. F. Cantor8, L. J. Addonizio9, J. L. Jefferies10, M. D. Everitt11, S. M. Ware12, T. Lee13, A. Lal14, J. Messere7, J. D. Wilkinson15, S. E. Lipshultz15. 1 _Cardiology, Children's Hosp of Philadelphia, Philadelphia, PA,_ 2 _Cardiology, Washington Univ, St. Louis, MO,_ 3 _Cardiology, Children's Hosp at Montefiore, New York, NY,_ 4 _Ann and Robert H. Lurie Children's Hosp of Chicago, Chicago, IL,_ 5 _Cardiology, Vanderbilt Univ, Nashville, TN,_ 6 _Cardiology, St. Jude Children's Research Hosp and Le Bonheur Children's Hosp, Memphis, TN,_ 7 _Cardiology, Boston Children's Hosp, Boston, MA,_ 8 _Cardiology, Stollery Children's Hosp, Edmonton, AB, Canada,_ 9 _Cardiology, Columbia Univ Medical Center, New York, NY,_ 10 _Cardiology, Cincinnati Children's Hosp Medical Center, Cincinnati, OH,_ 11 _Cardiology, Children's Hosp of Colorado, Denver, CO,_ 12 _Indiana Univ School of Med, Indianapolis, IN,_ 13 _Columbia Univ Mec Center, New York, NY,_ 14 _Cardiology, Primary Children's Hosp, Salt Lake City, UT,_ 15 _Wayne State Univ School of Med, Detroit, MI_

**8:45 AM (415)** _Outpatient Subcutaneous Treprostinil for Pediatric Single Ventricle Patients;_ S. L. Siehr, M. Ogawa, A. Romfh, D. N. Rosenthal, J. A. Feinstein. _Pediatric Cardiology, Stanford University Lucile Packard Children's Hospital, Palo Alto, CA_

**9:00 AM (416)** _Readmission Following Acute Myocarditis in Pediatric Patients;_ K. R. Knecht1, G. Boyle2, R. Butts3, S. R. Deshpande4, K. Gambetta5, A. K. Lal6, M. Richmond7, S. C. West8, C. Prada-Ruiz2. 1 _Univ of Arkansas for Med Sciences, Little Rock, AR,_ 2 _Cleveland Clinic Children's Hosp, Cleveland, OH,_ 3 _Med Univ of South Carolina, Charleston, SC,_ 4 _Emory Univ, Atlanta, GA,_ 5 _Children's Hosp of Chicago, Chicago, IL,_ 6 _Primary Children's Hosp, Salt Lake City, UT,_ 7 _Columbia Univ, New York, NY,_ 8 _Children's Hosp, Pittsburg, PA_

**9:15 AM (417)** _Variability in Resource Utilization and Outcomes in Cardiomyopathy and Heart Failure Related Hospitalizations among Pediatric Hospitals in the United States: Potential Role for a Collaborative Learning Network;_ P. Shamszad1, C. S. Almond2, K. P. Daly3, A. Lorts4, J. F. Price5, D. N. Rosenthal2, J. W. Rossano1. 1 _Children's Hosp of Phildelphia, Philadelphia, PA,_ 2 _Lucile Packard Children's Hosp, Palo Alto, CA,_ 3 _Boston Children's Hosp, Boston, MA,_ 4 _Cincinnati Children's Hosp Medical Center, Cincinnati, OH,_ 5 _Texas Children's Hosp, Houston, TX_

8:00 AM - 9:30 AM

Concurrent Session 46: From 'Jeans' to Proteins: Mechanisms of Ischemia Reperfusion Injury and Translation to Advanced Diagnostics

**Location** :

Washington Ballroom 1

Target Audience:

BSI, HF, HTX, LBCS, LTX, MCS

Chairs:

Edward Cantu, MD, and Joshua Diamond, MD

**8:00 AM (418)** _Regulated Necrotic Cell Death Mediated by Calpain and RIPK Is Induced by Prolonged Hypothermic Ischemia Followed by Normothermic Reperfusion;_ H. Kim, S. Keshavjee, M. Liu. _Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada_

**8:15 AM (419)** _The Donor Heart after Withdrawal of Life Support;_ M. J. Kearns, A. Cheung, J. Bashir, M. A. Seidman, J. H. Boyd. _UBC Centre for Heart & Lung Innovation, Vancouver, BC, Canada_

**8:30 AM (420)** _Cold Storage Stabilization of Gap Junctions Reduces Post Transplant Ischemia Reperfusion Injury;_ R. Finnegan1, P. Zhu1, S. Stephenson1, S. Nadig2, C. Atkinson3. 1 _Departments of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC,_ 2 _Departments of Surgery, Medical University of South Carolina, Charleston, SC,_ 3 _Departments of Microbiology and Immunology, and Surgery, Medical University of South Carolina, Charleston, SC_

**8:45 AM (421)** _Reproducibility of Genomic Data Using Standards-Cell Free DNA to Monitor Rejection after Heart Transplantation;_ S. Agbor-Enoh1, I. Tunc1, J. Doveikis1, K. Khush2, I. De Vlaminck3, A. Davis1, X. Wang1, M. A. Solomon1, J. Zhu1, H. A. Valantine1. 1 _Nat'l Inst. of Health, Bethesda, MD,_ 2 _Stanford University School of Medicine, Palo Alto, CA,_ 3 _Cornell University, Ithaca, NY_

**9:00 AM (422)** _Genomic Research Alliance for Transplantation (GRAfT): A Model for Long Term Transplant Studies in Thoracic Organ Transplantation;_ S. Agbor-Enoh1, U. Fideli1, J. Doveikis1, J. Zhu1, I. Tunc1, P. Shah2, S. Russell3, E. Feller4, K. Shah5, M. Rodrigo6, P. Shah7, S. Pham8, A. Iacono9, S. Nathan10, J. Orens11, N. GRAfT Investigators1, H. Valantine1. 1 _Nat'l Inst. of Health, Bethesda, MD,_ 2 _Johns Hopkins Hospital, Baltimore, MD,_ 3 _Cardiology, Johns Hopkins Hospital, Baltimore, MD,_ 4 _Cadiology, University of Maryland Medical Center, Baltimore, MD,_ 5 _Cardiology, Virginia Commonwealth University, Richmond, VA,_ 6 _Cardiology, Medstar Washington Hospital Center, Washington, DC,_ 7 _Cardiology, INOVA Fairfax Hospital, Fairfax, VA,_ 8 _Cadiothoracic Surgery, University of Maryland Medical Center, Baltimore, MD,_ 9 _Pulmonary and Critical Care Medicine, University of Maryland Medical Center, Baltimore, MD,_ 10 _Pulmonary and Critical Care Medicine, INOVA Fairfax Hospital, Fairfax, VA,_ 11 _Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD_

**9:15 AM (423)** _The Epigenomic Landscape of Dilated Cardiomyopathy;_ S. Lin1, Y. Lin2, J. D. Lee3, P. Chang3, M. Shi3, E. DePasquale1, A. Nsair1, M. Deng1, P. E. Oyer3, T. Quertermous3, M. P. Snyder3. 1 _UCLA, Los Angeles, CA,_ 2 _Washington University, St. Louis, MO,_ 3 _Stanford, Stanford, CA_

9:45 AM - 11:45 AM

Plenary Session - Pushing New Scientific Frontiers: It's In Our Heritage

**Location** :

Thurgood Marshall

Target Audience:

ALL

Chairs:

Jeffrey J. Teuteberg, MD, and Maryl R. Johnson, MD

9:45 AM

AWARDS PRESENTATIONS

10:05 AM

Lifetime Achievement Award to Adrian and Jean Kantrowitz

Robert L. Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

10:15 AM

The Influence of the Microbiota in Immunity and Transplantation

Jonathan S Bromberg, MD, PhD, University of Maryland School of Medicine, Baltimore, MD, USA

10:40 AM

**(424) FEATURED ABSTRACT:** PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management (PREVENT) _;_ S. Maltais1, A. Kilic2, S. Nathan3, M. Keebler4, S. Emani5, J. Ransom6, J. N. Katz7, B. Sheridan8, A. Brieke9, G. Egnaczyk10, J. W. Entwistle11, R. Adamson12, J. Stulak1, N. Uriel13, J. B. O'Connell14, D. J. Farrar14, K. S. Sundareswaran14, I. Gregoric3. 1 _Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN,_ 2 _Division of Cardiac Surgery, Ohio State University Medical Center, Columbus, OH,_ 3 _Memorial Hermann-Texas Medical Center, Houston, TX,_ 4 _Vanderbilt Heart and Vascular Institute, Vanderbilt University, Nashville, TN,_ 5 _Division of Cardiovascular Medicine, Ohio State University Medical Center, Columbus, OH,_ 6 _Baptist Health Heart and Transplant Institute, Little Rock, AR,_ 7 _Heart and Vascular Center, University of North Carolina, Chapel Hill, NC,_ 8 _Division of Cardiothoracic Surgery, University of North Carolina, Chapel Hill, NC,_ 9 _University of Colorado School of Medicine, Denver, CO,_ 10 _Christ Hospital, Cincinnati, OH,_ 11 _Thomas Jefferson University, Philadelphia, PA,_ 12 _Sharp Memorial Hospital, San Diego, CA,_ 13 _University of Chicago Medical Center, Chicago, IL,_ 14 _St.Jude Medical, Pleasanton, CA_

10:50 AM

Expert Discussant Q & A

Jan D Schmitto, MD, PhD, MBA, Hannover Medical School, Hannover, Germany

10:55 AM

Precision Medicine in Organ Transplantation: Moving from Off the Rack to Bespoke

Alexandre Loupy, MD, PhD, Necker Hospital, Paris, France

11:15 AM

PRESIDENT'S DEBATE: This House Believes That Regulatory Monitoring Adversely Affects Patient Outcomes (PRO)

Mandeep R. Mehra, MD, MBBS, FACC, FACP, Brigham & Women's Hospital, Boston, MA, USA

11:30 AM

PRESIDENT'S DEBATE: This House Believes That Regulatory Monitoring Adversely Affects Patient Outcomes (CON)

Joseph G Rogers, MD, Duke University Medical Center, Durham, NC, USA

12:00 PM - 1:30 PM

Concurrent Session 47: Medicines or Machines? The Failing Right Ventricle in MCS

**Location** :

Thurgood Marshall

Target Audience:

MCS, HF, NHSAH, PH)

Chairs:

J. Eduardo Rame, MD, and Evgenij V Potapov, MD, PhD

**12:00 PM (425)** _The Worldwide Experience of SynCardia Total Artificial Heart in Patients with Congenital Heart Disease;_ D. L. Morales1, R. Rizwan1, F. Zafar1, C. Villa2, J. L. Jefferies2, R. Bryant 3rd1, F. A. Arabia3, A. Lorts2. 1 _Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH,_ 2 _Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH,_ 3 _Cardiothoracic Surgery, Cedars-Sinai Medical Center, Los Angeles, CA_

**(426)** WITHDRAWN

**12:15 PM (323)** _Association of Late Aortic and Tricuspid Valve Regurgitation and Outcomes While on Left Ventricular Assist Device Therapy;_ J. M. Stulak1, V. Tchantchaleishvili2, S. Dunlay3, S. Sharma1, L. D. Joyce1, D. L. Joyce1, R. C. Daly1, S. Maltais1. 1 _Cardiovascular Surgery, Mayo Clinic, Rochester, MN,_ 2 _Cardiovascular Surgery, University of Rochester, Rochester, NY,_ 3 _Cardiovascular Diseases, Mayo Clinic, Rochester, MN_

**12:30 PM (427)** _Totally Percutaneous RVAD/ECMO Configuration Provides Versatile Support for RV Failure;_ A. Siddique1, J. E. Baus2, H. Merritt1, E. L. O'Leary3, T. R. Ryan1, N. T. McCain1, E. R. Lyden4, J. Y. Um1, M. J. Moulton1. 1 _Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE,_ 2 _Anesthesia, University of Nebraska Medical Center, Omaha, NE,_ 3 _Internal medicine, University of Nebraska Medical Center, Omaha, NE,_ 4 _Biostatistics, University of Nebraska Medical Center, Omaha, NE_

**12:45 PM (428)** _Mitral Regurgitation Is Associated with Right Ventricular Pulsatile Loading and Early Right Heart Failure After Left Ventricular Assist Device;_ E. W. Grandin1, A. A. Gulati2, G. S. Troutman1, P. Zamani1, J. A. Mazurek1, E. Y. Birati1, J. W. Wald1, K. B. Margulies1, P. Atluri3, J. E. Rame1. 1 _Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA,_ 2 _University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA,_ 3 _Division of Cardiothoracic Surgery, University of Pennsylvania, Philadelphia, PA_

**1:00 PM (429)** _Elevated Transpulmonary Gradient Is a Predictor of Survival in Patients with WHO Group II Pulmonary Hypertension Treated with Continuous-Flow Left Ventricular Assist Devices (CF-LVAD);_ J. Amione-Guerra, A. M. Cordero-Reyes, A. Bhimaraj, B. H. Trachtenberg, G. Torre-Amione, M. H. Park, J. D. Estep, G. Ashrith. _Methodist Debakey Heart Center, Houston Methodist Hospital, Houston, TX_

**1:15 PM (430)** _Pulmonary Hypertension Results in Worse Post-Transplant Survival in Left Ventricular Assist Device Patients;_ E. M. Schumer, M. C. Black, J. R. Trivedi, A. Cheng, H. T. Massey, M. S. Slaughter. _Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY_

12:00 PM - 1:30 PM

Concurrent Session 48: Not Just to Survive, But to Thrive: Comprehensive Care of the MCS Patient

**Location** :

Maryland Suite

Target Audience:

MCS, HTX, NHSAH)

Chairs:

Annemarie Kaan, MCN, RN, and Sean P Pinney, MD

**12:00 PM (431)** _A National Survey of Palliative Care Services within INTERMACs Centers;_ S. V. Pamboukian1, R. Tucker1, K. Swetz1, D. Kavalieratos2, J. N. Dionne-Odom1, J. Palmore1, P. Blood1, K. R. Allen1, C. Bourgeois1, G. A. Mancarella1, A. Kono3, M. A. Bakitas1. 1 _University of Alabama at Birmingham, Birmingham, AL,_ 2 _University of Pittsburgh, Pittsburgh, PA,_ 3 _Dartmouth-Hitchcock Medical Center, Lebanon, NH_

**12:15 PM (432)** _Patient-Caregiver Relationships and Outcomes after LVAD Implantation;_ M. S. Koeckert1, P. F. Vining1, A. Reyentovich2, S. D. Katz2, A. DeAnda1, D. E. Smith1, L. B. Balsam1. 1 _Cardiothoracic Surgery, NYU Medical Center, New York, NY,_ 2 _Cardiology, NYU Medical Center, New York, NY_

**12:30 PM (433)** _Pre-Operative Predictors for Admission to a Rehabilitation Facility after LVAD Implantation and Its Impact on Long Term Survival;_ F. John1, R. Sembrano2, S. Roy3, S. Gupta4, R. Nayak2, D. Plack5, R. Cogswell3. 1 _Pediatrics, University of Minnesota, Minneapolis, MN,_ 2 _Physical Medicine and Rehabilitation, University of Minnesota, Minneapolis, MN,_ 3 _Cardiology, University of Minnesota, Minneapolis, MN,_ 4 _Medicine, University of Minnesota, Minneapolis, MN,_ 5 _Cardiac Surgery, University of Minnesota, Minneapolis, MN_

**12:45 PM (434)** _Assessment of Cognitive Function Prior to and After Implantation of Left Ventricular Assist Device;_ C. K. McIlvennan1, K. Bryce2, J. Lindenfeld3, L. A. Allen1, D. E. Lanfear2. 1 _University of Colorado, Aurora, CO,_ 2 _Henry Ford, Detroit, MI,_ 3 _Vanderbilt, Nashville, TN_

**1:00 PM (435)** _Substantial Reduction in Driveline Infection Rates with the Modification of Driveline Dressing Protocols;_ M. Lander, N. Kunz, E. Dunn, K. Lockard, G. O'Shea, S. Weaver, T. Schweke, M. A. Shullo, L. Lagazzi, R. L. Kormos, J. J. Teuteberg. _Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA_

**1:15 PM (436)** _Survival and Thrombotic Events in Left Ventricular Assist Device Patients Are Not Influenced by Socioeconomic Status;_ S. B. Waters1, B. C. Sheridan2, R. Watkins3, M. Duva3, P. P. Chang1, J. N. Katz1. 1 _Cardiology, University of North Carolina, Chapel Hill, NC,_ 2 _Cardiothoracic Surgery, University of North Carolina, Chapel Hill, NC,_ 3 _Transplant, University of North Carolina, Chapel Hill, NC_

12:00 PM - 1:30 PM

Concurrent Session 49: My Heart Is Broken: Primary Graft Dysfunction and Early Problems

**Location** :

Virginia Suite

Target Audience:

HTX, BSI, ID, MCS, NHSAH, PATH, PEDS, PHARM

Chairs:

Javier Segovia, MD, PhD, and Ivan Knezevic, MD

**12:00 PM (437)** _Vasoplegia After Heart Transplantation: Unraveling the Enigma;_ F. Esmailian, P. Perry, M. Luu, J. Patel, M. Kittleson, L. Czer, T. Aintablian, P. Zarrini, A. Velleca, J. Rush, F. Arabia, J. A. Kobashigawa. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**12:15 PM (438)** _Application of the ISHLT Criteria for Primary Graft Dysfunction After Cardiac Transplantation: Risk Factors and Outcomes from a High-Volume Center;_ B. Lima1, J. J. Squiers2, G. Saracino3, T. Chamogeorgakis1, J. C. MacHannaford1, A. E. Rafael1, G. V. Gonazalez-Stawinksi1, S. A. Hall4, J. M. DiMaio2. 1 _Cardiac and Thoracic Surgery, Baylor University Medical Center, Dallas, TX,_ 2 _Baylor Research Institute, Baylor Scott & White Health, Dallas, TX, _3 _Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX,_ 4 _Department of Internal Medicine, Division of Cardiology, Baylor University Medical Center, Dallas, TX_

**12:30 PM (439)** _Recipient and Donor Risk Factors Associated with Primary Graft Failure Requiring Temporary Mechanical Circulatory Support < 24 Hours After Heart Transplantation; _M. Farr1, K. Takeda2, H. Takayama2, L. Truby1, S. W. Restaino1, M. Lippel1, R. Givens1, F. Latif1, R. Sorabella2, K. Clerkin1, P. Colombo1, B. Kalesan3, Y. Naka2, D. Mancini1. 1 _Medicine, Columbia University Medical Center, New York, NY,_ 2 _Surgery, Columbia University Medical Center, New York, NY,_ 3 _Epidemiology, Columbia University Medical Center, New York, NY_

**12:45 PM (440)** _Monocyte-Derived Macrophages Contribute to Primary Graft Dysfunction Following Cardiac Transplantation;_ K. J. Lavine1, W. Li2, M. Lam1, D. Kreisel2. 1 _Cardiology, Washington University, St Louis, MO,_ 2 _Surgery, Washington University, St Louis, MO_

**1:00 PM (441)** _Extracoporeal Membrane Oxygenator or Ventricular Assist Device for Primary Graft Failure after Orthotopic Heart Transplantation?;_ B. Li1, K. Takeda1, P. A. Kurlansky1, L. K. Truby2, S. Fukuhara1, P. F. Delle1, S. Sreekanth1, J. Han1, C. M. Mauro3, A. R. Garan2, V. K. Topkara2, M. Yuzefpolskaya2, P. C. Colombo2, M. A. Farr2, H. Takayama1, Y. Naka1. 1 _Surgery, Columbia University Medical Center, New York, NY,_ 2 _Medicine, Columbia University Medical Center, New York, NY,_ 3 _Biostatistics, Columbia University Medical Center, New York, NY_

**1:15 PM (442)** _ECMO for Primary Graft Failure Following Orthotopic Heart Transplantation;_ Y. Xia1, S. Forest1, R. Bello1, W. Jakobleff1, E. Borukhov1, U. Jorde2, D. Goldstein1. 1 _Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY,_ 2 _Medicine, Cardiology, Montefiore Medical Center, Bronx, NY_

12:00 PM - 1:30 PM

Concurrent Session 50: Recipient Factors and Outcome After Lung Transplantation: Are We Getting It Right?

**Location** :

Delaware Suite

Target Audience:

LTX, BSI, ID, NHSAH, PATH, PHARM

Chairs:

Laurie D Snyder, MD, and Goran Dellgren, MD, PhD

**12:00 PM (443)** _Impact of Multi-Drug Resistant Bacteria Detected De Novo Early after Lung Transplantation on Morbidity and Mortality;_ W. Sommer1, F. Ius1, L. Friedrich2, I. Tudorache1, C. Kuehn1, M. Avsar1, J. Salman1, T. Siemeni1, M. Greer1, A. Haverich1, G. Warnecke1. 1 _Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany,_ 2 _Department of Hospital Hygiene, Hannover Medical School, Hannover, Germany_

**12:15 PM (444)** _IgM Enriched Human Immunoglobulins and Rituximab Nullify the Mortality Risk Associated with Early Donor Specific Antibodies After Lung Transplantation;_ F. Ius1, W. Sommer1, M. Verboom2, C. Erdfelder1, I. Tudorache1, C. Kuehn1, M. Avsar1, J. Salman1, T. Siemeni1, U. Molitoris1, M. Greer3, R. Blasczyk2, M. Hallensleben2, N. Schwerk4, T. Welte3, A. Haverich1, J. Gottlieb3, G. Warnecke1. 1 _Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany,_ 2 _Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany,_ 3 _Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany,_ 4 _Department of Paediatric Pneumology, Hannover Medical School, Hannover, Germany_

**12:30 PM (445)** _Effect of De Novo Donor Specific Antibodies on the Incidence of Acute Cellular Rejection beyond One Year of Lung Transplantation;_ N. Sinha1, D. Nguyen2, A. Gaber3. 1 _Pulmonary Transplant, Houston Methodist Hospital, Houston, TX,_ 2 _Biostatistics, Houston Methodist Hospital, Houston, TX,_ 3 _JC Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, TX_

**12:45 PM (446)** _Metabolic Profile of Broncho-Alveolar Lavage Fluid in Lung Transplant Recipients Suggests Potential Early Biomarkers of Bronchiolitis Obliterans Syndrome;_ V. A. Poroyko1, A. Ulanov2, J. Becker3, O. Latif3, E. Garrity3, D. Gozal1, S. Bhorade4. 1 _Pediatrics, Univ of Chicago, Chicago, IL,_ 2 _Univ of Illinois, Chicago, IL,_ 3 _Univ of Chicago, Chicago, IL,_ 4 _Northwestern University, Chicago, IL_

**1:00 PM (447)** _C4d-Negative Antibody-Mediated Rejection After Lung Transplantation;_ P. R. Aguilar1, R. D. Yusen1, C. A. Witt1, D. E. Byers1, D. Kreisel2, E. P. Trulock1, T. Mohanakumar3, R. Hachem1. 1 _Pulmonary/Critical Care Medicine, Washington University, St. Louis, MO,_ 2 _Cardiothoracic Surgery, Washington University, St. Louis, MO,_ 3 _Surgery, Washington University, St. Louis, MO_

**1:15 PM (448)** _Outcomes in Lung Transplantation Following Allogeneic Stem-Cell Transplantation: A Pan-European Experience;_ M. Greer1, G. Riise2, L. Hansson3, M. Iversen4, P. Hämmäinen5, A. Roux6, S. Hirschi7, E. Lhuillier8, M. Reynaud-Gaubert9, F. Philit10, J. Claustre11, M. Stern6, J. Gottlieb1, P. Jaksch12, A. Holm13. 1 _Hanover Medical School, Hannover, Germany,_ 2 _Sahlgrenska University Hospital, Gothenburg, Sweden,_ 3 _Skåne University Hospital, Lund, Sweden,_ 4 _Rigshospitalet, Copenhagen, Denmark,_ 5 _Helsinki University Hospital, Helsinki, Finland,_ 6 _Hospital Foch, Suresnes, France,_ 7 _Strasbourg University Hospital, Strasbourg, France,_ 8 _Hospital Bichat, Paris, France,_ 9 _University North Hospital, Marseille, France,_ 10 _Hospital Louis Pradel, Bron, France,_ 11 _University Hospital Grenoble, Grenoble, France,_ 12 _University Hospital Vienna, Vienna, Austria,_ 13 _Oslo University Hospital Rikshospitalet, Oslo, Norway_

12:00 PM - 1:30 PM

Concurrent Session 51: Heart Failure Risk Prediction: From Molecules to Mechanism

**Location** :

Washington Ballroom 2

Target Audience:

HF, BSI, HTX, NHSAH

Chairs:

Kiran Khush, MD, MAS, and Manreet Kanwar, MD

**12:00 PM (449)** _Discharge ST2 Predicts Heart Failure Readmissions in Patients with Acute Decompensated Heart Failure (ADHF);_ J. Amione-Guerra1, A. S. Cruz-Solbes1, A. M. Cordero-Reyes1, A. Soliman1, B. H. Trachtenberg1, G. Ashrith1, M. E. El-Beheary1, J. Baird2, V. Nambi3, A. Bhimaraj1, J. D. Estep1. 1 _Methodist Debakey Heart Center, Houston Methodist Hospital, Houston, TX,_ 2 _Critical Diagnostics, San Diego, CA,_ 3 _Baylor College of Medicine, Houston, TX_

**12:15 PM (450)** _Modulation of Local and Systemic Relaxin-2 in Patients with End-Stage Chronic Heart Failure;_ I. Werner, V. Kina, M. Lupinski, U. A. Stock, A. Moritz, A. Beiras-Fernandez. _Cardiothoracic Surgery, JW Goethe University Hospital, Frankfurt, Germany_

**12:30 PM (451)** _Clinical Genetics in Cardio-Oncology;_ K. Dhar1, Y. Yi2, N. M. Weedman2, J. Kittrell2, S. Pandey2, J. Y. Um3, J. D. Eudy2, B. D. Lowes4. 1 _Internal Medicine, University of Nebraska Medical Center, Omaha, NE,_ 2 _University of Nebraska Medical Center, Omaha, NE,_ 3 _Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE,_ 4 _Cardiology, University of Nebraska Medical Center, Omaha, NE_

**12:45 PM (452)** _Cardiac Serum Biomarkers in Friedreich Ataxia May Reflect Fibrosis, Myocyte Injury, and Degree of Hypertrophy;_ C. Bui1, R. B. Wilson2, D. R. Lynch3, J. W. Rossano3, O. Elci3, K. Y. Lin3. 1 _Baylor College of Medicine, Houston, TX,_ 2 _University of Pennsylvania, Philadelphia, PA,_ 3 _Children's Hospital of Philadelphia, Philadelphia, PA_

**1:00 PM (453)** _Low Partial Pressure of End-Tidal Carbon Dioxide Predicts the Future Ventricular Assist Device Implantation in Patients with Chronic Advanced Heart Failure;_ O. Seguchi1, A. Nakano2, S. Nakajima1, H. Sunami1, T. Sato1, M. Yanase1, H. Hata3, T. Fujita3, J. Kobayashi3, M. Kitakaze4, N. Fukushima1, T. Nakatani1. 1 _Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan,_ 2 _Clinical Reserch, National Cerebral and Cardiovascular Center, Osaka, Japan,_ 3 _Adult Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan,_ 4 _Clinical Research, National Cerebral and Cardiovascular Center, Osaka, Japan_

**1:15 PM (454)** _LVOT VTI Outperforms Ejection Fraction and Doppler-Derived Cardiac Output for Predicting Outcomes in a Select Advanced Heart Failure Cohort;_ C. Tan1, A. Srivastava1, D. Rubenson1, M. R. Smith1, R. Mohan2, J. T. Heywood1. 1 _Cardiology, Scripps Clinic, La Jolla, CA,_ 2 _Cardiology, Cedars Sinai Medical Center, Los Angeles, CA_

12:00 PM - 1:30 PM

Concurrent Session 52: Factors Determining Outcomes in Pulmonary Hypertension

**Location** :

Washington Ballroom 1

Target Audience:

PH, BSI, HF, LTX, PEDS, PH, PHARM

Chairs:

Bradley Maron, MD, and C. Dario Vizza, MD

**12:00 PM (455)** _Polymer Based Nanotherapeutics Prevent the Progression of Pulmonary Hypertension in a Rat Model;_ V. Segura-Ibarra1, J. Amione-Guerra2, A. S. Cruz-Solbes2, K. A. Youker2, G. Torre-Amione2, G. Ashrith2, E. Blanco1. 1 _Nanomedicine, Houston Methodist Research Institue, Houston, TX,_ 2 _Methodist Debakey Heart Center, Houston Methodist Hospital, Houston, TX_

**12:15 PM (456)** _Incidence and Outcomes of Children with Idiopathic Pulmonary Arterial Hypertension - Results from a Bi-National Population Based Study;_ M. Rose1, P. M. Alexander2, C. O'Donnell3, S. Vidmar4, R. Justo5, M. Richardson6, G. Sholler7, S. Hope8, J. Ramsay9, D. J. Penny10, I. King11, R. G. Weintraub1. 1 _Cardiology, The Royal Children's Hospital, Melbourne, Australia,_ 2 _Cardiology, Boston Children's Hospital, Boston, MA,_ 3 _Cardiology, Starship Children's Hospital, Auckland, New Zealand,_ 4 _Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Melbourne, Australia,_ 5 _Cardiology, Lady Client Children's Hospital, Brisbane, Australia,_ 6 _Cardiology, Women's and Children's Hospital, Adelaide, Australia,_ 7 _Cardiology, The Children's Hospital at Westmead, Sydney, Australia,_ 8 _Cardiology, Monash Medical Centre, Melbourne, Australia,_ 9 _Cardiology, Princess Margaret Hospital, Perth, Australia,_ 10 _Cardiology, Texas Children's Hospital, Houston, TX,_ 11 _Cardiology, Murdoch Children's Research Institute, Melbourne, Australia_

**12:30 PM (457)** _Characteristics and Outcomes of 30-Day Hospital Readmissions in Children with Pulmonary Hypertension: A Multi-Institutional Analysis;_ J. D. Awerbach1, B. S. Moffett2, G. B. Mallory Jr.3, S. Kim2, A. G. Cabrera1. 1 _Pediatric Cardiology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX,_ 2 _Pharmacy, Texas Children's Hospital, Houston, TX,_ 3 _Pediatric Pulmonology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX_

**12:45 PM (458)** _Use of PAH-Specific Therapy in World Health Organization Group III Pulmonary Hypertension: A Systematic Review and Meta-Analysis;_ K. W. Prins, J. Markowitz, M. Pritzker, S. Duval, T. Thenappan. _Cardiovascular Division, University of Minnesota, Minneapolis, MN_

**1:00 PM (459)** _Outcome of Patients with Chronic Thromboembolic Disease in the Absence of Pulmonary Hypertension on Echocardiogram;_ L. Donahoe, J. Thenganatt, K. McRae, A. Bykova, J. Moric, J. Granton, M. De Perrot. _Toronto General Hospital, Toronto, ON, Canada_

**1:15 PM (460)** _Pre-operative Determinants of Reperfusion Lung Injury after Pulmonary Thromboendarterectomy;_ T. M. Fernandes, D. S. Poch, D. G. Papamatheakis, P. F. Fedullo, N. H. Kim, W. R. Auger, K. M. Kerr. _Division of Pulmonary and Critical Care, University of California, San Diego, La Jolla, CA_
POSTER SESSION 1

WEDNESDAY, APRIL 27, 2016

6:00 PM - 7:00 PM

Exhibit Hall B & C

BASIC SCIENCE

Target Audience:

BSI, HF, HTX, LTX, MCS, PATH, PEDS

Poster Discussants:

Derek Byers, Marcelo Cypel, Stephan Ensminger, Andrew Gelman, Aric Gregson, Christian Heim, Julia Klesney-Tait, Elizabeth Lendermon, Tereza Martinu, Thalachallour Mohanakumar, Simon Pecha, Masaaki Sato, Esther Shao, Heather Strah, Stijn Verleden

**(461)** _Ex Vivo Expanded Human Regulatory T Cells Suppress Allograft Induced Immune Responses in a Humanized Mouse Mode;_ L. Pauksch, W. Sommer, K. Jansson, A. Knoefel, T. Nakagiri, A. Haverich, G. Warnecke. _Department of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany_

**(462)** _Presence of Endothelial to Mesenchymal Transition in End Stage Human Myocardial Samples-Documentation in Human Heart Failure for the First Time;_ C. Uribe, A. S. Cruz-Solbes, K. Youker, A. M. Cordero-Reyes, J. Amione-Guerra, B. H. Trachtenberg, G. Ashrith, J. D. Estep, G. Torre-Amione, E. E. Suarez, J. P. Cooke, A. Bhimaraj. _Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX_

**(463)** _Kinetics of Dendritic and Polyfunctional T Cell Responses in a Mouse Minor Mismatched Orthotopic Single Lung Transplant Model;_ S. C. Juvet1, H. Oishi2, B. Joe3, K. Potluri3, S. Keshavjee2, T. Martinu4. 1 _University Health Network, Toronto, ON, Canada,_ 2 _Surgery, University Health Network, Toronto, ON, Canada,_ 3 _Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada,_ 4 _Medicine, University Health Network, Toronto, ON, Canada_

**(464)** _Reconditioning of Prolonged Warm Ischemic Lungs by High-Dose Bronchodilator Inhalation during Ex Vivo Lung Perfusion in a Canine Lung Transplantation Model;_ K. Hijiya, T. F. Chen-Yoshikawa, T. Kondo, H. Motoyama, A. Ohsumi, D. Nakajima, J. Sakamoto, K. Ohata, M. Takahashi, S. Tanaka, E. Miyamoto, A. Aoyama, H. Date. _Thoracic Surgery, Kyoto Univ, Kyoto, Japan_

**(465)** _Elevation in Activin A to Follistatin Ratios Following Lung Transplantation- A Potential Mediator and Therapeutic Target for CLAD?;_ M. A. Trotter1, M. Loskot1, B. J. Levvey1, T. Phan1, R. E. O'Hehir2, G. P. Westall1, D. M. de Krester3, G. I. Snell1. 1 _Lung Transplantation Service, The Alfred, Melbourne, Australia,_ 2 _Allergy, Immunology and Respiratory Medicine, The Alfred, Melbourne, Australia,_ 3 _Monash Institute of Medical Research, Monash University, Melbourne, Australia_

**(466)** _MicroRNA Analysis in a Mouse Heterotopic Tracheal Transplant Model;_ Y. Watanabe1, C. Ogura2, K. Hatanaka3, Y. Okada1, T. Watanabe1, H. Oishi1, Y. Matsuda1, H. Notsuda1, A. Harada2, M. Aoki2, T. Nagata2, K. Kariatsumari2, Y. Nakamura1, M. Sato2, T. Kondo1. 1 _Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan,_ 2 _Department of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan,_ 3 _Department of Molecular and Cellular Pathology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan_

**(467)** _Polymerized Human Serum Albumin as an Osmotic Molecule to Support Ex-Vivo Lung Perfusion;_ B. A. Whitson1, E. Eren1, E. Beal1, D. Hayes, Jr2, A. F. Palmer3, S. M. Black4. 1 _Department of Surgery, Wexner Med Ctr, Columbus, OH,_ 2 _The Ohio State University Wexner Medical Center, Columbus, OH,_ 3 _The Ohio State University, Columbus, OH,_ 4 _Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH_

**(468)** _Influence of Fatty Acids, Acetate, and Ketones on Myocardial Substrate Selection and TCA Cycle Intermediates During Hypothermic Machine Perfusion of Donor Hearts;_ C. Holmes, L. Powell, M. Peltz, M. Jessen. _Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX_

**(469)** _Lung Microbiome Predicts Myeloid Derived Suppressor Cell Response in Lung Transplant;_ N. S. Sharma, K. M. Wille, C. Hoopes, E. Diaz-Guzman, V. J. Thannickal, J. Deshane. _Pulmonary, Allergy and Critical Care, University of Alabama at Birmingham, Birmingham, AL_

**(470)** _Variable Effects of Serotonin Receptor Antagonists on the Development of Transplant Vasculopathy in Murine Aortic Allografts;_ C. Heim1, A. Gocht1, J. Distler2, B. Spriewald2, M. Ramsperger-Gleixner1, M. Weyand1, S. Ensminger3. 1 _Department of Cardiac Surgery, University of Erlangen, Erlangen, Germany,_ 2 _Department of Medicine, University of Erlangen, Erlangen, Germany,_ 3 _Department of Cardiac Surgery, HDZ NRW, Bad Oeynhausen, Germany_

**(471)** _The Establishment of an Ex Vivo Lung Perfusion in a Rat Lung Transplantation Model;_ A. Ohsumi, T. Kanou, T. K. Waddell, M. Liu, S. Keshavjee, M. Cypel. _Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, Toronto, ON, Canada_

**(472)** _The Interleukin 4 Receptor-α Potentiates the Effect of Oncostatin M Receptor on the Release of FGF23 by Cardiomyocytes;_ M. H. Richter1, R. Maringanti1, J. M. Adrian-Segarra2, H. Lautze3, M. Schönburg1, W. Skwara1, S. Hein1, A. van Linden1, T. Kubin2, T. Braun2, S. Kostin2, T. Walther1. 1 _Cardiac Surgery, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany,_ 2 _Heart and Lung Research, Max- Planck- Institute, Bad Nauheim, Germany,_ 3 _Anesthesiology, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany_

**(473)** _Combined Heart and Liver Retrieval after Circulatory Death with Normothermic Machine Reperfusion in a Porcine Model;_ H. Chew1, J. Cao1, K. Fernandez1, L. Gao1, J. Villanueva1, M. Hicks1, A. Jabbour1, H. Pleass1, K. Dhital2, P. Macdonald1. 1 _Transplant Laboratory, Victor Chang Cardiac Research Institiute, Sydney, Australia,_ 2 _Cardiothoracic Surgery, St Vincents Hospital, Sydney, Australia_

**(474)** _Refinement of Ex Vivo Lung Perfusion Techniques for Better Microvasculature Maintenance in Lung Grafts;_ K. Noda1, S. Haam1, Y. Wu2, J. D'Cunha1, J. D. Luketich1, N. Shigemura1. 1 _Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA,_ 2 _Department of Developmental Biology, University of Pittsburgh, Pittsburgh, PA_

**(475)** _A Novel Nanoscale Formulation of Hydrophobic Src Tyrosine Kinase Inhibitor PP2 Prevents Pulmonary Ischemia Reperfusion Induced Acute Lung Injury;_ T. Kanou, S. Pacheco, M. Chen, G. Zehong, X. Bai, D. Hwang, M. Cypel, S. Keshavjee, M. Liu. _Latner Thoracic Surgery Research Laboratories, Toronto General Research Instituite, Toronto, ON, Canada_

**(476)** _Donor Versus Recipient Origin of Fibroblasts in Murine Lung Allograft Fibrosis;_ C. Konoeda, T. Martinu, S. Juvet, G. Zehong, M. Yoshida, H. Oishi, P. Duchesneau, T. K. Waddell, M. Liu, S. Keshavjee. _Latner Thoracic Surgery Research Laboratories, University Health Network, University of Toronto, Toronto, ON, Canada_

**(477)** MOVED TO MINI ORAL SESSION 11

**(478)** _Development of an Unsupervised Classification with Multi-Level Analysis of the Heart Transplant Endomyocardial Biopsy;_ E. Chang1, G. Fishbein1, N. Jackson1, M. Bakir1, D. Liem1, G. Bondar1, S. Litovsky2, J. Tallaj2, C. Starling1, P. Ping1, E. Reed1, M. Deng1, E. Tabak3, M. Cadeiras1. 1 _UCLA, Los Angeles, CA,_ 2 _University of Alabama at Birmingham, Birmingham, AL,_ 3 _New York University, New York, NY_

**(479)** WITHDRAWN

**(480)** _Electrophysiological Investigations of Human iPS Cell-Derived Engineered Heart Tissue in a Guinea Pig Infarction Model;_ S. Pecha1, F. Weinberger2, K. Breckwoldt2, A. Hansen2, H. Reichenspurner1, T. Eschenhagen2. 1 _Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany,_ 2 _Experimental Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany_

**(481)** WITHDRAWN

**(482)** _aPC Pretreatment of hEPCR-Expressing PAECs Attenuates Endothelial Cell Damage and Thrombosis;_ C. T. Laird, B. French, D. G. Harris, X. Cheng, D. Ayares, R. N. Pierson, A. Azimzadeh. _University of Maryland School of Medicine, Baltimore, MD_

**(483)** _Control of Cardiomyocyte Proliferation Through p53/Mdm2-Regulated MicroRNAs;_ S. Stanley-Hasnain1, L. Hauck2, D. Grothe2, F. Billia2. 1 _Toronto General Research Institute, Toronto, ON, Canada,_ 2 _Research, Toronto General Research Institute, Toronto, ON, Canada_

**(484)** _Characteristic Trends during DCD Withdrawal;_ H. Chew, L. Gao, J. Villanueva, A. Doyle, J. Cao, G. Kumarasinghe, M. Hicks, A. Jabbour, K. Dhital, P. Macdonald. _Transplant Laboratory, Victor Chang Cardiac Research Institiute, Sydney, Australia_

**(485)** _Post-Conditioning with Cyclosporine: Impact on Ischemia Reperfusion Injury in a Rodent Model of Donor Heart Preservation;_ L. Gao1, J. Villanueva1, H. Chew1, J. Cao1, M. Hicks2, A. Jabbour3, P. S. Macdonald3. 1 _Transplant, Victor Chang Cardiac Research Institute, Sydney, Australia,_ 2 _Clinical Pharmacology & Toxicology, St Vincents Hospital, Sydney, Australia, _3 _Heart & Lung Transplantation, St Vincents Hospital, Sydney, Australia_

**(486)** _Ex Vivo Treatment of Donors with Nebulized N-Acetylcysteine Partially Improved Post-Transplant Lung Function;_ Y. Yamada, I. Iskender, S. Arni, S. Hillinger, T. Cosgun, W. Jungraithmayr, W. Weder, I. Inci. _Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland_

**(487)** _The Impact of Sevoflurane Preconditioning in Experimental Mouse Lung Transplantation;_ Y. Yamada, I. Laube, J. Jang, J. Bonvini, B. Beck-Schimmer, W. Weder, W. Jungraithmayr. _Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland_

**(488)** _Role of Heat Shock Proteins in Pharmacological Preconditioning for Lung Ischemia Reperfusion Injury;_ A. Shimamoto, M. Takao, H. Shimpo. _Mie Univ Graduate School of Medicine, Tsu, Japan_

**(489)** _Temporal Assessment of Endothelial to Mesenchymal Transition as a Contributor to Fibrosis in a Mouse Model of Heart Failure;_ A. S. Cruz-Solbes, C. Uribe, K. A. Youker, A. M. Cordero-Reyes, J. Amione-Guerra, G. Ashrith, B. H. Trachtenberg, J. D. Estep, G. Torre-Amione, J. P. Cooke, A. Bhimaraj. _Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX_

**(490)** _Identification of Hypoxic Cells in Lung Grafts for Future Cell Targeted Therapy for Obliterans Bronchiolitis;_ K. Noda1, H. Hara2, S. Haam1, J. D'Cunha1, J. D. Luketich1, N. Shigemura1. 1 _Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA,_ 2 _Department of Surgery, University of Pittsburgh, Pittsburgh, PA_

**(491)** _Impact of Myocardial Load on the Preservation of Donor Heart Function during Ex Vivo Perfusion;_ C. W. White1, S. Shan2, S. Hatami3, V. Gurtu3, A. Kinnaird3, N. Matsumura3, N. Aboelnazar3, J. R. Dyck3, G. D. Lopaschuk3, E. Michelakis3, J. Nagendran3, D. H. Freed3. 1 _Cardiac Surgery, University of Alberta, Edmonton, AB, Canada,_ 2 _University of Toronto, Toronto, ON, Canada,_ 3 _University of Alberta, Edmonton, AB, Canada_

**(492)** _Ex Vivo Testing of New Genetical Modifications for Cardiac Xenotransplantation;_ J. Abicht1, T. A. Mayr1, K. Fischer2, B. Reichart3, H. Niemann4, A. Panelli1, S. Guethoff5, P. Brenner5, A. Schnieke2. 1 _Anaesthesiology, Ludwig Maximilian University, Munich, Germany,_ 2 _Chair of Livestock Biotechnology, School of Life Sciences Weihenstephan, Technical University, Munich, Germany,_ 3 _Walter-Brendel-Centre, Ludwig Maximilian University, Munich, Germany,_ 4 _Institute of Farm Animal Genetics, Friedrich-Loeffler-Institute (FLI), Mariensee, Germany,_ 5 _Cardiac Surgery, Ludwig Maximilian University, Munich, Germany_

**(493)** _Mitochondrial Proteins Possess Antigenicity and Can Cause Rejection;_ T. Deuse1, X. Hu2, D. Wang2, M. Stubbendorff2, R. Itagaki2, A. Grabosch2, L. Graeves2, M. Alawi3, A. Gruenewald2, X. Hua2, J. Velden4, H. Reichenspurner1, R. C. Robbins5, R. Jaenisch6, I. Weissman7, S. Schrepfer2. 1 _CT Surgery, University Heart Center Hamburg, Hamburg, Germany,_ 2 _TSI Lab, University Heart Center Hamburg, Hamburg, Germany,_ 3 _Heinrich Pette Institute, University Medical Center Hamburg, Hamburg, Germany,_ 4 _Pathology, University Medical Center Hamburg, Hamburg, Germany,_ 5 _CT Surgery, Stanford University School of Medicine, Stanford, CA,_ 6 _Whitehead Institute, Boston, MA,_ 7 _Stem Cell Institute, Stanford University School of Medicine, Stanford, CA_

**(494)** _Allogeneic and Xenogeneic Immunity Is Potently Suppressed by Expanded Regulatory T Cells (Tregs) from Human Thymus;_ E. Dijke1, R. Hoeppli2, K. Seeberger3, I. Larsen1, I. Rebeyka4, D. Ross4, G. Korbutt3, M. Levings2, L. West1. 1 _Pediatrics/Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada,_ 2 _Surgery, University of British Columbia, Vancouver, BC, Canada,_ 3 _Surgery, University of Alberta, Edmonton, AB, Canada,_ 4 _Surgery/Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada_

**(495)** _Targeting Human Follicular T-B Cell Interactions to Prevent Antibody Mediated Allo-Immune Responses;_ C. C. Baan1, B. S. Rakké1, G. N. de Graav1, K. de Leur1, F. J. Dor2, M. Franquesa1. 1 _Internal Medicine, Erasmus MC, Rotterdam, Netherlands,_ 2 _Surgery, Erasmus MC, Rotterdam, Netherlands_

**(496)** _Mass Cytometric Deep Cellular Profiling of BAL in Human Lung Transplantation;_ S. C. Juvet1, T. Martinu1, L. Levy1, B. Joe2, C. Guidos3, S. Keshavjee4. 1 _Medicine, University Health Network, Toronto, ON, Canada,_ 2 _Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada,_ 3 _Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, ON, Canada,_ 4 _Surgery, University Health Network, Toronto, ON, Canada_

**(497)** WITHDRAWN

**(498)** _Xenogeneic Lung Transplantation: Extending Life-Supporting Organ Function Using Multi-Transgenic Donor Pigs and Targeted Drug Treatments;_ L. Burdorf1, C. Laird1, N. O'Neill1, S. S. Dahi1, N. Kubicki1, T. Zhang1, D. Harris1, D. Parsell1, E. Rybak1, J. Rabin1, I. Tatarov1, C. J. Phelps2, D. L. Ayares2, A. M. Azimzadeh1, R. N. Pierson III1. 1 _Surgery, University of Maryland, Baltimore, MD,_ 2 _Revivicor, Blacksburg, VA_

**(499)** _mTOR Inhibitors Ameliorate Ischemia-Reperfusion Injury through Endothelin-A Modulation and Reduction of Free Radical Production;_ I. Werner1, A. Hernandez-Sierra2, S. Brunner1, A. Kornberger1, A. Moritz1, A. Beiras-Fernandez1. 1 _Cardiothoracic Surgery, JW Goethe University Hospital, Frankfurt, Germany,_ 2 _Nephrology, Universidad Autonoma de Bucaramanga, Bucaramanga, Colombia_

**(500)** _CD8+ IL-17 Responses and Obliterative Airway Disease Persist in T-bet-/- Mouse Recipients of Lung Transplant Treated with Low Dose Azithromycin Therapy;_ E. A. Lendermon1, J. M. Dodd-o2, L. Guo1, T. A. Coon1, C. R. Ensor3, C. P. O'Donnell1, J. F. McDyer1. 1 _Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA,_ 2 _Department of Anesthesiology, Johns Hopkins University School of Medicine, Baltimore, MD,_ 3 _Department of Pharmacy, University of Pittsburgh, Pittsburgh, PA_

**(501)** _Modulation of Nesfatin, Visfatin and Resistin in Patients Undergoing Heart Transplantation;_ A. Beiras-Fernandez1, S. Reinwand1, S. Kreth2, A. Beiras3, A. Moritz1, I. Werner1. 1 _Cardiothoracic Surgery, JW Goethe University Hospital, Frankfurt, Germany,_ 2 _Anaesthesia, Klinikum Grosshadern, Munich, Germany,_ 3 _Histology, University of Santiago, Santiago, Spain_

**(502)** _Modulation of Leukocyte-Endothelium Interactions with rATGs after Ischemia-Reperfusion Injury in an Experimental Human Perfusion Model;_ A. Beiras-Fernandez1, A. Hernandez-Sierra1, E. Thein2, A. Moritz1, I. Werner1. 1 _Cardiothoracic Surgery, JW Goethe University Hospital, Frankfurt, Germany,_ 2 _Institute for Surgical Research, Ludwig-Maximilians-University, Munich, Germany_

**(503)** _The Immunobiology of the Y Chromosome in Embryonic Stem Cell Transplantation for Tissue and Organ Regeneration;_ S. T. Kueppers1, X. Hu1, T. Deuse2, D. Wang1, H. Reichenspurner2, S. Schrepfer1. 1 _TSI Lab, University Heart Center Hamburg, Hamburg, Germany,_ 2 _CT Surgery, University Heart Center Hamburg, Hamburg, Germany_

**(504)** _A Nude Mouse Model of Allosensitization Induced by Adoptive Transfer of Splenic T Helper Cells;_ I. Kim, N. Chai, S. Jordan, A. Klein, G. D. Wu. _Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA_

**(505)** _Relationship between Grafts' Quality, Glucose Consumption and IL-6 Production during Ex Vivo Lung Perfusion;_ K. Noda, S. Haam, J. D'Cunha, J. D. Luketich, N. Shigemura. _Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA_

**(506)** _Does a Leukocyte Filter Show Benefit in Ex-Vivo Lung Perfusion?;_ J. G. Luc, N. Aboelnazar, S. Hatami, A. Haromy, V. Vasanthan, C. W. White, D. H. Freed, J. Nagendran. _Department of Surgery, University of Alberta, Edmonton, AB, Canada_

HEART TRANSPLANTATION

Target Audience:

HTX, ID, MCS, NHSAH, PATH, PEDS, PHARM

Poster Discussants:

Markus Barten, Lavanya Bellumkonda, Tuvia Ben-Gal, Jennifer Cook, Eugene DePasquale, Tobias Deuse, Claudia Gidea, Gonzalo Gonzalez-Stawinski, Francisco Gonzalez-Vilchez, Shelley Hall, Sharon Hunt, Ivan Knezevic, Brian Lima, Donna Mancini, Marco Masetti, Daniela Pini, Keshava Rajagopal, Vivek Rao, Yazhini Ravi, George Sokos, Hannah Valantine, Melana Yuzefpolskaya

**(507)** _The Role of Loss-of-Function Mutations on Death and Development of Rejection in HTX/LTX Patients;_ J. van Setten1, N. de Jonge1, M. V. Holmes2, K. K. Khush3, N. K. Sweitzer4, P. Garcia-Pavia5, J. W. Rossano2, D. L. Dries6, L. Potena7, A. Zuckermann8, J. D. Christie2, D. S. Wilkes9, D. Lederer10, K. C. Meyer11, A. R. Glanville12, P. Corris13, A. Fisher13, S. M. Palmer14, J. A. Belperio15, R. A. de Weger1, H. G. Otten1, E. A. van de Graaf1, B. Keating2, F. W. Asselbergs1. 1 _UMC Utrecht, Utrecht, Netherlands,_ 2 _University of Pennsylvania, Philadelphia, PA,_ 3 _Stanford University, Stanford, CA,_ 4 _University of Wisconsin-Madison, Madison, WI,_ 5 _Puerta de Hierro University Hospital, Madrid, Spain,_ 6 _Yale Center for Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation, New Haven, CT,_ 7 _University of Bologna, Bologna, Italy,_ 8 _Medical University of Vienna, Vienna, Austria,_ 9 _Indiana University School of Medicine, Indianapolis, IN,_ 10 _Columbia University, New York, NY,_ 11 _University of Wisconsin School of Medicine and Public Health, Madison, Madison, WI,_ 12 _St Vincent's Hospital, Sydney, Australia,_ 13 _Newcastle University, Newcastle upon Tyne, United Kingdom,_ 14 _Duke University School of Medicine, Durham, NC,_ 15 _UCLA, Los Angeles, CA_

**(508)** _Tissue Characterization Using Novel CMR Based T1 and T2 Mapping Detects Early Myocardial Injury in Heart Transplant Recipients;_ M. Imran1, L. Wang1, J. McCrohon1, C. Yu1, J. Huang1, C. Holloway1, J. Otton2, K. Moffat3, R. Grover1, J. Ross3, E. Kotlyar1, A. Keogh1, C. Hayward1, P. Macdonald1, A. Jabbour1. 1 _Cardiology, St. Vincent`s Hospital, Sydney, Australia,_ 2 _Cardiology, Liverpool Hospital, Sydney, Australia,_ 3 _Medical Imaging, St. Vincent`s Hospital, Sydney, Australia_

**(509)** _Donor-Specific HLA-DQ Antibodies May Contribute to Poor Graft Outcome After Heart Transplantation;_ N. Selimovic, O. Omrani, J. Alburaiki, M. Al-Awwami. _Heart Centre, King Faisal Specialist Hospital &Research, Riyadh, Saudi Arabia_

**(510)** _The Impact of Late Antibody Mediated Rejection with Graft Dysfunction on Cardiac Allograft Vasculopathy and Survival;_ K. J. Clerkin1, S. W. Restaino1, C. C. Marboe2, E. R. Vasilescu2, E. Zorn3, D. M. Mancini1. 1 _Cardiology, Columbia University Medical Center, New York, NY,_ 2 _Pathology, Columbia University Medical Center, New York, NY,_ 3 _Immunology, Columbia University Medical Center, New York, NY_

**(511)** _The Number of Human Leukocyte Antigen DR Mismatch Is Associated with Early Post-Transplant Acute Cellular Rejection Among Heart Transplantation Recipients;_ D. Nitta1, K. Kinugawa2, T. Imamura3, M. Endo4, H. Maki1, E. Amiya1, M. Hatano1, O. Kinoshita5, K. Nawata5, M. Ono5, I. Komuro1. 1 _Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan,_ 2 _Department of Internal Medicine 2, Graduate School of Medicine and Pharmaceutical Sciences,University of Toyama, Toyama, Japan,_ 3 _Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo, Japan,_ 4 _Department of Organ Transplantation, Graduate School of Medicine, University of Tokyo, Tokyo, Japan,_ 5 _Department of Cardiothoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan_

**(512)** _Gene Expression Profiling to Predict and Define Cardiac Allograft Acute Cellular Rejection;_ D. Bodez1, H. Hocini2, N. Tchitcheck3, P. Tisserand2, N. Benhaiem4, C. Barau5, M. Kharoubi6, A. Guellich6, S. Guendouz6, C. Radu7, J. Couetil8, J. Dubois-Randé1, E. Teiger1, L. Hittinger9, Y. Lévy10, T. Damy1. 1 _Cardiology, Henri Mondor APHP Teaching Hospital, and IMRB, Créteil, France,_ 2 _Equipe 16, INSERM U955, IMRB, and VRI at H. Mondor Hospital, Créteil, France,_ 3 _Immunology of Viral Infections and Autoimmune Diseases Research Unit, UMR1184, IDMIT Infrastructure, Fontenay-aux-Roses, France,_ 4 _Pathology, Henri Mondor APHP Teaching Hospital, and IMRB, Créteil, France,_ 5 _Platform of Biological Resources, Henri Mondor APHP Teaching Hospital, and IMRB, Créteil, France,_ 6 _Cardiology, Henri Mondor APHP Teaching Hospital, Créteil, France,_ 7 _Cardiac Surgery, Henri Mondor APHP Teaching Hospital, Créteil, France,_ 8 _Cardiac Surgery, Henri Mondor APHP Teaching Hospital, and IMRB, Créteil, France,_ 9 _Cardiology, Henri Mondor APHP Teaching Hospital, IMRB and UPEC, Créteil, France,_ 10 _Clinical Immunology, Henri Mondor APHP Teaching Hospital, IMRB, and VRI, Créteil, France_

**(513)** _Diagnostic Value of Quantitative Tissue Markers (T2 Mapping and ECV) for Acute Cardiac Rejection Diagnosis: A Preliminary Experience;_ E. Vermes, C. Pantaleaon, J. Pucheux, A. Mirza, A. Delhommais, A. Sirinelli. _Heart Surgery, CHU Trousseau, Tours, France_

**(514)** _Organ Preservation and Reperfusion Influence on Outcome after Heart Transplantation;_ V. Jernryd1, C. Metzsch2, B. Andersson3, J. Nilsson1. 1 _Cardiothoracic Surgery, Lund University and Skane University Hospital, Lund, Sweden,_ 2 _Cardiothoracic Anaesthesiology, Lund University and Skane University Hospital, Lund, Sweden,_ 3 _Surgery, Lund University and Skane University Hospital, Lund, Sweden_

**(515)** _Elevated Rho Kinase (ROCK) Activity Correlates with Acute Rejection in Heart Transplant Recipients;_ B. Chung1, J. Chavez2, D. Zhang3, G. Sayer1, S. Adatya1, N. Sarswat1, D. Rodgers1, J. Zhou1, L. Zhang1, M. Knapp1, E. Karrar1, N. Uriel1, J. Liao1. 1 _University of Chicago, Chicago, IL,_ 2 _Northwestern University, Chicago, IL,_ 3 _University of Washington, Seattle, WA_

**(516)** _Telomere Length in Aortal Tissue and Heart Allograft Rejection in Patients after Transplantation;_ J. Vymetalova1, D. Dlouha2, J. A. Hubacek2, V. Lanska3, I. Malek1. 1 _Cardiology, IKEM, Prague, Czech Republic,_ 2 _Center for Experimental Medicine, IKEM, Prague, Czech Republic,_ 3 _Statistical Unit, IKEM, Prague, Czech Republic_

**(517)** _Loss of Correlation Between Naive and Memory Class-Switched B-Cells in Heart Recipients with Acute Cellular Rejection;_ J. Carbone1, A. Gallego1, N. Lanio1, L. Calahorra1, I. Sousa2, E. Sarmiento1. 1 _Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain,_ 2 _Cardiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain_

**(518)** _High Grade Cellular Rejection and Infection Post Heart Transplantation: Is There a Link?;_ A. Deka, J. Sturgess, B. Costello, E. Campos, B. Mohamedali. _Department of Cardiovascular Disease, Rush University Medical Center, Chicago, IL_

**(519)** _Trends of Early and Late Rejection Rates Following Heart Transplantation Over the Past Two Decades: Real World Data from a National Tertiary Center Registry;_ Y. Peled1, M. Katz2, Y. Har-Zahav1, Y. Shemesh1, M. Arad3, Y. Kassif1, N. Shlomo4, I. Goldenberg2, D. Freimark3, J. Lavee1. 1 _Heart Transplantation Unit, Sheba Medical Center Tel Hashomer, Ramat-Gan, Israel,_ 2 _Cardiology Department, Sheba Medical Center Tel Hashomer, Ramat-Gan, Israel,_ 3 _Heart Failure Unit, Sheba Medical Center Tel Hashomer, Ramat-Gan, Israel,_ 4 _Sheba Medical Center Tel Hashomer, Ramat-Gan, Israel_

**(520)** _Prolonged Ischemic Time of Donor Hearts: Indication for Additional Cardioplegic Preservation Before Graft Implantation ?;_ U. Boeken1, A. Albert1, A. Mehdiani1, G. Petrov1, B. Sowinski1, R. Westenfeld2, D. Saeed1, P. Akhyari1, A. Lichtenberg1. 1 _Cardiovascular Surgery, University Hospital, Duesseldorf, Germany,_ 2 _Cardiology, University Hospital, Duesseldorf, Germany_

**(521)** _Risk Stratification for Developing Cardiovascular Allograft Vasculopathy in Heart Transplant Recipients: Evaluation by Annual Intravascular Ultrasound;_ T. Sato1, O. Seguchi1, H. Ishibashi-Ueda2, M. Yanase1, N. Okada1, K. Kuroda1, E. Hisamatsu1, H. Sunami1, T. Watanabe1, S. Nakajima1, H. Hata3, T. Fujita1, N. Fukushima1, J. Kobayashi3, T. Nakatani1. 1 _Transplantation, National Cardiovascular Center, Osaka, Japan,_ 2 _Pathology, National Cardiovascular Center, Osaka, Japan,_ 3 _Cardiovascular Surgery, National Cardiovascular Center, Osaka, Japan_

**(522)** _Perfusion Cardiac Magnetic Resonance Imaging in Cardiac Allograft Vasculopathy;_ S. Chih1, A. M. Crean2, A. C. Alba2, C. S. Fan3, C. Manlhiot3, H. J. Ross2. 1 _University of Ottawa Heart Institute, Ottawa, ON, Canada,_ 2 _Toronto General Hospital - University Health Network, Toronto, ON, Canada,_ 3 _Cardiovascular Data Management Centre - University of Toronto, Toronto, ON, Canada_

**(523)** _What Are the Important Factors for Cardiac Vasculopathy Development After Heart Transplantation?;_ M. Sobieszczanska-Malek1, J. Korewicki1, M. Karczmarz1, K. Komuda1, S. Szymanska2, P. Bekta3, A. Parulski4, M. Jasinska5, M. Kuśmierczyk4, T. Zielinski1. 1 _Heart Failure and Transplantology, Institute of Cardiology, Warsaw, Poland,_ 2 _Pathology, The Children's Memorial Health Institute, Warsaw, Poland,_ 3 _Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland,_ 4 _Cardiosurgery and Transplantology, Institute of Cardiology, Warsaw, Poland,_ 5 _Anesthesiology, Institute of Cardiology, Warsaw, Poland_

**(524)** _Impact on Graft Survival of Medical Treatment and Percutaneous Coronary Intervention in Cardiac Allograft Vasculopathy;_ G. Galli1, A. A. Constantinescu1, J. J. Brugts1, R. van Domburg1, P. C. van de Woestijne2, A. A. Balk1, K. Caliskan1, O. C. Manintveld1. 1 _Cardiology, Erasmus MC, Rotterdam, Netherlands,_ 2 _Cardiothoracic Surgery, Erasmus MC, Rotterdam, Netherlands_

**(525)** _Cardiac Allograft Vasculopathy Assessed by 64 Slice Dual-Source Coronary Computed Tomographic Angiography: Retrospective Analysis of a Monocentric Experience;_ T. Dominici, M. Cottini, F. Sbaraglia, A. Pergolini, P. Lilla Della Monica, G. Di Stefano, V. Polizzi, M. Feccia, V. Buffa, V. Buffa, F. Musumeci. _Cardiac Surgery and Heart Transplantation Unit, San Camillo Forlanini Hospital Rome, Rome, Italy_

**(526)** _Heart Rate and Cardiac Allograft Vasculopathy in Heart Transplant Recipients;_ S. Varnado1, J. Y. Um2, H. Vongooru3, R. Zolty3, B. D. Lowes3, A. Burdorf3, B. Fenske1, A. Huntsberry1, A. Siddique2, M. J. Moulton2, E. Raichlin1. 1 _University of Nebraska Medical Center, Omaha, NE,_ 2 _Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE,_ 3 _Cardiology, University of Nebraska Medical Center, Omaha, NE_

**(527)** _Does ACE Inhibitor Use in Heart Transplantation Decrease the Development of Cardiac Allograft Vasculopathy?;_ J. Patel, M. Kittleson, L. Czer, T. Aintablian, M. Johl, T. Daun, B. Kearney, D. Chang, B. Azarbal, M. Hamilton, F. Esmailian, J. A. Kobashigawa. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**(528)** _The Clinical Application of Non-Invasive Assessment of Coronary Flow Reserve via Rubidium PET in Heart Transplant Patients;_ M. Kittleson, J. Patel, L. Czer, T. Aintablian, G. Rodriguez, K. Norland, N. Perry, D. Chang, F. Arabia, M. Hamilton, B. Azarbal, J. A. Kobashigawa. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**(529)** _Coronary Physiology Assessment After Heart Transplantation;_ O. Solberg1, K. Stavem2, A. Ragnarsson3, E. Gude1, A. K. Andreassen1, L. Gullestad1, K. Karason4, D. Ioanes4, L. Aaberge1. 1 _Dep of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway,_ 2 _Dep of Pulmonary Medicine, Akershus University Hospital Lørenskog, Akershus, Norway,_ 3 _Dep of Radiology, Oslo University Hospital Rikshospitalet, Oslo, Norway,_ 4 _Dep of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden_

**(530)** _Rejection and Cardiac Allograft Vasculopathy Are Both Associated with Increased Incidence of Sudden Cardiac Death Post-Heart Transplant: A Meta-Analysis;_ F. Foroutan1, A. Alba1, N. Ng Fat Hing1, C. Fan2, C. Manlhiot2, H. J. Ross1. 1 _Cardiology, Toronto General Hospital, Toronto, ON, Canada,_ 2 _Cardiovascular Data Management Centre, University of Toronto, Toronto, ON, Canada_

**(531)** _Opitcal Coherence Tomography Guided Allograft Vasculoptahy Interventions: A New Frontier;_ I. F. Édes, Á. Hajas, B. Sax, D. Becker, B. Merkely. _Heart and Vascular Center, Semmelweis University, Budapest, Hungary_

**(532)** _Evaluating Potential Risk Factors for Worsening Cardiac Allograft Vasculopathy;_ K. Hord1, R. Dolan1, Y. Huang2, A. Knezevic2, D. Gupta3. 1 _Emory University School of Medicine, Atlanta, GA,_ 2 _Rollins School of Public Health, Emory University, Atlanta, GA,_ 3 _Cardiology, Emory University School of Medicine, Atlanta, GA_

**(533)** _Immunosuppression and Cardiac Allograft Vasculopathy: A Multivariate Odds Ratio Analysis;_ K. Hord1, R. Dolan1, Y. Huang2, A. Knezevic2, D. Gupta3. 1 _Emory University School of Medicine, Atlanta, GA,_ 2 _Rollins School of Public Health, Emory University, Atlanta, GA,_ 3 _Cardiology, Emory University School of Medicine, Atlanta, GA_

**(534)** _Dobutamine Stress Echocardiography to Detect Early Cardiac Allograft Vasculopathy;_ K. J. Clerkin, A. R. Garan, M. A. Farr, S. W. Restaino, F. Latif, M. Yuzefpolskaya, P. C. Colombo, D. M. Mancini. _Cardiology, Columbia University Medical Center, New York, NY_

**(535)** _Cardiac Allograft Donor Age Is Associated with Increased Baseline Coronary Plaque Burden but Not with Its Progression as Assessed by Intravascular Ultrasound;_ R. Cheng, B. Azarbal, C. Vanichsarn, J. Patel, D. Chang, M. Kittleson, J. Kobashigawa. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**(536)** _Elevated Levels of Gut Microbe Metabolite Trimethylamine N-Oxide (TMAO) Levels Are Aassociated with Graft Arterial Disease Following Murine Heart Transplantation;_ S. M. Zeltzer, X. Wang, Z. Wang, S. Goparaju, N. Dvorina, W. Baldwin, S. Hazen, W. Tang. _Cellular and Molecular Biology, Cleveland Clinic Cleveland Clinic, Cleveland, OH_

**(537)** _Steps towards Personalization of Clinical Care in Era of Precision Medicine. Time Dependent Immune Phenomapping in Heart Transplantation and Emergence of Anti-HLA Class I and II Antibodies;_ M. Bakir, N. Jackson, E. Chang, D. Henriquez, C. Tseng, C. Starling, T. Khuu, D. Cruz, E. DePasquale, R. Ardehali, J. Zhang, J. Schaenman, B. Kubak, M. Kwon, A. Ardehali, E. Reed, M. Deng, M. Cadeiras. _Cardiology, UCLA, Los Angeles, CA_

**(538)** _Proteinuria the First Year After Heart Transplantation Is Associated with a Higher Rate of Decline in Glomerular Filtration Rate;_ C. Soderlund, E. Lofdahl, G. Radegran. _Department of Clinical Sciences Lund, Cardiology, Lund, Sweden_

**(539)** _Assessment of Cotinine Shows a Dose-Dependent Effect of Smoke Exposure on the Long Term Survival after Heart Transplantation;_ K. Uyanik-Uenal, A. Aliabadi, J. Goekler, O. Salameh, T. Haberl, K. Freystaetter, P. Kinsperger, R. Moayedifar, G. Laufer, A. Zuckermann. _Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria_

**(540)** _Safety and Efficacy of Immunoadsorption in Heart Transplantation Program;_ T. Gazdic1, I. Malek2, L. Pagacova3, A. Slavcev4, M. Hegarova2, L. Hoskova2, M. Kubanek2, J. Pirk1. 1 _Cardiovascular Surgery, Institution for Clinical and Experimental Medicine, Prague, Czech Republic,_ 2 _Cardiology, Institution for Clinical and Experimental Medicine, Prague, Czech Republic,_ 3 _Haematology, Institution for Clinical and Experimental Medicine, Prague, Czech Republic,_ 4 _Immunogenetics, Institution for Clinical and Experimental Medicine, Prague, Czech Republic_

**(541)** _Predictive Value of HLA and MICA Antibodies Monitoring during First Year after Heart Transplantation;_ T. Gazdic1, I. Malek2, M. Rodova3, A. Slavcev3, V. Lanska4, L. Voska5, J. Pirk1. 1 _Cardiovascular Surgery, Institution for Clinical and Experimental Medicine, Prague, Czech Republic,_ 2 _Cardiology, Institution for Clinical and Experimental Medicine, Prague, Czech Republic,_ 3 _Immunogenetics Department, Institution for Clinical and Experimental Medicine, Prague, Czech Republic,_ 4 _Statistical Unit, Institution for Clinical and Experimental Medicine, Prague, Czech Republic,_ 5 _Clinical and Transplant Pathology Department, Institution for Clinical and Experimental Medicine, Prague, Czech Republic_

**(542)** _Evolutive Tendency and Prognostic Value of Galectin-3 Serum Levels After Heart Transplantation;_ N. Suarez-Fuentetaja, E. Barge-Caballero, M. Paniagua-Martin, G. Barge-Caballero, D. Couto-Mallon, D. Vasquez-Echeverri, G. Marron-Linares, Z. Grille-Cancela, J. Vazquez-Rodriguez, M. Crespo-Leiro. _Cardiology Department, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain_

**(543)** _Tricuspid Annuloplasty Definitely Improves Patient Outcomes in the First Year After Heart Transplantation;_ M. Borkon1, S. Aggarwal1, G. Dryton1, A. Kao2, K. Allen1, R. Davis1, A. Pak1, E. Thompson1, A. Magalski2, B. Austin2, T. Khumari2, S. Lawhorne2, K. Gosch1. 1 _Department of CV Surgery, Saint Luke's Mid America Heart Institute, Kansas City, MO,_ 2 _Department of Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, MO_

**(544)** _Management and Outcomes of Upper Extremity Deep Venous Thrombosis in Heart Transplant Patients;_ A. W. Panakos, D. R. Kramer, M. McCarey, P. J. Mather. _Internal Medicine, Thomas Jefferson University, Philadelphia, PA_

**(545)** _Early and Long Term Results of Heart Transplantation after Reoperative Sternotomy;_ D. E. Sert, U. Kervan, S. Kocabeyoglu, E. Unal, K. Kavasoglu, M. Ozatik, F. Pac, S. Kucuker, M. Pac. _Cardiovascular Surgery, Turkey Yuksek Ihtisas Hospital, Ankara, Turkey_

**(546)** _Temporal Changes on the Risk of New Onset Diabetes Following Cardiac Transplantation Over 30 Years;_ N. Iannino1, S. de Denus1, A. Nasri1, A. Räkel2, M. Carrier1, A. Ducharme1, K. Lachance3, N. Racine1, G. Pelletier1, A. Fortier4, M. White1. 1 _Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada,_ 2 _Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada,_ 3 _Sanofi Canada, Laval, QC, Canada,_ 4 _Montreal Health Innovations Coordinating Center, Montreal, QC, Canada_

**(547)** _Reduction in Post-Heart Transplant ICU and Total Length of Stay by Standardization of Care Via a Multidisciplinary Approach;_ R. K. Cheng1, J. D. Pal2, N. A. Mokadam2, V. Chaudhari3, T. F. Dardas1, K. D. O'Brien1, J. W. Smith2, S. Moore1, W. C. Levy1, S. C. Masri1, A. Stempien-Otero1, C. Mahr1, D. P. Fishbein1. 1 _Cardiology, University of Washington, Seattle, WA,_ 2 _Cardiac Surgery, University of Washington, Seattle, WA,_ 3 _Medicine, University of Washington, Seattle, WA_

**(548)** _Use of a Highly Sensitive Assay for Cardiac Troponin T as an Adjunct to Diagnose Acute Rejection after Cardiac Transplant;_ U. Boeken1, A. Mehdiani1, C. Ballazs1, C. Sowa1, R. Westenfeld2, D. Saeed1, P. Akhyari1, A. Lichtenberg1. 1 _Cardiovascular Surgery, University Hospital, Duesseldorf, Germany,_ 2 _Cardiology, University Hospital, Duesseldorf, Germany_

**(549)** _Outcomes in Patients Older than 65 Years of Age Post Heart (HT) & Heart-Kidney Transplant (HKT); _A. Iyengar, C. Eisenring, A. Nsair, M. Deng, L. Reardon, A. Ardehali, E. DePasquale. _University of California - Los Angeles, Los Angeles, CA_

**(550)** _Relationship Between Brachial Artery Flow-Mediated Dilation and Clinical Characteristics of Heart Transplant Recipients;_ T. Watanabe, O. Seguchi, M. Yanase, T. Fujita, T. Sato, H. Sunami, S. Nakajima, K. Nishimura, E. Hisamatsu, K. Kuroda, N. Okada, K. Wada, H. Hata, H. Ishibashi-Ueda, Y. Miyamoto, J. Kobayashi, N. Fukushima, T. Nakatani. _Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan_

**(551)** _Poor Blood Pressure Control Is Independently Associated with Renal Dysfunction After Heart Transplant;_ M. Osnard1, A. D. Althouse2, L. Krall2, C. Newman2, C. Grabowski2, F. Speicher2, R. Zomak2, L. Lagazzi2, R. Kormos2, M. Shullo2, J. Teuteberg2. 1 _University of Pittsburgh School of Medicine, Pittsburgh, PA,_ 2 _University of Pittsburgh Medical Center, Pittsburgh, PA_

**(552)** _Post Heart Transplant Cancer Diagnosis Association with Human Leukocyte Antigen-G Genotypes;_ J. Lazarte1, L. Goldraich2, C. Manlhiot3, V. Rao3, D. Delgado2. 1 _Faculty of Medicine, University of Toronto, Toronto, ON, Canada,_ 2 _Cardiology, Toronto General Hospital, Toronto, ON, Canada,_ 3 _Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada_

**(553)** _Association between Karnofsky Functional Scale and Survival in Patients Listed for Heart Transplantation;_ S. G. Al-Kindi, M. Farhoud, M. Kattea, M. Ginwalla, C. ElAmm, M. Zacharias, R. Benatti, B. Sareyyupoglu, S. Deo, S. Park, G. H. Oliveira. _University Hospitals Case Medical Center, Cleveland, OH_

**(554)** _The Impact of Donor Specific Antibodies on Antibody Mediated Rejection;_ K. J. Clerkin1, S. W. Restaino1, E. R. Vasilescu2, E. Zorn3, C. C. Marboe2, D. M. Mancini1. 1 _Cardiology, Columbia University Medical Center, New York, NY,_ 2 _Pathology, Columbia University Medical Center, New York, NY,_ 3 _Immunology, Columbia University Medical Center, New York, NY_

**(555)** _Body Mass Index Adversely Affects Survival in Left Ventricular Assist Device Bridged Patients Undergoing Heart Transplantation;_ S. Deo1, S. Kumar2, S. Altarabsheh3, J. Kerner1, J. Benavides1, B. Sareyyupoglu1, B. Medalion1, Y. Elgudin1, C. Elamm4, M. Ginwalla4, R. Benatti4, M. Zacharias4, G. H. Oliveira4, G. C. Fonarow5, S. J. Park1. 1 _Cardiac Surgery, University Hospitals, Cleveland, OH,_ 2 _Advanced Heart Failure, UT Health Sciences Center, Houston, TX,_ 3 _Cardiac Surgery, Queen Alia Heart Institute, Amman, Jordan,_ 4 _Cardiology, University Hospitals, Cleveland, OH,_ 5 _Cardiology, Adamson- UCLA Cardiomyopathy Center, Los Angeles, CA_

**(556)** _Association of Heart Transplant Recipient Age and Body Mass Index with Microcirculatory Remodeling;_ G. Cohen, C. Strehl, H. Luikart, W. F. Fearon, K. Khush. _Stanford University, Stanford, CA_

**(557)** _Clinical Implication of Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies in Heart Transplant Recipients: Do We Really Have to Care All the DSA Positive Patients?;_ T. Sato1, O. Seguchi1, Y. Kanaumi2, M. Yanase1, N. Okada1, K. Kuroda1, E. Hisamatsu1, H. Sunami1, S. Nakajima1, H. Hata3, T. Fujita3, H. Ishibashi-Ueda4, N. Fukushima1, J. Kobayashi3, T. Nakatani1. 1 _Transplantation, National Cardiovascular Center, Osaka, Japan,_ 2 _Transfusion Medicine, National Cardiovascular Center, Osaka, Japan,_ 3 _Cardiovascular Surgery, National Cardiovascular Center, Osaka, Japan,_ 4 _Pathology, National Cardiovascular Center, Osaka, Japan_

**(558)** _Higher Rate of Hospitalizations for Infection and Cancer Than Rejection in Low Risk Heart Transplant Patients Followed by Gene Expression Profiling;_ J. J. Teuteberg1, M. A. Shullo1, P. J. Berman2, N. Haglund3, M. A. Wigger3, G. A. Ewald4. 1 _University of Pittsburgh, Pittsburgh, PA,_ 2 _Tampa General Hospital, Tampa, FL,_ 3 _Vanderbilt University, Nashville, TN,_ 4 _Washington University, St. Louis, MO_

**(559)** _Evaluation of Left Ventricular Myocardial Mechanics in Heart Transplant Recipients Using Three-Dimensional Speckle Tracking Echocardiography;_ A. Assabiny, A. Kovacs, A. Kosztin, B. F. Farkas, M. Tokodi, B. Sax, B. Merkely. _Heart and Vascular Center, Semmelweis University, Budapest, Hungary_

**(560)** _Significant Tricuspid Insufficiency After Cardiac Transplantation: Which Risk Factor Has the Most Influence;_ V. Hajiyev, C. Knosalla, M. Dandel, M. Pasic, S. Buz, R. Hetzer. _Cardiathoracic Surgery, German Heart Institute in Berlin, Berlin, Germany_

**(561)** _Our Experience with the Use of Allomap in Multiple Organ Recipients;_ S. Carey1, G. Saracino2, A. Jamil1, S. Hall1. 1 _Advanced Heart and Lung, Baylor University Medical Center, Dallas, TX,_ 2 _Baylor University Medical Center, Dallas, TX_

**(562)** _Limiting the Number of Endomyocardial Biopsies Does Not Impact One Year Survival Following Heart Transplantation;_ K. Balakrishnan1, R. Ratnagiri2, S. Rao3, M. Tungaturu3. 1 _Cardiac Surgery, Fortis Malar Hospital, Chennai, India,_ 2 _Cardiology, Fortis Malar Hospital, Chennai, India,_ 3 _Cardiac Anaesthesia, Fortis Malar Hospital, Chennai, India_

**(563)** _Vibration Controlled Transient Elastography for Identification of Hepatic Fibrosis in Patients Evaluated for Cardiac Transplantation or Left Ventricular Assist Device: A Pilot Study;_ D. Vucicevic, E. P. Kransdorf, D. E. Steidley, H. E. Vargas, E. J. Carey. _Mayo Clinic Arizona, Scottsdale, AZ_

**(564)** _Cardiac Troponin T in Heart Donors: Impact on Morbidity and Mortality After Transplantation;_ U. Boeken1, A. Albert1, A. Mehdiani1, G. Petrov1, R. Westenfeld2, D. Saeed1, P. Akhyari1, A. Lichtenberg1. 1 _Cardiovascular Surgery, University Hospital, Duesseldorf, Germany,_ 2 _Cardiology, University Hospital, Duesseldorf, Germany_

**(565)** _When a Prospective Crossmatch Is Warranted in the Virtual Crossmatch (VXM) Era;_ J. A. Kobashigawa1, J. Patel1, M. Kittleson1, L. Czer1, T. Aintablian1, M. Yang1, S. Sana1, J. Rush1, E. Stimpson1, D. Geft1, D. Ramzy1, N. Reinsmoen2. 1 _Cedars-Sinai Heart Institute, Los Angeles, CA,_ 2 _Cedars-Sinai Medical Center, Los Angeles, CA_

**(566)** _Characteristics and Co-Morbidities in Heart Transplant Recipients Who Survive into Their Eighties;_ D. Tabachnick1, J. Stehlik2, E. Gilbert2, J. Nativi-Nicolau2, J. Fang2, O. Wever-Pinzon2, S. Drakos2, D. Budge3, B. Kfoury3, R. Alharethi3, W. Caine4, C. Selzman1, S. McKellar1. 1 _Department of Cardiothoracic Surgery, University of Utah, Salt Lake City, UT,_ 2 _Department of Cardiology, University of Utah, Salt Lake City, UT,_ 3 _Department of Cardiology, Intermountain Medical Center, Salt Lake City, UT,_ 4 _Department of Cardiothoracic Surgery, Intermountain Medical Center, Salt Lake City, UT_

**(567)** _Preoperatively Impaired Renal Function Does Not Affect Long-Term Survival in Heart Transplanted Patients;_ O. Kolsrud1, K. Karason2, E. Holmberg3, S. Ricksten4, M. Felldin5, O. Samuelsson5, G. Dellgren6. 1 _Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden,_ 2 _Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden,_ 3 _Oncology, Sahlgrenska Academy, Gothenburg, Sweden,_ 4 _Cardiothoracic Anaesthesia and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden,_ 5 _Nephrology, Sahlgrenska University Hospital, Gothenburg, Sweden,_ 6 _Cardiothoracic Surgery and Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden_

**(568)** _How to Achieve Improved Outcome after Heart Transplantation?;_ G. Dellgren1, H. Liden1, S. Bartfay2, S. Ricksten3, J. Gäbel1, H. Rexius1, E. Bolano2, K. Karason2. 1 _Cardiothoracic Surgery, Sahlgrenska Univ Hospital, Goteborg, Sweden,_ 2 _Cardiology, Sahlgrenska Univ Hospital, Goteborg, Sweden,_ 3 _Cardiothoracic Anaesthesia and Intensive Care, Sahlgrenska Univ Hospital, Goteborg, Sweden_

**(569)** _Predictors of Normal Coronary Angiography in Older Donors: Results from a Prospective National Study;_ C. Cantrellle1, C. Lefeuvre2, T. Genet3, C. Legeai1, C. Jasseron1, I. Pipien1, E. Epailly4, D. Angoulvant3, O. Bastien1, R. Dorent1. 1 _Medical & Scientific, Agence de la biomedecine, La Plaine Saint Denis, France, _2 _Cardiology, Hôpital la Pitié-Salpêtrière, Paris cedex 13, France,_ 3 _Cardiology, Hopital Trousseau, Tours, France,_ 4 _Cardiology, Hopital Civil, Strasbourg, France_

**(570)** _Optimal Timing of Heart Transplantation After HeartMate II Left Ventricular Assist Device Implantation;_ R. J. Steffen1, E. H. Blackstone1, N. G. Smedira1, E. G. Soltesz1, K. J. Hoercher1, L. Thuita2, R. C. Starling3, M. Mountis3, N. Moazami1. 1 _Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH,_ 2 _Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH,_ 3 _Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH_

**(571)** _The Fate of Donor Hearts Rejected for Transplant: A Single Institutional Experience;_ D. J. Hall1, C. R. Matthews2, J. M. Aranda3, M. A. Ahmed3, J. A. Hill3, A. D. Szady3, J. R. Vilaro2, C. T. Klodell1, T. M. Beaver1. 1 _Division of Thoracic and Cardiovascular Surgery, University of Florida, Gainesville, FL,_ 2 _College of Medicine, University of Florida, Gainesville, FL,_ 3 _Division of Cardiovascular Medicine, University of Florida, Gainesville, FL_

**(572)** _Donor Heart Turn Down, Is It Rational?;_ J. Patel, M. Kittleson, L. Czer, D. Chang, T. Aintablian, E. C. Norris, A. Velleca, J. Rush, E. Stimpson, A. Hage, A. Trento, J. A. Kobashigawa. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**(573)** _The Impact of Donor Origin on Survival after Orthotopic Heart Transplantation;_ O. Kiamanesh, A. Khosla, E. Johansson, S. Virani, M. Davis, A. Cheung, J. Bashir, B. Munt, A. Ignaszewski, A. Kaan, M. Toma. _University of British Columbia, Vancouver, BC, Canada_

**(574)** _Risk Factors of Waiting List Mortality for Patients Awaiting Heart Transplant;_ J. R. Trivedi, E. Schumer, M. Black, H. T. Massey, A. Cheng, M. S. Slaughter. _Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY_

**(575)** _Impact of Size Mismatch on Heart Transplant Outcomes;_ K. Murphy1, E. P. Kransdorf2, S. Wilansky2, O. E. Pajaro3, D. E. Steidley2. 1 _Division of Internal Medicine, Mayo Clinic Arizona, Scottsdale, AZ,_ 2 _Division of Cardiovascular Diseases, Mayo Clinic Arizona, Phoenix, AZ,_ 3 _Division of Cardiothoracic Surgery, Mayo Clinic Arizona, Phoenix, AZ_

**(576)** WITHDRAWN

**(577)** _Pre-Operative Pulmonary Hypertension Does Impact Long Term Outcomes Following Heart Transplantation: Review of the United Network for Organ Sharing Database;_ M. L. Irons1, A. C. Gaffey1, C. W. Chen1, A. Vaidya2, M. A. Acker1, P. Atluri1. 1 _Division of Cardiovascular Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA,_ 2 _Division of Cardiology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA_

**(578)** _Does Pulmonary Hypertension Affect Survival after Heart Transplantation Based on Recipient Body Mass Index?;_ P. C. Rosas1, E. Stock2, E. A. Amulraj3, S. Emani4, R. C. Scott5, C. B. Sai-Sudhakar3, Y. Ravi3. 1 _Medical Physiology, Texas A &M University, Temple, TX, _2 _Center for Applied Health Research,, Central Texas Veterans Health Care System, Jointly With Baylor Scott & White Health, Temple, TX, _3 _Cardiothoracic Surgery-Surgery, Baylor Scott & White Healthcare Affliated With Texas A&M University, Temple, TX, _4 _Internal Medicine, The Ohio State University, Columbus, OH,_ 5 _Cardiology-Internal Medicine, Baylor Scott & White Healthcare Affliated With Texas A&M University, Temple, TX_

**(579)** _Influence of Duration of Continuous-Flow Ventricular Assist Device Support on Post-Transplant Outcome - Results Using the United Network for Organ Sharing Database;_ A. M. Bernhardt1, A. P. Levin2, A. Schaefer1, F. M. Wagner1, H. Reichenspurner1. 1 _Department of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany,_ 2 _Columbia University Medical Center, New York City, NY_

**(580)** _A Novel Cardiac Allocation Score for Predicting Wait-List and Post Transplant Survival;_ S. Margelis, P. Karas, E. Granger, P. Spratt, P. Jansz, C. Hayward, A. Jabbour, A. Keogh, E. Kotlyar, P. Macdonald, K. Dhital. _St Vincent's Hospital, Sydney, Australia_

**(581)** _Changing Characteristics of Heart Transplant Donors and Their Effect on Recipient Mortality;_ Y. Ravi1, E. M. Stock2, P. C. Rosas3, R. C. Scott4, E. A. Amulraj1, S. Emani5, C. B. Sai-Sudhakar1. 1 _Cardiothoracic Surgery-Surgery, Baylor Scott & White Healthcare Affliated With Texas A&M University, Temple, TX, _2 _Center for Applied Health Research,, Central Texas Veterans Health Care System, Jointly With Baylor Scott & White Health, Temple, TX, _3 _Medical Physiology, Texas A &M University, Temple, TX, _4 _Cardiology-Internal Medicine, Baylor Scott & White Healthcare Affliated With Texas A&M University, Temple, TX, _5 _Cardiology-Internal Medicine, The Ohio State University, Columbus, OH_

**(582)** _Impact of Donor Hypernatremia on Outcome After Cardiac Transplantation;_ U. Boeken1, A. Albert1, A. Mehdiani1, G. Petrov1, R. Westenfeld2, D. Saeed1, P. Akhyari1, A. Lichtenberg1. 1 _Cardiovascular Surgery, University Hospital, Duesseldorf, Germany,_ 2 _Cardiology, University Hospital, Duesseldorf, Germany_

**(583)** _Hypertonic Saline Solution Preserves Left Ventricular Function and Inhibit Myocardial Injury Triggered by Brain Death in Rats;_ L. F. Moreira, D. M. Magalhães, F. L. Zanoni, C. J. Correia, R. Simas, P. Sannomiya. _Department of Cardiovascular Surgery, Heart Institute (Incor), University of Sao Paulo Medical School, Sao Paulo, Brazil_

**(584)** _Thyroid Hormone Use During Cardiac Transplant Organ Procurement;_ L. B. Cooper1, C. A. Milano1, M. Williams1, W. Swafford1, D. Croezen2, A. B. Van Bakel3, J. G. Rogers1, C. B. Patel1. 1 _Duke University, Durham, NC,_ 2 _Carolina Donor Services, Durham, NC,_ 3 _Medical University of South Carolina, Charleston, SC_

**(585)** MOVED TO MINI ORAL SESSION 10

**(586)** _Evaluation of Thoracic Exception Policy for Highly Sensitized Patients;_ S. McKean. _Clinical, Advanced Practice, Donor Network West, San Ramon, CA_

**(587)** _The Interval between Brain Stem Death and Cardiac Assessment Influences the Retrieval of Hearts for Transplantation;_ R. V. Venkateswaran1, J. Lannon2, E. Wong2, M. Berman3, N. Howell4, J. Payne5, J. Dark6, N. R. Banner7. 1 _Director of Transplantation, Wythenshawe Hospital NHS Trust, Manchester, United Kingdom,_ 2 _Statistics Department, NHS Blood and Transplant, Bristol, United Kingdom,_ 3 _Consultant Transplant Surgeon, Papworth Hospital NHS Trust, Cambridge, United Kingdom,_ 4 _Consultant Transplant Surgeon, University Hospital Birmingham NHS Trust, Birmingham, United Kingdom,_ 5 _Consultant Cardiologist, Golden Jubilee Hospital, Glasgow, United Kingdom,_ 6 _Consultant Transplant Surgeon, Freeman Hospital NHS Trust, Newcastle upon Tyne, United Kingdom,_ 7 _Consultant Cardiologist, Harefield Hospital NHS Trust, London, United Kingdom_

**(588)** _A Comparison of ECMO, LVAD and Biventricular Support in Bridging to Heart Transplant in the OPTN Database;_ S. C. Silvestry1, J. Rogers2, L. B. Edwards3, E. Robbins-Callahan3, D. M. Meyer4. 1 _Thoracic Transplant, Florida Hospital Transplant Institute, Orlando, FL,_ 2 _Cardiology, Duke University, Durham, NC,_ 3 _UNOS, Richmond, VA,_ 4 _Cardiac Surgery, UT Southwestern, Dallas, TX_

**(589)** _The Role of Japanese Medical Consultant System on Improving Outcomes of Cardiac Recipients from Old Donors or Donors Who Died of Post-Resuscitation and Anoxia;_ N. Fukushima1, M. Ono2, Y. Saiki3, T. Ooka4, Y. Tanoue5, S. Saito6, S. Fukushima7. 1 _Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Suita, Japan,_ 2 _Department of Cardiovascular Surgery, Tokyo University, Tokyo, Japan,_ 3 _Department of Cardiovascular Surgery, Tohoku University, Sendai, Japan,_ 4 _Department of Cardiac Surgery, Hokkaido University, Sapporo, Japan,_ 5 _Department of Cardiovascular Surgery, Kyushu University, Fukuoka, Japan,_ 6 _Department of Cardiac Surgery, Tokyo Wemen's Medical University, Tokyo, Japan,_ 7 _Department of Cardiovascular Surgery, Osaka University, Suita, Japan_

**(590)** _The Paradoxical Relationship between Donor Distance from Transplant Center and Survival after Heart Transplantation;_ T. C. Crawford, J. Magruder, J. C. Grimm, K. J. Zehr, K. Mandal, J. V. Conte, G. J. Whitman, R. S. Higgins, D. E. Cameron, W. A. Baumgartner, C. M. Sciortino. _Cardiac Surgery, Johns Hopkins University, Baltimore, MD_

**(591)** _The Use of Social Media Application Software Using Smartphones in Donor Heart Evaluation;_ K. Balakrishnan1, M. Tungaturu2, S. Rao2, R. Ratnagiri3. 1 _Cardiac Surgery, Fortis Malar Hospital, Chennai, India,_ 2 _Cardiac Anesthesia, Fortis Malar Hospital, Chennai, India,_ 3 _Cardiology, Fortis Malar Hospital, Chennai, India_

**(592)** _Retrieval Team Initiated Early Donor Management (Scouting) Increases Donor Heart Acceptance Rate for Transplantation;_ C. Barbero, A. Ravaglioli, A. Page, B. Parizkova, M. Berman, C. Sudarshan, S. Large, S. Tsui. _Transplant Unit, Papworth Hospital, Cambridge, United Kingdom_

**(593)** _Time-Varying Mortality Risk Score for Candidates Awaiting Cardiac Transplantation;_ V. B. Cruz1, R. Steffen2, M. Koprivanac3, R. C. Starling2, D. O. Taylor2, K. Hoercher2, J. Rajeswaran4, N. Smedira2, E. Soltesz2, E. H. Blackstone2, N. Moazami2. 1 _Lerner College of Medicine, Cleveland Clinic, Cleveland, OH,_ 2 _Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH,_ 3 _General Surgery, Cleveland Clinic, Cleveland, OH,_ 4 _Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH_

**(594)** _Marijuana and Listing for Heart Transplant: A Global Survey;_ J. Neyer, A. Uberoi, M. Hamilton, J. A. Kobashigawa. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**(595)** _Donor Age for Heart Transplantation Does Not Affect Short or Mid-Term Outcomes;_ T. Chamogeorgakis, S. Joseph, S. Hall, G. Saracino, S. Carey, P. Kale, M. Sherwood, G. Gonzalez-Stawinski, B. Lima. _Baylor University Medical Center, Dallas, TX_

LUNG TRANSPLANTATION

Target Audience:

LTX, BSI, EEP, ID, NHSAH, PATH, PEDS, PH, PHARM

Poster Discussants:

Laveena Chhatwani, Fabio De Robertis, Kumud Dhital, Joshua Diamond, Cassie Kennedy, Lorriana Leard, Anne Olland, Michael Perch, Antonio Roman, Pali Shah, Ciara Shaver, Wiebke Sommer, Bart Vanaudenaerde, Keith Wille

**(596)** _Assessment of FEV1 Decline after Lung Transplantation Using Functional Respiratory Imaging;_ E. M. Barbosa1, F. Ferreira2, W. Vos2, C. Van Holsbeke2, L. Nuyttens3, W. De Backer4, J. De Baker2, J. C. Lee1. 1 _Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia, PA,_ 2 _FluidDA, Kontich, Belgium,_ 3 _FluidDA USA, North Brunswick, NJ,_ 4 _University Hospital Antwerp, Edegem, Belgium_

**(597)** _Lung Transplant Outcome: Eplets Compatibility and DSA Development;_ D. C. Walton1, S. J. Hiho1, L. S. Cantwell1, M. B. Diviney1, G. I. Snell2, M. A. Paraskeva2, G. P. Westall2. 1 _Victorian Transplantation and Immunogenetics Service, Australian Red Cross Blood Service, Melbourne, Australia,_ 2 _Lung Transplant Service, Alfred Hospital, Melbourne, Australia_

**(598)** _A Single Donor TARC/CCL17 Promotor Polymorphism Correlates with Serum TARC/CCL17 Levels and Is Associated with Impaired Clinical Outcome after Lung Transplantation;_ K. Budding1, J. van Setten2, O. A. van Rossum1, E. A. van de Graaf3, T. Kardol-Hoefnagel1, E. D. Oudijk4, C. E. Hack1, H. G. Otten1. 1 _Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands,_ 2 _Department of Cardiology, University Medical Center Utrecht, Utrecht, Netherlands,_ 3 _Department of Respiratory Medicine, University Medical Center Utrecht, Utrecht, Netherlands,_ 4 _Center of Interstitial Lung Diseases, St. Antonius Hospital, Nieuwegein, Netherlands_

**(599)** _Bile Acid Aspiration Associates with CLAD and Affects the Bronchial District Lipid Profile: Targeted Bile Acid Metabolomics and Lipidomics in Bronchial Washing;_ D. Briganti, C. Kim, B. Aramini, R. Nandakumar, B. Zhou, R. Chan, S. Sreekanth, K. Raza, H. Robbins, L. Shah, S. Arcasoy, J. Sonett, G. Di Paolo, S. Cremers, F. D'Ovidio. _Columbia University, New York City, NY_

**(600)** _Delayed Non-Myeloablative Irradiation after Lung Transplantation to Induce Allograft Acceptance in a Large Animal Model;_ J. Hahn1, K. Jansson1, W. Sommer1, M. Avsar1, J. Salman1, T. Siemeni1, A. Knoefel1, L. Pauksch1, B. Schröder2, A. Haverich1, G. Warnecke1. 1 _Medical School Hannover (MHH), Hannover, Germany,_ 2 _Tierärztliche Hochschule, Hannover, Germany_

**(601)** _The Presence of Complement (C4d) Broncho-Alveolar Lavage in Phenotypes of Chronic Lung Allograft Dysfunction;_ E. Vandermeulen, S. E. Verleden, D. Ruttens, H. Bellon, D. E. Van Raemdonck, R. Vos, G. M. Verleden, B. M. Vanaudenaerde. _Department of Pneumology, KULeuven, Leuven, Belgium_

**(602)** _Molecular Detection of Community Acquired Respiratory Viral Infections (CARV) and the Risk of BOS in Lung Transplant (LTx) Recipients;_ B. C. Bemiss, D. E. Byers, C. A. Witt, P. R. Aguilar, R. D. Yusen, E. P. Trulock, R. R. Hachem. _Washington University School of Medicine, Saint Louis, MO_

**(603)** _Natural History of Chronic Lung Allograft Dysfunction (CLAD) and Impact of Azithromycin (AZ) in Lung Transplant (LT) Recipients;_ A. Moniodis1, K. Townsend2, A. Rabin3, O. Aloum4, J. Stempel4, P. Burkett5, P. Camp6, M. Divo5, S. El-Chemaly5, H. Mallidi6, I. Rosas5, F. Anne5, S. Koo4, H. Goldberg5. 1 _Pulmonary and Critical Care, Brigham and Women's Hospital, Brookline, MA,_ 2 _Lung Transplant Program, Pharmacy Department, Brigham and Women's Hospital, Brookline, MA,_ 3 _Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA,_ 4 _Transplant Infectious Disease, Brigham and Women's Hospital, Boston, MA,_ 5 _Lung Transplant Program, Brigham and Women's Hospital, Boston, MA,_ 6 _Lung Transplant Program, Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, MA_

**(604)** _FVC and FEV1 Decline in Chronic Lung Allograft Dysfunction (CLAD) Phenotypes;_ J. L. Todd1, C. A. Finlen Copeland1, M. Neely2, S. M. Palmer1. 1 _Medicine, Duke Univ Med Ctr, Durham, NC,_ 2 _Biostatistics and Bioinformatics, Duke Univ Med Ctr, Durham, NC_

**(605)** _Long-Term Outcome of Double Lung Retransplantation After Heart and Lung Transplantation for Chronic Lung Allograft Dysfunction;_ L. Marien, O. Mercier, J. Le Pavec, J. Guihaire, S. Mussot, D. Fabre, L. Lamrani, P. Dartevelle, E. Fadel. _Centre Chirurgicale Marie Lannelongue, Paris, France_

**(606)** _Role of CD4+CD25highCD127- Treg Cells in Long Term Outcome of Lung Recipients;_ D. Piloni1, M. Morosini2, S. Magni2, A. Balderacchi2, L. Scudeller3, E. Cova2, T. Oggionni2, G. Stella2, C. Tinelli3, F. Antonacci2, F. Meloni1. 1 _Department of Internal Medicine, University of Pavia, Pavia, Italy,_ 2 _Cardiothoracic and Vascular Dept., Pneumology Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy,_ 3 _Clinical Epidemiology and Biometric Unit, Scientific Direction, IRCCS Policlinico San Matteo Foundation, Pavia, Italy_

**(607)** _Impact of Persistent Versus Transient Donor Specific HLA- Antibodies on Graft Outcome Following Lung Transplantation;_ D. Sroussi, C. Gauvain, E. Lhuillier, C. Dupin, G. Dauriat, G. Jebrak, P. Mordant, G. Thabut, H. Mal, C. Suberbielle, O. Brugière. _Hôpital Bichat, Paris, France_

**(608)** _Short Term Safety and Tolerance of Mesenchymal Stem Cells (MSC) Infusion as Cell Therapy for Patients Experiencing Treatment-Refractory Moderate Chronic Lung Allograft Dysfunction (CLAD);_ C. A. Keller1, A. L. Russell2, R. C. Lefavor2, C. M. Desmond2, K. E. Hurst1, H. A. David-Robinson1, D. G. Kontras1, A. C. Zubair2. 1 _Transplant Department, Mayo Clinic, Jacksonville, FL,_ 2 _Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL_

**(609)** _Serial Parametric Response Mapping to Diagnose Bronchiolitis Obliterans Syndrome;_ S. E. Verleden1, R. Vos1, E. Vandermeulen1, D. Ruttens1, H. Bellon1, D. Van Raemdonck1, G. M. Verleden1, C. Galban2, V. Lama2, B. Ross2, B. Vanaudenaerde1. 1 _KU Leuven, Leuven, Belgium,_ 2 _University of Michigan, Michigan, MI_

**(610)** _Bronchial & Alveolar Lipidomic Profile as a Marker of the Immunological and Functional Status of the Lung Allograft; _D. Briganti1, C. Kim1, B. Aramini1, R. Chan1, B. Zhou1, S. Sreekanth1, K. Raza1, H. Robbins1, L. Shah1, S. Arcasoy1, J. Sonett1, F. Meloni2, G. Di Paolo1, F. D'Ovidio1. 1 _Columbia University, New York City, NY,_ 2 _Università di Pavia, Pavia, Italy_

**(611)** _Association of Prolonged Hospital Stay during Transplant Surgery with Long Term Outcomes among Patients with Lung Transplantation;_ M. Mohanka, A. Banga. _UT Southwestern Medical Center, Dallas, TX_

**(612)** _Serum miRNAs as Potential Biomarkers for the Bronchiolitis Obliterans Syndrome after Lung Transplantation;_ K. Budding1, M. Rossato1, E. A. van de Graaf2, T. R. Radstake1, H. G. Otten1. 1 _Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands,_ 2 _Department of Respiratory Medicine, University Medical Center Utrecht, Utrecht, Netherlands_

**(613)** _Influence of Non-Donor Specific Antibodies on Chronic Lung Allograft Dysfunction -A New Risk Factor in Lung Transplantation? -;_ L. Mori1, J. D. Smith2, A. Montero-Fernandez3, A. Rice3, A. Sabashnikov4, M. Zeriouh5, M. Carby1, A. Reed1, A. R. Simon4, A. Popov4, S. Soresi1. 1 _Lung Failure & Transplantation, Royal Brompton & Harefield NHS Foundation Trust, Uxbridge, United Kingdom, _2 _Tissue Typing, Heart & Science Centre, Royal Brompton & Harefield NHS Foundation Trust, Uxbridge, United Kingdom, _3 _Department of Histopathology, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom, _4 _Department of Cardiothoracic Surgery &Transplantation, Royal Brompton & Harefield NHS Foundation Trust, Uxbridge, United Kingdom, _5 _Department of Cardiothoracic Surgery, University Hospital Cologne, Cologne, Germany_

**(614)** _A National Survey of Practice and Perceptions Regarding Anti-Fibrotic Medication in Lung Transplant Recipients;_ C. M. Patterson1, M. Durheim2, S. Palmer2, C. Finlen Copeland2, L. Snyder3. 1 _Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom,_ 2 _Duke University, Durham, NC,_ 3 _Duke University Med Ctr, Durham, NC_

**(615)** _How Important Is Coronary Artery Disease When Considering Lung Transplant Candidates?;_ M. Koprivanac1, M. Budev2, M. Kelava3, G. Pettersson2, K. McCurry2, D. Johnston1, P. Houghtaling1, E. Blackstone2, S. Murthy2. 1 _General Surgery/Cardiothoracic Surgery, Cleveland Clinic, Cleveland, OH,_ 2 _Cardiothoracic Surgery, Cleveland Clinic, Cleveland, OH,_ 3 _Anesthesiology, Cleveland Clinic, Cleveland, OH_

**(616)** _Racial and Ethnic Differences in Pre-Transplantation Panel Reactive Antibodies and Outcome Following Lung Transplantation;_ K. M. Wille, N. S. Sharma, B. Wei, F. Siric, C. Hoopes, E. Diaz-Guzman. _Univ of Alabama at Birmingham, Birmingham, AL_

**(617)** _Pulmonary Transplantation for End-Stage Silicosis: A Single Center Experience;_ W. Mao, X. Nie, W. Xia, M. Zheng, J. Chen. _Department of Lung Transplant Center, Key Laboratory of Human Organ Transplant in Jiangsu Province, Nanjing Medical University affiliated Wuxi People's Hospital, Wuxi, China_

**(618)** _Depression, Quality of Life, and Mortality Early Following Lung Transplantation;_ P. J. Smith, J. Blumenthal, J. Mathew, B. M. Hoffman, S. Rivelli, M. Durheim, S. M. Palmer. _Duke University Medical Center, Durham, NC_

**(619)** _Outcome of Patients with End-Stage Pulmonary Hypertension Who Received Double Lung Transplantation Instead of Heart-Lung Transplantation: A Comparative Retrospective Study;_ A. Gruner1, T. Kortchinsky1, O. Mercier2, S. Rezaiguia-Delclaux1, E. Fadel2, F. Stephan1. 1 _Reanimation Adulte, Hopital Marie Lannelongue, Le Plessis Robinson, France,_ 2 _Pole Thoracique et Vasculaire-Transplantation Pulmonaire, Hopital Marie Lannelongue, Le Plessis Robinson, France_

**(620)** _Lung Transplant Recipient Survival Following Urgent Inpatient Candidacy Evaluation;_ R. L. Sagana1, L. J. Stuckey2, J. Berry3, H. Collins1, A. Heinle1, L. Roaden1, D. Stepka1, A. Chang4, J. Lin4, K. Chan1. 1 _Internal Medicine, University of Michigan, Ann Arbor, MI,_ 2 _Pharmacy, University of Michigan, Ann Arbor, MI,_ 3 _Transplant Center, University of Michigan, Ann Arbor, MI,_ 4 _Thoracic Surgery, University of Michigan, Ann Arbor, MI_

**(621)** _De Novo Anti-HLA Class II Donor Specific Antibodies after Lung Transplantation Are Associated with Mortality after Lung Transplant Failure;_ B. Bahar, D. F. Dilling, Z. Du. _Loyola University Medical Center, Maywood, IL_

**(622)** _What Timing Is Best for Revascularization in Lung Transplant Candidates with Coronary Artery Disease? Pre-Lung Transplantation vs Intra-Lung Transplantation;_ T. Yoshizumi1, J. Gomez-Abraham1, A. Shiose1, F. Cordova2, G. Criner2, Y. Toyoda1. 1 _Cardiovascular Surgery, Temple University Hospital, Philadelphia, PA,_ 2 _Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, PA_

**(623)** _Sequential Bronchoalveolar Lavages Reflect Distinct Pulmonary Compartments: Clinical and Research Implications in Lung Transplantation;_ L. Levy, S. C. Juvet, L. G. Singer, S. Azad, B. Joe, M. Cypel, S. Keshavjee, T. Martinu. _Toronto Lung Transplant Program, Toronto, ON, Canada_

**(624)** _Lung Transplantation and Concomitant Treatment of Significant Coronary Artery Disease: Insights from a Single-Center Experience;_ F. Ius1, T. Siemeni1, W. Sommer1, I. Tudorache1, C. Kuehn1, M. Avsar1, J. Salman1, J. Optenhoefel1, J. Puntigam1, U. Molitoris1, M. Greer2, T. Welte2, A. Haverich1, J. Gottlieb2, G. Warnecke1. 1 _Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany,_ 2 _Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany_

**(625)** _The Optimal Number of Transbronchial Biopsies Needed to Evaluate Rejection in the Lung Allograft;_ H. Inaty, A. Jawad, C. Lane, W. Tsuang, J. Turowski, O. Akindipe, A. Mehta, M. Budev, M. Machuzak. _Pulmonary and Critical Care, Cleveland Clinic, Cleveland, OH_

**(626)** _Early Diagnosis of Gastroesophageal Reflux Disease After Lung Transplantation Using the RSI and Impact of Surgical Techniques: Minimally Invasive or Clamshell Incision, What Is Better?;_ S. Soresi1, A. Padukone2, A. Sabashnikov2, M. Zeriouh3, M. Carby1, A. Reed1, A. Simon2, A. Popov2. 1 _Lung Failure & Transplantation, Royal Brompton & Harefield NHS Foundation Trust, Uxbridge, United Kingdom, _2 _Department of Cardiothoracic Surgery &Transplantation, Royal Brompton & Harefield NHS Foundation Trust, Uxbridge, United Kingdom, _3 _Department of Cardiothoracic Surgery, University Hospital Cologne, Cologne, Germany_

**(627)** _V/Q SPECT CT in Screening for Pulmonary Embolus Following Lung Transplantation;_ O. Kadwani, C. Fowler, P. Dalal, M. Carby. _Transplant Medicine, Royal Brompton and Harefield NHS Trust, London, United Kingdom_

**(628)** _Is Routine Respiratory Viral PCR Testing in Lung Transplant Recipients Helpful?;_ K. Timov, E. Karimi, J. Salaie, A. Ball, K. Santhanakrishnan, M. Al-Aloul. _Cardiothoracic Transplant Unit, University Hospital of South Manchester, Manchester, United Kingdom_

**(629)** _Altered Surfactant Turn-Over Immediately after Lung Transplantation Is Associated with Impaired Graft Function at Three Months;_ L. Thakuria1, R. Romano1, G. Koster2, V. Goss2, P. Townsend2, A. Simon1, A. Popov1, F. de Robertis1, S. Soresi1, M. Carby1, A. Reed1, N. Marczin3, M. Griffiths4, A. Postle2. 1 _Dept of Cardiothoracic Transplantation, Harefield Hospital, Harefield, United Kingdom,_ 2 _Southampton Centre for Biomedical Research, Southampton General Hospital, Southampton, United Kingdom,_ 3 _Anaesthesia, Pain Medicine and Intensive Care, Imperial College London, London, United Kingdom,_ 4 _Intensive Care Unit, The Royal Brompton Hospital, London, United Kingdom_

**(630)** _Impact of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Outcomes after Lung Transplantation;_ R. Tomic, A. Keenan, E. Dincer, H. Kim. _Pulmonary and Critical Care Medicine, University of Minnesota, Minneapolis, MN_

**(631)** _Impact of Pre-Transplant Sensitization on the Development of Anti-HLA Antibodies after Lung Transplantation: A Prospective Pilot Study;_ S. Z. Cao1, A. Courtwright2, Y. Cui2, A. M. Lamattina2, S. Fried3, I. Wood4, I. Guleria1, P. Camp1, A. Chandraker1, E. Milford1, S. El-Chemaly1, H. J. Goldberg1. 1 _Harvard Medical School, Boston, MA,_ 2 _Division of Pulmonary and Critical Care Medicine, Brigham and Woman's Hospital, Boston, MA,_ 3 _Lung Transplant Program, Division of Pulmonary and Critical Care Medicine, Brigham and Woman's Hospital, Boston, MA,_ 4 _Clinical Laboratory Division, Tissue Typing Laboratory, Brigham and Woman's Hospital, Boston, MA_

**(632)** _Bronchial Disorders and Complications after Lung Transplant: Analysis of Risk Factors and Predictive Model of Onset;_ M. Schiavon, F. Calabrese, U. Fantoni, D. Gregori, G. Marulli, M. Loy, F. Lunardi, F. Calabrese, F. Rea. _Cardiac, Thoracic and Vascular Sciences, University of Padua, Padova, Italy_

**(633)** _Peri-Operative Transfusion Practices in Lung Transplant Patients;_ P. Nair1, S. Al-Soufi1, D. Lowe1, D. Behan2, M. Harkess3, J. Breeding1, D. Boyd4, K. Dhital5, P. Spratt1, A. Glanville6. 1 _Intensive Care Unit, St Vincent's Hospital, Sydney, Australia,_ 2 _Haematology, St Vincent's Hospital, Sydney, Australia,_ 3 _Cardiopulmonary Transplant Unit, St Vincent's Hospital, Sydney, Australia,_ 4 _Anaesthetics, St Vincent's Hospital, Sydney, Australia,_ 5 _Cardiothoracic Surgery, St Vincent's Hospital, Sydney, Australia,_ 6 _Thoracic Medicine and Transplant, St Vincent's Hospital, Sydney, Australia_

**(634)** _Evolving Risk Factors for Mortality after Lung Transplantation over the Last 10 Years: Insights from a Single-Centre Database;_ F. Ius1, M. Mehwald-Goeke1, W. Sommer1, M. Verboom2, C. Erdfelder1, I. Tudorache1, C. Kuehn1, M. Avsar1, J. Salman1, T. Siemeni1, D. Boethig1, M. Greer3, B. Gohrbandt4, N. Schwerk5, J. Gottlieb3, T. Welte3, A. Haverich1, G. Warnecke1. 1 _Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany,_ 2 _Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany,_ 3 _Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany,_ 4 _Department of Cardiovascular and Thoracic Surgery, Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany,_ 5 _Department of Paediatric Pneumology, Hannover Medical School, Hannover, Germany_

**(635)** _Impact of Operator and Anesthesia Choice on Bronchoscopic Biopsy Yield and Complications;_ L. Frye, T. Pena, A. Lanfranco, J. Lee. _Hospital of the University of Pennsylvania, Philadelphia, PA_

**(636)** _Outcome of Single Lung Transplantation for Lymphangioleiomyomatosis;_ T. Watanabe1, H. Mitomo1, S. Eba1, H. Notsuda1, Y. Watanabe1, H. Oishi1, H. Niikawa1, Y. Matsuda1, M. Noda1, T. Sado1, A. Sakurada1, Y. Hoshikawa1, M. Akiba1, T. Kondo1, K. Seyama2, Y. Okada1. 1 _Tohoku Univesity, Miyagi, Japan,_ 2 _Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan_

**(637)** _Microarray Analysis of Transbronchial Biopsies in Lung Transplant Recipients Detects Molecular Changes of T-cell Mediated Inflammation;_ K. Halloran1, J. Chang2, V. Ramassar2, A. Kapasi1, J. Weinkauf1, A. Hirji1, D. Lien1, J. Reeve2, P. Halloran2. 1 _Medicine, University of Alberta, Edmonton, AB, Canada,_ 2 _Alberta Transplant Applied Genomics Center, University of Alberta, Edmonton, AB, Canada_

**(638)** _Usage of Aprotinin (Trasylol) in Bilateral Lung Transplantation - Friend or Foe?;_ L. Ong1, S. Abraham2, G. Parry3, S. C. Clark1. 1 _Cardiothoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, United Kingdom,_ 2 _Anaesthetics and Intensive Care Unit, Freeman Hospital, Newcastle Upon Tyne, United Kingdom,_ 3 _Cardiothoracic Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom_

**(639)** _Early Acute Kidney Injury in Lung Transplantation Is Associated with Significant Mortality;_ A. T. Logan, J. P. Casale, C. T. Doligalski. _Pharmacy, Tampa General Hospital, Tampa, FL_

**(640)** _Extracorporeal Photopheresis in Chronic Lung Allograft Disfunction:Data Support Their Use?;_ M. Aguilar Pérez1, R. Laporta Hernandez1, M. Lazaro Carrasco de la Fuente1, C. De Miguel2, j. Bueno Cabrera2, P. Ussetti Gil1. 1 _Pulmonary Department, Universitary Puerta de Hierro Majadahonda Hospital, Madrid, Spain,_ 2 _Blood Bank. Hematology Department, Universitary Puerta de Hierro Majadahonda Hospital, Madrid, Spain_

**(641)** _Quantitation of the Effect of Azole Antifungals on Tacrolimus Clearance;_ D. R. Darley1, L. Carlos2, S. Hennig3, A. R. Glanville1. 1 _Thoracic Medicine, St Vincent's Hospital Darlinghurst, Sydney, Australia,_ 2 _Department of Pharmacy, St Vincent's Hospital Darlinghurst, Sydney, Australia,_ 3 _School of Pharmacy, University of Queensland, Brisbane, Australia_

**(642)** _IVIG Infusions Deplete Donor-Specific HLA Antibodies in Lung Transplant Recipients;_ J. Kukreja1, D. Kopchaliiska2, G. Dincheva1, E. Bush1, L. Leard3, M. Brzezinski4, S. Hays3, J. Singer3, R. Rajalingam2. 1 _Division of Cardiothoracic Surgery, Univ of California, San Francisco, CA,_ 2 _Immunogenetics and Transplantation Laboratory, Univ of California, San Francisco, CA,_ 3 _Division of Pulmonary Medicine, Univ of California, San Francisco, CA,_ 4 _Department of Anesthesia, Univ of California, San Francisco, CA_

**(643)** _Desensitization Therapy Before Lung Transplantation;_ P. R. Aguilar1, C. A. Witt1, B. C. Bemiss1, A. S. Krupnick2, D. Kreisel2, R. D. Yusen1, E. P. Trulock1, T. Mohanakumar3, R. R. Hachem1. 1 _Pulmonary/Critical Care Medicine, Washington University, St. Louis, MO,_ 2 _Cardiothoracic Surgery, Washington University, St. Louis, MO,_ 3 _Surgery, Washington University, St. Louis, MO_

**(644)** _Intravenous Immunoglobulin in Sensitized Lung Transplant Recipients and Early Outcomes;_ E. C. Benedetti, G. Chery, M. Hartwig, A. Hulbert, J. Reynolds, L. Snyder. _Duke University Hospital, Durham, NC_

**(645)** _Trough Blood Concentrations Are an Accurate Indicator of Tacrolimus Exposure Early Post Lung Transplantation;_ D. R. Darley1, L. Carlos2, A. R. Glanville1. 1 _Thoracic Medicine, St Vincent's Hospital Darlinghurst, Sydney, Australia,_ 2 _Department of Pharmacy, St Vincent's Hospital Darlinghurst, Sydney, Australia_

**(646)** _Pre-Treatment High Titer DSA Is Associated with Non-Responsiveness to Carfilzomib-Based AMR Therapy in Lung Transplant Recipients;_ A. Zeevi, M. Marrari, M. R. Morrell, S. A. Yousem, J. M. Pilewski, J. D'Cunha, J. F. McDyer, C. R. Ensor. _University of Pittsburgh, Pittsburgh, PA_

**(647)** _Prolonged Administration of Twice Daily Bolus Intravenous Tacrolimus Early after Lung Transplantation;_ Y. Hirano1, S. Sugimoto1, T. Mano1, T. Kurosaki2, S. Otani2, K. Miyoshi1, M. Yamane1, S. Miyoshi1, T. Oto2. 1 _General Thoracic Surgery, Okayama University Hospital, Okayama, Japan,_ 2 _Organ Transplant Center, Okayama University Hospital, Okayama, Japan_

MECHANICAL CIRCULATORY SUPPORT

Target Audience:

MCS, BSI, HF, ID, NHSAH, PH, PHARM

Poster Discussants:

Keith Aaronson, David DeNofrio, Doug Horstmanshof, Valluvan Jeevanandam, Charles Klodell, Ugolino Livi, Mathias Loebe, Claudius Mahr, Simon Maltais, Paul Mohasci, Samer Najjar, Takeshi Nakatani, Sanem Nalbantgil, Francis Pagani, Christopher Salerno, Murat Sargin, Josef Stehlik, George Wieselthaler

**(648)** _Diagnosis and Management of Pump Thrombosis in Patients with Continuous-Flow Ventricular Assist Devices;_ S. Ertugay1, C. Engin1, A. Daylan1, E. Pektok2, P. Ozturk1, S. Nalbantgil3, T. Yagdi1, M. Ozbaran1. 1 _Cardiovascular Surgery, Ege University Medical School Hospital, Izmir, Turkey,_ 2 _Cardiovascular Surgery, Istanbul Bilim University Medical School Hospital, Istanbul, Turkey,_ 3 _Cardiology, Ege University Medical School Hospital, Izmir, Turkey_

**(649)** _Thrombolysis for Pump Thrombosis after LVAD: Weighing Benefits and Risks;_ A. Kornberger1, U. A. Stock1, C. Reyher2, T. Bingold2, B. Assmus3, A. Moritz1, A. Beiras-Fernandez1. 1 _Thoracic, Cardiac and Thoracic Vascular Surgery, University Hospital Frankfurt, Frankfurt, Germany,_ 2 _Anaesthesia and Intensive Care, University Hospital Frankfurt, Frankfurt, Germany,_ 3 _Cardiology, University Hospital Frankfurt, Frankfurt, Germany_

**(650)** _Clopidogrel Does Not Increase Incidence of Bleeding in LVAD Patients;_ A. Bhatia, G. Sayer, S. Adatya, G. Kim, N. Sarswat, T. Ota, V. Jeevanandam, N. Uriel. _University of Chicago, Chicago, IL_

**(651)** _Risk Factors of Gastrointestinal Bleeding after Continuous Flow Left Ventricular Assist Device;_ O. Balcioglu1, S. Ertugay2, P. Ozturk2, C. Engin2, S. Nalbantgil3, S. Nalbantgil3, T. Yagdi2, M. Ozbaran2. 1 _Cardiovascular Surgery, Near East University Medical School Hospital, Nicosia, Cyprus,_ 2 _Cardiovascular Surgery, Ege University Medical School Hospital, Izmir, Turkey,_ 3 _Cardiology, Ege University Medical School Hospital, Izmir, Turkey_

**(652)** _LVAD Support Increases Plasma Iron Species: Implications for a Pathophysiologic Relationship between LVAD-Associated Hemolysis and Thrombosis;_ D. Zhang, J. Kang, G. Redline, J. Howard, M. Acker, P. Atluri, C. R. Bartoli. _University of Pennsylvania, Philadelphia, PA, PA_

**(653)** _Danazol as a Treatment to Reduce Reoccurrence of Hospitalization for Gastrointestinal Bleeding in Patient with Continuous Flow Left Ventricular Assist Device;_ C. Falls, M. Guglin. _Cardiology, University of Kentucky, Lexington, KY_

**(654)** _The Use of Heparin in the Setting of Elevated LDH and Suspected LVAD Pump Thrombus; a Single Center Experience;_ J. Spadafore, M. Marranca, M. Amity, L. Staley, L. Schroedl, E. Boldea, O. Pajaro. _Cardiovascular Surgery, Mayo Clinic Arizona, Phoenix, AZ_

**(655)** _Preoperative Risk Factors for Stroke After HeartWare Left Ventricular Assist Device Implantation: Texas Heart Institute Experience;_ M. Ono1, S. K. Singh2, W. E. Cohn1, A. B. Civitello1, O. Frazier1. 1 _Texas Heart Institute, Houston, TX,_ 2 _Baylor College of Medicine, Houston, TX_

**(656)** _Microbubbles in Patients with LVADs: Echocardiographic Markers for LVAD Pump Thrombosis?;_ L. A. Letarte, Z. Wang, M. E. Rodrigo, F. H. Sheikh, M. Hofmeyer, S. W. Boyce, S. S. Najjar, D. T. Majure. _MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC_

**(657)** _Clinical Variables Associated with Gastrointestinal Bleeding in Patients Supported by Continuous-Flow Left Ventricular Assist Devices;_ M. Stegman1, N. Balasubramanian2, N. Papillon3, E. E. Coglianese4. 1 _Loyola University Stritch School of Medicine, Maywood, IL,_ 2 _Department of Clinical Research, Loyola University Medical Center, Maywood, IL,_ 3 _Loyola University Medical Center, Maywood, IL,_ 4 _Division of Cardiology, Loyola University Medical Center, Maywood, IL_

**(658)** _The Clinical Relevance of Transcranial Doppler Detection of Micro-Embolic Signals in Patients with Heartmate II;_ O. Seguchi1, K. Saito2, K. Fukuma2, S. Nakajima1, H. Sunami1, T. Sato1, M. Yanase1, H. Hata3, T. Fujita3, K. Nagatsuka2, J. Kobayashi3, N. Fukushima1, T. Nakatani1. 1 _Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan,_ 2 _Cerebrovascular Medicine and Neurology, National Cerebral and Cardiovascular Center, Osaka, Japan,_ 3 _Adult Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan_

**(659)** _ABO Blood Group and Left Ventricular Assist Device Therapy: A Multi-Institutional Analysis Detects Significant Differences in Outcomes;_ J. M. Stulak1, S. Schettle1, S. Dunlay1, N. A. Haglund2, M. E. Davis2, P. Shah3, J. Cowger4, K. D. Aaronson5, F. D. Pagani5, S. Maltais1. 1 _Cardiovascular Surgery, Mayo Clinic, Rochester, MN,_ 2 _Cardiovascular Surgery, Vanderbilt Heart and Vascular Institute, Nashville, TN,_ 3 _Cardiovascular Surgery, Inova Fairfax Hospital, Falls Church, VA,_ 4 _Cardiovascular Surgery, St. Vincent's Hospital, Indianapolis, IN,_ 5 _Cardiovascular Surgery, University of Michigan Health System, Ann Arbor, MI_

**(660)** _Intermittent Low Speed Software (Lavare Cycle) May Not Reduce the Incidence of Gastro-Intestinal Bleeding Events in Patients with HeartWare HVAD;_ B. Maxhera1, A. Albert1, G. Petrov1, R. Westenfeld2, A. Lichtenberg1, D. Saeed1. 1 _Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany,_ 2 _Cardiology, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany_

**(661)** _Clinical Predictors of Pump Thrombosis in Explanted Ventricular Assist Devices;_ K. L. Koch1, A. Abou El Ela2, R. Hasan2, E. Sarosi3, F. Pagani4, J. Haft4. 1 _Medical School, University of Michigan, Ann Arbor, MI,_ 2 _Cardiology, University of Michigan, Ann Arbor, MI,_ 3 _Wesleyan, Middletown, CT,_ 4 _Cardiac Surgery, University of Michigan, Ann Arbor, MI_

**(662)** _Effect of an Institutional Protocol for Gastrointestinal Bleeding in Left Ventricular Assist Device Patients;_ A. H. Healy1, J. Colarusso1, S. H. McKellar1, A. Koliopoulou1, S. G. Drakos2, C. H. Selzman1. 1 _Surgery, University of Utah, Salt Lake City, UT,_ 2 _Medicine, University of Utah, Salt Lake City, UT_

**(663)** _Severity of Hemolysis Is Associated with Death and Ischemic Stroke during Veno-Arterial Extracorporeal Membrane Support;_ O. Saeed, W. Jakobleff Jr., M. Chau, S. Rangasamy, M. Algodi, M. Makkiya, M. Cruz, S. Patel, S. Murthy, D. Sims, J. Shin, D. Goldstein, U. Jorde. _Medicine, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY_

**(664)** _Speed Reduction Does Not Restore High Molecular Weight Von Willebrand Multimers during Heart Mate II Support: An In-Vivo Analysis;_ S. Patel, J. Patel, J. Rand, D. Goldstein, U. Jorde, O. Saeed. _Medicine, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY_

**(665)** _A Multicenter Evaluation of Octreotide for Ventricular Assist Device Related Gastrointestinal Bleeding;_ G. B. Smallfield1, S. Gunda1, S. Emani2, M. K. Kanwar3, N. Uriel4, P. C. Colombo5, P. A. Uber1, M. L. Sears1, K. B. Shah1. 1 _Virginia Commonwealth University, Richmond, VA,_ 2 _Ohio State University, Colombus, OH,_ 3 _Allegheny General Hospital, Pittsburgh, PA,_ 4 _University of Chicago, Chicago, IL,_ 5 _Columbia, New York, NY_

**(666)** _Eptifibatide in the Treatment of Pump Thrombosis: What Is the Prescription?;_ L. M. Peters, D. T. Majure, M. E. Rodrigo, F. H. Sheikh, M. Hofmeyer, E. J. Molina, S. W. Boyce, S. S. Najjar. _MedStar Washington Hospital Center, Washington, DC_

**(667)** _Abnormal Pre-Operative Mixing Studies Identify VAD Patients at High Risk for Spontaneous Bleeding;_ J. D. Remick1, L. Holton2, M. Mangum1, K. Evenson1, R. Lewis1, M. Puhlman1, C. Moore3, G. Ott1, J. Abraham1. 1 _Center for Advanced Heart Disease, Providence Heart & Vascular Institute, Portland, OR, _2 _Department of Medicine, Providence St. Vincent Medical Center, Portland, OR,_ 3 _Hematology and Oncology, Providence Cancer Center, Portland, OR_

**(668)** _Correlation of LVAD Outflow Graft Orientation with Aortic Root Thrombosis Rationalized by Patient Specific Computational Fluid Dynamics Simulations;_ M. Kassi1, C. Karmonik2, J. Engelke3, C. Eshelbrenner1, H. Rehman4, T. Belousova1, A. Bhimaraj1, J. Estep1, S. Chang1. 1 _Cardiology, Houston Methodist Hospital, Houston, TX,_ 2 _Research Instituite, Houston Methodist Hospital, Houston, TX,_ 3 _Houston Methodist Research Instituite, Houston, TX,_ 4 _Internal Medicine, Houston Methodist Hospital, Houston, TX_

**(669)** _Drive Line Infections Are Not Associated with an Increased Incidence of Thromboembolic Complications in Patients on Continuous Flow LVAD Support;_ L. Xuereb, B. Kaur, S. Akrawe, J. Rashty, H. W. Nemeh, J. Borgi, C. Tita, Y. Selektor, M. Velez, D. E. Lanfear, C. T. Williams, G. Paone, J. A. Morgan. _Cardiac Surgery, Henry Ford Hospital, Detroit, MI_

**(670)** _The Incidence of Spontaneous Intracranial Hemorrhage Is Associated with Infection in Patients with Mechanical Circulatory Support;_ T. Raymond, S. Mawri, G. Jacobsen, Y. Selektor, M. Velez, C. Williams, H. Nemeh, J. Borgi, J. Morgan, D. Lanfear, C. Tita. _Henry Ford Hospital, Detroit, MI_

**(671)** _Pre-Implant GI Evaluation and 12 Month Risk of GI Bleeding among Patients with CF-LVAD;_ V. Thohan1, F. X. Downey2, C. John2, N. Z. Sulemanjee1, O. M. Cheema1, T. E. Hastings1. 1 _Aurora Cardiovascular Services, Aurora Healthcare/St. Lukes Med Ctr, Milwaukee, WI,_ 2 _Aurora Cardiovascular Surgical Services, Aurora Healthcare/St. Lukes Med Ctr, Milwaukee, WI_

**(672)** _A Novel Technique to Study Arteriovenous Malformations in Left Ventricular Assist Device Patients with Gastrointestinal Bleeding;_ R. Agarwal1, M. J. Passineau2, R. Mitre3, C. Wu2, P. Correa-Jaque2, G. Lentz2, R. L. Benza1. 1 _Cardiology/Heart Failure and Transplantation, Allegheny General Hospital, Pittsburgh, PA,_ 2 _Allegheny Singer Research Institute, Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA,_ 3 _Section of Gastroenterology, Allegheny General Hospital, Pittsburgh, PA_

**(673)** _Three-Fold Increase in Bleeding Rate in LVAD Patients Bridged with Enoxaparin for Sub-Therapeutic INR;_ A. Bhatia, G. T. Sayer, S. Adatya, G. Kim, N. Sarswat, T. Ota, V. Jeevanandam, N. Uriel. _Internal Medicine, University of Chicago, Chicago, IL_

**(674)** _Use of Rosendaal Method for Calculating Time above Therapeutic INR Range as a Tool to Assess Relative Bleeding Risk in Patients with Left Ventricular Assist Devices;_ A. Rauf, A. K. Johnson, T. K. Buchmiller, N. C. Ridge, A. C. Miller, H. H. Choi, S. Stoker, R. Alharethi, W. T. Caine, D. Budge, K. Afshar, B. Y. Rasmusson, B. B. Reid, A. G. Kfoury. _Mechanical Circulatory Support, Intermountain Medical Center Intermountain Medical Center, Murray, UT_

**(675)** _The Effect of Preoperative Serum Iron Levels on Thromboembolic Events after Left Ventricular Assist Device Implantation;_ A. Arghami1, S. Maltais1, J. A. Schirger2, L. D. Joyce1, D. L. Joyce1, R. C. Daly1, J. M. Stulak1. 1 _Surgery, Mayo Clinic, Rochester, MN,_ 2 _Cardiovascular Diseases, Mayo Clinic, Rochester, MN_

**(676)** _Usefulness of a Multipronged Strategy to Prevent Device Thrombosis in HeartMate II Left Ventricular Assist Devices;_ P. C. Colombo1, M. Yuzefpolskaya1, D. Jennings1, J. Z. Willey2, M. Flannery3, B. Cagliostro1, A. R. Garan1, Y. Naka3, H. Takayama3, K. Takeda3, F. Castagna1, D. M. Mancini1, A. B. Eisenberger1, V. K. Topkara1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Neurology, Columbia University, New York, NY,_ 3 _Surgery, Columbia University, New York, NY_

**(677)** _Elevated Levels of 11-dehydrothromboxane B2 in Urine Is Associated with an Increased Risk of Bleeding in Patients Supported with a Continuous Flow-Left Ventricular Assist Device;_ D. Gupta, A. Pekarek, R. Cole, D. Nguyen, S. R. Laskar, A. L. Smith, K. Wittersheim, J. D. Vega. _Emory University School of Medicine, Atlanta, GA_

**(678)** _Reoperation for Bleeding Does Not Adversely Impact Long-Term Outcomes in LVAD Recipients;_ L. Xuereb, B. Kaur, S. Akrawe, J. Rashty, H. W. Nemeh, J. Borgi, D. E. Lanfear, C. T. Williams, G. Paone, J. A. Morgan. _Cadiac Surgery, Henry Ford Hospital, Detroit, MI_

**(679)** _Intestinal Microbiota Changes in Left Ventricular Assist Device Supported Patients with Gastrointestinal Bleeding;_ R. Y. Loyaga-Rendon1, R. Kumar2, D. Acharya1, S. V. Pamboukian1, J. Tallaj1, F. Siric3, C. Hoopes3, W. Holman3, J. Kirklin3, C. Morrow4. 1 _Division of Cardiology, University of Alabama at Birmingham, Birmingham, AL,_ 2 _Center for Clinical and Translational Sciences, University of Alabama at Birmingham, Birmingham, AL,_ 3 _Division of Cardiovascular Surgery, University of Alabama at Birmingham, Birmingham, AL,_ 4 _Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL_

**(680)** _Aortic Valve Opening Status and Gastrointestinal Bleeding Risk in Patients with HeartWare HVAD;_ B. Maxhera1, A. Albert1, G. Petrov1, R. Westenfeld2, A. Lichtenberg1, D. Saeed1. 1 _Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany,_ 2 _Cardiology, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany_

**(681)** _Triple Antithrombotic Therapy in Patients with Left Ventricular Assist Devices: A Single Center Experience;_ A. L. Bennett1, M. Pfeffer2, S. Thai3, B. Baetz3, P. Campbell4, H. Patel1, C. Eiswirth1, H. Ventura1, S. Krim1. 1 _John Ochsner Heart and Vascular Center, Ochsner Medical Center, New Orleans, LA,_ 2 _University of Queensland-Ochsner Clinical School, New Orleans, LA,_ 3 _Ochsner Medical Center, New Orleans, LA,_ 4 _Baptist Health Transplant Institute, Little Rock, AR_

**(682)** _Impact of Atrial Fibrillation on Pump Thrombosis and Thromboembolic Events in Long-Term Left Ventricular Assist Device Therapy;_ D. Pedde, S. Soltani, F. Kaufmann, M. Müller, P. Pergantis, V. Falk, T. Krabatsch, E. Potapov. _DHZB, Berlin, Germany_

**(683)** _A Single Center Experience of Device Exchange for Continuous Flow Left Ventricular Assist Device Thrombosis;_ K. J. Morine1, D. Mehak1, J. N. Upshaw1, D. T. Pham2, N. K. Kapur1, A. R. Vest1, D. DeNofrio1, M. S. Kiernan1. 1 _Tufts Medical Center, Boston, MA,_ 2 _Northwestern Memorial Hospital, Chicago, IL_

**(684)** _Continuous-Flow LVAD Support Alters Gastrointestinal Vascularity: A Likely Contributor to LVAD-Associated Gastrointestinal Bleeding;_ J. Kang1, P. Kwiatkowski2, M. Acker1, P. Atluri1, P. McConnell2, C. R. Bartoli1. 1 _University of Pennsylvania, Philadelphia, PA, PA,_ 2 _The Ohio State University, Columbus, OH, OH_

**(685)** _Discharge Lactate Dehydrogenase (LDH) Level Predicts Early Device Thrombosis in Patients with HEARTMATE II Left Ventricular Assist Devices: A Retrospective Cohort Analysis;_ V. K. Topkara1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, R. C. Givens1, J. A. Fried1, F. Castagna1, B. Cagliostro1, M. Flannery2, J. Z. Willey3, S. Restaino1, F. Latif1, M. A. Farr1, M. Maurer1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Surgery, Columbia University, New York, NY,_ 3 _Neurology, Columbia University, New York, NY_

**(686)** _Elevated Preoperative Plasma Free Hemoglobin and Hemin May Predict LVAD Thrombosis;_ D. Zhang, J. Kang, G. Redline, J. Howard, M. Acker, P. Atluri, C. R. Bartoli. _University of Pennsylvania, Philadelphia, PA, PA_

**(687)** _The Use of Integrilin Alone or in Combination with Heparin or Argatroban for Suspected Pump Thrombosis in Patients with Left Ventricular Assist Devices;_ A. Bitar, D. Abramov, R. Vijayakrishnan, A. Lenneman, J. Trivedi, T. H. Massey, A. Cheng, M. Slaughter, E. J. Birks. _Jewish Hospital/University of Louisville, Louisville, KY_

**(688)** _ABO Blood Group and Bleeding Post-LVAD;_ R. T. Cole, D. Gupta, J. Lee, J. Gandhi, C. Lambert, Y. Garcia-Bengochea, P. Sandesara, M. Yin, A. Smith, S. Laskar, A. Morris. _Cardiology, Emory Univ Sch of Med, Atlanta, GA_

**(689)** _Impact of Reduced Antiplatelet Therapy on Early Hematologic Adverse Events During Heart Mate II Support;_ O. Saeed, V. Alapati, A. Luke, A. Delaconcha, S. Murthy, J. Shin, D. Sims, S. Patel, D. Goldstein, U. Jorde. _Medicine, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY_

**(690)** _New Method to Route the Driveline of Implantable Left Ventricular Assisted Device for Prevention from Driveline Infection;_ S. Yoshitake, K. Nawata, O. Kinoshita, Y. Hoshino, Y. Itoda, A. Yamamoto, M. Kimura, H. Yamauchi, M. Ono. _Cardiac Surgery, Tokyo University Hospital, Tokyo, Japan_

**(691)** _Surgical Treatment of Mediastinitis with Omentoplasty in Ventricular Assist Device Patients: Report of Referral Center Experience;_ M. Pieri1, G. Arlt2, M. Müller2, V. Falk2, T. Krabatsch2, E. Potapov2. 1 _San Raffaele Hospital, Milan, Italy,_ 2 _Deutsches Herzzentrum Berlin, Berlin, Germany_

**(692)** _Infectious Complications in Extracorporeal Membrane Oxygenation (ECMO) Patients;_ P. Nair1, D. Austin2, S. Kerr3, S. Al-Soufi1, M. Connellan4, P. Spratt4. 1 _Intensive Care Unit, St Vincent's Hospital, Sydney, Australia,_ 2 _Intensive Care Unit, Alfred Hospital, Melbourne, Australia,_ 3 _Kirby Institute, UNSW, Sydney, Australia,_ 4 _Cardiothoracic Surgery, St Vincent's Hospital, Sydney, Australia_

**(693)** MOVED TO MINI ORAL SESSION 07

**(694)** _Surgical Management of Driveline Infections in Patients with Ventricular Assist Devices;_ M. Pieri1, A. Scandroglio1, G. Arlt2, V. Falk2, T. Krabatsch2, E. Potapov3. 1 _San Raffaele Hospital, Milan, Italy,_ 2 _Deutsches Herzzentrum Berlin, Berlin, Germany,_ 3 _Deutsches Herzzentrum Berlin, Berlin, Italy_

**(695)** _Left Ventricular Assist Device Related Infections: Does the Time of Onset Matter?;_ A. L. Lehnert, A. Hart, S. Branam, S. Brouse, M. Guglin. _University of Kentucky HealthCare, Lexington, KY_

**(696)** _Increased Driveline Infection with Betadine Antisepsis: Considerations for Chlorhexidine Intolerant Patients;_ A. Y. Son1, L. H. Stein1, A. Reyentovich2, S. D. Katz2, D. E. Smith1, A. DeAnda, Jr.1, L. B. Balsam1. 1 _Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY,_ 2 _Medicine, Division of Cardiology, NYU Langone Medical Center, New York, NY_

**(697)** _Effect of Tunneling Method on Driveline Infection: Looking Beyond the Silicone-Skin Interface (SSI) Registry;_ A. Y. Son1, L. H. Stein1, A. DeAnda, Jr.1, D. E. Smith1, S. D. Katz2, A. Reyentovich2, L. B. Balsam1. 1 _Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY,_ 2 _Medicine, Division of Cardiology, NYU Langone Medical Center, New York, NY_

**(698)** _Driveline Angle Is Crucial to Prevent Exit Site Infection in Patients with HeartMate II;_ Y. Matsumoto1, T. Fujita1, H. Hata1, Y. Shimahara1, S. Nakajima2, T. Sato2, O. Seguchi2, M. Yanase2, N. Fukushima2, T. Nakatani2, J. Kobayashi1. 1 _Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Suita, Japan,_ 2 _Transplantation, National Cerebral and Cardiovascular Center, Osaka, Suita, Japan_

**(699)** _Comparison of Device-Related Infections between Two Continuous Flow Ventricular Assist Devices;_ S. L. Porenta1, K. R. Shively1, T. F. Dardas1, R. K. Cheng2, J. D. Pal1, W. C. Levy2, D. P. Fishbein2, J. A. Bjelkengren1, J. A. Beckman1, C. Mahr2, N. A. Mokadam1, R. M. Rakita3. 1 _Cardiothoracic Surgery, University of Washington Medical Center, Seattle, WA,_ 2 _Cardiology, University of Washington Medical Center, Seattle, WA,_ 3 _Infectious Disease, University of Washington Medical Center, Seattle, WA_

**(700)** _Left Ventricular Assist Device - Related Infection: Long-Term Treatment Efficacy with Pump Exchange;_ A. S. Abou el ela, S. M. Peer, J. W. Haft, F. D. Pagani. _Cardiac Surgery, University of Michigan, Ann Arbor, MI_

**(701)** _MCS Driveline Infections: Are They Truly Risk Factors for Poor Outcome?;_ J. Moriguchi, L. Czer, H. Henry, R. Jocson, C. Runyan, T. Aintablian, E. Passano, D. Chang, D. Geft, F. Arabia. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**(702)** _Immunocompetence Status as Related to Infection in Heart Transplants after Ventricular Assist Device Implantation;_ J. Carbone1, M. Ruiz2, A. Gonzalez Pinto2, J. Barrios3, J. Hortal3, J. Fernandez-Yañez4, I. Sousa4, P. Diez4, J. Navarro1, E. Sarmiento1. 1 _Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain,_ 2 _Heart Surgery, Hospital General Universitario Gregorio Marañon, Madrid, Spain,_ 3 _Anesthesiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain,_ 4 _Cardiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain_

**(703)** _Distal Limb Perfusion - A Necessary Third Cannula in Extracorporeal Membrane Oxygenation;_ S. Zipfel1, S. Pecha1, S. Hakmi1, S. Braune2, S. Kluge2, M. Kubik1, H. Reichenspurner1, T. Deuse1. 1 _Heart an Vascular Surgery, Hamburg Heart Center, Hamburg, Germany,_ 2 _Intensive Care Medicine, Universital Hospital of Hamburg, Hamburg, Germany_

**(704)** _Hemolysis Is Associated with an Elevated Blood Pressure During Heart Mate II Support;_ O. Saeed, S. Patel, P. Vlismas, A. Luke, A. Delaconcha, S. Murthy, J. Shin, D. Sims, D. Goldstein, U. Jorde. _Medicine, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY_

**(705)** _Readmission During Long-Term Follow-Up After Left Ventricular Assist Device Implantation;_ H. Vidula1, V. Kutyifa1, B. Johnson2, D. Harrington2, A. Papernov1, J. Alexis1. 1 _Medicine, Univ of Rochester, Rochester, NY,_ 2 _Biostatistics, Univ of Rochester, Rochester, NY_

**(706)** _Right Ventricular Failure in Patients with Left Ventricular Assist Devices Is Associated with Downregulated Chemokine Receptors and Altered Right Ventricular Pressure Waveforms;_ T. N. Bachman1, R. Vanderpool2, M. Jacus3, A. Nayak4, O. Hunter5, A. Inashvili4, L. Lagazzi6, J. Teuteberg6, C. McTiernan2, K. Hanley-Yanez7, D. McNamara6, R. Kormos6, M. Simon2. 1 _University of Pittsburgh, Pittsburgh, PA,_ 2 _Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA,_ 3 _Bioengineering, University of Pittsburgh, Pittsburgh, PA,_ 4 _University of Pittsburgh Medical Center, Pittsburgh, PA,_ 5 _School of Medicine, University of Pittsburgh, Pittsburgh, PA,_ 6 _Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA,_ 7 _Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, PA_

**(707)** _Readmission within 30 Days after Left Ventricular Assist Device Implantation Is Associated with Increased Long-Term Mortality;_ S. Gupta1, S. Roy2, R. Cogswell2, T. Thenappan2, K. Liao3, R. John3. 1 _Medicine, University of Minnesota Health, Minneapolis, MN,_ 2 _Cardiology, University of Minnesota Health, Minneapolis, MN,_ 3 _Cardiothoracic Surgery, University of Minnesota Health, Minneapolis, MN_

**(708)** _Comparing Changes in Aortic and Mitral Valve Function with Axial (AX) Versus Centrifugal (CR) Left Ventricular Assist Devices;_ A. Rauf1, M. Al-Sarie2, J. Wever-Pinzon3, R. Alharethi1, J. Stehlik3, S. G. Drakos3, A. K. Johnson1, A. C. Miller1, H. H. Choi1, S. Stoker1, W. T. Caine1, D. Budge1, K. Afshar1, B. B. Reid1, A. G. Kfoury1. 1 _Mechanical Circulatory Support, Intermountain Medical Center Intermountain Medical Center, Murray, UT,_ 2 _Mechanical Circulatory Support, University of Utah Hospital, Salt Lake City, UT,_ 3 _University of Utah Hospital, Salt Lake City, UT_

**(709)** _Aortic Valve Opening Status and Stroke Risk in Patients with HeartWare HVAD;_ D. Saeed1, A. Albert1, B. Maxhera1, R. Westenfeld2, G. Petrov1, A. Lichtenberg1. 1 _Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany,_ 2 _Cardiology, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany_

**(710)** _Worsening Aortic Regurgitation During HeartWare HVAD Support Is Common Despite Optimization of Pump Speed and Use of the Lavare Cycle;_ V. Naruka1, S. J. Pettit2, J. K. Parameshwar2, S. S. Tsui2, C. Lewis2. 1 _Papworth Hospital and University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom,_ 2 _Transplant Unit, Papworth Hospital, Cambridge, United Kingdom_

**(711)** _Evaluating Predictive Parameters for Right Ventricular Failure During LVAD Implantation in a Single Center Patient Cohort;_ A. Schaefer, D. Reichart, A. M. Bernhardt, M. J. Barten, F. M. Wagner, T. Deuse, H. Reichenspurner. _Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany_

**(712)** _Inflow Restriction in the HeartMate II LVAD: A Late Complication;_ T. B. Icenogle1, A. Coletti1, N. Nair1, D. Sato1, P. R. Huber2, D. F. Lubbe2, D. Hollenbaugh2, A. Schmidt1. 1 _Mechanical Heart and Heart Transplantation, Providence Sacred Heart Medical Center, Spokane, WA,_ 2 _Providence Spokane Cardiology, Providence Sacred Heart Medical Center, Spokane, WA_

**(713)** _Combined Therapy of Ventricular Assist Device and Extracorporeal Membrane Oxygenator for Profound Acute Cardiopulmonary Failure;_ K. Fujita1, K. Takeda1, B. Li1, C. Mauro1, P. Kurlansky1, S. Sreekanth1, J. Han1, L. Truby1, R. Garan2, V. Topkara2, M. Yuzefpolskaya2, P. Colombo2, Y. Naka1, H. Takayama1. 1 _Department of Surgery, Columbia University Medical Center, New York, NY,_ 2 _Department of Medicine, Columbia University Medical Center, New York, NY_

**(714)** _Comparison of 6 Month Hospitalizations in Mechanical Circulatory Support Patients vs Heart Transplant Patients;_ M. Kittleson, J. Patel, L. Czer, E. Passano, T. Aintablian, C. Runyan, N. Huie, D. Chang, F. Esmailian, J. Moriguchi, J. A. Kobashigawa. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**(715)** _Incidence and Outcomes After Stroke on Rotary Flow Ventricular Assist Device Support;_ M. Bishawi1, J. Joseph1, B. Yerokun1, D. Ranney1, P. Winterton1, J. Schroder1, M. Daneshmand1, D. Bowles1, J. Rogers2, C. Milano1. 1 _Department of Surgery, Duke University, Durham, NC,_ 2 _Department of Medicine, Duke University, Durham, NC_

**(716)** _Predictors of Readmission in Long-Term Continuous Flow Left Ventricular Assist Device Support;_ J. Han1, K. Takeda1, C. M. Mauro2, P. A. Kurlansky1, A. R. Garan3, V. K. Topkara3, S. Sreekanth1, M. Yuzefpolskaya3, P. C. Colombo3, H. Takayama1, Y. Naka1. 1 _Division of Cardiothoracic Surgery, Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY,_ 2 _Department of Biostatistics, Columbia University Mailman School of Public Health, New York, NY,_ 3 _Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY_

**(717)** _Worsening Renal Function after Ventricular Assist Device Placement Is Associated with Twice the Risk of Death over 3 Years;_ J. E. Holtz1, A. N. Potter2, N. C. Macpherson1, D. Nguyen1, R. L. Kormos1, J. J. Teuteberg1, J. A. Kellum1. 1 _University of Pittsburgh Medical Center, Pittsburgh, PA,_ 2 _University of Pittsburgh, Pittsburgh, PA_

**(718)** _Circulating Biomarkers of Hemolysis Are Not Significantly Increased among Patients Supported with Micro-Axial Flow Catheters;_ M. Esposito, R. O'Kelly, N. Aghili, S. Annamalai, A. Hamadeh, M. Kiernan, A. Vest, D. DeNofrio, N. K. Kapur. _Cardiology, Tufts Medical Center, Boston, MA_

**(719)** _Retained Blood Syndrome Impacts Outcomes after Left Ventricular Assist Device Implantation;_ S. Maltais1, E. M. Boyle2, M. E. Davis3, J. M. Stulak1, L. P. Perrault4, N. A. Haglund3. 1 _Mayo Clinic, Rochester, MN,_ 2 _St-Charles Medical Center, Bend, OR,_ 3 _Vanderbilt, Nashville, TN,_ 4 _Montreal Heart, Montreal, QC, Canada_

**(720)** _RV Longitudinal Strain Predicts RV Failure and Other Adverse Events Post LVAD Implantation;_ M. Gibson, F. Sliwinski, J. Silva, E. Adler. _UC San Diego Medical Center, San Diego, CA_

**(721)** _The Impact of LVAD Complications on Short-Term Outcomes after Heart Transplantation;_ H. Shah1, M. Kahanda1, J. Schilling2, S. LaRue2, J. Shuster3, S. Sitner3. 1 _Internal Medicine, Barnes Jewish Hospital/Washington University, Saint Louis, MO,_ 2 _Cardiology, Barnes Jewish Hospital/Washington University, Saint Louis, MO,_ 3 _Cardiology, Barnes Jewish Hospital, Saint Louis, MO_

**(722)** _Outflow Graft Obstruction of the Heart Ware HVAD Left Ventricular Assist Device: A Single Center Case Series;_ R. K. Young, D. T. Majure, F. H. Sheikh, M. E. Rodrigo, G. Weigold, S. S. Najjar, S. W. Boyce. _MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, MD_

**(723)** _Survival and Driveline Infection Rates in Patients on Chronic Immunosuppressive Therapy Who Undergo Left Ventricular Assist Device Implantation;_ J. R. Spratt1, S. Roy2, D. Plack3, R. John1, K. Liao1, R. J. Cogswell2. 1 _Department of Surgery, University of Minnesota, Minneapolis, MN,_ 2 _Department of Medicine, University of Minnesota, Minneapolis, MN,_ 3 _University of Minnesota, Minneapolis, MN_

**(724)** _Fatal Flaw - Driveline Fracture as a Rare but Serious Complication of Mechanical Circulatory Support with Left Ventricular Assist Devices;_ Y. Boyechko, T. Tribble, M. Guglin. _Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY_

**(725)** _Risk Factors for the Development of Severe Hyperbilirubinemia after Left Ventricular Assist Device Implantation;_ R. Cogswell1, S. Gupta

2, B. Ramu1, M. Burns1, C. Martin1, T. Thenappan1, R. John3. 1 _Cardiology, University of Minnesota, Minneapolis, MN,_ 2 _Medicine, University of Minnesota, Minneapolis, MN,_ 3 _Cardiovascular Surgery, University of Minnesota, Minneapolis, MN_

**(726)** _Use of Tissue Plasminogen Activator (tPA) to Successfully Treat HeartWare LVAD (HVAD) Pump Thrombosis;_ L. L. Staley1, L. Schroedl1, D. E. Steidley2, R. Scott2, J. Spadafore1, M. E. Amity1, E. Boldea1, L. Lanza1, P. DeValeria1, B. W. Hardaway2, E. F. Kransdorf2, O. Pajaro1. 1 _Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ,_ 2 _Cardiology/Transplant, Mayo Clinic, Phoenix, AZ_

**(727)** _New Definition, Same Old Problem: Characterizing the Condition of Right Heart Failure in INTERMACS;_ J. Teuteberg1, R. L. Kormos1, F. D. Pagani2, M. S. Kiernan3, D. C. Naftel4, S. L. Myers4, S. V. Pamboukian4, J. K. Kirklin4. 1 _Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA,_ 2 _University of Michigan, Ann Arbor, MI,_ 3 _Tufts Medical Center, Boston, MA,_ 4 _University of Alabama at Birmingham, Birmingham, AL_

**(728)** _Avoiding Readmission After LVAD Implantation: Can We Predict It?;_ S. J. Forest, Y. Xia, D. J. Goldstein. _Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY_

PATHOLOGY

Target Audience:

PATH, HF, HTX, ID, LTX, MCS

Poster Discussants:

Fiorella Calabrese, Robert Padera, Katharina Wassilew

**(729)** _Identification of MicroRNA Expression Profile of Different Types of Rejection During the First Year After Heart Transplantation with Next Generation Sequencing Technology;_ A. Di Francesco1, M. Fedrigo1, F. De Pascale2, C. Castellani1, G. Feltrin1, G. Toscano1, A. Fraiese1, E. Benazzi3, A. Nocco3, G. Thiene1, M. Valente1, G. Gerosa1, G. Valle2, A. Angelini1. 1 _Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy,_ 2 _CRIBI Biotechnology Centre, University of Padova, Padova, Italy,_ 3 _Organ and Tissue Transplantation Immunology, Fondazione IRCSS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy_

**(730)** _Pathology of Ventricular Assist Devices: A Tertiary Care Center's 15-Year Experience;_ G. A. Fishbein, R. F. Padera. _Department of Pathology, Brigham and Women's Hospital, Boston, MA_

**(731)** _Creating Standardized Reporting for Non-Rejection Lung Transplant Pathology to Improve Interobserver Agreement;_ E. N. Pavlisko1, C. F. Farver2, D. M. Hwang3, W. D. Wallace4, P. B. Illei5, A. V. Arrossi2, D. N. Howell1, J. Todd6. 1 _Department of Pathology, Duke University Medical Center, Durham, NC,_ 2 _Pathology and Laboratory Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH,_ 3 _Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada,_ 4 _Department of Pathology, University of California, Los Angeles, Los Angeles, CA,_ 5 _Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD,_ 6 _Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, NC_

**(732)** _Histomorphology and C4d Expression Are Poor Predictors of Antibody-Mediated Rejection (AMR) in Lung Transplant Recipients;_ C. Kwong1, R. Essendrop1, E. Dixon2, S. Mehrotra1, E. M. Lowery2, J. P. Gagermeier3, K. M. Mirza1, V. Ananthanarayanan1. 1 _Pathology, Loyola University Medical Center, Maywood IL, IL,_ 2 _Pulmonary and Critical Care, Loyola University Medical Center, Maywood IL, IL,_ 3 _Pulmonary and Critical care, Loyola University Medical Center, Maywood IL, IL_

**(733)** _Airway Centered Neutrophils in Post-Transplant Transbronchial Biopsies: A Poor Predictor of Infection;_ P. Sojitra1, A. Muralidhar2, S. Quddus2, S. Mehrotra1, V. Ananthanarayanan1. 1 _Pathology, Loyola University Medical Center, Maywood, IL,_ 2 _Pulmonary and Critical Care Medicine, Loyola University Medical Center, Maywood, IL_

**(734)** _Ultrastructural Examination of Lung Transplant Allografts for Pulmonary Alveolar Proteinosis;_ A. C. Roden1, J. J. Maleszewski1, M. P. Alexander1, P. C. Abell Aleff2, E. S. Yi1, J. P. Scott3. 1 _Laboratory Medicine & Pathology, Mayo Clinic Rochester, Rochester, MN, _2 _Biochemistry & Molecular Biology, Mayo Clinic Rochester, Rochester, MN, _3 _Pulmonary & Critical Medicine, Mayo Clinic Rochester, Rochester, MN_
POSTER SESSION 2

THURSDAY, APRIL 28, 2016

6:00 PM - 7:00 PM

Exhibit Hall B & C

ECONOMICS, ETHICS, PUBLIC POLICY

Target Audience:

EEP, HF, HTX, MCS, NHSAH

Poster Discussants:

Gundeep Dhillon, Fabienne Dobbels, Steven Tsui

**(735)** _Expensive Taste: US Medicare Policy Regarding Destination Therapy VADs Leads to Additional Medical Costs;_ S. Emani1, B. Lampert1, S. Smith1, A. Pleister1, S. Wissman2, K. MacBrair2, A. Bergman2, B. Whitson3, A. Kilic3. 1 _Division of Cardiology, Ohio State University, Columbus, OH,_ 2 _Ohio State University, Columbus, OH,_ 3 _Division of Cardiothoracic Surgery, Ohio State University, Columbus, OH_

**(736)** _Financial Impact of Extracorporeal Life Support on Survivors Versus Non-Survivors;_ T. R. Ryan1, A. F. Burdorf2, B. D. Lowes2, J. Y. Um1, A. Siddique1, H. M. Merritt-Genore1, S. L. Varnado3, M. J. Moulton1. 1 _Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE,_ 2 _Internal Medicine - Cardiology, University of Nebraska Medical Center, Omaha, NE,_ 3 _Clinical Pharmacy, University of Nebraska Medical Center, Omaha, NE_

**(737)** _Success of Left Ventricular Assist Device Therapy in Rural United States Residents;_ N. Rajagopalan, A. L. Hart, S. M. Branam, M. Sekela, M. Guglin. _University of Kentucky, Lexington, KY_

**(738)** _Need and Supply of Heart Replacement Therapy in Italy, with U.S. as Benchmark;_ M. Frigerio1, G. Feltrin2. 1 _A. DeGasperis CardioCenter, Niguarda Ca' Granda Hospital, Milan, Italy,_ 2 _Regional Center for Transplant Coordination, Veneto Region, Padua, Italy_

**(739)** _Morbid Obesity in Heart Transplant Does Not Affect One Year Survival;_ M. Sherwood1, S. Joseph2, G. Saracino2, T. Chamogeorgakis2, G. V. Gonzalez-Stawinski2, S. Hall2, B. Lima2. 1 _Heart Failure/Cardiac Transplant, Baylor Univerisity Medical Center at Dallas, Dallas, TX,_ 2 _Baylor Univerisity Medical Center at Dallas, Dallas, TX_

**(740)** _Outcome of Heart Transplantation in Patients Supported by ECMO: Is the APACHE IV Score a Predictor of Survival?;_ A. Lechiancole, S. Sponga, I. Vendramin, M. Maiani, E. Spagna, R. Sappa, U. Livi. _Cardio-Thoracic Surgery of Udine, Cardio-Thoracic Surgery of Udine, Udine (UD), Italy_

**(741)** _Impact of Advanced Heart Failure on Hospital Readmissions in the Elderly;_ L. Miller1, M. R. Mehra2, J. D. Rich3, J. B. Oconnell4, R. Bostic4. 1 _Cardiovascular, Morgan Heart Institute, Clearwater, FL,_ 2 _Cardiovascular, Brigham and Women's Hosptial, Boston, MA,_ 3 _Cardiology, Northwestern University, Chicago, IL,_ 4 _Thoratec Corporation, Pleasanton, CA_

**(742)** _Establishing Institutional Costs in the Year Before and After VAD Implant and Before Heart Transplant;_ R. A. Prichard1, P. Newton2, S. Goodall3, L. Kershaw4, P. M. Davidson5, T. Homer6, F. McNeil6, C. S. Hayward1. 1 _Heart Lung Clinic, St Vincent's Hospital, Sydney, Australia,_ 2 _Centre for Cardiovascular and Chronic Care, University of Technology, Sydney, Australia,_ 3 _Centre for Health Economic Research and Evaluation, University of Technology, Sydney, Australia,_ 4 _St Vincent's Hospital, Sydney, Australia,_ 5 _Department of Acute and Chronic Care, Johns Hopkins University, Baltimore, MD,_ 6 _HeartWare International, Framingham, MA_

**(743)** _Ethical Analysis of Withdrawing Total Artificial Heart Support;_ E. S. DeMartino1, S. E. Wordingham2, D. P. Sulmasy3, J. M. Stulak4, B. A. Boilson5, K. R. Fuechtmann6, N. Singh7, O. E. Pajaro8, P. S. Mueller9. 1 _Pulmonary and Critical Care Medicine, Biomedical Ethics, Mayo Clinic, Rochester, MN,_ 2 _Palliative Medicine, Mayo Clinic, Scottsdale, AZ,_ 3 _Department of Medicine, MacLean Center for Clinical Medical Ethics, University of Chicago, Chicago, IL,_ 4 _Cardiovascular Surgery, Mayo Clinic, Rochester, MN,_ 5 _Cardiovascular Diseases, Mayo Clinic, Rochester, MN,_ 6 _Augsburg College, Minneapolis, MN,_ 7 _University of Wisconsin, Madison, WI,_ 8 _Cardiovascular Surgery, Mayo Clinic, Scottsdale, AZ,_ 9 _General Internal Medicine, Biomedical Ethics, Mayo Clinic, Rochester, MN_

**(744)** _Cost-Effectiveness Comparison of Intra Aortic Balloon Pump versus Left Ventricular Assist Devices as Bridge to Heart Transplant (BTT) Strategies;_ J. Amione-Guerra1, K. J. Elizondo1, A. S. Cruz-Solbes1, K. Kostick2, L. Loza1, A. Bhimaraj1, B. H. Trachtenberg1, G. Ashrith1, M. H. Park1, D. P. Bernard1, J. D. Estep1. 1 _Methodist Debakey Heart Center, Houston Methodist Hospital, Houston, TX,_ 2 _Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX_

HEART FAILURE

Target Audience:

HF, BSI, MCS, NHSAH, PHARM

Poster Discussants:

Sharon Chih, Monica Colvin, Choon Pin Lim, Maryse Palardy, Michael Pham, Stuart Russell

**(745)** _Beneficial Effects of Sildenafil in a Patients with Severe Tricuspid Regurgitation; Improvement in Quality of Life and Exercise Capacity;_ K. Kim. _Sejong General Hospital, Seoul, Korea, Republic of_

**(746)** _Perceived Health Status in Adult Fontan Patients: The Impact of Previous Heart Failure Hospitalization;_ L. J. Burchill1, W. M. Wilson2, H. J. Ross3, R. M. Wald4, A. H. Kovacs5. 1 _Adult Congenital Heart Program, Knight Cardiovascular Institute, Oregon Health Science University, Portland, OR,_ 2 _Adult Congenital Heart Program, Royal Melbourne Hospital, Melbourne, Australia,_ 3 _Cardiac Transplant Program, University Health Network, Toronto General Hospital, Toronto, ON, Canada,_ 4 _Toronto Congenital Cardiac Center for Adults, University Health Network, Toronto General Hospital, Toronto, ON, Canada,_ 5 _Adult Congenital Heart Program, Knight Cardiovascular Institute, Portland, OR_

**(747)** _Impact of Education Alone vs. Education and Medical Intervention vs. Standard Treatment in Re-Hospitalization for Heart Failure;_ J. Jimenez1, M. Salinero2, V. Pope2, L. Reyes2, C. Khanal2, M. Matos2, E. Stone2. 1 _MCVI-South Miami Hospital, Miami, FL,_ 2 _Cardiology, MCVI-South Miami Hospital, Miami, FL_

**(748)** _Heart Failure Patients' Quality of Life and Perception of Palliative Care;_ J. A. Anderson1, B. D. Lowes2, G. Canaris1, H. Vongooru2, R. Zolty2, E. Raichlin2, T. Diederich2. 1 _Internal Medicine, University of Nebraska Medical Center, Omaha, NE,_ 2 _Cardiology, University of Nebraska Medical Center, Omaha, NE_

**(749)** _Association of sST2 with GDF-15 and Matrix Metalloproteinases in Idiopathic Dilated Cardiomyopathy;_ N. Nair1, E. Gongora2. 1 _Cardiology, S and W Hospital , Temple ,TX , Texas Tech Health Sciences Center, Lubbock, TX,_ 2 _Cardiology, S and W Hospital , Temple ,TX , Memorial Cardiac and Vascular Institute, Hollywood, FL_

**(750)** _GDF-15 Correlates Positively with Matrix Metalloproteinases in Idiopathic Dilated Cardiomyopathy;_ N. Nair1, E. Gongora2. 1 _Cardiology, S &W, Temple , TX, Texas Tech Health Scieces Center, Lubbock, TX, _2 _Cardiology, S &W, Temple , TX, Memorial Heart and Vascular Center, Hollywood, FL_

**(751)** _Characterization of Patients with Predominantly Intramural Coronary Amyloidosis;_ F. Kamdar, J. Valent, C. D. Tan, E. R. Rodriguez, M. Hanna. _Cleveland Clinic, Cleveland, OH_

**(752)** _Echocardiographic Predictors of Admission among Ambulatory Patients with HFrEF;_ V. Thohan, N. Z. Sulemanjee, O. M. Cheema, T. E. Hastings, D. L. Zwicke. _Aurora Cardiovascular Services, Aurora Healthcare/St. Lukes Med Ctr, Milwaukee, WI_

**(753)** _Right Ventricular T1 Mapping: A Feasibility Study;_ B. H. Freed1, E. Semaan2, B. C. Benefield2, B. Spottiswoode2, C. Brady1, B. Allen2, S. J. Shah1, J. C. Carr2, M. Markl2, J. D. Collins2. 1 _Cardiology, Northwestern University, Chicago, IL,_ 2 _Radiology, Northwestern University, Chicago, IL_

**(754)** _Fick Cardiac Index Predicts Disease Progression in UNOS Status 2 Patients;_ K. P. Murphy1, A. R. Vest2, N. K. Kapur2, D. DeNofrio2, M. S. Kiernan2. 1 _Internal Medicine, Tufts Medical Center, Boston, MA,_ 2 _Cardiology, Tufts Medical Center, Boston, MA_

**(755)** _Utility of Wireless Pulmonary Artery Pressure Measurement System (CardioMEMS®) in Heart Failure Patients with Non-Cardiac Advanced Organ Failure or Organ Replacement;_ R. Araujo-Gutierrez, S. H. Ibarra-Cortez, M. Park, J. D. Estep, G. Ashrith, G. Torre-Amione, A. Bhimaraj, B. H. Trachtenberg. _Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX_

**(756)** _Prevalence of Advanced Heart Failure (AdHF) Utilizing the Latest Published Definitions Yields Higher Than Previously Published Data;_ A. J. Creamer. _Heart Failure, Houston Methodist, Houston, TX_

**(757)** _Monocyte Gene Expression before and after LVAD Implantation;_ N. Uriel1, D. E. Rodgers1, G. Sayer1, N. Sarswat1, G. H. Kim1, V. Jeevanandam1, J. Yee2, S. Adatya1. 1 _Cardiology, University of Chicago, Chicago, IL,_ 2 _CareDx, Brisbane, CA_

**(758)** _Are All Patients Equal in Response to Intra-Aortic Balloon Counterpulsation?;_ D. A. Baran, M. Cohen, G. K. Visweswaran, M. DiVita, A. Seliem, A. Dave, N. Wasty, J. E. Swinden, K. Liaquat. _Transplant Center, Newark Beth Israel Med Ctr, Newark, NJ_

**(759)** _Biventricular Impella Support: A Contemporary Approach to Acute Mechanical Circulatory Support for Cardiogenic Shock Due to Biventricular Failure;_ N. Aghili1, Y. Bader1, C. Kimmelstiel1, A. Weintraub1, M. Kiernan1, A. Vest1, D. DeNofrio1, D. Pham2, N. Kapur1. 1 _Tufts Medical Center, Boston, MA,_ 2 _Northwestern Memorial Hospital, Chicago, IL_

**(760)** _Surgical Therapy in End Stage Heart Failure: Should We Change Our Vision?;_ A. Forni, B. Chiominto, G. Faggian. _Cardiac Surgery, University Hospital of Verona, Verona, Italy_

**(761)** _Role of a Multidisciplinary Shock Team in the Management of Cardiogenic Shock;_ B. Ko, A. Tandar, T. Kang, S. McKellar, J. Stehlik, G. Stoddard, J. Morshedzadeh, A. Koliopoulou, E. Gilbert, J. Nativi-Nicolau, O. Wever-Pinzon, J. Fang, C. Selzman, F. Welt, S. Drakos. _Cardiovascular Division, University of Utah, Salt Lake City, UT_

HEART TRANSPLANTATION

Target Audience:

HTX, ID, MCS, NHSAH, PATH, PEDS, PHARM

Poster Discussants:

Alejandro Bertolotti, Robert Chen, Marisa Crespo-Leiro, Mani Daneshmand, Juan Delgado Jimenez, Howard Eisen, Maryjane Farr, Jan Gummert, A. G. Kfoury, Nicolas Manito, Sonia Mirabet, Jignesh Patel, Jacob Schroder, Rajamiyer Venkateswaran

**(762)** _Thymoglobulin Provides Protection Against Ischemia Reperfusion in the Immediate Post-Transplant Period;_ J. A. Kobashigawa, M. Kittleson, J. Patel, T. Aintablian, P. Zarrini, A. Lipson, T. Kao, T. Daun, D. Chang, A. Trento, A. Hage, L. Czer. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**(763)** _Immunosuppressant Regimen over Time and Their Association with Rejection, Graft Failure, and Mortality;_ Y. Ravi1, E. Stock2, P. C. Rosas3, A. K. Hasan4, L. Nikolaidis5, S. Bansal6, B. A. Whitson7, R. C. Scott5, C. B. Sai-Sudhakar1. 1 _Cardiac Surgery, Scott & White, Texas A&M, Temple, TX, _2 _Center for Applied Health Research, Scott & White, Texas A&M, Central Texas VA, Temple, TX, _3 _Medical Physiology, Texas A &M, Temple, TX, _4 _Cardiology-Internal Medicine, The Ohio State University, Columbus, OH,_ 5 _Cardiology-Internal Medicine, Scott & White, Texas A&M, Temple, TX, _6 _Cardiac Surgery, Mayo Clinic, Jacksonville, FL,_ 7 _Cardiac Surgery, The Ohio State University, Columbus, OH_

**(764)** _Lower Dose Tacrolimus Monotherapy in Heart Transplant Patients: Is It Safe;_ M. Luu, J. Patel, M. Kittleson, L. Czer, T. Aintablian, K. Norland, N. Perry, D. Chang, M. Hamilton, D. Geft, J. A. Kobashigawa. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**(765)** _Early Post-Operative Acute Kidney Injury in Heart Transplant Recipients: Who Gets It, and Does It Matter?;_ J. P. Casale, C. T. Doligalski, A. T. Logan. _Tampa General Hospital, Tampa, FL_

**(766)** _Long-term Effect on Albuminuria and Glomerular Filtration Rate of a Calcineurin Inhibitor-Free Everolimus Based Immunosuppressive Regimen after Heart Transplantation;_ L. M. Nelson1, A. K. Andreassen2, B. Andersson3, E. Gude2, H. Eiskjær4, G. Raadegran5, G. Dellgren6, L. Gullestad2, F. Gustafsson1. 1 _Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark,_ 2 _Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway,_ 3 _Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden,_ 4 _Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark,_ 5 _The Clinic for Heart Failure and Valvular Disease, Skåne University Hospital and Lund University, Lund, Sweden,_ 6 _Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden_

**(767)** _Impact of Treatment with m-TOR Inhibitors on Platelet Reactivity in Heart Transplant Patients Treated with Clopidogrel. Preliminary Results;_ J. Gonzalez-Costello, J. Ferreiro, J. Roca, A. Marcano, I. Rodríguez, J. Salazar-Mendiguchia, I. Tatjer, A. Miralles, N. Manito, A. Cequier. _Hospital Universitari de Bellvitge, Barcelona, Spain_

**(768)** _Proliferation Signal Inhibitors Prevent Donor-Specific Antibody Production in Sensitized Patients after Heart Transplantation;_ M. Kittleson, J. Patel, L. Czer, T. Aintablian, G. Rodriguez, A. Velleca, B. Kearney, D. Chang, M. Hamilton, F. Esmailian, X. Zhang, N. Reinsmoen, J. A. Kobashigawa. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**(769)** _Outcome of Patients Proceeding to Heart Transplant with Low Level Donor-Specific Antibodies: How Do They Do?;_ M. Kittleson, J. Patel, L. Czer, T. Aintablian, T. Daun, M. Johnson, D. Chang, A. Trento, D. Geft, J. A. Kobashigawa. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**(770)** _Lack of Rejection Despite Period of No Immunosuppression: The NoTac Case Series;_ D. A. Baran1, P. Rao2, D. Deo2, K. Liaquat1, J. Pieretti1, C. Gidea1, M. Munagala1, M. J. Zucker1. 1 _Transplant Center, Newark Beth Israel Med Ctr, Newark, NJ,_ 2 _Sharing Network Laboratory, New Providence, NJ_

**(771)** _Towards Reduced Nephrotoxicity Following Heart Transplantation by Extended-Release Calcineurin Inhibition- A Single Center Observational Study;_ S. Keymel1, B. Stanske1, V. Veulemans1, U. Boeken2, D. Saeed2, A. Lichtenberg2, M. Kelm1, R. Westenfeld1. 1 _Cardiology, University Hospital, Duesseldorf, Germany,_ 2 _Cardiovascular Surgery, University Hospital, Duesseldorf, Germany_

**(772)** _Novel Effect of Everolimus in Heart Transplant Recipients - Attenuation of Myocardial Hypertrophy and Improvement of Diastolic Function;_ T. Imamura1, K. Kinugawa1, D. Nitta2, M. Hatano2, Y. Itoda3, M. Kimura3, O. Kinoshita3, H. Yamauchi3, K. Nawata3, M. Ono3. 1 _Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo, Japan,_ 2 _Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan,_ 3 _Department of Cardiac Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan_

**(773)** _Alloantibody Desensitization Therapy in Bridge-to-Transplant Patients on Continuous-Flow Left Ventricular Assist Device Support;_ D. Bejar1, P. C. Colombo1, D. Jennings1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, F. Castagna1, M. Maurer1, E. Zorn1, F. Latif1, S. Restaino1, M. A. Farr1, Y. Naka2, D. M. Mancini1, V. K. Topkara1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Surgery, Columbia University, New York, NY_

**(774)** _CD38+DR+ Expression on Peripheral Monocytes and TLR2 Expression on Plasmocytoid Dendritic Cells May Be Early Markers for Severe Infection in Heart Transplantation;_ J. Carbone1, A. Gallego1, L. Calahorra1, I. Sousa2, P. Diez2, E. Sarmiento1. 1 _Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain,_ 2 _Cardiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain_

**(775)** _Outcomes of Rheumatic Heart Disease Following Heart Transplantation: ISHLT Registry Data;_ J. M. Dan1, J. Silva Enciso2, L. Edwards3, L. H. Lund4, S. Aslam1. 1 _Medicine, Division of Infectious Diseases, University of California, San Diego, La Jolla, CA,_ 2 _Medicine, Division of Cardiovascular Medicine, University of California, San Diego, San Diego, CA,_ 3 _United Network for Organ Sharing, Richmond, VA,_ 4 _Medicine and Cardiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden_

**(776)** _Outcomes of Heart Transplantation after Long-Term Circulatory Support by Ventricular Assist Devices with Driveline/Pump Infection;_ K. Nawata, O. Kinoshita, M. Kimura, H. Yamauchi, Y. Itoda, S. Yoshitake, Y. Hoshino, M. Ono. _The Department of Cardiothoracic Surgery, The University of Tokyo Hospital, Tokyo, Japan_

**(777)** _Cytomegalovirus Seropositivity Is Associated with Increased One Year Acute Rejection in Heart Transplant Recipients;_ Y. Xia1, R. Bello1, S. Forest1, D. Sims2, S. Patel3, D. Goldstein1. 1 _Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY,_ 2 _Medicine, Montefiore Medical Center, Bronx, NY,_ 3 _Medicine, Cardiology, Montefiore Medical Center, Bronx, NY_

**(778)** _CMV Reactivation Using Valganciclovir vs Valacyclovir in Moderate Risk Heart Transplant Recipients;_ S. Varnado, H. Brink, J. Balk, E. Raichlin, B. Lowes, H. Vongooru, A. Burdorf, J. Um, M. Moulton, A. Siddique, R. Zolty. _Nebraska Medicine, Omaha, NE_

**(779)** _Initial Experience of Heart Transplantation in India;_ K. krishan1, M. Shinde1, A. Asija1, P. Sinha1, R. Chand2, A. Koppula1. 1 _Cardiovascular Surgery, Max Super Speciality Hospital, Saket, New Delhi, India,_ 2 _Cardiovascular Anaesthesia, Max Super Speciality Hospital, Saket, New Delhi, India_

**(780)** _Treatment of Sleep Apnea with Heart Transplantation: Does It Help?;_ J. Patel, M. Kittleson, L. Czer, T. Aintablian, R. Sharoff, B. Kim, A. Velleca, B. Kearney, D. Chang, B. Azarbal, D. Chang, M. Hamilton, A. Trento, J. A. Kobashigawa. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**(781)** _Removal of Ventricular Assist Device at the Time of Heart Transplant in Sensitized Patients Results in Reduced Antibody Production;_ J. Moriguchi, M. Kittleson, J. Patel, L. Czer, T. Aintablian, R. Jocson, C. Runyan, D. Chang, B. Azarbal, F. Arabia, J. A. Kobashigawa. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**(782)** _A Novel Risk Score to Predict Prolonged Post-Operative Length of Stay after Heart Transplantation;_ T. C. Crawford1, J. Magruder1, J. C. Grimm1, N. Patel1, C. M. Sciortino1, K. J. Zehr1, K. Mandal1, J. V. Conte1, R. S. Higgins1, D. E. Cameron1, R. J. Tedford2, S. D. Russell2, G. J. Whitman1. 1 _Cardiac Surgery, Johns Hopkins University, Baltimore, MD,_ 2 _Cardiology, Johns Hopkins University, Baltimore, MD_

**(783)** _Simple Technique for Open Sternal Wound Closure after Cardiac Transplant or LVAD;_ U. Bansal1, A. Bansal2, J. K. Bhama3. 1 _School of Medicine, University of Pittsburgh, Pittsburgh, PA,_ 2 _John Ochsner Heart & Vascular Institute, Ochsner Clinic, New Orleans, LA, _3 _Heart & Vascular Center, University of Iowa Health Care, Iowa City, IA_

**(784)** _Post Heart Transplant Abandoned Lead Fragments: How to Avoid It?;_ S. Hakmi, S. Pecha, A. Bernhardt, T. Deuse, M. Barten, F. Wagner, H. Reichenspurner. _Cardiovascular Surgery, Univiversity Heart Center Hamburg, Hamburg, Germany_

**(785)** _The Prognostic Impact of One-Year Hemodynamics on Long-Term Survival After Heart Transplantation;_ E. Bollano1, K. Karason1, C. Hjalmarsson1, S. Bartfay1, B. Daka2, B. Andersson1, G. Dellgren3. 1 _Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden,_ 2 _Primary Health Care, Sahlgrenska Academy at Gotheburg University, Gothenburg, Sweden,_ 3 _Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden_

**(786)** _Desensitization in Total Artificial Heart Patients;_ J. Neyer, M. Kittleson, J. Patel, L. Czer, T. Aintablian, G. Rodriguez, R. Jocson, C. Runyan, D. Chang, J. Moriguchi, A. Trento, J. A. Kobashigawa, F. Arabia. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**(787)** _Palliative Care Integration into Cardiac Transplant Recipient Care: A Retrospective Case Series;_ H. Groninger1, M. Aggarwal2, K. Walker3, A. M. Kelemen1, R. M. Holder1, J. T. Panke1, G. Ruiz4. 1 _Medicine, MedStar Washington Hospital Center, Washington, DC,_ 2 _Medicine, MedStar Georgetown University Hospital, Washington, DC,_ 3 _Palliative Care, MedStar Health, Columbia, MD,_ 4 _Advanced Heart Failure, MedStar Heart and Vascular Institute, Washington, DC_

**(788)** _Risk of Post-Transplant Renal Dysfunction Is Increased in Patients Supported with Continuous-Flow Left Ventricular Assist Devices;_ V. K. Topkara1, P. N. Trinh2, A. Masoumi1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda3, H. Takayama3, J. Haythe1, M. Maurer1, F. Latif1, S. Restaino1, M. A. Farr1, D. M. Mancini1, Y. Naka3, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Epidemiology, Columbia University, New York, NY,_ 3 _Surgery, Columbia University, New York, NY_

**(789)** _Heart Transplantation in Seniors: The Impact of Age on Outcomes?;_ Y. Lin1, S. S. Kushwaha2, B. S. Edwards2, N. L. Pereira2, D. L. Joyce1, J. M. Stulak1, L. D. Joyce1, R. C. Daly1. 1 _Cardiovascular Surgery, Mayo Clinic, Rochester, MN,_ 2 _Cardiovascular Disease, Mayo Clinic, Rochester, MN_

**(790)** _Heterotopic Heart Transplantation in Argentina;_ C. Burgos, M. C. Rodriguez, C. Elisa, O. Mugianesi, J. Magistretti, M. Burgos, G. Bortman, S. V. Perrone. _Cardiovascuar Surgery & Transplant, Hospital Italiano de Mendoza, Guaymallen - Mendoza, Argentina_

**(791)** _Psychiatric Morbidity in De Novo Heart Transplant Recipients on Everolimus-Based Immunosuppression;_ B. S. Bürker1, U. F. Malt2, E. Gude3, L. Gullestad3, A. Relbo3, I. Grov3, A. K. Andreassen3, A. E. Fiane4, I. R. Haraldsen1. 1 _Department of Psychosomatic Medicine, Oslo University Hospital - Rikshospitalet, Oslo, Norway,_ 2 _Department of Research and Education, Oslo University Hospital - Rikshospitalet, Oslo, Norway,_ 3 _Department of Cardiology, Oslo University Hospital - Rikshospitalet, Oslo, Norway,_ 4 _Department of Cardiothoracic Surgery, Oslo University Hospital - Rikshospitalet, Oslo, Norway_

**(792)** _Transplantation versus Ventricular Assist Device for the Management of End-Stage Heart Failure: An Observational Comparison of Clinical and Economic Outcomes;_ N. Aissaoui1, M. Morshuis2, H. Maoulida3, J. Salem4, M. Brunn3, S. Varnous5, J. Gummert2, I. Durand-Zaleski3, P. Leprince5, J. Fagon1. 1 _Hopital Européen Georges Pompidou, Paris, France,_ 2 _Department of Thoracic & Cardiovascular Surgery, Heart and Diabetes Centre NRW, Ruhr-University of Bochum, Bad Oeynhausen, Germany, _3 _Epidémiologie Clinique, Évaluation Économique et Populations Vulnérables, UMRS 1123, URC, Hotel Dieu, Paris, France,_ 4 _Pharmacology and CIC-1421; INSERM, CIC-1421, GHPS, Paris, France,_ 5 _Cardiac Surgery, GHPS, Paris, France_

**(793)** _Clinical Usage of Marginal Donor Hearts in Transplantation: Experiences from Wuhan Union Hospital;_ n. Dong. _Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, WuHan, China_

**(794)** WITHDRAWN

**(795)** _Impact of Number of Pregnancies on Allosensitization and Heart Transplant Outcomes;_ S. G. Al-Kindi, P. Thakker, M. Farhoud, M. Kattea, M. Ginwalla, C. ElAmm, M. Zacharias, R. Benatti, S. V. Deo, B. Sareyyupoglu, S. Park, B. Medalion, G. H. Oliveira. _Harrington Heart and Vascular Institute, University Hospitals Case Medical Center, Cleveland, OH_

**(796)** _Extra-Corporeal Membrane Support as Bridge to Transplant - An Outcome Analysis of United Network for Organ Sharing Registry;_ S. K. Zalawadiya1, W. Cotts1, G. Bhat1, J. Lindenfeld2. 1 _Advanced Heart Failure/ Transplant Cardiology, Advocate Christ Medical Center, Oak Lawn, IL,_ 2 _Advanced Heart Failure/ Transplant Cardiology, Vanderbilt Medical Center, Nashville, TN_

**(797)** _Risk of Tumor Transmission After Thoracic Allograft Transplantation from Adult Donors with Central Nervous System Neoplasm-A UNOS Database Study;_ C. F. Hynes, K. Ramakrishnan, F. A. Alfares, K. M. Endicott, K. Hammond-Jack, D. Zurakowski, R. A. Jonas, D. S. Nath. _Children's National Medical Center, Washington, DC_

**(798)** _Use of Prothrombin Complex Concentrates (PCCs) in Patients Undergoing Heart Transplant Surgery: Clinical Experience at a University Hospital;_ S. L. Rao1, Y. P. Salamanca1, W. E. Pae2. 1 _Department of Anesthesiology & Perioperative Medicine, PennState Hershey Medical Center, Hershey, PA, _2 _Department of Surgery, PennState Hershey Medical Center, Hershey, PA_

**(799)** _Patients Save Lives: Donor Designation at the PCP Office;_ M. D. Enos. _Center for Organ Recover & Education, Pittsburgh, PA_

**(800)** _Cardiac Surgery after Heart Transplantation - Elective Operation or Last Exit Strategy?;_ J. Goekler, A. Aliabadi, O. Salameh, T. Haberl, K. Uyanik-Ünal, G. Laufer, A. Zuckermann. _Cardiac Surgery, Medical University Vienna, Vienna, Austria_

**(801)** _Population Profile Submitted to Cardiac Transplantation in a Brazilian Hospital: Comparison Involving the Registry of ISHLT;_ G. C. Lima, S. Mangini, B. Alves, J. Vieira, L. Pires, F. Vianna, F. Brito, J. Xavier, R. Poffo, F. Bacal. _Hospital Israelita Albert Einstein, São Paulo, Brazil_

**(802)** _Recipient Related Predictors of Mortality after Heart Transplantation: Results from a Contemporary Irish National Cohort;_ N. Ryan, M. Barrett, A. Eisaka, B. Parlon, J. Egan, N. G. Mahon, J. Mc Carthy, J. McGuinness, L. Noelke, C. M. Halley, J. O. O'Neill. _National Transplant Unit, Mater Misericordiae University Hospital, Dublin 7, Ireland_

**(803)** _Comparison of the Clinical Outcomes After De-Novo Heart Transplantation Between Adults with and without Congenital Heart Disease;_ A. Taylor1, J. Lannon2, T. Dominguez1, N. R. Banner3, D. Crossland4, J. Parameshwar5, R. Taylor2, R. Thompson6, R. Venkateswaran7, N. Al Attar8, M. Burch1. 1 _Cardiology, Great Ormond Street Hospital, London, United Kingdom,_ 2 _Statistics, NHSBT, Bristol, United Kingdom,_ 3 _Cardiology, Royal Brompton and Harefield, London, United Kingdom,_ 4 _Cardiology, Freeman Hospital, Newcastle, United Kingdom,_ 5 _Cardiology, Papworth Hospital, Cambridge, United Kingdom,_ 6 _Transplant, Queen Elizabeth Birmingham Hospital, Birmingham, United Kingdom,_ 7 _Surgery, Wythenshaw Hospital, Manchester, United Kingdom,_ 8 _Surgery, Golden Jubilee Hospital, Glasgow, United Kingdom_

**(804)** _Prothrombin Complex Concentrate Reduces Intraoperative Blood Product Utilization in Heart Transplantation;_ D. Enter1, M. Marsh2, N. Cool2, J. Kruse1, Z. Li1, A. Andrei1, A. Iddriss1, P. M. McCarthy1, C. Malaisrie1, A. Anderson3, J. Rich3, D. Pham1. 1 _Cardiac Surgery, Northwestern University, Chicago, IL,_ 2 _Pharmacy, Northwestern University, Chicago, IL,_ 3 _Cardiology, Northwestern University, Chicago, IL_

**(805)** _The Impact of Gender Mismatching on Early and Late Outcomes Following Heart Transplantation;_ Y. Peled1, J. Lavee1, M. Arad2, Y. Shemesh1, Y. Kassif1, Y. Har-Zahav1, I. Goldenberg3, D. Freimark2. 1 _Heart Transplantation Unit, Sheba Medical Center Tel Hashomer, Ramat Gan, Israel,_ 2 _Heart Failure Unit, Sheba Medical Center Tel Hashomer, Ramat Gan, Israel,_ 3 _Cardiology Department, Sheba Medical Center Tel Hashomer, Ramat Gan, Israel_

**(806)** _Prolonged Left Ventricular Assist Device Support Does Not Affect Post-Transplantation Survival;_ A. Cheng, J. R. Trivedi, E. M. Schumer, M. S. Slaughter, H. T. Massey. _Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, KY_

**(807)** _Effects of Increasing Donor Age on the Risk of Permanent Pacing after Orthotopic Heart Transplantation;_ F. Akca1, T. Szili-Torok2, R. Muslem2, S. Akin2, O. Manintveld2, A. Constantinescu2, O. Birim1, K. Caliskan2. 1 _Cardiothoracic Surgery, Erasmus MC, Rotterdam, Netherlands,_ 2 _Cardiology, Erasmus MC, Rotterdam, Netherlands_

**(808)** _Impact of Donor to Recipient Weight Ratios on Outcome After Cardiac Transplantation;_ U. Boeken1, A. Albert1, A. Mehdiani1, C. Sowa1, C. Ballazs1, R. Westenfeld2, P. Akhyari1, A. Lichtenberg1. 1 _Cardiovascular Surgery, University Hospital, Duesseldorf, Germany,_ 2 _Cardiology, University Hospital, Duesseldorf, Germany_

**(809)** _Severity of Hypertension After Heart Transplant: Does It Impact Outcome?;_ J. Patel, M. Kittleson, L. Czer, T. Aintablian, R. Sharoff, G. Rodriguez, B. Kearney, N. Perry, A. Hage, F. Esmailian, J. A. Kobashigawa. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**(810)** _Renal Function at One Year after Cardiac Transplantation but Not Acute Kidney Injury Is Highly Associated with Long-Term Survival and Loss of Renal Function;_ G. Fortrie1, O. C. Manintveld2, A. A. Constantinescu2, P. C. van de Woestijne3, M. G. Betjes1. 1 _Nephrology and Transplantation, Erasmus MC, Rotterdam, Netherlands,_ 2 _Cardiology, Erasmus MC, Rotterdam, Netherlands,_ 3 _Cardiothoracic Surgery, Erasmus MC, Rotterdam, Netherlands_

**(811)** _Usefulness of the "Impact Score" to Predict One-Year Mortality in a Hispanic Heart Transplant Cohort at a Single Center in Latin America;_ A. M. Bertolotti, M. Peradejordi, L. Favaloro, D. O. Absi, F. Renedo, A. Guazzone, R. Ratto, M. Candioti, R. Favaloro. _Intrathoracic Transplantation and Heart Failure Division, University Hospital Favaloro Foundation, Buenos Aires, Argentina_

**(812)** _Impact of Recipient Body Mass Index on Orthotopic Heart Transplantation Outcomes;_ A. Loforte1, M. Cefarelli1, G. Murana1, G. Jafrancesco1, J. Alfonsi1, E. Pilato1, S. Martin Suarez1, L. Potena2, F. Grigioni2, G. Marinelli1. 1 _Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy,_ 2 _Cardiology and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy_

**(813)** _Retrospective Single Centre Comparison of Outcomes between Standard Criteria and Marginal Criteria Brain Dead Heart Transplantation;_ H. Chew1, P. Lo2, J. Cao1, N. Sugianto3, K. Dhital4, E. Granger4, C. Hayward5, A. Jabbour5, P. Jansz4, A. Keogh5, E. Kotlyar5, P. Spratt4, P. Macdonald5. 1 _Transplant Laboratory, Victor Chang Cardiac Research Institiute, Sydney, Australia,_ 2 _University of New South Wales, Sydney, Australia,_ 3 _St Vincents Hospital, Sydney, Australia,_ 4 _Cardiothoracic Surgery, St Vincents Hospital, Sydney, Australia,_ 5 _Cardiology, St Vincents Hospital, Sydney, Australia_

**(814)** _Sarcopenia as a Predictor of Postoperative Hospital Stay in Heart Transplant Recipients;_ B. McGrath1, D. Vucicevic1, E. Kransdorf1, D. Steidley1, O. Pajaro2, E. Carey3. 1 _Division of Cardiovascular Diseases, Mayo Clinic Hospital, Phoenix, AZ,_ 2 _Division of Cardiothoracic Surgery, Mayo Clinic Hospital, Phoenix, AZ,_ 3 _Division of Hepatology, Mayo Clinic Hospital, Phoenix, AZ_

**(815)** _Increased Donor Selectivity Does NOT Decrease Primary Graft Failure After Heart Transplantation;_ P. Delle1, L. K. Soni1, Y. Coppleson1, P. Kurlansky1, S. Sreekanth1, J. Han1, B. Li1, A. R. Garan2, V. Topkara2, M. Yuzefpolskaya2, P. Colombo2, M. Farr2, K. Takeda1, Y. Naka1, H. Takayama1. 1 _Surgery, Columbia Presbyterian Medical Center, New York, NY,_ 2 _Cardiology, Columbia Presbyterian Medical Center, New York, NY_

**(816)** _Extracorporeal Membrane Oxygenation for Primary Graft Dysfunction Following Heart Transplantation: A Single Center Experience;_ N. Rajagopalan, D. R. Dennis, T. S. Mooney, T. Tribble, M. Guglin, M. Sekela. _University of Kentucky, Lexington, KY_

**(817)** _Primary Graft Failure Following Cardiac Transplantation Is Associated with Elevated Pre-Transplant Levels of Pro-Inflammatory Factors;_ D. Chatterjee1, K. J. Clerkin1, K. J. Rogers1, D. Mancini1, Y. Naka1, H. Takayama2, K. Takeda2, P. C. Colombo2, G. Vlad3, R. Vasilescu3, B. Levin4, M. A. Farr1, S. Restaino1, E. Zorn1. 1 _Dept. of Medicine, Columbia University, New York, NY,_ 2 _Dept. of Surgery, Columbia University, New York, NY,_ 3 _Dept. of Pathology & Cell Biology, Columbia University, New York, NY, _4 _Dept. of Biostatistics, Columbia University, New York, NY_

**(818)** _Primary Graft Dysfunction after Heart Transplantation with High Frequency of Marginal Donor Hearts;_ H. Hata1, T. Fujita1, H. Ishibashi-Ueda2, N. Fukushima3, T. Nakatani3, J. Kobayashi1. 1 _Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Japan,_ 2 _Pathology, National Cerebral and Cardiovascular Center, Suita, Japan,_ 3 _Transplantation, National Cerebral and Cardiovascular Center, Suita, Japan_

**(819)** _Prognostic Value of High Sensitivity Troponin-T to Identify Patients at Risk of Primary Graft Dysfunction After Heart Transplantation;_ A. Méndez1, J. Ordonez-Llanos2, S. Mirabet1, J. Galan3, M. Maestre3, V. Brossa1, M. Rivilla3, L. Lopez1, T. Koller3, A. Sionis1, E. Roig1. 1 _Cardiology, Hospital de Sant Pau, Barcelona, Spain,_ 2 _Biochemistry, Hospital de Sant Pau, Barcelona, Spain,_ 3 _Anesthesiology, Hospital de Sant Pau, Barcelona, Spain_

**(820)** _Chronic Lung Disease Fev1/Fvc <70% and Primary Graft Dysfunction; a Marker for Prolonged Intubation Immediately Post-Transplantation; _J. Patel, M. Kittleson, L. Czer, T. Aintablian, E. Stimpson, T. Daun, T. A. Manayan, G. Rodriguez, D. Chang, D. Ramzy, J. A. Kobashigawa. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**(821)** WITHDRAWN

**(822)** _Cardiac Allograft Sinus Tachycardia Is Associated with Impaired Exercise Tolerance;_ S. Varnado1, J. Y. Um2, H. Vongooru3, R. Zolty3, B. D. Lowes3, A. Huntsberry1, A. Burdorf3, B. Fenske3, A. Siddique2, M. J. Moulton2, E. Raichlin3. 1 _Nebraska Medicine, Omaha, NE,_ 2 _Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE,_ 3 _Cardiology, University of Nebraska Medical Center, Omaha, NE_

**(823)** _Heart-to-Heart: Using Patients' Native Hearts to Promote Lifestyle Change Post-Transplant;_ S. Carey1, S. Driver2, M. Reynolds3, J. Ko4, W. Roberts4, B. Lima4, S. Hall4. 1 _Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, TX,_ 2 _Rehabilitation Research, Baylor Institute for Rehabilitation, Dallas, TX,_ 3 _Baylor Institute for Rehabilitation, Dallas, TX,_ 4 _Baylor University Medical Center, Dallas, TX_

**(824)** _Long-Term Outcome of Bridge to Recovery in Patients with Advanced Heart Failure Due to Idiopathic Cardiomyopathy;_ C. Urabe1, O. Seguchi2, S. Nakajima2, H. Sunami2, T. Sato2, H. Hata3, M. Yanase2, T. Fujita3, J. Kobayashi3, N. Fukushima2, T. Nakatani2. 1 _National Cerebral and Cardiovascular Center, Suita, Japan,_ 2 _Transplantation, National Cerebral and Cardiovascular Center, Suita, Japan,_ 3 _Adult Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Japan_

**(825)** _Education Status as a Predictor of Outcomes in Orthotopic Heart Transplantation;_ M. Delibasic1, N. Dobrilovic2, J. Raman2, B. Mohamedali3. 1 _Internal Medicine, Mercy Hospital and Medical Center, Chicago, IL,_ 2 _Cardiovascular and Thoracic Surgery Department, Rush University Medical Center, Chicago, IL,_ 3 _Section of Cardiology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL_

**(826)** _Quality of Life after Urgent Heart Transplantation;_ B. Diaz Molina1, J. Lambert1, F. González Vilchez2, F. Fernández Cadenas3, M. Bernardo1, E. Velasco1, M. Martín1, C. Morís1. 1 _Cardiology, Hospital Universitario Central De Asturias, Oviedo, Spain,_ 2 _Cardiology, Hospital Universitario Marqués de Valdecilla, Santander, Spain,_ 3 _Digestive Diseases, Hospital Alvarez-Buylla, Mieres, Spain_

**(827)** _Impact of Reduced Creatinine Clearance on Early Heart Transplantation Outcomes: A Propensity Score Adjusted Analysis;_ H. Gasparovic1, D. Unic2, L. Svetina1, J. Samardzic1, M. Cikes1, Z. Baricevic1, B. Skoric1, T. Kopjar1, D. Anic1, V. Ivancan1, Z. Sutlic2, B. Biocina1, D. Milicic1. 1 _University Hospital Rebro Zagreb, Zagreb, Croatia,_ 2 _University Hospital Dubrava, Zagreb, Croatia_

LUNG TRANSPLANTATION

Target Audience:

LTX, BSI, EEP, ID, NHSAH, PATH, PEDS, PH, PHARM

Poster Discussants:

Clemens Aigner, Cecilia Chaparro, Laura Frye, Jens Gottlieb, Cynthia Gries, Are Martin Holm, Erika Lease, Gabriel Loor, Haifa Lyster, Monique Malouf, Hermann Reichenspurner, Robin Vos, David Weill, Stephanie Yerkovich

**(828)** _Comparison of De Novo Donor-Specific Anti-HLA Antibodies (DSAs) Between Living-Donor Lobar Lung Transplantation and Cadaveric Lung Transplantation;_ T. F. Chen-Yoshikawa, T. Kondo, A. Ohsumi, M. Saito, A. Takahagi, S. Tanaka, E. Miyamoto, M. Takahashi, K. Ohata, H. Motoyama, K. Hijiya, A. Aoyama, H. Date. _Thoracic Surgery, Kyoto University, Kyoto, Japan_

**(829)** _Prevalence of Antibody Mediated Rejection in Lung Transplant Recipients with Clinical Dysfunction and/or Histological Damage: The PADOVA Experience;_ F. Calabrese1, S. E. Vuljan1, F. Lunardi1, N. Nannini1, M. Seveso1, M. Loy2, E. Ruffoni2, M. Damin2, F. Rigon2, E. Cozzi2, F. Rea1. 1 _University of Padova, Padova, Italy,_ 2 _Padova Hospital, Padova, Italy_

**(830)** _Outcomes of Suspected Antibody-Mediated Rejection Post-Lung Transplantation;_ A. Hirji1, H. Zhao1, M. B. Ospina2, J. M. Tikkanen1, K. J. Tinckam1, L. G. Singer1, C. Chaparro1. 1 _University of Toronto, Toronto, ON, Canada,_ 2 _School of Public Health, University of Alberta, Edmonton, AB, Canada_

**(831)** _Lung Transplantation in Septuagenarians;_ A. Iyengar, O. Kwon, A. Bhutani, D. Ross, A. Ardehali. _University of California - Los Angeles, Los Angeles, CA_

**(832)** _A Strategy of Performing Coronary Artery Bypass Grafting (CABG) Prior to Wait-Listing Candidates for Lung Transplantation (LT) Is Safe and Feasible;_ N. Sinha1, S. Scheinin2, A. Siddiqui3, A. Goodarzi1, T. Kaleekal1, J. Youssef1, A. Gaber4. 1 _Pulmonary Transplant, Houston Methodist Hospital, Houston, TX,_ 2 _DeBakey Cardiovascular Center/Cardiothoracic Surgery, Houston Methodist Hospital, Houston, TX,_ 3 _Pulmonary, Houston Methodist Hospital, Houston, TX,_ 4 _JC Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, TX_

**(833)** _Lung Transplantation on Pirfenidone: A Single Center Experience;_ A. Mortensen1, L. Cherrier1, R. Walia2. 1 _St. Joseph's Hospital & Medical Center, Phoenix, AZ, _2 _Norton Thoracic Institute, St. Joseph's Hospital & Medical Center, Phoenix, AZ_

**(834)** _Combined Lung-Liver Transplantation: An Analysis of the UNOS Database;_ A. Iyengar, C. Eisenring, E. DePasquale, D. Ross, A. Ardehali. _University of California - Los Angeles, Los Angeles, CA_

**(835)** _Lung Transplantation for Systemic Sclerosis: Long-Term Survival, Freedom from BOS and Readmission Rates;_ A. Venado, D. Huang, J. R. Greenland, S. Hays, J. A. Golden, R. J. Shah, J. Kukreja, J. P. Singer, L. A. Leard. _Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California San Francisco, San Francisco, CA_

**(836)** _ECMO as a Bridge to Lung Transplantation: An Analysis of the UNOS Database;_ A. Iyengar, C. Eisenring, E. DePasquale, D. Ross, A. Ardehali. _University of California - Los Angeles, Los Angeles, CA_

**(837)** WITHDRAWN

**(838)** WITHDRAWN

**(839)** _Pulmonary Hypertension in COPD: A Survival Analysis of Patients Listed for Lung Transplantation;_ I. Timofte1, M. Terrin2, M. Wijesinha3, P. Sanchez4, R. Pierson4, E. Barr3, J. Kim1, Z. Kon4, S. Pham4, A. Iacono5. 1 _Pulmonary and Critical Care, UMMC, Baltimore, MD,_ 2 _: Epidemiology and Public Health, UMMC, Baltimore, MD,_ 3 _Epidemiology and Public Health, UMMC, Baltimore, MD,_ 4 _Surgery, UMMC, Baltimore, MD,_ 5 _Medicine, UMMC, Baltimore, MD_

**(840)** _Gender Differences in Long-Term Survival during the LAS Era: A Single Institution Analysis of 848 Transplant Recipients;_ G. Loor1, R. Brown2, R. Kelly1, K. Rudser2, S. Shumway1, C. Holley1, I. Cich3, M. Hertz4. 1 _Surgery, University of Minnesota, Minneapolis, MN,_ 2 _Biostatistics Division, University of Minnesota, Minneapolis, MN,_ 3 _University of Minnesota, Minneapolis, MN,_ 4 _Medicine, University of Minnesota, Minneapolis, MN_

**(841)** _Lung Transplantation in the LAS Era: Long-Term Analysis;_ A. Iyengar, O. Kwon, A. Bhutani, D. Ross, A. Ardehali. _University of California - Los Angeles, Los Angeles, CA_

**(842)** _Uncontrolled DCD with Prolonged Ex Vivo Lung Perfusion (EVLP): A Feasible Model for Donor Lung Recovery and Allocation;_ J. R. Spratt1, L. M. Mattison2, P. A. Iaizzo1, T. Iles1, W. D. Payne3, G. Loor4. 1 _Department of Surgery, University of Minnesota Medical School, Minneapolis, MN,_ 2 _Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN,_ 3 _LifeSource, Minneapolis, MN,_ 4 _Department of Surgery, University of Minnesota, Minneapolis, MN_

**(843)** _Detection of Lung-Specific Exosome in Perfusates of Ex Vivo Lung Perfusion System;_ T. Okamoto1, M. Mitsuhashi2, B. Soliman1, K. Abu-Elmagd1, K. R. McCurry3. 1 _Transplant Center, Cleveland Clinic, Cleveland, OH,_ 2 _NanoSomix, Aliso Viejo, CA,_ 3 _Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH_

**(844)** _Lung Transplantation after Ex-Vivo Lung Perfusion in Two Scandinavian Centres;_ T. Nilsson1, M. Zemtsovski2, A. Wallinder3, I. Henriksson2, S. Ricksten1, H. Møller-Sørensen2, G. C. Riise4, M. Perch5, M. Iversen5, G. Dellgren6. 1 _Cardiothoracic Anaesthesia and Intensive Care, Sahlgrenska Univ Hospital, Goteborg, Sweden,_ 2 _Cardiothoracic Anesthesia, Rigshospitalet, Copenhagen, Denmark,_ 3 _Cardiothoracic Surgery, Sahlgrenska Univ Hospital, Goteborg, Sweden,_ 4 _Transplant Institute, Sahlgrenska Univ Hospital, Goteborg, Sweden,_ 5 _Lung Transplant Unit, Rigshospitalet, Copenhagen, Denmark,_ 6 _Sahlgrenska Univ Hospital, Goteborg, Sweden_

**(845)** _Carbapenem-Resistant Klebsiella Pneumoniae in Lung Transplantation Recipients;_ L. Morlacchi1, V. Rossetti1, P. Tarsia1, C. Travierso1, L. Rosso2, M. Nosotti2, F. Blasi1. 1 _Department of Pathophysiology and Transplantation, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy,_ 2 _U.O. Chirurgia Toracica e dei Trapianti di Polmone, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy_

**(846)** _Donor Derived Disease Transmission Events in Thoracic Organ Transplantation: Data Reviewed by the OPTN Ad Hoc Disease Transmission Advisory Committee;_ J. M. Schaenman1, A. Wilk2, S. Tlusty2, M. A. Nalesnik3, M. G. Michaels4, C. Wolfe5, D. Kaul6. 1 _UCLA School of Medicine, Los Angeles, CA,_ 2 _United Network for Organ Sharing, Richmond, VA,_ 3 _University of Pittsburgh Medical Center, Pittsburgh, PA,_ 4 _University of Pittsburgh School of Medicine, Pittsburgh, PA,_ 5 _Duke University School of Medicine, Durham, NC,_ 6 _University of Michigan Medical School of Medicine, Ann Arbor, MI_

**(847)** _Trichosporon Infection in Lung Transplant Patients: An Emerging Fungal Infection?;_ S. V. Campos1, J. N. Almeida Jr2, M. N. Samano3, R. M. Carraro1, A. N. Costa1, R. O. Teixeira1, J. Afonso-Jr1, P. L. Camargo1, L. Abdalla3, L. M. Fernandes3, P. M. Pêgo-Fernandes3. 1 _Pneumology, Heart Institute of Sao Paulo Medical School, Sao Paulo, Brazil,_ 2 _Central Laboratory Division, Heart Institute of Sao Paulo Medical School, Sao Paulo, Brazil,_ 3 _Thoracic Surgery, Heart Institute of Sao Paulo Medical School, Sao Paulo, Brazil_

**(848)** _Fungal Colonization and Infection in Lung Transplant Recipients Receiving Posaconazole Prophylaxis;_ B. E. Cowan1, J. P. Singer1, R. J. Shah1, L. E. Leard1, J. Kukreja2, P. V. Chin-Hong1, K. Watkins3, R. Boettger3, J. A. Golden1, S. R. Hays1. 1 _Department of Medicine, University of California, San Francisco, San Francisco, CA,_ 2 _Department of Surgery, University of California, San Francisco, San Francisco, CA,_ 3 _Department of Pharmacy, University of California, San Francisco, San Francisco, CA_

**(849)** _Not Donor's but Recipient's Airway Organisms Are Relevant to Post-Lung Transplant Pneumonia;_ K. Miyoshi, Y. Konishi, T. Kurosaki, S. Otani, S. Sugimoto, M. Yamane, S. Miyoshi, T. Oto. _Department of Thoracic Surgery / Organ Transplant Centre, Okayama University Hospital, Okayama, Japan_

**(850)** _Use of Oral Ribavirin for Respiratory Viral Infections in Lung Transplant Patients;_ B. Garcia1, N. Sharma1, K. Johnson2, E. Diaz1, K. Wille1, J. Salgado3. 1 _Pulmonary, Allergy, and Critical Care Medicine, University of Alabama- Birmingham, Birmingham, AL,_ 2 _Internal Medicine, University of Florida, Gainesville, FL,_ 3 _Pulmonary and Critical Care Medicine, University of Florida, Gainesville, FL_

**(851)** _Assessment of CMV Specific T-Cell Immunity by the Quantiferon-CMV Assay in Lung Transplant Recipients: Brazilian Pilot Study;_ S. V. Campos1, A. Mamana2, M. N. Samano3, P. M. Pêgo-Fernandes3, C. M. Machado4. 1 _Pneumology, Heart Institute of Sao Paulo Medical School, Sao Paulo, Brazil,_ 2 _Tropical Medicine Institute, University of Sao Paulo Medical School, Sao Paulo, Brazil,_ 3 _Thoracic Surgery, Heart Institute of Sao Paulo Medical School, Sao Paulo, Brazil,_ 4 _Institute of Tropical Medicine, University of Sao Paulo Medical School, Sao Paulo, Brazil_

**(852)** _Outcomes Associated with Ganciclovir-Resistant Cytomegalovirus in Lung Transplant Recipients;_ S. Hammad, L. Shah, M. Restivo, H. Robbins, J. Scheffert. _NewYork-Presbyterian Hospital, New York, NY_

**(853)** _Posaconazol Tablets in Lung Transplant Recipients: Plasma Trough Levels and Influencing Factors;_ D. Stelzer1, F. Ihle2, A. Weber3, N. Kneidinger2, F. Ceelen2, G. Zimmermann2, R. Schramm4, H. Winter5, L. Frey6, M. Andraschko3, M. Vogeser7, J. Behr2, C. Neurohr2. 1 _Department of Internal Medicine V, Pharmacy, University of Munich, Munich, Germany,_ 2 _Department of Internal Medicine V, University of Munich, Munich, Germany,_ 3 _Pharmacy, University of Munich, Munich, Germany,_ 4 _Department of Cardiac Surgery, University of Munich, Munich, Germany,_ 5 _Department of Thoracic Surgery, University of Munich, Munich, Germany,_ 6 _Department of Anesthesiology, University of Munich, Munich, Germany,_ 7 _Institute of Laboratory Medicine, University of Munich, Munich, Germany_

**(854)** _Up to Six Years Experience of Lobar Lung Transplantation;_ D. T. Reichart1, B. Sill1, C. Oelschner1, M. Oldigs2, H. Klose3, M. Barten1, H. Reichenspurner1, T. Deuse1. 1 _Univ Hamburg Heart Center, Hamburg, Germany,_ 2 _Lung Clinic Grosshandsdorf, Großhandsdorf, Germany,_ 3 _University Clinic Hamburg, Hamburg, Germany_

**(855)** _10 Year Survival After Lung Transplantation: A Single Center Experience;_ H. Copeland1, D. Gutteridge2, D. Roe2, K. Lane3, C. Shen3, Z. Hashmi1, C. Hage2, I. Wang1, M. Duncan2, T. Wozniak1. 1 _Surgery, Indiana University, Indianapolis, IN,_ 2 _Medicine, Indiana University, Indianapolis, IN,_ 3 _Biostatistics, Indiana University, Indianapolis, IN_

**(856)** _Combined Lung-Liver Transplantation: The United States Experience;_ S. Pasupneti1, A. Lawrence1, L. Chhatwani1, K. Patel1, R. Ha2, J. Boyd2, G. Dhillon1, J. Mooney1. 1 _Pulmonary and Critical Care Medicine, Stanford University Hospitals, Stanford, CA,_ 2 _Cardiothoracic Surgery, Stanford University Hospitals, Stanford, CA_

**(857)** _Lung Transplantation from Donation after Circulatory Determined Dead (DCD) Donors: A Single Centre Experience;_ C. Barbero, S. Messer, P. Catarino, D. Thomas, C. Sudarshan, A. Ali, M. Berman, Y. Abu-Omar, D. P. Jenkins, J. Dunning, S. Tsui. _Transplant Unit, Papworth Hospital, Cambridge, United Kingdom_

**(858)** _Risk Factors for De Novo Malignancy Following Lung Transplantation;_ J. Magruder1, T. C. Crawford1, J. C. Grimm1, B. Kim1, A. S. Shah2, E. L. Bush1, R. S. Higgins1, C. A. Merlo3. 1 _Division of Cardiac Surgery, Johns Hopkins, Baltimore, MD,_ 2 _Department of Cardiac Surgery, Vanderbilt, Nashville, TN,_ 3 _Division of Pulmonary and Critical Care Medicine, Johns Hopkins, Baltimore, MD_

**(859)** _Gene Expression Profiling of Bronchoalveolar Lavage Cells during Aspergillus Colonization of the Lung Allograft;_ S. S. Weigt, X. Wang, V. Palchevskiy, N. Patel, A. DerHovanessian, M. Y. Shino, D. Sayah, A. L. Gregson, J. P. Lynch III, R. Saggar, D. J. Ross, A. Ardehali, D. Elashoff, J. A. Belperio. _UCLA, Los Angeles, CA_

**(860)** _Outcomes in Lung Transplant Recipients with COPD with and without Alpha-1-Antitrypsin Deficiency: Single Center Experience Over Four Decades;_ J. R. Spratt1, R. Z. Brown2, K. Rudser2, U. Goswami3, J. Patil4, I. Cich5, S. J. Shumway6, M. I. Hertz4, G. Loor6. 1 _Department of Surgery, University of Minnesota Medical School, Minneapolis, MN,_ 2 _Division of Biostatistics, University of Minnesota, Minneapolis, MN,_ 3 _Department of Medicine, University of Minnesota Medical School, Minneapolis, MN,_ 4 _Department of Medicine, University of Minnesota, Minneapolis, MN,_ 5 _University of Minnesota Medical School, Minneapolis, MN,_ 6 _Department of Surgery, University of Minnesota, Minneapolis, MN_

**(861)** _Intermediate-Term Change of Pulmonary Function and Lung Volume after Bilateral Living Donor Lobar Lung Transplantation;_ A. Takahagi, T. F. Chen-Yoshikawa, T. Kondo, M. Saito, S. Tanaka, E. Miyamoto, M. Takahashi, K. Ohata, H. Motoyama, K. Hijiya, A. Aoyama, H. Date, H. Date. _Thoracic Surgery, Kyoto University Gradual School, Kyoto, Japan_

**(862)** _Thoracic Cavity Volume Change after Lung Transplantation According to the Underlying End-Stage Lung Disease;_ C. Park1, S. Haam2, T. Kim1, H. Paik3, J. Lee3. 1 _Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of,_ 2 _Thoracic and Cardiovascular Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of,_ 3 _Thoracic and Cardiovascular Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of_

**(863)** _Characteristics of Various Categories of Controlled Donors after Circulatory Death Do Not Affect Outcome after Lung Transplantation; an Analysis of ISHLT DCD Registry Data;_ D. Van Raemdonck1, B. Levvey2, L. Edwards3, J. Stehlik4, M. Erasmus5, A. Glanville6, M. Hertz7, P. Hopkins8, D. Chambers8, M. Musk9, M. Budev10, D. Mason11, V. Puri12, R. Yusen12, F. D'Ovidio13, S. Keshavjee14, M. Cypel14, G. Snell2. 1 _Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium,_ 2 _Lung Transplant Service, Alfred Hospital, Melbourne, Australia,_ 3 _United Network for Organ Sharing, Richmond, VA,_ 4 _University of Utah, Salt Lake City, UT,_ 5 _Cardiothoracic Surgery, Universitair Medisch Centrum, Groningen, Netherlands,_ 6 _St Vincent's Hospital, Sydney, Australia,_ 7 _University of Minnesota Medical Center, Minneapolis, MN,_ 8 _Prince Charles Hospital, Brisbane, Australia,_ 9 _Royal Perth Hospital, Perth, Australia,_ 10 _The Cleveland Clinic Foundation, Cleveland, OH,_ 11 _Baylor University Medical Center, Dallas, TX,_ 12 _Barnes Jewish Hospital Washington University, St Louis, MO,_ 13 _Columbia University Medical Center, New York, NY,_ 14 _Thoracic Surgery, The Toronto General Hospital & Hospital for Sick Children, Toronto, ON, Canada_

**(864)** _Cervical Neoplasia in Female Lung Transplant Recipients: Inadequate Screening and a High Burden of Disease;_ M. Paraskeva1, S. R. Davis2, R. J. Bell2, A. M. Storch3, P. Robinson2. 1 _Alfred Hospital, Melbourne, Australia,_ 2 _Women's Health Program, Department of Preventative Medicine, Monash University, Melbourne, Australia,_ 3 _Monash University, Melbourne, Australia_

**(865)** _Body Mass Index in Lung Transplant Candidates: A Single Center Results;_ M. A. Kashem1, A. Shiose1, J. Gomez-Abraham1, T. Yoshizumi1, F. Cordova2, G. Criner2, Y. Toyoda1. 1 _Cardiovascular Surgery, Temple University, Philadelphia, PA,_ 2 _Thoracic and Pulmonary Medicine, Temple University, Philadelphia, PA_

**(866)** _Soluble CD14 and LBP as Markers for Primary Graft Dysfunction;_ K. Ramphal1, E. Cantu1, M. Porteous1, M. Oyster1, S. Kawut1, D. J. Lederer2, R. Shah3, S. Arcasoy2, L. Snyder4, M. Hartwig4, S. Palmer4, K. M. Wille5, L. Ware6, P. Shah7, M. Crespo8, C. Hage9, A. Weinacker10, V. Lama11, Y. Suzuki1, J. Orens7, J. D. Christie1, J. Diamond1. 1 _University of Pennsylvania, Philadelphia, PA,_ 2 _Columbia University, New York, NY,_ 3 _University of California San Francisco, San Francisco, CA,_ 4 _Duke University, Durham, NC,_ 5 _University of Alabama Birminghma, Birmingham, AL,_ 6 _Vaderbilt University, Nashville, TN,_ 7 _Johns Hopkins University, Baltimore, MD,_ 8 _University of Pittsburgh, Pittsburgh, PA,_ 9 _Indiana University, Indianapolis, IN,_ 10 _Stanford University, Stanford, CA,_ 11 _University of Michigan, Ann Arbor, MI_

**(867)** _Systemic Inflammatory State of the Organ Donor and Risk for Primary Graft Dysfunction Following Lung Transplantation;_ E. M. Lowery1, M. Yong1, L. Ramirez2, N. Balasubramanian3, S. Kliethermes3, J. Schwartz4, E. J. Kovacs2. 1 _Medicine, Loyola University Chicago, Chicago, IL,_ 2 _Surgery, Loyola University Chicago, Chicago, IL,_ 3 _Public Health, Loyola University Chicago, Chicago, IL,_ 4 _Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL_

**(868)** _Involvement of Rho-Kinase in Lung Ischemia-Reperfusion Injury Pathogenesis: Molecular Analysis in an Isolated Rat Lung Perfusion Model;_ K. Ohata, T. Chen-Yoshikawa, T. Menju, M. Saito, A. Takahagi, E. Miyamoto, S. Tanaka, M. Takahashi, T. Kondo, H. Motoyama, K. Hijiya, A. Aoyama, H. Date. _Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan_

**(869)** _Primary Graft Dysfunction in Lung Transplantation: A Detailed Predictive Model;_ A. Iyengar, A. Bhutani, O. Kwon, D. Ross, A. Ardehali. _University of California - Los Angeles, Los Angeles, CA_

**(870)** _Elevated Plasma PAI-1 Levels in the Donor Are Associated with the Development of Primary Graft Dysfunction in Lung Transplant Recipients;_ B. C. Hamilton1, G. R. Dincheva1, J. Abbott2, H. Zhuo2, J. A. Golden3, S. R. Hays3, M. Brzezinski4, J. P. Singer3, M. A. Matthay2, J. Kukreja1. 1 _Department of Surgery, Division of Cardiothoracic Surgery, UCSF, San Francisco, CA,_ 2 _Department of Medicine and Anesthesia, Cardiovascular Research Institute, UCSF, San Francisco, CA,_ 3 _Department of Medicine, Pulmonary and Critical Care, UCSF, San Francisco, CA,_ 4 _Department of Anesthesia, UCSF, San Francisco, CA_

**(871)** _Obese Recipients of Lung Transplant Have an Increased Risk of Primary Graft Dysfunction;_ I. Bello, L. Romero, M. Deu, A. Jauregui, J. Pérez, J. Ochoa, V. Díaz, L. Sanchez, F. Ascanio, J. Solé. _Thoracic Surgery, H. Universitario Vall d 'Hebron, Barcelona, Spain_

**(872)** _Pre-Transplant Frailty Is Associated with Hospital Readmissions and Rejection Following Lung Transplantation;_ M. Wilson1, A. Vakil1, E. Beam1, P. Chong2, R. Razonable1, S. Dunlay1, P. Kandel1, C. Undavalli1, C. Kennedy1. 1 _Mayo Clinic, Rochester, MN,_ 2 _University of North Carolina, Chapel Hill, NC_

**(873)** _The Prevalence and Prognostic Significance of Frailty in Patients with Advanced Lung Disease Referred for Lung Transplantation;_ E. Montgomery1, P. S. Macdonald2, A. R. Glanville1, M. Malouf1, A. Havryk1, M. Plit1, M. Benzimra1, A. L. Rigby1, M. Harkess1, N. DeTullio1, A. L. Smith1, A. Hogan1, P. S. Tunnicliff1, S. Jha3. 1 _Lung Transplant Program, St Vincent's Hospital, Sydney, Australia,_ 2 _Heart Transplant Program, St Vincent's Hospital, Sydney, Australia,_ 3 _Centre for Cardiovascular and Chronic Care, University of Technology, Sydney, Australia_

**(874)** _Frailty in Transplantation. The FIT Study;_ K. E. Morley, H. Chung, J. S. Parmar. _Transplant Continuing Care Unit, Papworth Hospital, Cambridge, United Kingdom_

**(875)** _Pregnancy Outcomes in 30 Lung Transplant Recipients;_ S. Constantinescu1, L. Coscia2, D. Armenti2, M. Moritz3. 1 _Medicine, Temple University School of Medicine, Philadelphia, PA,_ 2 _National Transplantation Pregnancy Registry, Philadelphia, PA,_ 3 _Lehigh Valley Health Network, Allentown, PA_

MECHANICAL CIRCULATORY SUPPORT

Target Audience:

MCS, BSI, HF, ID, NHSAH, PH, PHARM

Poster Discussants:

Ruchan Akar, Komarakshi Balakrishnan, Jay Baumwol, Shashank Desai, Gregory Ewald, Daniel Goldstein, George Javorsky, Manreet Kanwar, Jason Katz, Marc Katz, Brent Lampert, Nader Moazami, Chetan Patel, Edwardo Rame, Stephan Schubert, Palak Shah, Scott Silvestry, Cumara Sivathasan, Jeffrey Teuteberg, Neil Wrightson

**(876)** _Outcome of CentriMag Extracorporeal Mechanical Circulatory Support Use in Critical Cardiogenic Shock (INTERMACS 1) Patients;_ V. Mehta1, J. Hasan1, K. Oommen1, S. Shaw2, S. G. Williams2, J. Barnard1, N. Yonan1, R. V. Venkateswaran3. 1 _Cardiothoracic Surgery, University Hospital of South Manchester, Manchester, United Kingdom,_ 2 _Cardiology, University Hospital of South Manchester, Manchester, United Kingdom,_ 3 _Director of Transplantation, Cardiothoracic Surgery, University Hospital of South Manchester, Manchester, United Kingdom_

**(877)** WITHDRAWN

**(878)** _Right Ventricular Failure Post LVAD Implantation Corrected with Biventricular Support: An In-Vitro Model;_ S. Shehab1, S. M. Allida2, P. J. Newton2, P. M. Davidson3, P. S. MacDonalds1, P. C. Jansz1, C. S. Hayward1. 1 _Cardiology, St. Vincent's Hospital, Sydney, Australia,_ 2 _Centre of Cardiovascular and Chronic Care, University of technology, Syndey, Sydney, Australia,_ 3 _School of Nursing, John Hopkins University, Sydney, MD_

**(879)** _The Effect of Inflow Cannula Length on the Intraventricular Flow Field of the EvaHeart LVAD-Assisted Heart;_ K. May-Newman1, J. Moon1, V. Ramesh1, B. Herold1, R. Montes1, J. Campos1, P. Isingoma1, R. Benkowski2. 1 _Bioengineering, San Diego State University, San Diego, CA,_ 2 _B-Squared Medical Device Solutions, LLC, Fort Worth, TX_

**(880)** WITHDRAWN

**(881)** _Modulation of Autonomic Tone Assessed by Heart Rate Variability in Advanced Heart Failure Patients Treated with an Extra-Aortic Counterpulsation (EACP) System: A Single Center Experience;_ A. Kao1, D. Georgakopoulos2, J. Smith1, D. Pomfret3, S. Aggarwal4. 1 _Medicine, Saint Luke's Cardiovascular, Kansas City, MO,_ 2 _Sunshine Heart, Eden Prairie, MN,_ 3 _Sunshine Heart, Kansas City, MN,_ 4 _Cardiovascular and Thoracic Surgery, Saint Luke's Mid-America Heart and Lung, Kansas City, MO_

**(882)** _Off-Pump HeartWare HVAD Left Ventricular Assist Device Implantation;_ R. Moayedifar1, J. Riebandt1, T. Haberl1, K. Dimitrov1, D. Wiedemann1, T. Schlöglhofer2, H. Schima2, G. Laufer1, D. Zimpfer1. 1 _Department of Cardiac Surgery, Medical University Vienna, Vienna, Austria,_ 2 _Center for Medical Physics and Biomedical Engineering, Medical University Vienna, Vienna, Austria_

**(883)** _Association between Intraventricular Position of Inflow Cannula and Clinical Outcomes in LVAD Recipients;_ A. Anselmi1, S. Collin2, J. Verhoye1, P. Haigron2, E. Flécher1. 1 _Division of Thoracic, and Cardiovascular Surgery, Pontchaillou University Hospital, Rennes, France,_ 2 _INSERM, U1099, Rennes, F-35000, France; Université de Rennes 1, LTSI, Rennes, France_

**(884)** _Computed-Tomography Guided Apex Marking for Lateral Thoracotomy LVAD Implantation;_ D. Acharya, R. Loyaga-Rendon, S. Pamboukian, J. Tallaj, W. Holman, J. Kirklin, S. Singh. _University of Alabama at Birmingham, Birmingham, AL_

**(885)** _GLP In-Vivo Study and Durability Testing for Miniaturized EVAHEART KAIZEN (EVA-kai) System;_ H. Kanebako. _R & D Group, Sun Medical Technology Research Corp., Suwa, Japan_

**(886)** _A Single Center Evolution of Surgical Experience on HeartWare LVAD Minimally Invasive Implantation in High Risk Patients;_ L. Bagozzi, A. Guariento, J. Bejko, M. Carrozzini, M. Comisso, G. Bortolussi, M. Gallo, V. Tarzia, G. Gerosa, T. Bottio. _Department of Cardiology and Cardiovascular Surgery, University of Padua, Padova, Italy_

**(887)** _Left Ventricular Unloading in Relation to Cannula Position during Invasive Hemodynamic Ramp Test in Axial Flow Pumps;_ K. K. Marinescu, S. Adatya, N. Sarswat, G. Kim, S. Kalantari Tannenbaum, G. Sayer, N. Uriel. _University of Chicago, Chicago, IL_

**(888)** _Left Ventricular Assist Device Implantation by Lateral Thoracotomy to the Descending Aorta: A Propensity Matched Analysis to Standard Sternotomy Approach;_ M. Ozbaran1, T. Yagdi1, C. Engin1, S. Nalbantgil2, S. Ertugay1, P. Ozturk1. 1 _Cardiovascular Surgery, Ege Unv. Hospital, Izmir, Turkey,_ 2 _Cardiology, Ege Unv. Hospital, Izmir, Turkey_

**(889)** _Pathological Substrate of intermittent Low Speed Process on the Native Aortic Valve of Patients Assisted with Left Ventricular Assist Device;_ J. Bejko, M. Fedrigo, A. Di Francesco, G. Gerosa, T. Bottio, A. Angelini, G. Thiene. _Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy_

**(890)** _Novel Minimally Invasive Surgical Approach Using External Ventricular Assist Device and Extracorporeal Membrane Oxygenation in Refractory Cardiogenic Shock;_ K. Takeda1, R. A. Garan2, V. K. Topkara1, J. Han1, S. Sreekanth1, P. A. Kurlansky1, M. Yuzefpolskaya2, P. C. Colombo2, Y. Naka1, H. Takayama1. 1 _Cardiac Surgery, Columbia University, NY, NY,_ 2 _Cardiology, Columbia University, NY, NY_

**(891)** _ECPELLA: Combined Use of Extracorporeal Membrane Oxygenation and Percutaneous Microaxial Pump Left Ventricular Assist Device;_ O. Akanni1, K. Takeda1, L. Truby2, P. Kurlansky1, J. Han1, S. Sreekanth1, A. R. Garan2, V. K. Topkara2, M. Yuzefpolskaya2, P. Colombo2, A. Kirtane2, Y. Naka1, H. Takayama1. 1 _Department of Surgery, Columbia University, College of Physicians and Surgeons, New York, NY,_ 2 _Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY_

**(892)** _Initial Experience with a Percutaneous Dual Lumen Single Cannula Strategy for Temporary Right Ventricular Assist Device Support Following Durable LVAD Therapy;_ J. K. Bhama1, A. Bansal2, F. Zahr1, R. Patel2, S. Desai2, J. Goerbig-Campbell1, V. Cotarlan1, S. Krishnan1. 1 _Heart & Vascular Center, University of Iowa Health Care, Iowa City, IA, _2 _John Ochsner Heart & Vascular Institute, Ochsner Clinic, New Orleans, LA_

**(893)** _Sustainability of Pulmonary Hypertension Reversal Before and After Heart Transplantation in Patients Bridged with Continuous-Flow LVADs: Axial- vs Centrifugal-Flow;_ M. Al-Sarie, A. Rauf, C. Selzman, A. Kfouri, J. Doty, S. H. McKellar, A. Koliopoulou, J. Wever-Pinzon, Z. Abu Saleh, S. Wright, O. Wever-Pinzon, J. Nativi-Nicolau, J. Stehlik, S. G. Drakos. _UTAH Cardiac Transplant Program (University of Utah, Intermountain Medical Center, Salt Lake VA Medical Center), Salt Lake City, UT_

**(894)** _LVAD Implantation in Patients on ECLS;_ M. J. Morshuis1, A. Koster2, M. Schönbrodt1, J. Gummert1. 1 _Cardiothoracic Surgery, Heart Center NRW, Bad Oeynhausen, Germany,_ 2 _Anaesthesiology, Heart Center NRW, Bad Oeynhausen, Germany_

**(895)** _Is the Diameter of the Outflow Graft the Crucial Difference in Stroke Rates Between Heartmate II and HVAD? A Computational Fluid Dynamics Study;_ K. Balakrishnan1, S. Bhat2, J. Mathew2, R. Krishnakumar2. 1 _Cardiac Surgery, Fortis Malar Hospital, Chennai, India,_ 2 _Engineering Design, Indian Institute of Technology, Chennai, India_

**(896)** _Minimally Invasive Heartware HVAD Implantation with Outflow Graft Anastomosis to the Left Subclavian Artery;_ J. Riebandt1, D. Wiedemann1, T. Haberl1, T. Schloeglhofer2, R. Moayedifar1, K. Dimitrov1, G. Laufer1, D. Zimpfer1. 1 _Cardiac Surgery, Medical Univ Vienna, Vienna, Austria,_ 2 _Medical Physics and Biomedical Engineering, Medical Univ Vienna, Vienna, Austria_

**(897)** _Effect of HeartMate PHP on Resting Hemodynamics in Low Cardiac Output Patients Undergoing Elective High-Risk PCI;_ U. Jorde1, K. Ŝmudka2, A. Witkowski3, J. Granada4, B. Vesga4, A. Ebner5, A. Ochala6, N. van Mieghem7, R. van Geuns7, M. Zembala8, J. Maly9, P. Sood10, D. Dudek11. 1 _Montefiore Medical Center, Bronx, NY,_ 2 _John Paul II Hospital, Krakow, Poland,_ 3 _Cardinal Stefan Wyszynski Institute of Cardiology, Warsaw, Poland,_ 4 _Instituto del Corazon, Bucaramanga, Colombia,_ 5 _Sanatorio Italiano, Asuncion, Paraguay,_ 6 _Samodzielny Publiczny Szpital, Katowice, Poland,_ 7 _Erasmus Medical Center, Rotterdam, Netherlands,_ 8 _Slaskie Centrum Chorob Serca w Zabrzu, Zabrze, Poland,_ 9 _IKEM (Institute for Clinical and Experimental Medicine), Prague, Czech Republic,_ 10 _Thoratec Corporation, Pleasanton, CA,_ 11 _Montefiore Medical Center, Krakow, Poland_

**(898)** _Acute Hemodynamic Effects of Percutaneously-Deployed Axillary Intra-aortic Balloon Counterpulsation Pumps in Patients with Advanced Heart Failure;_ S. Annamalai, L. Buiten, V. Paruchuri, M. Esposito, K. Morine, R. O'Kelly, C. Kimmelstiel, M. Kiernan, A. Vest, J. Shih, D. Denofrio, N. K. Kapur. _Cardiology, Tufts Medical Center, Boston, MA_

**(899)** _Evaluation of Changes in Flow Associated with HeartMate II Inflow Cannula Angle Change ;_ J. H. Karimov, M. Tong, N. Byram, G. Sunagawa, R. Dessoffy, N. Moazami, R. Starling, K. Fukamachi. _The Cleveland Clinic, Cleveland, OH_

**(900)** _Acoustic Analysis of a Continuous-Flow Left Ventricular Assist Device before and after Suspected Pump Thrombosis;_ F. Castagna1, S. Pan2, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda3, H. Takayama3, K. Ross3, M. Torres3, R. A. Blum1, S. Singh1, D. M. Mancini1, Y. Naka3, P. C. Colombo1, S. Bulek4, V. K. Topkara1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Medicine, New York University, New York, NY,_ 3 _Surgery, Columbia University, New York, NY,_ 4 _Qualcomm Technology Inc, Auburn Hills, MI_

**(901)** _Extracorporeal Membrane Oxygenation Support Systems as Treatment for Refractory Cardiogenic Shock: Strategies and Predictors of Mortality;_ A. Loforte1, G. Murana1, G. Jafrancesco1, M. Cefarelli1, J. Alfonsi1, E. Pilato1, S. Martin Suarez1, F. Grigioni2, G. Frascaroli3, G. Marinelli1. 1 _Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy,_ 2 _Cardiology and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy,_ 3 _Anesthesiology and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy_

**(902)** _Validity and Reliability of a Next Generation Non-Invasive Blood Pressure Monitor in Patients with Continuous-Flow Left Ventricular Assist Device;_ F. Castagna1, B. J. McDonnell2, M. Yuzefpolskaya1, V. K. Topkara1, A. R. Garan1, J. Z. Willey3, P. N. Trinh4, K. Wong1, B. Cagliostro1, M. Flannery5, D. M. Mancini1, H. Takayama5, K. Takeda5, Y. Naka5, J. R. Cockcroft2, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Cardiology, Cardiff Metropolitan University, Cardiff, United Kingdom,_ 3 _Neurology, Columbia University, New York, NY,_ 4 _Epidemiology, Columbia University, New York, NY,_ 5 _Surgery, Columbia University, New York, NY_

**(903)** _Role of Mechanical Support in Post Myocardial Infarction Septal Defects Percutaneous Repair;_ A. Sundara Raman, B. Metz, B. Kar, A. Nascimbene, I. Gregoric, P. Loyalka. _Heart Failure, University of Texas, Houston, TX_

**(904)** _North American Experience with Biventricular HVAD Total Artificial Heart as a Successful Bridge to Orthotopic Heart Transplantation;_ M. S. Mulvihill1, M. A. Daneshmand1, C. B. Patel2, C. A. Milano1, J. N. Schroder1. 1 _Department of Surgery, Division of Cardiovascular and Thoracic Surgery, Duke University, Durham, NC,_ 2 _Department of Medicine, Duke University, Durham, NC_

**(905)** _Outcomes Following Minimally Invasive Implantation of a Centrifugal Continuous-Flow Left Ventricular Assist Device;_ M. A. Psotka1, D. Lowe2, J. C. Cox2, R. G. Kiel1, M. Janmohamed1, V. N. Selby1, T. De Marco1, L. Klein1, G. M. Wieselthaler2. 1 _Cardiology, University of California San Francisco, San Francisco, CA,_ 2 _Cardiothoracic Surgery, University of California San Francisco, San Francisco, CA_

**(906)** _Minimally-Invasive Access and Off-Pump LVAD Implantation - Strategies to Improve Outcomes;_ U. A. Stock1, A. Kornberger1, C. Reyher2, F. Jäger2, B. Assmus3, A. Moritz1, A. Beiras-Fernandez1. 1 _Thoracic, Cardiac and Thoracic Vascular Surgery, University Hospital Frankfurt, Frankfurt, Germany,_ 2 _Anaesthesia and Intensive Care, University Hospital Frankfurt, Frankfurt, Germany,_ 3 _Cardiology, University Hospital Frankfurt, Frankfurt, Germany_

**(907)** _Safety of Trans Esophageal Echocardiogram Guided Percutaneous Insertion of Bi-Caval Dual Lumen Cannula (AVALON ELITE®) for Veno-Venous Extracorporeal Membrane Oxygenation;_ S. Bressler, C. Brehm, A. Ghodsizad, M. Pfeiffer. _Heart & Vascular Intensive Care, PennState Hershey Medical Center, Hershey, PA_

**(908)** _A Mock Circulatory System to Research the HeartWare Pump Flow Waveform;_ G. M. Christensen, B. D. King, B. B. Reid, S. Stoker, R. Alharethi, K. T. Bjerregaard, D. M. Allen, A. K. Johnson, W. T. Caine, B. Y. Rasmusson, A. G. Kfoury. _Artificial Heart Program, Intermountain Medical Center, Murray, UT_

**(909)** WITHDRAWN

**(910)** _A Novel Cardiac Coordinate Modeling System for Three Dimensional Quantification of Inflow Cannula Malposition in HeartMate II Left Ventricular Assist Device Implantation;_ B. Lima1, O. Dur2, J. Chuang2, T. Chamogeorgakis1, D. Farrar2, K. Sundareswaran2, S. Hall1, G. Gonzalez-Stawinski1. 1 _Baylor University Medical Center, Dallas, TX,_ 2 _Thoratec, Pleasanton, CA_

**(911)** _Advanced Ventricular Assist Device with Pulse Augmentation and Automatic Regurgitant Flow Shutoff;_ K. Fukamachi1, D. J. Horvath1, N. Byram1, G. Sunagawa1, J. H. Karimov1, B. D. Kuban1, R. Dessoffy1, N. Moazami2. 1 _Biomedical Engineering, Cleveland Clinic Foundation, Cleveland, OH,_ 2 _Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH_

**(912)** _Digitizing Medication Adherence Monitoring with a Novel Ingestible Nanosensor - First in Man Application Among Recipients of Continuous Flow Left Ventricular Assist Devices;_ S. P. Bhavnani1, A. Srivastava2, D. Meyer3, R. Kuo4, J. Nowaczyk5, L. Wolman5, S. Baradarian3, T. Heywood2. 1 _Cardiology, Scripps Clinic and Research Institute, San Diego, CA,_ 2 _Heart Failure Research and Recovery Program, Scripps Clinic and Research Institute, San Diego, CA,_ 3 _Cardiothoracic Surgery, Scripps Clinic and Research Institute, San Diego, CA,_ 4 _Pharmacy, Scripps Clinic and Research Institute, San Diego, CA,_ 5 _Left Ventricular Assist Device Program, Scripps Clinic and Research Institute, San Diego, CA_

**(913)** _Myocardial and End-Organ Response after Long-Term Mechanical Unloading with Continuous-Flow Left Ventricular Assist Device: Axial- Versus Centrifugal-Flow;_ M. Al-Sarie, A. Rauf, J. Wever-Pinzon, A. Catino, J. Stehlik, A. Kfouri, S. H. McKellar, O. Wever-Pinzon, A. Kelkhoff, R. Alharethi, B. Reid, J. Fang, C. Selzman, S. G. Drakos. _UTAH Cardiac Transplant Program (University of Utah, Intermountain Medical Center, Salt Lake VA Medical Center), Salt Lake City, UT_

**(914)** _Expanded Experience with Percutaneous Placement of Axillary-Subclavian Intra-Aortic Balloon Pump that Permits Sitting Upright and Ambulation in Patients with Advanced Heart Failure;_ J. Amione-Guerra, A. M. Cordero-Reyes, A. S. Cruz-Solbes, A. Bhimaraj, B. H. Trachtenberg, G. Ashrith, C. H. Lin, B. Bruckner, E. E. Suarez, G. Torre-Amione, M. H. Park, J. D. Estep. _Methodist Debakey Heart Center, Houston Methodist Hospital, Houston, TX_

**(915)** _Contemporary Outcomes of Mechanical Circulatory Support for Cardiogenic Shock: Single Center Experience of over 300 Patients;_ S. Fukuhara, Y. Naka, K. Takeda, M. Yuzefpolskaya, B. Li, S. Sreekanth, P. C. Colombo, V. K. Topkara, A. R. Garan, P. Kurlansky, H. Takayama. _Columbia University Medical Center, New York, NY_

**(916)** _Very-Low Threshold for Indication of Temporary RVAD Support in LVAD Recipients: Towards a Monoventricular Philosophy? A Multicentre Experience;_ M. Pozzi1, J. Robin1, D. Grinberg1, L. Sebbag2, P. Boissonnat2, T. Bochaton2, I. Sanchez2, C. Flamens3, S. Paulus3, R. Giraud4, K. Bendjelid4, P. Meyer5, M. Licker6, C. Banfi7, J. Obadia1, M. Kirsch8. 1 _Department of Cardiac Surgery, "Louis Pradel" Cardiologic Hospital, Lyon, France,_ 2 _Department of Cardiology, "Louis Pradel" Cardiologic Hospital, Lyon, France,_ 3 _Department of Anesthesia and ICU, "Louis Pradel" Cardiologic Hospital, Lyon, France,_ 4 _Intensive Care Service, Geneva University Hospitals, Geneva, Switzerland,_ 5 _Division of Cardiology, Geneva University Hospitals, Geneva, Switzerland,_ 6 _Division of Anesthesiology, Geneva University Hospitals, Geneva, Switzerland,_ 7 _Division of Cardiovascular Surgery, Geneva University Hospitals, Geneva, Switzerland,_ 8 _Department of Cardiac Surgery, University Hospital of Lausanne, Lausanne, Switzerland_

**(917)** _Mid Term Results of Mechanical Circulatory Support in the Netherlands, a Single Centre Experience from the University Medical Centre Utrecht (UMCU);_ S. E. Felix1, F. Z. Ramjankhan2, F. de Heer2, N. de Jonge1, M. P. Buijsrogge2, W. J. Suyker2. 1 _Cardiology, University Medical Centre Utrecht, Utrecht, Netherlands,_ 2 _Cardiothoracic Surgery, University Medical Centre Utrecht, Utrecht, Netherlands_

**(918)** _Persistent Hyponatremia Early after LVAD Implantation Does Not Result in Poor Long-Term Outcomes;_ D. C. Rodriguez1, M. Algodi2, C. Berardi1, M. Makkiya1, N. Cyrille2, O. Saeed2, J. J. Shin2, S. R. Patel2, D. J. Goldstein3, U. P. Jorde2, D. B. Sims2. 1 _Medicine, Montefiore Medical Center, Bronx, NY,_ 2 _Cardiology, Montefiore Medical Center, Bronx, NY,_ 3 _Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY_

**(919)** _Single Center Experience with Successful Left Ventricular Assist Device Explantation Following Myocardial Recovery;_ A. Mirza1, F. Raza2, A. Shiose3, D. Schwartz2, Y. Toyoda3, R. Alvarez2, E. Hamad2. 1 _Internal Medicine, Temple University Hospital, Philadelphia, PA,_ 2 _Cardiology, Temple University Hospital, Philadelphia, PA,_ 3 _Cardiovascular Surgery, Temple University Hospital, Philadelphia, PA_

**(920)** _1040 Consecutive Adult Patients Treated with Extracorporeal Membrane Oxygenation for Refractory Postcardiotomy Cardiogenic Shock, Longterm Follow-Up;_ S. Lehmann, F. Emrich, C. D. Etz, A. Meyer, A. K. Funkat, A. Oberbach, M. Misfeld, J. Garbade, F. W. Mohr. _Heartcenter Leipzig, Leipzig, Germany_

**(921)** _How Does the Effect of Opening the Pericardium on Right Ventricular Failure after LVAD Implantation;_ U. Kervan, S. S. Kocabeyoglu, D. E. Sert, E. U. Unal, E. Aygun, M. Karahan, M. Pac. _Cardiovascular Surgery, Turkey Yuksek Ihtisas Hospital, Ankara, Turkey_

**(922)** _Report of Japanese Registry for Mechanically Assisted Circulatory Support (J-MACS) - Non-Pulsatile Implantable LVAS vs. Extracorporeal LVAD as Bridge to Transplantation;_ T. Nakatani1, K. Sase2, H. Oshiyama3, M. Akiyama4, M. Horie5, K. Nawata6, T. Nishinaka7, Y. Tanoue8, K. Toda9, M. Tozawa10, M. Yanase1, S. Yamazaki11, M. Ishida12, A. Hiramatsu12, S. Kitamura13. 1 _Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan,_ 2 _Juntendo University, Tokyo, Japan,_ 3 _Medical Technology Association of Japan, Tokyo, Japan,_ 4 _Tohoku University, Sendai, Japan,_ 5 _Nipro Corp, Osaka, Japan,_ 6 _The University of Tokyo, Tokyo, Japan,_ 7 _Tokyo Women's Medical University, Tokyo, Japan,_ 8 _Kyushu University, Fukuoka, Japan,_ 9 _Osaka University, Osaka, Japan,_ 10 _Century Medical, Inc., Tokyo, Japan,_ 11 _Sun Medical Technology Research Corp., Suwa, Japan,_ 12 _Pharmaceuticals and Medical Devices Agency, Tokyo, Japan,_ 13 _National Cerebral and Cardiovascular Center, Osaka, Japan_

**(923)** _Differences in Heat Generation Between Axial and Centrifugal Continuous Flow Left Ventricular Assist Devices;_ R. Y. Loyaga-Rendon1, S. V. Pamboukian1, D. Acharya1, J. Tallaj1, F. Siric2, C. Hoopes2, W. Holman2, J. Kirklin2, D. L. Smith3. 1 _Division of Cardiology, University of Alabama at Birmingham, Birmingham, AL,_ 2 _Division of Cardiovascular Surgery, University of Alabama at Birmingham, Birmingham, AL,_ 3 _Department of Nutritional Sciences, University of Alabama at Birmingham, Birmingham, AL_

**(924)** _Evaluation of Functional Capacity Scores After Left Ventricular Assist Device Implantation in Cases with End Stage Heart Failure;_ P. Ozturk1, S. Ertugay1, S. Nalbantgil2, H. Karapolat3, C. Engin4, T. Yagdi4, M. Ozbaran1. 1 _Ege Unv. Hospital, Izmir, Turkey,_ 2 _Cardiology, Ege Unv. Hospital, Izmir, Turkey,_ 3 _Physical Therapy and Rehabilitation (Cardiac Rehabilitation), Ege Unv. Hospital, Izmir, Turkey,_ 4 _Cardiovascular Surgery, Ege Unv. Hospital, Izmir, Turkey_

**(925)** _Boot Camp for Ventricular Assist Device Patient Recovery beyond Medical Management;_ E. A. Hamad, V. Devlin, K. McDonnell, N. Robinson, M. Welsh, E. Kerr, B. Cramer-Manchin, J. Merkel, L. Ciniglia, D. Dougherty, J. Wilson, R. Alvarez. _Dept of Medicine, Temple Univ Hosp, Philadelphia, PA_

**(926)** _Readmission Rates in Patients with Left Ventricular Assist Devices;_ J. Nativi-Nicolau, A. Healy, S. Abdelrahman, J. Jaramillo, A. Elmer, S. Tagge, S. McKellar, J. Stehlik, S. Drakos, J. Fang, E. M. Gilbert, O. Wever-Pinzon, K. Kawamoto, C. Selzman. _University of Utah Division of Cardiology, Salt Lake City, UT_

**(927)** _Clinical Outcomes and Survival after Continuous-Flow Left Ventricular Assist Device Therapy in United States Veterans: A Single Center Experience;_ E. Lushaj, L. Lozonschi, T. Kohmoto, S. Akhter, M. Murray, D. Murray, S. Osaki. _University of Wisconsin, Madison, WI_

**(928)** _Application of Extracorporeal Membrane Oxygenator (ECMO) Support in Adult Patients with Cardiogenic Shock as a Bridge to Implantable Left Ventricular Assist Device (LVAD);_ B. Soleimani1, C. Brehm2, E. Stephenson1, W. Pae1. 1 _Cardiothoracic Surgery, Penn State Hershey Medical Center, Hershey, PA,_ 2 _Heart & Vascular Institute, Penn State Hershey Medical Center, Hershey, PA_

**(929)** _The Value of N-Terminal Pro-Brain Natriuretic Peptide After LVAD Implantation;_ G. Lolay, M. Guglin, B. George, K. Kido, R. Charingo. _Cardiology, University of Kentucky Medical Center, Lexington, KY_

**(930)** _Hospital Readmission and Survival Rates One Year Post-ECMO Discharge;_ S. M. Evrard, K. Milley, J. Camuso, K. E. Perkins. _Cardiac Surgery, Massachusetts General Hospital, Boston, MA_

**(931)** _The In-Hospital Cost of Ventricular Assist Device Therapy: Implications for Patient Selection;_ A. Iyengar, O. Kwon, M. Tamrat, N. Satou, C. Gomez, R. J. Shemin, M. Kwon. _University of California - Los Angeles, Los Angeles, CA_

**(932)** _Improved Medical Resource Use by Deploying a Novel Multidisciplinary Team-Based In-Hospital MCS Unit;_ E. N. Lyons, K. A. Frankel, L. Coakley, M. Hickey, F. Melanson, E. G. Olanda, S. E. Shaughnessy, D. S. Medina, M. M. Givertz, G. S. Couper, M. R. Mehra, G. C. Stewart. _Brigham & Women's Hospital, Boston, MA_

**(933)** _PCI in Patients Supported with CF-LVADs: Indications, Safety, and Outcomes;_ E. C. Anyanwu1, S. Atman2, S. Nathan2, G. Sayer3, S. Adatya3, N. Sarswat3, T. Ota4, V. Jeevanandum4, N. Uriel3. 1 _Internal Medicine, University of Chicago, Chicago, IL,_ 2 _Interventional Cardiology, University of Chicago, Chicago, IL,_ 3 _Advanced Heart Failure, University of Chicago, Chicago, IL,_ 4 _Cardiac Surgery, University of Chicago, Chicago, IL_

**(934)** _Changes in Lipid Profile Subfractions on Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Therapy;_ V. K. Topkara1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, J. A. Fried1, K. Wong1, D. Jennings1, R. Te-Frey2, J. Haythe1, M. Maurer1, M. A. Farr1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Surgery, Columbia University, New York, NY_

**(935)** _Palliative Care Integration for Patients Receiving Left Ventricular Assist Device as Destination Therapy;_ H. Groninger1, M. Aggarwal2, K. A. Walker3, J. T. Panke1, A. M. Kelemen1, R. M. Holder1, G. Ruiz4. 1 _Medicine, MedStar Washington Hospital Center, Washington, DC,_ 2 _Medicine, MedStar Georgetown University Hospital, Washington, DC,_ 3 _Palliative Care, MedStar Health, Columbia, MD,_ 4 _Advanced Heart Failure, MedStar Heart and Vascular Institute, Washington, DC_

**(936)** _Greater Reduction in NT Pro-BNP Levels Post LVAD Is Associated with a Greater Improvement in Diabetes Control;_ S. Madan, P. Vlismas, O. Saeed, S. R. Patel, J. Shin, S. Murthy, D. Sims, U. Jorde. _Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, bronx, NY_

**(937)** _Prealbumin as a Predictor of Mortality After LVAD Implantation;_ M. E. Rodrigo, D. T. Majure, F. H. Sheikh, C. Bither, M. Hofmeyer, N. Shah, S. W. Boyce, S. S. Najjar. _MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC_

**(938)** _Sodium Nadir during Left Ventricular Assist Device Implantation Is Not Associated with Increased Mortality;_ S. Gupta1, S. Roy2, R. John3, R. Cogswell2. 1 _Medicine, University of Minnesota Health, Minneapolis, MN,_ 2 _Cardiology, University of Minnesota Health, Minneapolis, MN,_ 3 _Cardiothoracic Surgery, University of Minnesota Health, Minneapolis, MN_

**(939)** _Measuring Blood Pressure in Patients with Continuous-Flow Left Ventricular Assist Devices;_ K. L. Kerk1, T. H. Truong2, C. H. Lim1, T. E. Tan1, D. Sim3, C. P. Lim3, C. Sivathasan1. 1 _Cardiothoracic Surgery, National Heart Centre Singapore, Singapore, Singapore,_ 2 _SingHealth Transplant, Singapore Health Services, Singapore, Singapore,_ 3 _Cardiology, National Heart Centre Singapore, Singapore, Singapore_

**(940)** _The Nutritional Risk Index as a Marker for Outcomes Following Left Ventricular Assist Device Implantation;_ G. Yost1, G. Bhat2. 1 _Heart Transplant, Advocate Christ Medical Center, Oak Lawn, IL,_ 2 _Heart Institute, Advocate Christ Medical Center, Oak Lawn, IL_

**(941)** _Integration of Palliative Care in End of Life Care for Patients on Durable Mechanical Circulatory Support;_ H. J. Halazun1, S. Pinney1, N. Goldstein2, L. Gelfman2, K. Ashley1, A. Anyanwu1, A. Lala1. 1 _Cardiology, Mount Sinai Heart, New York, NY,_ 2 _Palliative Care, Mount Sinai, New York, NY_

**(942)** _Hospital Readmissions After Left Ventricular Assist Device Implantation;_ C. Heim, N. Mekkhala, M. Kondruweit, M. Weyand, R. Tandler. _Department of Cardiac Surgery, University of Erlangen, Erlangen, Germany_

**(943)** _Quality of Life among LVAD Recipients: A Comparison of Bridge-to Transplant vs. Destination Therapy Patients;_ K. D. Milley1, S. M. Evrard1, G. Lewis2, D. A. D'Alessandro3, T. E. MacGillivray3, S. C. Wiafe4, J. M. Camuso1, K. E. Perkins3. 1 _Cardiac Surgery Research, Massachusetts General Hospital, Boston, MA,_ 2 _Heart Failure/Cardiology, Massachusetts General Hospital, Boston, MA,_ 3 _Cardiac Surgery, Massachusetts General Hospital, Boston, MA,_ 4 _Cardiac Surgery/VAD Coordinator, Massachusetts General Hospital, Boston, MA_

**(944)** _The Real World: Self-Reported Dressing Practices in LVAD Outpatients;_ A. Kaan1, D. Christensen2, M. Mackay3. 1 _Acute Heart Failure Program, St. Paul's Hospital, Vancouver, BC, Canada,_ 2 _MyLVAD.com, Washington, DC,_ 3 _St Paul's Hospital & University of British Columbia, Vancouver, BC, Canada_

**(945)** _A Single Center U.S. Experience with the Implementation of Mandatory Patient and Caregiver Pre-Ventricular Assist Device Implantation Education;_ M. L. Safiran, E. Boyes, B. Duebner, E. Coglianese. _Heart Failure / Cardiac Transplant, Loyola University Medical Center, Maywood, IL_

NURSING, HEALTH SCIENCES, ALLIED HEALTH

Target Audience:

NHSAH, EEP, HF, HTX, LTX, MCS, PEDS, PH, PHARM

Poster Discussants:

Bryan Boling, Pamela Combs, Jennifer Franzwa, Bronwyn Levvey, Lauren Schneider, Diana Shellmer

**(946)** _Is Functional Status a Mediator of the Effect of the Sickness Behavior & Discomforts Symptom Clusters on Quality of Life in Heart Failure Patients?; _J. Salyer1, M. P. Flattery2. 1 _Adult Health, VCU Health System, Richmond, VA,_ 2 _Nursing, Pauley Heart Center, VCU Health System, Richmond, VA_

**(947)** _High Rates of Post-Transplant Depressive Symptoms Identified Using the CES-D;_ T. Holland, R. Byrd, R. Crouch, M. G. Hartwig, K. Holleman, A. Pastva, J. Reynolds, P. Smith, L. D. Snyder. _Duke University Med Ctr, Durham, NC_

**(948)** _The Positive Outcomes for Patients Receiving Animal Assisted Therapy after Lung Transplantation;_ K. Holleman, T. Holland, L. West, L. D. Snyder. _Duke University Med Ctr, Durham, NC_

**(949)** _Pre Lung Transplant Patients' Ability to Predict Post Lung Transplant Quality of Life with and without CLAD;_ M. Aversa1, N. A. Chowdhury2, G. Tomlinson1, L. G. Singer1. 1 _Department of Medicine, University of Toronto, Toronto, ON, Canada,_ 2 _Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada_

**(950)** _Relationship of Depression Symptoms with Sense of Coherence Among Japanese Patients After Implantation of Left Ventricular Assist Device;_ N. P. Kato1, I. Okada2, D. Nitta3, T. Imamura2, Y. Yamashita2, Y. Kagami4, M. Endo4, M. Hatano3, M. Ono5, T. Jaarsma1, K. Kinugawa6. 1 _Social and Welfare Studies, Linköping University, Linköping, Sweden,_ 2 _Therapeutic Strategy for Heart Failure, The University of Tokyo, Tokyo, Japan,_ 3 _Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan,_ 4 _Organ Transplantation, The University of Tokyo, Tokyo, Japan,_ 5 _Cardiovascular Surgery, The University of Tokyo, Tokyo, Japan,_ 6 _The 2nd Department of Internal Medicine, University of Toyama, Toyama, Japan_

**(951)** _Associations and Differences in Behavioral and Emotional Symptoms Among Parents, Teachers, and School-Aged Youth: The School Experience After Pediatric Heart Transplantation (HT);_ C. White-Williams1, P. Fazeli-Wheeler1, A. Crosswy1, M. Hubbard2, J. Kirklin1. 1 _University of Alabama, Birmingham, AL,_ 2 _Children's Hospital of Alabama, Birmingham, AL_

**(952)** _Implant Strategy Is Related to Health-Related Quality of Life at 2 Years After LVAD Implantation: An INTERMACS Analysis;_ K. L. Grady1, P. L. Fazeli2, C. White-Williams3, S. L. Myers4, S. V. Pamboukian5, D. C. Naftel4, J. K. Kirklin4. 1 _Surgery, Northwestern Mem Hosp, Chicago, IL,_ 2 _Psychology, University of Alabama at Birmingham, Birmingham, AL,_ 3 _Nursing, University of Alabama Medical Center, Birmingham, AL,_ 4 _Surgery, University of Alabama at Birmingham, Birmingham, AL,_ 5 _Medicine, University of Alabama at Birmingham, Birmingham, AL_

**(953)** _Patients Previously Supported by Veno-Arterial Extra Corporeal Membrane Oxygenation Have Good Long Term Quality of Life;_ K. Hryniewicz1, K. Wilson2, A. Pai2, R. Garberich3. 1 _Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN,_ 2 _Minneapolis Heart Institute Foundation, Minneapolis, MN,_ 3 _Minneapolis Heart Institute Foundation, Minneapolis Heart Institute Foundation, Minneapolis, MN_

**(954)** _Cognitive Function and Self-Care in Patients with Left Ventricular Assist Devices (LVADs);_ J. Casida1, F. D. Pagani2, H. Yarandi3, C. Williams4, M. Lefebvre2, S. Fox2, P. Lichtenberg5. 1 _School of Nursing, University of Michigan, Ann Arbor, MI,_ 2 _Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI,_ 3 _College of Nursing, Wayne State University, Detroit, MI,_ 4 _Advanced Heart Failure & Transplant, Henry Ford Hospital, Detroit, MI, _5 _Institute of Gerontology, Wayne State University, Deteroit, MI_

**(955)** _Does Age Affect Exercise Outcomes for Adult Cystic Fibrosis Lung Transplant Recipients?;_ L. M. Fuller1, G. Snell2, A. E. Holland1, M. Paraskeva2. 1 _Physiotherapy Department, The Alfred, Melbourne, Australia,_ 2 _Lung Transplant Services, The Alfred, Melbourne, Australia_

**(956)** _The Challenges Associated with the Ongoing Management of Heart Transplantation in Young Adults, Including Transitioning from Paediatric to Adult Care;_ G. Minio. _Transplant Services, Alfred Hospital, Melbourne, Australia_

**(957)** _Use of In-Situ Simulation Technique to Implement a Mechanical Circulatory Support Emergency Response System in the Pediatric Setting;_ A. Schubert, C. Villa, A. Gardner, D. Morales, A. Lorts. _Cincinnati Children's Hospital Medical Center, Cincinnati, OH_

**(958)** _Lung Transplant Patients and Carers Report Unmet Palliative Care Needs;_ C. Li1, A. Collins2, M. Gold1, J. Philip2, G. Snell1. 1 _Alfred Health, Melbourne, Australia,_ 2 _Centre for Palliative Care, St Vincent's Hospital, Melbourne, Australia_

**(959)** _A 7 Center Review of Left Ventricular Assist Device (LVAD) Caregiver Perceptions;_ S. Schettle1, L. Staley2, S. Schroeder3, A. Luckhardt1, S. Chillcott4, M. Kasper5, J. Bjelkengren6, C. Marchand7, J. Stulak1, S. Dunlay8. 1 _Cardiovascular Surgery, Mayo Clinic Rochester, Rochester, MN,_ 2 _Cardiovascular Surgery, Mayo Clinic Arizona, Phoenix, AZ,_ 3 _Cardiovascular Surgery, Bryan Heart, Lincoln, NE,_ 4 _Cardiovascular Surgery, Sharp Memorial Hospital, San Diego, CA,_ 5 _Cardiovascular Surgery, University Hospitals of Cleveland, Cleveland, OH,_ 6 _Cardiovascular Surgery, Providence Sacred Heart Medical Center, Spokane, WA,_ 7 _Cardiovascular Surgery, Thomas Jefferson University Hospital, Philadelphia, PA,_ 8 _Cardiology, Mayo Clinic Rochester, Rochester, MN_

**(960)** _Tales of Roller Coaster Rides and Resilience: Lung Transplant Caregivers in Their Own Words;_ A. J. Haines. _Acute and Tertiary Care, Univ Pittsburgh Sch Nursing, Monroeville, PA_

**(961)** _Getting a New Life: Women Living with a Left Ventricular Assist Device;_ A. D. Pal1, A. E. Berndt1, C. J. Braden1, J. H. Calhoon1, J. D. Pal2, S. L. Gill1. 1 _University of Texas Health Science Center, San Antonio, TX,_ 2 _Univ of Washington, Seattle, WA_

**(962)** _Non-Adherence to Medical Advice Does Not Impact Survival in a Bridge to Transplant (BTT) Left Ventricular Assist Device (LVAD) Program;_ A. Kaan, E. Johansson, W. Chiu, Q. Young, C. Cannon, S. Prytula, A. Cheung, M. Toma. _St. Paul's Hospital, Vancouver, BC, Canada_

**(963)** _A Review of Warfarin Management in Patients Supported with a Heartware HVAD Using Home INR Testing;_ A. Woods, G. MacGowan, S. Schueler, N. Robinson Smith, N. Wrightson. _Cardiothoracic, Newcastle upon Tyne NHS Foundations Trust, Newcastle upon Tyne, United Kingdom_

**(964)** _Implementing a Change Package to Improve the Anti-Coagulation Management of Pediatric Patients on Ventricular Assist Devices;_ A. Schubert, C. Villa, J. Brown, D. Morales, J. Sawyer, A. Gardner, A. Lorts. _Cincinnati Children's Hospital Medical Center, Cincinnati, OH_

**(965)** _Validating the Effectiveness of Ventricular Assist Device-Specific Education during the Pre-Discharge Phase;_ L. Coakley, D. S. Medina, M. Hickey, F. Melanson, E. G. Olanda, S. E. Shaughnessy, J. A. Smallwood, G. S. Couper, M. M. Givertz. _Brigham & Women's Hospital, Boston, MA_

**(966)** _Slow-Paced Respiration Therapy to Treat Sleep Disturbance and Symptoms in Pulmonary Arterial Hypertension;_ L. Matura1, J. Fargo2, J. S. Fritz1, K. A. Smith1, A. Vaidya1, D. Pinder1, C. Archer-Chicko1, D. Dubow1, H. I. Palevsky1, A. I. Pack1, M. S. Sommers1, S. M. Kawut1. 1 _University of Pennsylvania, Philadelphia, PA,_ 2 _Utah State University, Logan, UT_

**(967)** _Opportunities and Restrictions in Digitizing VAD Care;_ K. Vandersmissen, J. Driesen, H. Bollen, K. Van den Bossche, J. Cloetens, W. Droogne, F. Rega, B. Meyns. _Cardiac Surgery, UZ Leuven, Leuven, Belgium_

PEDIATRICS

Target Audience:

PEDS, HTX, ID, LTX, PHARM

Poster Discussants:

Jennifer Conway, George Mallory, Ernestina Melicoff-Portillo, Martin Schweiger, Melinda Solomon, Stuart Sweet, Josef Thul, Gary Visner

**(968)** _Impact of Infant Nutritional Status on Outcomes in Lung Transplant;_ S. Das1, S. Culhane2. 1 _Baylor College of Medicine, Houston, TX,_ 2 _Texas Children's Hospital, Houston, TX_

**(969)** _Evaluation of Epstein-Barr Viral Loads as a Predictor of Development of Post-Transplant Lymphoproliferative Disorder;_ A. Parrish1, M. Fenchel1, G. Storch2, R. Buller2, S. Mason2, S. Mason2, N. Williams3, D. Ikle4, S. Sweet2, L. Danziger-Isakov1. 1 _Cincinnati Children's Hosp Med Ctr, Cincinnati, OH,_ 2 _Washington University, St. Louis, MO,_ 3 _National Institutes of Health, Bethesda, MD,_ 4 _Rho, Inc., Chapel Hill, NC_

**(970)** _Prevalence of Malnutrition and Growth in Children after Lung Transplantation;_ M. C. Gazzaneo, G. Mackey, U. Kyle, S. Culhane, E. Melicoff-Portillo, S. Das, N. Crews, G. Mallory, L. Shekerdemian, J. Cossbu. _Pediatrics, Texas Children's Hospital, Houston, TX_

**(971)** _Improving Health Management: The Development of an Adolescent Specific Education Program;_ M. Paraskeva, R. Martin, K. Attard, B. Levvey, J. Marshall, B. Tarrant, S. Ivulich, G. P. Westall. _Lung Transplant Service, Alfred Hospital, Melbourne, Australia_

**(972)** _Pediatric Extracorporeal Membrane Oxygenation Support as Treatment for Refractory Cardiogenic Shock;_ A. Loforte1, G. Murana1, M. Sposito1, L. Careddu2, F. Petridis2, E. Angeli2, L. Ragni3, G. Frascaroli4, G. Gargiulo2. 1 _Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy,_ 2 _Pediatric Cardiac Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy,_ 3 _Pediatric Cardiology and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy,_ 4 _Anesthesiology and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy_

**(973)** _Cannula Site Management Strategies in Pediatric Ventricular Assist Device (VAD) Patients;_ M. V. Horn1, P. Shah2, J. Menteer1, C. Herrington1, D. Guadiz1, D. Dechant1, J. Szmuszkovicz1. 1 _Heart Institute, Children's Hospital Los Angeles, Los Angeles, CA,_ 2 _Hematology Oncology, Children's Hospital Los Angeles, Los Angeles, CA_

**(974)** _Incidence of Thrombo-Embolic Events of Intra-Corporeal Ventricular Assist Devices in Pediatrics - EUROMACS Analyses;_ M. Schweiger1, M. Hübler1, F. Berger2, O. Miera2, A. Loforte3, G. Gargiulo3, T. M. de By4, J. Gummert5, O. behalf of all EUROMACS Members6, P. Mohacsi7. 1 _Children's Hospital, Zurich, Switzerland,_ 2 _Klinik für Angeborene Herzfehler/Kinderkardiologie, Deutsches Herzzentrum, Berlin, Germany,_ 3 _Dipartimento di Chirurgia Cardio-Toraco-Vascolare e Trapianti, Policlinico S. Orsola-Malpighi, Università di Bologna, Bologna, Italy,_ 4 _Euromacs e.V., c/o Deutsches Herzzentrum Berlin, Germany,_ 5 _Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, Bad Oeynhausen, Switzerland,_ 6 _Euromacs e.V. c/o, Deutsches Herzzentrum, Berlin, Germany,_ 7 _Department of Cardiology, Swiss Cardiovascular Center, University Hospital (Inselspital), Bern, Switzerland_

**(975)** _ECMO Support in Infant Less Than 3 kg: Indications, Complications and Outcomes;_ S. R. Deshpande1, G. Kasniya2, J. Davis3, M. Paden3, A. J. Piazza4. 1 _Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA,_ 2 _Children's Healthcare of Atlanta, Atlanta, GA,_ 3 _Emory University Children's Healthcare of Atlanta, Atlanta, GA,_ 4 _Division of Neonatal-Perinatal Medicine, Emory University Children's Healthcare of Atlanta, Atlanta, GA_

**(976)** _Bridging Children to Transplant with Short Term VADs Does Not Affect Post-Transplant Mortality;_ C. Villa, R. Rizwan, F. Zafar, A. Lorts, D. Morales. _Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH_

**(977)** _Successful Treatment of VAD Pump Thrombosis in Four Pediatric Patients;_ D. Chetan, H. Buchholz, M. Bauman, V. Anand, P. Holinski, J. Conway. _Stollery Children's Hospital, Edmonton, AB, Canada_

**(978)** _Sensitization across the Age Spectrum Post VAD: Can We Detect Differences between Adults and Children?;_ A. Halpin1, B. Martin2, S. Urschel3, D. Kim1, L. West1, P. Campbell4, H. Buchholz5, J. Conway3. 1 _Department of Medicine, Pediatrics, University of Alberta, Edmonton, AB, Canada,_ 2 _Division of Cardiac Surgery, University of Alberta, Edmonton, AB, Canada,_ 3 _Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada,_ 4 _Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada,_ 5 _Stollery Children's Hospital and Mazankowski Heart Institute, University of Alberta, Edmonton, AB, Canada_

**(979)** WITHDRAWN

**(980)** _Worldwide Use of SynCardia Total Artificial Heart in Pediatric Population: A 30 Year Experience;_ A. Lorts1, R. Rizwan2, F. Zafar2, J. L. Jefferies1, J. S. Tweddell2, F. A. Arabia3, D. L. Morales2. 1 _Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH,_ 2 _Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH,_ 3 _Cardiothoracic Surgery, Cedars-Sinai Medical Center, Los Angeles, CA_

**(981)** _Pediatric Implantable Left Ventricular Assist Device Experience;_ S. Kocabeyoglu1, U. Kervan1, E. Unal1, D. Sert1, S. Koca2, K. Kavasoglu1, D. Bagrul2, F. Pac2, M. Pac1. 1 _Cardiovascular Surgery, Turkey Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey,_ 2 _Pediatric Cardiology, Turkey Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey_

**(982)** _Cost Effectiveness of Ventricular Assist Device Destination Therapy for Advanced Heart Failure in Duchenne Muscular Dystrophy;_ D. A. Magnetta1, J. Kang2, P. D. Wearden3, K. J. Smith4, B. Feingold1. 1 _Pediatric Cardiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA,_ 2 _School of Nursing, University of Pittsburgh, Pittsburgh, PA,_ 3 _Cardiothoracic Surgery, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA,_ 4 _Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA_

**(983)** _Jarvik 2000 in Pediatrics as a Bridge to Trasplantation or as Destination Therapy: Perioperative Management;_ F. Iodice1, G. Testa1, S. Morelli1, F. Gandolfo2, A. Amodeo2. 1 _Pediatric Intesive Cardiac Unit, Bambino Gesù Children's Hospital, Rome, Italy,_ 2 _Pediatric Cardiac Surgery, Bambino Gesù Children's Hospital, Rome, Italy_

PULMONARY HYPERTENSION

Target Audience:

PH, BSI, HF

Poster Discussants:

Eric Adler, Jose Cifrian, Rebecca Cogswell, Rachel Crackett, Mardi Gomberg-Maitland, Dana McGlothlin, Ioana Preston, Oksana Shlobin, Marc Simon, Dario Vizza

**(984)** WITHDRAWN

**(985)** WITHDRAWN

**(986)** MOVED TO MINI ORAL SESSION 12

**(987)** _Clinical and Pathologic Features in Lung or Heart and Lung Transplanted Patients with a Diagnosis of Pulmonary Sarcoidosis;_ P. Ausin1, J. Le Pavec1, S. Feuillet1, P. Dorfmuller1, S. Mussot1, L. Savale2, O. Mercier1, H. Nunes3, D. Valeyre3, E. Fadel1. 1 _Service de Chirurgie Thoracique, Hôpital Marie Lannelongue, Le Plessis Robinson, France,_ 2 _Service de Pneumologie, Hôpital Kremlin Bicètre, Paris, France,_ 3 _Service de Pneumologie, Hôpital Avicenne, Bobigny, France_

**(988)** _An Analysis of Mechanism of Hypoxia in Chronic Thromboembolic Pulmonary Hypertension;_ S. Minatsuki, H. Maki, M. Hatano, I. Komuro. _Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan_

**(989)** _Exercise CMR Can Evaluate RV Function and Hemodynamics in Patients with Pulmonary Arterial Hypertension: A Pilot Study;_ E. W. Pollock, S. Raman, V. Franco. _The Ohio State University, Columbus, OH_

**(990)** _Parenchymal Lung Disease in PAH Patients Managed with Prostacyclin Agonists;_ N. A. Weir, O. A. Shlobin, D. Brown, S. D. Nathan, S. Ahmad, C. King, A. Brown. _Inova Advanced Lung Disease & Transplant, Fairfax, VA_

**(991)** _Phenotypic Differences in Pulmonary Hypertension Due to Left Heart Disease (PHLHD) and Reversibility with Left Ventricular Assist Devices (LVAD);_ S. Lim, N. Howell, A. Ranasinghe, J. Mascaro. _University Hospital Birmingham, Birmingham, United Kingdom_

**(992)** _Tricuspid Regurgitation Is Associated with Pulmonary Hemodynamics and Right Ventricular Dysfunction in Pulmonary Arterial Hypertension But Does Not Alter the Geometry of Right Ventricular Contraction;_ J. Po, T. Meeran, R. Davey, R. Benza, A. Raina. _Allegheny General Hospital, Pittsburgh, PA_

**(993)** _A Coding Polymorphism in PFAS (The Gene Encoding Phosphoribosylformylglycinamidine Synthase) Is a Determinant of Prostacyclin Dose;_ V. Thomeas1, M. L. Maitland1, R. L. Benza2, M. Tamari3, E. R. Gamazon4, A. Konkashbaev4, H. Wheeler5, T. Hirota3, M. Kubo3, N. J. Cox4, M. Gomberg-Maitland1. 1 _University of Chicago, Chicago, IL,_ 2 _Allegheny General Hospital, Pittsburgh, PA,_ 3 _Institute of Physical and Chemical Research (RIKEN), Center for Integrative Medical Sciences, Yokohama, Japan,_ 4 _Vanderbilt University, Nashville, TN,_ 5 _Loyola Unviersity, Chicago, IL_

**(994)** _Left Ventricular Failure after Surgery to Correct Right Ventricular Pressure Overload in Pulmonary Hypertension Patients;_ T. Verbelen1, A. Van De Bruaene2, D. Van Raemdonck3, M. Delcroix4, F. Rega1, B. Meyns1. 1 _Cardiac Surgery, UZ Leuven, Leuven, Belgium,_ 2 _Cardiology, UZ Leuven, Leuven, Belgium,_ 3 _Thoracic Surgery, UZ Leuven, Leuven, Belgium,_ 4 _Pneumology, UZ Leuven, Leuven, Belgium_

**(995)** _Pulmonary Pulse-Wave Transit Time Is a Noninvasive Marker of Intrinsic Pulmonary Vascular Disease;_ K. W. Prins, E. K. Weir, J. Markowitz, M. Pritzker, R. Madlon-Kay, T. Thenappan. _Cardiovascular Division, University of Minnesota, Minneapolis, MN_

**(996)** _The Nuclear Orphan Receptors NR4A as Therapeutic Target in Pulmonary Arterial Hypertension Therapy;_ X. Nie, W. Mao, Y. Dai, J. Tan, J. Chen. _Department of Lung Transplant Center, Key Laboratory of Human Organ Transplant in Jiangsu Province, Nanjing Medical University affiliated Wuxi People's Hospital, Wuxi, China_

**(997)** _Right Atrial Pressure to Stroke Volume Ratio Predicts Mortality in Pulmonary Arterial Hypertension;_ S. Mazimba1, J. L. Kennedy1, K. C. Bilchick1, J. A. Wynter2, A. D. Mihalek1, J. A. Tallaj3. 1 _Cardiovascular Medicine, University of Virginia Health System, Charlottesville, VA,_ 2 _Department of Medicine, University of Virginia Health System, Charlottesville, VA,_ 3 _Cardiovascular Medicine, University of Alabama at Birmingham, Birmingham, AL_

**(998)** _The Long Noncoding RNA MEG3 Is an Emerging Factor in Hypoxia-Induced Pulmonary Hypertension;_ M. Brock1, C. Schuoler1, S. Ulrich1, R. Speich1, M. Gassmann2, M. Kohler1, L. C. Huber1. 1 _University Hospital, Zurich, Switzerland,_ 2 _University Zurich, Institute of Veterinary Physiology, Zurich, Switzerland_

**(999)** _Long-Term Safety and Tolerability of a New Formulation of Epoprostenol in Pulmonary Arterial Hypertension (PAH) Patients: Final Results from EPITOME-2;_ J. Granton1, E. Bergot2, A. Boonstra3, P. E. Subias4, N. Galiè5, D. Langleben6, J. C. Lemarié7, T. Pfister8, G. Simonneau9, O. Sitbon9, M. Delcroix10. 1 _University of Toronto, Toronto, ON, Canada,_ 2 _Hôpital Côte de Nacre-CHU, Caen, France,_ 3 _VU University Medical Center, Amsterdam, Netherlands,_ 4 _Hospital Universitario 12 de Octubre, Madrid, Spain,_ 5 _University of Bologna, Bologna, Italy,_ 6 _McGill University, Montreal, QC, Canada,_ 7 _Effi-Stat, Paris, France,_ 8 _Actelion Pharmaceuticals ltd, Allschwil, Switzerland,_ 9 _Hôpital Universitaire de Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France,_ 10 _Department of Pneumology, Gasthuisberg University Hospital, Leuven, Belgium_

**(1000)** _Fasudil Prevents Pulmonary Vascular Remodeling in a Rat Model of Pulmonary Hypertension with Left Heart;_ X. Zhou1, J. Wu2, F. Lin1, Q. Meng1, J. Liu1, H. Fan1, Z. Liu1. 1 _Tongji University School of Medicine, Shanghai East Hospital, Shanghai, China,_ 2 _Zhengzhou University, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China_

**(1001)** _Riociguat Significantly Improved SpO2 during Exercise in Patients with CTEPH;_ M. Hatano, H. Maki, T. Inaba, S. Minatsuki, I. Komuro. _Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan_

**(1002)** _Multi-Disciplinary Care Impacts Mortality in Children with Idiopathic Pulmonary Arterial Hypertension - Results from a Bi-National Population Based Study;_ P. M. Alexander1, M. Rose2, C. O'Donnell3, S. Vidmar4, R. Justo5, M. Richardson6, J. Ramsay7, S. Hope8, G. Sholler9, D. J. Penny10, I. King11, R. J. Weintraub2. 1 _Cardiology, Boston Children's Hospital, Boston, MA,_ 2 _Cardiology, The Royal Children's Hospital, Melbourne, Australia,_ 3 _Cardiology, Starship Children's Hospital, Auckland, New Zealand,_ 4 _Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Melbourne, Australia,_ 5 _Cardiology, Lady Client Children's Hospital, Brisbane, Australia,_ 6 _Cardiology, Women's and Children's Hospital, Adelaide, Australia,_ 7 _Cardiology, Princess Margaret Hospital for Children, Perth, Australia,_ 8 _Cardiology, Monash Medical Centre, Melbourne, Australia,_ 9 _Cardiology, The Children's Hospital at Westmead, Sydney, Australia,_ 10 _Cardiology, Texas Children's Hospital, Houston, TX,_ 11 _Cardiology, Murdoch Children's Research Institute, Melbourne, Australia_

**(1003)** _Serum Cytokine Profiling in Pulmonary Arterial Hypertension;_ A. H. Siddiqui1, N. A. Weir2, M. Lemma WoldeHanna2, A. J. Mazer1, A. Biancotto3, R. Cai1, G. Graninger1, B. Harper1, J. Sun1, S. D. Nathan2, R. L. Danner1, M. A. Solomon4, J. M. Elinoff1. 1 _Critical Care Medicine Department, National Institutes of Health, Bethesda, MD,_ 2 _Inova Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA,_ 3 _Center for Human Immunology, Autoimmunity, and Inflammation, National Institutes of Health, Bethesda, MD,_ 4 _Critical Care Medicine Department and Cardiovascular and Pulmonary Branch, NHLBI, National Institutes of Health, Bethesda, MD_

**(1004)** _PVR Predicts Cardiac Hospitalizations in Pulmonary Hypertension Associated with HFpEF and HFrEF;_ R. R. Vanderpool1, M. Saul2, S. Nouraie3, M. T. Gladwin1, M. A. Simon1. 1 _Heart, Blood, Lung and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA,_ 2 _Medicine, University of Pittsburgh, Pittsburgh, PA,_ 3 _Howard University, Washington DC, DC_

**(1005)** _Right Ventricular Performance with Exercise Declines Predictably in Patients with Idiopathic PAH;_ P. Jain, A. Jabbour, E. Kotlyar, C. Hayward, P. Macdonald, A. Keogh. _Cardiology, St Vincent's Hospital, Sydney, Australia_

**(1006)** _Change in PH Therapy from PDE5i to Riociguat Is Associated with Significant Incremental Increase in Cardiac Index, Decrease in Pulmonary Vascular Resistance and Mean Arterial Pressure;_ R. A. Davey, A. Raina, G. Sokos, M. Kanwar, M. Patarroyo Aponte, R. Agarwal, R. L. Benza. _Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA_

**(1007)** _Survival of the PAH and CTEPH Patients in the Swedish Pulmonary Arterial Hypertension Register 2000-2014;_ G. Rådegran1, B. Kjellström2, B. Ekmehag3, R. Hesselstrand4, B. Kornhall1, F. Larsen5, M. Nissel6, B. Rundkvist7, B. Ullman8, K. Wall9, G. Wikström10, M. Willehadson10, K. Jansson11, S. Söderberg12. 1 _Department of Clinical Sciences Lund, Cardiology, Lund University, Lund, Sweden,_ 2 _Cardiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden,_ 3 _Department of Public Health and Caring Science, Uppsala University, Uppsala, Sweden,_ 4 _Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden,_ 5 _Department of Molecular Medicine and Surgery, Section of Clinical Physiology, Karolinska Institute, Stockholm, Sweden,_ 6 _Department of Medicine, Karolinska Institute, Stockholm, Sweden,_ 7 _Department of Cardiology, The Sahlgenska Academy, Gothenburg University, Gothenburg, Sweden,_ 8 _Department of Cardiology, Karolinska Institute, Stockholm, Sweden,_ 9 _Department of Clinical Physiology, Örebro University, Örebro, Sweden,_ 10 _Department of Medical Sciences Cardiology, Uppsala University, Uppsala, Sweden,_ 11 _Departments of Cardiology and Clinical Physiology, Institution of Medicine and Health Sciences, Linköping University, Linköping, Sweden,_ 12 _Department of Public Health and Clinical Medicine, Cardiology and the Heart Centre, Umeå University, Umeå, Sweden_

**(1008)** _Autologous Transfusion of Stored Red Blood Cells Impairs Endothelium-Dependent Vasodilatation in Experimental Pulmonary Arterial Hypertension. This Effect Is Reversed by Inhaled Nitric Oxide;_ A. Rungatscher1, L. Daniele1, L. San Biagio1, S. Bombieri1, S. Hallström2, G. Luciani1, G. Faggian1. 1 _University f Verona, Verona, Italy,_ 2 _Institute of Physiological Chemistry, University of Graz Medical School, Graz, Austria_
POSTER SESSION 3

FRIDAY, APRIL 29, 2016

6:00 PM - 7:00 PM

Exhibit Hall B & C

INFECTIOUS DISEASES

Target Audience:

ID, HTX, LTX, MCS, NHSAH, PHARM

Poster Discussants:

Lara Danziger-Isakov, Martha Mooney, Orla Morrissey, Joanna Schaenman

**(1009)** WITHDRAWN

**(1010)** _Antimicrobial Activity of Cysteamine Against Antibiotic Resistant Pathogens Isolated from Cystic Fibrosis and Non- CF Patients Including Mycobacterium abscessus Complex from Lung Transplant Recipients;_ A. Perry, J. D. Perry, C. Preece, D. Tierney, S. Peart, F. K. Gould. _Microbiology Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom_

**(1011)** _Posaconazole Tablets Exposure in the Real-Life of Lung Transplantation;_ B. Douvry1, B. Toussaint2, A. Roux1, L. Lecuyer3, E. Rivaud1, L. Couderc1, V. Boussaud3, D. Grenet1, R. Guillemain3, E. M. Billaud2. 1 _Pneumology, Hosp Foch, Suresnes, France,_ 2 _Pharmacology, Hosp Georges Pompidou, Paris Cedex 15, France,_ 3 _Thoracic Transplantation, Hosp Georges Pompidou, Paris Cedex 15, France_

**(1012)** _Successful Heart Transplantation in Patients with Total Artificial Heart Infections;_ S. Taimur1, T. Sullivan1, M. Rana1, G. Patel1, K. Ashley2, J. Roldan2, B. Griffin2, S. Pinney3, A. Anyanwu4, S. Huprikar1. 1 _Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY,_ 2 _Mount Sinai Hospital, New York, NY,_ 3 _Department of Medicine, Division of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY,_ 4 _Department of Cardiothoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY_

**(1013)** _Stopping Conventional Showering Decreases Pseudomonas Exit Site Infections in Left Ventricular Assist Device Patients;_ N. Aburjania, S. Sherazi, V. Tchantchaleishvili, J. Alexis, C. Hay. _Infectious Diseases, University of Rochester, Rochester, NY_

**(1014)** _The Impact of the Exit Site Left Ventricle Assist Device Power Supply on Infection Incidence: A Single Center Experience;_ F. Toto, J. Bejko, M. Carrozzini, M. Comisso, G. Bortolussi, M. Gallo, D. Gregori, V. Tarzia, G. Gerosa, T. Bottio. _Department of Cardio-Thoracic and Vascular Sciences, University of Padua, Padua, Italy_

**(1015)** _Bacteremia Is Associated with Increased LVAD Mortality;_ M. Naidu1, M. R. Bochan2, M. Walsh3, T. P. Schleeter3, S. Moainie4, C. T. Salerno4, J. A. Cowger3. 1 _Internal Medicine, St. Vincent Heart Center of Indiana, Indianapolis, IN,_ 2 _Infectious Disease, St. Vincent Heart Center of Indiana, Indianapolis, IN,_ 3 _Cardiology, St. Vincent Heart Center of Indiana, Indianapolis, IN,_ 4 _Cardiac Surgery, St. Vincent Heart Center of Indiana, Indianapolis, IN_

**(1016)** _Successful Heart Transplantation in Patients with Active Staphylococcus Bloodstream Infection and Suspected Mechanical Circulatory Support Device Infection;_ T. Sullivan1, S. Taimur1, M. Rana1, G. Patel1, S. Pinney2, A. Anyanwu3, S. Huprikar1. 1 _Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY,_ 2 _Division of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY,_ 3 _Department of Cardiothoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY_

LUNG TRANSPLANTATION

Target Audience:

LTX, BSI, EEP, ID, LBCS, NHSAH, PATH, PEDS, PH, PHARM

Poster Discussants:

Amir Emtiazjoo, Allan Glanville, Matthew Hartwig, Michael Trotter, Gregor Warnecke, Glen Westall, Christopher Wigfield

**(1017)** _Transplantation of Lungs Recovered from Donors After Euthanasia Results in Excellent Long-Term Outcome;_ D. Van Raemdonck1, A. Neyrinck2, S. Van Cromphaut3, S. Verleden4, B. Vanaudenaerde4, D. Claes5, K. Degezelle5, B. Desschans5, R. Vos6, L. Dupont6, W. Coosemans1, H. Decaluwé1, L. Depypere1, P. Nafteux1, H. Van Veer1, P. De Leyn1, G. M. Verleden6. 1 _Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium,_ 2 _Anesthesiology, University Hospitals Leuven, Leuven, Belgium,_ 3 _Intensive Care Medicine, University Hospitals Leuven, Leuven, Belgium,_ 4 _Department of Clinical and Experimental Medicine, Katholieke Universiteit Leuven, Leuven, Belgium,_ 5 _Transplant Coordination, University Hospitals Leuven, Leuven, Belgium,_ 6 _Pneumology, University Hospitals Leuven, Leuven, Belgium_

**(1018)** _Bile Acid in Donor Bronchial Wash as a Biomarker of Gastric Acid Aspiration to Determine Suitability of Donor Lungs for Transplantation;_ D. Nakajima, M. Cypel, T. Martinu, T. Saito, S. Azad, W. Klement, M. Chen, T. K. Waddell, M. Liu, S. Keshavjee. _Toronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada_

**(1019)** _Cadaveric Lobar Lung Transplantation Based on the Experiences of Living-Donor Lobar Lung Transplantation;_ M. Irie, S. Sugimoto, T. Kurosaki, K. Miyoshi, S. Otani, M. Yamane, T. Oto, S. Miyoshi. _Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Hospital, Okayama, Japan_

**(1020)** _Regional Variation in Lung Transplantation in the Era of the Lung Allocation Score;_ V. Ambur1, S. Taghavi2, S. Jayarajan2, S. Kadakia1, H. Zhao1, J. Gomez-Abraham1, E. Leotta1, A. Shiose1, Y. Toyoda1. 1 _Temple University Hospital, Philadelphia, PA,_ 2 _Barnes-Jewish Hospital/Washington University in St. Louis, St. Louis, MO_

**(1021)** _Strategies of Donor Lung Preservation after Cessation of Circulation in Controlled DCDs;_ Y. Watanabe, D. Nakajima, M. Pipkin, M. Chen, J. Zhu, S. Eilert, C. Jaynes, A. Osumi, P. Pierre-Benoit, T. K. Waddell, M. Liu, S. Keshavjee, M. Cypel. _Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada_

**(1022)** _A Survival Benefit in More Recent Eras for Lung Transplant Recipients with a LAS in the Upper Quartile;_ T. C. Crawford1, J. C. Grimm1, J. Magruder1, C. M. Sciortino1, B. S. Kim1, E. L. Bush1, J. V. Conte1, R. S. Higgins1, A. S. Shah2, C. A. Merlo3. 1 _Cardiac Surgery, Johns Hopkins University, Baltimore, MD,_ 2 _Cardiac Surgery, Vanderbilt University, Nashville, TN,_ 3 _Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD_

**(1023)** _Preformed HLA Specific Antibodies in Adult Cardiothoracic Transplantation - Does the Presence of Low Levels Matter?;_ K. L. Booth1, V. Carter2, S. Clark1, G. Parry1. 1 _Cardiothoracic Transplantation, Freeman Hospital, Newcastle, United Kingdom,_ 2 _Cardiothoracic Transplantation, NHSBT, Newcastle, United Kingdom_

**(1024)** _OTO Score and Medium-Term Survival in Lung Transplantation;_ V. Rossetti1, L. Morlacchi1, A. D'Adda1, M. Pappalettera1, D. Tosi2, A. Palleschi2, P. Tarsia1, M. Nosotti2, F. Blasi1. 1 _U.O. Broncopneumologia, Dipartimento di Fisiopatologia e dei Trapianti, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano., Milano, Italy,_ 2 _U.O. Chirurgia Toracica e dei Trapianti di Polmone, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano., Milano, Italy_

**(1025)** _Management and Outcomes of Incidental Donor Derived Pulmonary Embolism;_ G. R. Dincheva1, A. S. Bratt1, B. C. Hamilton1, K. Rajalingam1, E. L. Bush1, P. Brandenhoff1, L. E. Leard2, R. J. Shah2, M. E. Kleinhenz2, M. Brzezinski3, J. A. Golden2, S. R. Hays2, J. P. Singer2, J. Kukreja1. 1 _Surgery; Division of Cardiothoracic Surgery, Univ of California, San Francisco, CA,_ 2 _Medicine, Univ of California, San Francisco, CA,_ 3 _Anesthesia, Univ of California, San Francisco, CA_

**(1026)** _The Paradoxical Impact of Warm Ischemia on Lung Allograft Survival;_ D. D. Odell1, E. Chan1, N. Shigemura1, M. R. Morrell2, M. M. Crespo2, J. M. Pilewski2, J. D. Luketich1, J. D'Cunha1. 1 _Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA,_ 2 _Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA_

**(1027)** _Does Hanging Donors Be Really Marginal for Lung Transplantation?;_ R. Renard1, T. Le Houerou1, P. Puyo1, P. Bonnette1, M. Glorion1, S. Abou Taam1, A. Roux2, M. Leguen3, F. Parquin1, A. Chapelier1, E. Sage1. 1 _Thoracic Surgery and Lung Transplant Department, Hôpital Foch, Suresnes, France,_ 2 _Pneumology and Lung Transplant Department, Hôpital Foch, Suresnes, France,_ 3 _Anaesthesiology Department, Hôpital Foch, Suresnes, France_

**(1028)** _ABO Compatibility in Lung Transplantation;_ D. Demos1, G. Divine2, G. Paone1, J. Borgi1, J. Morgan1, L. Allenspach3, L. Stagner3, H. Nemeh1. 1 _Cardiothoracic Surgery, Henry Ford Hospital, Detroit, MI,_ 2 _Public Health Sciences, Henry Ford Hospital, Detroit, MI,_ 3 _Pulmonary Medicine, Henry Ford Hospital, Detroit, MI_

**(1029)** _Correlation New UNOS LAS and ET LAS;_ G. D. Nossent1, J. Smits2, J. Gottlieb3. 1 _Lung Transplantation, UMCG, Groningen, Netherlands,_ 2 _Eurotransplant International Foundation, Leiden, Netherlands,_ 3 _Department of Pulmonary Medicine, Hannover Medical School, Hannover, Germany_

**(1030)** _How Big Is the Pool of Rejected Donor Lungs That Potentially Could Become Transplantable with EVLP? A Single Center Analysis of Registered Donor Data;_ A. Martens1, K. Degezelle2, B. Desschans2, D. E. Van Raemdonck3, B. M. Vanaudenaerde4, G. M. Verleden4, R. Vos4, S. E. Verleden4, A. P. Neyrinck1. 1 _Cardiovascular Sciences - Anesthesiology and Algology, KU Leuven, Leuven, Belgium,_ 2 _Transplant Coordination, UZ Leuven, Leuven, Belgium,_ 3 _Department of Clinical and Experimental Medicine - Experimental Thoracic Surgery, KU Leuven, Leuven, Belgium,_ 4 _Department of Clinical and Experimental Medicine - Pneumology, KU Leuven, Leuven, Belgium_

**(1031)** _Refinement of Lung Donor Scoring System with Consideration for Negative Impact of Prolonged Donor Intubation Time;_ S. Tanaka, K. Miyoshi, T. Kurosaki, S. Otani, S. Sugimoto, M. Yamane, T. Oto. _Okayama University Hospital, Okayama, Japan_

**(1032)** _Clinical Outcomes of Lung Transplantation from Extended Criteria Donor Lungs;_ H. Jung, H. Paik, J. Lee, S. Haam, C. Lee, Y. Do, K. Nam. _Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of_

**(1033)** _Massive Donor Transfusion Increases Recipient Early Mortality after Lung Transplantation;_ C. Borders, Y. Suzuki, C. Schaufler, J. Lasky, D. Mallem, J. Lee, K. Carney, C. Bermudez, J. Diamond, J. Christie, E. Cantu. _Hosp U. Pennsylvania, Philadelphia, PA_

**(1034)** _Lung Transplantation from Uncontrolled Circulatory Death Donors: Potential Benefits and Barriers;_ N. N. Niles1, M. Connellan1, A. R. Glanville2, G. W. Fulde3, E. K. Granger1. 1 _Department of Cardiothoracic Surgery, St. Vincent's Hospital, Sydney, Australia,_ 2 _Department of Thoracic Medicine, St. Vincent's Hospital, Sydney, Australia,_ 3 _Deparment of Emergency Medicine, St. Vincent's Hospital, Sydney, Australia_

**(1035)** _HLA-DQB-Matching Is Feasible and Does Not Prolong Wait Times for Lung Transplant Recipients;_ J. M. Tikkanen, A. Hirji, R. Zamel, H. Zhao, L. G. Singer, S. Keshavjee, K. Tinckam. _Toronto General Hospital, Toronto, ON, Canada_

**(1036)** _The Association between Donor-Recipient Race Matching and Survival Following Lung Transplantation Differs Based on Recipient Race;_ C. F. Evans1, P. G. Sanchez1, Z. N. Kon1, X. Wang1, H. Valantine2, S. Agbor-Enoh2, A. T. Iacono3, B. P. Griffith1, S. M. Pham1. 1 _Surgery, Univ of Maryland School of Medicine, Baltimore, MD,_ 2 _Genomic Research Alliance for Organ Transplantation, National Heart, Lung and Blood Institute, Bethesda, MD,_ 3 _Pulmonary and Transplant Medicine, R Adams Cowley Shock Trauma Center, Baltimore, MD_

**(1037)** _Veno-Arterial Extracorporeal Life Support (ECLS) After Bilateral Lung and Heart-Lung Transplantations for Pulmonary Hypertension;_ T. Kortchinsky1, S. Mussot2, S. Rezaiguia-Delclaux1, M. Artiguenave1, E. Fadel2, F. Stephan1. 1 _Reanimation Adulte, Hopital Marie Lannelongue, Le Plessis Robinson, France,_ 2 _Pole Thoracique et Vasculaire-Transplantation Pulmonaire, Hopital Marie Lannelongue, Le Plessis Robinson, France_

**(1038)** _Interim Results of a Phase II Clinical Trial Comparing Outcomes of Recipients of Lungs Recovered from Uncontrolled Donation After Circulatory Determination of Death Donors (uDCDDs) Assessed by Ex-Vivo Lung Perfusion (EVLP) and CT Scan to Outcomes of Recipients of Lungs from Brain-Dead Donors (BDDs);_ T. M. Egan1, B. Haithcock1, J. Long1, K. Birchard2, J. Lobo3, P. Stewart4, J. Blackwell1, D. Yuan1, C. Thys5, D. Karb6, S. Miller6, M. Hartwig7. 1 _Surgery, U. North Carolina Sch Med, Chapel Hill, NC,_ 2 _Radiology, U. North Carolina Sch Med, Chapel Hill, NC,_ 3 _Medicine, U. North Carolina Sch Med, Chapel Hill, NC,_ 4 _Biostatistics, U. North Carolina Sch Med Gillings School of Public Health, Chapel Hill, NC,_ 5 _Carolina Donor Serices, Durham, NC,_ 6 _U. North Carolina Sch Med, Chapel Hill, NC,_ 7 _Surgery, Duke University School of Medicine, Durham, NC_

MECHANICAL CIRCULATORY SUPPORT

Target Audience:

MCS, BSI, HF, ID, NHSAH, PH, PHARM

Poster Discussants:

Andrew Boyle, Jennifer Cowger, Stavros Drakos, Jerry Estep, Christopher Hayward, Ulrich Jorde, Susan Joseph, Anna Meyer, Sean Pinney, Evgenij Potapov, Victor Rossel, Jan Schmitto, Andre Simon, Mark Slaughter, Martin Strueber, Nir Uriel

**(1039)** _Successfully Weaned Patients after VA ECMO Due to Cardiogenic Shock: Etiology and 1-Year Survival;_ D. Pabst1, A. Ghodsizad1, A. El-Banayosy2, B. Soleimani1, C. Brehm1. 1 _Heart and Vascular Institute, Penn State Milton S. Hershey Medical Center, Hershey, PA,_ 2 _INTEGRIS Baptist Medical Center, Oklahoma City, OK_

**(1040)** _Left Ventricular Assist Device Placement with Concomitant Ventricular Reconstruction for Aneurysmal Disease;_ J. W. Smith, J. D. Pal, D. Walters, C. M. Mahr, N. A. Mokadam. _Univ of Washington, Seattle, WA_

**(1041)** _Left Ventricle Mechanical Circulatory Support Implantation as Successful Bridge to Transplantation for Patients with Cardiac Cachexia;_ M. Hegarova1, I. Malek1, V. Melenovsky1, Z. Dorazilova1, J. Kettner1, J. Maly2, I. Netuka2, J. Pirk2. 1 _Department of Cardiology, IKEM, Prague, Czech Republic,_ 2 _Department of Cardiovascular Surgery, IKEM, Prague, Czech Republic_

**(1042)** _A Novel Combined Endpoint Integrating Quality of Life Can Inform Decisions about VAD in Ambulatory Advanced Heart Failure;_ G. C. Stewart1, A. V. Ambardekar2, M. M. Kittleson3, M. Palardy4, A. DeVore5, J. T. Thibodeau6, J. J. Teuteberg7, L. M. Cadaret8, R. C. Forde-McLean9, M. M. Mountis10, S. V. Pamboukian11, R. Cantor11, R. Xie11, L. W. Stevenson1. 1 _Brigham & Women's Hospital, Boston, MA, _2 _University of Colorado Hospitals, Denver, CO,_ 3 _Cedars-Sinai Heart Institute, Los Angeles, CA,_ 4 _University of Michigan, Ann Arbor, MI,_ 5 _Duke University Medical Center, Durham, NC,_ 6 _University of Texas Southwestern, Dallas, TX,_ 7 _University of Pittsburgh Medical Center, Pittsburgh, PA,_ 8 _University of Iowa, Iowa City, IA,_ 9 _University of Pennsylvania, Philadelphia, PA,_ 10 _Cleveland Clinic, Cleveland, OH,_ 11 _University of Alabama Birmingham, Birmingham, AL_

**(1043)** _Myocarditis Treated with VA-ECMO: A Single Centers Experience;_ A. Burdorf, S. Varnado, J. L. Balk, T. Ryan, E. Raichlin, H. Vongooru, B. Lowes, R. Zolty, J. Um, H. Merritt-Genore, M. Moulton, A. Siddique. _Nebraska Medicine, Omaha, NE_

**(1044)** _Implantation of Continuous Flow-Left Ventricular Assist Devices (CF-LVAD) in the Extremely Obese (BMI ≥40 kg/m2): A Single Center Experience;_ J. Amione-Guerra, A. Bhimaraj, G. Ashrith, B. Bruckner, E. E. Suarez, M. H. Park, J. D. Estep, B. H. Trachtenberg. _Methodist Debakey Heart Center, Houston Methodist Hospital, Houston, TX_

**(1045)** _Cardiopulmonary Resuscitation - Is Veno-Arterial Extracorporeal Membrane Oxygenation an Option?;_ S. Zipfel1, S. Pecha2, S. Braune3, S. Kluge3, A. Bernhardt2, B. Sill1, S. Hakmi1, M. Kubik1, H. Reichenspurner1, T. Deuse1. 1 _Hamburg Heart Center, Hamburg, Germany,_ 2 _Heart an Vascular Surgery, Hamburg Heart Center, Hamburg, Germany,_ 3 _Intensive Care Medicine, Universital Hospital of Hamburg, Hamburg, Germany_

**(1046)** _Is "Cardiopulmonary Exercise Testing" Essential to Indicate Ventricular Assist Device in Patients with INTERMACS Profile 4-7?;_ T. Imamura1, K. Kinugawa1, D. Nitta2, M. Hatano2, Y. Itoda3, M. Kimura3, O. Kinoshita3, K. Nawata3, M. Ono3. 1 _Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo, Japan,_ 2 _Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan,_ 3 _Department of Cardiac Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan_

**(1047)** _Clinical and Hemodynamic Profile of Bridge to Recovery Patients Implanted with a Continuous Flow LVAD;_ O. Gerami1, H. Nazzari1, J. Bashir2, A. Kaan1, E. Johansson1, S. Virani1, M. Davis1, B. Munt1, A. Ignaszewski1, A. Cheung2, M. Toma1. 1 _Division of Cardiology, University of British Columbia, Vancouver, BC, Canada,_ 2 _Division of Cardiovascular Surgery, University of British Columbia, Vancouver, BC, Canada_

**(1048)** _Impact of Venous-Arterial Extracorporeal Membrane Oxygenation Standardized Guidelines: Worth the Effort?;_ A. C. Miller1, A. K. Rauf1, A. K. Johnson1, H. Choi1, R. Alharethi1, K. Afshar1, D. Budge1, J. Revenaugh1, S. Froebe2, B. Rasmusson1, S. Stoker1, W. Caine1, B. B. Reid1, A. G. Kfoury1. 1 _Intermountain Heart Institute, Intermountain Medical Center, Salt Lake City, UT,_ 2 _Perfusion, Intermountain Medical Center, Salt Lake City, UT_

**(1049)** _Patient Selection for Ventricular Assist Devices: What Happens in Real Practice?;_ Q. Yang1, M. Kanwar2, J. F. Antaki3, L. Carey3, J. Zimmerman1. 1 _School of Computer Science, Carnegie Mellon University, Pittsburgh, PA,_ 2 _Allegheny General Hospital, Pittsburgh, PA,_ 3 _Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA_

**(1050)** _Does INTERMACS Classification Predict Outcomes after LVAD Implantation?;_ S. Maltais1, N. A. Haglund2, M. E. Davis2, J. Cowger3, P. Shah4, P. Shah4, F. D. Pagani5, K. D. Aaronson5, S. M. Dunlay6, J. M. Stulak1. 1 _Cardiovascular Surgery, Mayo Clinic, Rochester, MN,_ 2 _Vanderbilt, Nashville, TN,_ 3 _St-Vincent Hospital, Rochester, MN,_ 4 _Inova Fairfax, Virginia, VA,_ 5 _Michigan, Michigan, MI,_ 6 _Mayo Clinic, Rochester, MN_

**(1051)** _Performance of Continuous Flow Left Ventricular Assist Devices for the Smaller Size Patient Population;_ T. Fujita1, H. Hata1, Y. Matsumoto1, Y. Shimahara1, O. Seguchi2, M. Yanase2, T. Nakatani2, N. Fukushima2, J. Kobayashi1. 1 _Cardiac Surgery, National Cerebral and Cardiovascular Center, Suita, Japan,_ 2 _Transplantation, National Cerebral and Cardiovascular Center, Suita, Japan_

**(1052)** _Combined Renal Risk Score Predicts Post-Implant Renal Failure in Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Patients;_ V. Topkara1, E. Coromilas1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, R. C. Li1, M. Tiburcio2, K. Ross2, R. N. Sladen3, D. M. Mancini1, Y. Naka2, J. Radhakrishnan1, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Surgery, Columbia University, New York, NY,_ 3 _Anesthesiology, Columbia University, New York, NY_

**(1053)** _No Distance Is Too Great: A Patient's Commute to Their Implantation Center Is Not Associated with Worse Outcomes Following Placement of a Left Ventricular Assist Device;_ M. Andrews1, S. Wesner1, R. Watkins1, J. N. Katz2. 1 _Transplantion, Univ of North Carolina, Chapel Hill, NC,_ 2 _Cardiology, Univ of North Carolina, Chapel Hill, NC_

**(1054)** _Impact of Preoperative Glycemic Control on Long-Term Mechanical Circulatory Support Device Implantation;_ E. A. Downs1, L. E. Johnston1, D. J. LaPar1, L. T. Yarboro1, J. A. Kern1, J. L. Kirby2, S. Mazimba2, A. M. Speir3, J. B. Rich4, M. A. Quader5, G. Ailawadi1, J. L. Kennedy2. 1 _Surgery, University of Virginia, Charlottesville, VA,_ 2 _Medicine, University of Virginia, Charlottesville, VA,_ 3 _Cardiovascular and Thoracic Associates, Inova Heart and Vascular Institute, Falls Church, VA,_ 4 _Virginia Cardiac Surgery Quality Initiative, Charlottesville, VA,_ 5 _Virginia Commonwealth University, Richmond, VA_

**(1055)** _Role of ECMO in Acute Myocardial Infarction Complicating Cardiogenic Shock;_ H. Lee1, S. Song2, S. Kim2, S. Oh1, N. Kim1, J. Kim1, S. Lee1, J. Park1, J. Oh1, J. Choi1, H. Lee1, K. Cha1, T. Hong1. 1 _Department of Cardiology, Pusan National University Hospital, Busan, Korea, Republic of,_ 2 _Department of Thoracic Surgery, Pusan National University Hospital, Busan, Korea, Republic of_

**(1056)** _Characteristics of Non-Compliant (NC) LVAD Patients;_ J. Larsen1, E. M. Dunn2, N. M. Kunz2, K. L. Lockard2, J. J. Teuteberg2, L. Lagazzi2, A. D. Althouse2, R. L. Kormos2. 1 _University of Pittsburgh School of Medicine, Pittsburgh, PA,_ 2 _The Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA_

**(1057)** _Arrhythmia History Predicts Morbidity and Mortality Following LVAD Implantation;_ A. R. Garan1, V. K. Topkara1, X. Mai1, B. C. Varr1, K. Wong1, F. Castagna1, P. N. Trinh2, S. Sreekanth3, M. Tiburcio3, M. Flannery3, D. L. Jennings1, K. Takeda3, H. Takayama3, Y. Naka3, M. Maurer1, D. M. Mancini1, M. Yuzefpolskaya1, W. Whang1, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Epidemiology, Columbia University, New York, NY,_ 3 _Surgery, Columbia University, New York, NY_

**(1058)** _QRS Duration Predicts Outcomes Following Implantation of a Left Ventricular Assist Device;_ A. R. Garan1, X. Mai1, V. K. Topkara1, K. J. Clerkin1, K. Wong1, F. Castagna1, P. N. Trinh2, S. Sreekanth3, D. L. Jennings1, M. F. Torres3, B. Cagliostro3, G. Parkis3, K. Takeda3, H. Takayama3, Y. Naka3, M. Maurer1, D. M. Mancini1, M. Yuzefpolskaya1, J. M. Dizon1, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Epidemiology, Columbia University, New York, NY,_ 3 _Surgery, Columbia University, New York, NY_

**(1059)** _LVAD Implantation in Cardiogenic Shock: Improved Outcome by Less Invasive Surgery;_ S. V. Rojas, M. Avsar, M. Hillert, J. S. Hanke, A. Uribarri, K. Tuemler, C. Kuehn, A. Haverich, J. D. Schmitto. _Department of Cardiothoracic-, Transplantation- and Vascular Surgery, Hannover Medical School, Hannover, Germany_

**(1060)** _Impact of Preoperative Variables on Hospital Length of Stay in Patients Undergoing Continuous Flow LVAD Implantation;_ D. Plack1, S. S. Roy2, R. Cogswell2, J. Spratt1, K. Liao1, R. John1. 1 _Department of Cardiothoracic Surgery, University of Minnesota Medical School, Minneapolis, MN,_ 2 _Department of Cardiology, University of Minnesota Medical School, Minneapolis, MN_

**(1061)** _Understanding Perceived Racial and Gender Differences in LVAD Use on the Transplant Waitlist;_ A. R. Alejos1, D. Schaubel2, J. Magee3, M. Colvin3, R. Sung3. 1 _University of Michigan Medical School, Ann Arbor, MI,_ 2 _University of Michigan School of Public Health, Ann Arbor, MI,_ 3 _University of Michigan Health System, Ann Arbor, MI_

**(1062)** WITHDRAWN

**(1063)** _How Can We Predict Bi-Ventricular Assist Device Requirement?;_ T. Imamura1, K. Kinugawa1, D. Nitta2, M. Hatano2, O. Kinoshita3, K. Nawata3, M. Ono3. 1 _Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo, Japan,_ 2 _Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan,_ 3 _Department of Cardiac Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan_

**(1064)** _Pre-Extra Corporeal Membrane Oxygenation (ECMO) MELD Score May Predict Meaningful Survival;_ M. Byku1, R. Piotrowski1, A. Itoh2, S. J. Larue1, J. M. Vader1, C. L. Holley1, G. A. Ewald1. 1 _Cardiology, Washington University in St. Louis, Saint Louis, MO,_ 2 _Cardiothoracic Surgery, Washington University in St. Louis, Saint Louis, MO_

**(1065)** _Mean Arterial Pressure to Central Venous Pressure Ratio - A Novel Marker for Right Ventricular Failure after Left Ventricular Assist Device Placement;_ B. Mohamedali1, G. Yost2, R. Doukky1, G. Bhat2. 1 _Cardiology, Rush University Medical Center, Chicago, IL,_ 2 _Heart Institute, Advocate Christ Med Center, Oak Lawn, IL_

**(1066)** MOVED TO MINI ORAL SESSION 08

**(1067)** _Changes in Left Ventricular Pacing Lead Impedance Correlate with Changes in Pulmonary Capillary Wedge Pressure during Hemodynamic Ramp Tests;_ J. D. Moss, E. E. Flatley, A. Oesterle, N. Sarswat, S. Adatya, G. H. Kim, G. Sayer, N. Uriel. _University of Chicago, Chicago, IL_

**(1068)** _Assessment of Ventricular Remodeling Post-LVAD with 3D Echocardiography and Surface Analysis;_ G. Sayer1, D. Medvedofsky1, S. Adatya1, N. Sarswat1, G. H. Kim1, K. Addetia1, E. Kruse1, T. Ota2, V. Jeevanandam2, R. Lang1, N. Uriel1. 1 _Division of Cardiology, University of Chicago, Chicago, IL,_ 2 _Cardiothoracic Surgery, University of Chicago, Chicago, IL_

**(1069)** _A Retrospective Cohort Analysis of Chimney Graft Versus Percutaneous PerfusionTechniques for Veno-Arterial Extracorporeal Membrane Oxygenation in Patients with Refractory Cardiogenic Shock;_ M. Cakici, E. Ozcinar, B. M. Inan, S. M. Durdu, C. M. Sarıcaoglu, A. Aral, M. Sirlak, R. A. Akar. _Department of Cardiovascular Surgery, Ankara University School of Medicine, Ankara, Turkey_

**(1070)** _Blood Product Utilization in Continuous Flow Left Ventricular Assist Devices: Single Institution Trends;_ P. B. Harrington, D. Nguyen, A. Pekarek, J. Binongo, Y. Lasajanak, J. D. Vega. _Cardiothoracic Surgery, Emory University, Atlanta, GA_

**(1071)** _Considering LV Dimension Is Important in Assessing the Risk of Right Ventricular Failure after Left Ventricular Assist Device Implantation;_ K. Nakamoto1, T. Ohtani1, H. Kioka1, Y. Tsukamoto1, D. Yoshioka2, S. Saito2, K. Toda2, Y. Sawa2, Y. Sakata1. 1 _Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan,_ 2 _Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Japan_

**(1072)** _Incidence and Predictors of Left Ventricular Functional Recovery on Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Support;_ V. K. Topkara1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, J. A. Fried1, B. Toennes1, F. Castagna1, A. M. Clemons1, J. Eadie2, B. Cagliostro1, S. Restaino1, M. Maurer1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Surgery, Columbia University, New York, NY_

**(1073)** _Can Patients with Restrictive Physiology Be Successfully Bridged to Transplant with Left Ventricular Support Alone Versus Biventricular Support?;_ C. Runyan, H. Henry, N. Huie, J. Moriguchi, M. Kittleson, L. Czer, D. Chang, E. Passano, T. Aintablian, J. A. Kobashigawa, F. Esmailian, F. Arabia. _Cedars-Sinai Heart Institute, Los Angeles, CA_

**(1074)** _Invasive and Noninvasive Hemodynamic Measures Correlate in Patients with Continuous Flow Left Ventricular Assist Devices;_ H. Fan, C. T. Sparrow, D. S. Raymer, M. E. Nassif, J. M. Vader, S. J. LaRue. _Washington Univ St. Louis, Saint Louis, MO_

**(1075)** _Effect of Biventricular Support on Exercise Capacity Compared to Left Ventricular Support Alone: Is This the Right Time for Endurance Testing?;_ J. Silva Enciso, K. Alqahtani, H. Tran, T. Upham, E. Adler, V. Pretorius. _University of California San Diego, San Diego, CA_

**(1076)** _Individual Optimal Blood Pressure Determined by Cerebral Autoregulation Monitoring During and After Continuous-Flow Left Ventricular Assist Device Implantation;_ M. Ono1, S. K. Singh2, K. K. Kibler3, R. Easley3, K. M. Brady3. 1 _Texas Heart Institute, Houston, TX,_ 2 _Baylor College of Medicine, Houston, TX,_ 3 _Texas Children's Hospital, Houston, TX_

**(1077)** _Impact of Aortic Insufficiency on Unloading Properties of Continuous-Flow Left Ventricular Assist Devices;_ G. Sayer1, E. Kruse1, K. Addetia1, J. Grinstein1, S. Adatya1, N. Sarswat1, G. H. Kim1, T. Ota2, V. Jeevanandam2, R. Lang1, N. Uriel1. 1 _Cardiology, University of Chicago, Chicago, IL,_ 2 _Cardiothoracic Surgery, University of Chicago, Chicago, IL_

**(1078)** _Implications of Exercise Oscillatory Ventilation Post Ventricular Assist Device Implantation;_ L. Elbaum1, S. Pinney2, A. Anyanwu3, A. Lala2. 1 _Medicine, Mount Sinai School of Medicine, New York, NY,_ 2 _Cardiology, The Mount Sinai Hospital, New York, NY,_ 3 _Cardiothoracic Surgery, The Mount Sinai Hospital, New York, NY_

**(1079)** _The Role of Inertgas-Rebreathing Method During Exercise Testing in LVAD Patients;_ N. Reiss, T. Schmidt, S. Mommertz, M. Altesellmeier, D. Willemsen, S. Schulte-Eistrup. _Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany_

**(1080)** _Correlation of Non-Invasive Flow Estimation of the Axial-Flow Left Ventricular Assist Device with Fick and Thermal Cardiac Output;_ V. Raje1, A. K. Mankad2. 1 _Cardiovascular Disease, Virginia Commonwealth University, Richmond, VA,_ 2 _Cardiovascular Disease, McGuire Veterans Medical Center, Richmond, VA_

**(1081)** _To Compress or Not to Compress: Revisiting the Use of Chest Compressions in LVAD Patients;_ J. Johannesen1, J. Whittier2, S. Kunnirickal2, S. Feitell3, T. Rowe4, W. Fischer5, S. R. Hankins2, H. J. Eisen2. 1 _Medicine, Drexel University, Philadelphia, PA,_ 2 _Cardiology/Medicine, Drexel University, Philadelphia, PA,_ 3 _Cardiology/Medicine, Cleveland Clinic Foundation, Cleveland, OH,_ 4 _Center for Advanced Heart Failure Care, Drexel University, Philadelphia, PA,_ 5 _Cardiothoracic Surgery, Drexel University, Philadelphia, PA_

**(1082)** _Routine Postoperative Cardiac Monitoring with Hemodynamic Transesophageal Echocardiography (hTEE) for Patients with Left Ventricular Assist Device (LVAD);_ N. Bahatyrevich, Q. Yang, H. Hirose, N. C. Cavarocchi. _Department of Surgery, Thomas Jefferson University, Philadelphia, PA_

**(1083)** _No Pulse, No Problem! Measuring Blood Pressure and Estimating Pulse Pressure in Centrifugal Flow Left Ventricular Assist Devices;_ J. E. Holtz1, A. N. Potter2, B. C. Lampert3, L. Lagazzi1, R. L. Kormos1, J. J. Teuteberg1. 1 _University of Pittsburgh Medical Center, Pittsburgh, PA,_ 2 _University of Pittsburgh, Pittsburgh, PA,_ 3 _The Ohio State University, Columbus, OH_

**(1084)** _Changes in Lipid Profile Following Durable Mechanical Circulatory Support: Confirming the "Lipid Paradox" in Heart Failure;_ K. S. Telukuntla1, T. C. Hanff1, E. W. Grandin2, J. A. Mazurek2, J. L. Howard3, J. W. Wald2, L. R. Goldberg2, M. L. Jessup2, M. A. Acker3, K. B. Margulies2, P. Atluri3, J. E. Rame2, E. Y. Birati2. 1 _Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA,_ 2 _Division of Cardiovascular Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA,_ 3 _Division of Cardiovascular Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA_

**(1085)** _Standardized Telephone Intervention Algorithm for Improved Ventricular Assist Device Outpatient Management;_ T. Schlöglhofer1, J. Horvat2, Z. Hartner2, J. Riebandt2, T. Haberl2, D. Wiedemann2, K. Dimitrov2, F. Moscato3, D. Zimpfer1, H. Schima1. 1 _Cardiac Surgery, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria,_ 2 _Cardiac Surgery, Medical University of Vienna, Vienna, Austria,_ 3 _Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria_

**(1086)** _VAD Weaning Protocol: A Guideline for Explantation;_ C. E. Weaver1, M. K. Bennett2, K. M. Hryniewicz2, M. A. Samara2, B. Sun3. 1 _Transplant & VAD Department, Abbott Northwestern Hospital, Minneapolis, MN, _2 _Advanced Heart Failure/VAD/Transplant, Minneapolis Heart Institute, Minneapolis, MN,_ 3 _Cardiothoracic Surgery, Minneapolis Heart Institute, Minneapolis, MN_

**(1087)** _Oxydative Stress in Heart Failure Patients after Implantation of Continuous Flow Left Ventricular Assist Devices;_ M. Hyden, R. Zolty, M. C. Zimmerman, E. Raichlin, H. Vongooru, A. Burdorf, S. Varnado, B. D. Lowes. _Cardiology, UNMC, Omaha, NE_

**(1088)** _Feasibility of 24-Hour Advanced Ambulatory Blood Pressure and Hemodynamic Monitoring in Patients with Continuous-Flow Left Ventricular Assist Device;_ F. Castagna1, B. J. McDonnell2, V. K. Topkara1, M. Yuzefpolskaya1, A. R. Garan1, K. Wong1, G. Parkis1, M. R. Torres3, M. Maurer1, K. Ross3, D. M. Mancini1, H. Takayama3, K. Takeda3, Y. Naka3, J. R. Cockcroft2, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Cardiology, Cardiff Metropolitan University, Cardiff, United Kingdom,_ 3 _Surgery, Columbia University, New York, NY_

**(1089)** _Lessons from a 7-Year Experience Using a Rescue-to-Bridge Strategy with TandemHeart to HeartMate II for Severe Refractory Cardiogenic Shock;_ K. W. Yount1, J. L. Kennedy2, J. D. Bergin2, M. Ragosta2, D. S. Lim2, A. Taylor2, J. A. Kern1, L. T. Yarboro1. 1 _Division of Thoracic & Cardiovascular Surgery, University of Virginia, Charlottesville, VA, _2 _Division of Cardiovascular Medicine, University of Virginia, Charlottesville, VA_

**(1090)** _Outcomes with Implementation of Algorithmic Hemodynamic Ramps in Patients with Continuous Flow LVADs;_ N. Sarswat, S. Adatya, G. Sayer, G. Kim, T. Ota, V. Jeevandandam, N. Uriel. _University of Chicago, Chicago, IL_

**(1091)** _Specialized Heart Clinic Versus Standard Anticoagulation Clinic Warfarin Management in Patients with Left Ventricular Assist Devices;_ A. McCarty, S. Lee, P. de Voest, J. McDermott. _Spectrum Health, Grand Rapids, MI_

**(1092)** _Invasive Hemodynamic Testing in Ambulatory Left Ventricular Assist Device Patients;_ N. Badoe, K. Abdullah, S. Phillips, J. Nabut, A. J. Rongione, S. S. Desai, P. Shah. _Inova Heart and Vascular Institute, Falls Church, VA_

**(1093)** _Inpatient Rehabilitation of Biventricular Support Patients - A Special Challenge;_ N. Reiss1, E. Deniz2, S. Jan2, D. Willemsen1. 1 _Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany,_ 2 _Medical School Hannover, Hannover, Germany_

**(1094)** _3D Surface Analysis of RV and LV Shapes as Predictors of Post-LVAD RV Failure;_ G. Sayer1, D. Medvedofsky1, S. Adatya1, N. Sarswat1, G. Kim1, K. Addetia1, E. Kruse1, T. Ota2, V. Jeevanandam2, R. Lang1, N. Uriel1. 1 _Division of Cardiology, University of Chicago, Chicago, IL,_ 2 _Cardiothoracic Surgery, University of Chicago, Chicago, IL_

**(1095)** _Vascular Reactivity Analysis in Patients with Continuous Flow Left Ventricular Assist Devices (CF-LVADs) - The Role of Endothelial Function in Continuous Flow Physiology;_ A. S. Cruz-Solbes, C. Uribe, K. A. Youker, B. H. Trachtenberg, G. Ashrith, J. D. Estep, G. Torre-Amione, B. A. Bruckner, J. P. Cooke, A. Bhimaraj. _Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX_

**(1096)** _Pump Speed Increase Improves Submaximal Exercise Tolerance in Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Patients-A Double Blind Randomized Trial;_ M. H. Jung1, B. Houston2, S. D. Russell2, F. Gustafsson1. 1 _Department of Cardiology, University Hospital Rigshospitalet., Copenhagen, Denmark,_ 2 _Department of Cardiology, Johns Hopkins Hospital, Baltimore, MD_

**(1097)** _Coagulation and Inflammation Profiles with Axial and Centrifugal Flow LVADs;_ V. Tarzia, G. Bortolussi, J. Bejko, M. Gallo, M. Comisso, M. Carrozzini, M. Nadali, R. Bianco, T. Bottio, G. Gerosa. _Cardiac Surgery, University of Padova, Padova, Italy_

**(1098)** _Advanced Heart Failure Therapies in a High Risk Urban Population;_ B. A. Smith1, N. Uriel1, S. Adatya1, G. Sayer1, N. Sarswat1, S. Kalantari Tannenbaum1, J. Grinstein1, K. Marinescu1, V. Kagan2, C. Juricek2, H. Ruedlinger2, V. Jeevanandam2, T. Ota2, G. Kim1. 1 _Division of Cardiology, University of Chicago, Chicago, IL,_ 2 _Cardiothoracic Surgery, University of Chicago, Chicago, IL_

**(1099)** _Clinical Experience with Long-Distance Transportation of Patients on Acute Mechanical Circulatory Support Devices;_ T. Kang1, B. Ko2, S. G. Drakos2, J. Stehlik2, E. M. Gilbert2, J. Nativi-Nicolau2, O. Wever-Pinzon2, J. C. Fang2, A. Koliopoulou1, S. I. Bott3, J. E. Tonna4, C. H. Selzman1, S. H. McKellar1. 1 _Cardiothoracic Surgery, Utah University Hospital, Salt Lake City, UT,_ 2 _Cardiovascular Medicine, Utah University Hospital, Salt Lake City, UT,_ 3 _Anesthesiology, Utah University Hospital, Salt Lake City, UT,_ 4 _Emergency Medicine, Utah University Hospital, Salt Lake City, UT_

**(1100)** _Lactate Dehydrogenase Isoenzyme Monitoring in Patients with Continuous-Flow Left Ventricular Assist Devices (CF-LVADs);_ V. K. Topkara1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama2, B. Cagliostro1, L. Effner2, F. Castagna1, S. Singh1, J. A. Fried1, J. Haythe1, M. Maurer1, M. A. Farr1, D. M. Mancini1, Y. Naka2, P. C. Colombo1. 1 _Medicine, Columbia University, New York, NY,_ 2 _Surgery, Columbia University, New York, NY_

**(1101)** _Patients with Continuous-Flow Left Ventricular Assist Devices Have a Reduced Baroreceptor Sensitivity Compared to Healthy Controls;_ W. K. Cornwell, T. Tarumi, Q. fu, M. Drazner, B. Levine. _Cardiology, Univ of Texas SW, Coppell, TX_

**(1102)** WITHDRAWN

**(1103)** _Investigating a Novel Synergy Applying Remote_ I _schemic Conditioning to_ M _odulate the Altered_ P _hysiology of Contin_ U _ous Flow_ L _eft Ventricular Assist Devices, to Reduce_ S _troke and Other Adverse_ E _ffects: The_ IMPULSE _Trial Pilot Results;_ D. Pujara, H. R. Mallidi, W. E. Cohn, J. Anand, O. H. Frazier, S. K. Singh. _Surgery, Baylor College of Medicine, Houston, TX_

**(1104)** _Plasma Proteomics in Left Ventricular Assist Device Recipients: A Pilot Study;_ C. L. Aquilante1, A. Brieke2, K. S. Fritz1, L. M. Saba1, D. L. Bain1, L. M. Wolfe3, R. L. Page II1, J. Lindenfeld4. 1 _Pharmaceutical Sciences, University of Colorado, Aurora, CO,_ 2 _Division of Cardiology, University of Colorado, Aurora, CO,_ 3 _Colorado State University, Fort Collins, CO,_ 4 _Vanderbilt Heart and Vascular Institute, Vanderbilt University, Nashville, TN_

**(1105)** _Does Right Ventricular-Arterial Coupling Predict Early Right Heart Failure in LVAD Recipients?;_ S. Airhart, R. Cheng, T. Dardas, J. Kirkpatrick, J. Pal, J. Smith, N. Mokadam, C. Mahr, C. Masri. _Cardiology, University of Washington, Seattle, WA_

**(1106)** _The Effect of Cardiac Rehabilitation on Functional Capacity, Psychological Symptoms and Quality of Life in Patiens with a Left Ventricular Assist Device;_ H. Karapolat1, E. Cinar1, K. Capaci1, C. Engin2, T. Yagdi2, M. Ozbaran2, S. Nalbantgil3, M. Zoghi3. 1 _Department of Physical Medicine and Rehabilitation, Ege University School of Medicine, Izmir, Turkey,_ 2 _Department of Cardiovascular Surgery, Ege University School of Medicine, Izmir, Turkey,_ 3 _Department of Cardiology, Ege University School of Medicine, Izmir, Turkey_

**(1107)** _Outcomes of Ventricular Assist Device Therapy for Patients at an INTERMACS Profile 1: Single Center Experience;_ O. Seguchi1, T. Fujita2, S. Nakajima1, H. Sunami1, T. Sato1, M. Yanase1, H. Hata3, J. Kobayashi2, N. Fukushima1, T. Nakatani1. 1 _Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan,_ 2 _Adult Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan,_ 3 _Adult Cadiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan_

**(1108)** _Agreeing to Disagree: A Comparison of Antiplatelet and Anticoagulant Management Strategies at US versus International HVAD Implanting Centers;_ J. J. Teuteberg1, K. D. Aaronson2, C. Mahr3, H. Reichenspurner4, T. Krabatsch5, C. B. Patel6, M. Strueber7, M. S. Kiernan8, D. Zimpfer9, M. V. Jacoski10, S. Schueler11. 1 _University of Pittsburgh Medical Center, Pittsburgh, PA,_ 2 _University of Michigan, Ann Arbor, IL,_ 3 _University of Washington, Seattle, WA,_ 4 _University Hospital Eppendorf, Hamburg, Germany,_ 5 _Deutsches Herzzentrum Berlin, Berlin, Germany,_ 6 _Duke University School of Medicine, Durham, NC,_ 7 _Spectrum Health, Grand Rapids, MO,_ 8 _Tufts Medical Center, Boston, MA,_ 9 _Medical University of Vienna, Vienna, Austria,_ 10 _Medical Affairs, HeartWare Inc., Framingham, MA,_ 11 _Newcastle upon Tyne Freeman Hospital, Newcastle upon Tyne, United Kingdom_

**(1109)** _The Role of Neurohormonal Therapy in Patients with Left Ventricular Assist Devices;_ R. Ghashghaei, R. Yousefzai, F. Liwinski, H. Tran, E. D. Adler. _Cardiology, University of California San Diego, San Diego, CA_

**(1110)** _Evaluation of Systemic Heparin vs. Bivalrudin Anticoagulation in Patients Supported by Extracorporeal Membrane Oxygenation;_ T. J. Berei, M. P. Lillyblad, K. M. Hryniewicz, K. Wilson, R. Garberich. _Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN_

**(1111)** _Evaluating the Safety and Efficacy of Enoxaparin in Bridging Mechanical Circulatory Support (MCS) Patients from Subtherapeutic to Therapeutic INR in an Outpatient Setting;_ L. D. Lam1, U. Duong2, L. Luu2, K. Del Rosario2, M. Fan2, P. Ambrose2, J. Moriguchi1, A. Francisco1. 1 _Cedars Sinai Medical Center, Los Angeles, CA,_ 2 _UCSF School of Pharmacy, San Francisco, CA_

**(1112)** _The Role of Biventricular Assist Device on Patients with Multiorgan Failure Due to Fulminant Myocarditis: Single-Center Experience;_ S. Nakajima1, N. Okada1, K. Kuroda1, E. Hisamatsu1, H. Sunami1, T. Sato1, O. Seguchi1, M. Yanase1, H. Hata2, T. Fujita2, N. Fukushima1, J. Kobayashi2, T. Nakatani1. 1 _Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan,_ 2 _Department of Adult Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan_

PEDIATRICS

Target Audience:

PEDS, HTX, ID, PHARM

Poster Discussants:

Juan Alejos, Estela Azeka, Ryan Butts, Michael Carboni, Michiel Dalinghaus, Susan Denfield, R. Erik Edens, Ranny Goldwasser, Stephan Schubert, Kurt Schumacher, Rakesh Singh, Tajinder Singh, Simon Urschel, Shawn West, Steven Zangwill

**(1113)** _Utility of a Novel Biomarker, Symmetric Dimethylarginine, to Assess Renal Function in Pediatric Heart Transplant Recipients;_ P. T. Thrush1, M. J. Bock2, S. Haymond3, C. L. Backer4, E. Pahl1. 1 _Pediatrics, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, _2 _Pediatrics, Loma Linda University, Loma Linda University Children's Hospital, Loma Linda, CA,_ 3 _Pathology, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, _4 _Surgery, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL_

**(1114)** _Risk of Death Due to Cardiac Arrest in Pediatric Heart Transplantation: Query of the UNOS Database;_ R. W. Loar1, S. W. Denfield1, H. Tunuguntla1, A. G. Cabrera1, J. F. Price1, W. Zhang2, K. Hosek2, J. J. Kim1, W. J. Dreyer1, A. Jeewa1. 1 _Pediatric Cardiology, Texas Children's Hospital/Baylor College of Medicine, Houston, TX,_ 2 _Outcomes and Impact Service, Texas Children's Hospital, Houston, TX_

**(1115)** _Heart Failure Related Hospitalizations in Children with Single Ventricle Heart Disease: Prevalence, Risk Factors for Mortality, and Economic Burden;_ A. Misfeldt1, D. J. Goldberg1, M. J. O'Conner1, P. Shamszad1, C. S. Almond2, C. E. Mascio3, K. Y. Lin1, X. Zhang1, J. Rychik1, R. E. Shaddy1, J. W. Rossano1. 1 _Dept of Pediatrics, The Cardiac Center, The Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA,_ 2 _Dept of Pediatrics, Div. of Cardiology, Lucile Packard Children's Hospital Stanford University, Palo Alto, CA,_ 3 _Dept of Surgery, The Cardiac Center, The Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA_

**(1116)** _Correlation between Solid Phase Assays and Positive CDC Crossmatches in a Surrogate Transplant Model;_ C. Chin1, E. Portwood2, P. Brailey2, B. Mantell1, A. Tica3, A. Girnita4. 1 _Cincinnati Children's Hospital, Cincinnati, OH,_ 2 _Hoxworth Blood Center, Cincinnati, OH,_ 3 _University of Medicine and Pharmacy, Craiova, Dolj, Romania,_ 4 _University of Cincinnati, Cincinnati, OH_

**(1117)** _Developmental Delay Is Not a Risk Factor for Poor Outcome in Pediatric Heart Transplantation;_ A. N. Goel1, A. Iyengar1, K. O. Schowengerdt2, A. Fiore2, C. Huddleston2. 1 _David Geffen School of Medicine at the University of California-Los Angeles, Los Angeles, CA,_ 2 _Saint Louis University School of Medicine, Saint Louis, MO_

**(1118)** _Functional Status of Children Supported on LVADs at Transplant: How Does It Compare to Children on Inotropic Support?;_ A. Bulic, K. Maeda, S. Chen, D. Rosenthal, J. Murray, P. Shuttleworth, C. Almond. _Division of Pediatric Cardiology, Stanford University, Palo Alto, CA_

**(1119)** _Platelet Activation, Receptor Shedding and Aggregation in Pediatric Patients with Congenital Heart Disease Undergoing Cardiopulmonary Bypass;_ N. K. Mondal, G. M. Pantalos, Z. Chen, J. Ding, M. Sobieski, S. C. Koenig, M. S. Slaughter, Z. J. Wu. _Cardiovascular and Thoracic Surgery, University of Louisville School of Medicine, Louisville, KY_

**(1120)** _Emergency Department Utilization by Pediatric Heart Transplant Recipients;_ C. A. Wittlieb-Weber1, J. W. Rossano2, D. R. Weber1, K. Y. Lin2, C. Ravishankar2, C. E. Mascio2, R. E. Shaddy2, M. J. O'Connor2. 1 _University of Rochester Medical Center, Rochester, NY,_ 2 _The Children's Hospital of Philadelphia, Philadelphia, PA_

**(1121)** _Impact of Pediatric Obesity on Heart Transplantation;_ E. Adams1, R. Biniwale2. 1 _David Geffen School of Medicine, UCLA, Los Angeles, CA,_ 2 _Cardiothoracic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA_

**(1122)** _Near Infra-Red Spectroscopy in Pediatric Heart Failure: A Novel Application of a Promising Technology;_ D. Gupta1, R. S. Samraj2, D. Lopez-Colon1, B. A. Pietra1, M. S. Bleiweis1, F. J. Fricker1. 1 _Congenital Heart Center, University of Florida, Gainesville, FL,_ 2 _Pediatric Critical Care, University of Florida, Gainesville, FL_

**(1123)** _Insights into Mixed Cellular and Antibody-Mediated Rejection (MR) in Pediatric Heart Transplant Recipients;_ H. S. Magdo1, D. V. Miller2, G. Snow3, K. M. Molina1, L. May1, H. E. Hammond2, J. Stehlik4, A. K. Lal1, D. Budge4, P. Revelo2, P. Burch5, A. Eckhauser5, A. G. Kfoury4. 1 _Pediatric Cardiology, University of Utah, Salt Lake City, UT,_ 2 _Pathology, Intermountain Medical Center, Salt Lake City, UT,_ 3 _Statistical Data Center, Intermountain Medical Center, Salt Lake City, UT,_ 4 _Cardiology, Intermountain Medical Center, Salt Lake City, UT,_ 5 _Surgery, University of Utah, Salt Lake City, UT_

**(1124)** _A Surprising Era Effect on Cardiac Allograft Vasculopathy: What Can We Learn and What Does This Mean for the Future?;_ K. R. Armstrong, C. Manlhiot, A. I. Dipchand. _Pediatric Cardiology, The Hospital for Sick Children, Toronto, ON, Canada_

**(1125)** _The Use of the Terminal Complement Inhibitor Eculizumab in Pediatric Heart Transplant Recipients;_ Y. M. Law1, K. Gambetta2, J. Scheel3, K. Daly4, K. Molina5. 1 _Pediatrics, Seattle Children 's Hospital, Seattle, WA,_ 2 _Pediatrics, Lurie Children's Hospital, Chicago, IL,_ 3 _Pediatrics, Children's National Healthcare, Washington, DC,_ 4 _Pediatrics, Boston Children's Hospital, Boston, MA,_ 5 _Pediatrics, Primary Children's Hospital, Salt lake City, UT_

**(1126)** _The Impact of Age on the Incidence and Prevalence of Moderate to Severe Cellular Rejection Detected by Routine Surveillance Biopsy in Pediatric Heart Transplantation;_ M. D. Zinn1, K. E. Simpson2, M. J. Wallendorf3, A. D. Osborne4, J. K. Kirklin5, C. E. Canter2. 1 _Pediatric Cardiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA,_ 2 _Pediatric Cardiology, St. Louis Children's Hospital, Washington University in St. Louis, St. Louis, MO,_ 3 _Biostatistics, Washington University School of Medicine, St. Louis, MO,_ 4 _Washington University School of Medicine, St. Louis, MO,_ 5 _Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL_

**(1127)** _Rehospitalization Following Pediatric Heart Transplant: Frequency, Indications, and Outcomes;_ S. A. Hollander1, C. S. Almond1, N. McDonald2, M. Mills3, D. M. Peng1, B. D. Kaufman1, S. Chen1, D. N. Rosenthal1. 1 _Pediatrics (Cardiology), Stanford University, Palo Alto, CA,_ 2 _Solid Organ Transplant Services, Lucile Packard Children's Hospital, Stanford, Palo Alto, CA,_ 3 _Pediatrics, Stanford University, Palo Alto, CA_

**(1128)** _Utility of the Routine Screening Echocardiogram After Endomyocardial Biopsy for Identification of Hemopericardium or Tricuspid Valve Injury;_ D. M. Peng1, A. K. Kipps1, M. Palmon2, T. Z. Khalapyan2, C. S. Almond1, S. Chen1, S. A. Hollander1, T. A. Tacy1, D. N. Rosenthal1, D. McElhinney2. 1 _Pediatrics (Cardiology), Stanford University/Lucile Packard Children's Hospital Stanford, Palo Alto, CA,_ 2 _Cardiothoracic Surgery, Stanford University, Palo Alto, CA_

**(1129)** _Prolonged Donor Ischemic Time Is Not Associated with Worse Cardiac Graft Function in Children;_ B. L. Wisotzkey1, S. P. Law2, T. V. Brogan3, E. L. Albers1, M. S. Kemna1, Y. M. Law1, L. C. Permut4, J. M. Chen4, D. M. McMullan4. 1 _Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA,_ 2 _Pediatric Cardiology, NewYork-Presbyterian/Morgan Stanley Children's Hospital, New York, NY,_ 3 _Pediatric Critical Care, Seattle Children's Hospital, Seattle, WA,_ 4 _Pediatric Cardiac Surgery, Seattle Children's Hospital, Seattle, WA_

**(1130)** _Timing of Tacrolimus Initiation and Impact on Renal Injury in Pediatric Heart Transplant Patients;_ G. Kasniya1, K. LaPorte2, W. T. Mahle3, S. R. Deshpande3. 1 _Pediatric Cardiology, Children's Healthcare of Atlanta, Atlanta, GA,_ 2 _Children's Healthcare of Atlanta, Atlanta, GA,_ 3 _Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA_

**(1131)** _Poverty Is an Independent Socioeconomic Risk Factor for Death Following Pediatric Heart Transplant;_ J. C. Dykes, D. M. Peng, C. S. Almond, L. M. Barkoff, B. Kaufman, D. Bernstein, D. N. Rosenthal, S. A. Hollander. _Pediatrics, Stanford University, Palo Alto, CA_

**(1132)** _Unhealthy Weight Gain in Pediatric Post-Heart Transplant Patients: Incidence and Risk Factors;_ H. M. Lim, P. Chau, A. R. Alejos, R. E. Lowery, S. Yu, K. R. Schumacher. _C.S. Mott Children's Hospital, Congenital Heart Center, University of Michigan, Ann Arbor, MI_

**(1133)** _Temporary Inactivation from the Waitlist Due to Decline in Health Does Not Affect Mid-Term Outcomes among Pediatric Heart Transplant Recipients;_ A. N. Goel1, A. Iyengar1, K. O. Schowengerdt2, A. Fiore2, C. Huddleston2. 1 _David Geffen School of Medicine at the University of California-Los Angeles, Los Angeles, CA,_ 2 _Saint Louis University School of Medicine, Saint Louis, MO_

**(1134)** _Allergies and Autoimmune Disorders in Children after Heart Transplantation;_ N. Avdimiretz1, S. Seitz2, M. Cheveldayoff2, S. Urschel3. 1 _Department of Pediatrics, University of Alberta, Edmonton, AB, Canada,_ 2 _Division of Pediatric Cardiology, University of Alberta, Edmonton, AB, Canada,_ 3 _Division of Pediatric Cardiology, Cardiac Transplant Research, University of Alberta, Edmonton, AB, Canada_

**(1135)** WITHDRAWN

**(1136)** _Preliminary Study: Left Ventricular Torsion in Clinically Stable Heart Transplant Recipients in Children;_ A. Pac, S. Koca, A. V. Kavurt, S. Kocabeyoglu, U. Kervan, I. Ece, M. Pac. _Yuksek Ihtisas Hospital, Ankara, Turkey_

**(1137)** _Venous Congestion Is Associated with Renal Impairment in Children with Cardiovascular Disease;_ H. P. Tunuguntla1, D. Guffey2, C. G. Minard2, A. Akcan-Arikan3, A. G. Cabrera1, A. Jeewa1, S. W. Denfield1, W. J. Dreyer1, C. Almond4, J. F. Price1. 1 _Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX,_ 2 _Dan L. Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX,_ 3 _Pediatric Medicine, Intensive Care, Texas Children's Hospital, Baylor College of Medicine, Houston, TX,_ 4 _Pediatric Cardiology, Lucile Packard Children's Hospital, Stanford School of Medicine, Palo Alto, CA_

**(1138)** _Nutritional Status of Children Undergoing Heart Transplantation at the Heart Institute of São Paulo (Incor) between 2013-2015;_ C. V. Campos, A. W. Siqueira, N. Myura, M. B. Jatene, E. Azeka. _Incor HCFMUSP, Sao Paulo, Brazil_

**(1139)** _Impact of Routine Surveillance Biopsy Intensity on the Diagnosis of Moderate to Severe Cellular Rejection and Survival After Pediatric Heart Transplantation;_ M. D. Zinn1, K. E. Simpson2, M. J. Wallendorf3, A. D. Osborne4, J. K. Kirklin5, C. E. Canter2. 1 _Pediatric Cardiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA,_ 2 _Pediatric Cardiology, St. Louis Children's Hospital, Washington University in St. Louis, St. Louis, MO,_ 3 _Biostatistics, Washington University School of Medicine, St. Louis, MO,_ 4 _Washington University School of Medicine, St. Louis, MO,_ 5 _Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL_

**(1140)** _Calcineurin-Inhibitor Minimization in Pediatric Heart Transplant Recipients;_ M. J. Bock1, T. Shankel2, J. Fitts3, R. Tan4, R. E. Chinnock2. 1 _Pediatric Cardiology, Loma Linda University Children's Hospital, Loma Linda, CA,_ 2 _Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA,_ 3 _Transplant Institute, Loma Linda University Medical Center, Loma Linda, CA,_ 4 _Pharmacy, Loma Linda University Medical Center, Loma Linda, CA_

**(1141)** _Pre-Clinical Testing Results for a New Infant-Sized VAD;_ W. J. Weiss1, J. B. Clark2, J. M. Izer3, B. Lukic4, T. K. Cooper5. 1 _Penn State Hershey Medical Center, Hershey, PA,_ 2 _Pediatrics and Surgery, Penn State Hershey Medical Center, Hershey, PA,_ 3 _Comparative Medicine, Penn State Hershey Medical Center, Hershey, PA,_ 4 _Surgery, Penn State Hershey Medical Center, Hershey, PA,_ 5 _Comparative Medicine and Pathology, Penn State Hershey Medical Center, Hershey, PA_

**(1142)** _Posterior Reversible Encephalopathy Syndrome after Pediatric Heart Transplantation;_ B. Eilers1, E. L. Albers2, Y. M. Law2, M. S. Kemna2. 1 _University of Washington, School of Medicine, Seattle, WA,_ 2 _Pediatric Cardiology, Seattle Children's Hospital/ University of Washington, Seattle, WA_

**(1143)** _Genetics of Pediatric Cardiomyopathy;_ C. Ellepola1, L. M. Knight2, S. R. Deshpande3. 1 _Emory University Children's Healthcare of Atlanta, Atlanta, GA,_ 2 _Sibley Heart Center Cardiology, Atlanta, GA,_ 3 _Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA_

**(1144)** _Hospital Readmissions in Children Following Orthotopic Heart Transplantation: Do Social Factors Matter?;_ N. Bansal, S. Aggarwal. _Pediatric Cardiology, Children's Hospital of Michigan, Detroit, MI_

**(1145)** _School Intervention: An Essential Element of Heart Transplant Care;_ K. K. Herma. _Herma Heart Center, Children's Hospital of Wisconsin, Milwaukee, WI_

**(1146)** _Steroid Maintenance in Preventing Rejection and Its Effects on Post-Transplant Morbidity;_ E. Adams1, R. Biniwale2. 1 _David Geffen School of Medicine, UCLA, Los Angeles, CA,_ 2 _Cardiothoracic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA_

**(1147)** _ADMA Does Not Correlate with Markers of Cardiac Dysfunction in Pediatric Heart Transplant Recipients;_ P. T. Thrush1, M. J. Bock2, S. Haymond3, C. L. Backer4, E. Pahl1. 1 _Pediatrics, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, _2 _Pediatrics, Loma Linda University, Loma Linda University Children's Hospital, Loma Linda, CA,_ 3 _Pathology, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, _4 _Surgery, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL_

**(1148)** _Exercise Tolerance in Pediatric Heart Transplantation Patients with Non-Cameral Coronary Artery Fistulae;_ A. M. Kane1, K. M. Ward2, K. Rychlik3, J. G. Gossett2. 1 _Department of Pediatrics, Division of Cardiology, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA,_ 2 _Department of Pediatrics, Division of Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, _3 _Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL_

**(1149)** _Coronary Flow Reserve Predicts Graft Loss in Pediatric Heart Transplant Patients;_ J. A. Kleinman1, S. M. Stack1, J. Gralla2, S. M. Miyamoto1, B. A. Pietra3, M. D. Everitt1, S. R. Auerbach1. 1 _Pediatrics, Division of Cardiology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO,_ 2 _Pediatrics, Children's Hospital Research Institute, University of Colorado School of Medicine, Aurora, CO,_ 3 _Pediatrics, Division of Cardiology, University of Florida, Gainesville, FL_

**(1150)** _The End-of-Life Experience in Pediatric Heart Transplant Recipients;_ S. A. Hollander1, J. C. Dykes1, S. Chen1, L. M. Barkoff2, D. N. Rosenthal1, D. Bernstein1, B. D. Kaufman1. 1 _Pediatrics (Cardiology), Stanford University, Palo Alto, CA,_ 2 _Solid Organ Transpant Services, Lucile Packard Children's Hospital, Stanford, Palo Alto, CA_

**(1151)** _Milrinone Use for Inotropic Support in Pediatric Acute Heart Failure: Utilization, Safety and Markers of Efficacy;_ S. R. Deshpande1, L. Smitley1, M. Carroll2, K. LaPorte2, W. T. Mahle1, K. O. Maher1. 1 _Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA,_ 2 _Children's Healthcare of Atlanta, Atlanta, GA_

**(1152)** _Pediatric Myocarditis in a Contemporary Multi-Center Cohort;_ R. J. Butts1, G. J. Boyle2, S. Deshpande3, K. Gambetta4, K. Knecht5, C. Prada Ruiz2, M. Richmond6, S. West7, A. Lal8. 1 _Pediatrics, Medical Univ of Sourth Carolina, Charleston, SC,_ 2 _Pediatrics, Cleveland Clinic Children's Hospital, Cleveland, OH,_ 3 _Pediatrics, Children's Healthcare of Atlanta /Emory University, Atlanta, GA,_ 4 _Pediatrics, Lucie Children's of Chicago, Chicago, IL,_ 5 _Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR,_ 6 _Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY,_ 7 _Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA,_ 8 _Pediatrics, Primary Children's Hospital, University of Utah, Salt Lake City, UT_

**(1153)** _A Single Center Pediatric Heart Recipients to Adult Services Retrospective Study of Sentinel Events;_ S. Adams, M. Wigger, I. Feurer. _Heart Transplant, Vanderbilt, Nashville, TN_

**(1154)** _Coronary Allograft Vasculopathy: A 25 Year Pediatric Experience;_ S. R. Deshpande1, S. Eick2, K. LaPorte3, R. Vincent1, K. Kanter4, W. T. Mahle1. 1 _Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA,_ 2 _Emory University, Atlanta, GA,_ 3 _Children's Healthcare of Atlanta, Atlanta, GA,_ 4 _Cardiothoracic Surgery, Emory University, Atlanta, GA_

**(1155)** _Pediatric Myocarditis: Variations in Immunotherapy and Impact on Outcomes;_ K. Gambetta1, G. J. Boyle2, R. J. Butts3, K. R. Knecht4, A. K. Lal5, Y. Law6, A. Prada-Ruiz7, M. E. Richmond8, S. C. West9, S. R. Deshpande10. 1 _Pediatric Cardiology, Ann & Robert H.Lurie Children's Hospital of Chicago, Chicago, GA, _2 _Pediatric Cardiology, Cleveland Clinic Children's, Cleveland, OH,_ 3 _Pediatrics, Medical University of South Carolina, Charleston, SC,_ 4 _Pediatric Cardiology, University of Arkansas for Medical Sciences, Little Rock, AR,_ 5 _Pediatric Cardiology, Primary Children's Hospital, University of Utah, Salt Lake City, UT,_ 6 _Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA,_ 7 _Cleveland Clinic Children's, Cleveland, OH,_ 8 _Morgan Stanley Children's Hospital of New York ,Columbia University, New York, NY,_ 9 _Pediatric Cardiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA,_ 10 _Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA_

**(1156)** _Long-Term Survival in Pediatric Heart Transplantation: A 30-Year Single-Center Experience;_ W. A. Zuckerman1, M. E. Richmond1, T. M. Lee1, S. P. Law1, R. J. Rodriguez1, P. J. Chai2, E. A. Bacha2, J. M. Quaegebeur2, D. Kalfa2, L. J. Addonizio1. 1 _Division of Pediatric Cardiology, Columbia University Medical Center Chidren 's Hospital of New York, New York, NY,_ 2 _Department of Cardiothoracic Surgery, Columbia University Medical Center Chidren 's Hospital of New York, New York, NY_

**(1157)** WITHDRAWN

**(1158)** _Antibody Mediated Rejection Is Associated with Worse Outcome Than Acute Cellular Rejection after Pediatric Heart Transplant;_ G. R. Vaughn1, Y. M. Law2, N. W. Jorgensen3, E. L. Albers2, B. J. Hong2, J. Friedland-Little2, M. S. Kemna2. 1 _Pediatric Cardiology, Rady Children's Hospital, San Diego, CA,_ 2 _Pediatric Cardiology, Seattle Children's Hospital/ University of Washington, Seattle, WA,_ 3 _Biostatistics, University of Washington, Seattle, WA_

**(1159)** _Liver Abnormalities and Post-Transplant Survival in Fontan Patients;_ S. C. Hofferberth1, T. P. Singh2, E. D. Blume2, F. Fynn-Thompson1. 1 _Department of Cardiac Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA,_ 2 _Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA_

**(1160)** _Modified Model for End-Stage Liver Disease eXcluding INR (MELD XI) Score Predicts Post-Heart Transplant Mortality Among Children with Congenital Heart Disease;_ J. E. Ryan, D. Hehir, M. A. McCulloch, S. Haldeman, C. Pizarro, R. R. Davies. _Cardiac Center, Nemours/Alfred I duPont Hospital for Children, Wilmington, DE_

**(1161)** _Hemodynamic Findings Associated with End-Organ Dysfunction in Children with End-Stage Heart Failure;_ S. Chen, D. B. McElhinney, J. C. Dykes, D. N. Rosenthal, S. A. Hollander, K. Maeda, K. Jensen, V. V. Yarlagadda, M. A. Ford, J. F. Price, C. S. Almond. _Stanford University, Palo Alto, CA_

**(1162)** _Pediatric Heart Transplant Donor and Recipient Factors Associated with Death or Re-Transplantation by One Year;_ D. Nandi1, L. Edwards2, M. J. O'Connor1, K. Y. Lin1, C. Ravishankar1, S. M. Paridon1, A. I. Dipchand3, R. E. Shaddy1, J. W. Rossano1. 1 _The Cardiac Center, Children's Hospital of Philadelphia, Philadelphia, PA,_ 2 _International Society for Heart & Lung Transplantation, Dallas, TX, _3 _Cardiomyopathy and Heart Function Program, Labatt Family Heart Centre, University of Toronto Hospital for Sick Children, Toronto, ON, Canada_

**(1163)** _The Fontan Liver after Cardiac Transplantation;_ E. Griffiths, H. S. Magdo, A. K. Lal, L. May, S. Menon, K. M. Molina. _University of Utah, Salt Lake City, UT_

**(1164)** _Expanding the Donor Pool: Regional and Age Variation in Pediatric Organ Donation Rates;_ J. Godown1, M. McKane1, B. A. Mettler2, D. A. Dodd1. 1 _Pediatric Cardiology, Monroe Carell Jr. Children's Hospital, Nashville, TN,_ 2 _Pediatric Cardiothoracic Surgery, Monroe Carell Jr. Children's Hospital, Nashville, TN_

**(1165)** _Impact of Geographic Distance from Transplant Center on Pediatric Heart Transplant Outcomes;_ M. G. McKane, D. A. Dodd, B. A. Mettler, J. Godown. _Department of Pediatrics, Division of Pediatric Cardiology, Vanderbilt University, Nashville, TN_

**(1166)** _Fontan Patients Have Similar Rates of Development of HLA Antibodies After Heart Transplant Regardless of PLE Status;_ K. E. Simpson1, C. Castleberry1, D. Phelan2, P. Eghtesady3, C. E. Canter1. 1 _Pediatrics, Washington Univ in St Louis, School of Medicine, Saint Louis, MO,_ 2 _Barnes-Jewish Hospital, HLA Laboratory, Saint Louis, MO,_ 3 _Surgery, Washington Univ in St Louis, School of Medicine, Saint Louis, MO_

**(1167)** _Optical Coherence Tomography After Pediatric Heart Transplantation - The Experience of 51 Examinations;_ S. M. Ulrich1, A. Lehner1, B. Heineking1, R. Polanetz1, J. Mehilli2, R. Schramm3, R. Kozlik-Feldmann4, R. Dalla Pozza1. 1 _Department of Pediatric Cardiology and Intensive Care Medicine, Ludwig-Maximilians-University Munich, Munich, Germany,_ 2 _Department of Cardiology, Ludwig-Maximilians-University Munich, Munich, Germany,_ 3 _Department of Heart Surgery, Ludwig-Maximilians-University Munich, Munich, Germany,_ 4 _Department of Pediatric Cardiology, University of Hamburg, Hamburg, Germany_

**(1168)** _Relationship between Hemodynamic Variables and NYHA/Ross Functional Capacity in Children with Advanced Heart Failure;_ J. C. Dykes, S. Chen, A. Lin, D. N. Rosenthal, K. Maeda, D. B. McElhinney, C. S. Almond. _Pediatrics, Stanford University, Palo Alto, CA_

**(1169)** _Mortality Is Increased in Pediatric Heart Transplant Recipients with a Positive Cross-Match;_ S. K. Nicholas1, T. J. Humlicek2, K. E. Hosek3, P. T. Jindra4, R. H. Kerman4, J. S. Orange1, J. S. Heinle5, S. W. Denfield1, A. Jeewa1, W. J. Dreyer1. 1 _Pediatrics, Baylor College of Medicine, Houston, TX,_ 2 _Pharmacy, Texas Children's Hospital, Houston, TX,_ 3 _Outcomes & Impact Service, Texas Children's Hospital, Houston, TX, _4 _Surgery, Immune Evaluation Laboratory, Baylor College of Medicine, Houston, TX,_ 5 _Surgery, Baylor College of Medicine, Houston, TX_

PHARMACY AND PHARMACOLOGY

Target Audience:

PHARM, HF, HTX, ID, LTX, MCS, NHSAH

Poster Discussants:

Chris Ensor, Edward Horn, Tam Khuu, Robert Page

**(1170)** _Dabigatran May Have More Significant Drug Interactions with Calcineurin Inhibitors Than Oral Anti-Xa Inhibitors;_ J. E. Shuster1, S. J. LaRue2, J. M. Vader2. 1 _Barnes-Jewish Hospital, Saint Louis, MO,_ 2 _Washington University School of Medicine in St Louis, Saint Louis, MO_

**(1171)** _Does On-Site Analysis of Serum Levels Optimise Management of Patients Taking Voriconazole? A Retrospective Cohort Study;_ P. Ging1, S. FitzGerald2, M. M. MacMahon3, A. Burgess1, C. Meegan1, J. J. Egan4. 1 _Pharmacy, Mater Misericordiae University Hospital, Dublin, Ireland,_ 2 _School Of Pharmacy, Royal College of Surgeons in Ireland, Dublin, Ireland,_ 3 _Biochemistry, Mater Misericordiae University Hospital, Dublin, Ireland,_ 4 _Heart and Lung Transplant Programme, Mater Misericordiae University Hospital, Dublin, Ireland_

**(1172)** _Warfarin, Rifampin, and LVADs- OH MY: Effect of Rifampin on INR and Time in the Therapeutic Range in Patients with a Left Ventricular Assist Device;_ J. E. Mangum, M. L. Hurtik, A. Pekarek, S. R. Laskar. _Emory University Hospital, Atlanta, GA_

**(1173)** _Intra-Patient Variability of Tacrolimus Levels and Cardiac Allograft Outcomes;_ H. Lyster, A. Suarez Barrientos, A. Khokar, J. Smith, N. Leaver, A. Simon, N. R. Banner. _Royal Brompton & Harefield NHS Foundation Trust, Middlesex, United Kingdom_

**(1174)** _Concomitant Warfarin and Aspirin Versus Warfarin Alone for the Prevention of Embolic Events in Patients with a Left Ventricular Assist Device [Thoratec HeartMate II®];_ J. S. Van Tuyl1, I. B. Hollis2, K. A. Alburikan3, R. Tran4, B. P. Murray2, J. E. Rodgers4, J. N. Katz5, B. Sheridan5. 1 _St. Louis College of Pharmacy, St. Louis, MO,_ 2 _University of North Carolina Hospitals, Chapel Hill, NC,_ 3 _King Saud University, Riyadh, Saudi Arabia,_ 4 _University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC,_ 5 _University of North Carolina School of Medicine, Chapel Hill, NC_

**(1175)** _Tacrolimus Immunosuppressive Regimens Are Associated with a Mortality Benefit in Lung Transplantation Recipients at a High-Volume Single Center;_ A. B. Lichvar, M. R. Morrell, J. Hayanga, J. M. Pilewski, M. M. Crespo, J. D'Cunha, A. Zeevi, J. F. McDyer, C. R. Ensor. _University of Pittsburgh, Pittsburgh, PA_

**(1176)** _Use of Pentoxifylline to Mitigate Amphotericin Induced Nephrotoxicity;_ K. B. Bain1, K. A. Fester1, C. A. Witt2, D. E. Byers2, R. D. Yusen2, R. R. Hachem2. 1 _Pharmacy, Barnes Jewish Hospital, St Louis, MO,_ 2 _Pulmonary and Critical Care Medicine, Washington University, St Louis, MO_

**(1177)** _Medication Regimen Complexity in Older Adults with Heart Failure;_ M. R. Cobretti1, K. M. Deininger1, S. A. Linnebur2, R. L. Page II2, J. Lindenfeld3, C. L. Aquilante1. 1 _Pharmaceutical Sciences, University of Colorado, Aurora, CO,_ 2 _Clinical Pharmacy, University of Colorado, Aurora, CO,_ 3 _Vanderbilt Heart and Vascular Institute, Vanderbilt University, Nashville, TN_

**(1178)** _Anticoagulation Monitoring in Left Ventricular Assist Device (LVAD) Patients;_ A. Sieg1, J. Gass1, P. Weeks1, A. Brown1, I. Rajapreyar2, I. Gregoric2. 1 _Pharmacy, Memorial Hermann - Texas Medical Center, Houston, TX,_ 2 _Program of Advanced Heart Failure, UTHealth Medical School, Houston, TX_

**(1179)** _Pre-Transplant Amiodarone Exposure Increases Mortality in Cardiac Transplant Recipients: A Meta-Analysis;_ D. L. Jennings1, W. L. Baker2. 1 _Department of Pharmacy, New York Presbyterian Columbia University Medical Center, New York, NY,_ 2 _Department of Pharmacy Practice, University of Connecticut, Storrs, CT_

**(1180)** _Rituximab for Antibody Mediated Rejection of Uncertain Benefit;_ C. R. McCorquodale1, L. M. Hanning2, J. S. Parmar1. 1 _Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom,_ 2 _Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom_

**(1181)** _Mycophenolate-Based Immunosuppressive Regimens Are Associated with a Mortality Benefit in Lung Transplantation Recipients at a Single High-Volume Center;_ A. B. Lichvar, M. R. Morrell, J. Hayanga, J. M. Pilewski, M. M. Crespo, J. D'Cunha, A. Zeevi, J. F. McDyer, C. R. Ensor. _University of Pittsburgh, Pittsburgh, PA_

**(1182)** _Thromboelastographic Evidence for Reduced Dose Enoxaparin or Fondaparinux Bridge Therapy in Mechanical Circulatory Support Patients with Sub-Therapeutic INR;_ R. H. Cosgrove1, R. L. Basken1, T. Kazui2, A. D. Dauenhauer1, B. K. Martinez1, R. G. Smith3, Z. I. Khalpey2. 1 _Department of Pharmacy Services, Banner University Medical Center - Tucson, Tucson, AZ,_ 2 _Department of Surgery, Banner University Medical Center - Tucson, Tucson, AZ,_ 3 _Artificial Heart Program, Banner University Medical Center - Tucson, Tucson, AZ_

**(1183)** _Safety and Efficacy of Recombinant Activated Factor VII (Novoseven) Administration in Pediatric ECMO Patients;_ G. Kasniya1, C. Salisbury2, M. L. Heard2, K. Maher3, S. R. Deshpande3. 1 _Pediatric Cardiology, Children's Healthcare of Atlanta, Atlanta, GA,_ 2 _Children's Healthcare of Atlanta, Atlanta, GA,_ 3 _Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA_

**(1184)** _Mycophenolate Mofetil in Adult Orthotopic Heart Transplant Recipients: How Much Is Too Much?;_ N. Passi1, J. Snead2, D. J. Goldstein3, S. Murthy1, S. R. Patel1, O. Saeed1, J. J. Shin1, D. B. Sims1, U. Jorde1, N. Siddiqi2. 1 _Department of Medicine, Montefiore Medical Center, Bronx, NY,_ 2 _Department of Pharmacy, Montefiore Medical Center, Bronx, NY,_ 3 _Department of Cardiovascular & Thoracic Surgery, Montefiore Medical Center, Bronx, NY_

JUNIOR FACULTY CLINICAL CASE REPORTS

Target Audience:

ALL

Poster Discussants:

Allen Anderson, Daniel Chambers, Erin Coglianese, Margot Davis, Mark Fenton, Benjamin Freed, Jason Fritz, Mary Keebler, Jesper Magnusson, Hirsch Mehta, Jutta Preiksaitis, Keyur Shah, Ashish Shah, Jorge Silva Enciso, Lianne Singer, Ajay Srivastava, Ryan Tedford, Mitesh Thakrar, Thenappan Thenappan, Marian Urban, Vincent Valentine

**(1185)** _89 Year Old Donor Heart: Alive and Kicking!;_ D. Narasimha, A. Sakr, L. Stoletniy. _Cardiology, Loma Linda University Medical Center, Redlands, CA_

**(1186)** _Massive Air Embolism Resulting in Ischemic Stroke After LVAD;_ A. Verma1, V. Sabharwal2, S. Desai3, E. Parrino1, A. Bansal1. 1 _Surgery, Ochsner Clinic Foundation, New Orleans, LA,_ 2 _Neurocrtical Care, Ochsner Clinic Foundation, New Orleans, LA,_ 3 _Heart Failure and Heart Transplant, Ochsner Clinic Foundation, New Orleans, LA_

**(1187)** _Primary Cardiac B-cell Lymphoma Masquerading as Acute Cellular Rejection;_ T. O. Thomas, R. Levy, G. Gilmore, J. Bryant, S. Pye, X. Garcia, E. Frazier, K. Knecht. _Pediatrics, Arkansas Children's Hospital, Little Rock, AR_

**(1188)** _Bridge to Diagnosis: Impella Support in a Pediatric Patient with Myocarditis;_ A. Jeewa, W. J. Dreyer, H. Justino, S. W. Denfield, I. Adachi, A. G. Cabrera, J. F. Price, S. C. Tume, S. A. Pimpalwar, E. D. McKenzie, D. R. Parekh. _Texas Children's Hospital/Baylor College of Medicine, Houston, TX_

**(1189)** _Plasma Exchange to Remove HIT Antibodies Prior to Left Ventricular Assist Device Implantation and Heart Transplantation;_ B. Ramu, C. M. Martin, R. J. Cogswell. _Cardiology, University of Minnesota, St Paul, MN_

**(1190)** _Lung Transplantation after Awake v-v ECMO Treatment with Extended Reconditioning with the Organ Care System -Pushing the Limits-;_ M. McGarvey1, B. Zych2, D. Garcia-Saez2, A. Simon2, A. Reed1, M. Carby1, A. Popov2, S. Soresi1. 1 _Lung Failure & Transplantation, Royal Brompton & Harefield NHS Foundation Trust, Uxbridge, United Kingdom, _2 _Department of Cardiothoracic Surgery &Transplantation, Royal Brompton & Harefield NHS Foundation Trust, Uxbridge, United Kingdom_

**(1191)** _Long Term Successful Biventricular Assist Device (BIVAD) Use in a Post-Transplant Patient: Lessons Learned;_ S. J. Wagner, J. Turek, J. Lampe, E. Edens. _Pediatric Cardiology, University of Iowa Hospitals and Clinics, Iowa City, IA_

**(1192)** _Outcome of Patients with Pulmonary Arteriovenous Malformations After Heart Transplant;_ B. L. Wisotzkey1, D. M. Magyar2, T. K. Jones1, M. S. Kemna1, E. L. Albers1, B. J. Hong1, J. M. Friedland-Little1, Y. M. Law1. 1 _Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA,_ 2 _Pediatrics, Seattle Children's Hospital, Seattle, WA_

**(1193)** _Unusual Pattern of Constrictive Pericarditis in the Patient Who Underwent Heart Transplantation;_ N. Ueda, O. Seguchi, S. Nakajima, T. Satou, M. Yanase, H. Hata, T. Fujita, H. Ueda, N. Hukushima, J. Kobayashi, T. Nakatani. _Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan_

**(1194)** _Cryptosporidium-Associated Elevated Tacrolimus Levels and EBV Viremia in a Pediatric Heart Transplant Recipient;_ V. A. Statler. _Department of Pediatrics, University of Louisville, Louisville, KY_

**(1195)** _Post-Fontan Protein-Losing Enteropathy: A Possible Context for Under-Recognized HLA Antibodies;_ N. Alami Laroussi1, A. Halpin2, L. Hidalgo2, J. A. Conway1, D. B. Ross3, C. Sergi4, L. J. West1, S. Urschel1. 1 _Pediatric Cardiology, Stollery Children's Hospital, Edmonton, AB, Canada,_ 2 _Immunology, Stollery Children's Hospital, Edmonton, AB, Canada,_ 3 _Pediatric Cardiovascular and Thoracic Surgery, Stollery Children's Hospital, Edmonton, AB, Canada,_ 4 _Pathology, Stollery Children's Hospital, Edmonton, AB, Canada_

**(1196)** _Bringing Complement Under Control: Atypical Hemolytic-Uremic Syndrome Successfully Treated with Eculizumab;_ M. E. Rodrigo, F. H. Sheikh, J. L. Rice, D. T. Majure, M. Hofmeyer, E. Molina, S. S. Najjar. _MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC_

**(1197)** _Successful Durable LVAD Implantation Following Repair of Acute Post-Myocardial Infarction Ventricular Septal Defect;_ V. Ton1, R. A. Garan1, V. Topkara1, M. Yuzefpolskaya1, P. C. Colombo1, H. Takayama2, Y. Naka2. 1 _Cardiology, Columbia University Medical Center, New York, NY,_ 2 _Cardiothoracic Surgery, Columbia University Medical Center, New York, NY_

**(1198)** _Safe Utilization of Hydrogen Gas in Clinical Setting after Lung Transplantation;_ T. Kawamura1, J. Yoshida2, T. Kimura1, S. Funaki1, Y. Shintani1, M. Minami1, A. Uchiyama2, Y. Fujino2, A. Nakao3, M. Okumura1. 1 _General Thoracic Surgery, Osaka University Graduate School of Medicine, Suita, Japan,_ 2 _Anesthesiology and Intensive Care, Osaka University Graduate School of Medicine, Suita, Japan,_ 3 _Emergency Disaster and Critical Care Medicine, Hyogo College of Medicine, Nishinomiya, Japan_

**(1199)** _The Role of Antibody Screening and Cardiac Biopsy in the Management of a Patient with Biventricular Assist Device Support as Bridge to Retransplantation While on Single Immunosuppressive Agent;_ M. Figura1, S. Zieroth2, F. Cordova2, P. Campbell1, S. Girgis1, H. Buchholz1, D. Freed1, D. Kim1. 1 _University of Alberta, Edmonton, AB, Canada,_ 2 _University of Manitoba, Winnipeg, MB, Canada_

**(1200)** _Hemodynamic Benefits of Oral Iron Supplementation for Anemia in Pulmonary Arterial Hypertension: Novel Insights from Wireless Hemodynamic Monitoring;_ M. Mehmood, R. L. Benza. _Allegheny General Hospital, Pittsburgh, PA_

**(1201)** _Pulmonary Artery Banding as an Alternative to Mechanical Support in an Infant with Severe Left Ventricular Dysfunction and Failure to Wean from Bypass;_ M. N. Kavarana1, J. R. Buckley2, S. Chowdhury2, A. M. Hlavacek2, A. J. Savage2, R. J. Butts2, S. M. Bradley1. 1 _Pediatric Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC,_ 2 _Pediatric Cardiology, Medical University of South Carolina, Charleston, SC_

**(1202)** _Recurrent Left Ventricular Assist Device Thrombosis Successfully Treated with Slow Thrombolytic Infusion Protocol;_ M. W. Choudhry1, W. I. Khalife1, K. F. Chatila1, M. Morsy1, I. Haider1, L. K. Low1, V. Conti2, V. G. Valentine3, G. Al-Dossari2. 1 _Division of Cardiology, University of Texas Medical Branch at Galveston, Galveston, TX,_ 2 _Division of Cardiothoracic Surgery, University of Texas Medical Branch at Galveston, Galveston, TX,_ 3 _Division of Pulmonary and Critical Care Medicine, University of Texas Medical Branch at Galveston, Galveston, TX_

**(1203)** _Outcomes Following LVAD Exchange from One Device Platform to Another in the Setting of LVAD Thrombosis;_ M. Dhande1, K. J. Morine1, J. N. Upshaw1, C. Vassalo1, J. Nilson1, N. K. Kapur1, A. R. Vest1, D. DeNofrio1, D. T. Pham2, M. S. Kiernan1. 1 _Tufts Medical Center, Boston, MA,_ 2 _Northwestern Memorial Hospital, Chicago, IL_

**(1204)** _Incidental Finding of Cardiac Sarcoma in a Donor Heart Leading to Abandonment of Transplantation Proceeding;_ S. Kumar, A. A. Mangi. _Division of Cardiac Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT_

**(1205)** _Catastrophic Antibody-Mediated Rejection in a Lung Recipient Associated with Unplanned Pregnancy;_ T. Sam1, D. P. Mason2, G. Schwartz2, K. Ausloos3, P. S. Garcha3, R. R. Rosenblatt3, M. Shiller4, M. Askar5, H. J. Huang3. 1 _Department of Pharmacy, Baylor University Medical Center, Dallas, TX,_ 2 _Department of Thoracic Surgery and Lung Transplantation, Baylor University Medical Center, Dallas, TX,_ 3 _Baylor Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX,_ 4 _Department of Pathology, Baylor University Medical Center, Dallas, TX,_ 5 _Transplant Immunology, Baylor University Medical Center, Dallas, TX_

**(1206)** _A Novel Intervention Utilizing Biventricular HVAD Support in Intermacs 1 Patients;_ H. Tran1, E. Adler1, T. Pollema2, V. Pretorius2, D. Cork1, J. Silva1. 1 _Internal Medicine, Division of Cardiology, University of California San Diego, San Diego, CA,_ 2 _Surgery, Division of Cardiothoracic Surgery, University of California San Diego, San Diego, CA_

**(1207)** _Lung Transplantation to the Cystic Fibrosis Recipient with Asymmetric Native Lungs and Hepatitis C;_ B. Kubisa1, M. Piotrowska1, M. Bielewicz1, J. Pieróg1, N. Wójcik1, A. Kubisa2, A. Nowicka3, P. Wasilewski4, T. Grodzki1. 1 _Departmment of Thoracic Surgery and Transplantation, Pomeranian Medical University of Szczecin, Szczecin, Poland,_ 2 _Internal Medicine Department, Pulmonary A. Sokoƚowski Hospital, Szczecin, Poland,_ 3 _Pulmonary Department, University Hospital of Lord's Transfiguration, Poznań, Poland,_ 4 _Intensive Care Unit, Pulmonary A. Sokoƚowski Hospital, Szczecin, Poland_

**(1208)** _Long-Term Use of Intrapericardial Continuous Flow LVADs in Children: 4½ Patient-Years of Follow Up in Three Patients;_ M. McCulloch1, S. Trivedi2, S. Haldeman1, S. S. Gidding1, C. Pizarro1, R. R. Davies1. 1 _Nemours Cardiac Center, AI duPont Hospital for Children, Wilmington, DE,_ 2 _AI duPont Hospital for Children, Wilmington, DE_

**(1209)** _Post Centrifugal Plasma Filtration (PCPF) in Acute Antibody Mediated Rejection (AMR) After Heart Transplantation;_ S. Lee, J. Kim. _Cardiology, Pusan National University Yangsan H., Yangsan, Korea, Republic of_

**(1210)** _Constrictive Pericarditis after Lung Transplantation for Bronchiectasis;_ F. M. Gouvêa, M. N. Samano, P. M. Pêgo-Fernandes, S. V. Campos, L. G. Abdalla, L. M. Fernandes. _Thoracic Surgery, São Paulo University Medical School, São Paulo, Brazil_

**(1211)** _15 Year Old Female Presenting with Hemiplegia Seven Years After Heart Transplantation;_ M. Bano, B. Das. _Pediatric Cardiology, UT Southwestern, Dallas, TX_

**(1212)** _Development of Allograft Cancer after Lung Transplantation;_ E. I. Schwarz1, C. Murer1, L. C. Huber1, B. D. Isenring1, M. M. Schuurmans1, I. Inci2, C. Benden1. 1 _Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland,_ 2 _Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland_

**(1213)** _The Impact of Cardiac Resynchronization Therapy on Hemodynamics and Flow Profiles in a Patient with a Continuous Flow Left Ventricular Assist Device: A Case Report;_ A. R. Vest, S. G. Barnes, M. K. Homoud, S. H. Maniar, M. S. Kiernan. _CardioVascular Center, Tufts Medical Center, Boston, MA_

**(1214)** _VT Storm Caused by Mechanical Irritation Due to a Percutaneous Left Ventricular Partitioning Device (PARACHUTE) Improved After Surgical Extraction and Implantation of LVAD;_ J. Raikhelkar, D. McNeely, G. Joshi, P. Stevens, N. Haglund, A. Shah, A. Kanagasundram, M. Keebler. _Vanderbilt University Medical Center, Nashville, TN_

**(1215)** _Graft Versus Host Disease Following Lung Transplantation;_ A. D. Parulekar, S. Yau, G. Dronavalli. _Baylor College of Medicine, Houston, TX_

**(1216)** _How Bad Is Too Bad? Heart Transplantation Post VAD Related Neurologic Injury;_ S. R. Deshpande1, M. Carroll2, J. J. Chern3, W. T. Mahle1, K. Kanter4. 1 _Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA,_ 2 _Children's Healthcare of Atlanta, Atlanta, GA,_ 3 _Department of Neurosurgery, Emory University Children's Healthcare of Atlanta, Atlanta, GA,_ 4 _Department of Cardiothoracic Surgery, Emory University Children's Healthcare of Atlanta, Atlanta, GA_

**(1217)** _Successful Long-Term Outcome After Lung Transplantation for Pulmonary Disorder Associated with Erdheim-Chester Disease;_ K. Hashimoto, K. Miyoshi, M. Yamane, T. Kurosaki, S. Otani, S. Sugimoto, T. Oto, S. Myoshi. _Department of Thoracic Surgery, Okayama University Hospital, Okyama, Japan_

**(1218)** _The Use of von Willebrand Factor (vWF) for Management of Recurrent GI Bleeding in Continuous Flow Left Ventricular Assist Device Recipients;_ S. P. Blevins1, S. P. Blevins1, S. Evans1, D. Sato1, L. Passey1, R. Oberst1, B. Moore1, S. Schaefer1, G. Evans1, S. Lewey1, P. J. Kaley1, G. E. Schlepp2, T. Icenogle1. 1 _Advanced Heart Therapy, Providence Sacred Heart Medical Center, Spokane, WA,_ 2 _Gastroenterology, Providence Sacred Heart Medical Center, Spokane, WA_

**(1219)** _An Unusual Cause of Post-Transplant Lymphadenopathy;_ T. O. Thomas1, J. Bryant2, G. Gilmore2, S. E. Pye2, K. R. Knecht1. 1 _Arkansas Children 's Hosp, Little Rock, AR,_ 2 _University of Arkansas for Medical Sciences, Little Rock, AR_

**(1220)** _Deleterious Effect of HLA Donor Specific Antibodies Mediated Rejection and Graft Dysfunction Following Lung Transplant Exacerbated by Lung Tissue Specific Autoantibodies;_ A. Zhang1, Y. Sun2, C. Lane1, W. Tsuang1, O. Akindipe1, Z. Tong1, A. Mehta1, L. Klingman1, R. Pei3. 1 _Cleveland Clinic, Cleveland, OH,_ 2 _Avalon Medical University, Curaçao, Netherlands,_ 3 _Thermo Fisher Scientific, Canoga Park, CA_

**(1221)** _Pediatric Cardiac Transplantation for Respiratory Insufficiency, Recurrent Chylothorax and Elevated PVR as Leading Problems of a Failing Fontan;_ G. Mansukhani1, N. Alami Laroussi2, I. Adatia2, A. Kakadekar3, D. B. Ross2, S. Urschel2. 1 _Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada,_ 2 _Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada,_ 3 _Royal University Hospital, University of Saskatchewan, Saskatoon, SK, Canada_

**(1222)** _Successfully Treat Pulmonary Hemorrhage by Repeated Therapeutic Bronchoscope and Inhaled Tranexamic Acid on Patient with Pulmonary Hypertension Receiving ECMO Support;_ P. Su, C. Ko, C. Hsu. _National Cheng Kung University Hospital, Tainan, Taiwan_

**(1223)** _Excessive Hemolysis in a Patient with JAK 2 Mutation After Total Artificial Heart Implantation Resolved by Changing from C2 Driver to Freedom Driver;_ E. A. Helwig, J. Pisano, B. Soleimani, E. Stephenson, W. Pae, A. Ghodsizad, C. Brehm. _Heart Vascular Intensive Care Unit, Penn State Hershey Medical Center, Hershey, PA_

**(1224)** _Restrictive Cardiomyopathy in Arthrogryposis and Freeman-Sheldon Syndrome: A Novel Association;_ B. J. Scherer1, S. Ware2, J. J. Parent2. 1 _Pediatrics, Riley Hospital at Indiana University Health, Indianapolis, IN,_ 2 _Pediatric Cardiology, Riley Hospital at Indiana University Health, Indianapolis, IN_

**(1225)** _ECMO Bridge to Recovery for Antibody Mediated Rejection after Lung Transplantation;_ D. Steimer1, P. S. Garcha2, H. Huang3, K. Ausloos3, H. K. Rokadia3, R. Rosenblatt3, M. Schiller4, H. Zhang4, M. Askar5, G. Schwartz6, D. D'Souza6, D. P. Mason6. 1 _General Surgery, Baylor University Medical Center, Dallas, TX,_ 2 _Pulmonary & Critical Care, Baylor University Medical Center, Dallas, OH, _3 _Pulmonary & Critical Care, Baylor University Medical Center, Dallas, TX, _4 _Pathology, Baylor University Medical Center, Dallas, TX,_ 5 _Transplant Immunology, Baylor University Medical Center, Dallas, TX,_ 6 _Thoracic Surgery, Baylor University Medical Center, Dallas, TX_

**(1226)** _Zygomycetes Myocarditis Early After Cardiac Transplantation;_ J. N. Upshaw1, L. Margoles2, A. R. Patel1, A. R. Vest1, Y. Golan2, D. DeNofrio1, K. Arkun3, M. S. Kiernan1. 1 _Cardiology, Tufts Medical Center, Boston, MA,_ 2 _Infectious Disease, Tufts Medical Center, Boston, MA,_ 3 _Pathology, Tufts Medical Center, Boston, MA_

**(1227)** _A Vent for the Heart to Breathe!;_ A. Z. Turk, S. Shaikh, V. Grewal, M. Kashef, A. Lotfi, M. Tidswell, J. A. Hernandez-Montfort. _Internal Medicine, Baystate Medical Center, Springfield, MA_

**(1228)** _A Case of Accelerated Antibody Mediated Rejection in the Modern Age of Single-Bead HLA Antigen and C1q Assays;_ J. Kim1, D. Kukuruga1, M. Wijesinha1, I. Timofte2, A. Iacono2, S. Pham1. 1 _University of Maryland, Baltimore, MD,_ 2 _Pulmonary Critical Care, University of Maryland, Baltimore, MD_

**(1229)** _OHT with Immune Accommodation;_ N. Ryan, G. Navas, A. Gough, M. Fay, C. Tracey, B. Parlon, D. Healy, L. Noelke, J. McCarthy, N. G. Mahon, C. M. Halley, J. McGuinness, J. O. O'Neill. _National Transplant Unit, Mater Misericordiae University Hospital, Dublin 7, Ireland_

**(1230)** _Too Much, Too Little, Too Late: Slowing the Runs;_ I. Haider1, W. Khalife1, M. Morsy1, K. Chatila1, G. Al-Dossari2, M. W. Choudhry1, K. Kislingbury2, S. Johnson1, V. Valentine1. 1 _Internal Medicine, University of Texas Medical Branch, Galveston, TX,_ 2 _Cardio-Thoracic Surgery, University of Texas Medical Branch, Galveston, TX_

**(1231)** _Dramatic Presentation of RV Failure Post Heart Transplantation;_ H. M. Kassis1, A. Adeniyi2, M. Mehmood3, B. Sossong3, A. Raina3. 1 _Cardiovascular Diseases, Allegheny General Hospital, Pittsburgh, PA,_ 2 _Advanced Heart Faiure, Transplantation and Pulmonary Hypertension, Allegheny General Hospital, Pittsburgh, PA,_ 3 _Advanced Heart Failure, Transplantation, and Pulmonary Hypertension, Allegheny General Hospital, Pittsburgh, PA_

**(1232)** _Untreatable Hypertension in a Lung Transplant Recipient: The Role of Non-HLA Antibodies;_ M. Schiavon1, F. Calabrese1, M. Seveso2, M. Loy1, P. Feltracco3, C. Carollo3, M. Cardillo4, E. Cozzi2, F. Rea1. 1 _Cardiac, Thoracic and Vascular Sciences, University of Padua, Padova, Italy,_ 2 _Department of Transfusion Medicine, Padua University Hospital, Padova, Italy,_ 3 _Padua University Hospital, Padova, Italy,_ 4 _Nord Italian Transplant Program, Milano, Italy_

**(1233)** _Hyperthyroidism after Heart Transplantation;_ S. Schmidt1, M. Rybczynski2, F. M. Wagner1, H. Reichenspurner1, M. J. Barten1. 1 _Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany,_ 2 _Cardiology, University Heart Center Hamburg, Hamburg, Germany_

**(1234)** _Please HELP! Successful Use of Mechanical Circulatory Support in a Peripartum Woman with HELLP Syndrome;_ N. B. Cyrille1, H. Chahal1, R. Jermyn2, O. Saeed1, J. Shin1, S. Murthy1, W. A. Jakobleff3, S. Patel1, U. Jorde1, D. Goldstein3, D. B. Sims1. 1 _Cardiology, Montefiore Medical Center, Bronx, NY,_ 2 _Cardiology, North Shore Long Island Jewish Hospital, Long Island, NY,_ 3 _Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY_

**(1235)** _Cardiac Hemochromatosis Treated with Prolonged ECMO Support and Chelation Therapy;_ H. Vidula1, V. Tchantchaleishvili2, L. Chen1, J. Alexis1. 1 _Medicine, Univ of Rochester, Rochester, NY,_ 2 _Surgery, Univ of Rochester, Rochester, NY_

**(1236)** _Logistic Ex-Vivo Lung Perfusion for Hyperimmunized Patients;_ J. De Wolf1, P. Puyo1, P. Bonnette1, A. Roux2, F. Parquin3, A. Chapelier1, E. Sage1. 1 _Thoracic Surgery and Lung Transplantation Department, Foch Hospital, Suresnes, France,_ 2 _Pneumology Department, Foch Hospital, Suresnes, France,_ 3 _Thoracic Intensive Care Unit, Foch Hospital, Suresnes, France_

**(1237)** _Pulmonary Kaposi's Sarcoma after Lung Transplantation, with 2-Year Follow-Up;_ J. Yoon1, N. Shigemura2, J. D'Cunha2, M. Mehrad3, M. Pipeling1. 1 _Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA,_ 2 _Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA,_ 3 _Department of Pathology, University of Pittsburgh, Pittsburgh, PA_

**(1238)** _Late Invasive Scedosporium Sternal Infection Post Bilateral Lung Transplant in a Patient with Cystic Fibrosis;_ M. Paraskeva1, O. C. Smibert2, J. Gooi3, C. O. Morrissey2, G. Snell1, G. P. Westall1, E. J. Denton1. 1 _Department of Allergy, Immunology and Respiratory, Alfred Hospital, Melbourne, Australia,_ 2 _Department of Infectious Diseases, Alfred Hospital, Melbourne, Australia,_ 3 _Department of Cardiothoracic Surgery, Alfred Hospital, Melbourne, Australia_

**(1239)** _Mechanical Circulatory Support in a Patient with Cardiomyopathy Due to Kearns-Sayre Syndrome;_ J. D. Pal, R. K. Cheng, J. W. Smith, J. L. Hermsen, N. A. Mokadam. _Univ of Washington, Seattle, WA_

**(1240)** _Dobutamine Induced Eosinophilic Cardiomyopathy;_ A. Narichania, W. T. Love, B. Hardaway. _Mayo Clinic Arizona, Scottsdale, AZ_

**(1241)** _The Perfect Storm: Two Forms of Cardiomyopathy Found in a Single Heart;_ H. P. Tunuguntla1, S. W. Denfield1, A. Landstrom1, Y. Fan1, D. L. Kearney2, A. G. Cabrera1, J. F. Price1, W. J. Dreyer1, A. Jeewa1. 1 _Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX,_ 2 _Pathology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX_

**(1242)** _Use of Eculizumab to Treat Life-Threatening Auto-Immune Hemolytic Anemia in a Heart Transplant Recipient;_ A. El-Bokl1, S. Wagner1, C. Nester1, J. Lampe1, E. Edens2. 1 _University of Iowa Children's Hospital, Iowa Ctiy, IA,_ 2 _Pediatric Cardiology, University of Iowa Children's Hospital, Iowa Ctiy, IA_

**(1243)** _Use of a Percutaneous Right Ventricular Assist Device for Right Ventricular Failure after LVAD Implant;_ A. R. Garan, K. Takeda, V. K. Topkara, S. Kalra, B. Toennes, Y. Naka, M. Yuzefpolskaya, P. C. Colombo, H. Takayama, A. Kirtane. _Columbia University, New York, NY_

**(1244)** _SVC Syndrome Following Orthotopic Heart Transplantation Resolved via AngioJet Thrombolysis: A Case Report;_ K. L. Sessions, J. H. Anderson, J. N. Johnson, N. W. Taggart. _Pediatric Cardiology, Mayo Clinic, Rochester, MN_

**(1245)** _Early Post-Transplant Constrictive Pericarditis in a Patient with Antibody Mediated Rejection;_ J. A. Hernandez-Montfort1, D. Baran2, M. Camacho2, C. Gidea2, J. Pieretti2, R. Yanagida2, M. J. Zucker2. 1 _Advanced Heart Failure Program, Baystate Health, Springfield, MA,_ 2 _Heart Failure and Cardiac Transplant, Newark Beth Israel Medical Center, Newark, NJ_

**(1246)** _Case Report: Stage IV Large Cell Neuroendocrine Lung Carcinoma Incidentally Discovered after Lung Transplant;_ A. S. Bratt1, G. R. Dincheva1, B. C. Hamilton1, E. L. Bush2, K. Rajalingam1, M. Brzezinski3, R. J. Shah4, J. A. Golden4, L. E. Leard4, M. E. Kleinhenz4, S. R. Hays4, J. P. Singer4, J. Kukreja1. 1 _Surgery; Division of Cardiothoracic Surgery, Univ of California, San Francisco, CA,_ 2 _Cardiothoracic Surgery, Johns Hopkins Hospital, Baltimore, MD,_ 3 _Anesthesia, Univ of California, San Francisco, CA,_ 4 _Medicine, Univ of California, San Francisco, CA_

**(1247)** _Pneumatosis Intestinalis Complicating Lung Transplantation after Hematopoietic Stem Cell Transplantation: Report of Two Cases;_ K. Mesaki1, S. Sugimoto1, S. Otani2, T. Kurosaki2, K. Miyoshi1, M. Yamane1, S. Miyoshi1, T. Oto2. 1 _Department of General Thoracic Surgery, Okayama University Hospital, Okayama, Japan,_ 2 _Organ Transplant Center, Okayama University Hospital, Okayama, Japan_

**(1248)** _Quantiferon-CMV Assay Guided Management of Resistant CMV Infection after Heart Transplantation;_ G. Poglajen, R. Okrajšek, S. Frljak, B. Vrtovec. _Advanced Heart Failure and Transplantation Programme, Dept. of Cardiology, UMC Ljubljana, Ljubljana, Slovenia_

**(1249)** _Plasmapheresis Prior to HVAD Implantation in a Patient with Acute Heparin Induced Thrombocytopenia;_ B. A. Smith1, S. Adatya1, G. Kim1, G. Sayer1, N. Sarswat1, S. Kalantari Tannenbaum1, J. Grinstein1, K. Marinescu1, V. Kagan2, C. Juricek2, H. Ruedlinger2, V. Jeevanandam2, T. Ota2, N. Uriel1. 1 _Division of Cardiology, University of Chicago, Chicago, IL,_ 2 _Cardiothoracic Surgery, University of Chicago, Chicago, IL_

**(1250)** _Safe and Successful Heart Transplantation Despite Factor Xa Inhibitor Treatment by Measuring Thrombin Generation;_ A. Oberbach, S. Feder, T. Siegemund, M. Friedrich, J. Fischer, A. Meyer, F. Mohr, S. Lehmann, D. Holzhey, J. Garbade. _Division of Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany_

**(1251)** _Neurotoxicity of Immunosuppressive Therapies in Heart Transplantation;_ A. B. de Sá, A. Salles, P. Sampaio, D. Menezes, L. Schutruk, V. Carvalho, D. Bezerra, L. Matos, T. Guimaraes, A. Siciliano, E. TInoco. _Post Surgery Unit, Pro Cardiaco Hospital, Rio de Janeiro, Brazil_

**(1252)** _Dual Sternotomy and Thoracotomy Implantation of HeartMate II in Patients with Previous CABG;_ A. Shiose, J. Gomez-Abraham, E. Hamad, R. J. Alvarez, D. Dries, D. R. Schwartz, A. Bove, L. Punnoose, Y. Toyoda. _Temple University Hospital, Philadelphia, PA_

**(1253)** _Sinusitis or Something More Sinister in Disguise: A Lung Transplant Recipient with Cystic Fibrosis, Fever and Sinus Drainage;_ E. Lowery. _Medicine, Loyola University Medical Center Loyola, Chicago, IL_

**(1254)** _A Case of Mediastinitis and Ruptured Aortic Pseudoaneurysm Post Orthotopic Heart Transplantation;_ A. Singh1, N. Afari-Armah2, A. Bove1, J. Gomez-Abraham3, A. Shiose3, D. R. Schwartz1, D. L. Dries1, L. Punnoose1, Y. Toyoda3, R. J. Alvarez1, E. A. Hamad1. 1 _Advanced Heart Failure and Transplant Cardiology, Temple University Hospital, Philadelphia, PA,_ 2 _Cardiology, Temple University Hospital, Philadelphia, PA,_ 3 _Cardiovascular Surgery, Temple University Hospital, Philadelphia, PA_

**(1255)** _Post Transplant Lymphoproliferative Disorder Presenting as Epstein-Barr Virus Meningoencephalitis;_ R. A. Varughese1, M. V. Thakrar1, J. Lategan1, J. Preiksaitis2, A. Kapasi2, K. Halloran2, J. G. Weinkauf2, D. C. Lien2, D. Helmersen1. 1 _University of Calgary, Calgary, AB, Canada,_ 2 _University of Alberta, Edmonton, AB, Canada_

**(1256)** _Heart Transplant Against Cross Match in a Highly Sensitized Congenital Heart Disease Patient and Successful Post-Transplant Management;_ S. R. Deshpande1, R. A. Bray2, H. M. Gebel2, K. LaPorte3, W. T. Mahle1. 1 _Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA,_ 2 _Pathology and Laboratory Medicine,, Emory University, Atlanta, GA,_ 3 _Children's Healthcare of Atlanta, Atlanta, GA_

**(1257)** _A Single Centre's Lung Transplantation Experience for Pulmonary Graft Versus Host Disease;_ R. A. Varughese1, M. V. Thakrar1, J. Weinkauf2, A. Daly1, A. Kapasi2, K. Halloran2, K. B. Jackson2, D. C. Lien2, D. Helmersen1. 1 _University of Calgary, Calgary, AB, Canada,_ 2 _University of Alberta, Edmonton, AB, Canada_

**(1258)** _Anticoagulation Strategies in a Ventricular Assist Device Patient with Heparin Induced Thrombocytopenia;_ A. M. Cook, E. Boyes, E. E. Coglianese. _Division of Cardiology, Loyola University Medical Center, Maywood, IL_

**(1259)** _Severed HeartWare Left Ventricular Assist Device Driveline with Successful Splicing;_ J. Leoni1, B. Gupta1, P. Patel1, D. Yip1, K. Landolfo2, J. Hosenpud1. 1 _Transplant, Mayo Clinic, Jacksonville, FL,_ 2 _Cardiothoracic Surgery, Mayo Clinic, Jacksonville, FL_

**(1260)** _Post-Transplant Lymphoproliferative Disease Affecting the Major Airways in a Lung Transplant Recipient;_ C. M. Patterson, O. H. Mohamedaly, L. A. Neilans, A. L. Gray. _Duke University, Durham, NC_

**(1261)** _Longest Continous Impella 5.0 LVAD Support Via Right Subclavian Artery Approach;_ A. Bansal1, E. Parrino2, S. Desai3, R. Patel4. 1 _Ochsner Clinic Foundation, New Orleans, LA,_ 2 _Surgery, Ochsner Clinic Foundation, New Orleans, LA,_ 3 _Heart Failure and Heart Transplant, Ochsner Clinic Foundation, New Orleans, LA,_ 4 _Interventional Cardiology, Ochsner Clinic Foundation, New Orleans, LA_

**(1262)** _Use of Cardiomems to Detect Abnormal Exercise Response in a Patient with a Left Ventricular Assist Device;_ R. Agarwal, M. Y. Kamath, P. Correa-Jaque, R. L. Benza. _Cardiology/Heart Failure and transplantation, Allegheny General Hospital, Pittsburgh, PA_

**(1263)** _Implantable Pulmonary Artery Pressure Sensor Detects Asymptomatic Atrial Fibrillation in Left Ventricular Assist Device Patient;_ B. C. Lampert, S. Emani, S. Smith, A. K. Hasan, W. T. Abraham, S. Wissman, K. MacBrair, A. Bergman, B. Whitson, A. Kilic. _Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH_

**(1264)** _Monomorphic Ventricular Tachycardia in a HeartMate II LVAD Patient; When Do You Consider Ablation Therapy?;_ J. P. Feliberti, T. Maglione, K. Mody, D. Iyer, A. Saluja, J. Almendral. _Cardiology, Rutgers Robert Wood Johnson, North Brunswick, NJ_

**(1265)** _Sympathectomy for Lung Transplant Recipients with Raynaud's;_ S. Tokman1, A. Omar1, P. Drotar2, M. A. Smith1, R. M. Bremner1, R. Walia1. 1 _Advanced Lung Disease, Norton Thoracic Institute, St. Joseph Hospital and Medical Center, Phoenix, AZ,_ 2 _Advanced Lung Disease, St. Joseph Hospital and Medical Center, Phoenix, AZ_

**(1266)** _Diffuse Alveolar Hemorrhage after Initiation of Extracorporeal Membrane Oxygenation for Refractory Hypoxemia Secondary to Acute Respiratory Distress Syndrome;_ A. Banga. _UT Southwestern Medical Center, Dallas, TX_

**(1267)** _A Case of Neonatal Left Ventricular Noncompaction: From Fetus to Transplant;_ S. Kirmani, B. Reinking, R. E. Edens. _Pediatric Cardiology, University of Iowa, Iowa City, IA_

**(1268)** _Occlusive PE to Left Main PA Following Lung Transplant Recannalized Using Directed Thrombolysis;_ J. R. Spratt1, M. Rosenberg2, P. Shrestha2, G. Pettersson3, J. Patil4, M. Hertz5, G. Loor1. 1 _Department of Surgery, University of Minnesota, Minneapolis, MN,_ 2 _Department of Radiology, University of Minnesota, Minneapolis, MN,_ 3 _Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH,_ 4 _Department of Medicine, University of Minnesota, Minneapolis, MN,_ 5 _Department of Medicine, University of Minnesota Medical School, Minneapolis, MN_

**(1269)** _Resolution of Recurrent Sustained Ventricular Tachycardia in a Patient on Left Ventricular Assist Device Support After Surgical Repositioning of the Inflow Cannula;_ A. Y. Son1, L. B. Balsam1, A. Reyentovich2, S. Pan2. 1 _Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY,_ 2 _Cardiology, NYU Langone Medical Center, New York, NY_

**(1270)** _Prior Mitral Valve Annuloplasty Could Be a Cause of Left Ventricular Assist Device-Induced Mitral Stenosis?;_ K. Kuroda1, O. Seguchi1, N. Okada1, E. Hisamatsu1, H. Sunami1, S. Nakajima1, T. Sato1, H. Hata2, M. Yanase1, T. Fujita2, N. Fukushima1, J. Kobayashi2, T. Nakatani1. 1 _Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan,_ 2 _Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan_

**(1271)** _Mycobacterium Abscessus Infection in a Patient with a Cardiovascular Implantable Electronic Device and Left Ventricular Assist Device;_ J. Wosik, A. Bran, T. Garcia, W. Cornwell, C. Fitzsimmons, D. Maxwell, F. Araj, A. Amin, R. Morlend, J. Thibodeau, M. Jessen, M. Drazner, R. La Hoz, P. Mammen, J. Le. _UTSW Medical Center, Dallas, TX_

**(1272)** _Successful Management of a Giant Left Ventricular Assist Device Pocket Abscess in an Elderly Patient;_ A. Pawale1, A. El-Eshmawi1, G. Patel2, S. Huprikar2, S. Pinney3, A. C. Anyanwu1. 1 _Cardiovascular Surgery, Mount Sinai Medical Center, New York, NY,_ 2 _Internal Medicine, Mount Sinai Medical Center, New York, NY,_ 3 _Cardiology, Mount Sinai Medical Center, New York, NY_

ISHLT ACADEMY: CORE COMPETENCIES IN

HEART FAILURE AND CARDIAC TRANSPLANT MEDICINE

Tuesday, April 26, 2016

Marriott Wardman Park Hotel, Thurgood Marshall Ballroom North

Washington, DC, USA

Scientific Program Committee

Chair: Teresa De Marco, MD, FACC, University of California, San Francisco, CA, USA

Co-Chair: Frances Johnson, MD, University of Iowa Hospital & Clinics, Iowa City, IA, USA

Co-Chair: Andrew Kao, MD, St. Luke's Cardiovascular Consultant, Kansas City, MO, USA

Educational Goals

The educational goals of this activity are to provide a concise review of clinical knowledge and essential professional skills to facilitate best practice of surgical and medical aspects involved in the care of patients with advanced heart failure.

Learning Objectives

At the conclusion of this meeting, participants will have improved competence and professional performance in their ability to:

1) Understand the general concepts, definitions and general principles of management of patients with heart failure with depressed and preserved ejection fraction.

2) Identify the clinical signs and risk factors of patients with late-stage heart failure.

3) Understand the general concepts, definitions and general principles of management of patients with pulmonary hypertension due to left heart disease.

4) Understand indications and timing for advanced therapies in late-stage heart failure.

5) Recognize the various types of mechanical circulatory support, their outcomes, and rates of adverse events.

6) Understand the general immunological basis for transplantation, its therapeutic targets and potential complications.

7) Understand the socio-economic burden of mechanical circulatory devices and heart transplantation.

Target Audience

While all members are invited to enroll, this course is primarily designed to be of benefit for clinicians and allied professionals who are in the early stages of their careers or who are in training, are part of a new program or desire an update on the current state of the field. The information presented is intended to provide a strong foundation of the overarching principles of heart failure and transplant medicine, rather than as a detailed update for those who are already proficient in the field.

Accreditation Statement

The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

ISHLT designates this live activity for a maximum of 8.25 _AMA PRA Category 1 Credits_ ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE Credit

This activity may be eligible for ACPE credit, see final CPE activity announcement for specific details.

Disclosure

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

SCIENTIFIC PROGRAM SCHEDULE

7:00 AM – 7:45 AM

REGISTRATION AND MORNING COFFEE

7:45 AM – 8:00 AM

WELCOME AND INTRODUCTIONS

Teresa De Marco, MD, FACC, University of California, San Francisco, CA, USA

Frances Johnson, MD, University of Iowa Hospital & Clinics, Iowa City, IA, USA

Andrew Kao, MD, St. Luke's Cardiovascular Consultant, Kansas City, MO, USA

8:00 AM – 8:45 AM

SESSION 1: HEART FAILURE: GENERAL OVERVIEW AND CONCEPTS

Chair: **** Andrew Kao, MD

**8:00 AM** Epidemiology and Natural History: Emphasis on Heart Failure with Reduced Ejection Fraction (HFrEF)

Lee Goldberg, MD, MPH, University of Pennsylvania, Philadelphia, PA, USA

**8:15 AM** Pathophysiology: Neurohormones and Beyond

Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

**8:30 AM** Types of Cardiomyopathies: Dilated, Hypertrophic, Infiltrative

Deborah Meyers, MD, FRACP, FACC, Texas Heart Institute, Houston, TX, USA

8:45 AM – 9:30 AM

SESSION 2: EVALUATION OF PATIENTS WITH HEART FAILURE

Chair: **** Andrew Kao, MD

**8:45 AM** Initial Evaluation and Screening Guidelines

Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

**9:00 AM** Role of Right Heart Catheterization and Hemodynamic Monitoring

James Fang, MD, University of Utah Health Sciences Center, Salt Lake City, UT, USA

**9:15 AM** Risk Stratification in HFrEF – Is it Time for Advanced Therapies?

Lee Goldberg, MD, MPH, University of Pennsylvania, Philadelphia, PA, USA

9:30 AM - 9:45 AM

COFFEE BREAK

9:45 AM – 10:50 AM

SESSION 3: MANAGEMENT OF THE PATIENT WITH CHRONIC LEFT VENTRICULAR SYSTOLIC DYSFUNCTION

Chair: **** Andrew Kao, MD

**9:45 AM** Pharmacologic Management of HFrEF: Evidence-based, Guideline-directed

JoAnn Lindenfeld, MD, Vanderbilt University, Nashville, TN, USA

**10:00 AM** Non-Pharmacologic Management: Impact of Lifestyle and Comorbidities

Peter MacDonald, MD, PhD, St. Vincent's Hospital, Sydney, Australia

**10:15 AM** Principles for Arrhythmia Management and Role of Electrical Device-Based Therapy for HFrEF

JoAnn Lindenfeld, MD, Vanderbilt University, Nashville, TN, USA

**10:35 AM** Surgical Management of Valvular Disease and Ischemic Heart Failure ****

Francis D. Pagani, MD, PhD, University of Michigan, Ann Arbor, MI, USA

10:50 AM – 11:50 AM

SESSION 4: ACUTE HEART FAILURE EVALUATION AND MANAGEMENT

Chair: **** Teresa De Marco, MD, FACC

**10:50 AM** Scope of the Problem and Pharmacologic Management: What Does the Evidence Show Us?

Heather J. Ross, MD, MHSc, FRCPC, Toronto General Hospital, Toronto, Canada

**11:05 AM** Crash and Burn: Percutaneous Tools for Acute, Severe Decompensation

Stuart Russell, MD, Johns Hopkins University, Baltimore, MD, USA

**11:20 AM** Transitions of Care: Home Inotropes, VADs, Palliative Care

Deborah Meyers, MD, FRACP, FACC, Texas Heart Institute, Houston, TX, USA

**11:35 AM** Panel Discussion

All morning speakers.

11:50 AM – 12:50 PM

**LUNCH BREAK** (a box lunch is included in the registration fee)

12:15 PM – 12:45 PM

SPECIAL LUNCH SESSION

Chair: **** Andrew Kao, MD

**12:15 PM** Case Presentation: Cardiorenal Syndrome: What is it and How is it Treated?

Maria Rosa Costanzo, MD, Midwest Heart Specialists-Advocate Medical, Naperville, IL, USA

**12:30 PM** Case Presentation: Cardiopulmonary Exercise Test Interpretation

Marco Guazzi, MD, PhD, IRCC Pol San Donato, Milan, Italy

12:50 PM – 1:10 PM

SESSION 5: HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)

Chair: **** Teresa De Marco, MD, FACC

**12:50 PM** Epidemiology, Diagnosis and Therapeutic Options: What is the Evidence Base for HFpEF?

Marco Guazzi, MD, PhD, IRCC Pol San Donato, Milan, Italy

1:10 PM - 1:50 PM

SESSION 6: PULMONARY HYPERTENSION

Chair: **** Teresa De Marco, MD, FACC

**1:10 PM** Pulmonary Hypertension Due to Left Heart Failure: Epidemiology, Pathophysiology, Diagnosis and Management Strategies

Jean-Luc Vachiery, MD, Erasme University Hospital – UBL, Brussels, Belgium

**1:30 PM** Case Presentation: Distinguishing PH Due to HFpEF from PAH - Now What?

James Fang, MD, University of Utah Health Sciences Center, Salt Lake City, UT, USA

**1:35 PM** Case Discussion **:** Marco Guazzi, MD, PhD, IRCC Pol San Donato, Milan, Italy; Jean-Luc Vachiery, MD, Erasme University Hospital – UBL, Brussels, Belgium

1:50 PM – 2:05 PM

COFFEE BREAK

2:05 PM – 3:40 PM

SESSION 7: HEART TRANSPLANTATION 101

Chair: **** Frances Johnson, MD

**2:05 PM** Evaluation of Heart Transplant Candidates – Let's Not Forget Congenital Heart Disease

Heather Ross, MD, MHSc, FRCPC, Toronto General Hospital, Toronto, Canada

**2:25 PM** Evaluation and Management of the Potential Heart Donor

Francis D. Pagani, MD, PhD, University of Michigan, Ann Arbor, MI, USA

**2:40 PM** Peri-Operative Management of the Heart Transplant Recipient

Peter MacDonald, MD, PhD, St. Vincent's Hospital, Sydney, Australia

**2:55 PM** Immunologic Concepts of Heart Transplantation

Maria Rosa Costanzo, MD, Midwest Heart Specialists – Advocate Medical, Naperville, IL, USA

**3:10 PM** Immunosuppression and Rejection

Luciano Potena, MD, PhD, University of Bologna, Italy

**3:25 PM** Long-Term Care of Heart Transplant Recipients

Luciano Potena, MD, PhD, University of Bologna, Italy

3:40 PM – 3:55 PM

COFFEE BREAK

3:55 PM – 5:10 PM

**SESSION 8:** **MECHANICAL CIRCULATORY SUPPORT**

Chair: **** Frances Johnson, MD

**3:55 PM** State-of-the-Art Devices and Outcomes

Paul Mohacsi, MD, Swiss Cardiovascular Center, Bern, Switzerland

**4:10 PM** Patient Selection and Timing

Stuart Russell, MD, Johns Hopkins University, Baltimore, MD, USA

**4:25 PM** Practical Peri-Operative Management of MCS Patients

Paul Mohacsi, MD, Swiss Cardiovascular Center, Bern, Switzerland

**4:40 PM** Adverse Events Post VAD Placement: Identification and Management

Geetha Bhat, MD, PhD, Advocate Christ Medical Center, Chicago, IL, USA

**4:55 PM** Case Presentation: The Challenges of Destination Therapy

Geetha Bhat, MD, PhD, Advocate Christ Medical Center, Chicago, IL, USA

**5:00 PM** Case Discussion **:** Paul Mohacsi, MD, Swiss Cardiovascular Center, Bern, Switzerland; Stuart Russell, MD, Johns Hopkins University, Baltimore, MD, USA

5:10 PM - 5:15 PM

COURSE SYNOPSIS

Frances Johnson, MD, University of Iowa Hospital & Clinics, Iowa City, IA, USA

5:15 PM ADJOURN

ISHLT ACADEMY: CORE COMPETENCIES IN

MECHANICAL CIRCULATORY SUPPORT

Tuesday, April 26, 2016

Marriott Wardman Park Hotel, Thurgood Marshall Ballroom East

Washington DC, USA

Scientific Program Committee

Chair: Jennifer Cowger, MD, MS, St. Vincent Heart Center of Indiana, Indianapolis, IN, USA

Co-Chair: Daniel Zimpfer, MD, Medical University of Vienna, Vienna, Austria

Co-Chair: Jennifer Beckman, MSN-FNP, RN, CHFN, University of Washington, Seattle, WA, USA

Educational Goals

The educational goals of this activity are to provide a concise review of clinical knowledge and essential professional skills to facilitate best practice of surgical and medical aspects involved in the care of patients during assessment as candidates and as recipients of mechanical circulatory support.

Target Audience

While all members are invited to enroll, this course is primarily designed to be of benefit for clinicians and allied professionals who are in the early stages of their careers or who are in training and/or are part of a new program or desire an update on the current state of the field. The information presented covers core competencies and is intended to provide a strong foundation of the overarching principles of mechanical support, rather than as a detailed update for those who are already proficient experts in the field.

Accreditation Statement

The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

ISHLT designates this live activity for a maximum of 8.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE Credit

This activity may be eligible for ACPE credit, see final CPE activity announcement for specific details.

Disclosure

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

Learning Objectives

At the conclusion of this meeting, participants will have improved competence and professional performance in their ability to:

Understand how to risk stratify patient with advanced heart failure in order to assess MCS surgical risk and optimally time mechanical circulatory support (MCS) implantation.

Recognize the medical and social factors which impact patient outcomes during short- and long-term MCS.

Recognize the various types of MCS support available for patients with advanced single or biventricular heart failure and the technological differences that may impact pump selection and patient/device management.

Optimize MCS implantation techniques and patient/pump management during the index admission intensive care unit and inpatient general care periods.

Manage patients and the MCS during outpatient long-term support with an understanding of interventions that can reduce patient- and device-related adverse events during MCS.

Diagnose and manage common clinical dilemmas and adverse encountered after MCS.

SCIENTIFIC PROGRAM SCHEDULE

7:15 AM – 8:00 AM

REGISTRATION AND MORNING COFFEE

8:00 AM - 9:15 AM

SESSION 1: REVIEW OF THE CURRENT STATE OF MCS

**Chair:** Stephan Schueler, MD, PhD, FRCS

**8:00 AM** Welcome and Overview

Jennifer Cowger, MD, MS, St. Vincent Heart Center of Indiana, Indianapolis, IN, USA

**8:15 AM** MCS Technology 101

Scott Silvestry, MD. Florida Hospital Transplant Institute, Orlando, FL, USA

_Review of current technologies available, pump behaviors with different loading conditions, and the TAH._

**8:30 AM** BTT and DT Outcome

Andreas O. Zuckermann, MD, PhD, University of Vienna, Vienna, Austria

Review state of outcomes and adverse events with current technologies

**8:45 AM** Short-term Support and Shock

Jonathan Haft, MD, University of Michigan, Ann Arbor, MI, USA

Overview of percutaneous technologies, biventricular support considerations, and ECMO.

9:00 AM Q&A

9:15 AM – 10:30 AM

SESSION 2: PATIENT SELECTION

**Chair:** Scott Silvestry, MD

**9:15 AM** When Should Patients be Referred: Warning Signs

Douglas Horstmanshof, MD, Integris Baptist Medical Center, Oklahoma City, OK, USA

Risk factors which presage patient decline (renal function, intolerance of medications, hospitalizations, etc, helping to risk stratify patients based on HF severity and MCS operative risk.

**9:30 AM** Assessing and Optimizing RV Function Preoperatively

Anna Meyer, MD, University of Leipzig, Leipzig, Germany

Impact of RV failure, pre-operative assessment and management of the RV including imaging and risk prediction.

**9:45 AM** Quality of Life After VAD and the Impact of Frailty and Social Behaviors on VAD Success

Susan Joseph, MD, Washington University School of Medicine, St. Louis, MO, USA

Other factors that can have a significant impact on success after VAD and some screening tools available for risk assessment.

**10:00** **AM** Other Medical Co-Morbidities that May Impact VAD Success

Douglas Horstmanshof, MD, Integris Baptist Medical Center, Oklahoma City, OK, USA

Impact of peripheral vascular disease, end-stage renal failure, and other chronic medical illnesses on short and long term VAD success.

10:15 AM Q&A

10:30 AM – 10:45 AM

COFFEE BREAK

10:45 AM – NOON

SESSION 3: SURGICAL CONSIDERATIONS

**Chair:** Vivek Rao, MD, PhD

**10:45 AM** Key Surgical Aspects of Implantation

Nader Moazami, MD, Cleveland Clinic, Cleveland, OH, USA

Overview of the most crucial surgical considerations: inflow cannula/pump placement, driveline, etc.

**11:05 AM** How Much Else is Too Much? ****

Daniel Zimpfer, MD, Medical University of Vienna, Vienna, Austria

Concomitant operative procedures: TV, Aortic valve, prior Dor, congenitals

**11:25 AM** Tailoring Pumps to Patients

Stephan Schueler, MD, PhD, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

Case based discussion of considerations for pump-patient matching

11:45 AM Q&A

NOON – 1:00 PM

**LUNCH BREAK** (a box lunch is included in the registration fee)

1:00 PM – 2:15 PM

SESSION 4: POSTOPERATIVE CARE

**Chair:** Andreas Zuckermann, MD

**1:00 PM** Managing the RV Postop

Stephan Schueler, MD, PhD, FRCS, Freeman Hospital, Newcastle upon Tyne, United Kingdom

Considerations for impact of LVAD pump speed on RV function and use of inotropes and pulmonary vasodilators

**1:20 PM** Anticoagulation and Antiplatelet Therapy

Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, Canada

Current MCS recommendation on when to start anticoagulation, antiplatelet therapy regimens, as well as data on platelet function testing and heparin level monitoring.

**1:40 PM** Pump Speed Optimization: The Role of Imaging and Hemodynamics **  
**Nir Uriel, MD, University of Chicago, Chicago, IL, USA  
 _Overview of how to meld imaging and hemodynamics to optimize pump settings_

2:00 PM Q&A

2:15-3:15 PM

SESSION 5: TRANSITION TO HOME

**Chair:** Nir Uriel, MD

**2:15 PM** VAD Education: Patient/Caregiver Assessments and Strategies for Successful VAD Self-Care

Thomas Schloeglhofer, BSc, Medical University of Vienna, Vienna, Austria

Approaches to education of the patient and caregiver prior to discharge, and strategies for educating the local medical community

**2:30 PM** Starting New: How to Start and Succeed in MCS

Michael Dickinson, MD, Spectrum Health, Grand Rapids, MI

Challenges to starting a VAD program and key elements of success.

**2:45 PM** The Outpatient Clinic: Laboratory, Blood pressure, and Echo Monitoring

Jennifer Beckman, MSN-FNP, RN, CHFN, University of Washington, Seattle, WA, USA

Lab, blood pressure and echo monitoring of VAD patients in the outpatient setting.

3:00 PM Q&A

3:15 PM - 3:30 PM

COFFEE BREAK

3:30 PM - 5:20 PM

SESSION 6: LONG TERM MANAGEMENT OF PATIENTS AND COMPLICATIONS

**Chair:** Nadir Moazami, MD

**3:30 PM** LVAD Infections: Prevention, Diagnosis, and Management

Margaret Hannan, MD, Mater Misericordiae University Hospital, Dublin, Ireland

VAD infections, radiology studies important for diagnosis, and therapeutic recommendations

**3:50 PM** Stroke: Risk factors for Hemorrhagic and Embolic CNS Complications and Management Strategies  
Samer Najjar MD, MedStar Heart institute, Washington, DC, USA  
 _Discuss diagnosis, risk factors, and management strategies for CNS events in MCS patients._

**4:10 PM** Pump Thrombosis: __ Diagnostic Strategies and Management Algorithms

Simon Maltais, MD, PhD, Mayo Clinic, Rochester, MN, USA __

Frequency, diagnosis, and management strategies for suspected pump thrombosis.

**4:30 PM** Aortic Insufficiency in LVAD Recipients _:_ Incidence, Screening, and Management

Jennifer Cowger, MD, MS, St Vincent Heart Center of Indiana, Indianapolis, IN, USA

Cumulative incidence, clinical consequences, and management of AI after LVAD.

**4:50 PM** GI Bleeding

Keyur Shah, MD, Virginia Commonwealth University, Richmond, VA, USA

_Frequency, diagnosis and management of GI bleeding after LVAD therapy, including new data on octreotide_

5:10 PM Q&A

5:20 PM SUMMARY

5:30 PM ADJOURN

ISHLT ACADEMY: MASTER CLASS IN

PULMONARY TRANSPLANTATION

Tuesday, April 26, 2016

Marriott Wardman Park Hotel, Thurgood Marshall Ballroom South and West

Washington, DC, USA

Chair: Kevin M. Chan, MD, University of Michigan Health Systems, Ann Arbor, MI, USA

Scientific Program Committee

Goran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden   
David Hormuth, MD, Indiana University School of Medicine, Indianapolis, IN, USA  
Lorriana Leard , MD, University of California San Francisco, San Francisco, CA, USA  
Geert M. Verleden, MD, PhD, FERS, University Hospital Gasthuisberg, Leuven, Belgium

**Course Summary:** The Pulmonary Council Education Workforce is proud to offer this educational opportunity to ISHLT members. This Master Class is intended for members with higher levels of expertise (completed the core curriculum course on lung transplantation and/or primary practice in lung transplantation ≥ 5 years) who have managed patients with one or more of the topics intended for discussion. The course setting will generate a highly interactive environment composed of a smaller group of individuals designed to enhance individual expertise and network development. Utilizing the concept of "convergent discussion", faculty moderators will use controversial statements or case presentations to lead the group through audience participation, towards specific answers based on practice gaps and learning objectives. Following a 15 minute introductory and overview presentation, each participant will rotate through 60 minute course deliberations on antibody mediated rejection (AMR), chronic lung allograft dysfunction (CLAD), extra-corporeal lung support (ECLS), and lung organ donor management. One to two references on each topic will be recommended reading to participants in preparation for this class. We anticipate that this method of collaborative learning will lead to application and integration of new knowledge into participant practice.

Educational Goals

The overarching goal is to provide an advanced learning opportunity for specialists in the field of lung transplantation on the treatment of AMR, CLAD, ECLS and organ donor management.

Target Audience

Experienced (primary practice in lung transplantation≥ 5 years or completed the ISHLT core curriculum course on lung transplantation) Transplant Pulmonologists/Respirologists, Cardiothoracic Surgeons with Lung Transplant experience, Physician Specialists in Lung Transplantation (Pathology, Immunology, Anesthesiology, etc), Nurses, Physician Assistants and Allied Health Professionals with involvement in Lung Transplantation.

Practice Gaps

**1:** The presence of HLA and non-HLA donor specific antibodies (DSA) is associated with various types of antibody mediated graft dysfunction. A surveillance strategy **** to monitor lung transplant recipients for donor HLA and non-HLA antibodies, understanding the criteria for AMR and developing an approach to management of clinical AMR, are practice gaps in specialist knowledge that result in limitations of clinical care.

**2:** Chronic lung allograft dysfunction (CLAD) encompasses a heterogeneous group of clinical syndromes with substantial variability in disease progression and response to treatment. However, optimal strategies for phenotyping, preventing, detecting and treating CLAD remain controversial. Individual practitioners often lack the depth of experience and knowledge to address these management issues.

**3: **The use of ECMO as a bridge-to-lung transplantation is becoming increasingly more common. The indications, management, transplant evaluation difficulties and the postoperative short-term management of these patients may be problematic. Practitioners may lack the extensive expertise required to appropriately address these decisions

**4:** Significant variability exists in the management of potential lung donors. Ventilator strategies and the recognition of the futility of continued donor management differ greatly between OPOs and transplant centers. An understanding that the standardization of lung donor management will lead to more uniform information across regions will close this practice gap in specialist knowledge.

Learning Objectives

Upon completion of the Master Class, participants will be able to:

Understand the strategies to monitor donor specific antibody activity in lung transplant recipients.

Diagnose, monitor and treat clinical antibody mediated rejection (AMR) in lung transplant recipients

Understand the role of testing, risk factors and features for the diagnosis and differentiation between restrictive versus obstructive chronic lung allograft dysfunction (CLAD)

Understand the significance of macrolide responsive CLAD and discuss the optimal modality and timing of treatment in non-responders according to CLAD phenotyping

Understand best practice plans for success using ECMO as a bridge to lung transplantation.

Discuss the different factors that should lead to ECMO termination without transplantation.

Understand a strategy of ventilator management and donor lung recruitment that will lead to more consistent outcomes.

Identify factors that will lead to the recognition of deteriorating donor lungs while understanding the role for ex-vivo lung perfusion (EVLP). **  
**

Accreditation Statement

The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

ISHLT designates this live activity for a maximum of 4.25 _AMA PRA Category 1 Credits_ ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE Credit

This activity may be eligible for ACPE credit, see final CPE activity announcement for specific details.

Disclosure

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

SCIENTIFIC PROGRAM – MORNING CLASS SCHEDULE

7:15 AM – 8:00 AM

**  
REGISTRATION AND MORNING COFFEE

8:00 AM - 8:15 AM  
WELCOME AND INTRODUCTIONS   
**Kevin M. Chan, MD, University of Michigan Health Center, Ann Arbor, MI, USA  
Lorriana Leard, MD, University of California San Francisco, San Francisco, CA, USA  
 **  
8:15 AM – 9:15 AM**

**SMALL GROUP INTERACTIVE DISCUSSION A:** **ANTIBODY MEDIATED REJECTION  
Moderator: **Lorriana Leard, MD

The presence of HLA and non-HLA donor specific antibodies (DSA) is associated with various types of antibody mediated graft dysfunction. Antibody mediated rejection (AMR) may also be a contributing factor to the development of chronic lung allograft dysfunction (CLAD) as well as decreased survival. The ISHLT has developed an Expert Consensus Document on the clinical and pathological definition of AMR. This has important implications for clinical practice, therapeutic interventions, and the design of research protocols.

8:15 AM

**Case Scenario: Asymptomatic lung transplant recipient found to have positive donor specific antibodies four weeks following the procedure**  
Deborah Levine, MD, University of Texas Health Science Center, San Antonio, TX, USA

Teaching/Discussion Points

a. What is included in an evaluation for Pulmonary AMR

b. Surveillance of pre-transplant and post-transplant DSA

c. What does a positive DSA mean in the face of normal graft function and normal pathology

d. Role of C4d staining in the evaluation of Pulmonary AMR

e. Is there a role for medical therapy in the setting of a positive DSA with no pathologic or clinical findings?

8:45 AM

Case Scenario: Lung transplant recipient found to have an abnormal CT of the chest, positive donor specific antibodies and histopathology consistent with antibody mediated rejection

Debbie Levine, MD. UT Health Science Center, San Antonio, TX, USA

Teaching/Discussion Points

a. What is Pulmonary AMR?

b. What are the pathologic findings of Pulmonary AMR?

c. What are the different treatment strategies for Pulmonary AMR?

d. When do you initiate therapy for Pulmonary AMR?

e. What indices indicate a positive response to therapy?

8:15 AM – 9:15 AM

**SMALL GROUP INTERACTIVE DISCUSSION B:** **CHRONIC LUNG ALLOGRAFT DYSFUNCTION (CLAD)**

**Moderator:** Geert M. Verleden, MD, PhD

It is becoming increasingly evident that chronic lung allograft dysfunction (CLAD) encompasses a heterogeneous group of clinical syndromes with substantial variability in disease progression and response to treatment. However, optimal strategies for phenotyping, preventing, detecting and treating CLAD remain controversial.

8:15 AM

Case Scenario: Bilateral lung recipient with a history of obstructive airway complications and declining graft function two years after transplantation

Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany

Teaching/Discussion Points

a. Differential diagnosis and confounders of CLAD

b. Baseline FEV1 in patients with obstructive airway complications

c. Role of bronchoalveolar lavage in identification of response of CLAD to therapy

d. Second line treatment options for CLAD

e. Photopheresis-when to start and when to stop

f. Is there a role of surgery in graft dysfunction

8:45 AM

Case Scenario: Bilateral lung recipient with declining lung function, obstructive pattern and evolving pulmonary opacities

Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany

Teaching/Discussion Points

a. CLAD phenotyping and differential diagnosis

b. Risk factors for CLAD

c. Criteria to phenotype CLAD

d. Evolution patterns within CLAD

d. Treatment of CLAD

e. Role of retransplantation, azithromycin, other treatment options?

9:15 AM – 9:20 AM

Speakers switch rooms; delegates remain seated

9:20 AM – 10:20 AM

SMALL GROUP INTERACTIVE DISCUSSION ROTATIONS A AND B REPEATED

10:20 AM – 10:45 PM  
COFFEE BREAK

10:45 AM – 11:45 AM

SMALL GROUP INTERACTIVE DISCUSSION C: EXTRACORPOREAL LUNG SUPPORT (ECLS) AS A BRIDGE TO TRANSPLANTATION

**Moderator:** Goran Dellgren, MD, PhD

The use of ECMO as a bridge-to-lung transplantation is becoming increasingly more common especially after improvements in technology that allow extra-corporeal lung support in the awake, ambulating patient. The indications, management, transplant evaluation difficulties and the postoperative short-term management of these patients may be problematic

10:45 AM

**Case Scenario: 65 year old woman with dermatomyositis related ILD is on vvECMO due to acute pneumonia and continues to deteriorate. The lung transplant team is consulted at this time** Jonathan Singer, MD, University of California Medical Center, San Francisco, CA, USA

Teaching/Discussion Points

a. ECMO decisions: vv and va ECMO – when should transition be considered?

b. Awake versus sedated?

c. Tracheostomy versus oral/nasal intubation?

d. Physiotherapy versus cautious conservative management

e. Kidney function decisions: RRT versus forced diuresis

f. How to manage work-up in non-listed patients when lung transplantation is the only remaining option?

11:15 AM

**Case Scenario: 30 year old man with CF, on the waiting list for lung transplantation, develops pneumonia requiring mechanical ventilation** **and subsequent ECMO support. Hemoptysis and barotrauma ensue  
** Jonathan Singer, MD, University of California Medical Center, San Francisco, CA, USA

Teaching/Discussion Points

a. When should complications on non-weanable ECMO be regarded as too much to pursue lung transplantation?

b. What combination of complications should result in ECMO termination without lung transplantation?

c. How do we balance empathy, hope and social needs in a patient that cannot be weaned from ECMO?

d. Ethical arguments to pursue/decline LTx in a young very sick patient that cannot be weaned from ECMO?

e. How to manage the patient when there is no other option than ECMO-termination?

f. How to manage the relatives when there is no other option than ECMO-termination?

10:45 AM – 11:45 AM

SMALL GROUP INTERACTIVE DISCUSSION D: LUNG DONOR MANAGEMENT

**Moderator:** David Hormuth, MD, Indiana University School of Medicine, Indianapolis, IN, USA

Significant variability exists in management of potential lung donors. Ventilator strategies, fluid choice and use of adjunctive antimicrobial and pharmacologic measures differ greatly between OPOs and transplant centers. While it must be recognized that some measures have significant implications on other potential donor organs, some affect the lungs alone. Standardization of lung donor management will allow standardized interpretable information across regions and the number of quality organs will be increased.

10:45 AM

Case Scenario: Forty year old male donor, nonsmoker, who suffered a traumatic brain injury. Bilateral lungs are offered to your recipient who is currently hospitalized for hypoxemia (LAS 54). PaO2/FiO2 = 276

Matthew Hartwig, MD, Duke University, Durham, NC, USA

Teaching/Discussion Points

a. Selection criteria

b. Recruitment techniques

c. Donor Operation management

d. Options to optimize post-transplant function

11:15 AM

Case Scenario: 32 year old male smoker, declared brain dead on hospital day 3; PaO2/FiO2 = 350. Lungs are accepted for your patient but the donor surgery is delayed and the most recent PaO2/FiO2 = 260

Matthew Hartwig, MD, Duke University, Durham, NC, USA

Teaching/Discussion Points

a. Analysis of deterioration of oxygenation

b. Futility- are these lungs no longer suitable

c. Intraoperative analysis - could a single lung be an option

d. Potential role for ex-vivo lung perfusion

11:45 AM – 11:50 AM

Speakers switch rooms; delegates remain seated

11:50 AM – 12:50 PM

SMALL GROUP INTERACTIVE DISCUSSION ROTATIONS C AND D REPEATED

12:50 PM – 1:00 PM  
CLOSING REMARKS

Kevin M. Chan, MD, University of Michigan Health Center, Ann Arbor, MI, USA  
Lorriana Leard , MD, University of California San Francisco, San Francisco, CA, USA **  
**

SCIENTIFIC PROGRAM – AFTERNOON CLASS SCHEDULE

1:15 PM – 2:00 PM

**  
REGISTRATION AND MORNING COFFEE

2:00 PM - 2:15 PM  
WELCOME AND INTRODUCTIONS   
**Kevin M. Chan, MD, University of Michigan Health Center, Ann Arbor, MI, USA  
Lorriana Leard , MD, University of California San Francisco, San Francisco, CA, USA  
 **  
2:15 PM – 3:15 PM**

**SMALL GROUP INTERACTIVE DISCUSSION A:** **ANTIBODY MEDIATED REJECTION  
Moderator: **Lorriana Leard, MD

The presence of HLA and non-HLA donor specific antibodies (DSA) is associated with various types of antibody mediated graft dysfunction. Antibody mediated rejection (AMR) may also be a contributing factor to the development of chronic lung allograft dysfunction (CLAD) as well as decreased survival. The ISHLT has developed an Expert Consensus Document on the clinical and pathological definition of AMR. This has important implications for clinical practice, therapeutic interventions, and the design of research protocols.

2:15 PM

**Case Scenario: Asymptomatic lung transplant recipient found to have positive donor specific antibodies four weeks following the procedure**  
Deborah Levine, MD, University of Texas Health Science Center, San Antonio, TX, USA

Teaching/Discussion Points

a. What is included in an evaluation for Pulmonary AMR

b. Surveillance of pre-transplant and post-transplant DSA

c. What does a positive DSA mean in the face of normal graft function and normal pathology

d. Role of C4d staining in the evaluation of Pulmonary AMR

e. Is there a role for medical therapy in the setting of a positive DSA with no pathologic or clinical findings?

2:45 PM

Case Scenario: Lung transplant recipient found to have an abnormal CT of the chest, positive donor specific antibodies and histopathology consistent with antibody mediated rejection

Deborah Levine, MD, University of Texas Health Science Center, San Antonio, TX, USA

Teaching/Discussion Points

a. What is Pulmonary AMR?

b. What are the pathologic findings of Pulmonary AMR?

c. What are the different treatment strategies for Pulmonary AMR?

d. When do you initiate therapy for Pulmonary AMR?

e. What indices indicate a positive response to therapy?

2:15 PM – 3:15 PM

**SMALL GROUP INTERACTIVE DISCUSSION B:** **CHRONIC LUNG ALLOGRAFT DYSFUNCTION (CLAD)**

**Moderator:** Geert M. Verleden, MD, PhD

It is becoming increasingly evident that chronic lung allograft dysfunction (CLAD) encompasses a heterogeneous group of clinical syndromes with substantial variability in disease progression and response to treatment. However, optimal strategies for phenotyping, preventing, detecting and treating CLAD remain controversial.

2:15 PM

Case Scenario: Bilateral lung recipient with a history of obstructive airway complications and declining graft function two years after transplantation

Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany

Teaching/Discussion Points

a. Differential diagnosis and confounders of CLAD

b. Baseline FEV1 in patients with obstructive airway complications

c. Role of bronchoalveolar lavage in identification of response of CLAD to therapy

d. Second line treatment options for CLAD

e. Photopheresis-when to start and when to stop

f. Is there a role of surgery in graft dysfunction

2:45 PM

Case Scenario: Bilateral lung recipient with declining lung function, obstructive pattern and evolving pulmonary opacities

Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany

Teaching/Discussion Points

a. CLAD phenotyping and differential diagnosis

b. Risk factors for CLAD

c. Criteria to phenotype CLAD

d. Evolution patterns within CLAD

d. Treatment of CLAD

e. Role of retransplantation, azithromycin, other treatment options?

3:15 PM – 3:20 PM

Speakers switch rooms; delegates remain seated

3:20 PM – 4:20 PM

SMALL GROUP INTERACTIVE DISCUSSION ROTATIONS A AND B REPEATED

4:20 PM – 4:45 PM  
COFFEE BREAK

4:45 PM – 5:45 PM

SMALL GROUP INTERACTIVE DISCUSSION C: EXTRACORPOREAL LUNG SUPPORT (ECLS) AS A BRIDGE TO TRANSPLANTATION

**Moderator:** Goran Dellgren, MD, PhD

The use of ECMO as a bridge-to-lung transplantation is becoming increasingly more common especially after improvements in technology that allow extra-corporeal lung support in the awake, ambulating patient. The indications, management, transplant evaluation difficulties and the postoperative short-term management of these patients may be problematic

4:45 PM

**Case Scenario: 65 year old woman with dermatomyositis related ILD is on vvECMO due to acute pneumonia and continues to deteriorate. The lung transplant team is consulted at this time** Jonathan Singer, MD, University of California Medical Center, San Francisco, CA, USA

Teaching/Discussion Points

a. ECMO decisions: vv and va ECMO – when should transition be considered?

b. Awake versus sedated?

c. Tracheostomy versus oral/nasal intubation?

d. Physiotherapy versus cautious conservative management

e. Kidney function decisions: RRT versus forced diuresis

f. How to manage work-up in non-listed patients when lung transplantation is the only remaining option?

5:15 PM

**Case Scenario: 30 year old man with CF, on the waiting list for lung transplantation, develops pneumonia requiring mechanical ventilation** **and subsequent ECMO support. Hemoptysis and barotrauma ensue  
** Jonathan Singer, MD, University of California Medical Center, San Francisco, CA, USA

Teaching/Discussion Points

a. When should complications on non-weanable ECMO be regarded as too much to pursue lung transplantation?

b. What combination of complications should result in ECMO termination without lung transplantation?

c. How do we balance empathy, hope and social needs in a patient that cannot be weaned from ECMO?

d. Ethical arguments to pursue/decline LTx in a young very sick patient that cannot be weaned from ECMO?

e. How to manage the patient when there is no other option than ECMO-termination?

f. How to manage the relatives when there is no other option than ECMO-termination?

4:45 PM – 5:45 PM

SMALL GROUP INTERACTIVE DISCUSSION D: LUNG DONOR MANAGEMENT

**Moderator:** David Hormuth, MD, Indiana University School of Medicine, Indianapolis, IN, USA

Significant variability exists in management of potential lung donors. Ventilator strategies, fluid choice and use of adjunctive antimicrobial and pharmacologic measures differ greatly between OPOs and transplant centers. While it must be recognized that some measures have significant implications on other potential donor organs, some affect the lungs alone. Standardization of lung donor management will allow standardized interpretable information across regions and the number of quality organs will be increased.

4:45 PM

Case Scenario: Forty year old male donor, nonsmoker, who suffered a traumatic brain injury. Bilateral lungs are offered to your recipient who is currently hospitalized for hypoxemia (LAS 54). PaO2/FiO2 = 276

Matthew Hartwig, MD, Duke University, Durham, NC, USA

Teaching/Discussion Points

a. Selection criteria

b. Recruitment techniques

c. Donor Operation management

d. Options to optimize post-transplant function

5:15 PM

Case Scenario: 32 year old male smoker, declared brain dead on hospital day 3; PaO2/FiO2 = 350. Lungs are accepted for your patient but the donor surgery is delayed and the most recent PaO2/FiO2 = 260

Matthew Hartwig, MD, Duke University, Durham, NC, USA

Teaching/Discussion Points

a. Analysis of deterioration of oxygenation

b. Futility- are these lungs no longer suitable

c. Intraoperative analysis - could a single lung be an option

d. Potential role for ex-vivo lung perfusion

5:45 PM – 5:50 PM

Speakers switch rooms; delegates remain seated

5:50 PM – 6:50 PM

SMALL GROUP INTERACTIVE DISCUSSION ROTATIONS C AND D REPEATED

6:50 PM – 7:00 PM  
CLOSING REMARKS

Kevin M. Chan, MD, University of Michigan Health Center, Ann Arbor, MI, USA  
Lorriana Leard , MD, University of California San Francisco, San Francisco, CA, USA  
 **  
**

ISHLT ACADEMY: MASTER CLASS IN

MECHANICAL CIRCULATORY SUPPORT (MCS)

Saturday, April 30, 2016

Marriott Wardman Park Hotel, Washington Ballrooms 2 and 3

Washington, DC, USA

**Chairs  
** Stavros Drakos, MD, University of Utah School of Medicine, Salt Lake City, UT, USA

Simon Maltais, MD, PhD, Mayo Clinic, Rochester, MN, USA

Scientific Program Committee

Navin Kapur, MD, Tufts Medical Center, Boston, MA, USA

Sanem Nalbantgil, MD, Ege University Medical Center, Izmir, Turkey

Salpy Pamboukian, MD, MSPH, University of Alabama at Birmingham, Birmingham, AL, USA

Vivek Rao, MD, PhD, University of Toronto, Toronto, ON, Canada

Jan Schmitto, MD, PhD, MBA, Hannover Medical School, Hannover, Germany

Course Summary

The MCS Master Class presents a unique international educational opportunity for specialists and developing experts in the field of Mechanical Circulatory Support. A concerted effort brings together faculty and experts to provide an interactive environment well beyond core competency training. The MCS Master Class is arranged in advanced breakout sessions for every participant to take full advantage of an integrated curriculum and the exceptional networking opportunity. The specific topics are devised according to defined clinical practice gaps in this fast developing specialty.

Educational Goals

The overarching goal is to provide an advanced learning opportunity for specialists and developing experts in the field of MCS and devices for treatment of heart failure patients.

Practice Gaps

**1:** The therapeutic options of acute cardiogenic shock have been evolving with the introduction of various reliable MCS options. Comprehensive clinical expertise of advanced usage of these therapies including patient and device selection and transition to next step therapies constitute currently major limitations in the care of these critically ill patients.

**2:** The diagnosis and therapy of complex and combined adverse events such as device thrombosis, gastrointestinal bleeding and thromboembolic complications is challenging and individual practitioners often face difficulties in developing effective strategies to appropriately identify and treat these adverse events.

**3:** With the rapid evolution of surgical approaches and significant advances in internal medicine, the individual practitioners may lack the extensive expertise required to appropriately select (a) patients and (b) surgical approaches to achieve the best possible outcome.

**4:** The diagnostic and therapeutic approaches for right ventricular failure and aortic insufficiency in MCS patients have recently been revolutionized with the introduction of hemodynamics, new echocardiographic criteria and new technologies/ therapeutic options. Such practice gaps in specialist knowledge and clinical skills constitute major limitations in the care of MCS patients.

Learning Objectives

**1:** Understand the technical and hemodynamic aspects of various acute circulatory support devices and review the evidence supporting their use in the setting of ischemic cardiogenic shock

**2:** Develop a systematic approach to diagnosis and therapy of complex adverse events after MCS implantation such as device thrombosis, recurrent gastrointestinal bleeding and thromboembolic complications.

**3:** Appropriately select patients for long-term MCS options with particular consideration in anticipated surgical management aspects (e.g. concomitant surgical interventions) and medical aspects like minimizing the risk for post-operative need for chronic dialysis.

**4:** Understand the diagnostic and therapeutic challenges of RV failure (both early and late) and aortic insufficiency during chronic MCS therapy

**  
Target Audience**

Cardiothoracic Surgeons and Cardiologists with MCS experience, Specialists in Heart Failure Care, allied health professionals with involvement in MCS patients, VAD Coordinators and critical care specialists, heart transplant professionals.

Accreditation Statement

The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

ISHLT designates this live activity for a maximum of 4.25 _AMA PRA Category 1 Credits_ ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE Credit

This activity may be eligible for ACPE credit, see final CPE activity announcement for specific details.

Disclosure

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

SCIENTIFIC PROGRAM SCHEDULE

1:00 PM – 1:45 PM

**  
REGISTRATION AND REFRESHMENTS

1:45 PM – 1:50 PM  
WELCOME AND INTRODUCTIONS   
**Stavros Drakos, MD, University of Utah School of Medicine, Salt Lake City, UT, USA

Simon Maltais, MD, PhD, Mayo Clinic, Rochester, MN, USA

1:50 PM – 2:50 PM

SMALL GROUP INTERACTIVE DISCUSSION A: Acute MCS for INTERMACS 0-1 Profiles

**Moderator:** **** Stavros Drakos, MD

1:50 PM

Case Scenario: Management challenges for patients with acute ischemic cardiogenic shock

Navin Kapur, MD, Tufts Medical Center, Boston, MA, USA

Teaching/Discussion Points

Cardiogenic shock definition and various approaches to classify it based on acuity and severity

Technical features of existing acute circulatory support device including: cannulation approaches, pump types, and advantages/ disadvantages of each device

Hemodynamic impact of each acute circulatory support device on ventricular function, left ventricular wall stress, and ventriculo-arterial coupling

Revascularization options and the role of acute circulatory support in the management of myocardial ischemia due to both abrupt coronary thrombosis or in the setting of chronic multivessel coronary disease

Existing evidence on the utilization of acute circulatory support in the setting of ischemic cardiogenic shock

Intra-procedural and post-procedural management of acute circulatory support devices for ischemic cardiogenic shock with a specific focus on assessing myocardial recovery while on circulatory support

2:20 PM

Case Scenario: Transition from short to long-term MCS support

Jan Schmitto, MD, PhD, MBA, Hannover Medical School, Hannover, Germany

Teaching/Discussion Points

Different option strategies for acute MCS support and assess utility vs. futility of support

How to balance efficacy and appropriateness of current available acute MCS options

Advantages and disadvantages for each acute device options and how to balance the choice of support with different clinical scenarios (univentricular vs. biventricular failure; cardiac vs. mixed cardiopulmonary collapse; short vs. prolonged acute MCS support)

Treatment option for frequent complications on acute MCS support (peripheral vascular compromise, left ventricular decompression and pulmonary edema, hemolysis and bleeding)

Left ventricular recovery assessment on acute device support

Right ventricular function and risk assessment for transition to long-term support

Appropriate timing and strategy for transition of acute to long-term support

1:50 PM – 2:50 PM

**SMALL GROUP INTERACTIVE DISCUSSION B:** **Complex Coagulation issues in MCS Patients**

**Moderator:** Simon Maltais, MD, PhD

1:50 PM

Case Scenario: The 'hemolyzing' patient - Will he clot or will he bleed?

Ulrich Jorde, MD, Montefiore Medical Center, Bronx, NY, USA

Teaching/Discussion Points

Workup of hemolysis

Treatment of hemolysis – one size fits all?

Proposal: Hemolysis alone requires device exchange!

Logfile analysis to diagnose and treat device thrombosis – device specific review.

Comprehensive treatment algorithm for device thrombosis with or without recurrent gastrointestinal bleeding: When to cut and when to bust.

Device thrombosis complicated by stroke – what now?

2:20 PM

**Case Scenario: Chronic infection management on durable support and thromboembolic complication  
** Stephan Schueler, MD, PhD, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Teaching/Discussion Points

Medical management of chronic driveline infection

Antibiotics strategies in MCS patients with chronic device related infections including IV vs. oral therapy and duration of treatment

Role of prophylactic antibiotics

Patients who have not experienced a device related infection

Patient who have had a previous device related infection

Utility vs. futility of surgical management

Role of less invasive surgical techniques including surgical debridement and use of wound vac therapy

Role of more invasive surgical strategies for infection management including device exchange and transplantation

Pathophysiology that leads to perturbations in coagulation cascade in chronically infected patients

Practical considerations in patients with bleeding/thrombotic complications with ongoing driveline infection.

Changes in anticoagulation targets in chronically infected patients

Management of infected patients with concomitant (bleeding or thromboembolism)

2:50 PM – 2:55 PM

Speakers switch rooms; moderators remain in the same room; delegates remain seated

2:55 PM – 3:55 PM

SMALL GROUP INTERACTIVE DISCUSSION ROTATIONS A AND B REPEATED

3:55 PM – 4:10 PM  
COFFEE BREAK

4:10 PM – 5:10 PM

SMALL GROUP INTERACTIVE DISCUSSION C: Patient Selection Challenges for long-term MCS Support

**Moderator:** Stavros Drakos, MD

4:10 PM

Case Scenario: Predicting renal function recovery in marginal MCS candidates

Meredith Brisco, MD, MSCE, Medical University of South Carolina, Charleston, SC, USA

Teaching/Discussion Points

Renal function in LVAD patients (estimation equations, creatinine clearance, proteinuria)

Heart failure-induced renal dysfunction with a high potential for recovery vs. intrinsic and irreversible kidney disease

Potential for renal recovery against the risk of acute kidney injury and need for chronic dialysis post operatively

Prevention of acute kidney injury (medication, imaging and hemodynamic considerations before surgery)

When to pull the trigger on dialysis

Important considerations when dialyzing an LVAD patient: method, duration, frequency of monitoring

4:40 PM

**Case Scenario:** Decision-making for concomitant surgical procedures for durable implants

**** Vivek Rao, MD, PhD, University of Toronto, Toronto, ON, Canada

Teaching/Discussion Points

Rationale for concomitant repair of the mitral and/or tricuspid valve at the time of LVAD implant

Risks and benefits of aortic valve intervention and surgical strategies to address it.

Organized surgical plan defining appropriateness of concomitant surgical intervention.

Risk of concomitant surgical interventions at the time of durable implant, balanced with indication for implant (bridge-to-transplantation, destination therapy, potential recovery)

4:10 PM – 5:10 PM

SMALL GROUP INTERACTIVE DISCUSSION D: Management of post-VAD complications

**Moderator:** Simon Maltais, MD, PhD

4:10 PM

Case Scenario: Management of early and late RV failure after LVAD implantation

Sanem Nalbantgil, MD, Ege University Medical Center, Izmir, Turkey

Teaching/Discussion Points

RV failure risk prediction and management before LVAD implantation (Pre-operative IABP or percutaneous RV support devices)

BiVAD vs. TAH vs. transplantation decision making

Medical management of early RV failure after durable LVAD support (emphasis on speed optimization, drug therapy)

Timing and selection of temporary RVAD support for early RV failure

Decision making for switch from temporary to durable RV support.

Definition and management of late RV failure after VAD implantation

4:40 PM

Case Scenario: Chronic aortic insufficiency on durable support: diagnosis and treatment

Nir Uriel, MD, University of Chicago, Chicago IL, USA

Teaching/Discussion Points

New echo criteria for aortic insufficiency in CF-LVAD

Hemodynamics effect of aortic insufficiency on LVAD

Treatment algorithms to decide on the need for intervention in patients with aortic insufficiency.

Current treatment options for patients with significant aortic insufficiency.

Potential effect of new CF-LVAD (HM 3, MVAD) on the development of aortic insufficiency.

Medical and surgical strategies to improve or correct aortic insufficiency post-LVAD implantation

5:10 PM – 5:15 PM

Speakers switch rooms; moderators remain in the same room; delegates remain seated

5:15 PM – 6:15 PM

SMALL GROUP INTERACTIVE DISCUSSION ROTATIONS C AND D REPEATED

6:15 PM – 6:30 PM  
CLOSING REMARKS

Stavros Drakos, MD, University of Utah School of Medicine, Salt Lake City, UT, USA

Simon Maltais, MD, PhD, Mayo Clinic, Rochester, MN, USA

**  
**

CORPORATE EVENTS AND INDUSTRY THEATERS LISTING

The following approved Corporate Events and Industry Theaters are taking place during the ISHLT Annual Meeting. The Industry Theaters will take place in the Washington 3 Ballroom. The entrance is from the Exhibit Hall directly across from booth 507.

Tuesday, April 26

Noon – 2:00 pm

_Lung Bioengineering_ : EVLP Site Tours

2:00 pm – 4:00 pm

_Lung Bioengineering_ : EVLP Site Tours

Wednesday, April 27

10:15 am – 11:15 am

_St. Jude_ : Industry Theater: From Early Onset to Advanced Stage: Building a Comprehensive Heart Failure Program with St. Jude Medical (Washington 3)

12:20 pm – 12:50 pm

_United Therapeutics_ : Industry Theater: Role and Clinical Application of an Oral Prostacyclin Class Therapy in the Early Treatment of Pulmonary Arterial Hypertension (Washington 3)

6:00 pm – 8:00 pm

_Lung Bioengineering_ : EVLP Site Tours

7:00 pm – 10:00 pm

_St. Jude_ : PREVENT Investigator Meeting (Hoover)

7:30 pm – 9:30 pm

_Actelion Pharmaceuticals/Medscape_ : The Evolving Landscape of PAH: 20 Years of Prostanoids and Beyond (Maryland)  
Supported by an educational grant from Actelion Pharmaceuticals, Ltd and accredited by Medscape Education

8:00 pm-10:00 pm  
 _Heartware:_ Corporate Update Presentation and Dinner (offsite)

Thursday, April 28

7:00 am -8:00 am

_Actelion Pharmaceuticals_ : Nordic Expert Group Meeting (Jackson)

7:00 am -8:00 am

_St. Jude_ : Japan MCS Update Breakfast (8206)

Noon – 1:00 pm

_St. Jude_ : Elevate Registry Publication/Presentation Committee Meeting (8206)

Noon – 2:00 pm

_Lung Bioengineering_ : EVLP Site Tours

12:55 pm – 1:55 pm

_Heartware_ : Industry Theater: Advancements in HVAD® Outcomes (Washington 3)

12:15 pm – 1:45 pm

Transmedics: The Organ Care System (OCS™) for Lung and Heart Perfusion – The Future is Near (Virginia)

5:30 pm- 6:30 pm  
 _Bayer_ : Industry Theater (Washington 3)

7:00 pm – 9:00 pm  
 _St. Jude_ : MCS Dinner Reception and Tech Fair (off-site)

Friday, April 29

7:00 am -8:00 am

_Actelion Pharmaceuticals_ : Nordic Expert Group Meeting (Jackson)

Noon – 1:30 pm

_St. Jude_ : MOMENTUM 3 Investigator Meeting (Washington 5)

Noon – 2:00 pm  
 _Gilead Sciences_ : Controversies in PAH: Experts Explore Combination Therapy (Maryland)

Noon – 2:00 pm

_CareDx_ : Detecting Rejection and Surveillance in Cardiac Transplantation: Applications of Genomic Medicine (Virginia)

Noon – 2:00 pm

_Lung Bioengineering_ : EVLP Site Tours

1:30 pm – 2:00 pm

_St. Jude_ : Industry Theater: ROADMAP and PREVENT: How We Continue to Optimize and Evolve HeartMate II Patient Selection, Implant and Management (Washington 3)

5:30 pm – 7:00 pm

_St. Jude_ : LIS/APICA Project Team Meeting (8206)

Saturday, April 30

2:00 pm – 6:00 pm

_Biotest AG_ : Biotest Expert Meeting: Immunoglobulins in Transplantation (Taylor)

2016 EXHIBITORS AND BOOTH NUMBERS

919 | Abiomed, Inc.

---|---

607 | Actelion Pharmaceuticals

408 | Alere VADCare Program

813 | Bayer Healthcare

3305 | Berlin Heart, Inc.

1004 | BiologicTx

1036 | Cardiac Assist, Inc.

911 | CareDx, Inc.

1018 | CARMAT

309 | Centurion Medical Products

917 | Corporate Endowment Solutions

1030 | Essential Pharmaceuticals, LLC

107 | Evaheart

1008 | Genentech, A member of the Roche Group

507 | Gilead Sciences, Inc.

413 | HeartWare

108 | INTERMACS – Interagency Registry for Mechanically Assisted Circulatory Support

106 | ISHLT Mechanically Assisted Circulatory Support Registry (IMACS)

1002 | ISHLT Transplant Registry

406 | Jarvik Heart Inc.

700 | Lung Bioengineering

1032 | Lung Biotechnology

908 | Maquet Medical Systems

1014 | Millar, Inc.

1028 | Minnetronix, Inc.

102 | Novartis

1022 | One Lambda, a Thermo Fisher Scientific Brand

1000 | Pediatric Heart Transplant Study (PHTS)

311 | Reliant Heart

909 | Scanlan International, Inc.

1012 | Scholten Surgical Instruments, Inc.

706 | St. Jude Medical

1010 | Sunshine Heart

104 | SynCardia Systems, Inc.

1006 | Texas Children's Hospital

613 | TransMedics, Inc.

407 | United Therapeutics

307 | University of Minnesota Health

401 | Vivoline Medical AB

205 | XVIVO Perfusion AB
2016 EXHIBITOR PRODUCT DESCRIPTIONS

ABIOMED, INC. Booth #919

22 Cherry Hill Drive

Danvers, MA

www.abiomed.com

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.

The Company's portfolio of products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the world's first total replacement heart to the World's Smallest Heart Pump, 1/100th the size of the heart with rapid and simple insertion, Abiomed is dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.

For additional information, please visit: www.abiomed.com.

ACTELION PHARMECEUTICALS US, INC. Booth #607

5000 Shoreline Court South

San Francisco CA, 94080

www.actelionus.com

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for diseases with significant unmet medical needs.

ALERE VADCARE® PROGRAM Booth #408

30 South Keller Road

Orlando, FL

<http://www.alere.com/en/home/products-services/cardiovascular/patient-health-monitoring-us/home-monitoring/vadcare-program.html>

The comprehensive Alere VADCare® Program helps you carefully and efficiently manage your patients after discharge to reduce the risk of hospital readmission. Alere fully supports the transition of VAD patients from hospital to home. Patients receive all of the necessary equipment and wound care supplies they need to take care of their VAD equipment and driveline exit site. Additional services through the Alere VADWatch® program include home INR monitoring; weight and blood pressure management; and tracking of VAD metrics in the Alere VADWatch® Data Management application, which gives clinicians secure, anytime access to patient data.

BAYER HEALTHCARE Booth #813

100 Bayer Blvd

Whippany, NJ, 07981

Bayer is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Medical Care, and Pharmaceuticals divisions. As a specialty pharmaceutical company, Bayer HealthCare provides products for Cardiopulmonary, Hematology, Neurology, Oncology and Women's Healthcare.

BERLIN HEART, INC. Booth #305

200 Valleywood Rd. Suite B100

The Woodlands, TX 77380

www.berlinheart.de

Berlin Heart, the only company worldwide, that develops, manufactures and distributes VADs for patients of every age and body size. EXCOR® Pediatric provides medium to long-term circulatory support specifically for infants and children awaiting heart transplants. EXCOR Pediatric is approved for use in the USA under HDE regulations by FDA

BIOLOGICTX Booth #1004

40-D Commerce Way

Totowa, NJ 07512

www.BiologicTx.com

BiologicTx is a national specialty pharmacy that joins the administration of therapeutics, research, and digital health to advance the practice of solid organ transplant and chronic specialties. BiologicTx is comprised of four operating segments: BiologicTx Pharmacy and Therapeutic Services, BiologicTx Clinical Trials™, BiologicTx Sequence, and BiologicTx Paired Donation™.

CARDIAC ASSIST, INC. Booth #1036

240 Alpha Drive

Pittsburgh, PA 15238

www.cardiacassist.com

CardiacAssist is the inventor of the world's most versatile temporary cardiopulmonary bypass device on the market, The TandemHeart® pump. Our pump can be used in a variety of configurations (surgical, percutaneous cardiac support, percutaneous respiratory support) when paired with our PROTEK line of cannulae. Visit our booth to learn more about our latest innovations, PROTEK Duo and Voyager Vest.

CAREDX, INC. Booth #911

3260 Bayshore Blvd.

Brisbane, CA 94005

www.caredx.com

Product Description: AlloMap is a non-invasive blood test for heart transplant patients. AlloMap is the first and only non-invasive test with a rapid turnaround time that helps physicians identify the risk of acute cellular rejection in heart transplant recipients.

CARMAT Booth #1018

36 Avenue de L'Europe

Velizy, 78140

FRANCE

CARMAT (the contraction of its founders' names, Pr Carpentier and Matra – now part of Airbus Group) develops a bioprosthetic implantable artificial heart, as well as its power supply and remote monitoring systems. The key differentiating features of this project are the use of bovine pericardium for most parts in contact with blood – including the pulsatile internal membrane - and real-time adjustment of flow and rate thanks to embedded sensors and electronics. CARMAT heart is an investigational device only. It started its First-in-Man trial in France in December 2013 and is not approved for clinical use anywhere in the world.

CENTURION MEDICAL PRODUCT Booth #309

100 Centurion Way

Williamston, MI 48895

www.centurionmp.com

Centurion Medical Products specializes in creating sterile procedural trays customized to meet your specific requirements. Centurion Driveline Maintenance Bundles are designed to provide optimal protection for LVAD driveline sites to reduce complications for your patients with LVADs. Intuitively designed to encourage best practices, our kits help to reduce the incidence of patient complications, unscheduled nursing visits, and hospital readmissions. We offer products that provide bacterial protection and long wear times. Featuring SorbaView SHIELD®, an all-in-one catheter dressing with a built-in stabilization device; and our Foley Anchor, to comfortably keep the driveline securely in place prevent stress at the site.

CORPORATE ENDOWMENT SOLUTIONS

4341 Acer Grove Rd

Springfield, IL 62711

ESSENTIAL PHARMACEUTICALS, LLC Booth #1030

100 Princeton South Corporate Center

Suite 140

Ewing NJ 08628

Essential Pharmaceuticals, LLC is a specialty pharmaceutical company devoted to the development and sales of pharmaceutical and biopharmaceutical products including Custodiol® HTK organ preservation solution. Originally developed for cardiac surgery, Custodiol® HTK offers superior convenience due to its easy handling characteristics, water like viscosity and no need for additives or filters which makes it a preferred solution for many transplant centers. Please visit us at our booth # 1030 or at www.essentialpharma.com or www.custodiol.com

EVAHEART, INC. Booth #107

6655 Travis St. Ste. 590

Houston, TX 77030

www.evaheart-usa.com

The EVAHEART Left Ventricular Assist System (LVAS)™ is a continuous-flow, hydraulically levitated centrifugal pump designed to support patients with end-stage heart failure as bridge-to-transplant therapy. The EVAHEART LVAS has been commercially available in Japan since 2010, and has successfully obtained CE marking approval.

Evaheart, Inc. (EVI) is a medical device company based in the Texas Medical center of Houston. EVI was established to gain regulatory approval and commercialize the EVAHEART LVAS in North America and to start distribution in Europe. Under an FDA-approved IDE, a bridge-to-transplant (BTT) clinical trial of the EVAHEART LVAS is ongoing in the US.

GENETECH, A MEMBER OF THE ROCHE GROUP Booth #1008

1 DNA Way

South San Francisco, CA 94080

www.gene.com

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 35 years. At Genentech, we use human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, we are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline.

GILEAD SCIENCES, INC. Booth #507

333 Lakeside Dr

Foster City, CA 94404

www.gilead.com

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.

HEARTWARE Booth #413

500 Old Connecticut Path

Framingham, MA 01701

At HeartWare, we are focused on enhancing outcomes in the treatment of end stage heart failure. We believe a commitment to quality and continuous learning, improving and innovating are requirements for a best in class global medical device company. As a leader in VAD support, HeartWare is committed to partnering with clinicians to help patients gain access to our technology. The HVAD® System has quickly become the VAD of choice, demonstrating high survival rates, low complication rates and improved quality of life.

Our goal: To meaningfully extend the lives of the heart failure patients by enhancing their quality of life.

INTERAGENCY REGISTRY FOR MECHANICALLY ASSISTED CIRCULATORY SUPPORT – INTERMACS  Booth #108

701 19th Street South

790 LHRB

Birmingham, AL 35294

www.intermacs.org

The Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) is a prospective North American registry established in 2005 for patients who are receiving mechanical circulatory support device (MCSD) therapy to treat advanced heart failure. The purpose of the registry is to collect and analyze clinical and laboratory data from patients who are receiving MCSDs for whom discharge from the hospital is feasible. Intermacs with over 17,000 patients, provides contemporary data to demonstrate the continued progress of outcomes, with additional insight into appropriate risk stratification and patient selection.

ISHLT MECHANICALLY ASSISTED CIRCULATORY SUPPORT REGISTRY (IMACS) Booth #106

701 19TH Street South, LHRB 790

Birmingham, AL 35294

<http://www.ishlt.org/registries/mcsdDatabase.asp>

IMACS is an international registry intended to enroll and follow patients who receive durable mechanically assisted circulatory support devices (MCSD) in all countries and hospitals that wish to participate. Durable devices are defined as those devices that are capable of allowing patient discharge with the device in place.

The primary goal of the IMACS Registry is to create, implement and analyze a registry that contains high standards for complete enrollment of patients and complete and accurate submission of MCSD data that allows participating centers to engage in important outcomes research about mechanical support devices.

ISHLT REGISTRIES Booth #1002

700 N 4th Street

Richmond, VA 23219

www.ishlt.org

ISHLT Thoracic Transplant Registry

ISHLT DCD Registry

ISHLT Pediatric Heart Failure Registry

JARVIK HEART, INC. Booth #406

333 West 52nd St

New York, NY 10019

www.jarvikheart.com

Jarvik Heart, Inc. is a privately held, New York based company that develops and manufactures miniaturized heart assist devices for the treatment of severe heart failure. The Jarvik 2000 is a battery-powered axial-flow left ventricular assist device (LVAD). It is the smallest implantable blood pump available for the long-term treatment of Heart Failure.

LUNG BIOENGINEERING Booth #700

1015 Spring Street

Silver Spring MD 20910

Lung Bioengineering was born from the difficult experiences of one PAH patient, our founder's daughter. When she was ten years old, she could barely walk to her school bus without becoming short of breath. Her doctors explained the prognosis of a typical PAH patient at that time. Her mother refused to accept this outcome and instead began looking for solutions to her daughter's condition. She was the first in an ever-expanding line of patients to inspire Lung Bioengineering to reach farther to develop novel therapies. People with PAH lead us to this path, and we forge ahead for them and others with chronic lung diseases.

Lung Bioengineering is conducting a clinical trial dedicated to ex vivo lung perfusion. A successful trial may pave the way towards expanding the supply of available lungs. (<http://lungbioengineering.com/>)

LUNG BIOTECHNOLOGY Booth#1032

1040 Spring Street, Silver Spring, MD 20910

<http://lungbiotechnology.com/>

Lung Biotechnology is building a bridge to the future with its focus on developing innovative therapies for patients with PAH and other chronic, life-threatening pulmonary diseases. Lung Biotechnology currently markets Tyvaso (treprostinil) inhalation solution and Adcirca (tadalafil), an oral medication. Visit lungbiotechnology.com, tyvaso.com and adcirca.com for more information.

MAQUET MEDICAL SYSTEMS Booth #908

45 Barbour Pond Drive

Wayne, NJ 07470 USA

www.getingegroup.com

MAQUET Medical Systems, USA is a market leader offering a comprehensive portfolio of products utilized in the Hybrid and Traditional OR, ICU, Cath Lab and in patient transport. Our products are designed to meet the needs of clinical professionals in the areas of: advanced hemodynamic monitoring, cardiothoracic and vascular surgery, thoracic drainage, cardiac intervention, perfusion, anesthesia and ventilation. MAQUET is focused on improving patient care and quality of life, providing clinicians with sustainable technologies that fit their daily practice and investing in the development of innovative solutions that will help further advance clinical practice and significantly improve patient outcomes.

MILLAR, INC. Booth #1014

6001-A Gulf Freeway

Houston, TX 77023

www.millar.com

Millar clinical products provide cath lab clinicians and cardiovascular researchers with complete insight into cardiovascular function for diagnosis or medical research. Our leading clinical product is the Mikro-Cath™ diagnostic pressure catheter used to obtain clean, blood pressure signals for accurate hemodynamic assessment in the cath lab. For a complete evaluation of cardiac function from a single catheterization, Millar offers the CD Leycom® Inca® Pressure-Volume (PV) Loop System and catheters for real-time pressure and volume data analysis. Millar is a unique provider of cardiovascular products that cover device and drug development from the first animal model through the final clinical trial.

MINNETRONIX, INC. Booth #1028

1645 Energy Park Drive

Saint Paul, MN, 55108

info@minnetronix.com

www.minnetronix.com

Minnetronix is a medical technology and innovation company with deep expertise in electronic and electromechanical devices. Founded in 1996, the company creates new technologies and therapies that solve unmet clinical and business needs for patients and medical device companies, including transcutaneous energy transmission systems (TETS) and mechanical circulatory support power and control systems. Minnetronix leverages its broad industry knowledge to provide innovative and strategic partnership options, as well as design, development, and manufacturing services. The company offers multiple pathways to create value, including intellectual property generation and new business models. Minnetronix is FDA Registered and ISO 13485 Certified.

NOVARTIS Booth #102

One Health Plaza

East Hanover, NJ 07936

ONE LAMBDA, A THERMO FISHER SCIENTIFIC BRAND Booth #1022

21001 Kittridge Street

Canoga Park, CA 91303

www.onelambda.com

One Lambda, Inc. is a leader in transplant diagnostics and offers a broad range of products to support clinicians and laboratories in the management of transplant patients. Donor specific antibody (DSA) testing and monitoring are specific tools which support this process. Visit the One Lambda booth to discover how we can help improve your standard of care by reducing the risk of Antibody‐Mediated Rejection (AMR) with our DSA monitoring products LABScreen™ Single Antigen and non‐HLA biomarker assays including AT1R, and complement binding (C1q) antibodies.

PHTS – PEDIATRIC HEART TRANSPLANT STUDY Booth #1000

701 19th Street South, LHRB 781

Birmingham, AL 35294

www.uab.edu/medicine/phts

The Pediatric Heart Transplant Study (PHTS) is an international registry established in 1993 for pediatric patients listed for heart transplantation. PHTS is dedicated to the advancement of the science and treatment of children during listing for and following heart transplantation. The purposes of the group are to establish and maintain a prospective, event driven database for heart transplantation, to encourage and stimulate basic and clinical research in the field of pediatric heart transplantation, and to promote new therapeutic strategies. The ultimate goal is to improve patient outcomes. The registry resides at the University of Alabama at Birmingham.

SCANLAN INTERNATIONAL, INC. Booth #909

One Scanlan Plaza

Saint Paul, Minnesota 55107

info@scanlangroup.com

www.scanlaninternational.com

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 titanium and stainless steel instrument designs including needle holders, forceps, scissors, clamps and specialty instruments. Featured instruments include the SCANLAN® _LEGACY_ titanium needle holders and forceps, full line of VATS / MIS Thoracoscopic instruments including the Chitwood Clamp, Knot Pusher, and SUPER CUT™ Suture Cutter; Axial Handle needle holders and forceps; Scanlan® SUPER CUT™ Scissors and Rendina needle holder. Single-use products include: Scanlan® VASCU-STATT® bulldog clamps, Aorta/Vein Punch and A/C Locator® graft markers. Also offering custom instrument designs and modifications for your individual needs.

SCHOLTEN SURGICAL INSTRUMENTS, INC. Booth #1012

170 Commerce St., Suite 101

Lodi, California 95240

www.bioptome.com

For more than thirty-five years, SSI has manufactured high quality endomyocardial biopsy forceps. The Scholten disposable Bioptome model is called the Novatome™ and, like its predecessor, is specifically designed to acquire maximum quality specimen size for accurate pathology results. Our device has earned a reputation for its ease of use, heart rhythm feedback, and is considered the "gold standard" by many. Our innovative design paired with over three decades of clinical experience makes our device the best choice for safety and performance. With the Novatome™, SSI continues to provide reliability, value, and forceps of the highest quality to your industry.

ST. JUDE MEDICAL Booth #706

6035 Stoneridge Dr.

Pleasanton, Ca. 94588

www.sjm.com

St. Jude Medical is a leading global medical device manufacturer and is dedicated to transforming the treatment of some of the world's most expensive epidemic diseases. The company has five major areas of focus that include heart failure, atrial fibrillation, neuromodulation, traditional cardiac rhythm management, and cardiovascular diseases. For more information, please visit sjm.com or follow us on Twitter @SJM_Media.

SUNSHINE HEART COMPANY Booth #1010

12988 Valley View Road

Eden Prairie, MN 55344

www.sunshineheart.com

The C-Pulse® Heart Assist System is a counterpulsation technology used to treat patients with moderate to severe heart failure (Class III/Ambulatory Class IV). The implantable device is placed outside the bloodstream and gives patients the ability to disconnect from the system. Preliminary results of the C-Pulse System have indicated relief of heart failure symptoms, improved quality of life and cardiac function, and reduced the need for heart failure hospitalization. The C-Pulse implant procedure can be performed minimally invasively.

SYNCARDIA SYSTEMS, INC. Booth #104

1992 E Silverlake Rd

Tucson, AZ 85713

TEXAS CHILDREN'S HOSPITAL Booth #1006

6621 Fannin St

Houston, TX 77030

www.texaschildrens.org

Texas Children's Hospital, a not-for-profit health care organization, is committed to creating a healthier future for children and women throughout the global community by leading in patient care, education and research. Consistently ranked as the best children's hospital in Texas, and among the top in the nation, Texas Children's has garnered widespread recognition for its expertise and breakthroughs in pediatric and women's health. The hospital includes the Jan and Dan Duncan Neurological Research Institute; the Feigin Center for pediatric research; Texas Children's Pavilion for Women, a comprehensive obstetrics/gynecology facility focusing on high-risk births; Texas Children's Hospital West Campus, a community hospital in suburban West Houston; and Texas Children's Hospital The Woodlands, a second community hospital planned to open in 2017.

TRANSMEDICS, INC. Booth #613

200 Minuteman Road, Suite 302

Andover, MA 01810

www.transmedics.com

TransMedics, Inc., based in Andover, MA, is the world's leader in portable ex-vivo warm perfusion and assessment of donor organs for transplantation, and has developed technologies to address the unmet need for more and better organs for transplantation.

The Organ Care System (OCS™) makes it possible to preserve donor lungs, hearts, livers, and kidneys in a functioning state from donor to recipient, and allows physicians to continuously monitor their quality and function. The OCS™ Heart and OCS™ Lung systems are CE-marked and in use in leading European transplant centers and are currently under investigation in the US.

UNITED THERAPEUTICS Booth #407

55 T.W. Alexander Drive

Research Triangle Park, NC 27709

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions.

VIVOLINE MEDICAL BOOTH #401

Propellervagen 16

224 78, Lund

SWEDEN

www.vivoline.se

Vivoline Medical's vision is to increase organ transplantation by developing state‐of‐the-art products that help to increase the amount of organs available for transplantation. The Vivoline ® LS2 is Vivoline Medical's second generation Ex Vivo Lung Perfusion (EVLP) system, and efficient ease of use has been prioritized. It is a compact, CE-Marked system, intended for ex vivo perfusion, evaluation and preservation of Lungs. Vivoline ® LS2...Simplifying EVLP.

XVIVO PERFUSION AB BOOTH#205

Box 53015

SE – 400 14 Göteborg

SWEDEN

www.xvivoperfusion.com

XVIVO manufactures and markets solutions for transplantation designed to preserve and evaluate organs and tissues prior to transplantation. The XPS™ is a flexible and comprehensive platform for normothermic EVLP empowering the user to remain in control of the entire process. Our principle solutions are Perfadex® for hypothermic flushing and preservation of donor lungs during transport and STEEN Solution™ for normothermic ex vivo lung evaluation and assessment. Our products are CE-marked and approved by the FDA.

XVIVO aims to:

-minimize ischemia-reperfusion injury by improving the solutions used for ex-vivo preservation of organs.

-extend the safe ex-vivo preservation time for organs prior to transplantation.   
-increase organ availability and transplantation success rates by introduction of new transplantation concepts and techniques
FUTURE ANNUAL MEETINGS

2017

**37** th **Annual Meeting and Scientific Sessions**

San Diego, CA, USA

April 5-8, 2017

2018

**38** th **Annual Meeting and Scientific Sessions**

Nice, France

April 11-14, 2018

2019

**39** th **Annual Meeting and Scientific Sessions**

Orlando, FL, USA

April 3-6, 2019

International Society for Heart and Lung Transplantation

14673 Midway Road, Suite 200

Addison, TX 75007 USA

+1-972-490-9495

www.ishlt.org
